cluster,concept,cuis
2884,glipizide ( n = $nmbr$ ),C0017642
2884,glipizide,C0017642
2883,glyburide ( n = $nmbr$ ),C0017628
2883,glyburide,C0017628
2882,good / moderate response,C0205170;C4085643
2882,good,C0205170
2881,glycated hemoglobin  n ( % ),C0062408;C3666909
2880,glycosylated hemoglobin  %,C0017853
2880,glycated hemoglobin — % -,C0017853
2880,glycated hemoglobin — %,C0017853
2880,glycated hemoglobin | |,C0017853
2880,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
2880,glycated hemoglobin - % ’,C0017853
2880,glycated hemoglobin ( % ),C0017853
2880,glycated hemoglobin  standardized level — %,C0017853
2880,glycated hemoglobin  median ( iqr ),C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
2880,glycated hemoglobin  %,C0017853
2880,glycated hemoglobin,C0017853
2880,glycated haemoglobin ( % ),C0017853
2880,glycated haemoglobin  %,C0017853
2880,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
2879,glycohemoglobin  %,C0202054;C0696092
2879,glycated hemoglobin level,C0202054
2879,glycated hemoglobin  nonstandardized level — %,C0202054
2878,glucose in urine    ≥ $nmbr$ +,C0004076
2877,glucose metabolism,C0596620
2876,glucose test,C0337438;C0595310
2875,glucosamine ( n = $nmbr$ ),C0017718
2875,glucosamine,C0017718
2874,uacr  mgg $nmbr$ ( gm ),C0017480;C3854019
2874,triglycerides  mmolt $nmbr$ ( gm * ),C0017480;C0041004;C3854019
2874,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
2874,gm,C0017480;C3854019
2874,germany,C0017480
2874,( gm ),C0017480;C3854019
2873,de ( n = $nmbr$ ),C0011198;C0017480;C3541240
2873,de $nmbr$ n = $nmbr$,C0011198;C0017480;C3541240
2873,de,C0011198;C0017480;C3541240
2872,who / idf ifg,C1334085;C1708411
2872,igt / ifg,C1334085;C1708411
2872,ifg and igt,C1334085;C1708411
2872,ifg / igt,C1334085;C1708411
2872,ifg,C1334085;C1708411
2872,ada ifg,C1060325;C1334085;C1708411;C3811629
2871,ipf - related,C0034069;C1800706
2871,ipf,C0034069;C1800706
2870,immunologic,C0152036;C0205470
2870,imm only,C0205171;C0205470;C1720467
2870,imm,C0205470
2869,natalizumab ( n = $nmbr$ ) f,C0016327;C1172734
2869,la grade b  n ( % ) f,C0016327;C1881342
2869,f * >,C0016327
2869,f,C0016327
2869,ancestry ( % ) f,C0016327
2869,? f ? n,C0016327
2869,$nmbr$ f $nmbr$ q % ),C0016327
2869,$nmbr$ f $nmbr$ l % $nmbr$,C0016327
2869,$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
2869,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f,C0016327
2868,f emale,C0016327
2868,f - plasma glucose  mmol / l,C0016327;C0202042;C0455280;C1532563
2868,f $nmbr$ vs placebo,C0016327
2867,lvh by echo or ecg,C0058928;C0149721;C1655045
2867,lvh - n = $nmbr$,C0149721
2867,lvh + n = $nmbr$,C0149721
2867,lvh,C0149721
2867,lv hypertrophy  n ( % ),C0149721
2867,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
2867,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
2867,left ventricular hypertrophy * *,C0149721;C3484363
2867,left ventricular hypertrophy ( % ),C0149721;C3484363
2867,left ventricular hypertrophy  n ( % ),C0149721;C3484363
2867,left ventricular hypertrophy,C0149721;C3484363
2866,lvh by echocardiography,C0013516;C0149721
2866,lvh by echocardiogram,C0013516;C0149721;C2243117
2866,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
2865,l vs . c,C0439394;C1706495;C3642217
2865,l compared wit,C0439394;C1706495;C3642217
2865,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
2865,l / ll,C0439394;C1706495;C3642217
2865,l / c,C0439394;C1706495;C3642217
2865,l . i ( $nmbr$ . $nmbr$ ),C0021966;C0221138;C0439394;C1706495;C3642217
2865,l ( % ),C0439394;C1706495;C3642217
2865,l $nmbr$ - $nmbr$ vs placebo,C0439394;C1706495;C3642217
2865,l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$,C0439394;C1706495;C3642217
2865,l $nmbr$,C0439394;C1706495;C3642217
2865,l,C0439394;C1706495;C3642217
2865,( l ) t,C0439394;C1706495;C3642217
2865,$nmbr$ . $nmbr$ ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
2864,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
2864,mdi,C0993596;C1839839;C4049613
2864,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
2864,gff mdi,C0993596;C1839839;C4049613
2864,ff mdi,C0993596;C1839839;C4049613;C4554348
2863,id ( n = $nmbr$ ),C0009450;C0600091;C1441613
2863,id,C0009450;C0600091;C1441613
2863,( id,C0009450;C0600091;C1441613
2862,meddra smq,C1140263
2861,mestizos,C0682082
2860,omeprazole,C0028978
2859,mexican,C0240339
2858,mexico,C0025885
2857,asthma exacerbations,C0349790
2857,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
2856,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
2856,copd exacerbation : no,C0740304
2855,complex lesions ^,C0221198;C0439855;C1704241
2855,anatomic complexity characteristics,C0439855;C0502371;C1704241
2854,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2854,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2854,depression ^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2854,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2854,depressed only,C0344315;C0549249
2854,depressed and low perceived social support,C0344315;C0549249
2853,documented symptomatic chdb,C0231220;C1301725;C1609436
2853,documented mi,C1301725;C1609436;C3810814
2853,documented hypoglycaemiac,C1301725;C1609436
2853,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
2852,qd,C0332173
2852,daily exercise ( % ),C0332173
2852,d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .,C0073187;C0332173;C4484261
2852,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
2852,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
2852,d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value ),C0073187;C0332173;C4484261
2852,d $nmbr$ vs warfarin,C0073187;C0332173;C4484261
2852,d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
2852,d $nmbr$ % ( n / n ),C0073187;C0332173;C4484261
2852,d  mitral stenosis vhd ( n = $nmbr$ ),C0026269;C0073187;C0264766;C0332173;C4484261
2852,d,C0073187;C0332173;C4484261
2851,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2851,daily,C0332173
2850,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2850,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
2850,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2850,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2850,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2850,minimum  maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2850,minimum,C1524031;C1552614;C2826545
2850,median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
2850,( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
2849,maximum cimt a med an,C0806909;C1552615;C2826546
2849,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
2849,maximum,C0806909;C1552615;C2826546
2849,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2849,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
2849,average maximum common and bifurcation cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546
2849,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2848,infliximab monotherapy,C0666743
2848,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
2848,infliximab - naive ( n = $nmbr$ ),C0666743
2848,infliximab - experienced ( n = $nmbr$ ),C0666743
2848,infliximab ( n = $nmbr$ ),C0666743
2848,infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % ),C0205195;C0439272;C0666743
2848,infliximab $nmbr$ mg / kg,C0439272;C0666743
2848,combined infliximab,C0205195;C0666743
2847,infliximab,C0666743
2847,inflix  yes,C0666743;C1549445;C1705108;C1710701
2847,inflix  no,C0666743
2846,tocilizumab ( n = $nmbr$ ),C1609165
2846,tocilizumab,C1609165
2846,mra use,C0243032;C1609165;C3891069
2846,mra regimen ( n - $nmbr$ ),C0040808;C0243032;C1609165;C2945654;C3891069
2846,mra  ( % ),C0243032;C1609165;C3891069
2846,mra,C0243032;C1609165;C3891069
2845,other chd,C0280604;C3542407
2845,no family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
2845,no chd simva ( „ = $nmbr$ ),C0280604;C3542407
2845,no chd simva ( n = $nmbr$ ],C0280604;C3542407
2845,no chd simva,C0280604;C3542407
2845,no chd eze / simva ( n = $nmbr$ ),C0280604;C3542407
2845,no chd eze / simva $nmbr$ = $nmbr$ },C0280604;C3542407
2845,no chd eze / simva,C0280604;C3542407
2845,no chd,C0280604;C3542407
2845,known chd,C0205309;C0280604;C3542407
2845,family history ot chd  n ( % ),C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
2845,family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
2845,chd status §,C0280604;C0449438;C3542407
2845,chd status,C0280604;C0449438;C3542407
2845,chd simva ( „ = $nmbr$ ),C0280604;C3542407
2845,chd simva $nmbr$ = $nmbr$ ],C0280604;C3542407
2845,chd simva,C0280604;C3542407
2845,chd risk - no . ( % ),C0280604;C3542407
2845,chd eze / simva ( „ = $nmbr$ ),C0280604;C3542407
2845,chd eze / simva ( n = $nmbr$ ],C0280604;C3542407
2845,chd eze / simva,C0280604;C3542407
2845,chd deaths,C0011065;C0280604;C1306577;C3542407
2845,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
2845,chd + cl all,C0280604;C0596019;C3542407
2845,chd *  n ( % ),C0280604;C3542407
2845,chd  n ( % ),C0280604;C3542407
2845,chd,C0280604;C3542407
2844,total diuretic dose ( iv + oral ) on day $nmbr$  mg,C0012798;C0022326;C2986497;C4265176
2844,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
2844,nyha iv  n ( % ),C0022326;C1275491;C4265176
2844,nyha iv  %,C0022326;C1275491;C4265176
2844,lll / iv,C0022326;C1261077;C4265176
2844,lll - iv,C0022326;C1261077;C4265176
2844,iv nitrates,C0022326;C4265176
2844,iv ( n z $nmbr$ ),C0022326;C4265176
2844,iv ( $nmbr$ ),C0022326;C4265176
2844,iv,C0022326;C4265176
2844,dyspnea at rest ( nyha iv )  ( % ),C0022326;C0743330;C1275491;C4265176
2844,dual iv,C0022326;C0205173;C1554184;C4265176
2844,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
2843,ng ( n = $nmbr$  $nmbr$ ),C0017887;C0028074
2843,ng,C0017887;C0028074
2843,need for $nmbr$ ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
2843,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
2842,tg ’,C0337445
2842,tg §,C0337445
2842,tg > $nmbr$ . $nmbr$,C0337445
2842,tg < = $nmbr$ . $nmbr$,C0337445
2842,tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ ),C0337445;C3715113
2842,tg +,C0337445
2842,tg *,C0337445
2842,tg ( mmol / l ) c,C0337445;C1532563
2842,tg ( mmol / l ),C0337445;C1532563
2842,tg ( mmol / l  median ),C0337445;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
2842,tg,C0337445
2841,tiotropium $nmbr$ gg qd,C0017454;C0018370;C0213771;C0332173
2841,olodaterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C2934193
2841,indacaterol $nmbr$ gg qd,C0017454;C0018370;C0332173;C1722260
2841,ind $nmbr$ gg q . d . n / n ( % ),C0017454;C0018370;C4049864
2841,gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
2841,gg,C0017454;C0018370
2841,formoterol $nmbr$ gg bid,C0017454;C0018370;C0060657
2841,formoterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C0060657
2841,ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C0205999;C4554348
2841,ff $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C4554348
2841,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
2840,om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0028971;C1319635;C1705272
2840,om $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0028971;C1319635;C1705272
2840,om $nmbr$ /,C0028971;C1705272
2840,new om,C0028971;C0205314;C1705272
2839,overweight ( bmi £ $nmbr$ to < $nmbr$ ),C0497406;C0578022
2839,overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ ),C0497406;C0578022
2839,overweight,C0497406
2839,bmi $nmbr$ – $nmbr$ overweight,C0497406;C0578022
2839,$nmbr$ - $nmbr$ . $nmbr$ : overweight,C0497406
2839,$nmbr$ - $nmbr$ - $nmbr$  overweight,C0497406
2838,slo days,C0439228;C1416602;C3539661
2838,hospital stay ( days ),C0439228;C3489408
2838,hospital stay  days,C0439228;C3489408
2838,^ $nmbr$ days,C0439228
2838,> = $nmbr$ days,C0439228
2838,> $nmbr$ days,C0439228
2838,< $nmbr$ days,C0439228
2838,( iqr ) — days,C0439228
2838,$nmbr$ — $nmbr$ days,C0439228
2838,$nmbr$ days,C0439228
2838,$nmbr$ - $nmbr$ days,C0439228
2837,subacute ( $nmbr$ - $nmbr$ days ),C0205365;C0439228
2837,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2837,> = medion ( $nmbr$ days ),C0439228
2837,> = median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2837,< median { $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2837,< median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2836,> $nmbr$ days ( % ),C0439228
2836,< $nmbr$ days ( n = $nmbr$ ),C0439228
2836,< $nmbr$ days ( % ),C0439228
2836,$nmbr$ days stroke ( ischemic ),C0439228
2836,$nmbr$ days new mi or definite acute st,C0205314;C0439228;C3810814
2836,$nmbr$ days new mi,C0205314;C0439228;C3810814
2836,$nmbr$ - $nmbr$ days ( % ),C0439228
2835,vte at day $nmbr$ +,C0332173;C0439228;C0439505;C0630906
2835,use of rescue albuterol  puffs / day *,C0001927;C0332173;C0439228;C0439505;C1524063;C1533107
2835,saba puffs per day at baseline,C0332173;C0439228;C0439505;C1533107
2835,every day,C0332173;C0439228;C0439505
2835,day $nmbr$ oral glucocorticoid use — no . { % ),C0017710;C0332173;C0439228;C0439505;C0442027;C4521986
2835,current smoker ( > $nmbr$ cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
2835,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
2835,albuterol use ( sd )  puffs / day,C0001927;C0042153;C0332173;C0439228;C0439505;C0457083;C1533107;C1947944;C2699239
2835,a ngina > $nmbr$ day s previously *,C0332173;C0439228;C0439505
2835,> $nmbr$ / day,C0332173;C0439228;C0439505
2835,$nmbr$ day l,C0332173;C0439228;C0439505
2835,$nmbr$ / day,C0332173;C0439228;C0439505
2835,$nmbr$ - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
2835,$nmbr$ - day cce,C0332173;C0439228;C0439505
2835,$nmbr$ - $nmbr$ / day,C0332173;C0439228;C0439505
2834,patient status after wake - up  % of days patient woke :,C0439228;C0449437;C1170730
2833,no . of days to randomization — median ( iqr ),C0439228
2833,no . of days to homa - ir testing — median ( iqr ),C0439228
2833,lmwh within $nmbr$ days before randomization — no . / total no . ( % ),C0019139;C0439228;C3536766
2832,days without albuterol use  * %,C0001927;C0042153;C0439228;C0457083;C1947944
2832,days with heartburna ( days ),C0439228
2831,lv systolic dysfunction  n ( % ),C0023128;C0731033;C0749225;C1881413
2831,lv heart structure,C0018787;C0023128;C0731033;C1881413
2831,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
2831,lv diastolic dysfunction  n ( % ),C0023128;C0520863;C0731033;C1881413
2831,latvia,C0023128
2830,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
2830,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
2830,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
2830,location of disease  n ( % ),C0012634;C0450429;C1515974;C4284930;C4284931
2830,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
2830,location  n ( % ),C0450429;C1515974;C4284930;C4284931
2830,location,C0450429;C1515974;C4284930;C4284931
2830,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
2830,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
2830,infarct location — no . / total no . ( % ),C0021308;C0450429;C1515974;C4284930;C4284931
2830,infarct location anterior,C0021308;C0450429;C1515974;C4284930;C4284931
2830,infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ ),C0021308;C0450429;C1515974;C4284930;C4284931
2830,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
2830,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
2830,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
2830,disease location  %,C0012634;C0450429;C1515974;C4284930;C4284931
2830,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
2829,lower dose,C0445550;C1708745
2829,lower - dose,C0445550;C1708745
2829,low dose,C0445550;C1708745
2829,low - dose statin,C0360714;C0445550;C1708745
2829,low - dose edoxaban vs warfarin,C0445550;C1708745;C2975435
2829,low - dose edoxaban ( n = $nmbr$ ),C0445550;C1708745;C2975435
2829,low - dose edoxaban,C0445550;C1708745;C2975435
2829,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
2828,lower risk ( n = $nmbr$ ),C3272281;C3538919
2828,lower risk,C3272281;C3538919
2828,low risk and more symptoms ( group b ),C3272281;C3538919
2828,low risk and fewer symptoms ( group a ),C3272281;C3538919
2828,low risk ( n $nmbr$ $nmbr$ ),C3272281;C3538919
2828,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
2828,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
2828,low risk ( $nmbr$ - $nmbr$ ),C3272281;C3538919
2828,low risk,C3272281;C3538919
2828,$nmbr$ - $nmbr$ ( low risk ),C3272281;C3538919
2827,lm bifurcation treated,C0184906;C1261082;C1551056;C3146289
2827,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
2827,lm $nmbr$ bid ( n = $nmbr$ ),C1261082;C1551056
2827,lm $nmbr$ $nmbr$,C1261082;C1551056
2827,left main coronary artery  n ( % ),C1261082
2827,left main coronary artery,C1261082
2826,left side only,C3842976
2826,left - sided disease only,C0012634;C3842976
2825,left sided colitis,C2887821
2825,left - sided colitis,C2887821
2824,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
2824,left side of colon,C0227388
2823,lvh by minnesota code  no . ( % ),C0009219;C0026183;C0149721;C0805701;C3889831
2823,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
2823,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
2822,lev status,C0023556;C0449438
2822,lev - naive,C0023556
2822,lev - exposed,C0023556
2822,lev ( n   =   $nmbr$ ),C0023556
2821,leisure,C0086542
2820,left shoulder,C0524469
2819,leflunomide,C0063041
2818,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
2818,left side  n ( % ),C0205091
2818,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
2818,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
2818,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
2818,left main,C0205091;C0205225;C0443246;C1542147;C1552822
2818,left circumflex  n ( % ),C0205091;C0443246;C1552822;C1880089
2818,left - sided colitisz,C0205091;C0443246
2818,left,C0205091;C0443246;C1552822
2817,patients with low ( < $nmbr$ mg / dl ) c $nmbr$,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low { < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
2817,low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low to medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
2817,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
2817,low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low c $nmbr$ / c $nmbr$ and anti - dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low c $nmbr$ ( < $nmbr$ mg / dl )  %,C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
2817,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low - medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
2817,low - ceiling diuretic,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( > $nmbr$ . $nmbr$ and < $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( < $nmbr$ % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( < $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
2817,low ( < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( $nmbr$ - $nmbr$ )  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low ( $nmbr$ - $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2817,$nmbr$ low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2816,total score on the sgrq - c  i,C0021966;C0221138;C2964552;C3826872
2816,stratum i,C0021966;C0221138
2816,period i,C0021966;C0221138;C0439531;C1948053
2816,pde - $nmbr$ i monotherapy,C0021966;C0221138
2816,pde - $nmbr$ i,C0021966;C0221138
2816,other ' i ',C0021966;C0221138
2816,infliiimab i,C0021966;C0221138
2816,ii $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138;C1710602;C4082587
2816,i u - uj,C0021966;C0221138;C0439148
2816,i or ii,C0021966;C0221138
2816,i no . of events,C0021966;C0221138
2816,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
2816,i / ii,C0021966;C0221138;C1710602;C4082587
2816,i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
2816,i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
2816,i - ^ w « - i - $nmbr$,C0021966;C0221138
2816,i ( $nmbr$ . i ),C0021966;C0221138
2816,i & ii : fev $nmbr$ > $nmbr$ % predicted,C0021966;C0221138;C1710602;C3714541;C4082587
2816,i % $nmbr$,C0021966;C0221138
2816,i $nmbr$ ± i $nmbr$,C0021966;C0221138
2816,i $nmbr$ ± $nmbr$ ii,C0021966;C0221138;C1710602;C4082587
2816,i $nmbr$ ± $nmbr$ i,C0021966;C0221138
2816,i $nmbr$ i ± i $nmbr$,C0021966;C0221138
2816,i $nmbr$ i ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
2816,i $nmbr$ i $nmbr$ ± $nmbr$,C0021966;C0221138
2816,i $nmbr$ i,C0021966;C0221138
2816,i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,C0021966;C0221138
2816,i $nmbr$ ( i $nmbr$ . i ),C0021966;C0221138
2816,i $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
2816,i,C0021966;C0221138
2816,ffa / i,C0015688;C0021966;C0221138
2816,ciass i,C0021966;C0221138
2816,bm i < $nmbr$,C0006416;C0021966;C0221138
2816,aqe i $nmbr$,C0021966;C0221138
2816,antithrombotic ! i,C0021966;C0221138
2816,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
2816,> o - $nmbr$ - i - i,C0021966;C0221138;C0483204
2816,> i,C0021966;C0221138
2816,< $nmbr$ kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
2816,- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ ),C0016327;C0021966;C0221138
2816,- b - i —,C0021966;C0221138
2816,- b - i -,C0021966;C0221138
2816,( i - blocker,C0021966;C0221138
2816,$nmbr$ — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
2816,$nmbr$ t i,C0021966;C0221138;C2603360
2816,$nmbr$ i - $nmbr$ - $nmbr$ ai,C0003504;C0021966;C0221138;C4551710
2816,$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ ),C0021966;C0221138
2816,$nmbr$ . i ± ii . $nmbr$,C0021966;C0221138;C1710602;C4082587
2816,$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ ),C0021966;C0221138
2816,$nmbr$ . $nmbr$ to . $nmbr$ . i . iot,C0006196;C0021966;C0221138
2816,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a,C0021966;C0221138
2816,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0021966;C0221138
2816,$nmbr$ . $nmbr$ ( io . i ),C0021966;C0221138;C1046794;C3146236
2816,$nmbr$ . $nmbr$ ( i $nmbr$ . s ),C0021966;C0221138
2816,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i ),C0021966;C0221138
2816,$nmbr$ - i,C0021966;C0221138
2816,$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i,C0021966;C0221138
2816,$nmbr$ ( $nmbr$ i . i ),C0021966;C0221138
2815,ecg - lvh ( sokolow - lyon ),C0232306
2815,ecg - lvh ( cornell ),C0232306
2815,baseline ecg with lvh  n ( % ),C0168634;C0232306;C1442488
2814,lvh on ecg,C0232306
2814,lvh by ecg or echocardiographyd,C0232306
2814,lvh by ecg or echocardiography  no ( % ),C0232306
2814,lvh by ecg or echo . n ( % ),C0232306
2814,lvh by ecg / echo,C0058928;C0232306;C1655045
2814,lvh by ecg,C0232306
2814,lv hypertrophy per ecg,C0232306
2813,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
2813,post - bronchodilator fevi $nmbr$ % predicted,C0849974;C1561566;C2599594;C4528367
2813,post - bronchodilator fevi  n ( % ),C0429706;C0849974;C1561566;C2599594;C4528367
2813,fevi percent predicted ( % ),C0429706;C0439165;C0849974;C1561566;C4528367
2813,fevi auc $nmbr$ - $nmbr$ l,C0376690;C0429706;C0849974;C1561566;C4528367
2813,fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
2813,fevi  l *,C0429706;C0849974;C1561566;C4528367
2813,fevi  l,C0429706;C0849974;C1561566;C4528367
2813,fevi  % predicted *,C0849974;C1561566;C4528367
2813,fevi  % predicted  mean ( sd ) $nmbr$,C0849974;C1561566;C4528367
2813,$nmbr$ ( fevi ^ $nmbr$ % pred ),C0849974;C1561566;C4528367
2813,$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred ),C0849974;C1561566;C4528367
2812,qrs interval > $nmbr$ msec — no . ( % ),C0439223;C0520880
2812,qrs > $nmbr$ msec $nmbr$ - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
2812,qrs < $nmbr$ msec,C0439223
2811,predose fvc ( l ) *,C0439565;C3714541;C3812758
2811,predose fvc ( l ),C0439565;C3714541;C3812758
2811,predose fev / fvc,C0439565;C3714541;C3812758
2811,predose fev -  at randomization,C0034656;C0439565;C3714541;C3812758
2811,predose fev $nmbr$ ( l ) *,C0439565;C3714541;C3812758
2811,pre - dose,C0439565;C3812758
2810,brv overalla ( n = $nmbr$ ),C0155502
2810,brv overall ( n = $nmbr$ ),C0155502;C0282416;C1561607
2810,brv overall,C0155502
2810,brv dosage  mg / d,C0155502;C0178602;C0439422;C2986497
2810,brv > $nmbr$ mg / day,C0155502;C0439422
2810,brv $nmbr$   mg / day,C0155502;C0439422
2810,brv $nmbr$ mg / day ( n = $nmbr$ ),C0155502;C0439422
2810,brv $nmbr$ mg / day ( n =,C0155502;C0439422
2809,prior smoker,C0337671
2809,previous smokers,C0337671
2809,previous smoker,C0337671
2809,former smokers,C0337671
2809,former smoker — no . { % ),C0337671
2809,former smoker — no . ( % ),C0337671
2809,former smoker ( n = $nmbr$ ),C0337671
2809,former smoker ( n = $nmbr$  $nmbr$ ),C0337671
2809,former smoker  n ( % ),C0337671
2809,former smoker,C0337671
2809,exsmoker,C0337671;C4555205
2809,ex - smokers : qvai $nmbr$ - sfc,C0337671;C4521536;C4555205
2809,ex - smokers ( n = $nmbr$ ),C0337671;C4555205
2809,ex - smokers ( itt ) ( n = $nmbr$ ),C0337671;C4555205
2809,ex - smokers $nmbr$,C0337671;C4555205
2809,ex - smokers,C0337671;C4555205
2809,ex - smoker / smoker  %,C0337671;C4555205
2809,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
2809,ex - smoker ( n z $nmbr$ ),C0337671;C4555205
2809,ex - smoker,C0337671;C4555205
2808,nonsmoker  n ( % ),C0337672;C0425293;C4554605
2808,nonsmoker,C0337672;C0425293;C4554605
2808,non - smoker ( n = $nmbr$  $nmbr$ ),C0337672;C0425293;C4554605
2808,non - smoker,C0337672;C0425293;C4554605
2808,never smoker,C0425293
2807,patients with only mrf hr ( $nmbr$ % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
2807,mrf subjects,C0312443;C1412879
2807,mrf,C0312443;C1412879
2806,less than $nmbr$ year,C0439092;C0439234;C0439508
2806,less than $nmbr$ mm hg,C0439092;C0439475
2806,less than $nmbr$ kg / m $nmbr$,C0439092;C1532718
2806,less than $nmbr$ . $nmbr$ %,C0439092
2806,less than $nmbr$ %,C0439092
2806,less than $nmbr$,C0439092
2805,bosentan use :,C0042153;C0252643;C0457083;C1947944
2805,bosentan ( n = $nmbr$ ),C0252643
2805,bosentan,C0252643
2804,lost bmd,C0745777;C3815882
2803,post - dose,C0439568
2802,post - mi,C0856742
2801,losartan plus lisinopril ( n = $nmbr$ ),C0065374;C0126174;C0332287
2801,losartan n = $nmbr$,C0126174
2801,losartan + placebo,C0032042;C0126174;C1696465;C1706408
2801,losartan + lisinopril,C0065374;C0126174
2801,losartan ( n = $nmbr$ ),C0126174
2801,losartan ( n = $nmbr$  $nmbr$ ),C0126174
2801,losartan  n / n ( % ),C0126174
2801,losartan,C0126174
2801,chf on losartan ( % ),C0018802;C0126174
2800,psa ‐ modified shs of hands and feet,C0018563;C0392747;C1552914;C3810537;C3813209;C3889737
2800,psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale ),C0392747;C3810537;C3813209;C3889737
2800,psa subtypes  n ( % ),C0449560;C3810537;C3813209
2800,psa reported  n ( % ),C3810537;C3813209
2800,psa - modified total shs,C3810537;C3813209
2800,psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
2800,psa - modified shs ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
2800,psa - modified mases score ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
2800,psa ( ng / ml ),C0439275;C3810537;C3813209
2800,psa ( n = $nmbr$ ),C3810537;C3813209
2800,psa,C3810537;C3813209
2800,no psa ( n = $nmbr$ ),C3810537;C3813209
2800,no psa,C3810537;C3813209
2799,pt . years = $nmbr$,C0032743;C0439234;C0699718
2799,pt,C0032743;C0699718
2798,pts,C1419129;C2698747
2798,no . pts,C1419129;C2698747
2798,# pts,C1419129;C2698747
2797,proton pump inhibitors,C0358591;C1384478;C3540020
2797,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
2797,proton pump inhibitor ( n  % ),C0358591;C3536754;C4521480
2797,proton pump inhibitor,C0358591;C3536754;C4521480
2797,proton - pump inhibitors,C0358591;C1384478;C3540020
2797,proton - pump inhibitor,C0358591;C3536754;C4521480
2796,regular ppi use,C0205272;C0358591;C0871125;C3811894
2796,ppi use within $nmbr$ months of randomization,C0358591;C0871125;C3811894
2796,ppi use at baseline,C0358591;C0871125;C3811894
2796,ppi use ( p = $nmbr$ . $nmbr$ t ),C0358591;C0871125;C3811894
2796,ppi use ( p = $nmbr$ - $nmbr$ t ),C0358591;C0871125;C3811894
2796,ppi use,C0358591;C0871125;C3811894
2796,ppi or h $nmbr$ receptor antagonist  n ( % ),C0358591;C0871125;C3811894
2796,ppi but no aspirin,C0358591;C0871125;C3811894
2796,ppi,C0358591;C0871125;C3811894
2796,nontrial ppi,C0358591;C0871125;C3811894
2796,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
2796,no regular ppi use,C0205272;C0358591;C0871125;C3811894
2796,no ppi,C0358591;C0871125;C3811894
2795,pump,C0182537
2795,off pump,C0182537;C1518543
2795,off - pump,C0182537;C1518543
2794,on pump,C3842462
2794,on - pump,C3842462
2793,puva,C0853073;C1704892
2792,uvb,C0454530;C0564461
2791,other outcomes,C1274040
2791,ischemic outcomes,C0475224;C1274040
2791,baseline outcomes,C0168634;C1274040;C1442488
2791,adverse outcome,C1274040
2790,result,C1274040;C1546471;C2825142
2790,ancova result,C0814908;C1274040;C1546471;C2825142
2789,outcomes,C1274040
2789,outcome type,C0332307;C1274040;C1547052
2789,outcome severity,C0439793;C0522510;C1274040
2789,outcome and metabolizer phenotype,C1274040
2789,outcome - variant,C0205419;C1274040
2789,outcome ( n  % },C1274040
2789,outcome,C1274040
2788,trend / het . test,C1521798;C4554533
2788,pvaluefor trend,C1521798;C4554533
2788,p value for trend across tertiles,C1521798;C1709380;C4554533
2788,p value for trend *,C1521798;C1709380;C4554533
2788,p value for trend,C1521798;C1709380;C4554533
2788,p trend,C0369773;C1521798;C2603361;C4554533
2788,p j $nmbr$ * trend,C1518835;C1521798;C4554533
2788,p for trend -,C0369773;C1521798;C2603361;C4554533
2788,p for trend,C0369773;C1521798;C2603361;C4554533
2788,p - value for trend across categories,C1521798;C1709380;C4554533
2788,p - value for trend *,C1521798;C1709380;C4554533
2788,p - value ( trend ),C1521798;C1709380;C4554533
2787,with laba  n ( % ) pretreatment,C1550147;C2709094;C3539075;C3539076
2787,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
2787,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
2787,pre - treatment [ n ( % ) ] c,C1550147;C2709094;C3539075;C3539076
2787,no pretreatment,C1550147;C2709094;C3539075;C3539076
2787,high - dose statin pretreatment ( n = $nmbr$ ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
2787,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
2787,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
2787,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
2787,$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ ),C0439590;C1550147;C2709094;C3539075;C3539076
2786,persistent wrf ( n = $nmbr$ ),C0205322;C0332996
2786,persistent or permanent immobilization,C0205322;C0332996
2786,persistent or paroxysmal,C0205322;C0332996
2786,persistent faol ( n [ $nmbr$ ),C0205322;C0332996
2786,persistent faod ( n [ $nmbr$ ),C0205322;C0332996
2786,persistent af  n ( % ),C0205322;C0332996;C0344434;C4049859
2786,persistent af,C0205322;C0332996;C0344434;C4049859
2786,persistent / permanent,C0205322;C0205355;C0332996
2786,persistent *,C0205322;C0332996
2786,persistent ( n  % ),C0205322;C0332996
2786,persistent  n ( % ),C0205322;C0332996
2786,persistent,C0205322;C0332996
2786,no persistent wrf ( n = $nmbr$  $nmbr$ ),C0205322;C0332996
2786,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
2785,penetrating no . of resections  n ( % ),C0205321
2785,penetrating disease  %,C0012634;C0205321
2785,penetrating,C0205321
2784,pef !,C0030771;C1518922;C1542834
2784,pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834
2783,emphysema ( n = $nmbr$ ),C0013990;C0034067
2783,emphysema ( itt ) ( n = $nmbr$ ),C0013990;C0034067
2783,emphysema ( % ),C0013990;C0034067
2783,emphysema,C0013990;C0034067
2782,qmax category  n ( % ) :,C0683312;C3889287
2782,mace category  n ( % ) [ ir ],C0022065;C0022071;C0349381;C0683312;C0949745;C1445339;C1448132;C3889287
2782,hemoglobin category,C0019046;C0683312;C3889287
2782,glycatedhemoglobin category  %,C0683312;C3889287
2782,egfr category  n ( % ),C0683312;C1739039;C3811844;C3812682;C3889287
2782,category — no . / total no . ( % ),C0683312;C3889287
2782,category $nmbr$ and $nmbr$,C0683312;C3889287
2782,category $nmbr$,C0683312;C3889287
2782,category,C0683312;C3889287
2782,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
2782,categorical variables,C0439828;C0683312;C3889287
2782,cardiovascular disease risk category,C0683312;C1113685;C3889287
2782,bmi category,C0578022;C0683312;C3889287
2782,background csdmard category,C0683312;C1706907;C3889287
2782,age category >,C0001779;C0683312;C3889287
2782,age category ( years )  n ( % ),C0683312;C1510829;C3889287
2782,age category ( % ),C0001779;C0683312;C3889287
2782,age category  n ( % ) < $nmbr$ years,C0683312;C1510829;C3889287
2782,age category  n ( % ) :,C0001779;C0683312;C3889287
2782,age category  n ( % ),C0001779;C0683312;C3889287
2782,age category,C0001779;C0683312;C3889287
2782,/ \ge category,C0683312;C1292300;C3538705;C3889287
2781,eo severity by la classification at baseline ( baseline of the healing study )  n ( % ),C0332120;C0439793;C0522510;C1881447
2781,eo,C0332120
2780,minority,C0026192
2779,nationality,C0027473
2778,abdominal obesity *,C0311277
2778,abdominal obesity,C0311277
2777,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
2777,abnormal,C0205161;C2347472;C2699333
2776,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
2776,anemia ( % ),C0002871;C1000483;C4554633
2776,anemia  no . / total ( % ) ”,C0002871;C1000483;C4554633
2776,anemia  %,C0002871;C1000483;C4554633
2776,anemia,C0002871;C1000483;C4554633
2775,medal,C0524670
2774,dermal,C0221928;C1522447
2773,americas * *,C0002454;C0596070
2773,americas ( n = $nmbr$ ),C0002454;C0596070
2773,americas  excluding us,C0002454;C0596070
2773,americas,C0002454;C0596070
2773,american,C0596070
2772,n america,C0002454;C0369718;C0441922
2772,america,C0002454
2771,range race  n ( % ),C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
2771,racial group  n ( % ),C0034510;C0441848;C1706779;C3669213;C3853635
2771,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
2771,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
2771,race_white  %,C0034510;C1706779;C3853635
2771,race — no . { % ) - i -,C0034510;C1706779;C3853635
2771,race — no . { % ) ' i ',C0034510;C1706779;C3853635
2771,race — no . / total no . ( % ) f,C0034510;C1706779;C3853635
2771,race — no . ( % ) 卞,C0034510;C1706779;C3853635
2771,race — no . ( % ) |,C0034510;C1706779;C3853635
2771,race — no . ( % ) f,C0034510;C1706779;C3853635
2771,race — no . ( % ) : t,C0034510;C1706779;C3853635
2771,race — no . ( % ) : c,C0034510;C1706779;C3853635
2771,race — no . ( % ) ' (,C0034510;C1706779;C3853635
2771,race — no . ( % ),C0034510;C1706779;C3853635
2771,race §,C0034510;C1706779;C3853635
2771,race white,C0034510;C1706779;C3853635
2771,race or ethnicity  n ( % ),C0034510;C1706779;C3853635
2771,race or ethnicity,C0034510;C1706779;C3853635
2771,race or ethnic origin,C0034510;C1706779;C3853635
2771,race or ethnic group — no . { % ) ■ ' ( white,C0034510;C1706779;C3853635
2771,race or ethnic group — no . f,C0034510;C1706779;C3853635
2771,race or ethnic group — no . / total no . ( % ) f,C0034510;C1706779;C3853635
2771,race or ethnic group — no . ( % ) f,C0034510;C1706779;C3853635
2771,race or ethnic group — no . ( % ) : t,C0034510;C1706779;C3853635
2771,race or ethnic group ( % ) f,C0034510;C1706779;C3853635
2771,race or ethnic group ( % ),C0034510;C1706779;C3853635
2771,race or ethnic group  no . ( % ),C0034510;C1706779;C3853635
2771,race or ethnic group  n ( % ) *,C0034510;C1706779;C3853635
2771,race or ethnic group,C0034510;C1706779;C3853635
2771,race or ethnic background — no . ( % ) f,C0034510;C1706779;C3853635
2771,race nonwhitet,C0034510;C1706779;C3853635
2771,race n ( % ),C0034510;C1706779;C3853635
2771,race and ss at baseline,C0034510;C1706779;C3853635
2771,race : white,C0034510;C1706779;C3853635
2771,race : non - white,C0034510;C1706779;C3853635
2771,race :,C0034510;C1706779;C3853635
2771,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
2771,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
2771,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
2771,race / ethnicity  zz ( % ),C0015031;C0034510;C0243103;C1706779;C2347310;C3853635
2771,race / ethnicity  no . ( % ) *,C0015031;C0034510;C0243103;C1706779;C3853635
2771,race / ethnicity  no . ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
2771,race / ethnicity  n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
2771,race / ethnicity  % white non - hispanic,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1518422;C1518424;C1533020;C1533021;C1706779;C3853635
2771,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
2771,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
2771,race - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
2771,race - nonwhite,C0034510;C1706779;C3853635
2771,race - non - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
2771,race - non - white,C0034510;C1706779;C3853635
2771,race - no . ( % ),C0034510;C1706779;C3853635
2771,race - n ( % ),C0034510;C1706779;C3853635
2771,race *,C0034510;C1706779;C3853635
2771,race ( white  n [ % ] ),C0034510;C1706779;C3853635
2771,race ( p = o - $nmbr$ ),C0034510;C1706779;C3853635
2771,race ( non - white ) ( % ),C0034510;C1706779;C3853635
2771,race ( % white ),C0034510;C1706779;C3853635
2771,race ( % ) white,C0034510;C1706779;C3853635
2771,race ( % ) *,C0034510;C1706779;C3853635
2771,race ( % ) ) ',C0034510;C1706779;C3853635
2771,race ( % ) $,C0034510;C1706779;C3853635
2771,race ( % ),C0034510;C1706779;C3853635
2771,race $nmbr$,C0034510;C1706779;C3853635
2771,race    n   ( % ),C0034510;C1706779;C3853635
2771,race  zz ( % ),C0034510;C1706779;C3853635
2771,race  white ( % ),C0034510;C1706779;C3853635
2771,race  white    n   ( % ),C0034510;C1706779;C3853635
2771,race  white  n ( % of patients ),C0034510;C1706779;C3853635
2771,race  white  n ( % ),C0034510;C1706779;C3853635
2771,race  while,C0034510;C1706779;C3853635
2771,race  nonwhite,C0034510;C1706779;C3853635
2771,race  non - white,C0034510;C1706779;C3853635
2771,race  no . / total ( % ),C0034510;C1706779;C3853635
2771,race  no . ( % ) white,C0034510;C1706779;C3853635
2771,race  no . ( % ) c,C0034510;C1706779;C3853635
2771,race  no . ( % ) b,C0034510;C1706779;C3853635
2771,race  no . ( % ) *,C0034510;C1706779;C3853635
2771,race  no . ( % ),C0034510;C1706779;C3853635
2771,race  n ( % ],C0034510;C1706779;C3853635
2771,race  n ( % ) ’,C0034510;C1706779;C3853635
2771,race  n ( % ) y,C0034510;C1706779;C3853635
2771,race  n ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
2771,race  n ( % ) t,C0034510;C1706779;C3853635
2771,race  n ( % ) b,C0034510;C1706779;C3853635
2771,race  n ( % ) a,C0034510;C1706779;C3853635
2771,race  n ( % ) :,C0034510;C1706779;C3853635
2771,race  n ( % ) +,C0034510;C1706779;C3853635
2771,race  n ( % ) *,C0034510;C1706779;C3853635
2771,race  n ( % ),C0034510;C1706779;C3853635
2771,race  black or african - american  n ( % ),C0034510;C1706779;C3853635
2771,race  asian  n ( % ),C0034510;C1706779;C3853635
2771,race  * ’ n ( % ),C0034510;C1706779;C3853635
2771,race  % white,C0034510;C1706779;C3853635
2771,race  % nonwhite,C0034510;C1706779;C3853635
2771,race  % caucasian,C0034510;C1706779;C3853635
2771,race  %,C0034510;C1706779;C3853635
2771,race,C0034510;C1706779;C3853635
2771,other race  n ( % ),C0034510;C1706779;C3853635
2771,other race,C0034510;C1706779;C3853635
2771,nonwhite race !,C0034510;C1706779;C3853635
2771,nonwhite race,C0034510;C1706779;C3853635
2771,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
2771,$ race was determined by the investigator during the patient ' s interview .,C0034510;C1706779;C3853635
2770,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
2770,magnetic resonance angiography,C0243032
2769,duration of prior alendronate use  months,C0102118;C0332152;C0439231;C1881378;C2826257;C2826775
2769,alendronate ( n = $nmbr$ ),C0102118
2769,alendronate,C0102118
2768,ranolazine vs . placebo km failure rate,C0073633
2768,ranolazine n = $nmbr$,C0073633
2768,ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ ),C0032042;C0073633;C1696465;C1706408
2768,ranolazine ( n = $nmbr$ ),C0073633
2768,ranolazine ( n = $nmbr$  $nmbr$ ),C0073633
2768,ranolazine ( n $nmbr$ $nmbr$ ),C0073633
2768,ranolazine  n   =   $nmbr$,C0073633
2768,ranolazine  n = i $nmbr$ i $nmbr$,C0021966;C0073633;C0221138
2768,ranolazine,C0073633
2767,cangrelor n / n ( % ),C1121991
2767,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
2767,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C1121991
2767,cangrelor ( n = $nmbr$ ) n / n ( % ),C1121991
2767,cangrelor ( n = $nmbr$ ),C1121991
2767,cangrelor  %,C1121991
2767,cangrelor,C1121991
2766,hospitalized angina,C0002962;C0701159
2766,hospitaiization for angina,C0002962
2766,current angina ( % ),C0002962;C0521116;C1705970
2766,current angina,C0002962;C0521116;C1705970
2766,angina .,C0002962
2766,angina,C0002962
2765,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
2765,angina status — no . ( % ),C0002962;C0449438
2765,angina pectoris — no . ( % ),C0002962
2765,angina pectoris  ( % ),C0002962
2765,angina or positive stress test,C0002962
2765,angina or acute mi,C0002962
2765,angina ( past $nmbr$ weeks ),C0002962;C2987125
2765,angina  n ( % ),C0002962
2764,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C2826257
2764,prior angina pectoris,C0002962;C0332152;C2826257
2764,prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
2764,prior angina  n / n ( % ),C0002962;C0332152;C2826257
2764,prior angina,C0002962;C0332152;C2826257
2764,no prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
2764,angina pectorisf,C0002962
2764,angina pectoris 本,C0002962
2764,angina pectoris *,C0002962
2764,angina pectoris,C0002962
2763,anakinra,C0245109
2762,canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
2762,canakinumab,C2718773
2762,all canakinumab,C2718773
2761,noncomplex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0700276;C1384516
2761,complex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0439855;C0700276;C1384516;C1704241
2761,anatomy,C0002808;C0700276;C1384516
2760,or for cana vs pbo ( $nmbr$ % ci ) §,C1418845
2760,or for cana vs pbo ( $nmbr$ % ci ) | |,C1418845
2760,cana $nmbr$ / met ( n = $nmbr$ ),C1418845
2760,cana $nmbr$ ( n = $nmbr$ ),C1418845
2760,cana,C1418845
2760,all cana,C1418845
2759,patients without syndesmophytes at baseline,C0030705;C0221690
2759,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
2759,patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
2759,patients with syndesmophytes at baseline,C0030705;C0221690
2759,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
2759,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
2759,patients with normoalbuminuria at baseline,C0030705
2759,patients with no prior cvd ( primary,C0007222;C0030705;C0332152;C2826257
2759,patients with microalbuminuria at baseline,C0030705;C0730345
2759,patients with macroalbuminuria at baseline,C0030705
2759,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *,C0017853;C0030705
2759,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *,C0017853;C0030705
2759,patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis,C0017853;C0030705
2759,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
2759,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
2759,patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
2759,patients taking oral corticosteroids at baseline  n ( % ),C0030705
2759,patients receiving immunosuppressive agents at baseline,C0030705
2759,patients receiving corticosteroids at baseline,C0030705
2759,patients not receiving immunosuppressive agents at baseline,C0030705
2759,patients not receiving corticosteroids at baseline,C0030705
2759,patients meeting the criteria to receive $nmbr$ mg of,C0030705
2759,of patients meeting criterion / total no . of patients,C0030705
2758,no . ( % ) of patients with ≥ $nmbr$ % bsa affected,C0030705
2758,no . ( % ) of patients with stroke,C0030705
2758,no . ( % ) of patients with atrial tachyarrhythmia,C0030705
2758,n ( % ) patients with risk faetors for cv disease aged > $nmbr$,C0030705;C0035647;C0369718;C0441922;C4552904
2757,randomised patients with enthesitis at baselinet,C0030705;C1282952
2757,patients without ra  as  or psa ( n = $nmbr$  $nmbr$ ),C0030705;C3538806;C4048756
2757,patients without draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
2757,patients without diabetesb,C0030705
2757,patients without diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
2757,patients without diabetes,C0011847;C0011849;C0030705
2757,patients without chronic,C0030705;C0205191
2757,patients without,C0030705
2757,patients with radiographic erosion  n / n ( % ),C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
2757,patients with ra  as  or psa ( n = $nmbr$ ),C0030705;C3538806;C4048756
2757,patients with pulmonary embolism,C0030705;C0034065
2757,patients with perianal fistulae  n [ % ],C0030705;C0267561
2757,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
2757,patients with nail psoriasis ( mnapsi > $nmbr$ ),C0030705;C0406322
2757,patients with measurement,C0030705;C0242485
2757,patients with improvement $ $nmbr$ . $nmbr$,C0030705;C2986411
2757,patients with fistulas at baseline,C0016169;C0030705
2757,patients with fingernail involvement,C0030705;C0222001;C1314939
2757,patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score,C0030705;C1282952
2757,patients with enthesitis at week $nmbr$  n ( % ),C0030705;C1282952
2757,patients with enthesitis at baseline  no .,C0030705;C1282952
2757,patients with enthesitis ( lei > $nmbr$ ),C0023401;C0030705;C0428209;C1282952
2757,patients with enthesitis  no . ( % ),C0030705;C1282952
2757,patients with enthesitis  n ( % ),C0030705;C1282952
2757,patients with enthesitis,C0030705;C1282952
2757,patients with end point,C0030705;C2349179;C2826544
2757,patients with draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
2757,patients with digits with dactylitis  n ( % ),C0030705;C0582802
2757,patients with diabetesb,C0030705
2757,patients with diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
2757,patients with diabetes mellitus,C0011849;C0030705
2757,patients with diabetes,C0011847;C0011849;C0030705
2757,patients with chronic,C0030705;C0205191
2757,patients with > $nmbr$ co - aeds,C0030705;C0180309;C3245499
2757,patients with > $nmbr$ % bsa,C0030705
2757,patients with $nmbr$ co - aeds,C0030705;C0180309;C3245499
2757,patients with $nmbr$ co - aed,C0030705;C0887457;C3245499
2757,patients who received $nmbr$ or $nmbr$ drugs,C0030705
2757,patients who received $nmbr$ drug,C0030705
2757,patients using concurrent tiotropium,C0030705
2757,patients treated with statins ( n = $nmbr$ ),C0030705
2757,patients treated with losartan ( n = $nmbr$ ),C0030705
2757,patients treated with insulin,C0030705
2757,patients treated with atenoloi ( n = $nmbr$ ),C0030705
2757,patients treated for > $nmbr$ weeks ( % ),C0030705
2757,patients treated and operated  n ( % ),C0030705
2757,patients treated,C0030705
2757,patients total no .,C0030705
2757,patients receiving statin,C0030705
2757,patients receiving mtx  n =,C0030705
2757,patients receiving mtx,C0030705
2757,patients receiving lcz  no . ( % ),C0030705
2757,patients receiving immunotherapy  no . ( % ),C0030705
2757,patients receiving enl  no . ( % ),C0030705
2757,patients receiving any uc medication  n ( % ),C0030705
2757,patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f,C0030705
2757,patients not treated with statins ( n = $nmbr$ ),C0030705
2757,patients not receiving statin,C0030705
2757,patients not receiving mtx  n =,C0030705
2757,patients assessed,C0030705
2757,patients > $nmbr$ y *,C0030705
2757,patients > $nmbr$ y,C0030705
2757,patients > $nmbr$ %,C0030705
2757,patients < $nmbr$ y *,C0030705
2757,patients < $nmbr$ y,C0030705
2757,patients < $nmbr$ %,C0030705
2757,patients ( treated set * )  n,C0030705
2757,patients ( n ),C0030705
2757,patients ( ft ),C0030705
2757,patients  no .,C0030705
2757,patient - reported hypertension — no . { % ),C0030705
2757,no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ ),C0030705
2757,no . ( % ) of patients with fingernail involvement,C0030705
2757,all patients with fistulas ( n = $nmbr$ ),C0016169;C0030705
2756,patients with pneumonia resulting in death  n ( % ),C0030705;C0032285
2756,patients with pneumonia events  n ( % ) #,C0030705;C0032285;C0441471;C3541888
2756,patients with pneumonia event  n ( % ) #,C0030705;C0032285;C0441471;C4019010
2756,patients with event / patients analyzed,C0030705;C0441471;C4019010
2756,patients with event / patients analysed,C0030705;C0441471;C4019010
2756,patients with event / analyzed,C0030705;C0441471;C4019010
2756,patients with event ( n  % ),C0030705;C0441471;C4019010
2756,patients with endpoin t  n ( % ),C0030705
2756,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
2756,patients with any clinical,C0030705;C0205210
2756,patients with an event per $nmbr$ patient - years,C0030705;C0441471;C4019010
2756,patients taking mtx  no . ( % ),C0030705
2756,patients taking mtx  n ( % ),C0030705
2756,patients aged > $nmbr$ y  no  ( ss ),C0030705
2756,patients    n   ( % ),C0030705
2756,patients  no . / total no . ( % ),C0030705
2756,patients  n / n ( % ) a,C0030705
2756,no . ( % ) with event [ incidence rate per $nmbr$ patient - y ],C0030705;C0441471;C1708485;C4019010
2755,patients with prior ml hr ( $nmbr$ % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
2755,patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C3887665
2755,patients entering pt period n = $nmbr$,C0030705
2754,subset of patients on metformin,C0030705;C1515021
2754,subset of patients not on metformin,C0030705;C1515021
2754,randomised patients with spondylitis at baseline  n,C0030705;C0038012
2754,patients  n ( % ),C0030705
2754,obese patients  ! n ( % ),C0028754;C0030705
2754,no . patients with,C0030705
2754,no . patients ( % ),C0030705
2754,no . of patients with ra,C0030705
2754,no . of patients with psa,C0030705
2754,no . of patients with events ( % ),C0030705
2754,no . of patients with as,C0030705
2754,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
2754,no . of patients / total no . ( % ),C0030705
2754,no . of patients / no . of events,C0030705
2754,no . of patients ( % ),C0030705
2754,itt patients  n ( % ),C0030705
2754,for patients using personal cgm,C0030705
2754,for patients not using personal cgm,C0030705
2754,all patients with opg n - $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
2754,all patients n = $nmbr$ $nmbr$,C0030705
2754,all patients n = $nmbr$,C0030705
2754,all patients ( « = $nmbr$ $nmbr$ ),C0030705
2754,all patients ( p = $nmbr$ . $nmbr$ ),C0030705
2754,all patients ( p < $nmbr$ . $nmbr$ ),C0030705
2754,all patients ( n   =   $nmbr$ ) b,C0030705
2754,all patients ( n = $nmbr$ ),C0030705
2754,all patients ( n = $nmbr$  $nmbr$ ),C0030705
2754,all patients ( n $nmbr$ $nmbr$ ),C0030705
2754,all patients  n =,C0030705
2754,aii patients ( n = $nmbr$ ),C0030705;C1424250;C2698414
2754,% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$,C0030705
2753,vents / patients,C0030705
2753,percentages of patients with event,C0030705;C0439165;C1549488;C1561533
2753,percentage patients reaching target,C0030705;C0439165;C1549488;C1561533
2753,percentage of patients with event,C0030705;C0439165;C1549488;C1561533
2753,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C1549488;C1561533
2753,percentage of patients receiving dose adjustment,C0030705;C0439165;C1549488;C1561533
2753,percent of patients,C0030705;C0439165
2753,of patients,C0030705
2753,all patients,C0030705
2753,( $nmbr$ patients ),C0030705
2753,% patients,C0030705
2752,randomised patients with dactylitis at baseline,C0030705;C0239161
2752,patients with dactylitisa,C0030705
2752,patients with dactylitis at week $nmbr$  n ( % ),C0030705;C0239161
2752,patients with dactylitis at baseline  no .,C0030705;C0239161
2752,patients with dactylitis  no . ( % ),C0030705;C0239161
2752,patients with dactylitis,C0030705;C0239161
2752,patients with $ $nmbr$ % bsa at baseline  no .,C0030705
2752,patients who used insulin pump,C0030705
2752,patients who received positive results on test for antibodies to infliximabt,C0030705
2752,patients who received negative results on test for antibodies to infliximabt,C0030705
2752,patients who received indeterminate results on test for antibodies to infliximabt,C0030705
2752,patients who had ulcerations at,C0030705
2752,patients who did not use insulin pump,C0030705
2752,patients randomly assigned,C0030705
2752,patients randomized  no .,C0030705
2752,patients randomized  n,C0030705
2752,patients randomized,C0030705
2752,patients randomised  n,C0030705
2752,patients on atorvastatin  rosuvastatin  or simvastatin at,C0030705;C0286651;C0965129
2752,patients included in analysis,C0030705
2752,patients in analysis  n,C0002778;C0030705;C0936012;C1524024
2752,patients having exacerbation,C0030705
2752,patients analyzed  n,C0030705
2752,patient presentation,C0030705;C0449450
2752,patient population,C0030705;C0032659;C1257890
2752,patient classification,C0008902;C0008903;C0030705;C0678229
2752,patient characteristic,C0030705
2751,remaining patients,C0030705;C1527428
2751,race  % of patients,C0030705;C0034510;C1706779;C3853635
2751,no . of patients,C0030705
2751,no . of hospitalised patients,C0030705
2751,anti - tnf - naive patients $nmbr$,C0030705;C1448177
2751,anti - tnf - naive patients,C0030705;C1448177
2751,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
2751,anti - tnf - experienced patients,C0030705;C1448177
2750,patients n,C0030705
2750,patients  n,C0030705
2750,patients,C0030705
2750,patient years,C0030705;C0439234
2750,patient,C0030705
2750,number ol ( % ) patients > $nmbr$ years,C0030705;C0237753;C0439234;C0449788
2750,ard ( $nmbr$ % cl ) per $nmbr$ patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
2749,randomized patients,C0030705;C0034656;C3815594
2749,randomised patients ( n ),C0030705
2749,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
2749,all randomized patients,C0030705;C0034656;C3815594
2748,other / missing,C1551393;C1705492;C3272743
2748,missing hb at yr $nmbr$,C0019046;C0439234;C1551393;C1705492;C3272743
2748,missing *,C1551393;C1705492;C3272743
2748,missing  n ( % ) a,C1551393;C1705492;C3272743
2748,missing,C1551393;C1705492;C3272743
2748,hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .,C0001779;C0005767;C0005768;C0012000;C0020261;C0030705;C0229664;C1551393;C1705492;C3272743
2747,poslmenopausal  ht,C0018510;C0677607
2746,premenopausal  %,C0279752
2746,premenopausal,C0279752
2745,menopause and ht,C0025320;C0567312
2745,menopause and hrt,C0025320;C0567312
2744,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
2744,postmenopausal and no ht,C0232970
2744,postmenopausal and no hrt,C0232970
2744,postmenopausal and current ht,C0232970
2744,postmenopausal and current hrt,C0232970
2744,postmenopausal ( % ),C0232970
2744,postmenopausal  no hrt,C0232970
2744,postmenopausal  never or past hormone therapy use,C0232970;C2003901
2744,postmenopausal  current hrt,C0232970;C0282402;C0521116;C1705970
2744,postmenopausal,C0232970
2744,post - menopausal ( a ),C0232970
2744,history of postmenopausal fracture *,C0232970;C1272071
2743,retinopathy — no . ( % ),C0035309;C1962966
2743,retinopathy — %,C0035309;C1962966
2743,retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0035309;C0205390;C1300072;C1306673;C1962966
2743,retinopathy,C0035309;C1962966
2742,neuropathy — no . ( % ),C0442874
2742,neuropathy,C0442874
2741,mar imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C3829202;C4255469
2741,imputed,C2699638
2741,cr imputation ( random . ) ( n = $nmbr$ ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
2741,bocf - iike imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C2984917
2740,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
2740,amputations  n ( % ),C0002688
2740,amputation — no . ( % ),C0002688;C0332840;C1546539
2740,amputation,C0002688;C0332840;C1546539
2739,nph,C0020258;C0027442
2738,pi,C0122626;C0429863;C3537219;C3539772
2737,pb,C1415801;C3819255
2736,nordic countries,C0036273
2735,nordic,C0331873
2734,north ameriea,C1709269
2734,north,C1709269
2733,forearm,C0016536
2732,korean,C1556095
2732,korea,C0022771
2731,row §,C1552840;C1552846
2731,row * n = $nmbr$,C1552840;C1552846
2731,row,C1552840;C1552846
2730,o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
2730,o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0029118;C0029434;C0483204
2730,o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o ),C0483204
2730,o $nmbr$,C0483204
2730,o,C0483204
2730,> o - $nmbr$ - ii,C0483204;C1710602;C4082587
2730,- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
2730,- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ ),C0483204
2730,$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % ),C0483204
2730,$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o ),C0483204
2730,$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ ),C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ ),C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ ),C0021966;C0221138;C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ ),C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ ),C0021966;C0221138;C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o ),C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ ),C0021966;C0221138;C0483204
2730,$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo ),C0483204
2730,$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ ),C0021966;C0221138;C0483204
2730,$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ ),C0483204
2730,$nmbr$ ( o - o $nmbr$ - o - $nmbr$ ),C0483204
2730,$nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
2730,$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
2729,czech repumc,C0337799
2728,korea  republic of,C0022773
2727,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
2727,> $nmbr$ % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
2726,kccq score,C3476798
2726,kccq ( $nmbr$ months ),C0439231;C3476798
2725,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
2725,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
2725,nste acs,C0742343;C4318612
2725,nste - acs,C0742343;C4318612
2725,no acs,C0742343;C4318612
2725,days from acs to randomization,C0439228;C0742343;C4318612
2725,days between acs and rand,C0439228;C0742343;C4318612
2725,acs type,C0332307;C0742343;C1547052;C4318612
2725,acs ( n = $nmbr$  $nmbr$ ),C0742343;C4318612
2725,acs ( n - $nmbr$  $nmbr$ ),C0742343;C4318612
2725,acs,C0742343;C4318612
2724,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
2724,csf a ( $nmbr$ ( pm ),C3540512;C3889436
2724,csf $nmbr$ s - hydroxy -,C3540512;C3889436
2724,csf,C3540512;C3889436
2723,sacral and / or lumbar,C0036037
2722,overall quality of life,C3641830
2721,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
2721,favors ff / vi favors placebo,C0205999;C0309049;C4554348
2721,favors favors lisinopril chlorthalidone,C0309049
2721,favors favors amlodipine chlorthalidone,C0309049
2720,no nasal polyps,C0027430
2720,nasal polyps  n ( % ),C0027430
2720,nasal polyps,C0027430
2720,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430
2720,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
2719,native hawaiian or other pacific islander,C0337920
2719,native hawaiian or other pacific,C0337920
2719,native hawaiian or,C0337920
2719,native hawaiian / pacific islander,C0242191;C0337920
2719,native hawaiian / other,C0337920
2719,hawaiian pacific islander,C0242191;C0337920
2719,hawaiian / pacific islander,C0242191;C0337920
2719,hawaiian / pacific,C0337920
2718,daily activities / social functioning,C0037395;C0871707
2718,daily activities,C0871707
2717,nyha_class,C1882083
2717,nyha class — no . ( % ) $,C1882083
2717,nyha class — no . ( % ),C1882083
2717,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
2717,nyha class not reported,C1882083
2717,nyha class ( when patient was last in stable condition before admission )  %,C1882083
2717,nyha class ( when patient was last in stable condition,C1882083
2717,nyha class $nmbr$ or higher,C1882083
2717,nyha class $nmbr$ - $nmbr$ : no { n = llll ),C1882083
2717,nyha class  n ( % ) i,C1882083
2717,nyha class  n ( % ),C1882083
2717,nyha class  ( % ),C1882083
2717,nyha class,C1882083
2717,nyha chf class,C0018802;C1882083
2717,new york heart association congestive heart failure class,C0018802;C1882083
2717,new york heart association class,C1882083
2716,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
2716,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
2716,nyha class iii or iv ( n = $nmbr$ ),C1882086
2716,nyha class iii or iv  n ( % ),C1882086
2716,nyha class iii  % ( n ),C1882086
2716,nyha class iii,C1882086
2715,residence in asia  n ( % ),C0003980;C0237096
2715,asia pacific or other,C0003980
2715,asia pacific and other,C0003980
2715,asia pacific ( n = $nmbr$ ),C0003980
2715,asia pacific,C0003980
2715,asia and pacific islands,C0003980
2715,asia / pacific / other,C0003980
2715,asia / pacific ( % ),C0003980
2715,asia / pacific,C0003980
2715,asia - pacific hr ( $nmbr$ % cl ),C0003980;C0596019
2715,asia - pacific,C0003980
2715,asia ( n = $nmbr$ ),C0003980
2715,asia ( n = $nmbr$  $nmbr$ ),C0003980
2715,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
2715,asia #,C0003980
2715,asia  pacific and other,C0003980
2715,asia,C0003980
2714,region  asia / paafic,C0003980;C0017446;C0205147
2714,getgoal - l - asia,C0003980
2714,asia pacific and south africa,C0003980
2714,asia pacific and africa,C0003980
2714,asia - pacific region and south africa,C0003980;C0017446;C0205147
2714,asia - pacific and south africa,C0003980
2713,p - value for east asian versus non - east asian *,C0078988;C1707877;C1709380
2713,other asian,C0078988
2713,oriental,C0078988;C0699027
2713,non - asian ( n = $nmbr$ $nmbr$ ),C0078988;C1518422
2713,non - asian,C0078988;C1518422
2713,east asian,C0078988;C1707877
2713,asians ( n = $nmbr$ ),C0078988
2713,asian or pacific islander,C0078988
2713,asian or oriental,C0078988
2713,asian / pacific islander  n ( % ),C0078988;C0242191
2713,asian / oriental,C0078988;C0699027
2713,asian *,C0078988
2713,asian ( n — $nmbr$ ),C0078988
2713,asian ( n   = $nmbr$ ),C0078988
2713,asian ( n = $nmbr$ ),C0078988
2713,asian ( n = $nmbr$  $nmbr$ ),C0078988
2713,asian ( $nmbr$ . $nmbr$ % ),C0078988
2713,asian  n ( % ),C0078988
2713,asian,C0078988
2712,eczema,C0013595;C4553957
2711,ankle edema,C0235439
2710,edge ii,C0205154;C1710602;C2697523;C4082587
2710,edge,C0205154;C2697523
2709,ne,C0027608;C0028219;C3538705
2709,( ne  ne ),C0027608;C0028219;C3538705
2709,$nmbr$ . $nmbr$ ( ne  ne ),C0027608;C0028219;C3538705
2708,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
2708,mean ± se,C0036919;C0444504;C2347634;C2348143
2708,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
2708,mean ( se ) trough  l,C0036919;C0444504;C0444506;C2347634;C2348143
2708,mean ( se ) auc ^ p l,C0036919;C0376690;C0444504;C2347634;C2348143
2708,mean ( se ) auc $nmbr$ - $nmbr$  l,C0036919;C0376690;C0444504;C2347634;C2348143
2708,mean ( se ),C0036919;C0444504;C2347634;C2348143
2708,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
2708,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
2708,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
2708,hscrp ( post - baseline / baseline ratio )  ls mean   ±   se,C0023668;C0036919;C0168634;C0444504;C0456603;C0687676;C1442488;C1547037;C1704687;C2347634;C2348143;C3469826
2708,calculated annual decline  mean ± se,C0036919;C0332181;C0444504;C0444686;C1441506;C2347634;C2348143
2708,( se ),C0036919
2708,% ( se ),C0036919
2707,se,C0036919
2707,( se ] tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
2707,( se ] tf hdl - c,C0036919;C3715113;C4048299;C4048587
2707,( se ] tf,C0036919;C4048299;C4048587
2707,( se ] t *,C0036919
2707,( se ] t,C0036919
2707,( se ] +,C0036919
2707,( se ) t *,C0036919
2706,« s $nmbr$ - $nmbr$,C0565930;C2603362
2706,| : s blocker,C0565930;C2603362
2706,s £ $nmbr$,C0565930;C2603362
2706,s fs $nmbr$,C0565930;C1517317;C2603362;C3814419
2706,s . e .,C0565930;C2603362
2706,s ( s $nmbr$,C0565930;C2603362
2706,s $nmbr$ yrs,C0565930;C2603362
2706,s $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
2706,s $nmbr$ - $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
2706,s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %,C0565930;C2603362
2706,s $nmbr$ ( $nmbr$ . s ),C0565930;C2603362
2706,s $nmbr$ %,C0565930;C2603362
2706,s $nmbr$,C0565930;C2603362
2706,s,C0565930;C2603362
2706,= s $nmbr$,C0565930;C2603362
2706,$nmbr$ s f $nmbr$ ),C0016327;C0565930;C2603362
2706,$nmbr$ s . $nmbr$ ± s . $nmbr$,C0565930;C2603362
2706,$nmbr$ ( $nmbr$ s . s ),C0565930;C2603362
2705,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
2705,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
2705,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
2705,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2705,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
2705,second co - primary,C0205436;C0457385;C0565930;C1561503;C1705190;C3245499
2705,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
2705,second ( n = $nmbr$ ),C0205436;C0457385;C0565930;C1561503;C1705190
2705,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2704,metabolism and nutrition,C0025519;C0025520
2703,metabolic syndromeb,C0311400;C1524026;C2707259
2702,mental status ( baseline spmsq scores )  n ( % ),C0168634;C0278060;C1442488
2702,mental status,C0278060
2701,patients with established cv disease aged > $nmbr$ years .,C0007222;C0030705;C0443211;C1272684;C1510829
2701,established cvd ( age > $nmbr$ ),C0001779;C0007222;C0443211;C1272684
2701,established cardiovascular disease,C0007222;C0443211;C1272684
2701,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
2701,established atherosclerotic disease  n ( % ),C0012634;C0333482;C0443211;C1272684
2701,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
2701,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
2701,established atherosclerotic,C0333482;C0443211;C1272684
2701,established ascvd or > $nmbr$ cv risk factors,C0443211;C1272684;C3665365
2701,established ascvd,C0443211;C1272684;C3665365
2701,established ( n = $nmbr$ ),C0443211;C1272684
2701,established,C0443211;C1272684
2700,stemi ( % ),C1536220;C3538872
2700,stemi,C1536220;C3538872
2700,st - elevation myocardial infarction,C1536220;C3538872
2700,prior stemi,C0332152;C1536220;C2826257;C3538872
2700,no prior stemi,C0332152;C1536220;C2826257;C3538872
2700,myocardial infarction without st - segment elevation — no . ( % ),C1536220
2699,st - segment — elevation myocardial infarction,C1536220
2699,st - segment elevation myocardial infarction,C1536220
2699,st - segment - elevation myocardial infarction — no . ( % ),C1536220
2699,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
2699,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
2698,active   versus   placebo,C0205177;C3853793;C3888249
2698,active vs placebo,C0205177;C3853793;C3888249
2698,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
2698,active smokers,C0205177;C0337664;C3853793;C3888249
2698,active smoker,C0205177;C0337664;C3853793;C3888249
2698,active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y,C0043193;C0205177;C1520135;C3853793;C3888249
2698,active or previous cancer,C0205177;C3853793;C3888249
2698,active comparatorb,C0205177;C3853793;C3888249
2698,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
2698,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
2698,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
2698,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
2698,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
2698,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
2698,active canakinumab ( n   =   $nmbr$  $nmbr$ ),C0205177;C2718773;C3853793;C3888249
2698,active a,C0205177;C3853793;C3888249
2698,active ( n = $nmbr$ ),C0205177;C3853793;C3888249
2698,active,C0205177;C3853793;C3888249
2697,selena - sledai activity  n ( % ),C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
2697,ease activity ],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
2697,disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s,C0205177;C0439167;C0439234;C0441655;C0449238;C0872146;C1292728;C1561536;C2926735;C3668946;C4049938;C4049939
2697,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
2697,activity ( $nmbr$ - $nmbr$ vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
2697,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
2696,hder *,C3898895
2695,lda  %,C4553195
2695,eda  %,C0162359;C1539327;C3539920;C3887494
2694,dd ( n = $nmbr$ ),C3538867;C3814791
2694,dd,C3538867;C3814791
2693,cdai §,C0683448;C1413248;C3273706
2693,cdai score §,C0683448;C1413248;C3273706
2693,cdai score < $nmbr$,C0683448;C1413248;C3273706
2693,cdai score  median ( min  max ),C0683448;C1413248;C3273706
2693,cdai score  mean ± sda,C0683448;C1413248;C3273706
2693,cdai score  mean ( s . d . ),C0683448;C1413248;C3273706
2693,cdai score,C0683448;C1413248;C3273706
2693,cdai > $nmbr$  n [ % ],C0683448;C1413248;C3273706
2693,cdai < $nmbr$ t,C0683448;C1413248;C3273706
2693,cdai < $nmbr$ . $nmbr$ *,C0683448;C1413248;C3273706
2693,cdai ( $nmbr$ - $nmbr$ ),C0683448;C1413248;C3273706
2693,cdai,C0683448;C1413248;C3273706
2692,sbp ( sd )  mm   hg,C0085805;C0439475;C2699239
2692,sbp  mm   hg ( sd ),C0085805;C0439475;C2699239
2692,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
2692,mssbp ± sd  mmhg,C0439475;C2699239
2692,mssbp  mmhg ( sd ),C0439475;C2699239
2692,msdbp ± sd  mmhg,C0439475;C2699239
2692,msdbp  mmhg ( sd ),C0439475;C2699239
2692,dbp ( sd )  mm   hg,C0439475;C0536221;C2699239;C3813197;C4281799
2692,blood pressure in mm hg  mean ( sd ),C0428886;C0439475;C0488053;C2699239
2692,blood pressure  mmhg  mean ( sd ),C0428886;C0439475;C2699239
2692,blood pressure  mm hg  mean ( sd ),C0428886;C0439475;C2699239
2692,blood pressure  mean ± sd mm hg,C0428886;C0439475;C2699239
2692,blood pressure  mean ( sd ) [ range ]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
2692,blood pressure  mean ( sd )  mm hg systolic,C0428886;C0439475;C2699239
2692,blood pressure  mean ( sd )  mm hg,C0428886;C0439475;C2699239
2691,± sd .,C2699239
2691,limb ( sd ),C0015385;C2699239
2691,hr  bpm ( sd ),C2699239
2691,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
2691,[ sd ],C2699239
2691,( sd ),C2699239
2690,symptom score ( sd ),C2699239;C3476546
2690,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
2690,sd or %,C2699239
2690,sd of sbp,C0085805;C2699239
2690,sd,C2699239
2690,mean ucsd - sobq score * ( sd ),C2699239;C3533236
2690,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
2690,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
2690,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
2689,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
2689,gene,C0017337
2688,gemfibrozil ( n = $nmbr$,C0017245
2688,gemfibrozil,C0017245
2687,gmr,C1522544;C1704695
2686,serms,C0732611
2685,grs,C1412761;C3539564
2684,> $nmbr$ drinks / wk,C0452428
2684,> $nmbr$ drinks / week,C0452428
2684,> $nmbr$ drinks / dav,C0452428
2684,> $nmbr$ drinks,C0452428
2684,> $nmbr$ ( $nmbr$ ) drinks / day if male ( female ),C0452428
2684,$nmbr$ drinks / wk,C0452428
2684,$nmbr$ drinks,C0452428
2684,$nmbr$ - $nmbr$ drinks / wk,C0452428
2684,$nmbr$ - $nmbr$ drinks / dav,C0452428
2684,$nmbr$ - $nmbr$ drinks,C0452428
2684,$nmbr$ + drinks / wk,C0452428
2683,ref §,C1425988
2683,ref .,C1425988
2683,( ref ),C1425988
2683,$nmbr$ . $nmbr$ ( ref . ),C1425988
2683,$nmbr$ ( ref ),C1425988
2682,serum uric acid  difference vs placebo ( $nmbr$ % cl ),C0455272;C0700634;C1705241;C1705242
2682,sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C1705241;C1705242
2682,sbp  difference,C0085805;C1705241;C1705242
2682,risk difference,C0035647;C1705241;C1705242;C4552904
2682,percentage difference ( $nmbr$ % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
2682,mean arterial pressure  difference,C0428886;C1705241;C1705242
2682,lsms difference ( $nmbr$ % ci ) $nmbr$,C0008107;C1705241;C1705242;C3259781
2682,lsm difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
2682,lsm difference,C1705241;C1705242
2682,ls means difference ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,ls means difference ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,ls mean difference vs placebo ( $nmbr$ % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
2682,ls - mean difference between treatment groups ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
2682,ls - mean between - group difference ( $nmbr$ % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
2682,least squares mean between - treatment difference ( $nmbr$ % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
2682,incidence rate difference  linagliptin - placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1708485;C2746078
2682,hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl ),C0019016;C1705241;C1705242;C1825777;C3538758
2682,estimated difference ( $nmbr$ % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
2682,estimated difference %,C0750572;C1705241;C1705242
2682,estimated difference,C0750572;C1705241;C1705242
2682,difference vs placebo * *,C1705241;C1705242
2682,difference vs placebo ( $nmbr$ % ci ),C1705241;C1705242
2682,difference vs placebo ',C1705241;C1705242
2682,difference vs placebo  % [ $nmbr$ % cl ]  p,C1705241;C1705242
2682,difference vs placebo,C1705241;C1705242
2682,difference vs pbo ( $nmbr$ % ci ),C1705241;C1705242
2682,difference vs pbo,C1705241;C1705242
2682,difference vs ff $nmbr$ pg ( $nmbr$ % ci ),C1705241;C1705242
2682,difference vs . placebo  kg ( $nmbr$ % cl ),C1705241;C1705242
2682,difference vs . placebo  % ( $nmbr$ % cl ),C1705241;C1705242
2682,difference vs . placebo,C1705241;C1705242
2682,difference vs . pbof mean ( s . e . ) t,C1705241;C1705242
2682,difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
2682,difference in sbp between treatment,C0085805;C1705241;C1705242
2682,difference in means ( $nmbr$ % cl ),C0596019;C1704970;C1705241;C1705242
2682,difference in means,C1704970;C1705241;C1705242
2682,difference in ls means ( $nmbr$ % ci ) versus placebo,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,difference in ls means ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,difference in ls means ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,difference in ls means ( $nmbr$ % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2682,difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
2682,difference in ls mean vs placebo ( $nmbr$ % ci )  %,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
2682,difference in ls mean $nmbr$ ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2682,difference from placeboa,C1705241;C1705242
2682,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
2682,difference from placebo * ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
2682,difference from placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
2682,difference from placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
2682,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
2682,difference from baselinea,C1705241;C1705242
2682,difference ff / vi versus uc  %,C0205999;C1705241;C1705242;C4554348
2682,difference ( tiotropium - placebo ) ml ( $nmbr$ % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
2682,difference ( se ),C0036919;C1705241;C1705242
2682,difference ( a ) vs placebo ( $nmbr$ % cl ),C1705241;C1705242
2682,difference ( % ),C1705241;C1705242
2682,difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
2682,difference ( $nmbr$ % ci ) *,C0008107;C1705241;C1705242;C3259781
2682,difference ( $nmbr$ % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
2682,difference $nmbr$ years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
2682,difference $nmbr$ years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
2682,difference $nmbr$,C1705241;C1705242
2682,difference,C1705241;C1705242
2682,ambulatory sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C0439841;C1705241;C1705242
2682,% difference  $nmbr$ % ci ),C0008107;C1705241;C1705242;C3259781
2682,% - point difference ( $nmbr$ % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
2681,secukinumab pooled †   ( n   = $nmbr$ ),C1709595;C2349200;C3179547;C4522255
2681,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
2681,any secukinumab ( n   = $nmbr$ ),C3179547
2680,secukinumab $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
2680,secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
2680,secukinumab,C3179547
2679,selexipag vs placebo hazard ratio ( $nmbr$ % cl ),C2000145
2679,selexipag ( n = $nmbr$ ),C2000145
2679,selexipag,C2000145
2678,sex  female    n   ( % ),C0086287
2678,sex  female  n ( % ),C0086287
2678,number of females n ( % ),C0086287;C0237753;C0449788
2678,females only,C0086287;C0205171;C1720467
2678,females  > $nmbr$ . $nmbr$,C0086287
2678,females  < $nmbr$ . $nmbr$,C0086287
2678,female sex — number ( % ),C0086287;C0237753;C0449788
2678,female sex — no . { % ),C0086287
2678,female sex — no . ( % ) race — no . ( % ) f,C0086287
2678,female sex — no . ( % ),C0086287
2678,female sex  no . / total ( % ),C0086287
2678,female sex  no . ( % ),C0086287
2678,female sex  n ( % ) race  n ( % ),C0034510;C0086287;C1706779;C3853635
2678,female  n ( % ) race  n ( % ),C0034510;C0043210;C0086287;C1705497;C1705498;C1706779;C3853635
2677,sex : female,C0086287
2677,sex ( female ),C0086287
2677,sex  female  %,C0086287
2677,sex  female,C0086287
2677,sex  % female,C0086287
2677,male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
2677,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
2677,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
2677,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
2677,females ( n = $nmbr$ ),C0086287
2677,females ( itt ) ( n = $nmbr$ ),C0086287
2677,females  n ( % ),C0086287
2677,females  > $nmbr$,C0086287
2677,females  < $nmbr$,C0086287
2677,females  %,C0086287
2677,females,C0086287
2677,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
2677,female subjects ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
2677,female simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
2677,female simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female simva,C0043210;C0086287;C1705497;C1705498
2677,female sex — %,C0086287
2677,female sex ( % ),C0086287
2677,female sex  n ( % ),C0086287
2677,female sex  %,C0086287
2677,female sex,C0086287
2677,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
2677,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
2677,female participants who are ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0679646;C1705497;C1705498
2677,female n ( % ),C0043210;C0086287;C1705497;C1705498
2677,female gender n ( % ),C0086287
2677,female gender ( % ),C0086287
2677,female gender,C0086287
2677,female eze / simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
2677,female eze / simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female eze / simva,C0043210;C0086287;C1705497;C1705498
2677,female : ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0439234;C1705497;C1705498
2677,female : premenopausal,C0043210;C0086287;C1705497;C1705498
2677,female : perimenopausal or < $nmbr$ years postmenopausal,C0043210;C0086287;C1705497;C1705498
2677,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
2677,female - n ( % ),C0043210;C0086287;C1705497;C1705498
2677,female ( n — $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female ( n   = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female ( n z $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female ( n = lll $nmbr$ ),C0043210;C0086287;C1261077;C1705497;C1705498
2677,female ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female ( n = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
2677,female ( % ),C0043210;C0086287;C1705497;C1705498
2677,female $nmbr$,C0043210;C0086287;C1705497;C1705498
2677,female  no . ( % ),C0043210;C0086287;C1705497;C1705498
2677,female  no ( % ),C0043210;C0086287;C1705497;C1705498
2677,female  n ( % ),C0043210;C0086287;C1705497;C1705498
2677,female  %,C0043210;C0086287;C1705497;C1705498
2677,female,C0043210;C0086287;C1705497;C1705498
2677,$nmbr$ ( except for female alone ),C0043210;C0086287;C1705497;C1705498
2676,smokers : qva $nmbr$ - $nmbr$ fc,C0337664;C2983605
2676,smokers  no . ( % ),C0337664
2676,smokers  n ( % ),C0337664
2676,smokers  %,C0337664
2676,smokers,C0337664
2676,smoker or ex - smoker  n ( % ),C0337664
2676,smoker ( % ) a,C0337664
2676,smoker ( % ),C0337664
2676,smoker  n ( % ),C0337664
2676,smoker  %,C0337664
2676,smoker  ! n ( % ),C0337664
2676,smoker,C0337664
2676,past smoker  n ( % ),C0337664;C1444637;C4284302
2676,noncurrent smoker,C0337664
2676,ever - smoker,C0337664;C3887636
2675,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex ( women  n [ % ] ),C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
2675,sex ( women  men ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
2675,sex ( p = $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
2675,sex ( interaction : p = $nmbr$ . $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
2675,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  no . ( % ) male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  no  ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  n ( % ) b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  n ( % ) *,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  men / women  %,C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
2675,sex  men ( % ),C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,intercourse satisfac -,C0009253
2675,> $nmbr$ yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2675,> $nmbr$ yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
2674,positive family history of type $nmbr$ diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
2674,family history ol diabetes ?,C1313937
2674,family history of diabetes — no . ( % ),C1313937
2674,family history of diabetes mellitus — no . { % ),C0260526;C1313937
2674,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
2674,family history of diabetes ( - ),C1313937
2674,family history of diabetes ( + ),C1313937
2674,family history of diabetes ( % ) *,C1313937
2673,family history of vte,C0241889;C0630906
2673,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
2673,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2673,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2673,family history of premature,C0151526;C0205252;C0241889;C4018905
2673,family history of cancerf,C0241889
2673,family history of cancera,C0241889
2673,family history ^,C0241889
2673,family history  n ( % ),C0241889
2672,smoking history — no . ( % ),C1519384
2672,smoking history : ex - smoker,C0337664;C1519384
2672,smoking history ( ever ),C1519384;C3887636
2672,smoking history    n   ( % ),C1519384
2672,smoking history  r ( % ),C0205090;C0684010;C1519384;C2603358
2672,smoking history  n ( % ),C1519384
2672,smoking history,C1519384
2672,history of smoking,C1519384
2671,stricturing,C1261287
2671,stenosis > $nmbr$ %,C0678234;C1261287;C2632116
2671,percent stenosis [ investigator ],C0035173;C0439165;C0678234;C1261287;C2632116
2671,percent stenosis [ core lab ],C0439165;C0678234;C1261287;C2632116;C4684837
2671,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
2671,ica stenosis $nmbr$ % - $nmbr$ % f,C0016327;C0201519;C0678234;C1261287;C2632116
2671,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
2671,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
2671,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
2671,% stenosis  as assessed by investigator,C0678234;C1261287;C2632116
2671,% stenosis  as assessed by core laboratory,C0678234;C1261287;C2632116
2670,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
2670,fasting triglycerides > $nmbr$ mg / dl *,C0015663;C0041004;C0439269
2670,fasting triglycerides  mg / dl,C0015663;C0041004;C0439269
2670,fasting triglycerides,C0015663;C0041004
2670,fasting tgs §,C0015663;C1156212;C1537574
2670,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
2670,fasting lipids ( mmol / $nmbr$ ),C0015663;C0023779;C0439190
2670,fasting lipid levels  mmol / l,C0015663;C0428460;C1532563
2670,fasting glucose — mg / dl,C0015663;C0017725;C0439269
2670,fasting glucose > $nmbr$ mg / dl *,C0015663;C0017725;C0439269
2670,fasting glucose > $nmbr$ mg / dl  n ( % ),C0015663;C0017725;C0439269
2670,fasting glucose *,C0015663;C0017725
2670,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
2670,fasting glucose  mg / dl ',C0015663;C0017725;C0439269
2670,fasting glucose  mg / dl,C0015663;C0017725;C0439269
2670,fasting glucose,C0015663;C0017725
2670,fasting free fatty acids ( ^ mol / liter ),C0015663
2670,fasting,C0015663
2669,fastest third,C0015663;C0205437;C0456962;C2985769
2669,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
2669,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
2669,faster aspart,C0015663;C0123677;C0456962;C2985769
2668,risk factor for venous thromboembolism  no . ( % ),C1521761;C2827422;C3495424;C3496592
2668,factors that confer a,C1521761;C2827422
2668,factor present,C0150312;C0449450;C1521761;C2827422
2668,factor at baseline,C0168634;C1442488;C1521761;C2827422
2668,factor absent,C1521761;C2827422
2668,factor *,C1521761;C2827422
2668,factor,C1521761;C2827422
2668,baseline factor,C0168634;C1442488;C1521761;C2827422
2667,aortic - valve replacement,C0003506
2666,post - menopausal without hormone replacement,C0019930
2666,post - menopausal with hormone replacement,C0019930
2665,distal forearm,C0588203
2664,diltiazem or verapamil,C0012373
2663,hospitalized without airway compromise,C0701159;C4055482
2663,airway compromise,C4055482
2662,high - school graduate or ged,C0870649;C1549971
2662,high - school graduate,C0870649;C1549971
2661,on step - $nmbr$ drug  %,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
2661,. $nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463
2661,$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
2660,spinal,C0521329
2659,spine *,C0037949;C2752558
2659,spine,C0037949;C2752558
2658,pint,C0560012;C3811619;C3890014;C3890556
2657,pin /,C0175718;C1168556;C1704584
2656,dpp ‐ $nmbr$ inhibitors,C0243077;C1414174
2656,dpp - $nmbr$ inhibitors,C0243077;C1414174
2656,dpp - $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
2656,dpp - $nmbr$ inhibitor,C1414174;C1999216
2656,dpp - $nmbr$,C1414174
2655,nesiritide ( n = $nmbr$ ),C0054015
2655,nesiritide  % z,C0054015
2655,bnp — pg / ml  i,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
2655,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2655,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0054015;C1095989;C1417808;C2982014
2655,bnp / ntbnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
2655,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
2655,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
2655,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
2655,bnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
2655,bnp  pg / mlt,C0030827;C0054015;C0072225;C1095989;C1266240;C1417808;C2982014;C4553833
2655,bnp  pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2655,bnp,C0054015;C1095989;C1417808;C2982014
2654,lama +,C0999593;C1416775
2654,lama ( tiotropium )  b   n ( % ),C0213771;C0999593;C1416775
2654,lama,C0999593;C1416775
2654,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
2654,laba / lama,C0999593;C1416775
2653,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
2653,la grade a  n ( % ) f,C0023031;C0023749;C0230347;C2346906;C4553351
2653,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
2653,fpg  mmol / la,C0023031;C0023749;C0230347;C0439190;C2346906;C4553351
2652,stage ii,C0441767
2652,gold stage ii,C0018026;C0441767;C1304897
2651,stage iii,C0441771
2651,gold stage iii,C0018026;C0441771;C1304897
2650,q wave mi,C0861151
2650,q - wave mi,C0861151
2649,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
2649,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
2649,agi,C1299007
2648,sdai < $nmbr$ t,C3871128
2648,sdai < $nmbr$ . $nmbr$ *,C3871128
2648,sdai ( $nmbr$ - $nmbr$ ),C3871128
2648,sdai,C3871128
2647,spain ( n = $nmbr$ ),C0037747
2647,spain,C0037747
2646,saudi arabia,C0036243
2646,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
2645,sama $nmbr$,C1075468
2645,sama  b   n ( % ),C1075468
2645,sama,C1075468
2644,stomach,C0038351;C3714551
2643,source,C0449416;C1705919;C4521696
2642,so $nmbr$ %,C0037640
2642,so,C0037640
2641,snp,C0752046;C1527094
2640,sleep,C0037313
2639,st / t wave,C0036056;C0429103;C3272372
2639,st - t wavett,C0036056;C3272372
2639,st - t waveft,C0036056;C3272372
2639,st - t wave changes,C0036056;C0429103;C3272372
2639,st - t wave abnormality d,C0036056;C1839341;C3272372
2639,st - t wave  no . ( % ),C0036056;C0429103;C3272372
2639,st - t wave  n ( % ),C0036056;C0429103;C3272372
2639,st - t wave,C0036056;C0429103;C3272372
2639,st - $nmbr$ ( ng / ml ),C0036056;C0439275;C3272372
2639,st -,C0036056;C3272372
2639,st +,C0036056;C3272372
2639,st,C0036056;C3272372
2639,> $nmbr$ st and < $nmbr$ nd quartile,C0036056;C3272372
2639,< $nmbr$ st quartile,C0036056;C2828255;C3272372
2639,$nmbr$ st < $nmbr$ . $nmbr$,C0036056;C3272372
2639,$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0036056;C0439284;C3272372
2638,college graduate or more,C0682187
2637,ohs graduate,C0268353;C1861455
2636,hs graduate / ged,C0588053;C1547183;C1880947
2635,• death from any cause,C0007465
2635,death from cardiovascular causes,C0007226;C0007465;C3887460
2635,death from any cause,C0007465
2635,cause of death unknown,C0007465;C4050444
2635,by cause of death,C0007465;C4050444
2634,renal disease ),C0022658
2634,renal disease,C0022658
2634,kidney disease ( usrds ),C0022658
2634,established renal disease *,C0022658;C0443211;C1272684
2634,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
2633,nephropathy,C0022658
2633,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
2632,subgoup_name,C0027365;C1547383;C4522128
2631,subgroup analyses,C2986480
2631,prespecified subgroup analyses,C2986480
2631,additional subgroup analyses,C1524062;C2986480
2630,bisphosphonates,C0012544;C3541401
2629,inappropriate,C1548788;C3537135;C3542467
2628,valproate,C0080356
2627,naproxen,C0027396
2626,ibuprofen,C0020740
2625,fibrous,C0016059;C0439709
2624,fibrates,C1449704;C3540783
2623,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0000545;C0003695;C0085805;C0282379;C0439175;C0439632;C0439810;C0456603;C0536221;C0578022;C1235746;C1547037;C1709380;C1711350;C1882141;C2316832;C2699193;C3813197;C4281799;C4554792
2623,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
2623,sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
2623,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0007787;C0012000;C0033095;C0085805;C0369637;C0441923;C0460139;C0488055;C0536221;C0871420;C0871470;C1306345;C1306620;C2699239;C3813197;C4281799;C4284008
2623,dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799
2623,dbp,C0536221;C3813197;C4281799
2623,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0004083;C0005767;C0005768;C0005823;C0017654;C0018787;C0018810;C0027976;C0033095;C0039155;C0054015;C0085805;C0205088;C0229664;C0237753;C0332126;C0439849;C0449788;C0460139;C0536221;C0596306;C0699792;C1095989;C1271104;C1272641;C1275491;C1305855;C1306345;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3813197;C3889152;C4050156;C4281799;C4283901;C4284008;C4284038
2622,swollen,C0038999
2622,question $nmbr$ ( pain / swelling in joints other than neck / back / hips ),C0003862;C0013604;C0038999;C1522634
2622,number of swollen joints ( $nmbr$ assessed ),C0038999;C0449813
2622,number of swollen joints ( $nmbr$ - $nmbr$ ),C0038999;C0449813
2621,swollen joints > $nmbr$  n ( % ),C0152031
2621,joint swelling  effusion  or both on clinical examination — no . ( % ),C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
2621,joint swelling  effusion  or both on clinical examination,C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
2621,joint swelling,C0152031
2620,ertugliflozin,C4079805
2619,sotagliflozin ( n = $nmbr$ ),C3896939
2619,sotagliflozin,C3896939
2618,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
2618,canagliflozin ( n = $nmbr$ ),C2974540
2618,canagliflozin,C2974540
2617,dapagliflozin ( n = $nmbr$ ),C2353951
2617,dapagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C2353951
2617,dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
2617,dapagliflozin  n *,C2353951
2617,dapagliflozin,C2353951
2616,pooled empagliflozin ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
2616,empagliflozin pooled ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
2616,empagliflozin ( n   =   $nmbr$ ),C3490348
2616,empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C3490348
2616,empagliflozin ( n = $nmbr$ ),C3490348
2616,empagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C3490348
2615,empagliflozin,C3490348
2615,$nmbr$ mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
2614,epilepsy with grand mal seizures on awakening,C0014549;C0494475
2613,emotional well - being,C2984554;C3641833
2612,any acuity bleeding,C0333276
2611,specific risk of bleeding ^,C0205369;C1552740;C3251812
2611,risk of bleeding,C3251812
2610,renal impairment *,C1565489
2610,renal impairment ( crcl < $nmbr$ ml / min ),C0439445;C1565489;C1846718
2610,renal impairment  n ( % ),C1565489
2610,renal impairment,C1565489
2609,impaired renal function †,C1565489
2609,impaired renal function §,C1565489
2609,history of impaired renal function  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
2609,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
2608,renal dysfunction,C1565489;C3279454
2608,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
2608,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
2608,no renal dysfunction,C1565489;C3279454
2607,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
2607,renal functionc  n ( % ),C0022646
2607,renal functionb,C0022646
2607,renal functiona,C0022646
2607,renal composite *,C0022646;C0205199;C1547335
2607,exploratory kidney and microvascular outcomes,C0022646;C0227665
2606,renal subgroup,C0022646;C1079230;C1515021
2606,renal impairmentt,C0022646
2606,renal impairmentf,C0022646
2606,renal events,C0022646;C0441471;C3541888
2606,renal,C0022646
2605,hyponatremia,C0020625;C4553967
2604,hypovolaemia,C0546884
2604,hypokalemia,C0020621;C4553966
2604,hypokalaemia,C0020621;C4553966
2603,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
2603,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2603,nonsevere hypoglycemia,C0020615;C4553659
2603,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
2603,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2603,no nonsevere hypoglycemia,C0020615;C4553659
2603,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
2603,hypoglycemia ^,C0020615;C4553659
2603,hypoglycemia,C0020615;C4553659
2603,b nonsevere hypoglycemia,C0020615;C4553659
2603,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2602,normoglycemic {,C0580545
2602,normoglycemic ^,C0580545
2602,normoglycemic $nmbr$,C0580545
2602,normoglycemic,C0580545
2602,normoglycemia ^,C0580545
2602,normoglycemia,C0580545
2602,baseline normoglycemia,C0168634;C0580545;C1442488
2601,low molecular weight heparin,C0019139;C3536766
2601,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
2601,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766
2601,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
2601,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
2601,low - molecular - weight heparin,C0019139;C3536766
2601,lmwh,C0019139;C3536766
2601,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
2601,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
2600,no mi ( n - $nmbr$  $nmbr$ ),C3810814
2600,mi or cad,C3810814
2600,index mi ( n - $nmbr$  $nmbr$ ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
2600,hx mi or stroke,C0262926;C3810814;C3814444
2600,any mi ( n - $nmbr$  $nmbr$ ),C3810814
2599,mi — no . ( % ),C3810814
2599,mi type unknown ( % ),C0332307;C1547052;C3810814
2599,mi > $nmbr$ months *,C0439231;C3810814
2599,mi < $nmbr$ months *,C0439231;C3810814
2599,mi *,C3810814
2599,mi  n ( % ),C3810814
2599,mi,C3810814
2598,• any mi,C3810814
2598,nocad / mi,C3810814
2598,no mi,C3810814
2598,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
2598,any mi,C3810814
2597,nonfatal mi ( n = $nmbr$ ),C3810814
2597,non - fatal mi,C1302234;C1518422;C1705232;C3810814
2597,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
2597,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
2597,fatal / nonfatal mi  n ( % ),C1302234;C1705232;C3810814
2596,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
2596,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
2596,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
2596,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
2596,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
2596,no myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
2596,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction within the previous $nmbr$ yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
2596,myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
2596,myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
2596,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction / cabg / pci < $nmbr$ years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
2596,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
2596,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction  n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction  ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
2596,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
2596,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
2596,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
2596,cv death  myocardial infarction  stroke,C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4552959;C4554100
2596,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
2596,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
2596,cardiovascular death  myocardial infarction  or stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
2596,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
2595,£ $nmbr$ min,C0702093;C1524029;C3813700
2595,£ $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
2595,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
2595,time to treatment initiation ( min,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
2595,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
2595,time to balloon / needle  min *,C0027551;C0040223;C0336867;C0441144;C0702093;C1524029;C1882041;C3541383;C3813700
2595,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
2595,symptoms onset to first balloon inflation  min,C0021398;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700;C4086878
2595,range : min  max,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
2595,range ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
2595,range  ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
2595,randomization to first balloon inflation  min,C0021398;C0034656;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700
2595,pm pef ( sd )  l / min,C0030266;C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700;C4049155
2595,pifr l / min,C0702093;C1524029;C3813700
2595,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
2595,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
2595,pef at baseline  l_ / min,C0030771;C0168634;C0702093;C1442488;C1518922;C1524029;C1542834;C3813700
2595,p $nmbr$ min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
2595,on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
2595,morning stiffness duration  min,C0449238;C0457086;C0702093;C1524029;C2926735;C3813700
2595,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
2595,min – max,C0702093;C1524029;C3813700
2595,min - ’,C0702093;C1524029;C3813700
2595,min - max age,C0001779;C0702093;C1524029;C3813700
2595,min - max,C0702093;C1524029;C3813700
2595,min  max,C0702093;C1524029;C3813700
2595,mean score ( min  max range ),C0702093;C1514721;C1524029;C2348147;C3533236;C3542016;C3813700
2595,mean duration of surgery ± sd  min,C0038894;C0038895;C0444504;C0449238;C0543467;C0702093;C1274039;C1524029;C2347634;C2348143;C2699239;C2926735;C3813700
2595,iduration of symptoms > $nmbr$ min,C0683368;C0702093;C1457887;C1524029;C3813700
2595,duration of symptoms > $nmbr$ min,C0436359;C0702093;C1524029;C3813700
2595,duration of ra  mean ( min - max ) ( yrs ),C0444504;C0449238;C0702093;C1524029;C2347634;C2348143;C2926735;C3538806;C3813700;C4048756
2595,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2595,duration of pci  min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2595,cross - damp time : < l : llhrs : min ( n = $nmbr$ ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
2595,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
2595,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
2595,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
2595,age  mean ( min - max ) ( yrs ),C0001779;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
2595,[ min  max ],C0702093;C1524029;C3813700
2595,> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
2595,> $nmbr$ min,C0702093;C1524029;C3813700
2595,> $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
2595,> $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
2595,< $nmbr$ min,C0702093;C1524029;C3813700
2595,< $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
2595,< $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
2595,( min ) *,C0702093;C1524029;C3813700
2595,$nmbr$ min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
2595,$nmbr$ min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
2595,$nmbr$ min,C0702093;C1524029;C3813700
2595,$nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
2595,$nmbr$ - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
2595,$nmbr$ - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
2595,$nmbr$ - min walk distance  ft,C0429886;C0702093;C1524029;C1881534;C3813700;C3890579
2595,$nmbr$ - $nmbr$ min,C0702093;C1524029;C3813700
2594,aspirin < $nmbr$ hours,C0004057;C0439227
2594,$nmbr$ - hour postload glucose,C0017725;C0439227;C0564385
2594,$nmbr$ - hour masbp  mm hg,C0439227;C0439475;C0564385
2594,$nmbr$ - hour madbp  mm hg,C0439227;C0439475;C0564385
2594,$nmbr$ - $nmbr$ hours,C0439227
2593,inflotmas io mgluj versus piecew,C1046794;C3146236
2593,$nmbr$ ( io - $nmbr$ % ),C1046794;C3146236
2592,angina symptoms ^,C0858277
2591,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450
2591,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392
2591,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C1313497;C1538440;C3273279
2590,renin - angiotensin - aldosterone system blocker,C0086907
2589,non - biological systemic,C0205373;C0445097
2588,serious teaes,C0205404
2588,serious aes,C0205404;C1412268;C2699274
2588,serious ae,C0205404;C3887670
2588,serious,C0205404
2588,any serious teaes,C0205404
2588,> $nmbr$ serious aes,C0205404;C1412268;C2699274
2587,syncope — no . ( % ),C0039070;C3541349;C4554644
2587,syncope,C0039070;C3541349;C4554644
2586,t - jj ( $nmbr$ - $nmbr$ ),C2603360
2586,t $nmbr$ dm,C0011816;C2603360;C3250443
2586,t $nmbr$ d,C2603360
2586,t,C2603360
2586,other ( $nmbr$ . $nmbr$ % ) t,C2603360
2586,of t $nmbr$ dm ( years ),C0011816;C0439234;C2603360;C3250443
2586,neither t $nmbr$ dm nor mets,C0011816;C2603360;C3250443
2586,$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u,C0439148;C2603360
2586,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t,C2603360
2585,lv mass,C0455825
2584,base,C0002055;C0178499;C1880279
2583,mae,C0286540;C4085238
2582,flecainide,C0016229
2581,bumetanide,C0006376
2580,hands,C0018563;C1552914
2580,hand,C0018563;C1552914
2579,haq score,C0102923;C0451208
2579,haq pain scale  mean,C0102923;C0444504;C0451208;C1504479;C2347634;C2348143
2579,haq,C0102923;C0451208
2578,taci ( n = $nmbr$ ),C0666480;C1425349;C4284230
2578,taci,C0666480;C1425349;C4284230
2577,paci ( n = $nmbr$ ),C1165245
2577,paci,C1165245
2576,laa ostium,C0444567
2575,alaska native,C0682125
2574,laci ( n = $nmbr$ ),C1420705;C3273314;C4281721
2574,laci,C1420705;C3273314;C4281721
2573,tertiary endpoints :,C0205372;C2349179
2573,tertiary end points,C0205372;C2349179
2573,tertiary,C0205372
2572,seropositivity status  n,C0449438;C0521143
2572,seropositivity,C0521143
2571,empty,C1880497
2571,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
2570,reteplase,C0256103
2569,streptokinase,C0038418
2568,nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
2567,no estimate,C0750572
2567,estimate,C0750572
2567,effect estimate,C0750572;C1280500;C1518681;C2348382
2566,lifestyle behaviours,C0004927;C0023676;C0677505
2566,lifestyle behaviors,C0004927;C0023676;C0677505
2566,lifestyle,C0023676
2565,heparin use,C0239945
2564,headache,C0018681;C4553197
2563,pelvic fractures,C0149531
2563,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
2563,hip fracture + > $nmbr$,C0019557;C0149531;C4552776
2563,hip fracture,C0019557;C0149531;C4552776
2562,use of hormone replacement therapy ( a ),C0282402;C1524063
2562,pre - menopausal without hormone replacement,C0206158;C0282402
2562,pre - menopausal with hormone replacement,C0206158;C0282402
2562,oral hypoglycemics hormone replacement,C0282402;C0359086
2562,hrt,C0282402
2562,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
2562,hormone replacement therapy,C0282402
2562,hormone replacement ! !,C0282402
2562,hormone replacement,C0282402
2561,laparoscopic cholecystectomy,C0162522
2560,atherectomy,C0162513
2559,carotid endarterectomy,C0014099
2558,laser or vitrectomy,C0023089;C0458142;C1023865;C1706315
2557,pain in extremity,C0030196;C4553007
2556,aerobic exercise,C0001701
2556,aerobic activity,C0001701
2555,tests for categoric,C0589061
2554,teaes of special interest,C0205555;C0543488
2554,special interest categories,C0205555;C0543488;C0683312
2553,perfusion defectsatinclusion,C0031001;C4281794
2552,personal relationships,C1552027
2551,heterozygous familial hypercholesterolemia †,C0342882
2551,heterozygous familial hypercholesterolemia,C0342882
2550,disease characteristics *,C0599878
2550,disease characteristics,C0599878
2550,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
2549,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
2549,disease characteristics  n ( % )  unless otherwise stated,C0599878
2548,radiographic characteristics at baseline and randomization,C0444708;C4684572
2548,no baseline characteristics,C4684572
2548,baseline characteristics,C4684572
2547,selected clinical characteristics — no . / total no . ( % ),C0683325;C1707391
2547,selected clinical characteristics  n ( % ),C0683325;C1707391
2547,selected clinical characteristics,C0683325;C1707391
2547,other clinical characteristics,C0683325
2547,clinical characteristics ( % ),C0683325
2547,clinical characteristics  n ( % ),C0683325
2547,clinical characteristics,C0683325
2546,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146
2546,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146
2546,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
2546,gastrointestinal area involved  n / total n ( % ),C0017446;C0205146;C0521362
2546,colonic area involved,C0009368;C0017446;C0205146
2546,arterial area ( mm $nmbr$ ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
2546,area of retinal thickening within the grid  mean ( sd )  dab,C0017446;C0205146;C1302690
2546,area of retinal hemorrhage within the grid  mean ( sd )  dab,C0017446;C0035317;C0205146
2546,area of fluorescein leakage within the grid  mean ( sd )  dab,C0017446;C0205146;C4476700
2546,area,C0017446;C0205146
2546,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
2545,question $nmbr$ ( discomfort from any areas tender to touch / pressure ),C0152054;C0205146;C0234234;C0439815;C0702221;C1522634;C2364135;C4319729
2545,areas,C0205146;C4319729
2544,> $nmbr$ : obese class iii,C1319441
2543,$nmbr$ - $nmbr$ . $nmbr$ : obese class ii,C3853263
2543,$nmbr$ - $nmbr$ . $nmbr$ : obese class i,C3853264
2542,nyha functional class i,C0205245;C0542341;C1882084;C2700217
2542,nyha class i,C1882084
2541,alt or ast > $nmbr$ x uln $nmbr$,C1266129;C4553172
2541,alt increased,C1266129;C4553172
2541,alt and / or ast > $nmbr$ times uln consecutive #,C1266129;C4553172
2541,alt ( units / l ),C0439339;C1266129;C4553172
2541,alt  u / l,C0439339;C1266129;C4553172
2540,notes :,C1317574
2539,not severe,C4316743
2538,not assessable,C1883425
2537,not available,C0686905
2536,nausea and / or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
2536,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
2535,skull  and facial bone fractures,C0037303;C2951888
2534,thoracic cage fractures,C0222762
2533,forearm fracture,C1305215
2532,foot fracture,C0272774
2531,wrist fracture,C0435630;C4553927
2530,humerus fracture,C0020162
2529,femur fracture,C0015802
2528,clavicle fracture,C0159658
2527,radius fracture,C0034628
2526,hand fracture,C0435632
2525,ankle fracture,C0159877;C4552974
2524,patella fracture,C0159849
2523,tibia fracture,C0040185
2523,fibula fracture,C0149699
2522,other diagnostic procedure *,C0430022;C1546908
2521,cardiac procedure :,C1279986
2520,duration of procedure,C2346509
2519,elective procedure,C0747973
2518,dental procedure,C0011331
2517,pre - procedure,C3272300
2517,post - procedure,C3272301
2516,chronic respiratory failure,C0264492
2515,intrathoracic or intraperitoneal surgery,C0595836
2514,outcome measure,C0086749
2513,patient - reported outcome measures,C4277735
2512,prior biologic therapeutic failures  n ( % ),C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
2512,heat failure,C0018837;C0231174;C0680095
2512,failure,C0231174;C0680095
2512,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
2512,> $nmbr$ failure,C0231174;C0680095
2511,therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ ),C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
2511,question $nmbr$ ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
2511,fatigue ( range $nmbr$ - $nmbr$ ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
2511,fatigue,C0015672;C3463815;C4050243;C4554645
2511,facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
2511,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
2510,mercaptopurine,C0000618
2510,azathioprine / $nmbr$ - mercaptopurine,C0000618;C0004482
2510,$nmbr$ - mercaptopurine / azathioprine,C0000618;C0004482
2510,$nmbr$ - mercaptopurine,C0000618
2509,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
2509,glimepiride,C0061323
2508,chloroquine,C0008269
2507,lamotrigine,C0064636;C0524166
2506,caffeine,C0006644;C0236734
2505,oxcarbazepine,C0069751
2504,torsemide,C0076840
2503,lacosamide,C0893761
2502,body height ( cm ),C0005890;C0487985
2501,body weiqht,C0242821;C0460148;C1268086;C4082212
2501,body weighta  kg,C0022718;C0242821;C0439209;C0460148;C1268086;C4054209;C4082212
2500,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
2500,body mass indext,C0518010
2500,body mass indexf  < $nmbr$,C0518010
2500,body mass indexf,C0518010
2500,body mass indexc,C0518010
2500,body mass indexb,C0518010
2500,body mass indexa,C0518010
2500,body mass  kg,C0022718;C0439209;C0518010;C4054209
2500,body - mass indexj,C0518010
2500,body - mass indexf,C0518010
2499,sodium - glucose cotransporter $nmbr$ inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
2499,sodium  meq / l,C0037473;C0439375;C0597484;C3541959;C3714642
2499,sodium,C0037473;C0597484;C3541959;C3714642
2498,severity ofcopd ( gold $nmbr$ )  n ( % ),C0018026;C0439793;C0522510;C1304897
2498,severity of the disease ( gold $nmbr$ )  n ( % ),C0018026;C0521117;C1304897
2498,severity of copd  n ( % ) ( gold $nmbr$ ) : moderate,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2498,severity of copd  ( gold $nmbr$ )  %,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2498,gold stage — no . ( % ) * *,C0018026;C1304897
2498,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
2498,gold stage [ n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage ( % ) : c,C0018026;C0441785;C1304897
2498,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage  nf * ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage  n ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage  %,C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
2498,gold ii,C0018026;C1304897;C1710602;C4082587
2498,gold groups a - d using mmrcb,C0018026;C1304897
2498,gold group  n ( % ),C0018026;C0441848;C1304897
2498,gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n,C0018026;C1304897
2498,gold grade $nmbr$ and ics users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
2498,gold grade $nmbr$ and ics non - users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
2498,gold d,C0018026;C1304897
2498,gold c,C0018026;C1304897
2498,gold b,C0018026;C1304897
2498,gold a,C0018026;C1304897
2498,gold $nmbr$ groups  n ( % ),C0018026;C1304897
2498,gold $nmbr$ - $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
2498,gold $nmbr$ - $nmbr$ ( n = $nmbr$ ),C0018026;C1304897
2498,gold $nmbr$ - $nmbr$,C0018026;C1304897
2498,gold $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
2498,gold $nmbr$,C0018026;C1304897
2498,gold  n ( % ),C0018026;C1304897
2497,this study,C0557651;C2603343
2497,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
2497,study druga,C0557651;C2603343
2497,study $nmbr$ . $nmbr$,C0557651;C2603343
2497,study $nmbr$,C0557651;C2603343
2497,study,C0557651;C2603343
2497,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
2497,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
2497,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C2603343
2497,in extension study,C0231448;C0557651;C1880641;C2603343
2497,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
2497,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
2497,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
2497,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
2496,sinus tracts / perforation  ' ^ n ( % ),C0544791;C0549099;C0854572;C1185740;C1881710
2495,number of draining fistulae per patient  n,C0237753;C0449788;C0544791
2495,no draining fistulas *,C0544791
2495,draining fistulae  n ( % ),C0544791
2494,glucosamine + chondroitin sulfate ( n = $nmbr$ ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
2494,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
2494,chondroitin sulfate ( n = $nmbr$ ),C0008466
2494,chondroitin sulfate,C0008466
2493,treatment with open - label perindopril,C0136123;C3640652
2493,perindopril,C0136123
2492,non - fibrin - specific,C0015982;C0205370
2492,fibrin - specilic,C0015982
2492,fibrin - specific,C0015982
2491,periostin low,C0219433;C1424662;C3812270
2491,periostin high,C0219433;C1424662;C3812270
2491,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
2491,periostin,C0219433;C1424662;C3812270
2491,low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205251;C0219433;C0439275;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
2491,high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2491,biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na,C0005516;C0205251;C0219433;C0439275;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
2491,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2491,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2490,tender joint count ( $nmbr$ - $nmbr$ possible joints ),C0240094;C4554549;C4696258
2489,tender joint count of $nmbr$ joints,C0451530
2489,tender joint count ( range $nmbr$ - $nmbr$ joints ),C0451530;C1514721;C2348147;C3542016
2489,tender joint count ( n / $nmbr$ ),C0451530
2489,tender joint count ( $nmbr$ joints ),C0451530
2489,tender joint count ( $nmbr$ - $nmbr$ joints ),C0451530
2489,tender joint count ( $nmbr$ - $nmbr$ ),C0451530
2489,tender joint count ( $nmbr$ - $nmbr$  per tender joint ),C0451530
2489,tender joint count  of $nmbr$,C0451530
2489,tender joint count,C0451530
2489,tender - joint count ( of $nmbr$ joints ),C0451530
2489,tender - joint count  of $nmbr$ joints examined,C0451530
2488,swollen joint count of $nmbr$ joints,C0451521
2488,swollen joint count ( range $nmbr$ - $nmbr$ joints ),C0451521;C1514721;C2348147;C3542016
2488,swollen joint count ( n / $nmbr$ ),C0451521
2488,swollen joint count ( $nmbr$ — $nmbr$  per swollen joint ),C0451521
2488,swollen joint count ( $nmbr$ joints ),C0451521
2488,swollen joint count ( $nmbr$ - $nmbr$ possible joints ),C0332149;C0451521;C1705910;C2362652
2488,swollen joint count ( $nmbr$ - $nmbr$ joints ),C0451521
2488,swollen joint count ( $nmbr$ - $nmbr$ ),C0451521
2488,swollen joint count  of $nmbr$,C0451521
2488,swollen joint count,C0451521
2488,swollen - joint count ( of $nmbr$ joints assessed ) — no .,C0451521
2488,swollen - joint count ( of $nmbr$ joints ),C0451521
2488,swollen - joint count  of $nmbr$ joints examined,C0451521
2487,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
2487,oct center point thickness  pm,C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732
2487,( points ),C1552961;C2347617;C3714763
2487,$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina ),C1552961;C2347617;C3714763
2487,$nmbr$ - point mace,C1552961;C2347617;C3714763
2486,indian ( indian subcontinent ),C0454693
2485,question $nmbr$ ( morning stiffness since arising ),C0457086;C1522634
2485,question $nmbr$ ( length of morning stiffness since arising ),C0457086;C1444754;C1522634;C1706316
2484,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
2484,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
2483,organ system involvement  no . ( % ),C0460002;C1314939
2483,involved gastrointestinal,C0521362;C1314939
2483,dip involvement  ! n ( % ),C1314939;C3539618
2482,pooled trials * n = $nmbr$,C0008976;C1709595;C2349200;C4522255
2482,pooled simva,C1709595;C2349200;C4522255
2482,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
2482,pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C1518422;C1709595;C2349200;C3281223;C4522255
2482,pooled itt,C1709595;C2349200;C4522255
2482,pooled eze / simva,C1709595;C2349200;C4522255
2482,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
2482,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
2482,pooled,C1709595;C2349200;C4522255
2481,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0337051;C0443252;C1509144;C1720467;C2349200
2481,pool of fh i and ii studies,C0337051;C1260386;C1509144;C2349200
2480,glinide 一 no . ( % ),C2266929
2480,glinide,C2266929
2479,lixisenatide ( n = $nmbr$ o ),C2973895
2479,lixisenatide ( n = $nmbr$ ),C2973895
2479,lixisenatide,C2973895
2478,gained bmd,C1517378
2477,chinese subgroup,C0008120;C0152035;C1079230;C1515021
2477,chinese,C0008120;C0152035
2476,stiffness subscale,C0427008
2476,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
2475,passive smoker,C0425309
2474,assigned to topiramate,C1516050;C1552601
2474,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
2473,time point,C2348792
2472,native latin,C0302891
2472,native coronary,C0018787;C0302891
2471,responders of three - item end point at $nmbr$ weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
2471,item,C1551338;C4554251
2470,thienopyridine + dipyridamole,C0012582;C1120149
2470,dipyridamole alone,C0012582
2470,dipyridamole,C0012582
2469,aspirin + dipyridamole ( n = $nmbr$ ),C0732279
2469,aspirin + dipyridamole,C0732279
2468,indian subpopulation,C1257890;C1524069
2468,indian ( american ) or alaskan native,C0596070;C1524069
2468,indian ( american ) or alaska native,C0596070;C1524069
2468,indian,C1524069
2467,timi flow ‡,C3272266
2467,final timi flow,C0205088;C1546485;C3272266;C3853528
2466,fish oil ( n = $nmbr$ ),C0016157
2466,fish oil,C0016157
2465,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
2465,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
2465,fibrinogen,C0016006;C1167394;C2587184;C3540039
2464,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
2464,final a $nmbr$ c ( % ),C0205088;C1546485;C3853528
2464,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
2464,final,C0205088;C1546485;C3853528
2463,italy ( n = $nmbr$ ),C0022277
2463,italy,C0022277
2462,not at goal,C0018017;C1518422;C1571704
2462,goal,C0018017;C1571704
2462,distance to ldl - c goal,C0012751;C0018017;C1571704
2462,at goal,C0018017;C1571704
2462,% to goal,C0018017;C1571704
2461,timi major / minor bleeding,C0019080;C4441842
2461,timi major / minor,C4441842
2460,immunomodulatory agents,C0005525
2460,immunomodulators,C0001551;C0005525;C1527392
2459,immobilization — no . ( % ),C0020944;C4048292
2459,immobilization at randomization  n ( % ),C0020944;C0034656;C4048292
2459,immobilization,C0020944;C4048292
2458,thrombolytic therapy,C0040044
2458,fibrinolytics,C0040044
2458,fibrinolytic therapy — no . ( % ),C0040044
2458,fibrinolytic,C0040044
2457,lymphocytes  $nmbr$ / + il,C0020898;C0021764;C0022271;C0024264;C4018897
2457,israel,C0022271
2457,il - $nmbr$,C0020898;C0021764;C0022271
2457,europe  israel  or australia,C0015176;C0022271
2457,canakinumab  il - $nmbr$ top tertilec,C0020898;C0021764;C0022271;C1704458;C2718773
2457,canakinumab  il - $nmbr$ middle tertile,C0020898;C0021764;C0022271;C0444598;C0549183;C1552826;C2718773
2457,canakinumab  il - $nmbr$ lowest tertile,C0020898;C0021764;C0022271;C1708760;C2718773
2457,canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
2457,canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
2456,cutoffs,C1442160
2455,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
2455,motor weakness,C1513492;C1705994;C3714552
2455,motor,C1513492;C1705994
2454,other / multiple,C0439064
2454,multiple tnfi and other bdmards §,C0439064
2454,multiple tnfi *,C0439064
2454,multiple diagnoses,C0011900;C0439064
2454,multiple ( $nmbr$ + ) chd risk,C0439064;C1282512
2454,multiple,C0439064
2453,hmgcoa rl,C0047420;C1419337;C3539667
2452,chylomicron triglycerides,C0008731;C0041004;C1325761
2452,chylomicron cholesterol,C0008377;C0008731;C1325761
2451,timi minor bleeding,C0019080;C0026193;C0205165
2451,minor bleeding,C0019080;C0026193;C0205165
2451,minor bleed,C0019080;C0026193;C0205165
2451,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
2451,minor,C0026193;C0205165
2450,smokinq status,C0449438
2450,other glucose status,C0017725;C0449438
2450,hormonal status,C0449438;C0458083
2450,frailty status,C0424594;C0449438
2450,emotional status,C0013987;C0449438;C0849912
2450,cortteosterom relrsclory status,C0449438
2450,aed inducer status,C0449438;C0887457;C3898767
2449,status ( spmsq > $nmbr$,C0449438
2449,status ( spmsq < $nmbr$,C0449438
2449,lev status  n ( % ),C0023556;C0449438
2449,ish status  n ( % ),C0449438
2449,h . pylori status  n ( % ),C0079488;C0449438
2449,aha status at screeningb  n ( % ),C0050451;C0449438;C0772110
2448,study drug,C0013175
2448,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
2448,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
2448,exposure to study drug — days,C0013175;C0332157;C0439228
2448,duration of study - drug administration — hr,C0013175;C2348354
2447,time from study drug administration to coronary revascularization  median ( iqr )  h,C0013175;C0040227;C0150270;C0206209;C2349982;C3469597
2447,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
2447,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
2447,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
2446,tobacco user,C3853727
2446,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
2446,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
2446,tobacco use  yes  n ( % ),C0040335;C0543414;C0841002;C1549445;C1705108;C1710701;C3853727
2446,tobacco use  n ( % ),C0040335;C0543414;C0841002;C3853727
2446,tobacco use,C0040335;C0543414;C0841002;C3853727
2446,prior tobacco use  n ( % ),C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
2446,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
2446,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
2446,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
2445,tobacco abuse,C0040336
2445,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
2444,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
2444,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
2444,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
2444,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
2444,mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
2444,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
2444,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
2444,follow - up in - trial at $nmbr$ yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
2444,follow - up,C0589120;C1522577;C1704685;C3274571
2444,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2444,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
2444,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
2444,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
2444,at end of follow - up — no . / total no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2444,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2444,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2444,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
2444,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
2443,inhaled §,C0004048
2443,inhaled j $nmbr$ - agonist §,C0004048;C2987634
2443,inhaled corticosteroid - yes  n ( % ),C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
2443,inhaled corticosteroid,C0001617;C0004048;C3536709
2443,inhaled ^,C0004048
2443,figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .,C0001617;C0004048;C0016529;C0032042;C0032659;C0040363;C0041260;C0332152;C0740175;C0815320;C1257890;C1306036;C1696465;C1706408;C1883351;C2257086;C3536709;C3669034;C4551720
2443,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0001617;C0004048;C0007450;C0016529;C0018026;C0024115;C0024117;C0034394;C0152277;C0205191;C0205246;C0325090;C0424093;C0521346;C0524517;C0549186;C0585361;C0815320;C0871420;C1304897;C1306036;C1412502;C1443200;C1546767;C1553316;C2348867;C3536709;C3665481;C3714496;C3714541;C3826872;C3826977;C4050461;C4277733;C4284282;C4551720
2442,morning,C0332170
2442,duration of morning,C0332170;C0449238;C2926735
2441,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
2441,doxazosin,C0114873
2440,tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
2440,tofacitinib,C2930696
2439,fondaparinux — no . ( % ),C1098510
2439,fondaparinux ( n = $nmbr$ ),C1098510
2439,fondaparinux ( n = $nmbr$  $nmbr$ ),C1098510
2439,fondaparinux,C1098510
2439,commercially available fondaparinux,C0470187;C1098510
2438,normalized womac score,C0449820;C1882115;C4050231
2438,normalized,C1882115
2437,losmapimod ( n = $nmbr$ ),C3272847
2437,losmapimod,C3272847
2436,nontraumatic leg or foot amputation,C0023216;C1140621
2436,lower limbs,C0023216
2436,lower limb fractures,C0023216
2436,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
2436,lower - limb arterial — no . ( % ),C0023216
2435,renal function  normal - mild,C0205307;C0231683;C0232804;C0439166;C2347086;C2945599;C4553972
2435,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
2435,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
2435,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
2435,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
2435,normal responders ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal responder ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
2435,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal hba $nmbr$ c  n = $nmbr$,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
2435,normal fasting glucose level ( n = $nmbr$ ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
2435,normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1739039;C2347086;C3811844;C3812682;C4553972
2435,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
2435,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
2435,normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g ),C0168634;C0205307;C0231683;C0439166;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
2435,normal > $nmbr$ - $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
2435,normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
2435,normal ( ≤   uln ) n   =   $nmbr$,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
2435,normal ( £ $nmbr$ ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
2435,normal ( egfr ≥ $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
2435,normal ( egfr > $nmbr$ ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
2435,normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
2435,normal ( > $nmbr$ ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
2435,normal ( > $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal ( < $nmbr$ . $nmbr$ u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
2435,normal  < $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
2435,normal,C0205307;C0231683;C0439166;C2347086;C4553972
2435,medium normal ( n = $nmbr$ ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
2435,lowest normal ( n = $nmbr$ ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
2435,low normal ( n = $nmbr$ ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
2435,high normal ( n = $nmbr$ ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
2435,crp ( normal < $nmbr$ . $nmbr$ mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
2434,tophi present  n ( % ),C0221248
2434,presence of tophi  n ( % ),C0150312;C0221248;C0392148;C3854307
2434,presence of tophi,C0150312;C0221248;C0392148;C3854307
2434,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
2433,adherence to study regimen — no . ( % ) ff,C1510802
2433,adherence to study regimen — no . ( % ),C1510802
2433,adherence > $nmbr$ %,C1510802
2432,rectum and sigmoid colon only,C0034896
2432,rectum,C0034896
2431,dermatitis atopic,C0011603
2430,cholecystitis chronic,C0008325;C1963083;C4553186
2429,enthesitis score *,C0449820;C1282952;C4050231
2429,enthesitis count,C0750480;C1282952;C1705566
2429,enthesitis  n ( % ),C1282952
2429,enthesitis  % §,C1282952
2429,enthesitis,C1282952
2428,edss stratification . no . ( % ),C0451246;C1514983;C3887783
2428,edss stratification  no . ( % ),C0451246;C1514983;C3887783
2428,edss score,C0451246;C3887783
2427,other diuretic,C0012798
2427,non diuretics,C0012798;C1518422
2427,diuretics ^,C0012798
2427,diuretics * *,C0012798
2427,diuretics ( % ),C0012798
2427,diuretics  n ( % ),C0012798
2427,diuretics  %,C0012798
2427,diuretics,C0012798
2427,diuretic use,C0012798;C0042153;C0457083;C1947944
2427,diuretic n ( % ),C0012798
2427,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
2427,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
2427,diuretic drugs,C0012798;C0013227;C3687832
2427,diuretic ( any ),C0012798
2427,diuretic,C0012798
2426,diuretic — no . / total no . ( % ),C0012798
2426,diuretic — no . ( % ) surgery,C0012798
2426,diuretic agents ( excluding antialdosterone ),C0012798;C0450442;C1254351;C1521826
2426,diuretic agents,C0012798;C0450442;C1254351;C1521826
2426,diuretic agent,C0012798;C0450442;C1254351;C1521826
2425,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
2425,time from qualifying ecg to balloon inflation,C0040223;C1514624;C1623258;C3541383
2425,si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs,C1623258;C4050619
2425,ecg left ventricular,C1623258
2425,ecg changes ( % ) t,C1623258
2425,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
2425,ecg and imaging data,C1623258
2425,ecg abnormality ( resting )  %,C1623258;C1704258
2425,ecg,C1623258
2425,due to ecg changes,C1623258
2424,lvh by electrocardiogram  n ( % ),C0013798;C0149721;C1547122;C1623258
2424,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
2424,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
2424,electrocardiography,C0013798;C1623258
2424,electrocardiograph results  no . ( % ),C0013798;C0180600;C1623258
2424,electrocardiogram,C0013798;C1547122;C1623258
2423,fgf - $nmbr$ low / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
2423,fgf - $nmbr$ low / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
2423,fgf - $nmbr$ high / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
2423,fgf - $nmbr$ high / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
2423,elevated vs normalb,C0205250;C3163633
2423,elevated vs . normalc,C0205250;C3163633
2423,elevated vs . normalb,C0205250;C3163633
2423,elevated troponin — %,C0041199;C0205250;C3163633
2423,elevated troponin ( > $nmbr$ . $nmbr$ pg / l ),C0041199;C0205250;C0439278;C3163633
2423,elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %,C0041199;C0205250;C0439268;C3163633
2423,elevated troponin,C0041199;C0205250;C3163633
2423,elevated tg,C0205250;C0337445;C3163633
2423,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
2423,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
2423,elevated hscrp,C0205250;C3163633
2423,elevated fasting glucose,C0205250;C3163633
2423,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C3163633
2423,elevated cardiac markers,C0205250;C1271630;C3163633
2423,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
2423,elevated biomarkers and st - segment changes,C0005516;C0205250;C3163633
2423,elevated at wk $nmbr$ — no . ( % ) $nmbr$,C0205250;C0332174;C0439230;C3163633
2423,elevated at wk $nmbr$ — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
2423,age > $nmbr$ yr  elevated biomarkers  and st - segment changes,C0001779;C0005516;C0205250;C0439234;C3163633
2423,age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular,C0001779;C0005516;C0205250;C0439234;C3163633
2422,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
2422,ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
2422,high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high titre ( > $nmbr$ times of uln )  n ( % ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high crp or esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2422,high crp and esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2422,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( n = $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( i $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
2422,high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ . $nmbr$ u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ )  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( > $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( $nmbr$ - $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high ( $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2422,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2421,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
2421,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
2421,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2421,total daily insulin dose  units / kgt,C0021641;C0439148;C1519795;C1533581;C1579433;C2348070;C3714501;C3853603
2421,total daily insulin dose  u,C0021641;C0439148;C1533581;C1579433;C2348070;C3714501
2421,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
2421,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
2421,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2421,placebo + insulin ( n   = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
2421,placebo + insulin ( n = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
2421,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
2421,oad plus insulin,C0021641;C1533581;C1579433;C3714501
2421,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
2421,mean ± sd fasting insulin  uu / ml,C0015663;C0021641;C0439342;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
2421,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
2421,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
2421,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
2421,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
2421,insulin treated,C0021641;C1533581;C1579433;C3714501
2421,insulin therapy  n ( % ) 本,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
2421,insulin therapy  n ( % ),C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
2421,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
2421,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
2421,insulin plus > $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2421,insulin plus $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2421,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2421,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
2421,insulin dependentc,C0021641;C1533581;C1579433;C3714501
2421,insulin based,C0021641;C1533581;C1579433;C3714501
2421,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
2421,insulin alone,C0021641;C1533581;C1579433;C3714501
2421,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
2421,insulin - treated dm,C0021641;C1533581;C1579433;C3714501
2421,insulin - treated diabetes  %,C0021641;C1533581;C1579433;C3714501
2421,insulin - treated diabetes,C0021641;C1533581;C1579433;C3714501
2421,insulin - treated,C0021641;C1533581;C1579433;C3714501
2421,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
2421,insulin - requiring,C0021641;C1533581;C1579433;C3714501
2421,insulin - naive  n ( % ),C0021641;C1533581;C1579433;C3714501
2421,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
2421,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
2421,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
2421,insulin + oad,C0021641;C1533581;C1579433;C3714501
2421,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
2421,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
2421,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
2421,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
2421,insulin ( % ),C0021641;C1533581;C1579433;C3714501
2421,insulin  pmol / l,C0021641;C0439284;C1533581;C1579433;C3714501
2421,insulin  n ( % ),C0021641;C1533581;C1579433;C3714501
2421,insulin,C0021641;C1533581;C1579433;C3714501
2421,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
2421,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
2421,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2421,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
2421,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
2421,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2421,fasting insulin  pmol / l ( mean ± sd ),C0015663;C0021641;C0439284;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
2421,fasting insulin  iiiu / ml  mean ± sd,C0015663;C0021641;C0439526;C0444504;C1533581;C1579433;C1705224;C2347634;C2348143;C2699239;C3714501;C3887665
2421,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
2421,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2421,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
2421,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
2421,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
2421,$nmbr$ - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
2420,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
2420,severe ( ipss > $nmbr$ ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
2420,severe ( ipss > $nmbr$ ) ( n = $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
2420,moderate ( ipss < $nmbr$ ) ( n = $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
2420,mean ipss  voiding subscore ( sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
2420,mean ipss  storage sub - score ( sd ),C0337174;C0542339;C1019118;C1264637;C1698986;C1753314;C1998280;C2699239;C2827405;C3533236;C3811063
2420,ipss voiding subscore,C1019118;C1998280;C2827405;C3811063
2420,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
2420,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
2420,ipss hrql,C1019118;C1998280;C2827405;C3811063
2420,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
2420,ipss - v,C1019118;C1998280;C2827405;C3811063
2420,ipss - s,C1019118;C1998280;C2827405;C3811063
2420,ipss  “ / o,C1019118;C1998280;C2827405;C3811063
2420,ipss,C1019118;C1998280;C2827405;C3811063
2420,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
2420,= international prostate symptom score,C1998280
2419,relative risk comparing icd therapy and placebo,C0021122;C0039798;C0087111;C0242492;C1363945;C1707455
2419,relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0039798;C0087111;C0242492;C0596019;C1363945;C1707455
2419,icd vs . placebo,C0021122
2419,icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0021122;C0039798;C0087111;C1363945
2419,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
2419,icd or crt - d,C0021122
2419,icd / crt - d  n ( % ),C0021122
2419,icd  n ( % ),C0021122
2419,icd  %,C0021122
2419,icd,C0021122
2418,tk,C0041405;C0220928;C4050092
2417,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
2417,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
2417,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
2417,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
2417,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
2417,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
2417,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023823;C0039411;C0040642;C0041004;C0041405;C0041698;C1436327;C1824670;C2744579;C2983605;C2986463;C3272447;C3884535;C3890735;C4048285;C4521369;C4522122;C4552600
2417,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0001645;C0003195;C0003591;C0003594;C0006684;C0008377;C0011849;C0012634;C0017977;C0023821;C0023824;C0039411;C0040642;C0041004;C0041405;C0041698;C0201950;C0202117;C0428473;C0441885;C0543421;C0549183;C0871420;C1319793;C1824670;C2698967;C2757014;C3272447;C3541930;C3715113;C4522122
2417,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
2417,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having,C0023128;C0039411;C0040642;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C3272447;C3642216;C4522122
2416,v total ( n = $nmbr$ ),C0439175;C0439810
2416,total updrs score ( range  $nmbr$ — $nmbr$ ) y,C0439175;C0439810;C3639721
2416,total updrs score ( range  $nmbr$ - $nmbr$ ) 卞,C0439175;C0439810;C3639721
2416,total updrs score ( baseline )  mean ( sd ),C0439175;C0439810;C3639721
2416,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
2416,total stent length  mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
2416,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
2416,total sgrq score,C0439175;C0439810
2416,total sample = $nmbr$ ( % ),C0370003;C0439175;C0439810;C2347026
2416,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
2416,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
2416,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
2416,total randomized  n,C0034656;C0439175;C0439810;C3815594
2416,total randomized,C0439175;C0439810
2416,total randomised ( n ),C0439175;C0439810
2416,total phase $nmbr$ pooled ( n = $nmbr$ ),C0205390;C0439175;C0439810;C1710475
2416,total patients n = $nmbr$,C0030705;C0439175;C0439810
2416,total patients  n,C0030705;C0439175;C0439810
2416,total patients,C0030705;C0439175;C0439810
2416,total occlusion  n ( % ),C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
2416,total number of patients,C0439175;C0439810;C2360800
2416,total number of events / participants,C0439175;C0439810;C0679646;C4330837
2416,total no . of patients,C0439175;C0439810
2416,total no . of events / total no . of participants,C0439175;C0439810
2416,total no . of events / participants,C0439175;C0439810
2416,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810
2416,total no . $nmbr$,C0439175;C0439810
2416,total no .,C0439175;C0439810
2416,total n   =   $nmbr$,C0439175;C0439810
2416,total n = $nmbr$ n ( % ),C0439175;C0439810
2416,total n = $nmbr$,C0439175;C0439810
2416,total n $nmbr$,C0439175;C0439810
2416,total n,C0439175;C0439810
2416,total ldl - c *,C0439175;C0439810
2416,total invasive cancer,C0439175;C0439810;C0677898
2416,total included in combined analysis,C0439175;C0439810
2416,total ige — lu / ml,C0439175;C0439810;C2697941
2416,total ige  geometric,C0439175;C0439810
2416,total hipc,C0439175;C0439810
2416,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
2416,total haq  $nmbr$ - $nmbr$,C0102923;C0439175;C0439810;C0451208
2416,total hands score,C0018563;C0439175;C0439810;C1552914
2416,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
2416,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C1333400
2416,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C1333400
2416,total deaths  n,C0011065;C0439175;C0439810;C1306577
2416,total deaths,C0011065;C0439175;C0439810;C1306577
2416,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
2416,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
2416,total cohort,C0009247;C0439175;C0439810;C0599755
2416,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
2416,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
2416,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
2416,total c ( mg / dl ) *,C0439175;C0439269;C0439810
2416,total c,C0439175;C0439810
2416,total > atients,C0439175;C0439810
2416,total - c,C0439175;C0439810
2416,total *,C0439175;C0439810
2416,total ( v = $nmbr$  $nmbr$ ),C0439175;C0439810
2416,total ( n   =   $nmbr$ ),C0439175;C0439810
2416,total ( n   = $nmbr$ ),C0439175;C0439810
2416,total ( n [ $nmbr$ ),C0439175;C0439810
2416,total ( n = $nmbr$ ),C0439175;C0439810
2416,total ( n = $nmbr$ $nmbr$ ),C0439175;C0439810
2416,total ( n = $nmbr$  $nmbr$ ) - -,C0439175;C0439810
2416,total ( n = $nmbr$  $nmbr$ ),C0439175;C0439810
2416,total ( n ),C0439175;C0439810
2416,total ( n $nmbr$ $nmbr$ ),C0439175;C0439810
2416,total $nmbr$,C0439175;C0439810
2416,total !,C0439175;C0439810
2416,total  n = $nmbr$ $nmbr$,C0439175;C0439810
2416,total  n = $nmbr$,C0439175;C0439810
2416,total,C0439175;C0439810
2416,sgrq - c total scoreb,C0439175;C0439810;C3826872
2416,o total randomized,C0439175;C0439810;C0483204
2416,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
2416,no . / total no . ( % ) t,C0439175;C0439810
2416,no . / total no . ( % ),C0439175;C0439810
2416,no . / total 	 no . ( % ),C0439175;C0439810
2416,no . / total,C0439175;C0439810
2416,men  total ( n 二 $nmbr$ ),C0025266;C0439175;C0439810
2416,men  total ( n = $nmbr$ ),C0025266;C0439175;C0439810
2416,linagliptin  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C2746078;C3541888
2416,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
2416,hf  total,C0018488;C0439175;C0439810;C1313497;C1538440;C3273279
2416,event / total,C0439175;C0439810;C0441471;C4019010
2416,duration of total exposure to study treatment  weeks,C0439175;C0439810;C2826870
2416,cvd  total,C0007222;C0439175;C0439810
2416,chd  total,C0280604;C0439175;C0439810;C3542407
2416,asian itt population total ( n = $nmbr$ ),C0032659;C0078988;C0439175;C0439810;C1257890
2416,$nmbr$ — no . / total no . ( % ),C0439175;C0439810
2416,$nmbr$ - $nmbr$ — no . / total no . ( % ),C0439175;C0439810
2416,$nmbr$  no . / total no . ( % ),C0439175;C0439810
2415,tpm subgroup  n = $nmbr$,C0076829;C1079230;C1515021
2415,subgroups,C1079230
2415,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2415,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
2415,subgroup p valuef,C1079230;C1515021
2415,subgroup p value 本,C1079230;C1515021;C1709380
2415,subgroup p value !,C1079230;C1515021;C1709380
2415,subgroup p - value $nmbr$,C1079230;C1515021;C1709380
2415,subgroup overall,C0282416;C1079230;C1515021;C1561607
2415,subgroup no .,C1079230;C1515021
2415,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
2415,subgroup levels,C0441889;C1079230;C1515021
2415,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2415,subgroup based on :,C1079230;C1515021
2415,subgroup $nmbr$,C1079230;C1515021
2415,subgroup,C1079230;C1515021
2415,secondary prevention subgroup,C0679699;C1079230;C1515021
2415,primary prevention subgroup,C0033144;C1079230;C1515021
2415,prespecified subgroups,C1079230
2415,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
2415,p  subgroup *,C0369773;C1079230;C1515021;C2603361
2415,outcome_subgroup,C1079230;C1274040;C1515021
2415,m $nmbr$ subgroup,C0369637;C0441923;C1079230;C1515021
2415,ltg subgroup  n = $nmbr$,C1079230;C1420817;C1515021;C4521367;C4521846
2415,genetic subgroup,C0017296;C0314603;C1079230;C1515021
2415,diuretic subgroup,C0012798;C1079230;C1515021
2415,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
2415,baseline subgroup,C0168634;C1079230;C1442488;C1515021
2415,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
2415,baseline hba $nmbr$ c subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
2415,asubset of the ≥ $nmbr$ years subgroup .,C0439234;C1079230;C1515021
2415,( subgroup ),C1079230;C1515021
2415,( a ) bmi subgroups,C0578022;C1079230
2414,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
2414,cough ( leading to study drug discontinuation ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2414,cough ( investigator reported ),C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727
2414,cough  n ( % ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2414,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2414,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2413,ill -,C0231218
2412,alleles,C0002085
2411,all mis *,C0687670;C1333208;C1412384;C3538735
2411,all mis,C0687670;C1333208;C1412384;C3538735
2410,quality of life,C0034380;C0518214
2410,qol,C0518214
2409,total bilirubin > $nmbr$ x uln $nmbr$,C0005437;C0368753;C1519815
2409,total bilirubin  mg / dl,C0005437;C0368753;C0439269
2408,total body ( without head ),C0018670;C0229960;C1706305
2408,total body,C0229960
2407,h pylori serology *,C0036745;C0079488;C0220911;C0455278
2406,olodaterol sgg,C2934193
2406,olodaterol $nmbr$ pg,C0030827;C0072225;C1266240;C2934193
2406,olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
2406,olodaterol $nmbr$ jig,C2934193
2406,olodaterol,C2934193
2405,tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2405,tadalafil $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2405,tadalafil,C1176316
2404,trandolapril ( n = $nmbr$ ),C0076891
2404,trandolapril,C0076891
2403,black / african,C0337824
2402,hispanic american,C0019576
2402,hispanic / latin american,C0019576
2401,question $nmbr$ ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
2401,neck pain,C0007859;C1963180;C4553909
2401,back pain,C0004604;C1963071;C4553945
2400,statin + er niacin ( n = $nmbr$ ),C0027996;C0360714;C1142562;C3810541;C3811131
2400,niacin ( n = $nmbr$ ),C0027996;C1142562
2400,niacin  n ( % ),C0027996;C1142562
2400,niacin,C0027996;C1142562
2399,vertebrobasilar infarct,C0021308;C0545733
2399,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
2399,prior infarction,C0021308;C0332152;C2826257
2399,nonfatal myocardiail infarction,C0021308
2399,nonfatai myocardiai infarction,C0021308
2399,no infarct visible,C0021308
2399,myocardiai infarction,C0021308
2399,infarct size,C0021308;C0456389
2399,carotid infarct,C0021308;C0741968
2399,cardioembolic infarction  n ( % ),C0021308
2399,atherothrombotic infarction  n ( % ),C0021308
2399,any infarct,C0021308
2398,q waves in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
2398,q wave in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
2398,infarct territory ( % ),C0021308;C1301808;C2983136
2397,infarction before age $nmbr$ ( a ),C0001779;C0021308
2397,infarction > $nmbr$ days previously,C0021308;C0439228
2397,infarction $nmbr$ - $nmbr$ days,C0021308;C0439228
2397,infarct ion w ithin previous $nmbr$ day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
2397,infarct - related vessel ( % ),C0021308
2396,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
2396,transient ischemic attack,C0007787;C0917805
2396,transient ischaemic attack — no . ( % ),C0007787;C0917805
2396,transient ischaemic attack,C0007787;C0917805
2396,tia  n ( % ),C0007787;C0917805;C1054154
2396,tia,C0007787;C0917805;C1054154
2396,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
2396,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
2396,hemispheric tia n = $nmbr$,C0007787;C0205139;C0917805;C1054154
2395,coronary bypass graft,C1260596
2394,coronar y - artery bypass grafting,C0450140;C0741847
2394,arterial graft,C0450140
2393,north america plus australia and new zealand,C0004340;C0028405;C0332287
2393,north america n z $nmbr$,C0028405
2393,north america hr ( $nmbr$ % cl ),C0028405;C0596019
2393,north america / oceania,C0028405;C0282279;C4085681
2393,north america *,C0028405
2393,north america ( plus australia and new zealand ),C0004340;C0028405;C0332287
2393,north america ( plus america and new zealand ),C0028405;C0332287
2393,north america ( n = $nmbr$ ),C0028405
2393,north america ( % ),C0028405
2393,north america,C0028405
2392,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
2392,other forms of atherosclerosis ^,C0003850;C0004153;C0348078;C0376315
2392,other forms of,C0348078;C0376315
2392,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
2391,short term ^,C0443303
2391,short term ( n = $nmbr$ ) +,C0443303
2390,orthopnea  ( % ),C0085619
2390,orthopnea,C0085619
2389,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4521986
2389,oral β - adrenergics  n ( % ),C0001637;C0442027;C4521986
2389,oral treprostinil ( n = $nmbr$ ),C0442027;C1145760;C4521986
2389,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
2389,oral or other systemic corticosteroid,C0442027;C4521986
2389,oral fi - blockers,C0442027;C4050619;C4521986
2389,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
2389,oral antidiabetes combination therapy without insulina  n ( % ),C0009429;C0442027;C0556895;C4521986
2389,oral ( % ),C0442027;C4521986
2389,oral,C0442027;C4521986
2389,no po,C0032729;C0442027
2388,previous coronary angioplasty  n ( % ),C2114427
2387,previous coronary artery bypass surgery  no . ( % ),C2144990
2387,previous coronary artery bypass grafting,C2144990
2387,previous coronary artery bypass graft,C2144990
2387,previous coronary - artery bypass grafting,C2144990
2386,native coronary - artery lesions,C0205042;C0221198;C0302891
2386,coronary artery treated  no . ( % ),C0205042
2386,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
2386,coronary artery,C0205042
2385,nice secondary prevention onlyb,C0679699;C4087029
2385,nice primary prevention onlyb,C0033144;C4087029
2384,coronary events $nmbr$,C0741923
2384,acute coronary event,C0205178;C0741923
2383,no . of coronary vessels with > $nmbr$ % diameter stenosis,C0010075
2382,coronary artery stenosis > $nmbr$ %,C0242231
2382,> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0242231;C0741968
2382,> $nmbr$ % coronary stenosis,C0242231
2381,left main coronary artery bifurcation,C3898614
2380,ischemic coronary artery disease,C0852149
2379,single vessel coronary artery disease †,C0581374
2379,single vessel coronary artery disease *,C0581374
2379,single vessel coronary artery disease $nmbr$,C0581374
2379,multi - vessel coronary artery disease,C1299432
2378,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
2378,coronar y artery disease,C0852949
2378,coronaiy artery disease,C0852949
2377,history of coronary artery disease — no . { % ),C1881055
2377,history of coronary artery disease - n ( % ),C1881055
2377,history of coronary artery disease,C1881055
2376,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
2376,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
2376,previous coronary artery disease  n ( % ),C0010054;C0010068;C0205156;C1552607;C1956346
2376,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
2376,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
2376,multivessel coronary artery disease,C0010054;C0010068;C1956346
2376,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
2376,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
2376,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
2376,coronary heart disease ( % ),C0010054;C0010068;C1956346
2376,coronary heart disease  n ( % ) t,C0010054;C0010068;C1956346
2376,coronary heart disease  n ( % ) b,C0010054;C0010068;C1956346
2376,coronary heart disease,C0010054;C0010068;C1956346
2376,coronary disease,C0010068;C1956346
2376,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
2376,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
2376,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
2376,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
2376,coronary artery disease — %,C0010054;C0010068;C1956346
2376,coronary artery disease §,C0010054;C0010068;C1956346
2376,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
2376,coronary artery disease ^,C0010054;C0010068;C1956346
2376,coronary artery disease *,C0010054;C0010068;C1956346
2376,coronary artery disease ( n = $nmbr$ $nmbr$ ),C0010054;C0010068;C1956346
2376,coronary artery disease ( % ),C0010054;C0010068;C1956346
2376,coronary artery disease    n   ( % ),C0010054;C0010068;C1956346
2376,coronary artery disease  n ( % ),C0010054;C0010068;C1956346
2376,coronary artery disease  %,C0010054;C0010068;C1956346
2376,coronary artery disease,C0010054;C0010068;C1956346
2376,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
2376,any coronary artery disease,C0010054;C0010068;C1956346
2375,risk marker and model,C1519104
2374,sle markers  n ( % ),C0005516;C0024141
2374,biomarker low,C0005516
2374,biomarker levels,C0005516;C0441889
2374,biomarker high,C0005516
2373,biomarker status,C0449442
2372,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
2372,cardiac biomarker  n ( % ),C1271630
2372,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
2372,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
2371,micral test result,C0456984;C0587081
2371,laboratory findings,C0587081
2370,prior llt,C0332152;C2347090;C2826257
2370,no prior llt,C0332152;C2347090;C2826257
2370,allhat - llt,C2347090
2369,transient st elevation,C0040704;C0205374;C0520886
2369,transient,C0040704;C0205374
2369,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
2369,associated with transient or reversible risk factor,C0040704;C0205374;C0332281
2368,temporary risk factor,C0035648;C0205374;C1548539;C3245481
2368,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
2367,severe oa symptoms at baselined,C0029408;C0436345;C3887876
2367,oa,C0029408;C3887876
2367,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
2366,osteoarthritis,C0029408
2366,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
2365,oma / oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
2365,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
2365,oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
2365,oat,C0028753;C0331496;C0939905;C3539067;C3897364
2364,pre fvc % pred,C0332152;C0740175;C2257086;C3669034;C3714541
2364,pre fev $nmbr$   % pred,C0332152;C0740175;C2257086;C3669034;C3714541
2364,pre - bd fvc s $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
2364,pre - bd fvc < $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
2364,mild ( fev  > $nmbr$ % predicted ),C2945599;C3714541
2364,iv : fev $nmbr$ < $nmbr$ % predicted,C0022326;C3714541;C4265176
2364,fev $nmbr$ % pred,C3714541
2364,absolute decline in fvc > $nmbr$ % predicted or death  n ( % ),C0205344;C3714541
2364,absolute decline in fvc > $nmbr$ % predicted,C0205344;C3714541
2364,$nmbr$ ( fev $nmbr$ < $nmbr$ % pred ),C3714541
2363,screening % predicted fev $nmbr$,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
2363,percent of predicted fev $nmbr$,C1882327;C3714541
2363,fvc % predicted !  t,C3714541
2363,fvc  % predicted  mean ( sd ),C3714541
2363,fev $nmbr$ percent predicted ( sd ),C0439165;C3714541
2363,fev $nmbr$ ( % predicted normal ),C3714541
2363,fev $nmbr$ % predicted ≥ $nmbr$ %,C3714541
2363,fev $nmbr$ % predicted normal,C3714541
2363,fev $nmbr$ % predicted at baseline,C3714541
2363,fev $nmbr$ % predicted < $nmbr$ %,C3714541
2363,fev $nmbr$ % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
2363,fev $nmbr$ % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
2363,fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
2363,% predicted fev ^,C0681842;C1882327;C3714541
2363,% predicted fev $nmbr$,C0681842;C1882327;C3714541
2363,% predicted fev,C0681842;C1882327;C3714541
2362,post fvc % pred,C0687676;C1704687;C3469826;C3714541
2362,post fvc,C0687676;C1704687;C3469826;C3714541
2362,post fev $nmbr$   % pred,C0687676;C1704687;C3469826;C3714541
2362,post fev $nmbr$,C0687676;C1704687;C3469826;C3714541
2362,fev $nmbr$ / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
2362,fev $nmbr$ / fvc ( post - albuterol ),C3714541
2362,fev $nmbr$ / fvc  post - albuterol  %,C3714541
2362,fev $nmbr$ ( post - albuterol )  l,C0001927;C0687676;C1704687;C3469826;C3714541
2362,fev $nmbr$ % predicted ( post salbutamol ),C3714541
2362,fev $nmbr$ % predicted  post - albuterol  %,C3714541
2362,fev $nmbr$ % pred . ( post - albuterol )  %,C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
2362,fev $nmbr$  post - albuterol  l,C0001927;C0687676;C1704687;C3469826;C3714541
2361,fvc ∗,C3714541
2361,fvc — liters,C0475211;C3714541
2361,fvc ( liters ),C0475211;C3714541
2361,fvc ( l ) *,C3714541
2361,fvc ( l ),C3714541
2361,fvc  ml,C0439526;C1705224;C3714541;C3887665
2361,fvc  l,C3714541
2361,fvc,C3714541
2361,fev_ ( l ) :,C3714541
2361,fev auc i $nmbr$ h,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
2361,fev $nmbr$ — liters,C0475211;C3714541
2361,fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0376690;C3714541
2361,fev $nmbr$ / fvc %,C3714541
2361,fev $nmbr$ / fvc  % a,C3714541
2361,fev $nmbr$ / fvc  % *,C3714541
2361,fev $nmbr$ / fvc,C3714541
2361,fev $nmbr$ ( liters ),C0475211;C3714541
2361,fev $nmbr$ ( l ),C3714541
2361,fev $nmbr$  la,C0023031;C0023749;C0230347;C2346906;C3714541;C4553351
2361,fev $nmbr$  l *,C3714541
2361,fev $nmbr$  l,C3714541
2361,fev $nmbr$,C3714541
2361,fev,C3714541
2360,trough fev $nmbr$,C0444506;C3714541
2360,c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
2359,prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
2359,pre - bronchodilator fev  % predicted,C2599602;C3714541
2359,pre - bronchodilation fvc,C0439566;C3714541
2359,pre - bronchodilation fev $nmbr$,C0439566;C3714541
2359,post - bronchodilation fvc,C0439576;C3714541
2359,post - bronchodilation fev $nmbr$,C0439576;C3714541
2359,mean prebronchodilator fev $nmbr$ ( sd )  % predicted,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2359,fvc pre - bronchodilator,C2599602;C3714541
2359,fvc post - bronchodilator,C3714541
2359,fev $nmbr$ prebronchodilator [ l ]  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2359,fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd,C0219433;C0444504;C1549735;C2347634;C2348143;C2599602;C2699239;C3541307;C3714541;C4049640;C4049767
2359,fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2359,fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d,C2599602;C3714541
2359,fev $nmbr$ pre - bronchodilator,C2599602;C3714541
2359,fev $nmbr$ post - bronchodilator,C3714541
2359,fev $nmbr$ / fvc prebronchodilatort,C3714541
2359,fev $nmbr$ / fvc prebronchodilator  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2359,fev $nmbr$ ( l ) pre - bronchodilator,C2599602;C3714541
2359,fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
2359,baseline pre - bronchodilator fev $nmbr$  l,C0168634;C1442488;C2599602;C3714541
2358,prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2358,pre - bronchodilator mean ( sd ) fev $nmbr$  . l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
2358,post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd ),C0444504;C0456603;C1547037;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$  l  mean ( sd ) c,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
2358,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean postbronchodilatora fev $nmbr$  % predicted ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
2358,mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean ( sd ) postbronchodilator fev $nmbr$ % predicted,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted,C0439165;C0444504;C1549488;C1561533;C2347634;C2348143;C2599594;C2699239;C3714541
2358,mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
2358,fvc > $nmbr$ % predicted,C3714541
2358,fvc < $nmbr$ % predicted,C3714541
2358,fvc ( % predicted ),C3714541
2358,fvc  % predicted,C3714541
2358,fev $nmbr$ post - bronchodilator  % predicted normal,C3714541
2358,fev $nmbr$ ( % predicted ),C3714541
2358,fev $nmbr$ % predicted,C3714541
2358,fev $nmbr$  mean  l,C0444504;C2347634;C2348143;C3714541
2358,fev $nmbr$  mean  % predicted,C0444504;C2347634;C2348143;C3714541
2358,fev $nmbr$  % predicteda,C3714541
2358,fev $nmbr$  % predicted,C3714541
2358,fev  > $nmbr$ % predicted,C3714541
2358,fev  < $nmbr$ % predicted,C3714541
2358,fev  % predicted,C3714541
2357,fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412
2357,fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412
2357,fp ( n   = $nmbr$  $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
2357,fp ( n [ $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
2357,fp ( n = $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
2357,fp,C0016704;C1419068;C1419906;C3541238;C3541412
2356,flex aln ^,C0729594;C2681220
2355,fg > $nmbr$,C0016703;C0439214;C2348814
2354,lei > $nmbr$ ( n = $nmbr$ ),C0023401;C0428209
2354,lei $nmbr$,C0023401;C0428209
2353,ldl - cz,C0206578
2353,ez / simva n = $nmbr$ n ( % ),C0206578
2353,ez / simva < % >,C0206578
2353,ez / simva $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
2353,ez / simva $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
2353,ez / simva,C0206578
2353,czech republic,C0206578
2353,all ez / simva,C0206578
2353,a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$,C0206578
2353,a $nmbr$ + ez n = $nmbr$,C0206578
2353,a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0206578
2353,a $nmbr$ + ez $nmbr$,C0206578
2352,alt  ast  or both > $nmbr$ x uln,C3831581
2351,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
2351,grip strength < meidan,C0429271;C2598165
2350,£ $nmbr$ m b ' m in,C1709500
2350,bloodpressure  mean ( sd )  m m hg,C0025424;C0428257;C0428886;C1709500;C2347108;C2347109;C2348272;C2699239
2349,st segment depression,C0520887
2349,st depression > $nmbr$ mm,C0520887;C4330985;C4554674
2349,st - segment depression > $nmbr$ mm — no . ( % ),C0520887;C4330985;C4554674
2349,st - segment depression > $nmbr$ mm,C0520887;C4330985;C4554674
2349,st - segment depression,C0520887
2348,st depression or elevation,C0520887
2348,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
2348,st - segment depression or t - wave inversion on ecg,C0520887
2348,st - depression and t - wave inversion,C0520887
2348,no st depression or elevation,C0520887
2347,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
2347,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
2347,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
2347,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
2347,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
2347,met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ ),C0392707;C0428210;C1550543;C3539705;C4317104
2347,met / tzd,C0428210;C1550543;C4317104
2347,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
2347,met ( n = $nmbr$ ),C0428210;C1550543;C4317104
2347,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
2347,add - on to met + su $nmbr$,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
2347,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
2347,add - on to met $nmbr$,C0428210;C1550543;C1883712;C4317104
2347,add - on to met,C0428210;C1550543;C1883712;C4317104
2346,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
2346,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
2346,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
2346,seated sbp at $nmbr$ weeks  mmhg + * *,C0085805;C0277814;C0439230;C0439475;C1283233
2346,seated sbp at $nmbr$ weeks  mmhg +,C0085805;C0277814;C0439230;C0439475;C1283233
2346,seated sbp  n,C0085805;C0277814;C1283233
2345,sitting systolic blood pressure ( mm hg ),C0277814;C2584297;C4050224
2345,sitting pulse  bpma,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
2345,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
2345,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
2345,baseline sitting sbp  $nmbr$ mm hg,C0085805;C0168634;C0277814;C0439475;C1442488;C2584297;C4050224
2345,baseline sitting dbp  * mm hg,C0168634;C0277814;C0439475;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
2344,tj ( $nmbr$ - $nmbr$ ),C0039247
2344,tj ( $nmbr$ % ),C0039247
2344,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
2344,- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti,C0039247;C0040302;C1553045;C1704756
2343,tt,C1452561;C4554543
2342,tgt,C1421391;C1428265;C4321338
2341,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
2341,gt,C1435727;C1704693;C2697657
2340,ze + statin,C0360714
2340,pbo + statin n = $nmbr$,C0031962;C0360714
2340,pbo + statin $nmbr$,C0031962;C0360714
2340,pbo + statin,C0031962;C0360714
2340,other statin,C0360714
2340,no statin,C0360714
2340,neither pbo + statin eze + statin,C0031962;C0360714
2340,eze + statin n = $nmbr$,C0360714
2340,eze + statin,C0360714
2340,baseline statin usec,C0168634;C0360714;C0439224;C1442488
2340,baseline statin,C0168634;C0360714;C1442488
2340,baseiine statin,C0360714
2340,any statin,C0360714
2339,statin with niacin,C0027996;C0360714;C1142562
2339,statin with fibrate,C0360714
2339,niacin + statin,C0027996;C0360714;C1142562
2339,llv wlalil $nmbr$ statin,C0360714
2339,extended - release niacin plus statin ( n = $nmbr$ ),C0027996;C0332287;C0360714;C1142562;C1707968
2338,statins  n ( % ),C0360714
2338,statins,C0360714
2338,statin use ( % ),C0042153;C0360714;C0457083;C1947944
2338,statin use  n ( % ),C0042153;C0360714;C0457083;C1947944
2338,statin use,C0042153;C0360714;C0457083;C1947944
2338,statin usage,C0360714;C0457083
2338,statin ( n = $nmbr$ ),C0360714
2338,statin ( n - $nmbr$ ),C0360714
2338,statin  n ( % ),C0360714
2338,statin  % ( n ),C0360714
2338,statin,C0360714
2338,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1947944;C2945760
2338,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
2338,no statin vs statin alone vs any statin plus other llt,C0360714
2338,no statin use,C0042153;C0360714;C0457083;C1947944
2338,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
2338,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
2338,moderate - intensity statin,C0360714;C4081855
2338,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
2338,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
2338,high - dose statin use  n ( % ) e,C0042153;C0360714;C0444956;C0457083;C1947944
2338,all patients on maximally tolerated statin ± other llt,C0030705;C0360714
2337,statins used during follow - up,C0360714
2337,statins / ezetimibe,C0360714;C1142985
2337,statin without other llt,C0360714;C2347090
2337,statin with other llt,C0360714;C2347090
2337,statin with ezetimibe,C0360714;C1142985
2337,statin or ezetimibe,C0360714
2337,statin only ( n = $nmbr$  $nmbr$ ),C0205171;C0360714;C1720467
2337,statin only  n ( % ),C0205171;C0360714;C1720467
2337,statin only,C0205171;C0360714;C1720467
2337,statin monotherapy,C0360714
2337,statin medication,C0013227;C0360714;C3244316;C4284232
2337,statin and / or ezetimibe,C0360714
2337,statin alone,C0360714
2337,statin + fibrate or niacin,C0360714
2337,statin + fibrate or,C0360714
2337,statin + ezetimibe { n = $nmbr$  $nmbr$ ),C0360714;C1142985
2337,statin + ezetimibe ( n = $nmbr$ . $nmbr$ ),C0360714;C1142985
2337,statin + ezetimibe  n ( % ),C0360714;C1142985
2337,statin + ezetimibe,C0360714;C1142985
2337,statin ( s ),C0360714
2337,statin ( open ),C0360714
2337,statin ( % ),C0360714
2337,no statin ( + / - llt ),C0360714;C2347090
2337,ltt other than statin,C0360714
2337,llt other than statin at randomization,C0360714;C2347090
2337,any statin versus no statin at randomization,C0360714
2337,any statin + other llt,C0360714
2337,any statin ( with / without llt ),C0360714
2337,any llt other than statins  n ( % ) b,C0360714;C2347090
2336,statins 一 no . ( % ),C0360714
2336,statins  no . ( % ),C0360714
2336,statin — no . / total no . ( % ),C0360714
2336,statin use — no . { % ),C0360714
2336,statin use at study entry  n ( % ),C0360714;C0869040;C1705654
2336,statin potency stratum  n ( % ),C0360714;C3245505
2336,statin potency medium ( n = $nmbr$ ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
2336,statin intolerant *,C0231200;C0360714
2336,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
2336,statin intensity $nmbr$ * $nmbr$,C0360714;C0522510
2336,statin and / or other lipid - lowering agent therapy,C0360714
2336,combined statin and other lipid - lowering agent use,C0205195;C0360714
2335,moderate - dose statin,C0360714;C1709056
2335,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
2335,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
2334,total comparators ( n = $nmbr$ ),C0439175;C0439810;C1707454;C4553389;C4553390
2334,favors comparator,C0309049;C1707454;C4553389;C4553390
2334,comparator,C1707454;C4553389;C4553390
2333,pairwise comparison,C1707455
2333,comparison,C1707455
2333,a compared wi,C0043193;C1520135;C1707455
2333,a compared w,C1707455
2332,poor compliance / noncompliance,C0032646;C0376405;C0457432
2332,noncompliant,C0457432
2332,non - compliance,C0376405;C0457432
2331,loop or thiazide diuretic ^,C0445022
2331,loop or thiazide diuretic : ! :,C0445022
2331,loop or thiazide diuretic #,C0445022
2331,loop or thiazide diuretic,C0445022
2331,loop diureties,C0445022
2331,loop,C0445022
2330,lymphadenopathy,C0497156;C4282165
2329,myopathy,C0026848
2328,dilated cardiomyopathy,C0007193;C2984282
2327,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
2327,ischaemic dilated cardiomyopathy,C1960867
2326,hypertrophic cardiomyopathy,C0007194;C4551472
2325,non - ischaemic cardiomyopathy,C0349782;C1518422
2325,ischemic cardiomyopathy,C0349782
2325,ischaemic cardiomyopathy,C0349782
2324,two - dimensional echocardiography,C0013524
2323,normal coronary angiography,C0853522
2322,computed tomographic angiography,C1536105
2321,radionuclide ventriculography,C0017200;C0034610
2320,duplex ultrasonography,C3825392
2319,univariate p - value,C1709380
2319,rr ( $nmbr$ aci ) [ p value ],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
2319,nteraction p value,C1709380
2319,multivariate p - value,C1709380
2319,interactior p - value,C1709380
2319,heterogeneity p value,C0019409;C0242960;C1709380
2319,chi - square p value,C1552646;C1709380
2319,bonferroni - adjusted p value  d vs a,C1709380;C1879894
2319,bonferroni - adjusted p value  c vs a,C1709380;C1879894
2319,bonferroni - adjusted p value  b vs a,C1709380;C1879894
2318,p value § ( < $nmbr$ vs . > = $nmbr$ years ),C1709380
2318,p value ( vs . previous time point ),C1709380
2318,p value ( on vs off omt ),C1709380
2318,p value ( men versus women ),C0025266;C1709380
2318,p value ( cangrelor versus clopidogrel in women ),C1121991;C1709380
2318,p value ( cangrelor versus clopidogrel in men ),C1121991;C1709380
2318,p value ( aged > $nmbr$ vs . < $nmbr$ years ),C0001779;C0001792;C1709380;C1999167
2317,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
2317,p — value for interaction,C1704675;C1709380
2317,p ‐ value *,C1709380
2317,p ‐ value,C1709380
2317,p   values of interaction,C1704675;C1709380
2317,p   values for interaction,C1704675;C1709380
2317,p   value for interaction,C1704675;C1709380
2317,p   value,C1709380
2317,p values,C1709380
2317,p value 十,C1709380
2317,p value ∥,C1709380
2317,p value § ® ( w,C1709380
2317,p value within category,C0683312;C1709380;C3889287
2317,p value versus placebo,C1709380
2317,p value interaction,C1704675;C1709380
2317,p value for interactiont,C1709380
2317,p value for interaction ®,C1704675;C1709380
2317,p value for interaction ^,C1704675;C1709380
2317,p value for interaction,C1704675;C1709380
2317,p value for,C1709380
2317,p value fo interactio,C1709380
2317,p value f,C0016327;C1709380
2317,p value c,C1709380
2317,p value by gt,C1435727;C1704693;C1709380;C2697657
2317,p value * $nmbr$,C1709380
2317,p value *,C1709380
2317,p value ( nominal ),C1709380
2317,p value ( interaction ),C1704675;C1709380
2317,p value ( inter ),C1709380
2317,p value ( int ),C1709380;C3272375
2317,p value $nmbr$ . $nmbr$,C1709380
2317,p value $nmbr$,C1709380
2317,p value,C1709380
2317,p - value ‘ ’,C1709380
2317,p - value ¶,C1709380
2317,p - value },C1709380
2317,p - value vs . placebo,C1709380
2317,p - value n / n ( % ),C1709380
2317,p - value low vs . high nfs ^,C1709380
2317,p - value interaction,C1704675;C1709380
2317,p - value for variance,C1709380;C1711260;C2348152
2317,p - value for interaction,C1704675;C1709380
2317,p - value for,C1709380
2317,p - value * ' ',C1709380
2317,p - value *,C1709380
2317,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
2317,p - value ( vs placebo ),C1709380
2317,p - value ( overall ),C0282416;C1561607;C1709380
2317,p - value ( lnteraction ),C1709380
2317,p - value ( interaction ) ≠,C1704675;C1709380
2317,p - value ( int ),C1709380;C3272375
2317,p - value ( anova ),C0753802;C1709380
2317,p - value $nmbr$,C1709380
2317,p - value,C1709380
2317,p ' value,C1709380
2317,adjusted p - value for interaction,C0456081;C1704675;C1709380
2317,* p value,C1709380
2317,$nmbr$ p value,C1709380
2316,py = $nmbr$ . $nmbr$ ),C0030428;C3538810
2316,py = $nmbr$ ),C0030428;C3538810
2316,py *,C0030428;C3538810
2316,pa,C0030428;C3541314
2316,no pa,C0030428;C3541314
2316,$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C3541888
2316,$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C4019010
2316,$nmbr$ . $nmbr$ per $nmbr$ py,C0030428;C3538810
2315,om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2315,om $nmbr$ mg / aml $nmbr$ mg,C0023465;C0023467;C0028971;C1319635;C1705272
2315,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2315,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2315,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
2315,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
2315,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
2315,om $nmbr$ / aml $nmbr$ /,C0023465;C0023467;C0028971;C1705272
2315,aml vs . lis,C0023465;C0023467
2315,aml vs . chl,C0023465;C0023467
2315,aml / hctz ( n = $nmbr$ ),C0020261;C0023465;C0023467
2315,aml ( n = $nmbr$ ),C0023465;C0023467
2315,aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
2315,aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C1319635
2315,aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
2315,aml $nmbr$ /,C0023465;C0023467
2315,aml,C0023465;C0023467
2315,a / aml ( n = $nmbr$ ),C0023465;C0023467
2314,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
2314,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2314,type of ml  no . ( % ),C0332307;C0439526;C1547052;C1705224;C3887665
2314,quartiles of fgf - $nmbr$ ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
2314,pvr  ml,C0242852;C0439526;C0456261;C1419141;C1705224;C3887665
2314,pv  ml,C0030840;C0032463;C0439526;C1705224;C3887665
2314,prior ml or stroke at baseline,C0332152;C0439526;C1705224;C2826257;C3887665
2314,prior ml or abnormal angiogram,C0332152;C0439526;C1705224;C2826257;C3887665
2314,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2314,prior history ml or stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
2314,previous ml or abnormal angiogram,C0205156;C0439526;C1552607;C1705224;C3887665
2314,previous ml ( interaction : p = $nmbr$ . $nmbr$ ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
2314,nontatal ml,C0439526;C1705224;C3887665
2314,nonfatal ml,C0439526;C1705224;C3887665
2314,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
2314,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
2314,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
2314,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2314,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
2314,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2314,ml c,C0439526;C1705224;C3887665
2314,ml ),C0439526;C1705224;C3887665
2314,ml,C0439526;C1705224;C3887665
2314,lvesv ( ml ),C0439526;C1705224;C3887665
2314,lvedv ( ml ),C0439526;C1705224;C3887665
2314,low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ ),C0014467;C0205251;C0439526;C1079230;C1515021;C1550472;C1705224;C3887665;C3890211;C4048187;C4321351;C4522223
2314,lav ( ml ),C0019682;C0439526;C1705224;C3887665
2314,high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
2314,decline #   ml · yr − $nmbr$,C0439234;C0439526;C1705224;C3887665
2314,cvdeath  ml  or ischemic stroke,C0439526;C1705224;C3887665
2314,alvesv ( per ml ),C0439526;C1705224;C3887665
2314,alvedv ( per ml ),C0439526;C1705224;C3887665
2314,alav ( per ml ),C0439526;C1705224;C3887665
2314,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
2314,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
2314,adjusted rate of fev $nmbr$   decline ( se )  ml / yr,C0036919;C0439234;C0439526;C0456081;C0871208;C1521828;C1705224;C3714541;C3887665
2314,> = $nmbr$ ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
2314,> $nmbr$ ml,C0439526;C1705224;C3887665
2314,< $nmbr$ ml,C0439526;C1705224;C3887665
2314,* nonfatal ml,C0439526;C1705224;C3887665
2314,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §,C0439526;C1705224;C3887665
2314,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
2314,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
2314,$nmbr$ - $nmbr$ ml / rain,C0034640;C0439526;C1705224;C3887665
2313,mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C1856453
2312,thrombocytopenia,C0040034;C0392386
2312,profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0392386;C0439808
2311,thrombophilia  no . ( % ) e,C0398623
2311,thrombophilia,C0398623
2311,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
2311,known thrombophilia — no . ( % ),C0205309;C0398623
2311,known thrombophilia,C0205309;C0398623
2310,thrombolysis,C0520997
2310,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
2309,weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg,C0022718;C0039725;C0039738;C0439209;C0549183;C0552346;C0876920;C1420718;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
2309,uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1300563;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,th c,C0039725;C0039738;C1420718;C4282123;C4285344
2309,th ( $nmbr$ % ),C0039725;C0039738;C1420718;C4282123;C4285344
2309,on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
2309,median ( $nmbr$ th  $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
2309,low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023824;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023822;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$,C0005893;C0039725;C0039738;C0549183;C0578022;C0876920;C1264641;C1305855;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
2309,age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
2309,age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,age  y ( $nmbr$ th  $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
2309,age  median ( $nmbr$ th — $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,age  median ( $nmbr$ th - $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
2309,$nmbr$ th — $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
2309,$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
2309,$nmbr$ th - $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
2308,fall in last $nmbr$ months ( % ),C0085639;C0238715;C0439231;C4553726
2307,month $nmbr$,C0332177;C0439231
2307,hba $nmbr$ c month $nmbr$ ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
2307,ccsc at $nmbr$ month before enrollment,C0332177;C0439231;C1516705
2307,> $nmbr$ month n = $nmbr$,C0332177;C0439231
2307,< $nmbr$ month n = $nmbr$,C0332177;C0439231
2307,$nmbr$ months,C0439231
2307,$nmbr$ month l,C0332177;C0439231
2306,s $nmbr$ months,C0439231;C0565930;C2603362
2306,intensified $nmbr$ months ( n - $nmbr$ ),C0439231
2306,^ $nmbr$ months,C0439231
2306,> $nmbr$ months ( n = $nmbr$  $nmbr$ ),C0439231
2306,> $nmbr$ months  n ( % ),C0439231
2306,> $nmbr$ months,C0439231
2306,< $nmbr$ months in - $nmbr$ kill,C0162388;C0439231;C0681205;C1550555
2306,< $nmbr$ months  n ( % ),C0439231
2306,< $nmbr$ months,C0439231
2306,$nmbr$ – $nmbr$ months,C0439231
2306,$nmbr$ tob $nmbr$ months  n ( % ),C0439231;C1420851
2306,$nmbr$ tob $nmbr$ months,C0439231;C1420851
2306,$nmbr$ - < $nmbr$ months  n ( % ),C0439231
2306,$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ ),C0439231;C1570610
2306,$nmbr$ - $nmbr$ months ( n = $nmbr$ ),C0439231
2306,$nmbr$ - $nmbr$ months  n ( % ),C0439231
2306,$nmbr$ - $nmbr$ months,C0439231
2305,poor outcome at $nmbr$ months,C0439231;C3806166
2305,months since ra was first diagnosed  mean ( sd ),C0439231
2305,months since first ra symptom  mean ( sd ) f,C0439231
2305,months ( log - transformed ),C0439231
2305,duration of sulphonylurea use ( months )  mean ± s . d .,C0038766;C0439231;C0444504;C1881378;C2347634;C2348143;C2826775;C3536898
2305,duration of previous use of vka  months,C0205156;C0439231;C1552607;C1881378;C2826775
2305,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
2305,duration of dementia symptoms  months,C0011265;C0436359;C0439231;C0497327
2304,smoking status current smoker ( n = $nmbr$ ),C1519386;C3173209;C3241966
2304,smoking history : current smoker,C1519384;C3173209;C3241966
2304,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
2304,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
2304,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
2304,current smokers *,C3173209;C3241966
2304,current smokers ( n = $nmbr$ ),C3173209;C3241966
2304,current smokers ( itt ) ( n = $nmbr$ ),C3173209;C3241966
2304,current smokers ( % ),C3173209;C3241966
2304,current smokers    n   ( % ),C3173209;C3241966
2304,current smokers  n ( % ),C3173209;C3241966
2304,current smokers  %,C3173209;C3241966
2304,current smokers,C3173209;C3241966
2304,current smoker 一 no . ( % ),C3173209;C3241966
2304,current smoker — no . { % ),C3173209;C3241966
2304,current smoker — no . of patients ( % ),C3173209;C3241966
2304,current smoker — no . / total no . ( % ),C3173209;C3241966
2304,current smoker — no . ( % ) blood pressure — mm hg,C3173209;C3241966
2304,current smoker — no . ( % ),C3173209;C3241966
2304,current smoker »,C3173209;C3241966
2304,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
2304,current smoker at screeninga  n ( % ),C3173209;C3241966
2304,current smoker at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
2304,current smoker at baseline    n   ( % ),C0168634;C1442488;C3173209;C3241966
2304,current smoker : ex - smoker ( % ),C3173209;C3241966
2304,current smoker ( n z $nmbr$ ),C3173209;C3241966
2304,current smoker ( n = $nmbr$ ),C3173209;C3241966
2304,current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ ),C0205156;C0750523;C3173209;C3241966
2304,current smoker ( n = $nmbr$  $nmbr$ ),C3173209;C3241966
2304,current smoker ( % ),C3173209;C3241966
2304,current smoker  no . ( % ),C3173209;C3241966
2304,current smoker  no ( % ),C3173209;C3241966
2304,current smoker  n [ % ],C3173209;C3241966
2304,current smoker  n / n ( % ),C3173209;C3241966
2304,current smoker  n ( % },C3173209;C3241966
2304,current smoker  n ( % of patients ),C0030705;C3173209;C3241966
2304,current smoker  n ( % ) post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3173209;C3241966
2304,current smoker  n ( % ),C3173209;C3241966
2304,current smoker  %,C3173209;C3241966
2304,current smoker,C3173209;C3241966
2304,> $nmbr$ . $nmbr$ bpm current smoker,C3173209;C3241966
2303,ind / glyb n = $nmbr$,C1415124;C4049864
2303,ind $nmbr$ mg q . d . n = $nmbr$,C0439422;C4049864
2302,bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$,C2700462;C2945744;C3540627;C3815109
2302,bud $nmbr$ ptg n = $nmbr$,C0039512;C1418830;C2700462;C2945744
2301,≤ $nmbr$ ug / g,C0439272
2301,tcz $nmbr$ mg / kg n = $nmbr$,C0439272
2301,abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
2301,abatacept $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
2301,abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
2301,> $nmbr$ ug / g,C0439272
2301,$nmbr$ mg / kg ( n = $nmbr$ ),C0439272
2301,$nmbr$ mg / kg,C0439272
2300,≥ $nmbr$ to < $nmbr$ mg / g,C1300563
2300,≥ $nmbr$ mg / g,C1300563
2300,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
2300,uacr ( mg / g ),C1300563
2300,uac > $nmbr$ mg / g,C1300563
2300,uac $nmbr$ - $nmbr$ mg / g,C1300563
2300,normoalbuminuria ( uacr < $nmbr$ mg / g ),C1300563
2300,mg / g,C1300563
2300,cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
2300,cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
2300,acr > $nmbr$ mg / g,C1300563;C1412134;C1515941
2300,> = $nmbr$ mg / g,C1300563
2300,> $nmbr$ to $nmbr$ mg / g,C1300563
2300,> $nmbr$ mg / g,C1300563
2300,< $nmbr$ mg / g,C1300563
2300,$nmbr$ − $nmbr$ mg / g,C1300563
2300,$nmbr$ to $nmbr$ mg / g,C1300563
2300,$nmbr$ mg / g,C1300563
2300,$nmbr$ - $nmbr$ mg / g,C1300563
2299,uacra  mg / g  n ( % ),C1300563
2299,uacra  mg / g  gmean = gcv,C0017066;C1300563
2299,uacr — mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
2299,uacr *  mg / g ( q $nmbr$  q $nmbr$ ),C1300563
2299,uacr ( mg / g  median [ iqr ] ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
2299,uacr  mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
2299,^ $nmbr$ mg / g  n ( % ),C1300563
2299,< $nmbr$ mg / g  n ( % ),C1300563
2299,$nmbr$ mg / g  n ( % ),C1300563
2298,$nmbr$ . $nmbr$ ± $nmbr$ . lf,C1416933;C2986618;C4554443
2297,$nmbr$ to < $nmbr$ cel,C0208736;C0346421;C0439237;C1413336
2296,> $nmbr$ / $nmbr$ lung fields,C0225759
2295,< $nmbr$ . $nmbr$ tng > cll,C0023434
2294,iee at baseline : < $nmbr$ iu / l,C0168634;C0439457;C1442488
2294,> $nmbr$ to < $nmbr$ iu / l,C0439457
2294,> $nmbr$ iu / l,C0439457
2293,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
2293,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
2293,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
2293,nt - probnp — pg / ml,C0439297;C0669479;C0754710
2293,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
2293,nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ ),C0439297;C0669479;C0754710
2293,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
2293,nt - probnp $nmbr$ pmol - l - $nmbr$,C0439284;C0669479;C0754710
2293,nt - probnp  pmol / l ^,C0439284;C0669479;C0754710
2293,nt - probnp  pmol / l,C0439284;C0669479;C0754710
2293,nt - probnp  pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
2293,nt - probnp  pg / ml,C0439297;C0669479;C0754710
2293,nt - probnp  median pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
2293,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
2293,nt - pro bnp,C0669479;C0754710
2293,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
2293,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
2293,nt - pro - bnp,C0669479;C0754710
2293,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
2292,long term *,C0443252
2292,long term ( n = $nmbr$ ) +,C0443252
2292,long - term warfarin ( n = $nmbr$ ),C0043031;C0443252
2292,long - term warfarin ( n - $nmbr$ ),C0043031;C0443252
2292,long - term aspirin,C0004057;C0443252
2291,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
2291,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
2291,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
2291,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
2290,coenzyme q $nmbr$ p  g / ml #,C0041536;C1300565
2290,coenzyme q $nmbr$  ^ g / ml #,C0041536;C1300565
2290,coenzyme q $nmbr$,C0041536
2290,all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ ),C0041536
2289,hormone - refractory prostate carcinoma,C1328504
2288,squamous cell carcinoma,C0007137;C1302853
2287,necrotic core  mm ^,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653;C4330985;C4554674
2287,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
2287,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
2286,etn  no,C0014758;C0717758
2286,etanercept ( n = $nmbr$ ),C0717758
2286,etanercept,C0717758
2285,abatacept ‡,C1619966
2285,abatacept plus mtx ( n = $nmbr$ ),C0025677;C1417487;C1619966
2285,abatacept monotherapy ( n = $nmbr$ ),C1619966
2285,abatacept ( n = $nmbr$ * ),C1619966
2285,abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ ),C1619966
2285,abatacept,C1619966
2284,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
2284,abatacept / open - label abatacept,C1619966;C1709323
2283,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
2283,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
2283,beta bloekers,C0330390;C0439096;C2004068
2283,beta $nmbr$ selective,C0330390;C0439096;C2004068
2283,adjustedb  c beta ( se ),C0036919;C0330390;C0439096;C2004068
2282,ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
2282,ezetimibe $nmbr$ mg ( n — $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
2282,ezetimibe $nmbr$ mg ( n = $nmbr$ * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
2282,ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
2282,ezetimibe  n ( % ),C1142985
2281,ezetimibe use,C0042153;C0457083;C1142985;C1947944
2281,ezetimibe,C1142985
2280,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
2280,ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
2280,ezetimibe / simvastatin,C1532737
2280,ezetimibe + simvastatin ( n = $nmbr$ * ),C1532737
2280,ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * ),C1532737
2279,catecholamines or corticosteroids without hospitalization,C0007412
2278,systemic corticosteroids — no . ( % ),C4053960
2278,systemic corticosteroids  n ( % ) a,C4053960
2278,systemic corticosteroids  n ( % ),C4053960
2278,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
2277,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C1514873;C3536709
2277,prior corticosteroid treatment,C0001617;C1514463;C3536709
2277,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
2277,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
2277,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
2277,no corticosteroid + no imm  n,C0001617;C3536709
2277,no corticosteroid  no imm,C0001617;C3536709
2277,no corticosteroid,C0001617;C3536709
2277,neither corticosteroid nor immunosuppressant,C0001617;C3536709
2277,immy ( without corticosteroid )  n,C0001617;C3536709
2277,imm + corticosteroid  n,C0001617;C0205470;C3536709
2277,imm ( without corticosteroid ),C0001617;C0205470;C3536709
2277,corticosteroid or immunosuppressant,C0001617;C3536709
2277,corticosteroid or azathioprine / $nmbr$ - mercaptopurine,C0001617;C3536709
2277,corticosteroid and immunosuppressant,C0001617;C3536709
2277,corticosteroid - azathioprine / $nmbr$ - mercaptopurine,C0000618;C0001617;C0004482;C3536709
2277,corticosteroid + imm,C0001617;C0205470;C3536709
2277,corticosteroid ( without imm )  n,C0001617;C0205470;C3536709
2277,corticosteroid ( without imm ),C0001617;C0205470;C3536709
2277,corticosteroid ( with or without immunosuppressants ),C0001617;C3536709
2277,corticosteroid,C0001617;C3536709
2276,refractory to corticosteroids  n ( % ),C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
2276,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
2276,no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
2276,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
2276,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids ( excluding budesonide ),C0001617;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids ' $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
2276,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
2276,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
2276,concomitant oral corticosteroids  n ( % ) * *,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
2276,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
2276,> $nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
2275,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
2275,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
2275,atherosclerotic vascular disease — no .,C0004153
2275,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
2275,atherosclerotic vascular disease history  no . ( % ) ‡,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
2275,atherosclerotic vascular disease history  n ( % ) t,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
2275,atherosclerotic vascular disease  n ( % ) §,C0004153
2275,atherosclerotic cardiovascular disease *,C0004153
2275,atherosclerotic cardiovascular disease,C0004153
2274,other atherosclerotic event,C0333482;C0441471;C4019010
2274,other atherosclerotic cvdd  e,C0333482;C1859330
2274,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
2274,other atherosclerotic cvd * *,C0007222;C0333482
2274,other atherosclerotic cvd,C0007222;C0333482
2274,other atherosclerotic,C0333482
2274,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
2274,atherosclerotic disease *,C0012634;C0333482
2274,atherosclerotic disease ( % ),C0012634;C0333482
2274,atherosclerotic cvdj,C0333482
2274,atherosclerotic cvd §,C0007222;C0333482
2274,atherosclerotic cvd,C0007222;C0333482
2273,environmental stimuli,C0450025
2272,univariate logistic modela,C0242415
2272,multivariate logistic modelb,C0242415
2271,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
2270,antithrombotic / coagulant,C0009117
2269,antithrombotic agents  n ( % ),C1704311
2269,antithrombotic agents,C1704311
2268,symptomatic pe,C0070939;C0231220;C1880476;C4284304
2268,symptomatic padt,C0231220
2268,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
2268,symptomatic,C0231220
2268,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
2267,symptomatic remissionb n / n ( % ),C0231220
2267,symptomatic hypotension with sbp < $nmbr$ mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
2267,symptomatic hypotension ( sbp < $nmbr$ mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
2267,symptomatic hypotension,C0020649;C0231220;C3163620
2266,uncontrolled on oad ( s ),C0205318
2266,uncontrolled on basal insulin,C0205318;C0650607
2266,uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$,C0205318;C2919686
2266,uncontrolled,C0205318
2265,contrast volume > $nmbr$ ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
2265,contrast volume > $nmbr$ ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
2265,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
2265,contrast volume  ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
2265,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
2265,contrast used ( ml ) *,C0009924;C1979874
2264,oral corticosteroid use  n ( % ),C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
2264,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
2264,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
2264,current corticosteroid use  n,C0239126;C0521116;C1705970
2264,corticosteroid use at randomization    n   ( % ),C0034656;C0239126
2264,corticosteroid use at randomization,C0034656;C0239126
2264,corticosteroid use  n ( % ),C0239126
2264,corticosteroid use  %,C0239126
2264,corticosteroid use  $nmbr$ n ( % ),C0239126
2264,corticosteroid use,C0239126
2264,concomitant corticosteroid use  n ( % ),C0239126;C0521115
2264,concomitant corticosteroid use,C0239126;C0521115
2263,most common concomitant aeds  n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
2263,most common concomitant aeds  d n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
2263,main concomitant treatments  no . ( % ),C0087111;C0205225;C0521115;C1542147
2263,concomitant oads  n ( % ),C0521115
2263,concomitant aedsb    n   ( % ),C0521115
2263,concomitant aedsb  n ( % ),C0521115
2263,concomitant aeds  n ( % ),C0180309;C0521115
2262,concomitant use of nsaids to week $nmbr$,C0003211;C0521115;C1524063
2262,concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate,C0242708;C0439858;C0521115;C1524063;C1883254
2262,concomitant use of bosentan  n ( % ),C0252643;C0521115;C1524063
2261,no concomitant antiplatelet,C0521115
2261,concomitant use of mtx to week $nmbr$,C0025677;C0521115;C1417487;C1524063
2261,concomitant treatments at randomization,C0034656;C0087111;C0521115
2261,concomitant mtx —,C0025677;C0521115;C1417487
2261,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
2261,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
2261,concomitant drug treatment,C0150270;C0521115;C3469597
2261,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
2261,concomitant drug therapies  n ( % ),C0013216;C0521115
2261,concomitant antiplatelet,C0521115
2261,concomitant aedsa,C0521115
2261,concomitant,C0521115
2260,no antiplatelet therapy,C1096021
2260,long - term antiplatelet therapy,C0443252;C1096021
2260,dual antiplatelet therapy,C0205173;C1096021;C1554184
2260,antiplatelet therapy §,C1096021
2260,antiplatelet therapy dual,C1096021
2260,antiplatelet therapy,C1096021
2259,statin therapy,C1278454
2259,prerandomization statin therapy,C1278454
2259,intensity of statin therapy at baseline — no . { % ),C0522510;C1278454
2259,intensity of statin therapy,C0522510;C1278454
2258,phototherapy,C0031765
2257,estrogen therapy,C0279494
2256,anticoagulant therapy,C0150457
2255,no diuretic therapy,C0948575
2255,diuretic therapy,C0948575
2254,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
2254,combination therapy * *,C0009429;C0556895
2254,combination therapy ( n = $nmbr$ ),C0009429;C0556895
2254,combination therapy  n = $nmbr$,C0009429;C0556895
2253,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
2253,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
2253,medications at study entry — no . / total no . ( % ),C0013175;C1705654
2253,entry hip fracture location  n ( % ),C1705654;C3260017
2253,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
2253,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
2253,controllertreatment before entry *,C1705654
2252,udy entry,C1705654
2252,entry category,C0683312;C1705654;C3889287
2252,at entry,C1705654
2251,unknown — no . { % ),C0439673;C3541433;C4050014
2251,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
2251,unknown or missing,C0439673;C3541433;C4050014
2251,unknown / missing,C0439673;C3541433;C4050014
2251,unknown ( none of the above ),C0439673;C3541433;C4050014
2251,unknown ( % ),C0439673;C3541433;C4050014
2251,unknown,C0439673;C3541433;C4050014
2251,non - detectable / unknown  n ( % ),C0439673;C1518422;C3541433;C3830527;C4050014
2251,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
2251,no / unknown,C0439673;C3541433;C4050014
2250,knees ( n ),C0022742
2250,knee,C0022742;C0022745;C1963703
2250,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
2250,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
2249,pravastatin sodium,C0700474
2248,orthostatic hypotension,C0020651
2247,propafenone,C0033429
2246,prostate biopsy,C0194804
2245,prostate cancer,C0376358;C0600139;C2984325;C3541264
2244,unstable but no rest angina,C0443343;C1883468
2244,unstable anginat,C0443343;C1883468
2244,unstable anginad,C0443343;C1883468
2244,unstable,C0443343;C1883468
2244,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
2243,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
2243,probable stent thrombosis,C0033204;C0332148;C3897493
2243,probable,C0033204;C0332148
2243,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
2242,no . japanese,C0376247;C1556094
2242,japanese subpopulation,C0376247;C1257890;C1556094
2242,japanese subgroup ( n = $nmbr$ ),C0376247;C1079230;C1515021;C1556094
2242,japanese,C0376247;C1556094
2241,era monotherapy,C1521863;C3495919
2241,era and pde - $nmbr$ i,C1521863;C3495919
2241,era and pde $nmbr$ inhibitors,C1521863;C3495919
2241,era,C1521863;C3495919
2240,vein graft stented,C0042449;C0181074;C0332835;C1961139
2240,graft occlusionsa,C0181074;C0332835;C1961139
2240,graft  n ( % ),C0181074;C0332835;C1961139
2240,graft,C0181074;C0332835;C1961139
2239,lipid profile,C0023779;C1979963;C2003903
2239,fatty acid profile,C0015684;C1979963;C2003903
2238,non - frail,C0871754;C1518422
2238,frail,C0871754
2237,updrs  part ii ( adl ),C0001288;C0449719;C1420005;C1709471;C1710602;C3639721;C4082587
2237,adl,C0001288;C1420005
2236,overall dlqi score $nmbr$,C0282416;C1561607;C3899393
2236,overall dlqi score,C0282416;C1561607;C3899393
2236,dlqi §,C3899393
2236,dlqi score,C3899393
2236,dlqi  $nmbr$ - $nmbr$ *,C3899393
2236,dlqi,C3899393
2235,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
2235,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
2235,gastrointestinal bleeding,C0017181
2234,upper gastrointestinal tract,C3203348
2234,upper gastrointestinal,C3203348
2234,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
2233,terminal ileum,C0227327
2232,terrible,C3827840
2231,heritable,C0439660
2230,tertiary amines,C3653356
2229,sertraline,C0074393;C0524265
2228,prior vka experience,C0237607;C0332152;C0596545;C2826257
2228,experienced,C0237607;C0596545
2228,experience ( n  % ),C0237607;C0596545
2228,experience,C0237607;C0596545
2228,clinic research experience  n ( % ),C0008972;C0237607;C0596545
2228,cdmard experience  n ( % ),C0237607;C0596545
2228,> $nmbr$ yr warfarin experience,C0043031;C0237607;C0439234;C0596545
2227,everolimus - eluting,C0541315
2227,everolimus,C0541315
2226,evening mealb,C0587117
2226,evening,C0587117
2225,never used lev,C0023556;C1273517;C2003901
2225,never took alendronate,C2003901
2225,never smoking,C2003901
2225,never smoked — no . ( % ),C2003901
2225,never smoked  n ( % ),C0037366;C0439994;C1881674;C2003901
2225,never smoked,C2003901
2225,never or past,C2003901
2225,never drink,C2003901
2225,never been on a vka,C2003901
2225,never / rarely,C0522498;C2003901
2225,never,C2003901
2224,uc disease duration ( y ),C0872146
2224,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
2224,duration of disease — yr ^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
2224,duration of disease — yr : t,C0439234;C0872146
2224,duration of disease — yr,C0439234;C0872146
2224,duration of disease since,C0872146
2224,duration of disease ( yr ),C0439234;C0872146
2224,duration of disease ( years ),C0439234;C0872146
2224,duration of disease  years,C0439234;C0872146
2224,duration of disease  y,C0872146
2224,duration of disease  n ( % ),C0872146
2224,disease duration b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
2224,disease duration > $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
2224,disease duration ( yr ),C0439234;C0872146
2224,disease duration ( years ),C0439234;C0872146
2224,disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
2224,disease duration  years,C0439234;C0872146
2224,disease duration  y,C0872146
2224,disease duration  mean yr ( sd ),C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
2224,disease duration,C0872146
2223,duration of disease before baseline,C0872146
2223,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
2222,moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274776
2222,moderate dysfunction,C3274776
2221,risk ratio [ $nmbr$ % cl ],C0028873;C0242492;C0596019
2221,odds ‐ ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
2221,odds ratios ( $nmbr$ % ci ),C0008107;C0028873;C3259781
2221,odds ratio versus placebo ( $nmbr$ % ci ),C0028873
2221,odds ratio and $nmbr$ % cl,C0028873
2221,odds ratio adj ( $nmbr$ % cl ),C0001552;C0028873;C0596019;C2826286
2221,odds ratio ( $nmbr$ % cl ),C0028873;C0596019
2221,odds ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
2221,odds ratio,C0028873
2221,estimated odds ratio,C0028873;C0750572
2220,t $nmbr$ dm duration  y,C0011816;C0449238;C2603360;C2926735;C3250443
2220,symptom duration  months,C0439231;C0449238;C1457887;C2926735;C3854129
2220,symptom duration,C0449238;C1457887;C2926735;C3854129
2220,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
2220,ra symptom duration < $nmbr$ months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
2220,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
2220,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
2220,mean duration of pd  yr,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
2220,known duration of type $nmbr$ diabetes,C0205309;C0449238;C1320657;C2926735
2220,known duration of t $nmbr$ dm  y,C0011816;C0205309;C0449238;C2926735;C3250443
2220,known duration,C0205309;C0449238;C2926735
2220,extended - duration enoxaparin ( n = $nmbr$ ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
2220,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
2220,ed duration,C0449238;C2926735;C3538926
2220,duration since diagnosis ( years ),C0449238;C2926735
2220,duration of type $nmbr$ diabetes,C0449238;C1320657;C2926735
2220,duration of t $nmbr$ dm ( % ),C0011816;C0449238;C2926735;C3250443
2220,duration of t $nmbr$ dm  y,C0011816;C0449238;C2926735;C3250443
2220,duration of t $nmbr$ dm,C0011816;C0449238;C2926735;C3250443
2220,duration of t $nmbr$ d  y,C0449238;C2926735
2220,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
2220,duration of rat  years,C0034693;C0034721;C0439234;C0449238;C2926735
2220,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
2220,duration of ra ( time from symptom onset )  years,C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
2220,duration of ra,C0449238;C2926735;C3538806;C4048756
2220,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
2220,duration of pd  y,C0449238;C2926735;C4553228;C4553229
2220,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
2220,duration of infusion during medical management — hr,C0449238;C0574032;C1827465;C2926735
2220,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735
2220,duration of infusion before cabg — hr,C0449238;C0574032;C1827465;C2926735
2220,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735
2220,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
2220,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
2220,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
2220,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
2220,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
2220,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
2220,duration of asthma > $nmbr$ years,C0004096;C0439234;C0449238;C2926735;C2984299
2220,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
2220,duration of asthma  years,C0004096;C0439234;C0449238;C2926735;C2984299
2220,duration of asthma  y,C0004096;C0449238;C2926735;C2984299
2220,duration of asthma,C0004096;C0449238;C2926735;C2984299
2220,duration of assigned regimen before surgery post - randomisation characteristic * *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
2220,duration of assigned regimen before surgery post - randomisation characteristic *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
2220,duration of assigned regimen before surgery,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
2220,duration of as  years,C0449238;C2926735
2220,duration of as  n ( % ),C0449238;C2926735
2220,duration of,C0449238;C2926735
2220,duration alendronate use  years ( meanisd ),C0042153;C0102118;C0439234;C0449238;C0457083;C1947944;C2926735
2220,duration,C0449238;C2926735
2220,dm duration,C0011816;C0449238;C2926735;C3250443
2220,cornell voltage x duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
2220,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
2220,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
2220,cornell voltage - duration product  mm × ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
2220,cornell voltage - duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
2220,asthma duration ( sd )  years,C0004096;C0439234;C0449238;C2699239;C2926735;C2984299
2219,mh + crpnorr,C0026514;C2930980
2218,poor,C0032854;C0542537;C2700379
2217,fair or poor,C2911689
2217,fair / poor,C0032854;C0542537;C2700379;C2911689
2216,upper tertile : > $nmbr$ . $nmbr$,C1282910
2216,upper,C1282910
2216,none of the above,C1282910;C1552828
2216,any of the above,C1282910;C1552828
2216,all of the above,C1282910;C1552828
2215,logistic regression,C0206031
2215,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828
2215,aunivariate logistic regression .,C0206031
2214,previously untreated isolated systolic hypertension,C0332155;C0745133
2214,isolated systolic hypertension ⁎,C0745133
2214,isolated systolic hypertension ^,C0745133
2214,isolated systolic hypertension  n ( ' % >,C0745133
2214,isolated systolic hypertension  n ( % ) “,C0745133
2214,isolated systolic hypertension,C0745133
2213,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
2213,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
2213,ischemic stroke subtype,C0449560;C0948008
2213,ischemic stroke or see,C0948008
2213,ischemic stroke ( vs . tia ),C0948008
2213,ischemic stroke ( incl . uncertain ),C0948008
2213,ischemic stroke ( % ),C0948008
2213,ischaemic stroke  n ( % ),C0948008
2212,• ischemic stroke,C0948008
2212,prior ischemic stroke,C0332152;C0948008;C2826257
2212,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
2212,nonfatal ischemic stroke,C0948008
2212,minor ischaemic stroke,C0026193;C0205165;C0948008
2212,ischemic stroke,C0948008
2212,ischaemic stroke,C0948008
2212,all ischemic stroke,C0948008
2211,seizure worry,C0036572;C0233481;C1959629;C4553401
2211,seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401
2211,seizure types reported during baseline  n ( % ) a,C0036572;C0332307;C1959629;C4553401
2211,seizure types reported during baseline  b n ( % ),C0036572;C0332307;C1959629;C4553401
2210,time from end of fit  years ( meanisd ),C0036572;C0439234;C1522314;C2349186;C4048158;C4553125
2210,convulsion,C0036572;C4048158
2209,cancer surgery,C0920424
2208,minor surgery,C0038904
2208,major surgery,C0679637
2207,urgent surgery,C2188405
2207,emergent / urgent surgery,C0750573;C2188405
2206,sbp ( office measurement )  mmhg,C0085805;C0242485;C0439475;C0442603
2206,measurements,C0242485
2206,measure,C0079809;C0242485
2206,lipid measure *,C0023779;C0079809;C0242485
2206,dbp ( office measurement )  mmhg,C0242485;C0439475;C0442603;C0536221;C3813197;C4281799
2205,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
2205,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
2205,valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
2205,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
2205,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
2205,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
2205,surgery,C0038894;C0038895;C0543467;C1274039
2205,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
2205,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
2205,operative procedure,C0543467;C0677612
2205,cardiac valve surgery : no ( n = $nmbr$ ),C0018821;C0018826;C0038894;C0038895;C0184252;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
2205,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
2204,mean score on das $nmbr$ - $nmbr$ ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
2204,hs - crp < $nmbr$ . $nmbr$ nlg l,C3890735;C4048285
2204,hs - crp < $nmbr$ . $nmbr$ g / l,C0439294;C0456615;C3890735;C4048285
2204,hs - crp,C3890735;C4048285
2204,das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % ),C0051767;C0057671;C3890735;C4048285
2204,das $nmbr$ ‐ crp,C0051767;C0057671;C3890735;C4048285
2204,das $nmbr$ - crp §,C0051767;C0057671;C3890735;C4048285
2204,das $nmbr$ - crp,C0051767;C0057671;C3890735;C4048285
2204,das $nmbr$ ( crp ),C0051767;C0057671;C3890735;C4048285
2204,crp,C3890735;C4048285
2204,c . das $nmbr$ - crp < $nmbr$ . $nmbr$,C0051767;C0057671;C3890735;C4048285
2204,asdas - crp   <   $nmbr$ . $nmbr$,C3890735;C4048285
2204,asdas - crp δ   ≥   $nmbr$ . $nmbr$,C3890735;C4048285
2204,asdas - crp *,C3890735;C4048285
2203,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
2203,median c - reactive protein — mg / dl ^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
2203,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
2203,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
2203,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
2203,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
2203,high - sensitivity c - reactive protein  mg / ltt,C0006560;C0024671;C0026410;C0439269;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
2203,high - sensitivity c - reactive protein  mg / l,C0006560;C0439268;C1413716;C1441604;C4048285
2203,das $nmbr$ ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
2203,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
2203,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
2203,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
2203,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
2203,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
2203,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
2203,c - reactive protein  u / l,C0006560;C0439339;C1413716;C4048285
2203,c - reactive protein  mg / l,C0006560;C0439268;C1413716;C4048285
2203,c - reactive protein  * mg / l,C0006560;C0439268;C1413716;C4048285
2203,c - reactive protein,C0006560;C1413716;C4048285
2202,week $nmbr$ ( geometric mean  cv ),C0332174;C0439230;C2986759;C3538987;C4048877;C4318503
2202,urine acr geometric mean ( cv % )  a  b mg / g,C0042036;C0042037;C1300563;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
2202,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
2202,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
2202,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
2202,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
2202,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
2202,no cv event ( n = $nmbr$  $nmbr$ ),C0441471;C3538987;C4019010;C4048877;C4318503
2202,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
2202,mdrd egfr geometric mean ( cv % )  a  b ml /,C0439526;C1705224;C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C3887665;C4048877;C4318503
2202,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
2202,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
2202,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
2202,cv risk factors  % of patients,C0030705;C0035648;C1553898;C3538987;C4048877;C4318503
2202,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
2202,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
2202,cv risk factor,C0035648;C3538987;C4048877;C4318503
2202,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
2202,cv historya,C3538987;C4048877;C4318503
2202,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
2202,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
2202,cv,C3538987;C4048877;C4318503
2202,baseline ( geometric mean  cv ),C0168634;C1442488;C2986759;C3538987;C4048877;C4318503
2202,ascvdor > $nmbr$ cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
2202,> $nmbr$ additional cv risk factors $nmbr$,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
2201,chads score  n ( % ),C0007928;C1413373
2201,chads score,C0007928;C1413373
2201,chads - $nmbr$ score,C0007928;C1413373
2201,chads $nmbr$   score    n   ( % ),C0007928;C1413373
2201,chads $nmbr$ scoret,C0007928;C1413373
2201,chads $nmbr$ scoref,C0007928;C1413373
2201,chads $nmbr$ scoreb,C0007928;C1413373
2201,chads $nmbr$ score per outcome stroke or systemic embolism,C0007928;C1413373
2201,chads $nmbr$ score > $nmbr$,C0007928;C1413373
2201,chads $nmbr$ score *,C0007928;C1413373
2201,chads $nmbr$ score $nmbr$ - $nmbr$  n ( % ),C0007928;C1413373
2201,chads $nmbr$ score $nmbr$,C0007928;C1413373
2201,chads $nmbr$ score  n ( % ),C0007928;C1413373
2201,chads $nmbr$ score  mean ± sd,C0007928;C1413373
2201,chads $nmbr$ score  mean ( ± sd ),C0007928;C1413373
2201,chads $nmbr$ score,C0007928;C1413373
2201,chads $nmbr$ components  n ( % ),C0007928;C0449432;C1413373
2201,chads $nmbr$ ^,C0007928;C1413373
2201,chads $nmbr$ < $nmbr$,C0007928;C1413373
2201,chads $nmbr$,C0007928;C1413373
2201,chad $nmbr$ > $nmbr$,C0007928;C1413373
2201,> $nmbr$ ( n  % ) chads $nmbr$ score,C0007928;C0369718;C0441922;C1413373
2200,previous cd related surgery ( ref ) a,C0007928;C0034283;C0205156;C1552607;C4552032
2200,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
2200,patients with early cd ( n = $nmbr$ ),C0007928;C0030705;C0034283;C1279919;C4552032
2200,no previous cd related surgery $nmbr$,C0007928;C0034283;C0205156;C1552607;C4552032
2200,cd duration  y,C0007928;C0034283;C0449238;C2926735;C4552032
2200,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
2200,cd [ gemini $nmbr$ ] * ’,C0007928;C0034283;C4552032
2200,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
2199,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
2199,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
2199,multivessel cad  n ( % ),C1504769;C2239547;C3813548;C4284121
2199,family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
2199,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
2199,familv historv of cad,C1504769;C2239547;C3813548;C4284121
2199,cad and abi < $nmbr$ - $nmbr$ §,C1504769;C2239547;C3813548;C4284121
2199,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
2199,cad *,C1504769;C2239547;C3813548;C4284121
2199,cad,C1504769;C2239547;C3813548;C4284121
2198,tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
2198,tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
2198,igg ( > $nmbr$ . $nmbr$ g / l )  %,C0439294;C0456615
2198,apob  g / l,C0003593;C0439294;C0456615;C3252643
2198,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
2198,> $nmbr$ . $nmbr$ - g / l,C0439294;C0456615
2198,$nmbr$ . $nmbr$ ( g . l ),C0439294;C0456615
2197,involved gl areas,C0018229;C1423073;C1427674;C1879646
2197,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
2197,bsl hb  gl - $nmbr$,C0018229;C0019046;C1423073;C1427674;C1549954
2196,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
2196,fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ ),C0340427;C0439267;C1413520;C3539652
2196,fdc $nmbr$ / $nmbr$ pg vs placebo,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2196,fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2196,fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2196,fdc $nmbr$ / $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2195,olodaterol $nmbr$ m g,C0456715;C2934193
2195,alvmi ( per g / m $nmbr$ ),C0456715
2194,> $nmbr$ ^ mol / liter — no . ( % ),C0347982
2194,( $nmbr$ - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
2193,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
2193,fl ( $nmbr$ b ),C1300812;C1708024
2193,fl ( $nmbr$ . $nmbr$ ),C1300812;C1708024
2192,qmaxi rn l / s,C2827110;C3540639;C4281819
2191,urine qmax  ml / s,C0042036;C0042037;C0439390;C2963137
2191,qmax ( ml / s ),C0439390
2191,qmax  ml / s,C0439390
2191,> $nmbr$ ml / s,C0439390
2191,< $nmbr$ ml / s,C0439390
2190,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
2190,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
2190,epa  mol %,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
2190,aa  mol %,C0027960;C0282379;C0324740;C0439189;C1235746;C1456781;C1824986;C1882141;C3665593;C4554792
2189,> $nmbr$ per pl in $nmbr$ months before screening,C0439231;C3897966;C4049765
2189,> $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
2189,< $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
2189,/ pl $nmbr$ $nmbr$,C3897966;C4049765
2189,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
2188,rrr ( $nmbr$ % cl ),C0596019
2188,rr ( cl ),C0596019;C4554402
2188,rr ( $nmbr$ % cl ) p value,C0596019;C1709380;C4554402
2188,rr ( $nmbr$ % cl ) [ / ’ value ],C0596019;C1522609;C4554402
2188,rr ( $nmbr$ % cl ),C0596019;C4554402
2188,qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ ),C0596019;C2349943;C3539704;C3713294
2188,qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ ),C0596019;C2349943;C3539704;C3713294
2188,lsm ( $nmbr$ % cl ),C0596019
2188,hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
2188,hr ( $nmbr$ % cl ) pvalue,C0596019
2188,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ ),C0596019
2188,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),C0596019
2188,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ ),C0596019
2188,hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ ),C0596019
2188,hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *,C0596019
2188,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
2188,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
2188,hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo,C0216784;C0596019;C2985465
2188,hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo,C0596019;C0903898;C2985465
2188,hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0596019;C2985465
2188,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ ),C0596019
2188,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
2188,$nmbr$ cl ),C0596019
2188,$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
2188,$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
2188,$nmbr$ ( $nmbr$ cl ),C0596019
2188,$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ ),C0596019
2187,ratet ( $nmbr$ % cl ),C0596019
2187,p ( $nmbr$ % cl ),C0369773;C0596019;C2603361
2187,orc ( $nmbr$ % cl ),C0596019;C1167125
2187,oradj ( $nmbr$ % cl ),C0596019
2187,hr ( $nmbr$ % cl ) *,C0596019
2187,hr ( $nmbr$ % cl ),C0596019
2187,hr $nmbr$ % cl,C0596019
2187,hr  ( $nmbr$ % cl ),C0596019
2187,hr  $nmbr$ % cl,C0596019
2187,cl - $nmbr$ ],C0596019
2187,cl $nmbr$ %,C0596019
2187,arr ( $nmbr$ % cl ),C0596019;C2170357;C4084934
2187,adj . hr ( $nmbr$ % cl ) a,C0001552;C0596019;C2826286
2187,[ $nmbr$ % cl ],C0596019
2187,( %  $nmbr$ % cl ),C0596019
2187,( $nmbr$ % cl ),C0596019
2187,$nmbr$ % cl,C0596019
2186,normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C4296962
2186,crcl of $nmbr$ - $nmbr$ ml min '  n ( % ),C0439445;C1846718
2186,crcl at randomization - ml / min,C0034656;C0439445;C1846718
2186,crcl at randomization  ml / min,C0034656;C0439445;C1846718
2186,crcl < $nmbr$,C1846718
2186,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
2186,crcl $nmbr$ - $nmbr$,C1846718
2186,> $nmbr$ crcl,C1846718
2186,< $nmbr$ crcl  n ( % ),C1846718
2186,< $nmbr$ crcl,C1846718
2186,$nmbr$ - $nmbr$ crcl,C1846718
2185,stratified hazard ratio ( $nmbr$ % ci ),C0008107;C0205363;C2985465;C3259781
2185,strata modelb hr  $nmbr$ % ci  p value,C0008107;C1709380;C3259781
2185,rr ^ ( $nmbr$ % ci ),C0008107;C3259781;C4554402
2185,rr ( $nmbr$ % ci ) c,C0008107;C3259781;C4554402
2185,rr ( $nmbr$ % ci ) *,C0008107;C3259781;C4554402
2185,rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
2185,risk reduction ( %  $nmbr$ % ci ),C0008107;C1137094;C3259781
2185,relative risk { $nmbr$ % ci ),C0008107;C0242492;C3259781
2185,relative risk ( $nmbr$ % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
2185,relative risk ( $nmbr$ % ci ),C0008107;C0242492;C3259781
2185,reduction in risk ( $nmbr$ % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
2185,reduction in risk % ( $nmbr$ % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
2185,ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
2185,ratio fp / sal : sal ( $nmbr$ % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
2185,ratio ( $nmbr$ % ci ) *,C0008107;C0456603;C1547037;C3259781
2185,rate ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
2185,r elative risk ( $nmbr$ % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
2185,proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %,C0008107;C1709707;C3259781
2185,oradj ( $nmbr$ % ci ),C0008107;C3259781
2185,no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
2185,multivariable adjusted model hr ( $nmbr$ % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
2185,multivariable adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
2185,mean sf $nmbr$ score ( $nmbr$ % ci ),C0008107;C0037712;C3259781;C3533236
2185,mean pasi score ( $nmbr$ % ci ),C0008107;C3259781;C3533236;C4528685
2185,mean ham - d score ( $nmbr$ % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
2185,lsm ( $nmbr$ % ci ),C0008107;C3259781
2185,hradjusted ( $nmbr$ % ci ) b,C0008107;C3259781
2185,hradj ( $nmbr$ % ci ),C0008107;C3259781
2185,hr with edoxaban ( $nmbr$ % ci ),C0008107;C2975435;C3259781
2185,hr [ $nmbr$ % ci ),C0008107;C3259781
2185,hr ( $nmbr$ s % ci ),C0008107;C3259781
2185,hr ( $nmbr$ % ci ) “,C0008107;C3259781
2185,hr ( $nmbr$ % ci ) p   value,C0008107;C1709380;C3259781
2185,hr ( $nmbr$ % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
2185,hr ( $nmbr$ % ci ) *,C0008107;C3259781
2185,hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
2185,hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
2185,hr ( $nmbr$ % ci ),C0008107;C3259781
2185,hr $nmbr$ % ci,C0008107;C3259781
2185,hr  ( $nmbr$ % ci ),C0008107;C3259781
2185,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
2185,hazard ratiof ( $nmbr$ % ci ),C0008107;C0598697;C3259781
2185,harzard ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
2185,harzar ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
2185,from baseline ( $nmbr$ % ci ),C0008107;C0168634;C1442488;C3259781
2185,ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
2185,ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
2185,ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
2185,ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
2185,etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C3259781
2185,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
2185,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
2185,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
2185,etd ( % ) [ $nmbr$ % ci ],C0008107;C1180255;C3259781
2185,etd ( $nmbr$ % ci ),C0008107;C1180255;C3259781
2185,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
2185,d ( $nmbr$ % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
2185,cox hr ( $nmbr$ % ci ),C0008107;C1565830;C3259781
2185,cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c,C0008107;C0205341;C3259781
2185,cmh rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
2185,arr ( $nmbr$ % ci ),C0008107;C2170357;C3259781;C4084934
2185,adjusted ⁎ hazard ratio ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
2185,adjusted modelc hr  $nmbr$ % ci  p value,C0008107;C0456081;C1709380;C3259781
2185,adjusted hr * ( $nmbr$ % ci ),C0008107;C0456081;C3259781
2185,adjusted hr ( $nmbr$ % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
2185,adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$,C0008107;C0456081;C3259781
2185,adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
2185,adjusted hr  $nmbr$ % ci,C0008107;C0456081;C3259781
2185,adjusted hazard ratio ≠ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
2185,adjusted hazard ratio ‡ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
2185,adjusted hazard ratio § ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
2185,adjusted hazard ratio ( $nmbr$ % ci ) †,C0008107;C0456081;C2985465;C3259781
2185,absolute risk reduction ( $nmbr$ % ci )  % / y,C0008107;C3179139;C3259781
2185,[ $nmbr$ % ci ] *,C0008107;C3259781
2185,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$,C0008107;C3259781
2185,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$,C0008107;C3259781
2185,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
2185,* ci denotes confidence interval .,C0008107;C3259781
2185,( ci ) b,C0008107;C3259781
2185,( $nmbr$ % ci ] h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
2185,( $nmbr$ % ci ] $nmbr$,C0008107;C3259781
2185,( $nmbr$ % ci ) p value,C0008107;C1709380;C3259781
2185,( $nmbr$ % ci ) c,C0008107;C3259781
2185,( $nmbr$ % ci ) b,C0008107;C3259781
2185,( $nmbr$ % ci ) a,C0008107;C3259781
2185,( $nmbr$ % ci ),C0008107;C3259781
2185,% risk reduction ( $nmbr$ % ci ),C0008107;C1137094;C3259781
2185,% ( $nmbr$ % ci ),C0008107;C3259781
2185,$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
2185,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0008107;C3259781
2185,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ),C0008107;C3259781
2185,$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$,C0008107;C3259781
2185,$nmbr$ % ci for difference,C0008107;C1705241;C1705242;C3259781
2185,$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,C0008107;C3259781
2185,$nmbr$ % ci $nmbr$,C0008107;C3259781
2185,$nmbr$ % ci,C0008107;C3259781
2184,y es,C0013754;C0205944
2183,no cases,C0868928;C1533148
2183,cases,C0868928;C1533148
2182,subsets,C1515021
2182,other climate subset,C0008946;C1515021
2182,ics subset,C0815320;C1515021;C4551720
2182,ics / laba subset,C0815320;C1515021;C4551720
2182,hot climate subset,C0178683;C1515021
2181,user,C1548600;C1706077
2181,statin users ( n = $nmbr$ ),C0360714;C1706077
2181,statin users,C0360714;C1706077
2181,statin non - users ( n = $nmbr$ ),C0360714;C1518422;C1706077
2181,non - user $nmbr$,C1518422;C1548600;C1706077
2181,laba users,C1706077
2181,laba non - users,C1518422;C1706077
2181,ics non - users,C0815320;C1518422;C1706077;C4551720
2180,baseline acq - $nmbr$ score,C0168634;C1442488;C2919686
2180,acq - $nmbr$ scoret,C2919686
2180,acq - $nmbr$ score 本,C2919686
2180,acq - $nmbr$ score *,C2919686
2180,acq - $nmbr$ score ' ! ',C2919686
2180,acq - $nmbr$ score,C2919686
2180,acq $nmbr$ score,C2919686
2179,aqlq score,C4055434
2179,aqlq ( si + $nmbr$ score ’,C0449820;C4050231;C4055434
2179,aqlq ( s ) score,C0449820;C4050231;C4055434
2179,aqlq ( s ) + $nmbr$ scorets,C4055434
2179,aqlq ( s ) + $nmbr$ scored,C4055434
2179,aqlq ( s ) + $nmbr$ score : §,C0449820;C4050231;C4055434
2178,gds score *,C0451184;C1149049;C1418244
2177,midas score,C1309950;C1423498;C4049617
2176,bii score,C1413059
2175,sss score,C0037052;C0723181
2174,nihss score,C1697238
2174,nih stroke scale,C1697238;C3484372
2173,total vdh - s score ( $nmbr$ - $nmbr$ ) ( n ),C2964552
2173,total vdh - s score,C2964552
2173,total score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C1947916;C2964552
2173,total feet score,C0016504;C0347981;C2964552
2172,total score §,C2964552
2172,total score > $nmbr$,C2964552
2172,total score < $nmbr$,C2964552
2172,total score,C2964552
2172,sgrq total score * *,C2964552
2172,sgrq total score $nmbr$,C2964552
2172,sgrq total score,C2964552
2172,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
2172,ibdq total score,C2964552
2172,eacit - e total score ) |,C2964552
2172,ccq total score,C2964552
2172,cat total score $nmbr$,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
2172,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
2172,acq - $nmbr$ total score ∗,C2919686;C2964552
2171,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
2171,pfo closure group ( n = $nmbr$ ),C0185003;C0441848;C1521802
2171,pfo closure,C0185003;C1521802
2171,laa closure ( n = $nmbr$ ),C0185003;C1521802
2171,laa closure ( n - $nmbr$ ),C0185003;C1521802
2171,laa closure,C0185003;C1521802
2171,closure,C0185003;C1521802
2171,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
2170,bundle branch block,C0006384;C1879286
2169,left bundle - branch block,C0023211;C0344420;C2828132
2168,spirometry after bronchodilation §,C0037981;C1371299;C3537072
2168,before bronchodilation — liters §,C0475211;C1371299;C3537072
2168,before bronchodilation,C1371299;C3537072
2168,after bronchodilation,C1371299;C3537072
2167,early death,C1836407
2166,mental health,C0025353
2165,sudden death,C0011071;C1964022;C4554103
2164,sudden cardiac death §,C0085298
2163,using hrt or raloxifene at baseline ( % ),C1524063
2163,using alendronate at baseline ( % ),C1524063
2163,use of statins,C0360714;C1524063
2163,use of statin at any follow - up visit ( % ),C0360714;C1524063
2163,use of proton inhibitors  n ( % ),C0033727;C0243077;C1524063
2163,use of pci or thrombolysis within one day of randomization,C1524063;C4049621
2163,use of methotrexate at randomization —,C0025677;C1524063
2163,use of low - dose aspirin ( < $nmbr$ mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
2163,use of low - dose aspirin ( < $nmbr$,C1524063;C2608320
2163,use of ics at baseline  %,C0815320;C1524063;C4551720
2163,use of diuretics  n ( % ),C0012798;C1524063
2163,use of aspirin at time of qualifying event ( % ),C0004057;C1524063
2162,use of systemic glucocorticoid at random -,C0017710;C0205373;C1524063
2162,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
2162,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C1524063;C3540777;C3540778
2162,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C1524063;C3540777;C3540778
2162,use of high - dose inhaled glucocorticoid — no . { % ),C0444956;C1524063
2161,use of ticagrelor,C1524063;C1999375
2161,use of clopidogrel,C0070166;C1524063
2161,use of ace inhibitor,C0003015;C1524063;C4541021
2161,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
2160,postoperative use of p - blocker,C0032790;C1524063
2160,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
2160,diabetes with no use of diabetes drugs,C0020616;C1524063
2159,total bleeds,C0232100
2159,total bleeding,C0232100
2158,rectal bleeding subscore {,C0018932;C0267596
2158,rectal bleeding subscore,C0018932;C0267596
2157,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788
2157,> $nmbr$ beds,C0004916
2157,< $nmbr$ beds,C0004916
2156,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
2156,bleeding outcomes,C0019080;C1274040
2156,bleeding end points,C0019080;C2349179
2156,bleeding,C0019080
2156,any overt bleed,C0019080
2156,any gusto bleeding,C0019080
2155,standard care,C1442989;C1947933;C2828392
2155,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
2155,care,C1947933
2154,usual care ( n = $nmbr$ la ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
2154,usual care ( n = $nmbr$ a ),C1947933;C3538928
2154,usual care ( n = $nmbr$ ),C1947933;C3538928
2154,usual care,C1947933;C3538928
2153,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
2153,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
2153,mace +,C0349381;C0949745;C1445339
2153,mace,C0349381;C0949745;C1445339
2153,hard mace,C0018599;C0349381;C0949745;C1445339
2153,expanded mace,C0205229;C0349381;C0949745;C1445339
2153,b mace,C0349381;C0949745;C1445339
2153,adjudicated mace $nmbr$,C0349381;C0949745;C1445339
2153,$nmbr$ - polnt mace,C0349381;C0949745;C1445339
2152,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
2151,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
2151,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
2151,overall efficacy,C0282416;C1280519;C1561607;C1707887
2151,efficacy variable,C0439828;C1280519;C1707887;C4553760
2151,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
2151,efficacy measures,C1280519;C1707887
2151,efficacy endpoints *,C1280519;C1707887;C2349179
2151,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
2151,efficacy end points,C1280519;C1707887;C2349179
2151,efficacy and safety : net adverse clinical events *,C1280519;C1707887
2151,efficacy    n   ( % ) a,C1280519;C1707887
2151,efficacy,C1280519;C1707887
2150,rhinitis,C0035455
2149,cystitis,C0010692;C0600041;C1963088
2148,osteitis,C0029400
2147,uveitis,C0042164;C1963266
2146,bursitis,C0006444
2145,bronchitis,C0006277
2144,synovitis,C0039103
2143,sinusitis,C0037199;C4553555
2142,tendonitis,C0039503
2141,pancolitis,C0868908
2140,spondylitis,C0038012
2140,non - spondylitis,C0038012;C1518422
2139,lifestyle modifications,C0870811;C2960841
2138,coexisting conditions,C0679225
2137,serious infections,C0205404;C3714514
2137,infections and infestations,C3714514
2137,infections,C3714514
2136,additional investigations,C2359834
2135,laboratory investigations,C0022877;C1261322;C3244292;C4283904
2135,investigations,C1261322
2134,oropharyngeal pain,C2363731;C4554669
2133,pharyngitis,C0031350;C4553308
2132,nasopharyngitis,C0027441
2131,secondary endpoints :,C4528314
2131,key secondary end point : st,C0036056;C3272372;C4528314
2130,phenobarbital,C0031412
2129,chondroitin,C0008454
2128,phenytoin,C0031507;C0202454
2127,lung neoplasm malignant,C0024121
2126,inflammation,C0021368
2126,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
2125,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
2125,inflammatory,C0333348
2124,primary indication,C1549995
2123,limb amputation,C0002689
2122,type of hospitalization,C3177060
2121,required hospitalization,C1708385
2120,method of insulin administration,C0025663;C0199782;C0449851;C0871511
2120,insulin administration,C0199782
2119,mouth ulceration,C0149745
2118,lung infection,C0876973;C4552950
2117,omega $nmbr$ allocation,C1706778;C1719844
2117,n - $nmbr$ allocation,C0369718;C0441922;C1706778
2117,insulin glargine allocation,C0907402;C1706778
2117,glargine allocation,C0907402;C1706778
2116,telmisartan group ( n = $nmbr$ ),C0248719;C0441848
2116,telmisartan ( n = $nmbr$ ),C0248719
2116,telmisartan ( n = $nmbr$  $nmbr$ ),C0248719
2116,telmisartan,C0248719
2115,irbesartan ( n = $nmbr$ ),C0288171
2115,irbesartan,C0288171
2114,valsartan n / n,C0216784
2114,valsartan / hctz,C0020261;C0216784
2114,valsartan ( n = $nmbr$ ),C0216784
2114,valsartan  n / n ( % ),C0216784
2114,valsartan  n ( % ),C0216784
2114,valsartan,C0216784
2113,rosuvastatin   n   =   $nmbr$,C0965129
2113,rosuvastatin n = $nmbr$,C0965129
2113,rosuvastatin +,C0965129
2113,rosuvastatin ( n = $nmbr$ . $nmbr$ ),C0965129
2113,rosuvastatin ( n = $nmbr$ ),C0965129
2113,rosuvastatin ( n = $nmbr$  $nmbr$ ),C0965129
2113,rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
2113,rosuvastatin  n ( % ),C0965129
2113,rosuvastatin,C0965129
2113,i rosuvastatin ( n = $nmbr$ ),C0021966;C0221138;C0965129
2113,$nmbr$ mg  rosuvastatin $nmbr$ mg .,C0965129;C1319635
2112,tolvaptan ( n = $nmbr$ ),C1176308
2112,tolvaptan,C1176308
2111,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
2111,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
2111,ra,C3538806;C4048756
2111,all - baricitinib ra ( n = $nmbr$ ) *,C3538806;C4044947;C4048756
2110,medical therapy only ( n = $nmbr$ ),C0205171;C0418981;C1720467
2110,medical therapy only,C0205171;C0418981;C1720467
2110,medical therapy alone,C0418981
2110,medical therapy ( n = $nmbr$ ),C0418981
2110,medical therapy,C0418981
2110,medical therapies,C0418981
2109,medical treatment  n ( % ),C0679624
2109,medical treatment,C0679624
2108,general health vas  $nmbr$ - $nmbr$ mm,C0042815;C0424575;C3536884;C3827561;C4018875;C4330985;C4554674
2108,general health ( self - reported ),C0424575;C4018875
2108,general health  self - reported,C0424575;C4018875
2108,general health,C0424575;C4018875
2107,physical exam oedema,C0013604;C0031809;C1717255
2107,edema peripheral,C0013604;C1717255
2107,edema  peripheral,C0013604;C1717255
2107,edema  n ( % ),C0013604;C1717255
2107,edema  ( % ),C0013604;C1717255
2107,edema  % z,C0013604;C1717255
2106,pdqol scale,C0175659;C0349674;C1947916
2106,pasi score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
2106,morning stiffness severity  $nmbr$ - $nmbr$ scale,C0175659;C0349674;C0439793;C0457086;C0522510;C1947916
2106,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
2106,jsn score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231
2106,individuals with t $nmbr$ dm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
2106,haq score ( $nmbr$ – $nmbr$ scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
2106,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
2106,geometric mean blood eosinophil count on loge scale — cells / ^ ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
2106,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
2106,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C1947916;C1963185
2106,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
2105,overall ® $nmbr$ . $nmbr$,C0282416;C1561607
2105,overall treatment effect,C0282416;C1518681;C1561607
2105,overall study population,C0282416;C1561607;C2348561
2105,overall study period,C0282416;C1561607
2105,overall pad,C0282416;C1561607
2105,overall n = $nmbr$  $nmbr$,C0282416;C1561607
2105,overall n ( n / loopy ),C0282416;C1561607
2105,overall hr ( $nmbr$ % cl ),C0282416;C0596019;C1561607
2105,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
2105,overall ctd,C0282416;C1335071;C1442905;C1561607
2105,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
2105,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
2105,overall a phase population,C0282416;C1561607
2105,overall ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0282416;C1561607
2105,overall ( pp ) ( n = $nmbr$ ),C0030375;C0063017;C0282416;C1561607;C4319755
2105,overall ( per protocol ) ( n = $nmbr$ ),C0282416;C1561607;C1698058
2105,overall ( n = u $nmbr$ ),C0282416;C0439148;C1561607
2105,overall ( n = $nmbr$ vs $nmbr$ ),C0282416;C1561607
2105,overall ( n = $nmbr$ ),C0282416;C1561607
2105,overall ( n = $nmbr$  $nmbr$ ),C0282416;C1561607
2105,overall ( itt ) ( n = $nmbr$ ),C0282416;C1561607
2105,overall ( $nmbr$  $nmbr$ ),C0282416;C1561607
2105,overall $nmbr$,C0282416;C1561607
2105,overall  qvai $nmbr$ - sfc,C0282416;C1561607;C4521536
2105,overall  n = $nmbr$,C0282416;C1561607
2105,overall,C0282416;C1561607
2105,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
2105,calima overall ( n = $nmbr$ ),C0282416;C1561607
2105,a . overall and subgroups bv statin potency - -,C0282416;C1561607
2105,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
2104,values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0005823;C0022709;C0042295;C0054015;C0332307;C0428772;C0488728;C0597357;C0600137;C1095989;C1144709;C1291218;C1417808;C1452534;C1547052;C2709270;C2982014;C3537020;C3683557;C3888198
2104,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
2104,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0428772;C0488728
2104,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a,C0428772;C0488728
2104,lvef — no . ( % )  i,C0428772;C0488728
2104,lvef within $nmbr$ months  %,C0428772;C0439231;C0488728
2104,lvef within $nmbr$ mo  %,C0026544;C0332177;C0428772;C0488728
2104,lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline,C0428772;C0488728
2104,lvef > $nmbr$ %,C0428772;C0488728
2104,lvef < $nmbr$ . $nmbr$,C0428772;C0488728
2104,lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “,C0428772;C0488728
2104,lvef < $nmbr$ %,C0428772;C0488728
2104,lvef ( u ),C0428772;C0439148;C0488728
2104,lvef ( % ),C0428772;C0488728
2104,lvef  %,C0428772;C0488728
2104,lvef,C0428772;C0488728
2104,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0488728
2104,left ventricular ejection fraction — % §,C0428772;C0488728
2104,left ventricular ejection fraction — %,C0428772;C0488728
2104,left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
2104,left ventricular ejection fraction within previous $nmbr$ mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
2104,left ventricular ejection fraction < $nmbr$ %,C0428772;C0488728
2104,left ventricular ejection fraction ( % ),C0428772;C0488728
2104,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
2104,left ventricular ejection fraction  % *,C0428772;C0488728
2104,left ventricular ejection fraction  %,C0428772;C0488728
2104,left ventricular ejection fraction,C0428772;C0488728
2104,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0005823;C0010055;C0018787;C0018801;C0021122;C0022709;C0024117;C0085805;C0155626;C0162589;C0185098;C0205042;C0428772;C0439849;C0488055;C0488728;C0521942;C0536221;C0596306;C0699792;C0815017;C0871470;C1264633;C1271104;C1272641;C1275491;C1305855;C1306620;C1511726;C1532338;C1554103;C2733342;C2825184;C3245479;C3714741;C3813197;C3888198;C4281799
2104,data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0010055;C0011198;C0014442;C0017480;C0018801;C0021122;C0024117;C0032042;C0042508;C0085805;C0155626;C0162589;C0428772;C0428883;C0488055;C0488728;C0521942;C0815017;C0871470;C0965129;C1306620;C1452534;C1511726;C1532338;C1696465;C1706408;C3245479;C3541240;C3714741;C3888198;C4284014;C4521602
2103,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
2103,treated vessel ( s ),C0005847;C1522326
2103,treated vessel !,C0005847;C1522326
2103,treated vessel,C0005847;C1522326
2103,single vessel coronary artery diseasea,C0005847;C0265903
2103,no . of vessels with > $nmbr$ % stenosis,C0005847
2103,multi vessel ( or left main ),C0005847;C0439064;C3266262
2103,$nmbr$ vessels or left main,C0005847
2102,vessel treated  n,C0005847
2102,restenotic vessel,C0005847;C0333186
2102,one vessel,C0005847;C0205447
2102,number of vessels treated  index pci,C0005847;C0237753;C0449788
2102,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
2102,number of treated vessels,C0005847;C0237753;C0449788;C1522326
2102,no . of vessels treated,C0005847
2102,no . of vessels,C0005847
2102,no . of treated vessels,C0005847;C1522326
2102,> $nmbr$ vessels treated,C0005847
2102,> $nmbr$ lesions per vessel,C0005847;C0221198
2102,> $nmbr$ diseased vessels,C0005847
2102,$nmbr$ vessels,C0005847
2102,$nmbr$ vessel,C0005847
2101,vascular territory # $nmbr$,C0005847;C1301808;C1558950;C1801960;C2983136
2101,vascular risk score — no . { % ) ^,C0005847;C0035647;C1558950;C1801960;C4552904
2101,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
2101,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
2101,vascular history  %,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
2101,vascular disordersb,C0005847;C1558950;C1801960
2101,vascular accidents  n ( % ),C0000924;C0005847;C1558950;C1801960
2101,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
2101,vascular,C0005847;C1558950;C1801960
2101,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
2101,no culprit vessel identified,C0005847
2101,culprit vessel,C0005847
2101,any vascular diasease,C0005847;C1558950;C1801960
2101,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
2100,sbp > $nmbr$ mnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
2100,sbp ( sd ),C0085805;C2699239
2100,sbp  last,C0085805
2100,sbp,C0085805
2100,ambulatory sbp  n,C0085805;C0439841
2099,low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205251;C1079230;C1415800;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
2099,high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2099,feno — ppb,C1415800
2099,> $nmbr$ to < $nmbr$ ppb,C1415800
2099,> $nmbr$ ppb,C1415800
2099,< $nmbr$ ppb,C1415800
2098,vdz / pbo [ n = $nmbr$ ],C0031962
2098,pbo n = $nmbr$,C0031962
2098,pbo n ( % ),C0031962
2098,pbo - sc every other week ( n = $nmbr$ ),C0031962;C0282380
2098,pbo ( n   =   $nmbr$ ),C0031962
2098,pbo ( n = $nmbr$ ) vs,C0031962
2098,pbo ( n = $nmbr$ ),C0031962
2098,pbo ( n - $nmbr$ ),C0031962
2098,pbo ( n $nmbr$ ),C0031962
2098,pbo ( n $nmbr$ $nmbr$ ),C0031962
2098,pbo  no . ( o / o ) ^ ’,C0031962
2098,pbo  no . ( % ) ^,C0031962
2098,pbo  n = $nmbr$,C0031962
2098,ind + pbo ( n = $nmbr$ ),C0031962;C4049864
2098,ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1334085;C1708411
2097,pbo + mtx to mtx,C0025677;C0031962;C1417487
2097,pbo + mtx n = $nmbr$,C0025677;C0031962;C1417487
2097,pbo + mtx ^ mtx,C0025677;C0031962;C1417487
2097,pbo + mtx,C0025677;C0031962;C1417487
2097,pbo,C0031962
2097,flex pbo ®,C0031962
2096,r - tpa,C0032143
2096,alteplase group ( n = $nmbr$ ),C0032143;C0441848
2096,alteplase ( n = $nmbr$ ),C0032143
2096,alteplase,C0032143
2095,vdz / pla n = $nmbr$,C0456170
2095,pla « = $nmbr$,C0456170
2095,pla n = $nmbr$,C0456170
2095,pla,C0456170
2095,atio - pla,C0456170
2094,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
2094,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
2094,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
2094,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2094,pad details  n ( % ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2094,pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2094,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2094,no pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2093,suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
2093,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
2093,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
2093,estradiol quartiles,C0014912;C2828255
2092,st - segment deviation timi risk score  %,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
2092,st - segment deviation > $nmbr$ mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
2092,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
2092,deviation  mm,C0012727;C0205419;C1705236;C4330985;C4554674
2091,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
2091,mean wall thickness ( cm ),C0677535;C4054557
2090,relative risk ® ( $nmbr$ % cl ),C0242492;C0596019
2090,relative risk ® ' ( $nmbr$ % cl ),C0242492;C0596019
2090,relative risk vs . placebo ( $nmbr$ % cl ),C0242492
2090,relative risk reduction ( $nmbr$ % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
2090,relative risk reduction ( $nmbr$ % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
2090,relative risk * ( $nmbr$ % cl ),C0242492;C0596019
2090,relative risk ( $nmbr$ % cl ),C0242492;C0596019
2089,size of left atrium normal — no . ( % ) £,C0225860;C0456389
2089,left atrial diameter : < $nmbr$ mm ( n = $nmbr$ ),C0225860;C0225861;C1301886;C4330985;C4554674
2089,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
2089,left atrial diameter,C0225860;C0225861;C1301886
2089,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
2088,treated with losartan ( n = $nmbr$ ),C0126174;C0332293
2088,treated with laba  %,C0332293
2088,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
2088,treated with cabg — no . / total no . ( % ),C0010055;C0332293
2088,treated with atenolol ( n = $nmbr$ ),C0004147;C0332293
2087,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
2087,treatment duration  days,C0439228;C0444921;C3259042
2087,duration of treatment in the healing study  n,C0444921
2086,stratification factors,C1514984
2086,stratification factor : menopausal status  n ( % ),C1513126;C1514984
2085,atorvastatin { n = $nmbr$  $nmbr$ ),C0286651
2085,atorvastatin monotherapy ( n = $nmbr$ * ),C0286651
2085,atorvastatin ( n = $nmbr$  $nmbr$ ),C0286651
2085,atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0286651;C1142985;C1319635
2085,atorvastatin $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2085,atorvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2085,atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2085,atorvastatin $nmbr$ mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2085,atorvastatin  n ( % ),C0286651
2085,atorvastatin,C0286651
2084,fluvastatin ( n = $nmbr$ ),C0082608
2084,clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
2083,normal albuminuria ( uacr < $nmbr$ ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
2083,macro - albuminuria,C0001925;C2984010
2083,any albuminuria — no . ( % ),C0001925
2083,any albuminuria,C0001925
2083,albuminuria,C0001925
2082,albuminuria < $nmbr$ gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
2082,albuminuria ( g / g ),C0001925;C1319635
2081,albuminuria and previous maerovaseular disease without established renal disease,C0001925
2081,albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g ),C0001925;C0702093;C1524029;C1635169;C1739039;C3811844;C3812682;C3813700
2080,mepolizumab,C0969324
2079,dupilumab $nmbr$,C3660996
2078,vedolizumab n = $nmbr$,C2742797
2078,vedolizumab cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755;C2742797
2078,vedolizumab,C2742797
2077,golimumab $nmbr$ mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
2077,golimumab,C2353893
2076,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
2076,omalizumab ( lsm ),C0966225
2076,omalizumab,C0966225
2075,evolocumab + soc ( n = $nmbr$ ),C3529352
2075,evolocumab ( n = $nmbr$ ),C3529352
2075,evolocumab ( $nmbr$ mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
2075,evolocumab $nmbr$ mg monthly ( n = $nmbr$ ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
2075,evolocumab,C3529352
2074,benralizumab q $nmbr$ w ( n = $nmbr$ ),C2982078
2074,benralizumab q $nmbr$ w ( n - $nmbr$ ),C2982078
2074,benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
2074,benralizumab,C2982078
2073,lebrikizumab ( n = $nmbr$ ),C2981360
2073,lebrikizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2073,lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2073,lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2073,lebrikizumab $nmbr$ - $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2072,reslizumab ( n = $nmbr$ ),C1869620
2072,reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ ),C0439272;C1869620
2072,reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1869620
2072,reslizumab,C1869620
2072,b reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
2072,a reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
2071,treatment satisfaction,C3476649
2070,ultrasound carotid arteries,C0948945
2069,notable abnormalities,C0000768;C0000769;C4288581
2069,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
2068,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
2068,patient - reported outcomes,C2987124
2067,no reperfusion,C0035124;C0684253
2067,acute reperfusion,C0035124;C0205178;C0684253
2066,mycophenolate ( any derivative ),C0883242
2065,sulphonamides  urea derivatives,C0038760;C0041942;C0243072
2064,propionic acid derivatives,C0033482;C0695274;C3540752
2063,dopa and dopa derivativese,C0013023
2062,adamantane derivatives,C3653470
2061,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
2061,other defined,C1704788;C3539106
2060,renal parameters,C0022646;C0449381
2060,parameters,C0449381
2060,other lipid parameters,C0023779;C0449381
2060,lipid parameters,C0023779;C0449381
2060,glycaemic parameters,C0005802;C0449381
2060,biometric parameters,C0005544;C0449381;C2718322
2059,height in meters .,C0441074;C0489786
2059,> = $nmbr$ meters,C0441074
2059,< $nmbr$ meters,C0441074
2058,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0231174;C0680095;C0699733;C2024216;C4554158
2058,devices,C0025080;C0220819;C0699733
2057,furosemide equivalent  mg / kg,C0016860;C0205163;C0439185;C0439272
2057,furosemide,C0016860
2056,apremilast $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
2056,apremilast,C1678805
2055,triacylglycerol  mmol / le,C0023190;C0041004;C0439090;C0439190;C1423767;C2697858
2055,total cholesterol  mmol / le,C0023190;C0201950;C0439090;C0439190;C0543421;C1423767;C2697858
2055,fema le,C0023190;C0439090;C1423767;C2697858
2054,thromboembolism,C0040038
2053,systemic embolism,C0013922;C0205373;C1704212
2053,non cns embolism,C0013922;C1518422;C1704212;C3714787
2053,embolism,C0013922;C1704212
2053,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
2052,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
2051,very severe n z $nmbr$,C3641272;C4050419
2051,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
2051,very severe ( itt ) ( n = $nmbr$ ),C3641272;C4050419
2051,very severe ( gold $nmbr$ ),C0018026;C1304897;C3641272;C4050419
2051,very severe  gold $nmbr$,C0018026;C1304897;C3641272;C4050419
2051,very severe,C3641272;C4050419
2051,$nmbr$ - $nmbr$ ( very severe ),C3641272;C4050419
2050,severe / moderate,C1299393
2050,moderate - to - severe copd exacerbation,C0740304;C1299393
2050,gusto severe / moderate,C1299393
2049,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
2049,re - medy,C0556581;C2986904
2049,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
2049,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
2049,re - cover $nmbr$ warfarin,C0180153;C0556581;C1999244;C2986904;C3888055
2049,re - cover $nmbr$ dabigatran,C0180153;C0556581;C1999244;C2986904;C3888055
2048,prednisone use  %,C0032952;C0042153;C0457083;C1947944
2048,prednisone,C0032952
2048,% pred,C0032952;C0044955
2047,smedian prednisone dose  n ( % ),C0032952;C0178602;C0869039;C1114758
2047,prednisone or equivalent dose ( mg / day ),C0032952
2047,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
2047,prednisone - equivalent dose  mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
2047,oral glucocorticoid dose  mg ( prednisone equivalent ),C0017710;C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0442027;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761;C4521986
2047,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
2047,< median prednisone dose  n ( % ),C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
2046,patients with ascvd but no prior ml hr ( $nmbr$ % cl ),C0030705;C3665365
2046,other ascvd  no . ( % ),C3665365
2046,other ascvd,C3665365
2046,no ascvd,C3665365
2046,ascvd no prior ml,C3665365
2046,ascvd including tia,C3665365
2046,ascvd as per protocol,C1698058;C3665365
2046,ascvd * . n ( % ),C3665365
2046,ascvd  n ( % ),C3665365
2046,ascvd  b no . ( % ),C3665365
2046,ascvd,C3665365
2045,hgb  g / dl < $nmbr$ men  < $nmbr$ women,C0019029;C0019046;C0025266;C0043210;C0439267;C0518015;C1424337
2045,hgb  g / dl,C0019029;C0019046;C0439267;C0518015;C1424337
2045,hb decrease ≥ $nmbr$ g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
2045,hb  g / dl,C0019046;C0439267;C3642216;C3843510
2045,albumin  g / dl,C0001924;C0439267
2044,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
2044,g - blockers,C0439267
2043,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
2043,vi $nmbr$   µ g,C0205999;C0439267
2043,gly $nmbr$ μ g bid,C0017890;C0439267;C0523677
2043,glu $nmbr$ asp g . t,C0125690;C0439267
2042,tiotropium $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
2042,tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ ),C0213771;C0439267
2042,tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
2042,formoterol $nmbr$   μ g ( n   =   $nmbr$ ),C0060657;C0439267
2042,bdp / ff / g ( n = $nmbr$ ),C0004906;C0439267;C1422585;C1538710;C4554348
2042,aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ ),C0439267;C2699757
2042,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b,C0439267;C2699757
2042,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a,C0439267;C2699757
2042,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ),C0439267;C2699757
2042,$nmbr$ μ g bid ( n = $nmbr$ ),C0439267
2042,$nmbr$ μ g ( n = $nmbr$ ),C0439267
2041,g + c,C0439267
2041,g,C0439267
2041,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
2041,$nmbr$ a . g,C0439267
2040,vildagliptin + metformin ( vldm ),C0025598;C1570906
2040,vildagliptin ( n = $nmbr$ ),C1570906
2040,vildagliptin $nmbr$ mg qd n = $nmbr$,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
2040,vildagliptin $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
2040,vildagliptin $nmbr$ mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
2040,vildagliptin $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
2040,vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
2040,vildagliptin,C1570906
2039,with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
2039,with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
2039,with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
2039,with alogliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
2039,alogliptin ( n = $nmbr$ ),C1958126
2039,alogliptin  n ( % ),C1958126
2039,alogliptin,C1958126
2038,linagliptin / metformin,C3264599
2037,sitagliptin ± oad,C1565750
2037,sitagliptin no . / total no .,C1565750
2037,sitagliptin n = $nmbr$,C1565750
2037,sitagliptin ( n = $nmbr$ ),C1565750
2037,sitagliptin $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
2037,sitagliptin $nmbr$,C1565750
2037,sitagliptin,C1565750
2036,saxagliptin ( n = $nmbr$ ),C1611934
2036,saxagliptin ( n = $nmbr$  $nmbr$ ),C1611934
2036,saxagliptin ( % ),C1611934
2036,saxagliptin $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
2036,saxagliptin,C1611934
2035,dulaglutide $nmbr$ . $nmbr$ mgf,C1366394;C3179549;C3712803;C3887684
2034,liraglutide n ( % ),C1456408
2034,liraglutide ( « = $nmbr$ ),C1456408
2034,liraglutide ( n = $nmbr$ ),C1456408
2034,liraglutide ( n = $nmbr$  $nmbr$ ),C1456408
2034,liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
2034,liraglutide,C1456408
2033,semaglutide exposure  nmol / l,C0274281;C0332157;C0439282;C3885068
2033,semaglutide ( n = $nmbr$ ),C3885068
2033,semaglutide,C3885068
2032,multivitamins,C0301532;C3714835
2031,mucolytics,C0026698
2031,mucolytic agent,C0026698
2030,lira,C1555441
2029,ultra,C0728475
2028,previous limb or foot amputation,C0015385;C0205156;C1552607
2028,limb,C0015385
2027,vldl cholesterol,C0023826;C0523560
2027,vldl - c,C0523560
2027,vldl,C0523560
2026,ldlc : hdlc,C1416822;C1704429
2026,ldlc,C1416822
2025,ld,C0694649
2025,cg / ld,C0043444;C0694649;C1567075;C3540479
2025,< $nmbr$ . $nmbr$ ld,C0694649
2024,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
2024,total - c : hdl - c,C0439175;C0439810;C3715113
2024,non - hdl choleslerol,C1518422;C3715113
2024,ldl - c : hdl - c,C3715113
2024,ldl - c / hdl - cx,C3715113
2024,ldl - c / hdl - c,C3715113
2024,hdl choleslerol,C3715113
2023,hdl - cy,C0010622;C0332298;C2239193;C3715113
2023,hdl - cd,C0007928;C0034283;C3715113;C4552032
2023,hdl - c,C3715113
2023,hdl *,C3715113
2023,hdl $nmbr$ - c,C3715113
2023,hdl $nmbr$,C3715113
2023,hdl,C3715113
2022,reduced hdl cholesterol,C0151691
2022,low hdl cholesterol * |,C0151691
2022,low hdl cholesterol,C0151691
2022,low hdl - c,C0151691
2021,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
2021,mean age ± s . d .  years,C0444504;C1510829;C2347634;C2348143
2021,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
2021,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
2021,mean age ( years ),C0444504;C1510829;C2347634;C2348143
2021,mean age ( years  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2021,mean age  years ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2021,mean age  years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2021,mean age  years ( $nmbr$ % ci ),C0008107;C0444504;C1510829;C2347634;C2348143;C3259781
2021,mean age  years,C0444504;C1510829;C2347634;C2348143
2021,age mean age  years sex,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143
2021,age in years  mean,C0444504;C1510829;C2347634;C2348143
2021,age [ years ],C1510829
2021,age > = $nmbr$ years old,C1510829
2021,age > $nmbr$ years ( median ),C1510829
2021,age > $nmbr$ years  %,C1510829
2021,age > $nmbr$ ( years ) t,C1510829
2021,age < $nmbr$ years old,C1510829
2021,age < $nmbr$ years ( median ),C1510829
2021,age ( years ) a,C1510829
2021,age ( years ) :,C1510829
2021,age ( years ) +,C1510829
2021,age ( years ) *,C1510829
2021,age ( years )  mean ± s . d .,C0444504;C1510829;C2347634;C2348143
2021,age ( years )  mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
2021,age ( years ),C1510829
2021,age $ $nmbr$ years § *,C1510829
2021,age  years “,C1510829
2021,age  years mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
2021,age  years ^,C1510829
2021,age  years *,C1510829
2021,age  years ( mean _ + sd ) sex  n ( % ) :,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143;C2699239
2021,age  years $nmbr$ ',C1510829
2021,age  ( years ),C1510829
2021,> $nmbr$ years of age  n ( % ),C1510829
2020,i $nmbr$ years of age,C0021966;C0221138;C1510829
2020,age $nmbr$ years or more,C1510829
2020,> $nmbr$ years of age,C1510829
2020,< $nmbr$ years of age,C1510829
2019,age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
2019,age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
2019,age ≥ $nmbr$ years  n ( % ),C1510829
2019,age ≥ $nmbr$ years,C1510829
2019,age £ $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
2019,age years,C1510829
2019,age s $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
2019,age range ( years ),C1510829;C1514721;C2348147;C3542016
2019,age range  years,C1510829;C1514721;C2348147;C3542016
2019,age in years,C1510829
2019,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
2019,age groiro : < $nmbr$ years,C1510829
2019,age at entry ( years ),C1510829;C1705654
2019,age [ years ] ( interaction : p = $nmbr$ . $nmbr$ ),C1510829;C1704675
2019,age > = $nmbr$ years,C1510829
2019,age > $nmbr$ years ( n = $nmbr$ ),C1510829
2019,age > $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
2019,age > $nmbr$ years $nmbr$,C1510829
2019,age > $nmbr$ years  n ( % ),C1510829
2019,age > $nmbr$ years,C1510829
2019,age < $nmbr$ years — no . ( % ),C1510829
2019,age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
2019,age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
2019,age < $nmbr$ years ( n = $nmbr$ ),C1510829
2019,age < $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
2019,age < $nmbr$ years ( n =,C1510829
2019,age < $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
2019,age < $nmbr$ years $nmbr$,C1510829
2019,age < $nmbr$ years  n ( % ),C1510829
2019,age < $nmbr$ years,C1510829
2019,age : > $nmbr$ years,C1510829
2019,age : < $nmbr$ years ( n = $nmbr$ ),C1510829
2019,age : < $nmbr$ years,C1510829
2019,age . years,C1510829
2019,age - years,C1510829
2019,age ( years ) : > $nmbr$,C1510829
2019,age ( years ) : < $nmbr$,C1510829
2019,age ( years ) : $nmbr$ - < $nmbr$,C1510829
2019,age ( years ( s . d . ) ),C1510829
2019,age ( years  sd ),C1510829;C2699239
2019,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
2019,age ( per $nmbr$ years ),C1510829
2019,age $nmbr$ years ( n = $nmbr$ ),C1510829
2019,age $nmbr$ years,C1510829
2019,age $nmbr$ - $nmbr$ years ( n = $nmbr$ ),C1510829
2019,age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
2019,age $nmbr$ + years,C1510829
2019,age  years ( sd ),C1510829;C2699239
2019,age  years,C1510829
2019,age  median ( range ) ( years ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2019,age  mean ( range ) years,C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
2019,age  $nmbr$ years,C1510829
2018,gender n ( % ),C0079399;C1522384
2018,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender [ n ( % ) ],C0079399;C1522384
2018,gender : male    n   ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender :,C0079399;C1522384
2018,gender - n ( % ),C0079399;C1522384
2018,gender - male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
2018,gender ( male )  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender ( female : male  % ),C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
2018,gender    n   ( % men ),C0025266;C0079399;C1522384
2018,gender    n   ( % ),C0079399;C1522384
2018,gender  women n  % ),C0043210;C0079399;C1522384
2018,gender  no . ( % ),C0079399;C1522384
2018,gender  n ( % ],C0079399;C1522384
2018,gender  n ( % ),C0079399;C1522384
2018,gender  male ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender  male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender  male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2018,gender  female  n ( % ),C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
2018,gender  % of patients,C0030705;C0079399;C1522384
2018,gender  %,C0079399;C1522384
2018,gender,C0079399;C1522384
2018,female sex  n ( % of patients ),C0009253;C0030705;C0036864;C0043210;C0079399;C0086287;C0150831;C0150905;C0804628;C1314687;C1522384;C1705497;C1705498
2018,eze / simva gender,C0079399;C1522384
2018,age  y sex  no . ( % ),C0001779;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2018,age  y gender  n ( % ),C0001779;C0079399;C1522384
2017,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
2017,tier $nmbr$ aes,C1412268;C2699274
2017,other selected aes,C1412268;C1707391;C2699274
2017,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
2017,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
2017,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
2017,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
2017,any aes  n ( % ),C1412268;C2699274
2017,any aes,C1412268;C2699274
2017,aes related to,C1412268;C2699274
2017,aes leading to dose reduction of study drugb,C1412268;C2699274
2017,aes leading to discontinuation of study drugb,C1412268;C2699274
2017,aes leading to,C1412268;C2699274
2017,aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §,C0030705;C0376247;C1412268;C1556094;C2699274
2017,aes *,C1412268;C2699274
2017,> $nmbr$ aes leading to discontinuation,C1412268;C2699274
2017,> $nmbr$ aes,C1412268;C2699274
2016,hormone therapy use,C0042153;C0279025;C0457083;C1947944
2016,hormone therapy,C0279025
2016,hormonal therapy — no . ( % ),C0279025
2015,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
2015,combined therapy vsdutasteride,C0033972
2015,combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$,C0033972
2014,standard therapy ( n = $nmbr$ ),C2936643
2014,standard therapy,C2936643
2013,pharmacotherapy,C0013216;C0013217
2013,other drug therapy  n ( % ),C0013216;C0013217
2013,drug therapy at admission 一 no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
2013,drug therapy at admission — no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
2013,drug therapy  no . ( % ),C0013216;C0013217
2013,drug therapy  n ( % ),C0013216;C0013217
2013,drug therapy,C0013216;C0013217
2012,unhappy,C1688635
2011,nap,C0870935;C1423800;C4283878
2010,hungary,C0020174
2009,voluntary,C0439656;C3543419
2008,sedentary,C0205254
2007,permanent users  n,C0205355;C1706077
2007,permanent users,C0205355;C1706077
2007,permanent af,C0205355;C0344434;C4049859
2007,permanent ( n  % ),C0205355
2007,permanent  n ( % ),C0205355
2007,permanent,C0205355
2006,perianal or anus,C0442158
2006,perianal gi tract,C0017189;C0442158
2006,perianal  n ( % ),C0442158
2005,peripheral vasodilators,C0724804
2004,peripheral sensory neuropathy,C0151313;C4554142
2003,peripheral neuropathy,C0031117
2002,peripheral edema,C0085649
2001,peripheral embolism,C0013922;C0205100;C1704212
2001,peripheral,C0205100
2000,very high vs . normalb,C0442804;C4321397
2000,very high vs . normal,C0442804;C4321397
2000,very high ( >   $nmbr$ xuln ) n   =   $nmbr$,C0442804;C4321397
2000,very high,C0442804;C4321397
1999,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
1999,vorapaxar no . ( $nmbr$ - y km % ),C2974521
1999,vorapaxar n = $nmbr$,C2974521
1999,vorapaxar group ( n = $nmbr$ ),C0441848;C2974521
1999,vorapaxar ( n = $nmbr$ . $nmbr$ ),C2974521
1999,vorapaxar ( n = $nmbr$ )  n ( % ),C2974521
1999,vorapaxar ( n = $nmbr$ ),C2974521
1999,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521
1999,vorapaxar ( n = $nmbr$  $nmbr$ ),C2974521
1999,vorapaxar $nmbr$ - y,C2974521
1999,vorapaxar,C2974521
1998,verapamil sr strategy ( n = $nmbr$  $nmbr$ ),C0679199;C1527129
1998,verapamil sr n = $nmbr$ no . ( % ),C1527129
1998,verapamil sr n = $nmbr$,C1527129
1998,verapamil sr ( no . = $nmbr$ ),C1527129
1998,verapamil sr,C1527129
1998,verapamil - sr strategy,C0679199;C1527129
1998,verapamil - sr ( « = $nmbr$ $nmbr$ ),C1527129
1997,carvedilol  % ( n ),C0054836
1997,carvedilol,C0054836
1996,varespladib ( n = $nmbr$ ),C2713485
1996,varespladib,C2713485
1995,variables .,C0439828
1995,variables *,C0439828
1995,variables $nmbr$,C0439828
1995,variables,C0439828
1995,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
1995,variable ' ! ',C0439828;C4553760
1995,variable,C0439828;C4553760
1995,stratification variables,C0439828;C1514983
1994,early use intended,C1279919
1994,early routine,C0205547;C1279919
1994,early load,C1279919
1994,early eptifibatide,C0253563;C1279919
1994,early clopidogrel intended,C0070166;C1279919
1994,early - start group ( n = $nmbr$ ),C1279919
1994,early - eptifibatide group ( n = $nmbr$ ),C0253563;C0441848;C1279919
1994,early ( n = $nmbr$ ),C1279919
1994,early  n ( % ),C1279919
1994,early,C1279919
1993,lrg,C1428862
1992,hrg,C1437978;C1705020
1991,arr ( % ),C2170357;C4084934
1991,arr,C2170357;C4084934
1990,use of rescue medication,C0240320
1990,use of other medications — no . ( % ),C0240320
1990,rescue medication use  inh / d {,C0022209;C0240320
1990,prior medication use  n ( % ),C0240320;C0332152;C2826257
1990,medication use,C0240320
1990,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
1990,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
1990,concomitant medication use,C0240320;C0521115
1990,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
1989,no use ofdiabetes drugs — no . ( % ),C0240320
1989,medication use before enrollment  no . ( % ),C0240320;C1516879;C1696073;C3888021
1989,medication use at entry ( % ),C0240320;C1705654
1989,medication use ( % ),C0240320
1989,medication use  n ( % ),C0240320
1988,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
1988,incidence of each outcome,C0021149;C0220856;C1274040
1988,incidence ^,C0021149;C0220856
1988,incidence *,C0021149;C0220856
1988,incidence  ° / o ( $nmbr$ / $nmbr$ cl ),C0021149;C0220856;C0596019
1988,incidence  %,C0021149;C0220856
1988,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
1988,event incidence / n,C0021149;C0220856;C0441471;C4019010
1988,event / patients in group ( incidence / $nmbr$ person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
1988,cumulative incidence lyear,C0021149;C0220856;C1511559
1988,cumulative incidence $nmbr$ years,C0021149;C0220856;C0439234;C1511559
1988,^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .,C0021149;C0220856;C0374505
1988,$nmbr$ - year cumulative incidence  % ( ci ),C0008107;C0021149;C0220856;C0439234;C0439508;C1511559;C3259781
1987,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
1987,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4521986
1987,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0040223;C0205435;C0220880;C0441471;C1279901;C3541383;C4019010
1987,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
1987,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
1987,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
1987,time - to - first - infusion from hip surgery ( days )  n ( % ),C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
1987,received first loading dose,C0205435;C1279901;C1514756;C3714444
1987,mean time to first subcutaneous injectiong  h in relation to surgery  hr,C0033727;C0040223;C0205435;C0369286;C0441932;C0443315;C0444504;C0564385;C1279901;C2347634;C2348143;C3541383;C4528284
1987,mean time to first oral dose postsurgeryh  hr,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
1987,first year *,C0205435;C0439234;C0439508;C1279901
1987,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
1987,first loading dose,C0205435;C1279901;C3714444
1987,first hhf,C0205435;C1279901
1987,first diagnosed,C0205435;C1279901
1987,first - recorded event  no . ( and % ) of patients,C0205435;C1279901
1987,first - generation stentt,C0079411;C0205435;C1279901;C3146294
1987,first ( n = $nmbr$ ),C0205435;C1279901
1987,components of the first cid,C0205435;C0449432;C1279901;C1707433
1986,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1555582;C1705685
1986,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
1986,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
1986,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
1986,initial heparin treatment duration on or after randomization,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1986,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1986,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
1986,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
1986,> = $nmbr$ day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1986,> = $nmbr$ ^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1985,serum k + level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261
1985,patients with level > $nmbr$ pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
1985,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
1985,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
1985,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
1985,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
1985,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
1985,level of thyroperoxidase antibody at baseline,C0021965;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1547707;C2946261;C3272921
1985,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
1985,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
1985,level $nmbr$ immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
1985,level $nmbr$ immobility ^,C0231441;C0441889;C0456079;C1547707;C2946261
1985,level $nmbr$,C0441889;C0456079;C1547707;C2946261
1985,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
1985,ldl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261
1985,hscrp level,C0441889;C0456079;C1547707;C2946261
1985,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1985,hdl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261;C3715113
1985,hdl - c level  < $nmbr$ mg / dld,C0024671;C0026410;C0439269;C0441889;C0456079;C1414063;C1547707;C1960952;C2346927;C2826331;C2946261;C3715113;C4321396;C4521761
1985,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
1985,european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
1985,elevated natriuretic peptide level ( n = $nmbr$ ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
1985,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
1985,cardiac troponin t level > $nmbr$ . $nmbr$ pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
1985,cardiac troponin t level  median ( iqr )  pg / l,C0439278;C0441889;C0456079;C0549183;C0876920;C1547707;C2347635;C2348144;C2939193;C2946261;C3538889
1985,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
1985,baseline total pcsk $nmbr$ level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
1985,baseline total pcsk $nmbr$ level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
1985,baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1985,baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1985,baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1985,baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1985,baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1985,baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1985,baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1985,baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1985,baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1985,baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1985,baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1985,baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1985,baseline free pcsk $nmbr$ level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
1985,baseline free pcsk $nmbr$ level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
1985,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
1985,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
1985,> $nmbr$ . $nmbr$ hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1984,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
1984,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups,C0015663;C0020443;C0369773;C0439209;C0439300;C0439583;C0441889;C0456079;C0456962;C0475211;C0750194;C0871208;C1316572;C1317574;C1516879;C1521828;C1522133;C1547707;C1696073;C1704788;C1707455;C1719797;C2603361;C2911648;C2919575;C2946261;C2985769;C3539106;C3888021
1983,flex ain ' ’,C0347129
1983,ain  no . ( % ) “ *,C0347129
1983,ain  no . ( % ) * *,C0347129
1982,anacetrapib ( n = $nmbr$ ),C2604745
1982,anacetrapib ( n = $nmbr$  $nmbr$ ),C2604745
1982,anacetrapib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1982,anacetrapib $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1982,anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1981,placebo - control study,C0683952
1980,spacer use during the study,C0221874;C0869040
1979,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419
1979,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
1978,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
1978,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
1977,b - agonists ( short - acting ) a,C0243192;C2987634
1977,b - agonists ( long - acting ) a,C0243192;C2987634
1976,absolute time spent “ on ” without troublesome dyskinesia  h / day,C0439546
1976,absolute time spent “ on ” with troublesome dyskinesia  h / day,C0439546
1976,absolute time spent “ on ”  h / day,C0439546
1975,eosinophils ( cells / ll ) inclusion criteria  n ( % ),C0682547
1975,eosinophil counf cells pl ',C0682547;C3897966;C4049765
1975,baseline eosinophil < $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1975,baseline eosinophil $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1974,target nail napsi score ( $nmbr$ – $nmbr$ scale ),C0027342;C1432728;C1521840;C2986546;C3538766
1974,nail involvement  %,C0027342;C1314939;C1432728;C3538766
1973,metabolizer phenotype ( % ) §,C0031437;C1285572
1973,clinical copd phenotype ^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
1972,sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ ),C0030827;C0072225;C0585361;C1266240;C4521536
1972,sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
1972,salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
1972,sal $nmbr$ pg ( n = $nmbr$ ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
1972,qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ ),C0030827;C0072225;C0332173;C1266240
1972,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
1972,nt - probnp  pg / mlt,C0030827;C0072225;C0669479;C0754710;C1266240;C4553833
1972,indacaterol $nmbr$ pg,C0030827;C0072225;C1266240;C1722260
1972,gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$,C0030827;C0072225;C0152277;C1266240;C1415124
1972,fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
1972,formoterol $nmbr$ pg vs placebo,C0030827;C0060657;C0072225;C1266240
1972,formoterol $nmbr$ pg,C0030827;C0060657;C0072225;C1266240
1972,ff $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
1972,aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
1972,aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C2699757
1972,aclidinium $nmbr$ pg,C0030827;C0072225;C1266240;C2699757
1972,ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
1972,ab $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240
1971,diffusion capacity of the lung for carbon monoxide  % predicted !,C0231971
1970,ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness,C0029040
1969,either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years,C3844638
1968,values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295
1968,values were calculated using t tests for continuous variables and chi - square,C0042295
1968,nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0042295;C0669479;C0754710
1968,laboratory values in patients with history of diabetes,C0022877;C0030705;C0042295;C3244292;C4283904
1968,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
1968,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
1968,( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled,C0042295
1967,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0005910;C0042295;C0043100;C0332288;C0439209;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
1967,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0332288
1966,method used to diagnose the incident pulmonary embolism  no . ( % ),C0025663;C0449851;C0871511
1966,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
1965,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931
1965,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C1301931;C1524003;C3541383
1964,menopausal status and use of ht,C1513126
1964,menopausal status and use of hrt ( % ) y,C1513126
1964,menopausal status and hormone therapy use premenopausal,C1513126
1964,menopausal status and hormone therapy use,C1513126
1963,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
1963,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
1963,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
1962,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
1962,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
1962,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
1962,fasting plasma glucose categories  n ( % ),C0015663;C0202042;C0455280;C0683312
1962,fasting plasma glucose *,C0015663;C0202042;C0455280
1962,fasting plasma glucose ( mmol / l ) $nmbr$,C0015663;C0202042;C0455280;C1532563
1962,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
1962,fasting plasma glucose ( mg / dl ) $nmbr$,C0015663;C0202042;C0439269;C0455280
1962,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
1962,fasting plasma glucose $nmbr$ medan,C0015663;C0202042;C0455280
1962,fasting plasma glucose  mg / dl,C0015663;C0202042;C0439269;C0455280
1962,fasting plasma glucose,C0015663;C0202042;C0455280
1962,fascng plasma glucose a medan,C0202042;C0455280
1962,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
1962,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
1962,$nmbr$ - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
1962,$nmbr$ - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
1961,migraine — no . ( % ) $,C0149931
1961,migraine severity score,C0149931;C0457451
1961,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
1961,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
1960,mitral regurgitation  n ( % ),C0026266
1960,mitral regurgitation  ( % ),C0026266
1960,mitral insufficiency  n ( % ),C0026266
1960,mitral insufficiency,C0026266
1959,daily iglar dose at week $nmbr$ ( u ),C0560588;C2348070
1959,daily dose of study medication prescribed,C0013175;C2348070
1959,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
1958,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
1958,average daily dose,C1510992;C2348070;C2825518
1957,intravenous vasoactive drugs  % y,C0683092;C1980011
1956,intravenous vasodilators ( % ),C0443081
1955,total intravenous loop diuretics  mg,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C1960952;C2346927;C4321396;C4521761
1955,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
1955,intravenous nitrates,C0028125;C0348016
1955,intravenous loop diuretics !,C0348016;C0354100
1955,intravenous inotropes or vasopressors ( % ),C0348016;C1258199
1955,intravenous dobutamine,C0012963;C0348016
1955,intravenous ( n = $nmbr$ ),C0348016
1954,indacaterol n = $nmbr$,C1722260
1954,indacaterol group ( n = $nmbr$ ),C0441848;C1722260
1954,indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .,C0439417;C1722260;C3814772
1954,indacaterol - glycopyrronium group ( n = $nmbr$ ),C0441848;C1722260;C3814772
1954,indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C1722260
1954,indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211;C1722260
1954,indacaterol $nmbr$ ug ( n = $nmbr$ ),C0041573;C0439211;C1722260
1954,indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1953,indacaterol + tiotropium ( n [ $nmbr$ ),C0213771;C1722260
1953,differences between indacaterol + tiotropium versus tiotropium + placebo,C0213771;C1705241;C1705242;C1722260
1952,waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl,C0025266;C0043210;C0455829
1952,waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women ),C0025266;C0455829
1952,men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
1952,men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
1952,men : qvai $nmbr$ - sfc,C0025266;C4521536
1952,men ( n 二 $nmbr$ ),C0025266
1952,men ( n [ % ] ),C0025266
1952,men ( n = $nmbr$ vs $nmbr$ ),C0025266
1952,men ( n = $nmbr$ )  n / n ( % ),C0025266
1952,men ( n = $nmbr$ ),C0025266
1952,men ( n = $nmbr$ $nmbr$ ),C0025266
1952,men ( n  % ),C0025266
1952,men ( % ),C0025266
1952,men    n   ( % ),C0025266
1952,men  no . ( % ),C0025266
1952,men  n ( % ) *,C0025266
1952,men  n ( % ),C0025266
1952,men  > $nmbr$ cm,C0025266
1952,men  < $nmbr$ cm,C0025266
1952,men  %,C0025266
1952,low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl ),C0025266;C0151691;C0439269
1952,high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl ),C0025266;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
1951,no . men,C0025266
1951,men,C0025266
1951,gmi ( men ),C0025266
1951,chd men,C0025266;C0280604;C3542407
1951,chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0007820;C0025266;C0280604;C3542407
1951,all men,C0025266
1951,$nmbr$ - $nmbr$ ( men ),C0025266
1950,left circumflex coronary artery,C0226037
1950,left circumflex artery  n ( % ),C0226037
1950,left circumflex artery,C0226037
1949,left circumflex,C0205091;C0443246;C1552822;C1880089
1949,circumflex,C1880089
1948,hip circumference — cm,C0562350
1947,waist circumference — cmj,C0455829
1947,waist circumference — cm,C0455829
1947,waist circumference .,C0455829
1947,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
1947,waist circumference ( cm ),C0455829
1947,waist circumference  mean ( sd )  in,C0444504;C0455829;C2347634;C2348143;C2699239
1947,waist circumference  mean ( sd )  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1947,waist circumference  cm mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1947,waist circumference  cm ( sd ),C0455829;C2699239
1947,waist circumference  cm  mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1947,waist circumference  cm,C0455829
1947,waist circumference  ( cm ),C0455829
1947,waist circumference,C0455829
1947,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1946,ileum or colon,C0020885
1946,ileum only,C0020885;C0205171;C1720467
1946,ileum and colon  n ( % ),C0020885
1946,ileum and colon  ' n ( % ),C0020885
1946,ileum and colon,C0020885
1946,ileum,C0020885
1945,dense calcium  mm ’,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611;C4330985;C4554674
1945,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
1945,calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611
1945,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
1945,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
1945,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
1945,calcium  mmol $nmbr$ $nmbr$,C0006675;C0006726;C0439190;C2936886;C3540037;C3714611
1944,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
1944,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
1944,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
1943,walk for exercise ( % ),C0015259;C0080331;C1522704
1943,walk for exercise,C0015259;C0080331;C1522704
1943,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
1943,exercise status,C0015259;C0449438;C1522704
1943,exercise at least weekly ( a ),C0015259;C1522704
1943,exercise > once weekly ?,C0015259;C1522704
1943,exercise > once weekly,C0015259;C1522704
1943,exercise ( % ),C0015259;C1522704
1943,exercise  n ( % ),C0015259;C1522704
1943,exercise,C0015259;C1522704
1942,some physical activity,C0015259;C0026606
1942,physical activity §,C0015259;C0026606
1942,physical activity ( hours walking / wk ),C0015259;C0026606;C0439227
1942,physical activity  kcal / wk < $nmbr$,C0015259;C0026606;C0332174;C0439230;C0439259
1942,physical activity  kcal / wk *,C0015259;C0026606;C0332174;C0439230;C0439259
1942,physical activity  kcal / wk,C0015259;C0026606;C0332174;C0439230;C0439259
1942,intense physical activity,C0015259;C0026606;C0522510
1941,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects with imputed value for end ‐ of ‐ treatment body weight,C0681850;C1522609;C1550501;C1706203;C2349001;C2697811;C2699638
1941,subjects who did receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects who did not receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects ( n ),C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects $ $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects  $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
1941,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1941,subject disposition  n ( % ),C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
1941,subject completion status  n ( % ),C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
1941,number of subjects in analysis,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1941,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1941,non - diabetic subjects  n = $nmbr$,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
1941,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1941,diabetic subjects  n = $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
1941,( $nmbr$ subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
1940,bladder,C0005682;C4319531
1939,non - lad artery,C0003842;C0226004;C1518422
1939,lad artery,C0003842;C0226004
1939,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
1938,hazard ratiof,C0598697
1938,hazard interaction,C0598697;C1704675
1938,hazard inleraction,C0598697
1938,hazard,C0598697
1937,three arm,C0205449;C0446516;C3715044;C4553528
1937,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
1937,czp combined arms ( n = $nmbr$ ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
1937,arm,C0446516;C3715044;C4553528
1936,subarachnoid hemorrhage,C0038525
1935,subdural / epidural,C0038541;C0228134;C0812144
1934,lumbar epidural,C0581283
1933,structural,C0678594
1932,intracerebral,C0442111
1931,intraperitoneal,C0442120
1930,intracranial,C0524466
1930,extracranial,C0580586
1929,t - score categories lumbar spineb,C0024090;C0683312;C3854607
1929,lumbar,C0024090
1928,war,C0043027
1927,ag,C0002037;C0051080;C0152305;C3888235
1926,aa,C0282379;C1235746;C1882141;C4554792
1925,ovary,C0029939;C0227898
1924,avr,C0449217
1923,warfarin naive,C0043031
1923,warfarin n = $nmbr$ n / n ( % ),C0043031
1923,warfarin n = $nmbr$,C0043031
1923,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
1923,warfarin group ( n = $nmbr$ ),C0043031;C0441848
1923,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
1923,warfarin ( s $nmbr$ % cl ),C0043031;C0596019
1923,warfarin ( n = $nmbr$ )  n ( % / y ),C0043031
1923,warfarin ( n = $nmbr$ ),C0043031
1923,warfarin ( n - $nmbr$  $nmbr$ ),C0043031
1923,warfarin ( % ),C0043031
1923,warfarin % ( n / n ),C0043031
1923,warfarin  no . ( % ),C0043031
1923,warfarin,C0043031
1923,warf,C0043031
1923,> $nmbr$ days warfarin,C0043031;C0439228
1922,urinary acr,C0042027;C1412134;C1515941;C1524119
1922,sprint acr > $nmbr$ - $nmbr$,C1412134;C1515941
1922,sprint acr < $nmbr$ - $nmbr$,C1412134;C1515941
1922,evaluable for acr $nmbr$ at week $nmbr$  n,C1412134;C1515941;C1516986
1922,categories of urinary acr  ^ g / mg,C0042027;C0683312;C1300563;C1412134;C1515941;C1524119
1922,b . acr $nmbr$,C1412134;C1515941
1922,acr deciles,C1412134;C1515941
1922,acr $nmbr$,C1412134;C1515941
1922,acr,C1412134;C1515941
1922,accord acr > $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
1922,accord acr < $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
1922,a . acr $nmbr$,C1412134;C1515941
1921,week $nmbr$ overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
1921,week $nmbr$ ( itt population ),C0032659;C0332174;C0439230;C1257890
1921,uplift ® population,C0032659;C1257890
1921,subpopulation,C1257890
1921,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
1921,populations :,C0032659;C1257890
1921,population,C0032659;C1257890
1921,overall vero population,C0032659;C0282416;C1257890;C1561607
1921,overall population ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1921,overall population ( n - $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1921,overall population,C0032659;C0282416;C1257890;C1561607
1921,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
1921,overall freedom population ( n = $nmbr$ ),C0016694;C0032659;C0282416;C1257890;C1561607
1921,open - label population,C0032659;C1257890;C1709323
1921,mn population  n,C0026327;C0026405;C0032659;C1257890;C4285072
1921,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
1921,mitt population ( n = $nmbr$ ),C0032659;C1257890
1921,mitt population,C0032659;C1257890
1921,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
1921,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1921,itt population  n,C0032659;C1257890
1921,itt population,C0032659;C1257890
1921,intent - to - treat population  n ( % ),C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1921,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1921,full population,C0032659;C0443225;C1257890
1921,disease activity outcomes ( itt population ) week $nmbr$,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
1921,d population,C0032659;C0073187;C0332173;C1257890;C4484261
1921,copd population ( n = $nmbr$ ),C0024117;C0032659;C1257890;C1412502;C3714496
1920,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
1920,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
1920,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
1920,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
1920,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
1920,patients in the placebo group  nt - probnp values were reported for $nmbr$ patients,C0030705;C0032042;C0042295;C0441833;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
1920,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
1920,p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo,C0020625;C0032042;C0441833;C0687744;C1176308;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408;C1709380;C4553967
1920,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
1920,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
1920,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
1920,in the spironolactone group and $nmbr$ patients in the placebo group .,C0037982;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1920,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
1920,group dif . ( $nmbr$ ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
1920,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
1920,gold $nmbr$ groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
1920,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
1920,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
1920,epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1920,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1920,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
1920,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
1920,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
1920,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
1920,bmi group ( kg / m ^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
1920,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
1920,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0005910;C0009226;C0011816;C0011849;C0013227;C0019016;C0019046;C0022709;C0025598;C0029167;C0032042;C0040372;C0043100;C0073187;C0175795;C0304289;C0332173;C0332287;C0439209;C0441833;C0521115;C0681850;C0687744;C0700307;C1185738;C1254351;C1257890;C1305855;C1305866;C1512211;C1519504;C1550501;C1696465;C1705104;C1705428;C1705429;C1706132;C1706203;C1706408;C1825777;C2349001;C2697811;C3250443;C3538758;C4288115;C4484261;C4553328
1920,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C0008107;C0008377;C0019409;C0023820;C0034656;C0042295;C0231290;C0242960;C0332282;C0332287;C0441833;C0475211;C0687744;C1079230;C1257890;C1511726;C1518681;C1519504;C1705428;C1705429;C1719797;C1883712;C2911648;C3245479;C3259781;C3714741
1920,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1920,$nmbr$ - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
1919,rv and pulmonary vascular,C0035190;C3889272
1918,lacunar,C0241970;C1459585
1917,glomerular,C0022663;C0268731
1916,ulcers / gangrene,C0017086;C0041582
1916,ulcer  n ( % ) a,C0041582;C3887532
1916,ulcer,C0041582;C3887532
1915,plac,C0048838
1914,b lack,C0332268
1913,other / multiracial,C1881928
1913,multiracial or other,C1881928
1913,multiracial  n ( % ),C1881928
1913,multiracial,C1881928
1912,mean lumbar spine t score,C0024091;C3533236;C3887615
1912,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
1912,lumbar spine bmd t -,C0024091;C3887615
1912,lumbar spine,C0024091;C3887615
1911,updrs score,C3639721
1911,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
1911,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
1910,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0456389
1910,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788
1910,weekly number of hives score $nmbr$,C0042109;C0237753;C0332174;C0449788
1910,urticaria,C0042109;C1559188
1909,eligibility stratum,C0013893;C1548635
1909,eligibility strata,C0013893;C1548635
1909,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
1909,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors  no . ( % ) t,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors  % t ascvo,C0013893;C0035648;C1548635;C1553898
1909,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
1909,* eligibility risk factors  n ( % ) *,C0013893;C0035648;C1548635;C1553898
1908,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
1908,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
1908,b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo,C0015684;C0582802;C0679214;C1555721;C1698987;C1706204;C1719844;C3241971
1908,b digit symbol substitution  insulin glargine vs standard care,C0291665;C0582802;C0679214;C0907402;C1555721;C1698987;C1706204;C3241971
1907,weeks_measured,C0439230
1907,weeks,C0439230
1907,week   $nmbr$,C0332174;C0439230
1907,week and,C0332174;C0439230
1907,week - $nmbr$ changea,C0332174;C0439230;C4349366
1907,week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230
1907,week $nmbr$ outcomes,C0332174;C0439230;C1274040
1907,week $nmbr$ outcome,C0332174;C0439230;C1274040
1907,week $nmbr$ mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
1907,week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1907,week $nmbr$ crp,C0332174;C0439230;C3890735;C4048285
1907,week $nmbr$ a,C0332174;C0439230
1907,week $nmbr$ / et,C0332174;C0439230
1907,week $nmbr$ * ’ ’,C0332174;C0439230
1907,week $nmbr$ *,C0332174;C0439230
1907,week $nmbr$ ( non - ee responders ),C0332174;C0439230;C1518422
1907,week $nmbr$ ( mmol / l ),C0332174;C0439230;C1532563
1907,week $nmbr$ ( before ee ),C0332174;C0439230
1907,week $nmbr$ % of patients,C0030705;C0332174;C0439230
1907,week $nmbr$  % ( n ) §,C0332174;C0439230
1907,week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §,C0332174;C0439230
1907,week $nmbr$  % ( n ) j,C0332174;C0439230
1907,week $nmbr$  % ( n ) ^,C0332174;C0439230
1907,week $nmbr$  % ( n ) * *,C0332174;C0439230
1907,week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
1907,week $nmbr$  % ( n ) $nmbr$,C0332174;C0439230
1907,week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
1907,week $nmbr$  % ( n ) #,C0332174;C0439230
1907,week $nmbr$  % ( n ),C0332174;C0439230
1907,week $nmbr$,C0332174;C0439230
1907,week,C0332174;C0439230
1907,triglycerides ( week $nmbr$ ) a,C0041004;C0332174;C0439230
1907,tdi total score ( week $nmbr$,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
1907,sgrq total score ( week,C0332174;C0439230;C2964552
1907,score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C0036919;C0332174;C0439230;C1705241;C1705242;C3259781;C3533236
1907,pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1907,night - time awakenings / week,C0332174;C0439230;C0860510
1907,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1907,mtx dose > $nmbr$ mg / week  %,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1907,mtx average weekly dose  mg / week  mean ( sd ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1510992;C1960952;C2346927;C2347634;C2348143;C2699239;C2825518;C4321396;C4521761
1907,ldl particle size ( week $nmbr$ ),C0332174;C0439230;C3641256
1907,ldl particle numbers ( week $nmbr$ ),C0237753;C0332174;C0439230;C0449788;C2612459
1907,hdl cholesterol ( week $nmbr$ ) a,C0023822;C0332174;C0392885;C0439230
1907,habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ ),C0205353;C0332174;C0439230;C0556216;C1519269
1907,fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0031962;C0036919;C0332174;C0439230;C0444504;C1705241;C1705242;C2347634;C2348025;C2348143;C3714541
1907,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1907,clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
1907,cfb at week $nmbr$,C0009002;C0332174;C0439230;C1824728
1907,calculated ldl cholesterol ( week $nmbr$ ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
1907,beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % ),C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
1907,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1907,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1907,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1907,at week $nmbr$,C0332174;C0439230
1907,apob ( week $nmbr$ ),C0003593;C0332174;C0439230;C3252643
1907,additional radiographic findings at week $nmbr$,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
1907,acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230;C1412134;C1515941
1907,> $nmbr$ weeks,C0439230
1907,> $nmbr$ to < $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1907,> $nmbr$ servings / wk ( n = $nmbr$ ),C0332174;C0439230;C1519269
1907,> $nmbr$ / week,C0332174;C0439230
1907,> $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1907,< $nmbr$ weeks,C0439230
1907,< $nmbr$ week,C0332174;C0439230
1907,- - week $nmbr$ - -,C0332174;C0439230
1907,( week ),C0332174;C0439230
1907,$nmbr$ wk,C0332174;C0439230
1907,$nmbr$ week,C0332174;C0439230
1907,$nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1907,$nmbr$ / week,C0332174;C0439230
1907,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1907,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1907,$nmbr$ - $nmbr$ / week,C0332174;C0439230
1906,bw at $nmbr$ weeks  kg +,C0005910;C0006041;C0022718;C0439209;C0439230;C2986891;C4054209
1906,at weeks $nmbr$ and $nmbr$,C0439230
1906,at six weeks,C0205452;C0439230
1905,« $nmbr$ kg,C0022718;C0439209;C4054209
1905,£ $nmbr$ kg,C0022718;C0439209;C4054209
1905,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
1905,q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1905,q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1905,q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1905,o $nmbr$ kg  n ( % ),C0022718;C0439209;C0483204;C4054209
1905,nonobese ( < $nmbr$ kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
1905,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
1905,low body weight ( < $nmbr$ kg ),C0022718;C0041667;C0439209;C4054209
1905,kg,C0022718;C0439209;C4054209
1905,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
1905,dose adjustment reason < $nmbr$ kg,C0022718;C0439209;C2826286;C4054209
1905,bw  kg,C0005910;C0006041;C0022718;C0439209;C2986891;C4054209
1905,bmi : < $nmbr$ kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
1905,bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
1905,baseline weight  kg,C0022718;C0439209;C1303013;C4054209
1905,> = $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1905,> = $nmbr$ kg,C0022718;C0439209;C4054209
1905,> $nmbr$ kg — no . ( % ),C0022718;C0439209;C4054209
1905,> $nmbr$ kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
1905,> $nmbr$ kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
1905,> $nmbr$ kg,C0022718;C0439209;C4054209
1905,> $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1905,> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1905,> $nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
1905,< = € $nmbr$ kg,C0022718;C0439209;C4054209
1905,< = $nmbr$ kg,C0022718;C0439209;C4054209
1905,< $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1905,< $nmbr$ kg  n ( % ),C0022718;C0439209;C4054209
1905,< $nmbr$ kg  mj ( reference ),C0022718;C0439209;C0439254;C4054209;C4284025
1905,< $nmbr$ kg,C0022718;C0439209;C4054209
1905,< $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1905,. $nmbr$ kg,C0022718;C0439209;C4054209
1905,$nmbr$ to < $nmbr$ kg,C0022718;C0439209;C4054209
1905,$nmbr$ kg,C0022718;C0439209;C4054209
1905,$nmbr$ - < $nmbr$ kg,C0022718;C0439209;C4054209
1905,$nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
1905,# $nmbr$ kg,C0022718;C0439209;C4054209
1904,treatment with sulphonylurea + biguanide  n { % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
1904,treatment with sulphonylurea + biguanide  n ( % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
1904,treatment with sulphonylurea  n ( % ),C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
1904,sulphonylureas only,C0038766;C0205171;C1720467
1904,sulphonylureas,C0038766
1904,sulphonylurea,C0038766;C3536898
1904,sulfonylureas,C0038766;C3653359
1904,sulfonylurea — no . ( % ),C0038766;C3536898
1904,sulfonylurea derivatives,C0038766
1904,sulfonylurea based,C0038766;C3536898
1904,sulfonylurea,C0038766;C3536898
1904,other sulfonylurea 一 no . ( % ),C0038766;C3536898
1904,on sulfonylurea,C0038766;C3536898
1904,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
1904,any sulfonylurea,C0038766;C3536898
1903,weight  kg blood pressure  mm hg,C0005823;C0005910;C0022718;C0043100;C0439209;C0439475;C1271104;C1272641;C1305866;C1705104;C4054209
1903,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
1903,lvh by ecgt blood pressure  mm hg,C0005823;C0149721;C0439475;C1271104;C1272641
1903,heart rate ( sd )  bpm blood pressure  mm hg,C0005823;C0018810;C0439475;C1271104;C1272641;C2699239
1903,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1903,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1903,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure while seated — mm hg,C0005823;C1271104;C1272641
1903,blood pressure systolic  mm hg,C0005823;C0039155;C0439475;C1271104;C1272641
1903,blood pressure eontrolt,C0005823;C1271104;C1272641
1903,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1903,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1903,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
1903,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
1903,blood pressure > $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure < $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % ),C0005823;C0439475;C1271104;C1272641
1903,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
1903,blood pressure ( mm hg ) systolic,C0005823;C0439475;C1271104;C1272641
1903,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
1903,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
1903,blood pressure ( % ),C0005823;C1271104;C1272641
1903,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
1903,blood pressure  mmhg systolic,C0005823;C0439475;C1271104;C1272641
1903,blood pressure  mmhg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure  mm hg,C0005823;C0439475;C1271104;C1272641
1903,blood pressure  mm,C0005823;C1271104;C1272641;C4330985;C4554674
1903,blood pressure,C0005823;C1271104;C1272641
1903,arterial blood pressure  mm hg,C0439475;C1272641
1902,kdl cholesterol ( mmol / ),C0008377;C0439190
1902,hba $nmbr$ c — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
1902,csf cholesterol,C0008377;C3540512;C3889436
1902,cholesterol — mmol / liter,C0008377;C0439190;C0475211
1902,cholesterol ( ng / ml ),C0008377;C0439275
1902,cholesterol ( mmol / l ),C0008377;C1532563
1902,cholesterol ( % ),C0008377
1902,cholesterol  mmol / l,C0008377;C1532563
1902,cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % ),C0008377;C1532563
1902,cholesterol,C0008377
1902,aldl cholesterol,C0008377
1901,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
1901,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
1901,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
1901,hypercholesterolemia — no . ( % ),C0020443;C1522133
1901,hypercholesterolemia *,C0020443;C1522133
1901,hypercholesterolemia ( > $nmbr$ mg / dl ),C0020443;C0439269;C1522133
1901,hypercholesterolemia ( % ),C0020443;C1522133
1901,hypercholesterolemia  no . ( % ),C0020443;C1522133
1901,hypercholesterolemia  n ( % ),C0020443;C1522133
1901,hypercholesterolemia,C0020443;C1522133
1901,hypercholesterolaemia ( % ),C0020443;C1522133
1901,hypercholesterolaemia,C0020443;C1522133
1901,elevated cholesterol,C0020443
1900,non ‐ elderly,C0001792;C1518422;C1999167
1900,non - elderly ( < $nmbr$ years ),C0001792;C0439234;C1518422;C1999167
1900,elderly ( > $nmbr$ years ),C0001792;C0439234;C1999167
1900,elderly,C0001792;C1999167
1899,angiography — no . ( % ),C0002978
1899,angiography and revascularization,C0002978
1899,angiography,C0002978
1899,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
1899,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
1899,angiographic data and treatment :,C0002978;C1511726;C3245479;C3714741
1899,angiographic data,C0002978;C1511726;C3245479;C3714741
1898,diagnostic angiography,C0002978
1898,contrast angiography,C0002978;C0009924;C1979874
1898,additional angiography,C0002978;C1524062
1898,> $nmbr$ ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
1897,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
1897,symptomatic heart fail,C0018787;C0231220
1897,hospitaiization for heart faiiure,C0018787
1897,cor revasc,C0018787;C0056331;C0378365
1897,congestive heart,C0018787;C0742742
1896,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
1896,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
1896,heart failurea,C0018787
1896,coronary,C0018787
1896,cardiac stretch,C0018787;C0600080;C1522601
1896,cardiac risk,C0018787;C0035647;C1522601;C4552904
1896,cardiac parameters,C0018787;C0449381;C1522601
1896,cardiac mediations,C0018787;C0680727;C1522601
1896,cardiac failurec,C0018787;C1522601
1896,cardiac enzyates raised,C0018787;C1522601
1896,cardiac diseasec,C0018787;C1522601
1896,cardiac and echocardiography parameters,C0018787;C1522601
1896,cardiac,C0018787;C1522601
1896,bmi ( kg / m $nmbr$ ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
1895,taiwan,C0039260
1894,cuban,C1553379
1893,caribbean,C0043122;C0206155;C1331005
1892,china / tjapan,C0008115
1892,china / japan,C0008115;C0022341
1892,china,C0008115
1891,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
1891,white race ( n = $nmbr$ $nmbr$ ),C0007457;C0043157
1891,white race  n ( % ),C0007457;C0043157
1891,caucasians,C0007457;C0043157
1891,caucasian simva,C0007457;C0043157
1891,caucasian race ( % ),C0007457
1891,caucasian race,C0007457
1891,caucasian eze / simva,C0007457;C0043157
1891,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
1891,caucasian ( % ),C0007457;C0043157
1891,caucasian $nmbr$,C0007457;C0043157
1891,caucasian  %,C0007457;C0043157
1891,caucasian,C0007457;C0043157
1890,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1890,white race — no . { % ) t,C0007457;C0043157;C0220938
1890,white race — no . { % ) - i -,C0007457;C0043157;C0220938
1890,white race — no . { % ) ' i ',C0007457;C0043157;C0220938
1890,white race — no . { % ) $,C0007457;C0043157;C0220938
1890,white race — no . / total no . ( % ) f,C0007457;C0043157;C0220938
1890,white race — no . / total no . ( % ) $,C0007457;C0043157;C0220938
1890,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0043157;C0220938
1890,white race — no . ( % ) f,C0007457;C0043157;C0220938
1890,white race — no . ( % ) : t,C0007457;C0043157;C0220938
1890,white race — no . ( % ) :,C0007457;C0043157;C0220938
1890,white race  %,C0007457;C0043157
1890,white race,C0007457;C0043157
1890,white or caucasian  n ( % ),C0007457;C0043157;C0220938
1890,white not of hispanic origin,C0007457;C0043157;C0220938
1890,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1890,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
1890,white ethnic origin,C0007457;C0015031;C0043157;C0220938
1890,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
1890,white / other,C0007457;C0043157;C0220938
1890,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
1890,white / caucasian,C0043157
1890,white ( n — $nmbr$ ),C0007457;C0043157;C0220938
1890,white ( n   = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1890,white ( n = $nmbr$ ),C0007457;C0043157;C0220938
1890,white ( n = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1890,white ( $nmbr$ . $nmbr$ % ),C0007457;C0043157;C0220938
1890,white  no . ( % ),C0007457;C0043157;C0220938
1890,white  n / n ( % ),C0007457;C0043157;C0220938
1890,white  n ( % ),C0007457;C0043157;C0220938
1890,white  %,C0007457;C0043157;C0220938
1890,white,C0007457;C0043157;C0220938
1890,racea white,C0007457;C0043157;C0220938
1890,non white,C0007457;C0043157;C0220938;C1518422
1890,non - white raceb,C0007457;C0043157;C0220938;C1518422
1890,non - white race,C0007457;C0043157;C1518422
1890,non - white,C0007457;C0043157;C0220938;C1518422
1890,non - caucasian simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1890,non - caucasian simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1890,non - caucasian simva,C0007457;C0043157;C1518422
1890,non - caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1890,non - caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1890,non - caucasian eze / simva,C0007457;C0043157;C1518422
1890,non - caucasian,C0007457;C0043157;C1518422
1890,caucasians ( n = $nmbr$ ),C0007457;C0043157
1890,caucasian simva ( „ = $nmbr$ },C0007457;C0043157
1890,caucasian simva ( n = $nmbr$ ),C0007457;C0043157
1890,caucasian n = $nmbr$  $nmbr$,C0007457;C0043157
1890,caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157
1890,caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157
1890,caucasian  n ( % ) *,C0007457;C0043157
1890,caucasian  n ( % ),C0007457;C0043157
1889,total hip or knee replacement,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1889,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
1889,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
1889,total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1889,total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C2699239;C3538851;C4284725
1889,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
1889,standardized total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1889,hip + other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725
1889,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
1889,hip + $nmbr$ vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
1889,hip  wrist  or spine *,C0019552;C0022122;C0043262;C1322271;C1505163;C3538851;C4284725
1889,hip  femur,C0015811;C0019552;C0022122;C1505163;C3538851;C4284725
1889,hip,C0019552;C0022122;C1505163;C3538851;C4284725
1888,p value for adjusted hr,C0456081;C1709380
1888,nonblack ( n = $nmbr$ )  adjusted hazard ratio *,C0456081;C2985465
1888,black ( n = $nmbr$ )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
1888,adjusted *   hr,C0456081
1888,adjusted,C0456081
1887,adjusted or ( $nmbr$ % cl ),C0456081
1887,adjusted or ( $nmbr$ % ci ) c,C0456081
1887,adjusted or ( $nmbr$ % ci ) b,C0456081
1887,adjusted hr losartan vs atenolol *,C0126174;C0456081
1887,adjusted hr * ( $nmbr$ % cl ) pvalue,C0456081;C0596019
1887,adjusted hr ( enl vs lcz ) ( $nmbr$ % cl ),C0456081
1887,adjusted hr ( $nmbr$ % cl ),C0456081;C0596019
1887,adjusted * or ( $nmbr$ % ci ) p value,C0456081
1887,adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl ),C0126174;C0456081;C1137094
1887,adjusted $nmbr$ or ( $nmbr$ % cl ),C0456081
1886,unadjusted p value,C1439367;C1709380
1886,unadjusted p - value for interaction,C1439367;C1704675;C1709380
1886,unadjusted or ( $nmbr$ % ci ) p value,C1439367
1886,unadjusted model hr  $nmbr$ % ci  p value,C0008107;C1439367;C1709380;C3161035;C3259781;C3274659;C3714583;C3853906
1886,unadjusted irr,C1439367;C4082285
1886,unadjusted hr .,C1439367
1886,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
1886,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
1886,unadjusted hr ( $nmbr$ % ci ) a,C0008107;C1439367;C3259781
1886,unadjusted hr,C1439367
1886,unadjusted,C1439367
1885,with ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
1885,tg  triglycerides . * median values ( standard deviation for medians ) .,C0041004;C0042295;C0399532;C0549183;C1442989;C2828392
1885,standard therapyy ( n = $nmbr$ ),C1442989;C2828392
1885,standard care n ( % ) / $nmbr$ py,C0030428;C1442989;C1947933;C2828392;C3538810
1885,standard care n ( % ),C1442989;C1947933;C2828392
1885,standard care allocation,C1442989;C1706778;C1947933;C2828392
1885,standard care ( n = $nmbr$ ),C1442989;C1947933;C2828392
1885,standard allocation,C1442989;C1706778;C2828392
1885,standard ( n = $nmbr$ ),C1442989;C2828392
1885,standard ( $nmbr$ ),C1442989;C2828392
1885,standard,C1442989;C2828392
1885,sd  standard,C1442989;C2699239;C2828392
1885,no - ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
1885,$nmbr$ standard ( n = $nmbr$ ),C1442989;C2828392
1884,with des,C0011702;C4551552
1884,older des ( n = $nmbr$ ),C0011702;C0580836;C4551552
1884,no des,C0011702;C4551552
1884,new des ( n = $nmbr$ ),C0011702;C0205314;C4551552
1884,des implantation for restenosis  n ( % ),C0011702;C0021107;C0029976;C0333186;C4551552
1884,des,C0011702;C4551552
1883,≥ $nmbr$ sae,C1519255;C1622657;C4553214
1883,serious adverse events,C1519255
1883,saes,C1519255;C1622657;C4553214
1883,due to sae,C1519255;C1622657;C4553214
1883,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
1883,because of sae,C1519255;C1622657;C4553214
1883,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
1883,any sae,C1519255;C1622657;C4553214
1882,used,C1273517
1881,pleased,C3829994;C4264468
1880,unclassified,C0205426;C1546437;C2347854;C4085229
1879,unspecified,C0205370;C1549663;C2983689;C4048188
1878,sys : ns dia : < $nmbr$ . $nmbr$,C0038944;C1112705;C1425041;C1705982;C1706546
1878,ns,C0038944;C1112705;C1705982
1877,with events ( % ),C0441471;C3541888
1877,total events  n,C0439175;C0439810;C0441471;C3541888
1877,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
1877,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
1877,rosuvastatin  events / patients ( % ),C0030705;C0441471;C0965129;C3541888
1877,pneumonia events  n,C0032285;C0441471;C3541888
1877,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
1877,patients with uncomplicated events ( p = o - $nmbr$ 十 ),C0030705;C0441471;C0443334;C3541888
1877,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
1877,patients with hospitalized pneumonia events  n ( % ),C0032285;C0441471;C0870668;C3541888
1877,patients with complicated events ( p = $nmbr$ - $nmbr$ 十 ),C0030705;C0231242;C0441471;C3541888
1877,patients with complicated events,C0030705;C0231242;C0441471;C3541888
1877,patients / events n,C0030705;C0441471;C3541888
1877,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
1877,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
1877,no of events womenmen *,C0441471;C3541888
1877,no of events women men *,C0025266;C0043210;C0441471;C3541888
1877,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
1877,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1877,no . of events / totol no . ( % ),C0441471;C3541888
1877,no . of events / total no . ( % ),C0441471;C3541888
1877,no . of events / total no . $nmbr$ % ),C0441471;C3541888
1877,no . of events / total,C0441471;C3541888
1877,no . of events / sample size i i,C0441471;C3541888
1877,no . of events / sample size,C0441471;C3541888
1877,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
1877,no . of events / patients,C0030705;C0441471;C3541888
1877,no . of events / no . of patients,C0441471;C3541888
1877,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
1877,no . of events,C0441471;C3541888
1877,neurologicai events,C0441471;C3541888
1877,n events / n subjects,C0369718;C0441471;C0441922;C3541888
1877,n events / n at risk,C0369718;C0441471;C0441922;C3541888
1877,n events ( % ),C0369718;C0441471;C0441922;C3541888
1877,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
1877,hospitalized pneumonia events  n,C0032285;C0441471;C0701159;C3541888
1877,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
1877,freqency of events,C0441471;C3541888
1877,events requiring assistance,C0441471;C3541888
1877,events consistent with volume depletion,C0441471;C3541888
1877,events consistent with uti,C0441471;C3541888
1877,events consistent with genital infection,C0441471;C3541888
1877,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
1877,events / n,C0441471;C3541888
1877,events ( % ),C0441471;C3541888
1877,events  no .,C0441471;C3541888
1877,events  n ( % / y ),C0441471;C3541888
1877,events  n ( % ),C0441471;C3541888
1877,events,C0441471;C3541888
1877,epa hr events ( % ),C0441471;C3541888
1877,cvd events,C0007222;C0441471;C3541888
1877,cumulative events,C0441471;C1511559;C3541888
1877,composite events,C0205199;C0441471;C1547335;C3541888
1877,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1877,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
1877,bleeding events during first $nmbr$ days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
1877,biochemical events,C0205474;C0441471;C3541888
1877,adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0871208;C1521828;C3541888
1877,adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0701159;C0871208;C1521828;C3541888
1877,$nmbr$ no . of events,C0441471;C3541888
1877,$nmbr$ events [ $nmbr$ . $nmbr$ ],C0441471;C3541888
1877,$nmbr$ events,C0441471;C3541888
1876,w event ( rate ),C0441471;C0871208;C1521828;C4019010
1876,vorapaxar event rate ( n = $nmbr$ )  %,C0441471;C0871208;C1521828;C2974521;C4019010
1876,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1876,probability  of event %,C0033204;C0441471;C4019010
1876,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
1876,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
1876,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
1876,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
1876,prior lgi event,C0332152;C0441471;C2826257;C4019010
1876,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1876,placebo event rate ( n = $nmbr$ )  %,C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
1876,participants with an event per $nmbr$ patient - years,C0441471;C0679646;C4019010
1876,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
1876,overal event rate,C0441471;C0871208;C1521828;C4019010
1876,normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
1876,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1876,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
1876,no prior lgi event,C0332152;C0441471;C2826257;C4019010
1876,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1876,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
1876,n ( $nmbr$ yr km event rate  % ),C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
1876,km event ( % ) at $nmbr$ y,C0441471;C3887676;C4019010
1876,impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
1876,gastrointestinal event,C0441471;C0521362;C4019010
1876,event { n ( % ),C0441471;C4019010
1876,event rates  %,C0441471;C0871208;C1521828;C4019010
1876,event rate ( per $nmbr$ person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1876,event rate ( per $nmbr$ person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1876,event rate ( per $nmbr$,C0441471;C0871208;C1521828;C4019010
1876,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1876,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
1876,event rate,C0441471;C0871208;C1521828;C4019010
1876,event during overall,C0282416;C0441471;C1561607;C4019010
1876,event during on -,C0441471;C4019010
1876,event / patients ( $nmbr$ / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
1876,event ( p = $nmbr$ . $nmbr$ o + ),C0441471;C4019010
1876,event ( % ),C0441471;C4019010
1876,event  n ( % ),C0441471;C4019010
1876,event,C0441471;C4019010
1876,empagliflozin n with event / n,C0441471;C3490348;C4019010
1876,atients with event,C0441471;C4019010
1876,any event,C0441471;C4019010
1876,acs event,C0441471;C0742343;C4019010;C4318612
1875,ischemic hf  % ( n ),C0018488;C0475224;C1313497;C1538440;C3273279
1875,ischaemic skin lesions,C0037284;C0475224
1875,ischaemic or unknown stroke,C0475224
1875,ischaemic ( n = $nmbr$ l $nmbr$ ),C0475224
1875,ischaemic ( n = $nmbr$ ),C0475224
1875,ischaemic  n ( % ),C0475224
1874,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
1874,ischemic tvr,C0475224
1874,ischemic cause,C0015127;C0475224;C1524003
1874,ischemic,C0475224
1874,ischaemic cause,C0015127;C0475224;C1524003
1874,ischaemic,C0475224
1873,symptomatic ich,C0019191;C0231220;C3272597;C3281105
1873,ich,C0019191;C3272597;C3281105
1872,with highest hba $nmbr$ cc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
1872,cc,C0008318;C3538933
1871,simvastatin monotherapy ( n = $nmbr$  $nmbr$ * ),C0074554
1871,simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ ),C0074554;C0439422
1871,simvastatin ( $nmbr$ / $nmbr$ mg / d ),C0074554;C0439422
1871,simvastatin,C0074554
1871,placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ ),C0032042;C0074554;C0439422;C1696465;C1706408
1871,placebo + $nmbr$ mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
1871,exetimibe / simvastatin,C0074554
1870,simvastatin ( n = $nmbr$ . $nmbr$ ),C0074554
1870,simvastatin ( n = $nmbr$ ),C0074554
1870,simvastatin ( n = $nmbr$  $nmbr$ ),C0074554
1870,simvastatin $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1870,simvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1870,simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1870,simvastatin  n ( % ),C0074554
1869,with long - acting j $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
1869,short - acting b $nmbr$ - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
1869,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1869,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
1869,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1869,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1869,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1869,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
1869,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
1869,long - acting b $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
1869,long - acting ^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1869,long - acting  intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
1869,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1869,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
1869,baseline short - acting anticholinergics  n ( % ),C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1869,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1869,act total score ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
1869,act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
1869,act . $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
1869,act - $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
1868,south american,C0425359
1868,north american,C0425358;C2700615
1867,south asian,C1519427
1867,south asia,C0037723;C1519427
1866,south america ( n = $nmbr$ ),C0037713
1866,south america ( % ),C0037713
1866,south america,C0037713
1866,south africa / south america,C0001737;C0002454;C0037712;C0037713
1865,southern hemisphere,C0205139;C1710133
1865,south or central american,C1710133
1865,south or central america,C1710133
1865,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
1865,south  n ( % ),C1710133
1864,total asthma symptom score :,C0004096;C2984299;C3533163
1864,total asthma symptom score  mean ± sdz,C0004096;C0444504;C2347634;C2348143;C2984299;C3533163
1864,total asthma symptom score  mean ± sd ‡,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
1864,total asthma symptom score,C0004096;C2984299;C3533163
1864,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
1864,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
1864,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
1864,asthma population ( n = $nmbr$ ),C0004096;C0032659;C1257890;C2984299
1864,asthma - related health -,C0004096;C2984299
1864,asthma,C0004096;C2984299
1863,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,with corticosteroid treatment > $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1863,with corticosteroid treatment < $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1863,vka therapy,C0039798;C0087111;C1363945
1863,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
1863,type of insulin therapy — no . ( % ) $nmbr$,C0039798;C0087111;C0457592;C1363945
1863,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
1863,treatments at randomisation,C0034656;C0087111
1863,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,treatment after randomization  in the single - dummy phase — days ],C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
1863,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
1863,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0039798;C0087111;C0178602;C0366686;C0682295;C0869039;C1114758;C1363945;C1880019;C4303340
1863,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
1863,therapy,C0039798;C0087111;C1363945
1863,therapies,C0087111
1863,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0019409;C0022885;C0039593;C0039798;C0087111;C0205120;C0205448;C0242960;C0332849;C0392366;C0441833;C0456984;C0489786;C0687744;C1257890;C1515976;C1519504;C1522326;C1533734;C1552595;C1552839;C1704675;C1705169;C1705428;C1705429;C1707455;C3538994;C3831328;C3887704;C4048755;C4318744
1863,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
1863,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
1863,sample size  n ( % ) by treatment,C0037793;C0039798;C0087111;C0242618;C0456389;C1522326;C1533734;C1705169;C3538994;C3887704
1863,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
1863,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
1863,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
1863,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1863,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1863,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
1863,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0023779;C0039798;C0087111;C0184661;C0189695;C0242751;C0392347;C0441994;C0522523;C0545743;C0680443;C0886296;C1273869;C1511726;C1522326;C1533734;C1705169;C2003888;C2827881;C3245479;C3538994;C3714741;C3887704;C4049621
1863,oab therapy,C0039798;C0087111;C1363945
1863,noninsulin therapy,C0039798;C0087111;C1363945
1863,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
1863,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
1863,long term vka therapy,C0039798;C0087111;C0443252;C1363945
1863,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
1863,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
1863,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
1863,ineffective therapy,C0039798;C0087111;C1363945;C3242229
1863,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy,C0020473;C0039798;C0042153;C0087111;C0428465;C0457083;C1363945;C1947944;C4555212
1863,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
1863,h $nmbr$ blocker ( n  % ) long - term vka therapy,C0033727;C0039798;C0087111;C0369286;C0441932;C0443252;C0564385;C1363945;C4528284
1863,ed therapy,C0039798;C0087111;C1363945;C3538926
1863,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
1863,diabetic therapy use  n ( % ) * no therapy,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
1863,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1863,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
1863,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
1863,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .,C0008107;C0009667;C0017431;C0017446;C0022661;C0030705;C0039798;C0087111;C0126174;C0205147;C0233324;C0683454;C1280500;C1515273;C1518681;C1522326;C1533734;C1704675;C1705169;C1705313;C1707455;C2348382;C2360800;C2826302;C3259781;C3538994;C3887704
1863,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
1863,background therapy,C0039798;C0087111;C1363945;C1706907
1863,background lipid therapy per acc / aha definition    n   ( % ) a,C0023767;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
1863,background aha therapy at screening  n ( % ) §,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1863,background aha therapy at screening  n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1863,background aha therapy at screening  n,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1863,background aha therapy at screening  a   n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1863,background aha therapy at screening  a,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1863,atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .,C0018017;C0023824;C0039798;C0087111;C0210243;C0237455;C0286651;C0332174;C0439230;C0674679;C0680230;C1079230;C1145759;C1334862;C1515021;C1518422;C1522326;C1533734;C1571704;C1704675;C1705169;C1709380;C2360800;C3538994;C3887704
1863,any therapy — no . ( % ),C0039798;C0087111;C1363945
1863,antithrombotic therapy,C0039798;C0087111;C1363945
1863,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
1863,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
1863,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
1863,all treatments,C0087111
1863,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
1863,* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the,C0039798;C0087111;C0439175;C0439810;C0589120;C0667477;C0699794;C0871208;C1521828;C1522326;C1522577;C1533734;C1704685;C1705169;C1708728;C1709380;C2360800;C2986775;C3274571;C3538994;C3887704;C4086639
1862,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
1862,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
1862,treatment stratum ^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
1862,treatment groups [ n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
1862,treatment groups  n ( % ),C0039798;C0087111;C0441848;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment group  on - treatment il - $nmbr$ threshold,C0020898;C0021764;C0022271;C0039798;C0087111;C0441833;C0449864;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
1862,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
1862,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment for latent tuberculosis ^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
1862,treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment difference ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1862,treatment difference ( $nmbr$ % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
1862,treatment difference % ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1862,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
1862,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1862,treatment diff . vs tio ( $nmbr$ % ci ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
1862,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
1862,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment before randomization  %,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,treatment ( de vs warfarin ) by thrombophilia interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,treated,C1522326
1862,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1862,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1862,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
1862,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
1862,p  treatment - by - region interaction,C0017446;C0039798;C0087111;C0205147;C0369773;C1522326;C1533734;C1704675;C1705169;C2603361;C3538994;C3887704
1862,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
1862,on antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
1862,no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1862,month $nmbr$ subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1862,ls mean treatment difference ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1862,ls mean [ $nmbr$ % ci ] treatment difference vs placebo,C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1862,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
1862,lcz $nmbr$ treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,interaction between treatment and baseline bmi category,C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
1862,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
1862,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1862,events treatment ( $nmbr$ ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
1862,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1862,epa treatment ( n = $nmbr$ ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,continuous lvef $nmbr$ treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1862,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
1862,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
1862,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
1862,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
1862,background treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
1862,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
1862,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
1862,antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1862,anti - hypertensive treatment history  n ( % ),C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0432633;C0857121;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1862,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
1862,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1862,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
1862,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1862,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1862,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1861,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0012113;C0030705;C0034656;C0035171;C0036043;C0038013;C0039798;C0041912;C0087111;C0274281;C0332157;C0332174;C0332257;C0333052;C0374505;C0439230;C0439531;C0439751;C0441471;C0441655;C0444667;C0680240;C0868928;C0871208;C0877248;C1140263;C1412268;C1511726;C1512346;C1519255;C1521828;C1522326;C1533148;C1533734;C1552866;C1622657;C1705169;C1705187;C1706408;C1709637;C1948053;C2347664;C2360800;C2607870;C2699274;C2700399;C2983265;C2986888;C3179547;C3245479;C3538994;C3541888;C3714741;C3815594;C3887670;C3887704;C4553214
1861,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .,C0002778;C0003364;C0034036;C0034037;C0039798;C0040808;C0085805;C0087111;C0201976;C0221102;C0232108;C0242492;C0332307;C0439234;C0439508;C0439828;C0441833;C0504085;C0600061;C0687744;C0750591;C0936012;C0947630;C1257890;C1272641;C1274040;C1516050;C1519504;C1522326;C1524024;C1533734;C1547052;C1704324;C1705169;C1705428;C1705429;C2699704;C2945654;C3161035;C3538994;C3887704;C4288391
1861,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .,C0001924;C0009667;C0010294;C0019046;C0022661;C0036773;C0080103;C0126174;C0168634;C0201976;C0205345;C0229671;C0242492;C0301630;C0392756;C0439234;C0439508;C0441471;C0456603;C0486293;C0589120;C0596019;C0597277;C0600061;C0728877;C0871208;C1137094;C1293152;C1442488;C1518681;C1521828;C1522577;C1546774;C1547037;C1547039;C1549954;C1550100;C1561535;C1626828;C1704685;C1708601;C1708728;C2986775;C3274571;C3541888;C4281686;C4551656
1861,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0030705;C0168634;C0201976;C0439234;C0441471;C0589120;C0596019;C0597277;C0600061;C0683312;C0871208;C1442488;C1521828;C1522577;C1549954;C1565830;C1704685;C1708601;C2985465;C3161035;C3274571;C3274659;C3541888;C3714583;C3853906;C3889287
1861,bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp,C0005823;C0008107;C0009667;C0012634;C0017446;C0022661;C0030705;C0034510;C0035078;C0039155;C0039798;C0040223;C0087111;C0205088;C0205147;C0441471;C0441833;C0687744;C0871208;C1257890;C1319635;C1519504;C1521828;C1522326;C1533734;C1705169;C1705428;C1705429;C1706779;C2316810;C2826245;C2985465;C3259781;C3538994;C3541383;C3853635;C3887704;C4019010
1860,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0001675;C0001779;C0001792;C0003364;C0003850;C0004153;C0005823;C0007273;C0008377;C0011198;C0017480;C0019664;C0019665;C0020538;C0030688;C0040704;C0042295;C0080103;C0151526;C0205252;C0205345;C0205374;C0262512;C0262926;C0277793;C0280604;C0439234;C0439475;C0441833;C0441889;C0449286;C0542560;C0679841;C1261512;C1271104;C1272641;C1304680;C1425219;C1516050;C1518340;C1547039;C1552601;C1705255;C1706365;C1706450;C1963138;C1999167;C1999270;C2004062;C2348088;C2744579;C3245503;C3541240;C3542407;C4018905;C4552600
1860,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .,C0001675;C0015663;C0017725;C0020261;C0023822;C0024671;C0025266;C0026410;C0028754;C0039798;C0041004;C0042295;C0087111;C0205437;C0220825;C0231290;C0243161;C0262926;C0332282;C0439070;C0439269;C0439475;C0441833;C0524620;C0600653;C0687744;C0918012;C1257890;C1261322;C1511790;C1519504;C1522326;C1532718;C1533734;C1547282;C1552854;C1637833;C1704706;C1705160;C1705169;C1705428;C1705429;C1706365;C1960952;C1963185;C1999270;C2241628;C2346927;C2986546;C3538994;C3539687;C3887704;C4321396;C4521761
1860,treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0005823;C0011849;C0012641;C0018787;C0023822;C0030705;C0035647;C0037623;C0039411;C0039798;C0040642;C0041004;C0041405;C0041698;C0042295;C0065055;C0085805;C0087111;C0168634;C0184661;C0201950;C0205251;C0237403;C0280604;C0332293;C0374505;C0428883;C0439828;C0441833;C0443252;C0488055;C0543421;C0549178;C0687744;C0871420;C0871470;C0886296;C1257890;C1273869;C1305855;C1306620;C1415692;C1442488;C1519504;C1522326;C1522609;C1533734;C1550472;C1705169;C1705428;C1705429;C1707455;C1708288;C1824670;C1947933;C2699239;C2986530;C3272447;C3538994;C3542407;C3887704;C3890211;C4048187;C4318478;C4321351;C4522122;C4522223;C4552904
1860,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .,C0001675;C0005507;C0006560;C0011847;C0011849;C0030705;C0042295;C0065055;C0087111;C0150375;C0168634;C0243073;C0369773;C0679841;C1292734;C1413716;C1441604;C1442488;C1510438;C1522326;C1706450;C2603361;C2983605;C3245503;C3642216;C3898312;C4048285
1860,ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0001675;C0002680;C0006938;C0011816;C0011849;C0023732;C0025424;C0025663;C0028873;C0030705;C0033095;C0035648;C0037623;C0039798;C0065055;C0085805;C0086858;C0087111;C0162791;C0168634;C0178587;C0205145;C0205246;C0205430;C0220845;C0282423;C0428257;C0428883;C0439070;C0439475;C0441833;C0445247;C0449438;C0449851;C0456081;C0460139;C0552449;C0680230;C0750572;C0871511;C1306345;C1415692;C1442488;C1515974;C1521840;C1522326;C1533734;C1705160;C1705169;C1705241;C1705242;C1706365;C1706450;C1708288;C1999270;C2347108;C2347109;C2348272;C2744579;C2825164;C2986546;C3160715;C3245503;C3250443;C3538994;C3887704;C3887950;C4050020;C4068104;C4284008;C4318478;C4552600
1859,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
1859,aspirin or other antiplatelet or anticoagulant agent,C0004057
1859,aspirin or other antiplatelet drug,C0004057
1859,aspirin or other antiplatelet agents,C0004057
1859,aspirin or other antiplatelet agent,C0004057
1859,aspirin and other antiplatelet,C0004057
1859,aspirin alone group no of events / total n ( % ),C0004057;C2826346
1859,aspirin / other antiplatelet agents  n ( % ),C0004057
1859,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
1859,aspirin / antiplatelet,C0004057
1859,aspirin ( n = $nmbr$ ) no . of participants with events ( % ),C0004057
1858,prior aspirin,C0004057;C0332152;C2826257
1858,no prior aspirin,C0004057;C0332152;C2826257
1858,no aspirin,C0004057
1858,medication use ( % ) aspirin,C0004057;C0240320
1858,baseiine aspirin,C0004057
1858,acetylsalicylic acid,C0004057
1858,acetyl - salicylic acid,C0004057
1857,without aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1857,with aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1857,no aspirin or ppi,C0004057
1857,aspirin 一 no . ( % ),C0004057
1857,aspirin — no . ( % ),C0004057
1857,aspirin or thienopyridines ( % ),C0004057
1857,aspirin only ( n = $nmbr$  $nmbr$ ),C0004057;C0205171;C1720467
1857,aspirin only,C0004057;C0205171;C1720467
1857,aspirin but no ppi,C0004057
1857,aspirin and thienopyridine therapy,C0004057
1857,aspirin and ppi,C0004057
1857,aspirin < $nmbr$ day,C0004057;C0332173;C0439228;C0439505
1857,aspirin - erdp ( n = $nmbr$  $nmbr$ ),C0004057
1857,aspirin + thienopyridine,C0004057;C1120149
1857,aspirin ( n = $nmbr$ ),C0004057
1857,aspirin ( n = $nmbr$ $nmbr$ ),C0004057
1857,aspirin ( n = $nmbr$  $nmbr$ ),C0004057
1857,aspirin ( n  % ),C0004057
1857,aspirin ( any dose ),C0004057
1857,aspirin ( % ),C0004057
1857,aspirin $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1857,aspirin $nmbr$  $nmbr$,C0004057
1857,aspirin $nmbr$,C0004057
1857,aspirin  no . ( % ),C0004057
1857,aspirin  n ( % ),C0004057
1857,aspirin,C0004057
1857,$nmbr$ aspirin ( n = $nmbr$ $nmbr$ ),C0004057
1856,therapy ( asa $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
1856,therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
1856,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
1856,pfo + asa,C0004057;C3853627
1856,no asa,C0004057;C3853627
1856,baseline $nmbr$ - asa,C0004057;C0168634;C1442488;C3853627
1856,aspirin ( asa ) ( » = $nmbr$ $nmbr$ ),C0004057;C3853627
1856,asas partial remission    n   ( % ),C0004057;C1521726;C3853627;C4552913;C4552914
1856,asas partial remission  %,C0004057;C1521726;C3853627;C4552913;C4552914
1856,asas $nmbr$ / $nmbr$    n   ( % ),C0004057;C3853627
1856,asas $nmbr$ / $nmbr$    %,C0004057;C3853627
1856,asas $nmbr$    %,C0004057;C3853627
1856,asas $nmbr$  %,C0004057;C3853627
1856,asas $nmbr$,C0004057;C3853627
1856,asa or antiplatelet agent,C0004057;C3853627
1856,asa  n ( % ),C0004057;C3853627
1856,asa,C0004057;C3853627
1855,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977
1855,combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036
1854,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
1854,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
1854,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
1854,aspirin use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
1854,aspirin use ( p = $nmbr$ - $nmbr$ 十 ),C0004057;C0042153;C0457083;C1947944
1854,aspirin use ( p = $nmbr$ - $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
1854,aspirin use ( > $nmbr$ mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
1854,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
1854,aspirin use,C0004057;C0042153;C0457083;C1947944
1854,aspirin alone,C0004057
1853,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
1853,established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
1853,chronic kidney disease †,C1561643;C4553188
1853,chronic kidney disease ( % ),C1561643;C4553188
1853,chronic kidney disease  no . ( % ) t,C1561643;C4553188
1853,chronic kidney disease  n ( % ),C1561643;C4553188
1853,chronic kidney disease,C1561643;C4553188
1852,chronic renal insufficiency  %,C0403447;C1561643
1852,chronic renal insufficiency,C0403447;C1561643
1852,chronic renal failure  n ( % ),C0022661;C1561643;C2316810
1852,chronic renal failure,C0022661;C1561643;C2316810
1852,chronic renal disease — no . ( % ),C0022661;C1561643
1852,chronic renal disease,C0022661;C1561643
1851,without ckd ( $nmbr$ ),C1561643
1851,with ckd ( $nmbr$ ),C1561643
1851,no ckd n,C1561643
1851,no ckd ( % ),C1561643
1851,no ckd,C1561643
1851,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
1851,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
1850,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
1850,ckd ( egfr < $nmbr$ b ),C1561643;C1739039;C3811844;C3812682
1850,ckd ( egfr < $nmbr$ )  n ( % ),C1561643;C1739039;C3811844;C3812682
1850,ckd  n ( % ) t,C1561643
1849,ckd stages,C1306673;C1561643
1849,ckd stage $nmbr$ ( % ),C0205390;C1300072;C1306673;C1561643
1849,ckd stage $nmbr$,C0205390;C1300072;C1306673;C1561643
1849,ckd n,C1561643
1849,ckd *,C1561643
1849,ckd,C1561643
1848,prior copd medicationa  n ( % ),C0024117;C0332152;C1412502;C2826257;C3714496
1848,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
1848,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
1848,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
1848,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
1848,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd — days ^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
1848,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd  yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd  years,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
1848,duration of copd  y,C0024117;C0449238;C1412502;C2926735;C3714496
1848,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
1848,copd — no . ( % ) medication use,C0024117;C1412502;C3714496
1848,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
1848,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
1848,copd severityy,C0024117;C1412502;C3714496
1848,copd severitya    n   ( % ),C0024117;C1412502;C3714496
1848,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
1848,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
1848,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
1848,copd severity ( gold $nmbr$ ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
1848,copd severity  n ( % ) a,C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd severity  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd severity  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd severity  %,C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
1848,copd or asthma  ( % ),C0024117;C1412502;C3714496
1848,copd or asthma,C0024117;C1412502;C3714496
1848,copd medication taken for at least $nmbr$ months before study entry,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1848,copd medication taken for at least $nmbr$ months before st,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1848,copd duration  y,C0024117;C0449238;C1412502;C2926735;C3714496
1848,copd - rosuvastatin ( n = $nmbr$ ),C0024117;C0965129;C1412502;C3714496
1848,copd - rosuvastatin ( $nmbr$ pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
1848,copd ( n = $nmbr$ ),C0024117;C1412502;C3714496
1848,copd ( % ),C0024117;C1412502;C3714496
1848,copd    n   ( % ),C0024117;C1412502;C3714496
1848,copd,C0024117;C1412502;C3714496
1848,chronic obstructive pulmonary disease — no . ( % ),C0024117
1848,chronic obstructive pulmonary disease  n ( % ),C0024117
1848,chronic obstructive pulmonary disease,C0024117
1848,chronic obstructive lung disease,C0024117
1848,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1847,without concomitant ics,C0521115;C0815320;C4551720
1847,with ics  n ( % ),C0815320;C4551720
1847,with concomitant ics,C0521115;C0815320;C4551720
1847,use of ics,C0815320;C1524063;C4551720
1847,total ics dose at entry  / xg / d,C0017209;C0815320;C1292284;C1421532;C1705654;C2986497;C4551720
1847,total daily dose of ics  mean  μ gc,C0444504;C0815320;C2347634;C2348070;C2348143;C3537453;C4281799;C4551720
1847,other ics versus no ics,C0815320;C4551720
1847,other ics,C0815320;C4551720
1847,no ics,C0815320;C4551720
1847,neither ics nor laba,C0815320;C4551720
1847,mean ics use at enrolment ( pg ) *,C0444504;C0815320;C2347634;C2348143;C4551720
1847,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0444504;C0815320;C2347634;C2348143;C4551720
1847,laba   +   ics,C0815320;C4551720
1847,laba / ics use at screening  n ( % ),C0815320;C4551720
1847,laba / ics #,C0815320;C4551720
1847,laba + ics versus indzgly lsm difference ( $nmbr$ % cl ),C0815320;C4551720
1847,laba + ics n = $nmbr$,C0815320;C4551720
1847,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
1847,laba + ics,C0815320;C4551720
1847,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1847,ics users at baseline  n ( % ),C0168634;C0815320;C1442488;C1706077;C4551720
1847,ics users at baseline  %,C0168634;C0815320;C1442488;C1706077;C4551720
1847,ics users : qvai $nmbr$ - sfc,C0815320;C1706077;C4521536;C4551720
1847,ics users  n ( % ),C0815320;C1706077;C4551720
1847,ics users,C0815320;C1706077;C4551720
1847,ics use yes / no  %,C0815320;C4551720
1847,ics use yes,C0815320;C4551720
1847,ics use no,C0815320;C4551720
1847,ics use at screeningg  n ( % ),C0815320;C4551720
1847,ics use at screening  n ( % ),C0815320;C4551720
1847,ics use at screening,C0815320;C4551720
1847,ics use at enrollment  mean  mg / d,C0815320;C4551720
1847,ics use at baseline : yes,C0815320;C4551720
1847,ics use at baseline : no,C0815320;C4551720
1847,ics use at baseline  n ( % ),C0815320;C4551720
1847,ics use at baseline,C0815320;C4551720
1847,ics use  yes / no %,C0815320;C4551720
1847,ics use  yes / no  %,C0815320;C4551720
1847,ics use  %,C0815320;C4551720
1847,ics use,C0815320;C4551720
1847,ics usage,C0457083;C0815320;C4551720
1847,ics plus laba,C0815320;C4551720
1847,ics only,C0205171;C0815320;C1720467;C4551720
1847,ics nonusers  n ( % ),C0815320;C4551720
1847,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1847,ics non - users : qvai $nmbr$ - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
1847,ics no laba,C0815320;C4551720
1847,ics dose of stable maintenance treatment ( μ g ) ∗  †,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
1847,ics alone,C0815320;C4551720
1847,ics ? laba ( free or fdc ),C0815320;C4551720
1847,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
1847,ics : no,C0815320;C4551720
1847,ics / lama,C0815320;C0999593;C1416775;C4551720
1847,ics / labd,C0396059;C0815320;C4551720
1847,ics / laba therapy  n ( % ),C0039798;C0087111;C0815320;C1363945;C4551720
1847,ics / laba,C0815320;C4551720
1847,ics + laba,C0815320;C4551720
1847,ics # #,C0815320;C4551720
1847,ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0815320;C4551720
1847,ics  no laba  n ( % ),C0815320;C4551720
1847,ics  n ( % ),C0815320;C4551720
1847,ics,C0815320;C4551720
1847,high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1847,high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1847,high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1847,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ),C0178602;C0815320;C2986497;C4551720
1847,calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y,C0178602;C0815320;C2986497;C4551720
1847,baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0815320;C1442488;C2827928;C4551720
1847,- ics / + laba n z $nmbr$,C0815320;C4551720
1847,+ ics / + laba nz $nmbr$,C0027978;C0815320;C4551720
1847,+ ics / + laba n z $nmbr$,C0815320;C4551720
1846,without t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
1846,without dm ( n = $nmbr$ i $nmbr$ * ),C0011816;C3250443
1846,without dm,C0011816;C3250443
1846,with t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
1846,with dm,C0011816;C3250443
1846,patients without dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
1846,patients without dm ( n = $nmbr$  $nmbr$ ),C0011816;C0030705;C3250443
1846,patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
1846,patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
1846,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
1846,patients with dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
1846,no dm ( n = $nmbr$ ),C0011816;C3250443
1846,no dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
1846,no dm,C0011816;C3250443
1846,new dm,C0011816;C0205314;C3250443
1846,dm or diabetic complications,C0011816;C3250443
1846,dm or ckd *,C0011816;C3250443
1846,dm absent,C0011816;C3250443
1846,dm ( n = $nmbr$ ),C0011816;C3250443
1846,dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
1846,dm  n ( % ),C0011816;C3250443
1846,dm,C0011816;C3250443
1846,diff_measure ( dm added this as table had multiple headings ),C0011816;C0079809;C0242485;C3250443
1845,waist - to - hip  male,C0019552;C0022122;C0086582;C0230097;C1505163;C1706180;C1706428;C1706429;C3538851;C4284725
1845,waist - to - hip  female,C0019552;C0022122;C0043210;C0086287;C0230097;C1505163;C1705497;C1705498;C3538851;C4284725
1845,waist ( cm ),C0230097
1844,waisthip ratio,C0205682;C0456603;C1547037
1844,waist : hip ratio,C0205682
1844,waist - to - hip ratio,C0205682
1844,waist - hip ratio,C0205682
1843,ast increased,C1415181;C3891303
1843,ast  u / l,C0439339;C1415181;C3891303
1842,within last $nmbr$ d,C1517741
1842,last study visit,C1517741
1841,total basdai score  mean   ±   sd,C0439175;C0439810;C1998004
1841,total basdai score  mean ( sd ),C0439175;C0439810;C1998004
1841,basdai ⁎ ⁎,C1998004
1841,basdai score  mean ( sd ),C1998004
1841,basdai $nmbr$  n ( % ),C1998004
1841,basdai $nmbr$  %,C1998004
1841,basdai  total  mean ± sd,C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
1840,basdai score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
1840,basdai responses at week $nmbr$,C0332174;C0439230;C0871261;C1998004
1840,basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
1839,both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use,C1122087
1839,both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use,C1122087
1839,both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use,C1122087
1839,both adalimumab groups ( n = $nmbr$ ),C1122087
1839,adalimumab group ( n = $nmbr$ ) t,C0036669;C1122087
1839,adalimumab croup  n / n ( % ),C0010380;C1122087
1839,adalimumab ( n = $nmbr$ ),C1122087
1839,adalimumab,C1122087
1838,systolic bp ( mmhg ) *,C0439475;C0871470
1838,systolic bp ( mmhg ),C0439475;C0871470
1838,systolic bp ( mm hg ),C0439475;C0871470
1838,systolic bp  mmhg ( sd ),C0439475;C0871470;C2699239
1838,systolic bp  mmhg,C0439475;C0871470
1838,systolic bp  mm hg,C0439475;C0871470
1838,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
1838,systolic blood pressure ^,C0488055;C0871470;C1306620
1838,systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0439475;C0488055;C0871470;C1306620;C1704675
1838,systolic blood pressure > $nmbr$ mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure > $nmbr$ mm hg or diastolic,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure > $nmbr$ mm hg  n ( % ),C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure < $nmbr$ mm hg and diastolic,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mmhg *,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mmhg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mm   hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mm hq,C0488055;C0871470;C1306620;C4330985;C4554674
1838,systolic blood pressure  mm hg ^,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mm hg < $nmbr$,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  mm hg ( sd ),C0439475;C0488055;C0871470;C1306620;C2699239
1838,systolic blood pressure  mm hg,C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure  ( mm hg ),C0439475;C0488055;C0871470;C1306620
1838,systolic blood pressure,C0488055;C0871470;C1306620
1838,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
1838,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
1838,mean systolic blood pressure  mm hg ( sd ),C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1837,systolic bp at baseline :,C0168634;C0871470;C1442488
1837,systolic bp,C0871470
1837,baseline systolic bp,C0168634;C0871470;C1442488
1836,dyslipidemia — no . { % ),C0242339
1836,dyslipidemia — no . ( % ) |,C0242339
1836,dyslipidemia — no . ( % ),C0242339
1836,dyslipidemia $nmbr$,C0242339
1836,dyslipidemia  n ( % ),C0242339
1836,dyslipidemia,C0242339
1836,dyslipidaemia 本,C0242339
1836,dyslipidaemia — no . ( % ),C0242339
1836,dyslipidaemia including hypercholesterol — no . ( % ),C0242339
1836,dyslipidaemia and hypertensiont,C0242339
1836,dyslipidaemia and hypertension  n ( % ),C0242339
1836,dyslipidaemia  n ( % ),C0242339
1836,dyslipidaemia,C0242339
1836,baseline dyslipidemia,C0168634;C0242339;C1442488
1835,symptomatic deep - vein thrombosis,C0149871;C0231220
1835,residual deep - vein thrombosis  no . ( % ),C0149871;C1609982
1835,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
1835,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
1835,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
1835,neither deep - vein thrombosis nor pulmonary embolism §,C0149871
1835,neither deep - vein thrombosis nor pulmonary embolism ^,C0149871
1835,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
1835,deep vein thrombosis only,C0149871;C0205171;C1720467
1835,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0149871
1835,deep - vein thrombosis only,C0149871;C0205171;C1720467
1835,deep - vein thrombosis ( % ),C0149871
1835,deep - vein thrombosis,C0149871
1835,both deep - vein thrombosis and pulmonary embolism,C0149871
1834,without dvt dvt alone,C0149871;C2926618;C3899446
1834,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
1834,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
1834,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
1834,dvt,C0149871;C2926618;C3899446
1834,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0521115;C2926618;C3899446
1834,concomitant dvt  n ( % ),C0149871;C0521115;C2926618;C3899446
1834,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0149871;C1314792;C2926618;C3899446
1834,causes of dvt or pe  n ( % ),C0015127;C0149871;C1314792;C2926618;C3899446
1834,cause of dvt or pe — no . ( % ),C0015127;C0149871;C1524003;C2926618;C3899446
1833,volumetric bmd by qct,C0412669;C0445383
1832,morphometric vertebral,C0200760;C0549207
1831,geometric mean uacr,C2986759
1831,geometric mean of baseline,C0168634;C1442488;C2986759
1831,geometric mean,C2986759
1831,baseline geometric mean ( $nmbr$ ® / l ),C0168634;C1442488;C2986759
1830,tiotropium salmeterol no . of patients / total no .,C0073992;C0213771
1830,salmeterol ( n [ $nmbr$ ),C0073992
1830,salmeterol ( n = $nmbr$ ),C0073992
1830,salmeterol $nmbr$ gg bid,C0017454;C0018370;C0073992
1830,salmeterol,C0073992
1829,the metabolic syndrome ^,C0524620
1829,no metabolic syndrome,C0524620
1829,metabolic syndrome — no . ( % ) ^,C0524620
1829,metabolic syndrome — no . ( % ) $nmbr$,C0524620
1829,metabolic syndrome — no . ( % ) !,C0524620
1829,metabolic syndrome w / o t $nmbr$ dm,C0011816;C0524620;C3250443
1829,metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata,C0524620
1829,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
1829,metabolic syndrome * n = $nmbr$,C0524620
1829,metabolic syndrome *,C0524620
1829,metabolic syndrome ( n = $nmbr$ ),C0524620
1829,metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics ),C0524620;C1521970
1829,metabolic syndrome ( % ) b,C0524620
1829,metabolic syndrome ( % ),C0524620
1829,metabolic syndrome $nmbr$ baseline lipids  mg / dl,C0023779;C0168634;C0439269;C0524620;C1442488
1829,metabolic syndrome $nmbr$ *,C0524620
1829,metabolic syndrome  n / n ( % ) *,C0524620
1829,metabolic syndrome  n ( % ),C0524620
1829,metabolic syndrome  ! n ( % ),C0524620
1829,metabolic syndrome,C0524620
1828,without metabolic syndrome,C0524620
1828,with metabolic syndrome,C0524620
1828,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
1828,participants without metabolic syndrome,C0524620;C0679646
1828,participants with metabolic syndrome,C0524620;C0679646
1827,metformin 一 no . ( % ),C0025598
1827,metformin — no . ( % ),C0025598
1827,metformin ± other oral anti - dm drugs,C0025598
1827,metformin use  n ( % ),C0025598;C0042153;C0457083;C1947944
1827,metformin open - label *,C0025598
1827,metformin only,C0025598;C0205171;C1720467
1827,metformin monotherapy,C0025598
1827,metformin : no / yes  %,C0025598
1827,metformin ( n = $nmbr$ ),C0025598
1827,metformin ( n $nmbr$ $nmbr$ ),C0025598
1827,metformin  n ( % ),C0025598
1826,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1826,metformin dose,C0025598;C0178602;C0869039;C1114758
1826,metformin alone,C0025598
1826,metformin - dose,C0025598;C0178602;C0869039;C1114758
1826,metformin ( hdm ),C0025598
1826,mean ( s . d . ) metformin dose †  mg / day,C0025598;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
1826,distribution of metformin dose at randomization  n ( % ),C0025598;C0178602;C0520511;C0869039;C1114758;C1704711
1825,plus metformin,C0025598;C0332287
1825,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
1825,not on metformin,C0025598;C1518422
1825,no metformin,C0025598
1825,metformin + sulphonylureas,C0025598;C0038766
1825,metformin,C0025598
1825,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
1824,idm,C0270221
1823,ramus,C3538818
1822,cards,C2930619;C3275277
1821,without stent,C0038257
1821,with stent ^ l,C0038257
1821,with stent,C0038257
1821,with any stent,C0038257
1821,stenting plus medical therapy ( n = $nmbr$ ),C0038257;C0418981;C2348535
1821,stent plus medical therapy,C0038257;C0418981
1821,stent group ( n = $nmbr$ ),C0038257;C0441848
1821,stent ( n = $nmbr$ ),C0038257
1821,multivessel stenting,C0038257;C2348535
1821,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
1820,stent,C0038257
1820,prior stent,C0038257;C0332152;C2826257
1820,other stent,C0038257
1820,no . of stents,C0038257
1820,minimum stent diameter,C0038257;C4054490
1819,without mets,C0812270;C1705694;C2939420
1819,with mets,C0812270;C1705694;C2939420
1819,mets w / o t $nmbr$ dm,C0011816;C0812270;C1705694;C2939420;C3250443
1819,mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C0812270;C1705694;C2939420
1819,mets  n ( % ),C0812270;C1705694;C2939420
1819,mets,C0812270;C1705694;C2939420
1819,i without mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
1819,i with mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
1818,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
1818,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
1818,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
1818,methotrexate use,C0025677;C0042153;C0457083;C1947944
1818,methotrexate,C0025677
1818,csdmard otherthan methotrexate,C0025677
1818,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
1818,concomitant methotrexate use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1947944
1818,concomitant methotrexate  n ( % ),C0025677;C0521115
1818,concomitant csdmards other than methotrexate  n ( % ),C0025677;C0521115
1818,. $nmbr$ kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
1817,methotrexate user,C0025677;C1548600;C1706077
1817,methotrexate plus other csdmardfl,C0025677
1817,methotrexate alone ^,C0025677
1816,tcz + mtx ( n ),C0025677;C1417487
1816,ssz + mtx ( n = $nmbr$ ),C0025677;C1417487
1816,non - mtx csdmards,C0025677;C1417487;C1518422
1816,non - mtx,C0025677;C1417487;C1518422
1816,mtx ≥ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx ≤ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx £ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
1816,mtx only,C0025677;C0205171;C1417487;C1720467
1816,mtx naive or free,C0025677;C1417487
1816,mtx n = $nmbr$,C0025677;C1417487
1816,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
1816,mtx > $nmbr$ – $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx > $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx > $nmbr$ and £ $nmbr$ mg / week,C0025677;C1417487
1816,mtx > $nmbr$ and si $nmbr$ mg / week,C0025677;C1417487
1816,mtx < $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1816,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
1816,mtx + othetcsdmards,C0025677;C1417487
1816,mtx + other csomards,C0025677;C1417487
1816,mtx + other csdmards,C0025677;C1417487
1816,mtx + non - mtx,C0025677;C1417487;C1518422
1816,mtx ( n = $nmbr$ ),C0025677;C1417487
1816,mtx ( n ),C0025677;C1417487
1816,mtx,C0025677;C1417487
1816,lef + mtx ( n = $nmbr$ ),C0025677;C1417487
1816,hcq + mtx ( n = $nmbr$ ),C0020336;C0025677;C1417487
1816,etn + mtx ( n = $nmbr$ ),C0014758;C0025677;C0717758;C1417487
1816,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1816,czp + mtx n = $nmbr$,C0025677;C0054841;C1417487;C1861828;C1872109
1816,czp + mtx ^ mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1816,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1816,csdmards + mtx ( n = $nmbr$ ),C0025677;C1417487
1816,$nmbr$ tcz + mtx mtx,C0025677;C1417487
1816,$nmbr$ tcz + mtx,C0025677;C1417487
1816,$nmbr$ non - mtx,C0025677;C1417487;C1518422
1815,nyha class iv,C1882087
1814,nyha classes iii - iv,C0278962
1814,nyha class iii / iv,C0278962
1813,nyha class ii ( n = $nmbr$ l $nmbr$ ),C1882085
1813,nyha class ii ( n = $nmbr$ ),C1882085
1813,nyha class ii,C1882085
1813,nyha class > ii,C1882085
1813,nyha class  n ( % ) ii,C1882085
1812,killip class lll - iv,C1261077;C2697847
1811,killip class ii - iv  n ( % ),C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
1811,killip class ii  iii  or iv — %,C0439070;C1705160;C1710602;C2697845;C2697846;C4082587
1811,killip class > ii ( % ),C2697845
1810,killip class i — no . ( % ),C2697844
1810,killip class > i  %,C2697844
1809,vein bypass graft stented,C0398147
1808,prior bypass graft surgery,C0185098;C0455610
1808,bypass graft §,C0185098
1808,bypass graft,C0185098
1807,previous bypass surgery  n ( % ),C0205156;C1536078;C1552607
1807,bypass surgery,C1536078
1806,psoriasis duration  yrs *,C0033860;C0449238;C2926735
1806,psoriasis duration  years,C0033860;C0439234;C0449238;C2926735
1806,psoriasis covering > $nmbr$ % bsa  n ( % ) §,C0033860;C0180153;C0439844
1806,psoriasis characteristics,C0033860;C1521970
1806,psoriasis bsa > $nmbr$ %  n ( % ),C0033860
1806,psoriasis affecting > $nmbr$ % of body - surface,C0033860;C0392760;C0489451;C1314939
1806,psoriasis > $nmbr$ % of bsa,C0033860
1806,psoriasis ( n =,C0033860
1806,psoriasis,C0033860
1805,£ $nmbr$ % bsa psoriasis  no . ( % ),C0033860
1805,without psoriasis ( zi = $nmbr$ ),C0033860;C0043476
1805,without psoriasis ( zi = $nmbr$  $nmbr$ ),C0033860;C0043476
1805,without psoriasis ( n = $nmbr$ ),C0033860
1805,without psoriasis ( n = $nmbr$  $nmbr$ ),C0033860
1805,with psoriasis ( zi = $nmbr$ ),C0033860;C0043476
1805,with psoriasis ( n = $nmbr$ ),C0033860
1805,randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1805,patients without psoriasis ( n = $nmbr$ ),C0030705;C0033860
1805,patients with psoriasis > $nmbr$ % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
1805,patients with psoriasis ( n = $nmbr$ ),C0030705;C0033860
1805,patients with psoriasis ( bsa ≥   $nmbr$ % ),C0030705;C0033860
1805,patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % ),C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1805,dlqi ( patients with £ $nmbr$ % bsa psoriasis ),C0030705;C0033860;C3899393
1804,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
1804,pcs score ( $nmbr$ – $nmbr$ scale ),C1864389;C1882368
1804,pcs score,C1864389;C1882368
1803,pulse pressure ( mmhg ),C0439475;C0949236
1803,pulse pressure ( mm hg ),C0439475;C0949236
1803,pulse pressure,C0949236
1802,systoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1802,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
1802,pressure,C0033095;C0460139;C1306345;C4284008
1802,diastoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1801,physiological measures,C0079809;C0205463;C1879489
1801,measures of lung function,C0035245;C0079809;C1879489
1801,measures ( mmol / l ),C0079809;C0242485;C1879489
1801,measures ( % ),C0079809;C1879489
1801,measures,C0079809;C1879489
1801,ipeated - measures state examinatioi,C0079809;C1879489
1800,physician global assessment of disease,C0012634;C4050369
1800,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
1800,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
1800,physician ' s global assessment !,C4050369
1800,physician ' s global assessment,C4050369
1799,pga subscore,C0016410;C3541266;C4050369
1799,pga  $nmbr$ - $nmbr$,C0016410;C3541266;C4050369
1799,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
1798,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
1798,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
1798,potassium supplement,C0304475
1798,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
1798,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
1798,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
1798,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
1798,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
1798,potassium  mmol / l,C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
1798,potassium  meq / l,C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
1798,potassium  meq / dl  mean,C0032821;C0202194;C0304475;C0444504;C0597277;C1532568;C2347634;C2348143;C3714637
1798,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
1798,hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
1798,hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
1797,normal function or mild impairment,C4296962
1796,infarct on brain imaging 丰,C0751955
1796,infarct on brain imaging ^,C0751955
1795,infarction  date not reported,C0011008;C0021308;C2348077
1795,dates of recruitment,C0011008;C2348077;C2949735
1794,hypertension requiring treatment,C0578998
1794,hypertension  receiving treatment  n ( % ),C0578998;C1514756
1793,saphenous vein graft,C0729538
1793,saphenous - vein graft,C0729538
1792,symptom onset to randomization,C0034656;C4086878
1792,symptom onset to pci  h,C0033727;C0369286;C0441932;C0564385;C4049621;C4086878;C4528284
1792,symptom onset to hospitalization,C0019993;C4086878
1792,symptom onset to hospital admission,C0184666;C4086878
1792,symptom onset - to - randomization,C0034656;C4086878
1792,symptom onset - to -,C4086878
1792,symptom onset,C4086878
1791,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
1791,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685;C4086878
1790,without tamsulosin,C0257343
1790,with tamsulosin,C0257343
1790,tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0257343
1790,tamsulosin ( n = $nmbr$ ),C0257343
1790,tamsulosin $nmbr$ . $nmbr$ mg vs . placebo,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1790,tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1790,tamsulosin,C0257343
1789,geographic distribution - no . ( % ),C0681686
1789,age  years geographical distribution of patients,C0030705;C0681686;C1510829
1788,age distribution  years  n ( % ),C0001782;C0439234;C0520511;C1510829;C1704711
1788,age distribution  n ( % ),C0001782
1788,age distribution,C0001782
1787,score distribution : < $nmbr$,C0449820;C0520511;C1704711;C4050231
1787,score distribution :,C0449820;C0520511;C1704711;C4050231
1787,distribution — no . { % ),C0520511;C1704711
1787,distribution — no . ( % ),C0520511;C1704711
1787,distribution time,C0040223;C0520511;C1704711;C3541383
1787,bmi distribution  n ( % ),C0520511;C0578022;C1704711
1787,a $nmbr$ c distribution ( % ),C0520511;C1704711
1786,dactylitis severity score ) score > $nmbr$ — no . { % ),C0239161;C0457451
1786,dactylitis score ( $nmbr$ – $nmbr$ scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
1786,dactylitis score ( $nmbr$ - $nmbr$ ),C0239161;C0449820;C4050231
1786,dactylitis score,C0239161;C0449820;C4050231
1786,dactylitis count,C0239161;C0750480;C1705566
1786,dactylitis  n ( % ),C0239161
1786,dactylitis  % #,C0239161
1786,dactylitis,C0239161
1785,no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778
1785,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1785,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
1785,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
1785,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
1785,glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778
1785,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1785,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
1785,glucocorticoids *,C0017710;C3540777;C3540778
1785,glucocorticoids,C0017710;C3540777;C3540778
1785,glucocorticoid ],C0017710
1785,glucocorticoid,C0017710
1785,any glucocorticoid *,C0017710
1784,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415
1784,oral glucocorticoid use,C0017710;C1527415
1783,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
1783,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
1783,biological,C0005532;C0205460
1783,biologic naive,C0005515;C0205460
1783,biologic,C0005515;C0205460
1782,other biologic agent,C0005515
1782,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
1782,biologic agents,C0005515
1781,use of loop diuretics  n ( % ),C0354100;C1524063
1781,use of loop diuretics,C0354100;C1524063
1781,loop diuretics,C0354100
1781,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
1781,loop diuretic,C0354100;C3536704
1780,lung,C0024109
1780,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
1779,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
1779,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
1779,pulmonary embolismb  n / n ( % ),C0024109;C2707265;C2709248;C4522268
1779,pulmonary embolisma  n / n ( % ),C0024109;C2707265;C2709248;C4522268
1779,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
1779,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
1779,baseline pulmonary medication  b n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
1779,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
1779,any pulmonary medication  n ( % ),C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
1779,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
1778,lowest tg tertile,C0337445;C1708760
1778,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
1778,lowest,C1708760
1777,with lowest hba $nmbr$ cd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
1777,with lowest bwb,C1708760
1776,others  n ( % ),C1955473;C3539125
1776,others  classes i and iiic,C0441885;C1319793;C1955473;C2698967;C3539125
1776,others,C1955473;C3539125
1776,all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
1776,all others  n ( % ),C1955473;C3539125
1776,all others,C1955473;C3539125
1775,non high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956;C1518422
1775,higher dose,C0444956
1775,higher - dose,C0444956
1775,high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956
1775,high dose,C0444956
1775,high - dose statin,C0360714;C0444956
1775,high - dose aspirin,C0004057;C0444956
1775,high - dose arb ( n = $nmbr$ ),C0444956;C3888198
1774,height loss ( cm ),C0424641
1774,height loss,C0424641
1773,with highest bwa,C0006041;C1522410
1773,highest tg tertile,C0337445;C1522410
1773,highest killip classiciation pre - pci,C1522410
1773,highest,C1522410
1772,work and school,C0043227
1771,schwab & england score,C0014282
1770,womac pain score,C0582148
1770,haq pain score,C0102923;C0451208;C0582148
1769,voiding subscore,C0042034;C4067975
1768,irritative subscore,C0441723;C1706307;C2700617
1767,storage subscore,C0337174;C1698986;C1753314
1767,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
1766,whole cohort,C0009247;C0444667;C0599755
1766,secondary - prevention cohort,C0009247;C0599755;C0679699
1766,primary - prevention cohort,C0009247;C0033144;C0599755
1766,itt cohort  overall study period,C0009247;C0599755
1766,full cohort,C0009247;C0443225;C0599755
1766,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
1766,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
1766,entire cohort,C0009247;C0439751;C0444667;C0599755
1766,cohort $nmbr$ ( n = $nmbr$ ) f,C0009247;C0016327;C0599755
1766,cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755
1766,cohort,C0009247;C0599755
1766,$nmbr$ mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
1765,women  qva $nmbr$ - sfc,C0043210;C4521536
1765,sfc ( n   = $nmbr$  $nmbr$ ),C4521536
1765,sfc ( n [ $nmbr$ ),C4521536
1765,sfc ( n = $nmbr$ ),C4521536
1765,sfc $nmbr$ mg / $nmbr$ mg,C1319635;C4521536
1765,sfc,C4521536
1765,severe cord * : qvai $nmbr$ - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
1765,moderate cord * : qva $nmbr$ - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
1765,age > $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
1765,age < $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
1764,su monotherapy,C0038642;C1705534
1764,su / tzd,C0038642;C1705534
1764,su / met,C0038642;C1705534
1764,su  n ( % ),C0038642;C1705534
1764,su,C0038642;C1705534
1764,metformin ? su,C0025598;C0038642;C1705534
1764,metformin + su + tzd,C0025598;C0038642;C1705534
1764,metformin + su,C0025598;C0038642;C1705534
1763,alirocumab n = $nmbr$,C3491162
1763,alirocumab ( n = $nmbr$ ),C3491162
1763,alirocumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
1763,alirocumab,C3491162
1762,rituximab  n = $nmbr$,C0393022
1762,rituximab,C0393022
1761,ustekinumab ® ( n = $nmbr$ ),C1608841
1761,ustekinumab combined,C1608841
1761,ustekinumab ' ’ ( n = $nmbr$ ),C1608841
1761,ustekinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
1761,ustekinumab,C1608841
1760,of variation )  iu,C0049272;C0205419;C0439453;C0694756
1760,iuss score  mean ( sd ),C0439453
1760,iu,C0049272;C0439453;C0694756
1759,wrist,C0043262;C1322271
1758,rib,C0035561
1757,lipc,C1416867
1756,lis,C2247545
1756,lips,C0023759
1755,middle tg tertile,C0337445;C0444598;C0549183;C1552826
1755,middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$,C0444598;C0549183;C1552826
1755,middle east  africa  or asia - pacific,C0001737;C0001741;C0026068;C0444598;C0549183;C1552826
1755,middle,C0444598;C0549183;C1552826
1754,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,£ median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,£ median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,wt  second  median,C0205436;C0457385;C0549183;C0565930;C0876920;C1561503;C1705190;C1883559;C2347635;C2348144;C2700323;C2939193
1754,weight ( median [ iqr ] )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1754,weight  median ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2699239;C2939193;C4054209
1754,weight  median ( iqr )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1754,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
1754,weight  kg  median ( $nmbr$ th  $nmbr$ th ),C0005910;C0022718;C0039725;C0039738;C0043100;C0439209;C0549183;C0876920;C1305866;C1420718;C1705104;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
1754,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
1754,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1754,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1754,urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C0455271;C0549183;C0876920;C1318330;C1627892;C2347635;C2348144;C2939193
1754,uacr  median ( iqr )  mg / g,C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
1754,triglycerides ( mmol / l ) ( median  iqr ),C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,triglycerides ( median  iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,triglycerides  median ( ql  q $nmbr$ )  mmol / l,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,triglycerides  median ( qi  q $nmbr$ )  mmol / l,C0041004;C0376586;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,triglycerides  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
1754,triglycerides  median ( iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ],C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
1754,total ige levelx ( iu / ml )  median ( range ),C0439175;C0439458;C0439810;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,total cholesterol ( median  iqr )  mg / dl,C0201950;C0439269;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
1754,time to end - of - study ivus  median ( iqr )  days,C0439548;C0444930;C0549183;C0557651;C0876920;C1456025;C2347635;C2348144;C2603343;C2746065;C2939193
1754,time from  median ( iqr )  h,C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C3541383;C4528284
1754,tg mg / dl  median ( sd ),C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
1754,tg ( mg / dl )  median ± sd,C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
1754,tg  median ( sdy rng / cjl,C0337445;C0549183;C0876920;C1424906;C2347635;C2348144;C2939193
1754,tg  median ( min  max ),C0337445;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,tg  median ( interquartile range ),C0337445;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1754,systolic blood pressure ( median $nmbr$ . $nmbr$ ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
1754,systolic blood pressure  mm hg  median ( range ),C0439475;C0488055;C0549183;C0871470;C0876920;C1306620;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,serum ctx - $nmbr$  ng / ml  median ( iqr ),C0010377;C0229671;C0439275;C0549183;C0631180;C0876920;C1546774;C1550100;C2347635;C2348144;C2939193;C3539598
1754,serum cholesterol  median ( iqr )  mg / dl,C0439269;C0549183;C0587184;C0876920;C2347635;C2348144;C2939193
1754,seizure frequency during $nmbr$ ‐ week baseline  median ( range ),C0149775;C0168634;C0332174;C0439230;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
1754,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
1754,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
1754,score improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411;C4050231
1754,sbp > median ( n = $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
1754,sbp < median ( n = $nmbr$ o $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
1754,sbp ( mm hg )  median ( iqr ),C0085805;C0439475;C0549183;C0876920;C2347635;C2348144;C2939193
1754,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
1754,pulse pressure ( median $nmbr$ . $nmbr$ ],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
1754,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1754,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1754,pra  median ( min  max )  ng / ml / h,C0033727;C0369286;C0441932;C0549183;C0564385;C0633231;C0702093;C0876920;C1141951;C1419788;C1524029;C1533072;C2347635;C2348144;C2827900;C2939193;C3274822;C3669212;C3813700;C4050009;C4283900;C4528284
1754,percent improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439165;C0439230;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411
1754,pci duration in min ( median  iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
1754,pasi [ c ]  median ( min - max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C4528685
1754,pasi  median ( range ) * *,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4528685
1754,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
1754,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
1754,mtss  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
1754,mmp - $nmbr$  median ( iqr )  gg / l,C0017454;C0018370;C0549183;C0623362;C0876920;C0919336;C2347635;C2348144;C2939193
1754,medians ( iqr ),C0549183
1754,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
1754,median — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median §,C0549183;C0876920;C2347635;C2348144;C2939193
1754,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median time to first exacerbation ( months [ $nmbr$ % ci ] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
1754,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
1754,median time since diagnosis * ( range )  yr,C0040223;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383
1754,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
1754,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
1754,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
1754,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
1754,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
1754,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
1754,median m / kg $nmbr$ ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1754,median infusions — no . ( range ),C0549183;C0574032;C0876920;C2347635;C2348144;C2939193
1754,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
1754,median feno  ppba,C0549183;C0876920;C2347635;C2348144;C2939193
1754,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
1754,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
1754,median duration oftype $nmbr$ diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1754,median duration of symptoms ( range )  yr,C0436359;C0439234;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1754,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
1754,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
1754,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
1754,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
1754,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
1754,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
1754,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1754,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
1754,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median age [ interquartile range ] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1754,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,median age ( $nmbr$ %  $nmbr$ % )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median age  years ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,median age  y ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median ( range ) treatment duration  d,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
1754,median ( range ) total ige level ( iuml ~ ’ ) $nmbr$,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
1754,median ( range ) duration of hospital stayi  d,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
1754,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
1754,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
1754,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median ( q $nmbr$ – q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
1754,median ( q $nmbr$ : q $nmbr$ ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
1754,median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
1754,median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
1754,median ( q $nmbr$ : q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( q $nmbr$  q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight,C0168634;C0444504;C0549183;C0876920;C1442488;C2347634;C2347635;C2348143;C2348144;C2939193
1754,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score,C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
1754,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
1754,median ( iqr )  h,C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
1754,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1754,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1754,median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f,C0008107;C0034746;C0332174;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
1754,median  y ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median  range,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,median  ml,C0439526;C0549183;C0876920;C1705224;C2347635;C2348144;C2939193;C3887665
1754,median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,median  iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,median  iqr,C0549183;C0876920;C2347635;C2348144;C2939193
1754,median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,lvef  %  median ( iqr ),C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
1754,lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
1754,lp ( a )  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
1754,local eosinophil count [ cells / µ l ]  median ( range ),C0200638;C0205276;C0347983;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,local eosinophil count [ cells / ml ]  median ( range ),C0200638;C0205276;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2699156;C2939193;C3542016
1754,lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
1754,lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l,C0065058;C0125953;C0376586;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
1754,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
1754,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
1754,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
1754,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
1754,left ventricular ejection fraction  median ( iqr )  %,C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
1754,ldl cholesterol ( mmol / l ) ( median  iqr ),C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,ldl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1754,laboratory parameters  median ( iqr ),C0022877;C0449381;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
1754,jsn  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,insulin dose ( iu / day )  median,C0366513;C0439465;C0549183;C0876920;C2347635;C2348144;C2939193
1754,insulin  median ( ql  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
1754,insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
1754,insulin  iu / ml  median ( q $nmbr$  q $nmbr$ ),C0021641;C0439458;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
1754,index event to randomization  median ( iqr )  h,C0033727;C0034656;C0369286;C0441471;C0441932;C0549183;C0564385;C0600653;C0876920;C0918012;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C4019010;C4528284
1754,ige ( ku / l )  median ( range ) c,C0439340;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,hscrp ( mg / l )  median ( minimum ‒ maximum ),C0439268;C0549183;C0806909;C0876920;C1524031;C1552614;C1552615;C2347635;C2348144;C2826545;C2826546;C2939193
1754,hscrp ( mg / l )  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
1754,hscrp ( mg / l )  median ( first  third quartiles ),C0205435;C0205437;C0439268;C0549183;C0876920;C1279901;C2347635;C2348144;C2828255;C2939193
1754,hscrp  mg / l  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
1754,hscrp  median ( min  max )  mg / l,C0549183;C0876920;C2347635;C2348144;C2827895;C2939193
1754,hscrp  median ( iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
1754,hs - crp ( mg / l  median ),C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,hs - crp ( median  iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
1754,homa_ % b  median ( q $nmbr$  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
1754,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
1754,homa . % b  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
1754,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
1754,homa - ir  median ( q $nmbr$  q $nmbr$ ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
1754,hemoglobin ale  %  median ( iqr ),C0019046;C0549183;C0678386;C0876920;C2347635;C2348144;C2632076;C2939193
1754,heart rate ( median $nmbr$ . $nmbr$ },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
1754,hdl cholesterol ( mmol / l ) ( median  iqr ),C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,hdl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
1754,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbalc in %  median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbalc  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,hba $nmbr$ c ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
1754,hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1754,fpg  median ( ql  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1754,final median  mg / l,C0205088;C0439268;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
1754,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
1754,fasting tgs  median ( q $nmbr$ : q $nmbr$ ),C0015663;C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
1754,fasting serum glucose ( mg / dl )  median ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
1754,fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ ),C0015663;C0202041;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193;C3534430
1754,fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
1754,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
1754,fasting insulin  * median ( iqr )  gu / ml,C0015663;C0021641;C0120446;C0439526;C0549183;C0876920;C1533581;C1579433;C1705224;C2347635;C2348144;C2939193;C3714501;C3887515;C3887665
1754,euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £,C0039725;C0039738;C0242415;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
1754,euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §,C0039725;C0039738;C0442796;C0549183;C0876920;C1420718;C1550602;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
1754,esr ( mm / h )  median ( min - max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
1754,esr ( mm / h )  median ( min  max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
1754,esr  median ( range ) mm / hour,C0439227;C0549183;C0564385;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3811131;C4330985;C4554674
1754,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
1754,eosinophil count ( cells / pl )  median ( range ) c,C0007584;C0007634;C0200638;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3897966;C4049765
1754,enthesitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1282952;C1442488;C2347635;C2348144;C2939193;C4050231
1754,egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr ),C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
1754,egfr  median ( sd )  ml / min,C0439445;C0549183;C0876920;C1739039;C2347635;C2348144;C2699239;C2939193;C3811844;C3812682
1754,duration of pci ( min )  median n ( iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
1754,duration of pci ( min )  median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
1754,duration of disease ( y )  median ( min  max },C0549183;C0702093;C0872146;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,duration of diabetes mellitus  median ( iqr )  y,C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1754,duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ ),C0439231;C0449238;C0521116;C0549183;C0876920;C1514721;C1517205;C1705970;C2347635;C2348144;C2348147;C2926735;C2939193;C3540542;C3542016
1754,disease duration ( y )  median ( m / n  max ),C0369637;C0441923;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1754,disease duration  years : median ( range ),C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,disease duration  year ( median ),C0439234;C0439508;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1754,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,difference  % median,C0549183;C0876920;C1705241;C1705242;C2347635;C2348144;C2939193
1754,diastolic blood pressure  mm hg  median ( range ),C0428883;C0439475;C0549183;C0876920;C1305849;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,diabetes duration  median ( iqr )  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1754,dbp ( mm hg )  median ( iqr ),C0439475;C0536221;C0549183;C0876920;C2347635;C2348144;C2939193;C3813197;C4281799
1754,dactylitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0239161;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C4050231
1754,crp median ( se )  rng / l,C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,crp [ mg / l ]  median,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,crp ( mg / l ) [ b ]  median ( min - max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,crp ( mg / l )  median ± sd,C0439268;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3890735;C4048285
1754,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
1754,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
1754,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
1754,crp  mg / dl  median,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,crp  median ( range ) mg / literl,C0024671;C0026410;C0439269;C0549183;C0876920;C1514721;C1960952;C2346927;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285;C4321396;C4521761
1754,crp  median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1754,creatinine ( ^ mol / l ) ( median  iqr ),C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
1754,crcl  median ( iqr )  ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
1754,complete mayo clinic score  median ( min  max },C0002424;C0205197;C0442592;C0449820;C0454788;C0549183;C0702093;C0725685;C0876920;C1077578;C1524029;C2347635;C2348144;C2939193;C3813700;C3853530;C4050231;C4283785
1754,clinical variables  median ( iqr ),C0205210;C0439828;C0549183;C0876920;C2347635;C2348144;C2939193
1754,cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr ),C0162734;C0369637;C0439445;C0441923;C0549183;C0876920;C1561643;C2347635;C2348144;C2939193;C4281721
1754,c - reactive protein  median ( q $nmbr$  q $nmbr$ ),C0006560;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
1754,c - reactive protein  median ( iqr )  mg / l,C0006560;C0439268;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
1754,c - peptide  median ( ql  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
1754,c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
1754,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
1754,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
1754,body mass index  median ( iqr ) b,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
1754,body mass index  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
1754,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1754,bnp  * median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1754,bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1754,bmi ( median  iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1754,bmi ( kg / m $nmbr$ )  median ( range ),C0549183;C0578022;C0876920;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
1754,bmi  median ( sd )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2699239;C2939193
1754,bmi  median ( iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1754,bmi  median ( iqr ),C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
1754,bmi  kg / m $nmbr$  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1754,below median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,baseline tg  ( mg / dl )  median ( iqr ),C0168634;C0337445;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline tav - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline tav - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline pos frequency per $nmbr$ days  median ( min  max ),C0168634;C0549183;C0585290;C0702093;C0876920;C1262869;C1442488;C1524029;C2347635;C2348144;C2939193;C3496112;C3496399;C3813700
1754,baseline pav - > = median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline pav - < median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline median [ mg / l ],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1754,baseline median  mg / l,C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline median  mg / dl,C0168634;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline lipoprotein ( a ) ( nmol / l )  median ( iqr ),C0065058;C0125953;C0168634;C0439282;C0549183;C0876920;C1096202;C1439335;C1442488;C2347635;C2348144;C2939193
1754,baseline laboratory values  median ( iqr ) d,C0022877;C0042295;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C3244292;C4283904
1754,baseline hemoglobin  median ( iqr  g / dl ),C0019046;C0168634;C0439267;C0549183;C0876920;C1319312;C1442488;C2347635;C2348144;C2939193;C3642216
1754,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1754,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
1754,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
1754,baseline fev $nmbr$  median ( range )  l,C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3714541
1754,baseline creatinine  median ( range ) mg / dl,C0010294;C0168634;C0439269;C0549183;C0876920;C1442488;C1514721;C1561535;C2347635;C2348144;C2348147;C2939193;C3542016
1754,and after pci  median ( iqr )  d,C0549183;C0876920;C2347635;C2348144;C2939193;C4049621
1754,albumin / creatinine ratio - mg / mmol  median ( iqr ),C0486293;C0549183;C0567349;C0876920;C1318293;C2347635;C2348144;C2348885;C2939193
1754,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age in years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age - years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age ( years ) - > = median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age ( years ) - < median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age ( y )  median ( min  max },C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,age ( y )  median ( min  max ),C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,age ( y )  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age ( median [ iqr ] )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age ( median  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age ( median  iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  yrs  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  yrs  median ( $nmbr$ th  $nmbr$ th ),C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1754,age  year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  y  median ( q $nmbr$ – q $nmbr$ ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  median years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age  median ( iqr )  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1754,age  median ( iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1754,age  median ( interquartile range )  y,C0001779;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1754,age  median ( $nmbr$ th  $nmbr$ th )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1754,a median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,a $nmbr$ c > = median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,a $nmbr$ c < median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,a $nmbr$ c < $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,a $nmbr$ = $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,^ median > median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,^ median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,> median ( $nmbr$ mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
1754,> median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1754,> median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,> median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,> median ( $nmbr$ % ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,> median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
1754,> median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,> $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,< median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1754,< median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
1754,< median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
1754,< median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,< $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1754,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1754,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
1754,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
1754,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
1754,( median  h ),C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
1754,& median,C0549183;C0876920;C2347635;C2348144;C2939193
1754,$nmbr$ - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
1753,pvd,C0085096;C4521226
1753,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .,C0003211;C0007787;C0013227;C0019664;C0019665;C0020443;C0023779;C0042373;C0085096;C0149721;C0262512;C0262926;C0439165;C0441994;C0455536;C0679646;C0700287;C0802604;C0917805;C1054154;C1522133;C1524063;C1549488;C1561533;C1705255;C2003888;C2004062;C2598133;C2698741;C4284232;C4521226;C4554048
1753,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .,C0003211;C0007787;C0012634;C0023779;C0030685;C0035078;C0085096;C0149721;C0201976;C0282402;C0340279;C0391871;C0439180;C0441994;C0600061;C0680255;C0753208;C1283071;C1305855;C1515187;C1565489;C1704788;C1709991;C1963578;C2003888;C3539106;C3813610;C3890900;C3891546;C4521226
1752,peripheral vascular disease  n ( % ),C0085096
1752,peripheral vascular disease,C0085096
1752,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
1752,peripheral arterial disease — no . ( % ),C0085096;C1704436
1752,peripheral arterial disease §,C0085096;C1704436
1752,peripheral arterial disease ( n = $nmbr$ $nmbr$ ),C0085096;C1704436
1752,peripheral arterial disease  n ( % ),C0085096;C1704436
1752,peripheral arterial disease,C0085096;C1704436
1752,any peripheral arterial disease,C0085096;C1704436
1752,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
1751,ltg - naive,C1420817;C4521367;C4521846
1751,ltg - exposed,C1420817;C4521367;C4521846
1750,atm - locus,C1708726;C3711796
1750,atm - locm,C3711796
1749,js $nmbr$ - agonists,C0243192;C1552154;C2987634
1749,$nmbr$ [ $nmbr$ - $nmbr$ js,C1552154
1748,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
1748,m $nmbr$ s,C0439493;C1513009
1747,ff / vi ( n   =   $nmbr$ ),C0205999;C4554348
1747,ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ ),C0205999;C1319635;C4554348
1747,ff / vi $nmbr$ / $nmbr$   µ g,C0205999;C0439267;C4554348
1747,ff / vi $nmbr$ / $nmbr$ pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
1747,ff / vi $nmbr$ . $nmbr$,C0205999;C4554348
1747,ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999;C4554348
1747,ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % ),C0205999;C4554348
1747,ff / vi,C0205999;C4554348
1747,ff - blocker,C4554348
1747,ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
1747,ff $nmbr$   µ g,C0439267;C4554348
1747,ff $nmbr$ pgod,C4554348
1747,ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
1746,£ l $nmbr$ kg,C1637390
1745,- o . os,C2673162
1744,$nmbr$ % clf,C3540486;C4553190
1743,$nmbr$ % cit,C0008864;C0523573;C1427027;C4553421
1742,crp   ≤   uln,C1519815;C3890735;C4048285
1742,crp   >   uln,C1519815;C3890735;C4048285
1742,cpk > $nmbr$ times uln,C0040223;C1519815;C1632851
1742,> $nmbr$ uln,C1519815
1741,ck > $nmbr$ xuln,C0009212;C0010287;C1872855
1741,ck > $nmbr$ x uln $nmbr$,C0009212;C0010287;C1519815;C1872855
1740,x cr $nmbr$ . $nmbr$ x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1740,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
1740,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1740,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1740,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1739,cardiac glycosides,C0007158
1738,digitalis glycoside,C0012253
1737,radial access site,C0442038;C0589360;C0920847
1737,access site,C0589360
1736,oral aminosalicylates,C0368663;C0442027;C4521986
1736,no aminosalicylates  n,C0368663
1736,aminosalicylates * *,C0368663
1736,aminosalicylates  n,C0368663
1736,aminosalicylates,C0368663
1736,aminosalicylate,C0368663;C2825094
1736,$nmbr$ - aminosalicylates ’ i  i ‘,C0021966;C0221138;C0368663
1736,$nmbr$ - aminosalicylates | | | |,C0368663
1736,$nmbr$ - aminosalicylates {,C0368663
1735,internal carotid artery sites,C0007276;C0205145
1735,common carotid artery sites,C0007272;C0162859;C0205145
1735,carotid bulb sites,C0007281;C0205145
1735,$nmbr$ carotid artery sites,C0007272;C0162859;C0205145
1734,us site,C0205145;C1515974;C2825164
1734,sites,C0205145
1734,site,C0205145;C1515974;C2825164
1734,critical site,C0205145;C1511545;C1515974;C2825164
1734,any site,C0205145;C1515974;C2825164
1734,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C1171258;C1515974;C2825164
1733,anaesthesia / analgesia,C0002905
1732,anti - anaemics,C0857322
1731,angiogenesis,C0302600;C1519670
1730,methylxanthines,C0066447
1729,philippines,C0031529
1728,more than $nmbr$ vessels stented,C0005847;C0205172
1728,more than $nmbr$ lesions per vessel,C0205172
1727,“ on ” without troublesome dyskinesia,C0013384
1727,“ on ” with troublesome dyskinesia,C0013384
1726,xanthines $nmbr$,C0043318;C3541955
1726,xanthines  b   n ( % ),C0043318;C3541955
1726,xanthines,C0043318;C3541955
1726,xanthine,C0043314;C0043318
1725,cerebral hemorrhage,C2937358
1724,cerebral embolism,C0007780
1723,cerebral thrombosis,C0079102;C0151945;C0795687
1722,chd plus cerebral infarction,C0007785;C0280604;C3542407
1722,chd + cerebral infarction,C0007785;C0280604;C3542407
1722,cerebral ischemia,C0007785;C0917798
1722,cerebral infarction,C0007785
1721,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
1721,use of parenteral antithrombotic,C0030547;C1524063;C4522267
1721,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
1720,sf - $nmbr$ physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
1720,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
1720,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
1720,physical examinations,C0031809
1720,physical examination,C0031809;C1744699
1720,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
1720,physical characteristics,C0031809;C0205485;C1509143;C1521970
1720,physical and cognitive examination : ! :,C0031809;C0205485;C1509143
1719,erysipelas,C0014733
1718,prior angioplasty,C0162577;C0332152;C1548817;C2826257
1718,peripheral angioplasty,C0162577;C0205100;C1548817
1718,angioplasty,C0162577;C1548817
1717,familial,C0015576;C0241888
1717,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
1716,delighted,C3830544
1715,whitea,C1021495
1714,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
1714,limited,C0439801;C2674459;C3542948;C4050251
1713,thyroid hormone,C0040135;C4522017
1712,thyroid disease,C0040128
1711,thiazide diuretics,C0012802
1711,thiazide diuretic *,C0012802;C3536861
1711,thiazide diuretic,C0012802;C3536861
1711,diuretic thiazide,C0012802
1711,any thiazide diuretic,C0012802;C3536861
1710,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
1710,myocardial ischaemia,C0010054;C0151744
1710,ischemic heart disease *,C0010054;C0151744
1710,ischemic heart disease ( % ),C0010054;C0151744
1710,ischemic heart disease  no . ( % ),C0010054;C0151744
1710,ischemic heart disease  n ( % ),C0010054;C0151744
1710,ischemic heart disease  ( % ),C0010054;C0151744
1710,ischemic heart disease  %,C0010054;C0151744
1710,ischemic heart disease,C0010054;C0151744
1710,ischaemic heart disease or cerebrovascular disorder  n ( % ),C0010054;C0151744
1710,ischaemic heart disease  n ( % ),C0010054;C0151744
1710,ischaemic heart disease,C0010054;C0151744
1710,ihd,C0151744
1710,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744;C0205195
1709,total mayo score $ | |,C0454788;C1077578;C2964552
1709,total mayo score,C0454788;C1077578;C2964552
1709,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
1709,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
1709,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
1709,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
1709,mayo < $nmbr$  n,C0454788;C1077578
1709,mayo $ $nmbr$  n,C0454788;C1077578
1709,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
1708,tnfi - ir,C0022065;C0022071;C1448132
1708,tnf - ir,C0022065;C0022071;C1448132;C1448177
1708,on metformin ir or metformin xr $nmbr$   mg / d,C0022065;C0022071;C0025598;C1448132
1708,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
1708,homa - ir ( % ) b,C0022065;C0022071;C1448132
1708,homa - ir,C0022065;C0022071;C1448132
1708,dmard - ir,C0022065;C0022071;C0242708;C1448132
1708,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
1708,bdmard - ir,C0022065;C0022071;C1448132
1707,dmard | |,C0242708
1707,dmard user,C0242708;C1548600;C1706077
1707,dmard or corticosteroid,C0242708
1707,dmard at baseline,C0168634;C0242708;C1442488
1706,dmard − ( n   =   $nmbr$ ),C0242708
1706,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
1706,dmard + ( n   =   $nmbr$ ),C0242708
1705,patients with prior dmard use  n ( % ) a,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
1705,other dmards,C0242708
1705,other dmard use,C0042153;C0242708;C0457083;C1947944
1705,baseline dmard use  n ( % ),C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
1704,ldl : hdl ratio,C0428621
1704,ldl - c : hdl - c ratio,C0428621
1704,ldl - c / hdl - c ratio,C0428621
1703,ldl - c goal attainment,C0680230
1703,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
1702,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
1702,bdi focal score $nmbr$,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1702,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1701,other glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1701,hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ],C0018301;C0243071;C1422069;C1425391;C1539338;C2350813;C2985465
1701,glp - $nmbr$ receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1701,glp - $nmbr$ receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1701,glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1701,glp - $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
1700,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
1700,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os ),C0229090;C0230028;C0262950;C0393706;C1561953
1699,fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes,C0439269;C1532563;C2983605
1699,fc - ldl - c  friedewald - calculated,C2983605
1698,> $nmbr$ / tmol / liter — no . ( % ),C0475211
1698,> $nmbr$ . $nmbr$ pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
1698,> $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
1698,< $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
1698,< $nmbr$ . $nmbr$ mmol / liter triglyceride level,C0428475;C0439190;C0475211
1698,< $nmbr$ . $nmbr$ mmol / liter estimated gfr,C0439190;C0475211
1698,< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
1697,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
1697,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
1697,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
1697,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
1697,plasma glucose $nmbr$ hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
1697,glucose — mmol / liter,C0017725;C0439190;C0475211
1697,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
1697,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
1697,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
1697,> $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
1697,< $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
1696,£ $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1696,supine after $nmbr$ minutes change from baseline,C0038846;C0439232;C0700321;C0702093;C1282918;C2347166
1696,standing after $nmbr$ minutes change from baseline,C0231472;C0439232;C0700321;C0702093;C1282918;C2347166
1696,standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1705241;C2347166;C4319952
1696,minutes from symptom onset to prehospital ecg  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C2347166;C4086878
1696,minutes from prehospital ecg to pci  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C1623258;C2347166
1696,minutes from pre - pci angiography to post - pci angiography  median ( iqr ),C0002978;C0332152;C0439232;C0700321;C0702093;C0740175;C1282918;C2257086;C2347166;C3669034;C4049621
1696,< $nmbr$ ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1696,< $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1696,( < $nmbr$ ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1696,$nmbr$ to < $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1696,$nmbr$ - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
1695,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
1695,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
1694,st - segment depression > $nmbr$ . $nmbr$ mv on admission  %,C0520887;C1454484;C1705503;C4281602
1694,st - segment depression > $nmbr$ . $nmbr$ mv,C0520887;C1454484;C1705503;C4281602
1694,st - segment depression < $nmbr$ . $nmbr$ mv  %,C0520887;C1454484;C1705503;C4281602
1694,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
1694,sokoiow - lyon voitage  mv,C1454484;C1705503;C4281602
1693,south africa,C0037712
1693,short form $nmbr$ ( sf - $nmbr$ ),C0037712;C2964478
1693,sf ‐ $nmbr$ health survey,C0018762;C0037712
1693,sf - $nmbr$ summary scores,C0037712;C1552616;C1706244
1693,sf - $nmbr$ pcs score,C0037712;C1864389;C1882368
1693,sf - $nmbr$ pcs,C0037712;C1864389;C1882368
1693,sf - $nmbr$ mcs score,C0037712
1693,sf - $nmbr$ mcs,C0037712
1693,sf $nmbr$ - pcs,C0037712;C1864389;C1882368
1693,australia / new zealand / south africa,C0037712;C4289954
1692,> $nmbr$ rd quartile,C0694666;C2828255;C4553350
1692,$nmbr$ rd > $nmbr$ . $nmbr$,C0694666;C4553350
1691,third heart sound  n ( % ),C0232237;C0232278
1691,third heart sound,C0232237;C0232278
1690,^ $nmbr$ hrs,C1568891
1690,> $nmbr$ hrs,C1568891
1690,> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ ),C0702093;C1524029;C1568891;C3813700
1690,< $nmbr$ hrs,C1568891
1689,itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1689,itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1689,itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1689,itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1689,itch nrs $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
1689,itch nrs,C0033774;C1422257;C2240043;C4050142
1688,xi = ° - ° $nmbr$,C1720296
1688,xi = oo  p = o - $nmbr$,C1720296
1688,xi = o - $nmbr$  p = o - $nmbr$,C1720296
1688,xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$,C1720296
1688,xi = $nmbr$ . $nmbr$,C1720296
1688,xi = $nmbr$ - l  p = $nmbr$ - $nmbr$,C1720296
1688,xi = $nmbr$ - $nmbr$  p = o - l,C1720296
1688,xi = $nmbr$ - $nmbr$  p = $nmbr$ - l,C1720296
1688,xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,C1720296
1688,xi = $nmbr$ - $nmbr$  p = $nmbr$,C1720296
1688,xi = $nmbr$ - $nmbr$,C1720296
1688,xi = $nmbr$,C1720296
1687,years male gender  n ( % ),C0086582;C0439234;C1706180
1687,sexa male,C0086582;C1706180;C1706428;C1706429
1687,sex : male ( n = $nmbr$ ),C0086582
1687,sex : male,C0086582
1687,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1687,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1687,sex ( male ) - no . ( % ),C0086582
1687,sex ( male )  n ( % ),C0086582
1687,sex ( male )  %,C0086582
1687,sex ( male ),C0086582
1687,sex ( male  % ),C0086582
1687,sex  n ( % ) male,C0086582
1687,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1687,sex  male  no . ( % ),C0086582
1687,sex  male  n ( % ),C0086582
1687,sex  male,C0086582
1687,sex  % male,C0086582
1687,overall  male : female,C0043210;C0086287;C0086582;C0282416;C1561607;C1705497;C1705498;C1706180;C1706428;C1706429
1687,males [ n ( % ) ],C0086582
1687,males ( n = $nmbr$ ),C0086582
1687,males ( itt ) ( n = $nmbr$ ),C0086582
1687,males ( % ),C0086582
1687,males  n ( % ),C0086582
1687,males  > $nmbr$ . $nmbr$,C0086582
1687,males  > $nmbr$,C0086582
1687,males  < $nmbr$ . $nmbr$,C0086582
1687,males  < $nmbr$,C0086582
1687,males  %,C0086582
1687,males,C0086582
1687,male vs . female,C0086582;C1706180;C1706428;C1706429
1687,male subjects ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
1687,male simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male simva,C0086582;C1706180;C1706428;C1706429
1687,male sex 一 no . ( % ),C0086582
1687,male sex — no . { % ),C0086582
1687,male sex — no . ( % ) f,C0086582
1687,male sex — no . ( % ),C0086582
1687,male sex — %,C0086582
1687,male sex ^,C0086582
1687,male sex \ no . ( % ),C0086582
1687,male sex ( % ),C0086582
1687,male sex  no . ( % ),C0086582
1687,male sex  n [ % ],C0086582
1687,male sex  n ( % ),C0086582
1687,male sex  ( % ),C0086582
1687,male sex  %,C0086582
1687,male sex,C0086582
1687,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
1687,male gender ( % ),C0086582;C1706180
1687,male gender    n   ( % ),C0086582;C1706180
1687,male gender  n ( % ),C0086582;C1706180
1687,male gender,C0086582;C1706180
1687,male eze / simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
1687,male eze / simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male eze / simva,C0086582;C1706180;C1706428;C1706429
1687,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
1687,male *  n ( % ),C0086582;C1706180;C1706428;C1706429
1687,male ( n   = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male ( n z $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male ( n - $nmbr$ ),C0086582;C1706180;C1706428;C1706429
1687,male ( % ),C0086582;C1706180;C1706428;C1706429
1687,male    n   ( % ),C0086582;C1706180;C1706428;C1706429
1687,male  no ( % ),C0086582;C1706180;C1706428;C1706429
1687,male  n / n ( % ),C0086582;C1706180;C1706428;C1706429
1687,male  n ( % ),C0086582;C1706180;C1706428;C1706429
1687,male  n,C0086582;C1706180;C1706428;C1706429
1687,male  % ( n ),C0086582;C1706180;C1706428;C1706429
1687,male  %,C0086582;C1706180;C1706428;C1706429
1687,male,C0086582;C1706180;C1706428;C1706429
1687,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
1687,genital mycotic infections male $nmbr$,C0086582;C0740330;C1706180;C1706428;C1706429
1687,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1687,gender  n [ % ] male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1687,gender  n ( % ) male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1687,gender  male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1687,[ cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1687,[ cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1686,sex ( male ) ethnic origin,C0015031;C0086582
1686,male sex — no . of patients ( % ),C0086582
1686,male sex — no . / total no . ( % ),C0086582
1686,male sex — no . ( % ) weight — no . ( % ),C0086582
1686,male sex — no . ( % ) risk factors,C0086582
1686,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
1686,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582
1686,male sex ( % ) race or ethnic group ( % ) f,C0034510;C0086582;C1706779;C3853635
1686,male sex  no . / total no . ( % ),C0086582
1685,other / mixed ( n = $nmbr$ ),C0205430;C3160715
1685,mixed ( n = $nmbr$ ),C0205430;C3160715
1685,mixed ( itt ) ( n = $nmbr$ ),C0205430;C3160715
1685,mixed,C0205430;C3160715
1685,insulin lispro mix $nmbr$,C0205430;C0293359;C1421951;C1720722;C4553942
1684,years of follow - up  mean ( sd ) [ maximum ],C0439234;C0444504;C0589120;C0806909;C1522577;C1552615;C1704685;C2347634;C2348143;C2699239;C2826546;C3274571
1684,years of education  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1684,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
1684,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
1684,weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0022718;C0332174;C0439209;C0439230;C0444504;C1303013;C2347634;C2348143;C2699239;C4054209
1684,weight  mean ± sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weight  mean ( sd ) lbs .,C0005910;C0043100;C0439219;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C3161851
1684,weight  mean ( sd ) kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weight  mean ( sd ) ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weight  mean ( sd )  kgb,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
1684,weight  mean ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weight  mean $nmbr$ sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,weeko mean + sem,C0444504;C2347634;C2348143
1684,week $nmbr$ mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1684,week $nmbr$ mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
1684,week $nmbr$ mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
1684,week $nmbr$ mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
1684,week $nmbr$ mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1684,week $nmbr$ hba $nmbr$ c  mean ( s . e . ),C0019016;C0332174;C0439230;C0444504;C1825777;C2347634;C2348143;C3538758
1684,week $nmbr$ fpg  mean ( s . e . ),C0332174;C0439230;C0444504;C2347634;C2348143
1684,week $nmbr$ ( mean  sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1684,vital signs  mean ( sd ),C0150404;C0444504;C0518766;C2347634;C2348143;C2699239
1684,vessel size  mean ( sd )  mm,C0005847;C0444504;C0456389;C2347634;C2348143;C2699239;C4330985;C4554674
1684,van der heijde mtss  mean ( sd ),C0444504;C0557775;C1511780;C2347634;C2348143;C2699239
1684,untreated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,untreated at baseline  mean ( sd )  mm hg,C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,units per week  mean ( sd ),C0444504;C0560588;C2347634;C2348143;C2699239
1684,uc duration  y  mean ( range ),C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2926735;C3542016
1684,type $nmbr$ collagen  mean ( sd )  ng / ml £,C0009325;C0332307;C0439275;C0444504;C1547052;C2347634;C2348143;C2699239
1684,triglycerides ( mmol / l )  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
1684,triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1684,triglycerides  mmol / l  mean ± sd,C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
1684,triglycerides  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
1684,triglyceride  mg / dl  mean ( sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1684,triacylglycerol  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
1684,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
1684,treated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
1684,treated at baseline  mean ( sd )  mm hg,C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
1684,total stent length ( mm )  mean ± sd,C0038257;C0439175;C0439810;C0444504;C1444754;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
1684,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
1684,total periventricular wml score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552
1684,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
1684,total macular volume  mean ( sd )  mm $nmbr$,C0332574;C0444504;C0449468;C2347634;C2348143;C2699239;C4330985;C4554674
1684,total length of implanted stents  mm  mean ( sd ),C0021102;C0439175;C0439810;C0444504;C0449462;C2347634;C2348143;C2699239;C2828363;C4330985;C4554674
1684,total cigarette pack - years  mean ( sd ),C0439175;C0439810;C0444504;C1303175;C2347634;C2348143;C2699239
1684,total cholesterol ( mmol / l )  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
1684,total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
1684,total cholesterol  mmol / l  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
1684,total cholesterol  mg / dl  mean ( sd ),C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
1684,total cholesterol  mean ( sd )  mg / dl,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
1684,total cholesterol  mean ( sd ),C0201950;C0444504;C0543421;C2347634;C2348143;C2699239
1684,total c ( mmol / l  mean ),C0439175;C0439810;C0444504;C1532563;C2347634;C2348143
1684,total basdai  mean ( sd ),C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
1684,total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd,C0004604;C0175659;C0349674;C0444504;C1947916;C1963071;C2347634;C2348143;C2699239;C2964552;C4330985;C4553945;C4554674
1684,total back pain  mean ( sd ),C0004604;C0439175;C0439810;C0444504;C1963071;C2347634;C2348143;C2699239;C4553945
1684,total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0004600;C0042815;C0205095;C0439175;C0439810;C0444504;C0460009;C1995000;C2347634;C2348143;C2699239;C4330985;C4554674
1684,tjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
1684,tjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,tjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,time  mean ( sd )  min procedure,C0040223;C0184661;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C2700391;C3274430;C3539779;C3541383;C3813700
1684,tg  mg / dl  mean ± sd,C0337445;C0439269;C0444504;C2347634;C2348143;C2699239
1684,tender joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451530;C2347634;C2348143;C2699239
1684,tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1684,tender joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451530;C2347634;C2348143;C2699239
1684,tender joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1684,tender joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
1684,tchdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,tc level  mean ( sd ) mg / dl,C0039411;C0040642;C0041405;C0041698;C0439269;C0441889;C0444504;C0456079;C1547707;C1824670;C2347634;C2348143;C2699239;C2946261;C3272447;C4522122
1684,tc  mg / dl  mean ± sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
1684,tc  mg / dl  mean + sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
1684,tc  mean ( sd )  rrig / dl,C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C3642216;C4522122
1684,tc  mean ( sd ),C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
1684,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
1684,systolic pulmonary arterial pressure  mean ( sd )  mm hg,C0024109;C0039155;C0439475;C0444504;C0871470;C1168098;C2347634;C2348143;C2699239;C2707265;C2709248;C4522268
1684,systolic pressure at ankle level ( mmhg )  mean ± sd,C0003086;C0003087;C0039155;C0439475;C0441889;C0444504;C0445074;C0456079;C0871470;C1547707;C2347634;C2348143;C2699239;C2946261
1684,systolic bp  mmhg  mean ± sd,C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1684,systolic bp  mmhg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1684,systolic bp  mm   hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1684,systolic bp  mm hg ( mean ) nyha class,C0039155;C0439475;C0444504;C0488053;C0871470;C1882083;C2347634;C2348143
1684,systolic bp  mm hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1684,systolic blood pressure mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure ( mmhg )  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure ( mm hg )  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure  mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure  mm hg  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure  mm hg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic blood pressure  mean ( sd )  mm hga,C0039155;C0428886;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239;C4330985;C4554674
1684,systolic blood pressure  mean ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1684,systolic ( mean  sd ),C0039155;C0444504;C2347634;C2348143;C2699239
1684,systolic  mean ( sd )  mm hg h,C0025424;C0039155;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
1684,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
1684,swollen joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451521;C2347634;C2348143;C2699239
1684,swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1684,swollen joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451521;C2347634;C2348143;C2699239
1684,swollen joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1684,swollen joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
1684,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
1684,sjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
1684,sjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,sjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,size ( cm $nmbr$ ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
1684,shs  mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,shs  mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
1684,sgrq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,sf - $nmbr$ v $nmbr$ pcs  mean [ sd ],C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
1684,sf - $nmbr$ v $nmbr$ mcs  mean [ sd ],C0037712;C0444504;C2347634;C2348143;C2699239
1684,sf - $nmbr$ pcs  mean ± sd,C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
1684,sf - $nmbr$ mcs  mean ± sd,C0037712;C0444504;C2347634;C2348143;C2699239
1684,sesbp ( mmhg ) [ mean _sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
1684,sesbp ( mmhg ) [ mean - sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
1684,ses - cd  mean ( sd ),C0007928;C0034283;C0444504;C2347634;C2348143;C2699239;C4552032
1684,serum total cholesterol ( mmol / l )  mean ( sd ),C0444504;C0587184;C1287371;C1532563;C2347634;C2348143;C2699239
1684,serum potassium level  mean ( sd )  meq / l,C0302353;C0439375;C0444504;C0543465;C2347634;C2348143;C2699239
1684,serum potassium  mean ( sd ) mmol / l,C0302353;C0444504;C0543465;C1532563;C2347634;C2348143;C2699239
1684,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
1684,serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd ),C0019020;C0444504;C0683149;C2347634;C2348143;C2699239;C3889898
1684,serum creatinine level  mean ( sd )  mg / dl,C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine - mean ( sd  n ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine ( pmol / l )  mean ( sd ),C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine  mg / dl  mean ( sd ),C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine  mean ( sd ) mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine  mean ( sd )  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum creatinine  gmol / ' l  mean ( sd ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
1684,serum cholesterol  mean ( sd ) mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
1684,serum cholesterol  mean ( sd )  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
1684,serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd ),C0220853;C0439275;C0444504;C0683149;C2347634;C2348143;C2699239
1684,sedbp ( mmhg ) [ mean_ sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
1684,sedbp ( mmhg ) [ mean _sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
1684,seated sbp  mean ( sd )  mmhg,C0085805;C0277814;C0439475;C0444504;C1283233;C2347634;C2348143;C2699239
1684,seated dbp  mean ( sd )  mmhg,C0277814;C0439475;C0444504;C0536221;C1283233;C2347634;C2348143;C2699239;C3813197;C4281799
1684,sdai  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3871128
1684,scsbp  mean ( sd )  mmhge,C0444504;C2347634;C2348143;C2699239
1684,scdbp  mean ( sd )  mmhgf,C0444504;C2347634;C2348143;C2699239
1684,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp ( mmhg )  mean ± sd,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp ( mmhg )  mean ( sd ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp ( mmghg )  mean ( sd ),C0085805;C0444504;C2347634;C2348143;C2699239
1684,sbp ( mean over $nmbr$ h )  mmhg,C0033727;C0085805;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1684,sbp  mm hg ( office measurement )  mean ( sd ),C0085805;C0242485;C0439475;C0442603;C0444504;C2347634;C2348143;C2699239
1684,sbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0085805;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
1684,sbp  mm hg  mean ± sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
1684,sbp  mm hg  mean + sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
1684,sbp  mean ± sd ( mmhg ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp  mean = sd  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp  mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp  mean ( sd )  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,sbp  mean ( sd )  mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1684,risk factors bmi ( kg / m $nmbr$ )  mean + sd,C0035648;C0444504;C0578022;C1532718;C1553898;C2347634;C2348143;C2699239
1684,reversibility to salbutamolc  d  mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2699239
1684,reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$,C0444504;C0449261;C2347634;C2348143;C2699239;C2987634
1684,reversibility ( anticholinergic )  %  mean ( sd ) $,C0242896;C0444504;C0449261;C2347634;C2348143;C2699239;C3537004
1684,rescue use : mean no . of inhalations / d,C0042153;C0444504;C0457083;C1947944;C2347634;C2348143
1684,rescue medication use  mean inhalations / previous $nmbr$ d,C0004048;C0205156;C0240320;C0354922;C0444504;C1552607;C2347634;C2348143
1684,ra duration ( years )  mean ( s . e . ),C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3538806;C4048756
1684,qmax  ml / s  mean ( sd ),C0439390;C0444504;C2347634;C2348143;C2699239
1684,pvr volume  ml  mean ( sd ),C0242852;C0439526;C0444504;C0449468;C0456261;C1419141;C1690016;C1705102;C1705224;C2347634;C2348143;C2699239;C2700258;C3887665
1684,pulse rate ( mean $nmbr$ h )  bpm *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1684,pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1684,pulmonary function tests ( post - bronchodilator )  mean ( sd ),C0024119;C0444504;C2347634;C2348143;C2598152;C2599594;C2699239
1684,ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †,C0444504;C1292728;C2347634;C2348143;C2699239;C4330985;C4554674
1684,psoriasis duration ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,psa duration ( years )  mean ( sd ),C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3810537;C3813209
1684,psa  ng / ml  mean ( sd ),C0439275;C0444504;C2347634;C2348143;C2699239;C3810537;C3813209
1684,ppbc score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,potassium ( meql )  mean + sd  available for $nmbr$ patients,C0032821;C0202194;C0304475;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
1684,potassium  mean ( sd )  meq / l,C0032821;C0202194;C0304475;C0439375;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
1684,plp - c  mean ( sd )  mg / dl,C0034266;C0439269;C0444504;C1175541;C1257874;C1705623;C2347634;C2348143;C2699239
1684,pioglitazone dose  mean ( sd )  mg,C0024671;C0026410;C0071097;C0178602;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,physician global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4050369
1684,physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4050369;C4330985;C4554674
1684,physician ' s global assessment . mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239;C4050369
1684,phosphatase  mean ( sd )  ng / ' mlf,C0017887;C0028074;C0031678;C0066495;C0444504;C1149880;C2347634;C2348143;C2699239;C4522024
1684,pga score  mean ( sd ),C0016410;C0444504;C0449820;C2347634;C2348143;C2699239;C3541266;C4050231;C4050369
1684,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
1684,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
1684,pav  mean ( $nmbr$ % ci ),C0008107;C0058890;C0444504;C2347634;C2348143;C3259781
1684,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
1684,patient global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
1684,patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd ),C0030193;C0030198;C0030705;C0444504;C0518090;C0679830;C1962977;C2347634;C2348143;C2699239;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
1684,patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4054228;C4330985;C4554674
1684,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
1684,pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
1684,pasi score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
1684,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
1684,pasi score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
1684,pasi  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4528685
1684,partial mayo score  mean ( sd ),C0444504;C0449820;C0454788;C0728938;C1077578;C1550516;C2347634;C2348143;C2699239;C4050231
1684,pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd,C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd ),C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C4330985;C4554674
1684,pack - years  mean ( sd ),C0444504;C1277691;C2347634;C2348143;C2699239
1684,ocs dose *  mean ( sd ),C0178602;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
1684,oab - q score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3641332;C4050231
1684,number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0234234;C0444504;C0449813;C2347634;C2348143;C2699239
1684,number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0038999;C0444504;C0449813;C2347634;C2348143;C2699239
1684,number of implanted stents  n  mean ( sd ),C0237753;C0444504;C0449788;C0522776;C2347634;C2348143;C2699239
1684,number of diseased vessels  mean ( sd ),C0005847;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
1684,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
1684,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
1684,non - hdl - c  mmol / l  mean ( sd ),C0444504;C1518422;C1532563;C2347634;C2348143;C2699239;C3715113
1684,non - hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
1684,non - hdl - c  mean ( sd )  rng / dl,C0444504;C1518422;C2347634;C2348143;C2699239;C3642216;C3715113
1684,non - hdl - c  mean ( sd ),C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
1684,nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0042815;C0444504;C1970122;C2347634;C2348143;C2699239;C3536884;C3827561;C4330985;C4554674
1684,no . previous dmard  mean ( sd ),C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
1684,nighttime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0240526;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
1684,nighttime mean dbp ( abpm ) at week $nmbr$  mmhg,C0240526;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1684,mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
1684,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
1684,mtss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,msasss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,ms  mean [ sd ],C0444504;C2347634;C2348143;C2349943;C2699239;C3539704;C3713294
1684,motor updrs subscore ( baseline )  mean ( sd ),C0168634;C0444504;C1442488;C1513492;C1705994;C2347634;C2348143;C2699239;C3639721
1684,mnapsi  mean [ sd ] d,C0444504;C2347634;C2348143;C2699239
1684,mnapsi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
1684,mental activities updrs subscore ( baseline )  mean ( sd ),C0168634;C0229992;C0441655;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721
1684,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
1684,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
1684,mean — yr,C0439234;C0444504;C2347634;C2348143
1684,mean — mm hg,C0439475;C0444504;C2347634;C2348143
1684,mean — ml / min,C0439445;C0444504;C2347634;C2348143
1684,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
1684,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
1684,mean — g / dl,C0439267;C0444504;C2347634;C2348143
1684,mean — %,C0444504;C2347634;C2348143
1684,mean ±   sd,C0444504;C2347634;C2348143;C2699239
1684,mean ± sd unless otherwise indicated,C0444504;C2347634;C2348143;C2699239
1684,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1684,mean ± sd msdbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1684,mean ± sd bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
1684,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
1684,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
1684,mean ± sd $nmbr$ - h adbp  mm hg,C0033727;C0168370;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1684,mean ± sd  n ( % ),C0444504;C2347634;C2348143;C2699239
1684,mean ± sd  n,C0444504;C2347634;C2348143;C2699239
1684,mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,mean ± s . d . hba $nmbr$ c,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
1684,mean ± s . d . fpg,C0444504;C2347634;C2348143
1684,mean ± s . d . bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1684,mean ± s . d . age  years,C0444504;C1510829;C2347634;C2348143
1684,mean ± s . d .,C0444504;C2347634;C2348143
1684,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
1684,mean yearly decline,C0444504;C2347634;C2348143
1684,mean weight  kg  mean = sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1684,mean treatment exposure  wk,C0039798;C0087111;C0274281;C0332157;C0332174;C0439230;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
1684,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
1684,mean total serum ige ( sd )  iu / ml,C0229671;C0439175;C0439458;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
1684,mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0439175;C0439810;C0444504;C0578022;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
1684,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1684,mean systolic bp  mmhg  mean = sd,C0439475;C0444504;C0871470;C2347634;C2348143;C2699239
1684,mean sitting systolic blood pressure,C0444504;C2347634;C2348143
1684,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
1684,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
1684,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
1684,mean serum potassium  mg / dl,C0302353;C0439269;C0444504;C0543465;C2347634;C2348143
1684,mean serum glucose  mg / dl  mean = sd,C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
1684,mean serum creatinine  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143
1684,mean serum cholesterol  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143
1684,mean selena - sledai score ± sd,C0444504;C0451528;C2347634;C2348143
1684,mean sd mssbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1684,mean sd ldl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1684,mean sd hdl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,mean sd fpg  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1684,mean sd $nmbr$ - h asbp  mm hg,C0033727;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1684,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
1684,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
1684,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
1684,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
1684,mean or n,C0444504;C2347634;C2348143
1684,mean of mean cimt  mean ( sd )  mm,C0444504;C2347634;C2348143;C2699239;C4330985;C4554674
1684,mean of maximum cimt  mean ( sd )  mm,C0444504;C0806909;C1552615;C2347634;C2348143;C2699239;C2826546;C4330985;C4554674
1684,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
1684,mean number of puffs per day,C0237753;C0444504;C0449788;C1533107;C2347634;C2348143
1684,mean number of caes in past $nmbr$ months ( number per patient ) ] |,C0237753;C0444504;C0449788;C2347634;C2348143
1684,mean number of antihypertensive medications at $nmbr$ year   *,C0003364;C0444504;C1718138;C2347634;C2348143
1684,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C2347634;C2348143
1684,mean no . agents ( sd ) other medications,C0444504;C2347634;C2348143
1684,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
1684,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
1684,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1684,mean involved bsa  % ( $nmbr$ % ci ),C0444504;C2347634;C2348143
1684,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
1684,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
1684,mean hbaic = • = s . d .  %,C0444504;C2347634;C2348143
1684,mean hba $nmbr$ c ± s . d .  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
1684,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
1684,mean fpg  mmol / l,C0444504;C1532563;C2347634;C2348143
1684,mean fev $nmbr$  l ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1684,mean doseb,C0444504;C2347634;C2348143
1684,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
1684,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
1684,mean dlqi score ( $nmbr$ % ci ),C0444504;C2347634;C2348143;C3899393
1684,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
1684,mean disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143
1684,mean disease duration  y ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
1684,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
1684,mean difference ( $nmbr$ % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1684,mean diastolic bp  mmhg  mean = sd,C0428883;C0439475;C0444504;C2347634;C2348143;C2699239
1684,mean crp level  mg / l ( sd ),C0439268;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
1684,mean copd duration  y ( sd ),C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1684,mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
1684,mean cdai score ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
1684,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
1684,mean body mass index ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,mean body mass index ( kg / m $nmbr$ ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1684,mean body mass index ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1684,mean body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1684,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
1684,mean body - mass index ( = sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,mean body - mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1684,mean bmii 士 s . d .  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143
1684,mean bmi ± sd ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean bmi ± s . d .  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143
1684,mean bmi ± s . d .  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1684,mean bmi ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
1684,mean bmi ( kg / m $nmbr$ ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean bmi ( $nmbr$ % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
1684,mean bmi  kg / m $nmbr$ ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean bmi  kg / m $nmbr$ ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean bmi  kg / m $nmbr$ ( s . d . ),C0022718;C0439209;C0444504;C0578022;C1512018;C2347634;C2348143;C4054209
1684,mean bmi,C0444504;C0578022;C2347634;C2348143
1684,mean bmd ( = sd )  g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
1684,mean bm $nmbr$ ± s . d .  kg / m $nmbr$,C0006416;C0444504;C1532718;C2347634;C2348143
1684,mean baseline ucdai score,C0168634;C0444504;C1442488;C2347634;C2348143
1684,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
1684,mean baseline ei score,C0022067;C0168634;C0444504;C1414370;C1442488;C2347634;C2348143;C2348481
1684,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
1684,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
1684,mean asui scored,C0444504;C2347634;C2348143
1684,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
1684,mean alc  %,C0444504;C1424945;C2347634;C2348143;C3811058
1684,mean age 士 s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
1684,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
1684,mean age ± s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
1684,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
1684,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
1684,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean age ( y ),C0001779;C0444504;C2347634;C2348143
1684,mean age ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1684,mean age ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,mean age ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean age  yrs,C0001779;C0444504;C2347634;C2348143
1684,mean age  y ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean age  y  mean = sd,C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean age  y,C0001779;C0444504;C2347634;C2348143
1684,mean acrn,C0444504;C2347634;C2348143
1684,mean acq - $nmbr$ scores,C0444504;C2347634;C2348143;C2919686
1684,mean acq - $nmbr$ score at randomization  !,C0444504;C2347634;C2348143;C2919686
1684,mean a ± sem ( % ),C0444504;C2347634;C2348143
1684,mean a ± sdt,C0444504;C2347634;C2348143
1684,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
1684,mean a ± sd  mg / dl ( mmol / $nmbr$ ),C0444504;C2347634;C2348143
1684,mean = sd,C0444504;C2347634;C2348143;C2699239
1684,mean - sd change in pre - bronchodilator fev $nmbr$  l,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
1684,mean *,C0444504;C2347634;C2348143
1684,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
1684,mean ( ± s . d . ),C0444504;C2347634;C2348143
1684,mean ( sd ) years daily ocs use  n ( % ),C0332173;C0439234;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
1684,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
1684,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
1684,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
1684,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
1684,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
1684,mean ( sd ) periostin  ng / ml,C0219433;C0439275;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
1684,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
1684,mean ( sd ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
1684,mean ( sd ) improvement from baseline to week $nmbr$ in basdai,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
1684,mean ( sd ) hba $nmbr$ c level  %,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
1684,mean ( sd ) hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,mean ( sd ) fevi / fvc  %,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
1684,mean ( sd ) fevi / evc  %,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
1684,mean ( sd ) fevi  ml,C0429706;C0439526;C0444504;C0849974;C1561566;C1705224;C2347634;C2348143;C2699239;C3887665;C4528367
1684,mean ( sd ) fev $nmbr$ postbronchodilator  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1684,mean ( sd ) fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2699239;C3714541
1684,mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1684,mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
1684,mean ( sd ) fev $nmbr$  l,C0444504;C2347634;C2348143;C2699239;C3714541
1684,mean ( sd ) feno  ppb,C0444504;C1415800;C2347634;C2348143;C2699239
1684,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) esr  mm / h *,C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
1684,mean ( sd ) eevi  ml,C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
1684,mean ( sd ) duration of t $nmbr$ dm  y,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
1684,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
1684,mean ( sd ) duration of smoking  pack - years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
1684,mean ( sd ) duration of copd  years,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1684,mean ( sd ) disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1684,mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
1684,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,mean ( sd ) change from pre - to post - bronchodilator fevi  nil,C0332152;C0442734;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
1684,mean ( sd ) change from pre - to post - bronchodilator fevi  ml,C0332152;C0439526;C0444504;C0687676;C0740175;C1704687;C1705224;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034;C3887665
1684,mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
1684,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
1684,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,mean ( sd ) body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,mean ( sd ) bmi ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean ( sd ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
1684,mean ( sd ) bmd in g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) baseline scores,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
1684,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,mean ( sd ) age  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) age  years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,mean ( sd ) age  y race  n ( % ) *,C0001779;C0034510;C0444504;C1706779;C2347634;C2348143;C2699239;C3853635
1684,mean ( sd ) age  y,C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) [ range ],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) % reversibility fev $nmbr$ at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
1684,mean ( sd ) % predicted normal fev $nmbr$,C0444504;C2347634;C2348143;C2699239
1684,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
1684,mean ( sd ) % of predicted normal fev $nmbr$,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
1684,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
1684,mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0444504;C2347634;C2348143;C2699239
1684,mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
1684,mean ( sd )  ng / ml £,C0439275;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd )  mmhg,C0439475;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd )  mg / kg $nmbr$,C0439272;C0444504;C2347634;C2348143;C2699239
1684,mean ( sd )  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143;C2699239
1684,mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,mean ( s . e . ) t,C0444504;C2347634;C2348143
1684,mean ( s . e . ),C0444504;C2347634;C2348143
1684,mean ( s . d . ) total pcsk $nmbr$  ng / ml,C0439175;C0439275;C0439810;C0444504;C2347634;C2348143
1684,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
1684,mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143
1684,mean ( s . d . ) ldl particle size  nm,C0203634;C0312860;C0444504;C2347634;C2348143;C3641256;C3890923
1684,mean ( s . d . ) ldl particle number  nmol / l,C0237753;C0439282;C0444504;C0449788;C2347634;C2348143;C2612459
1684,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
1684,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
1684,mean ( s . d . ) free pcsk $nmbr$  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
1684,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
1684,mean ( s . d . ) duration of t $nmbr$ dm  years,C0011816;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
1684,mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143
1684,mean ( s . d . ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1684,mean ( s . d . ) baseline hba $nmbr$ c  %,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
1684,mean ( s . d . ) baseline fpg  mmol / l,C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
1684,mean ( s . d . ) apoc - ll $nmbr$  mg / dl,C0003594;C0444504;C2347634;C2348143
1684,mean ( s . d . ) apob  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C3252643
1684,mean ( s . d . ) age  years,C0444504;C1510829;C2347634;C2348143
1684,mean ( s . d . ),C0444504;C2347634;C2348143
1684,mean ( median ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C0549183;C0876920;C1960952;C2346927;C2347634;C2347635;C2348143;C2348144;C2939193;C4321396;C4521761
1684,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
1684,mean ( $nmbr$ % ci ) difference vs saxa + dapa + met,C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1684,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
1684,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
1684,mean % predicted value prebronchodilation,C0444504;C2347634;C2348143
1684,mean % predicted fvc ( sd ),C0444504;C2347634;C2348143
1684,mean % predicted dlco * ( sd ),C0444504;C2347634;C2348143
1684,mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
1684,mean $nmbr$ mwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
1684,mean  sd,C0444504;C2347634;C2348143;C2699239
1684,mean  ml ( sd ),C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
1684,mean  mg / dl,C0439269;C0444504;C2347634;C2348143
1684,mean,C0444504;C2347634;C2348143
1684,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
1684,mayo score  mean ( sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
1684,mayo clinic score  mean ± sd,C0002424;C0442592;C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
1684,mases ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1684,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1684,lung function  mean,C0035245;C0444504;C2347634;C2348143
1684,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
1684,ls mean difference ( se ) vs placebo,C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
1684,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
1684,ls mean difference ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1684,ls mean difference ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1684,ls mean ( $nmbr$ % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
1684,ls mean ( $nmbr$ % ci )  %,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
1684,ls mean ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
1684,ls mean,C0023668;C0444504;C2347634;C2348143
1684,ls - mean difference ® ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1684,lp ( a )  nmol / l  mean ( sd ),C0065058;C0439282;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
1684,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
1684,low - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023824;C0444504;C1532563;C2347634;C2348143;C2699239
1684,lipids  mean ( sd )  mg / dlt,C0023779;C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
1684,lipids  mean ( sd )  mg / dlf,C0023779;C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,lipid values  mean ( sd ),C0023779;C0042295;C0444504;C2347634;C2348143;C2699239
1684,lipid parameters  mg / dl  mean ( sd ),C0023779;C0439269;C0444504;C0449381;C2347634;C2348143;C2699239
1684,levodopa dose  mean ± sd  mg / day,C0023570;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
1684,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
1684,lei  mean [ sd ] c,C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
1684,lei  mean ( sd ),C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
1684,left ventricular ejection fraction  mean ( sd )  %,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1684,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
1684,leeds dactylitis index - basic  mean ( sd ) ’ ' ^,C0239161;C0444504;C0600653;C0918012;C1527178;C1552854;C1637833;C2347634;C2348143;C2699239;C2986546
1684,least - squares mean difference ( $nmbr$ % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1684,least - squares mean difference ( $nmbr$ % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1684,ldl cholesterol ( mmol / l )  mean ( sd ),C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1684,ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl cholesterol  mmol / l  mean ± sd,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1684,ldl cholesterol  mmol / l  mean ( sd ) §,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1684,ldl cholesterol  mean ( sd )  mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl / hdl cholesterol ratio  mean ( sd ) §,C0008377;C0428621;C0444504;C2347634;C2348143;C2699239
1684,ldl - to - hdl cholesterol ratio  mean ( sd ),C0008377;C0428621;C0444504;C1171408;C2347634;C2348143;C2699239
1684,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,ldl - cholesterol  mg / dl  mean ( sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl - cholesterol  mean ( sd ) mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261
1684,ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] ),C0444504;C1532563;C2347634;C2348143;C2699239
1684,ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1684,ldl - c / hdl - c ratio  mean ( sd ),C0428621;C0444504;C2347634;C2348143;C2699239
1684,ldl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143
1684,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
1684,ldl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1684,ldl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1684,ldl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,ldi  mean [ sd ] b,C0444504;C2347634;C2348143;C2699239
1684,ldi  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239
1684,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
1684,jsn score  mean $nmbr$ sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,jsn  mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1684,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
1684,intensity of rest pain ( mmvas )  mean ± sd,C0035253;C0234253;C0444504;C0522510;C1320357;C1622890;C2347634;C2348143;C2699239;C4085211
1684,in previous year  mean ( sd ),C0205156;C0439234;C0439508;C0444504;C1552607;C2347634;C2348143;C2699239
1684,in ibdq total score at week $nmbr$  mean [ se ],C0036919;C0332174;C0439175;C0439230;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
1684,imaging data  mean ( sd ),C0011923;C0079595;C0444504;C1511726;C2347634;C2348143;C2699239;C3245479;C3714741
1684,ileum ses - cd score  mean ( sd ),C0007928;C0020885;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4552032
1684,ibdq total score  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C2964552
1684,ibdq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,ibdq  mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,hscrp  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,hours from clopidogrel loading  mean ( sd ),C0070166;C0439227;C0444504;C1708715;C2347634;C2348143;C2699239
1684,homa - ir  mean ( sd ),C0022065;C0022071;C0444504;C1448132;C2347634;C2348143;C2699239
1684,high - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023822;C0444504;C1532563;C2347634;C2348143;C2699239
1684,hemoglobin a $nmbr$ c  mean ( sd )  % b,C0062248;C0444504;C2347634;C2348143;C2699239
1684,hemoglobin a $nmbr$ c  mean ( sd )  %,C0019020;C0444504;C2347634;C2348143;C2699239;C3889898
1684,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
1684,height ( cm )  mean ( sd ) a,C0444504;C0489786;C2347634;C2348143;C2699239
1684,height ( cm )  mean ( s . e . ),C0439392;C0444504;C0489786;C2347634;C2348143
1684,height  mean ( sd )  cm,C0444504;C0489786;C2347634;C2348143;C2699239
1684,height  cm ( mean ± s . d . ),C0439392;C0444504;C0489786;C2347634;C2348143
1684,height  cm  mean ( sd ),C0444504;C0489786;C2347634;C2348143;C2699239
1684,heart rate  min_ $nmbr$ ( mean ),C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
1684,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
1684,heart rate  mean ( sd ) [ range ]  beats / min,C0018810;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ ),C0018810;C0444504;C2347634;C2348143;C2699239
1684,heart rate  mean ( sd )  beats / min,C0018810;C0444504;C2347634;C2348143;C2699239
1684,heart rate  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
1684,heart rate  bpm  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
1684,hdl cholesterol ( mmol / l )  mean ( sd ),C0023822;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
1684,hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
1684,hdl cholesterol  mmol / l  women  mean ± sd,C0023822;C0043210;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
1684,hdl cholesterol  mmol / l  men  mean ± sd,C0023822;C0025266;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
1684,hdl cholesterol  mean ( sd )  mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
1684,hdl - cholesterol  mg / dl  mean ( sd ),C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
1684,hdl - cholesterol  mean ( sd ) mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
1684,hdl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3715113
1684,hdl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143;C3715113
1684,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3715113
1684,hdl  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1684,hbalc ( % )  mean ( sd ) ^,C0444504;C2347634;C2348143;C2699239
1684,hbalc  mean ( s . d . ),C0444504;C2347634;C2348143
1684,hbalc  %  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,hbaic ( % )  mean ± s . d .,C0444504;C2347634;C2348143
1684,hba $nmbr$ ca  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3887642
1684,hba $nmbr$ c ( % )  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  mmol / mol  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
1684,hba $nmbr$ c  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  % ( mean ± sd ) [ range ],C0019016;C0444504;C1514721;C1825777;C2347634;C2348143;C2348147;C2699239;C3538758;C3542016
1684,hba $nmbr$ c  % ( mean $nmbr$ sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  %  mean ( sd ) b,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,hba $nmbr$ c  %  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1684,haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd,C0444504;C0449820;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4050231;C4321476
1684,haq - di total score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552;C3826998;C4321476
1684,haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3826998;C4050231;C4321476
1684,haq - di ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1684,haq - di  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4321476
1684,haq - di  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1684,haq - di  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
1684,haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients,C0019046;C0439267;C0444504;C1319312;C2347634;C2348143;C2699239;C3642216
1684,hab $nmbr$ c ( mean ± sem )  %,C0444504;C2347634;C2348143
1684,gout history  mean ± sd years,C0018099;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
1684,glycohemoglobin  %  mean ( sd ),C0202054;C0444504;C0696092;C2347634;C2348143;C2699239
1684,glycated hemoglobin  mean ( sd )  %,C0017853;C0444504;C2347634;C2348143;C2699239
1684,glycated hemoglobin  %  mean ( sd ),C0017853;C0444504;C2347634;C2348143;C2699239
1684,fvc  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1684,fsn score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,fsg  mg / dl ( mean ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239
1684,fpi  mean ( sd )  pu / rnff,C0018387;C0444504;C2347634;C2348143;C2699239
1684,fpi  mean ( sd )  pu / mlt,C0018387;C0444504;C2347634;C2348143;C2699239;C4553833
1684,fpg ( mmol / l )  mean ± s . d .,C0439433;C0444504;C2347634;C2348143
1684,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg ( mmol / l )  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg  mmol / l ( mean ± sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
1684,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg  mean ( sd )  mg / dlt,C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
1684,fpg  mean ( sd )  mg / dlf,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1684,fpg  mean ( sd )  mg / dl [ mmol / l ],C0439269;C0444504;C1532563;C2347634;C2348143;C2699239
1684,fpg  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1684,flex baseline bmd  mean ( sd )  g / cm $nmbr$,C0168634;C0439267;C0444504;C1442488;C2347634;C2348143;C2699239
1684,final mean  mg / dl,C0205088;C0439269;C0444504;C1546485;C2347634;C2348143;C3853528
1684,fevi  l  mean ( sd ) $nmbr$,C0429706;C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
1684,fev $nmbr$ / fvc  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1684,fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$,C0444504;C2347634;C2348143;C2699239;C3714541
1684,fev $nmbr$ ( l )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1684,fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc,C0005126;C0332152;C0444504;C0740175;C2257086;C2344255;C2347634;C2348143;C2699239;C3669034;C3714541;C4050145
1684,fev $nmbr$  litres ( pre salbutamol )  mean ( sd ),C0001927;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
1684,fev $nmbr$  litres ( pre ipratropium )  mean ( sd ),C0027235;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
1684,fev $nmbr$  litres ( post ipratropium )  mean ( sd ),C0027235;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
1684,fev $nmbr$  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
1684,fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
1684,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,fcal  mg / g  mean ± sd,C0444504;C1300563;C2347634;C2348143;C2699239
1684,fasting triglycerides  mean ( sd ) mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1684,fasting triglycerides  mean ( sd )  mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1684,fasting triglyceride level  mean ( sd )  mg / dl,C0015663;C0428475;C0439269;C0444504;C2347634;C2348143;C2699239
1684,fasting serum glucose level  mean ( sd )  mg / dl,C0015663;C0202045;C0229671;C0439269;C0444504;C0583332;C1546774;C1550100;C2347634;C2348143;C2699239
1684,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
1684,fasting plasma glucose  mg / dl  mean ( sd ),C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
1684,fasting glucose  mg / dl  mean ( sd ) §,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
1684,fasting glucose  mean ( sd )  mg / dl,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
1684,fasting blood glucose  mean ( sd )  mg / dlt,C0024671;C0026410;C0428568;C0439269;C0444504;C1261430;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
1684,fas  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,exact - pro total score  mean ( sd ),C0033382;C0444504;C0523852;C2347634;C2348143;C2699239;C2828393;C2964552;C2987124;C4050514
1684,estimated mean $nmbr$ % cl,C0444504;C0596019;C0750572;C2347634;C2348143
1684,estimated mean,C0444504;C0750572;C2347634;C2348143
1684,esr ( mm / h )  mean ( sd ),C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
1684,esr  mean ± sd mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3811131
1684,erosion score  mean ± sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
1684,erosion score  mean $nmbr$ sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
1684,erosion  mean ± sd,C0333307;C0444504;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524
1684,enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1282952;C2347634;C2348143;C2699239;C4050231
1684,egfr — mean ( sd  n ),C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1684,egfr  mean ± sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1684,ef ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,education in years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1684,education  yrs  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
1684,education  years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1684,education  y  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
1684,education  mean ( sd ) years,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1684,education  mean ( sd )  ya,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
1684,education  mean ( sd )  y,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
1684,duration of ra  mean ± sd years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3538806;C4048756
1684,duration of psoriasis ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of paod ( years )  mean ± sd,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of oral antidiabetic treatment  y  mean ( sd ),C0442027;C0444504;C0444921;C0935929;C2347634;C2348143;C2699239;C4521986
1684,duration of initial anticoagulation  mean ( sd )  mo,C0003281;C0026544;C0205265;C0332177;C0444504;C0449238;C1279901;C1555582;C1705685;C2347634;C2348143;C2699239;C2917212;C2919015;C2926735;C3537050
1684,duration of epilepsy  years  mean ( sd ),C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of epilepsy  mean ( sd )  years,C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes mellitus  y  mean ( sd ) §,C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes ( years )  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes ( years )  mean  ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes  years  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes  y  mean ( sd ),C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of diabetes  mean ( sd )  y,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,duration of copd ( years )  mean ( sd ),C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1684,duration of alendronate use  mean ( sd )  y,C0102118;C0444504;C1881378;C2347634;C2348143;C2699239;C2826775
1684,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,dlqi ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3899393
1684,disease duration [ year ]  mean ± sda,C0276477;C0439234;C0439508;C0444504;C0872146;C1428349;C1553165;C2347634;C2348143
1684,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
1684,disease duration ( yr )  mean ± sd,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1684,disease duration ( years )  mean ± s . d .,C0439234;C0444504;C0872146;C2347634;C2348143
1684,disease duration  yrs  mean ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
1684,disease duration  y  mean ± sd,C0444504;C0872146;C2347634;C2348143;C2699239
1684,disease duration  mean [ sd ] years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1684,dietary calcium intake  mean ( sd )  mg / d,C0439422;C0444504;C0489458;C2347634;C2348143;C2699239
1684,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
1684,diastolic bp  mmhg  mean ± sd,C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
1684,diastolic bp  mm   hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
1684,diastolic bp  mm hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
1684,diastolic blood pressure mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1684,diastolic blood pressure ( mm hg )  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1684,diastolic blood pressure  mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1684,diastolic blood pressure  mm hg  mean ± sd,C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1684,diastolic blood pressure  mm hg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1684,diastolic ( mean  sd ),C0012000;C0444504;C2347634;C2348143;C2699239
1684,diastolic  mean ( sd )  mm hg,C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
1684,diary variables  mean ( sd ),C0376660;C0439828;C0444504;C2347634;C2348143;C2699239
1684,diagnosis ( y )  mean ( sd ),C0011900;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239
1684,diabetesduration  mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
1684,diabetes history  mean ( sd )  years,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
1684,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,diabetes duration  years ( mean ± sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,dha intake on food frequency questionnaire  mean ( sd )  mg / d,C0034394;C0142831;C0439422;C0444504;C1286336;C1512806;C2347634;C2348143;C2348308;C2699239;C2986698
1684,demographic characteristics  mean ± sd unless otherwise indicated,C0444504;C0683970;C2347634;C2348143;C2699239
1684,demographic characteristics  mean ( sd )  unless otherwise stated,C0444504;C0683970;C2347634;C2348143;C2699239
1684,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp ( mmhg )  mean ( sd ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp ( mmghg )  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp ( mean over $nmbr$ h )  mmhg,C0033727;C0369286;C0439475;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
1684,dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C0536221;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mm hg ( office measurement )  mean ( sd ),C0242485;C0439475;C0442603;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0428257;C0444504;C0456680;C0536221;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239;C3813197;C4281799
1684,dbp  mm hg  mean ± sdc,C0439475;C0444504;C0536221;C1419891;C2347634;C2348143;C3273112;C3813197;C4281799
1684,dbp  mean ± sd ( mmhg ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mean ( sd )  mmhg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mean ( sd )  mm hg glycaemic parameters,C0005802;C0439475;C0444504;C0449381;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mean ( sd )  mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,dbp  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1684,daytime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0332169;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
1684,daytime mean dbp ( abpm ) at week $nmbr$  mmhg,C0332169;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1684,das - $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,das $nmbr$ - hscrp  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
1684,das $nmbr$ - esr  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
1684,das $nmbr$ ( esr )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
1684,das $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,das $nmbr$  mean ± sd,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
1684,das $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
1684,daily “ off ” time  mean ± sd  h / dayf,C0033727;C0040223;C0332173;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C3541383;C4528284
1684,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
1684,dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0750480;C1705566;C2347634;C2348143;C2699239
1684,d - dimer level  mean ( sd )  ng / mld,C0017887;C0023522;C0028074;C0060323;C0441889;C0444504;C0456079;C1539265;C1547707;C2347634;C2348143;C2699239;C2946261;C3539688;C3539689
1684,cwt  mean ( se )  mm,C0036919;C0444504;C2347634;C2348143;C4330985;C4554674
1684,cumulative nsaid score  mean   ±   sd,C0003211;C0444504;C0449820;C1511559;C2347634;C2348143;C2699239;C3536840;C4050231
1684,crusade bleeding score  mean ( sd ) ^,C0019080;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,crp level  mean ± sd mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
1684,crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd ),C0086715;C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,crp ( mg / l )  mean ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,crp  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,crp  mean mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1684,crp  mean [ sd ] mg / $nmbr$,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C3890735;C4048285;C4321396;C4521761
1684,creatinine ( mg / dl )  mean ( sd ),C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
1684,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
1684,crcl  ml / min mean ( sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
1684,crcl  mean  ml / min ( ± sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
1684,copd duration  mean ( sd )  yr *,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1684,continuous variables  mean ( sd ) ^,C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
1684,continuous variables  mean ( sd ),C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
1684,concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ],C0001617;C0368663;C0444504;C0449820;C0454788;C0521115;C1077578;C2347634;C2348143;C2699239;C3539185;C3540725;C3540726;C3540727;C4050231
1684,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
1684,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
1684,comorbidity score  mean ( sd ) t,C0009488;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1684,colon ' ses - cd score  mean ( sd ),C0007928;C0009368;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C3888384;C4050231;C4552032
1684,cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e,C0444504;C0450989;C1516691;C2347634;C2348143;C2699239
1684,clinical dementia rating sum of boxes  mean ( sd ) f,C0444504;C0451074;C1515051;C1517104;C2347634;C2348143;C2699239
1684,cigarette smoking  mean pack - years ( sd ),C0037369;C0444504;C0453996;C1303175;C1881674;C2347634;C2348143;C2699239
1684,cholesterol - mean ( sd  n ),C0008377;C0444504;C2347634;C2348143;C2699239
1684,cholesterol  mg / dl  mean ( sd ) §,C0008377;C0439269;C0444504;C2347634;C2348143;C2699239
1684,chads $nmbr$  mean ± sd,C0007928;C0444504;C1413373;C2347634;C2348143;C2699239
1684,cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd,C0444504;C0449820;C1420648;C2347634;C2348143;C2699239;C3714751;C4050231
1684,cha $nmbr$ ds $nmbr$ - vasc  mean ± sd,C0444504;C1420648;C2347634;C2348143;C2699239;C3714751
1684,cdai  mean [ sd ],C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
1684,cdai  mean ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
1684,cat score  mean ( sd ),C0007450;C0325090;C0444504;C0449820;C0524517;C1443200;C2347634;C2348143;C2699239;C3665481;C4050231;C4050461;C4284282
1684,caleitonin  ng / l  males mean ± sd,C0086582;C0439297;C0444504;C2347634;C2348143;C2699239
1684,caleitonin  ng / l  females mean ± sd,C0086287;C0439297;C0444504;C2347634;C2348143;C2699239
1684,bw  mean ( sd )  kg,C0005910;C0006041;C0022718;C0439209;C0444504;C2347634;C2348143;C2699239;C2986891;C4054209
1684,bsa ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,bone mineral density ( g / cm $nmbr$ )  mean ( sd ),C0005938;C0177804;C0439267;C0444504;C2347634;C2348143;C2699239
1684,bone erosion score  mean ( sd ),C0444504;C0449820;C0587240;C2347634;C2348143;C2699239;C4050231
1684,body weight ( kg )  mean ± sd,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1684,body weight ( kg )  mean ( sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1684,body weight ( kg )  mean ( s . d . ),C0005910;C0444504;C1275571;C1305866;C2347634;C2348143
1684,body weight  mean ± sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1684,body weight  mean = sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1684,body weight  kg ( mean ± sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1684,body massindex  mean ( sd ) a,C0242821;C0444504;C0460148;C1268086;C2347634;C2348143;C2699239;C4082212
1684,body mass index [ kg / m $nmbr$ ]  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,body mass index ( kg / m $nmbr$ ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index ( kg / m $nmbr$ )  mean ( sd ) c,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean ± sd ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd ) t,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd ) kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd ) d,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd ) [ range ] a,C0005893;C0444504;C0578022;C1305855;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,body mass index  mean ( sd ) ( kg m ) $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,body mass index  kg / rn \ mean ( sd ),C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
1684,body mass index  kg / m ^ mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  kg / m $nmbr$ ( mean ± sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  kg / m $nmbr$  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  kg / m $nmbr$  mean + sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  kg / m $nmbr$  mean ( sd ) §,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body mass index  kg / m $nmbr$  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body - mass index ( kg / m $nmbr$ ) ( mean  sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body - mass index ( kg / m $nmbr$ )  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1684,body - mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1684,bmi — mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0012727;C0020261;C0205419;C0428886;C0444504;C1305855;C1705236;C2347634;C2348143
1684,bmi in kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .,C0017480;C0033727;C0039155;C0042036;C0042037;C0085805;C0152060;C0369286;C0428883;C0428886;C0441932;C0444504;C0488053;C0488055;C0564385;C0700320;C0871470;C1305855;C1306620;C1441672;C1511726;C1522472;C1552923;C1705191;C2347634;C2348143;C2699638;C2963137;C3245479;C3714523;C3714741;C3854019;C4528284
1684,bmi ( kg / m ^ )  mean ± s . d .,C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C0578022;C1275571;C1513009;C2347634;C2348143;C4054209
1684,bmi ( kg / m ^ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ ) [ mean - sd ],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ )  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ )  mean ( sd ) a,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi ( kg / m $nmbr$ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ± sd,C0444504;C0578022;C2347634;C2348143;C2699239
1684,bmi  mean ( sd ) kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ( sd ) b,C0444504;C0578022;C2347634;C2348143;C2699239
1684,bmi  mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ( sd )  kg / rn $nmbr$,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
1684,bmi  mean ( sd )  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ( sd )  kg / m $nmbr$ c,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  mean ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
1684,bmi  mean  kg / m $nmbr$ ( ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m ^  mean ( sd ) ’,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m ^  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m $nmbr$ ( mean $nmbr$ sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m $nmbr$  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m $nmbr$  mean + sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bmi  kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1684,bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . ),C0006416;C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C1275571;C1513009;C2347634;C2348143;C4054209
1684,blood pressure : systolic / diastolic ( mm hg ) ( mean  sd ),C0439475;C0444504;C2347634;C2348143;C2699239;C2704328
1684,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
1684,bl mean  mg / dl ( mmol / $nmbr$ ),C0005918;C0006413;C0439190;C0439269;C0444504;C0567349;C1552663;C2347634;C2348143;C2348885;C2827109;C3642216
1684,biochemical parameters at randomization  mean,C0034656;C0205474;C0444504;C0449381;C2347634;C2348143
1684,biochemical measures  mean ( sd ),C0079809;C0205474;C0444504;C1879489;C2347634;C2348143;C2699239
1684,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
1684,beam values ( mg / dl )  mean ( sd ),C0042295;C0338248;C0439269;C0444504;C2347634;C2347880;C2348143;C2699239;C4521565
1684,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
1684,basfi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,baseline total ipss  mean ( sd ),C0168634;C0439175;C0439810;C0444504;C1019118;C1442488;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1684,baseline tjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline systolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274438
1684,baseline sua  mean ± sd mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline spga  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline skin pain vas  mean ( sd ),C0042815;C0168634;C0241136;C0444099;C0444504;C1123023;C1442488;C1963195;C2347634;C2348143;C2699239;C3536884;C3827561;C4520765
1684,baseline sjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline sesbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline sedbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline sbp  mean ± sd  mm hg,C0085805;C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline pasi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C4528685
1684,baseline mssbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline msdbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline mean serum uric acid  pmol / l ( sd ),C0168634;C0439284;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143;C2699239
1684,baseline mean seated sbp  mm hg ( sd ),C0085805;C0168634;C0277814;C0439475;C0444504;C1283233;C1442488;C2347634;C2348143;C2699239
1684,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline mean fev $nmbr$ ( sd )  ml,C0168634;C0439526;C0444504;C1442488;C1705224;C2347634;C2348143;C2699239;C3714541;C3887665
1684,baseline mean ambulatory sbp  mm hg ( sd ) *,C0085805;C0168634;C0439475;C0439841;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline mean ( mg / dl ],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
1684,baseline mean  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
1684,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1684,baseline lipids  mean ± sd ( mmol / $nmbr$ ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239
1684,baseline hbi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline hba $nmbr$ c  mean ( s . e . ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
1684,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
1684,baseline fpg  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
1684,baseline dlqi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3899393
1684,baseline diastolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274392
1684,baseline dbp  mean ± sd  mm hg,C0168634;C0439475;C0444504;C0536221;C1442488;C2347634;C2348143;C2699239;C3813197;C4281799
1684,baseline das $nmbr$  mean ( s . e . ),C0051767;C0057671;C0168634;C0444504;C1442488;C2347634;C2348143
1684,baseline characteristics  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239;C4684572
1684,baseline cdai  mean ( sd ),C0168634;C0444504;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706
1684,baseline bsa  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline bii  mean ( sd ),C0168634;C0444504;C1413059;C1442488;C2347634;C2348143;C2699239
1684,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
1684,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline . mean _ sd  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline ( mean  sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,baseline  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1684,at femoral neck  mean ( sd ),C0015815;C0444504;C2347634;C2348143;C2699239
1684,as duration  y  mean ( sd ),C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1684,aqlq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
1684,aqlq score  mean,C0444504;C0449820;C2347634;C2348143;C4050231;C4055434
1684,aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f,C0016327;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
1684,apolipoprotein b  mean ( sd )  g / l,C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239
1684,apob  g / l  mean ( sd ),C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239;C3252643
1684,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
1684,apo b  mg / dl  mean ( sd ),C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
1684,apo b  mean ( sd )  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
1684,apo b  mean ( sd ),C0003593;C0444504;C2347634;C2348143;C2699239;C3252643
1684,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
1684,apo a - $nmbr$  mean ( sd )  mg / dl,C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
1684,apo a $nmbr$  mg / dl  mean ( sd ),C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
1684,apo a $nmbr$  mean ( sd ),C0003592;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
1684,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
1684,anthropometrics  mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,allergic rhinitis duration  mean ± sd  y *,C0444504;C0449238;C1334103;C2347634;C2348143;C2607914;C2699239;C2926735;C4552864
1684,all participants  mm hg : sbp  mean ( sd ),C0085805;C0439475;C0444504;C0679646;C2347634;C2348143;C2699239
1684,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,age in years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
1684,age at enrollment ( years )  mean ( sd ),C0444504;C1510829;C1516879;C1696073;C2347634;C2348143;C2699239;C3888021
1684,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( yrs )  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years ) ( mean  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years )  mean   ±   sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years )  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years )  mean _ sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( years )  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age ( year )  mean ± sd,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
1684,age  yr mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1684,age  years mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years ( mean = sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years ( mean $nmbr$ sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years  mean + sd,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  y mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  y ( mean ± s . d . ),C0001779;C0444504;C2347634;C2348143
1684,age  y  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  y  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ± sd years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ± sd ( year ),C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
1684,age  mean ± sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ± sd  y,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean yr ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1684,age  mean years ( sd ) ’ gender  n ( % ),C0079399;C0444504;C1510829;C1522384;C2347634;C2348143;C2699239
1684,age  mean years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean years  [ sd ],C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean = sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ( sd ) years  n ( % ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ( sd ) [ range ]  y,C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1684,age  mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ( sd )  yrs,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( sd )  yearsa,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean ( sd )  y ethnicity  no . ( % ),C0001779;C0015031;C0243103;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean ( s . e . ),C0001779;C0444504;C2347634;C2348143
1684,age  mean $nmbr$ sd years,C0444504;C1510829;C2347634;C2348143;C2699239
1684,age  mean  yrs ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1684,age  mean  years ( ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1684,adjusted mean ± se ( $nmbr$ % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
1684,adjusted mean difference ( $nmbr$ % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
1684,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
1684,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
1684,adjusted mean ( se ) trough fevi  ml,C0036919;C0429706;C0439526;C0444504;C0444506;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
1684,adjusted mean ( se ) fevi auco_ $nmbr$  ml,C0036919;C0429706;C0439526;C0444504;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
1684,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
1684,activity ( range $nmbr$ - $nmbr$ )  mean ± sd,C0205177;C0439167;C0441655;C0444504;C1514721;C1561536;C2347634;C2348143;C2348147;C2699239;C3542016;C3668946;C4049938;C4049939
1684,activities of daily living updrs subscore ( baseline )  mean ( sd ),C0001288;C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721;C4050548
1684,acr ( mg / g )  mean ( sd ),C0444504;C1300563;C1412134;C1515941;C2347634;C2348143;C2699239
1684,acq score  mean,C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
1684,acq - $nmbr$ score  mean ( sd ) e,C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
1684,acq $nmbr$ score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
1684,> mean,C0444504;C2347634;C2348143
1684,> $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
1684,< mean,C0444504;C2347634;C2348143
1684,< $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
1684,( sd ) l / min acq - $nmbr$ score  mean ( sd ),C0444504;C0449820;C0702093;C1524029;C2347634;C2348143;C2699239;C2919686;C3813700;C4050231
1684,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
1684,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
1684,( mean difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1684,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
1684,( mean % difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1684,( % )  $nmbr$ mean ( sd ),C0444504;C2347634;C2348143;C2699239
1684,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
1684,$nmbr$ mo  mean ( sd ) x,C0026544;C0332177;C0444504;C2347634;C2348143;C2699239
1684,$nmbr$ baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
1684,$nmbr$ - h pmg  mmol / l ( mean ± sd ),C0444504;C2347634;C2348143;C2699239;C2827804
1683,marital status  married,C0024819;C1716536;C3172566
1682,smoking status — no . { % ),C1519386
1682,smoking status — no . ( % ),C1519386
1682,smoking status current,C0521116;C1519386;C1705970
1682,smoking status . no . ( % ),C1519386
1682,smoking status *,C1519386
1682,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
1682,smoking status ( ongoing ) ( n ),C0549178;C1519386
1682,smoking status ( % ),C1519386
1682,smoking status  no . ( % ),C1519386
1682,smoking status  n [ % ] ®,C1519386
1682,smoking status  n ( % ) former,C1519386
1682,smoking status  n ( % ) *,C1519386
1682,smoking status  n ( % ),C1519386
1682,smoking status,C1519386
1681,missing data — no . / total no . ( % ),C4684714
1681,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
1681,missing data,C4684714
1680,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
1680,mini - mental state examination  mean ( sd ) d,C0444504;C0451306;C2347634;C2348143;C2699239
1680,mini - mental state examination,C0451306
1680,a mini - mental state examination  insulin glargine vs standard care,C0451306;C0907402
1679,mmse score *,C0449820;C0451306;C4050231
1679,mmse score,C0449820;C0451306;C4050231
1679,mmse > $nmbr$,C0451306
1679,mmse < $nmbr$,C0451306
1679,mmse ( points ),C0451306
1679,mmse $nmbr$ - $nmbr$,C0451306
1678,years  n ( % ) smoking  n ( % ) current,C0037369;C0439234;C0453996;C0521116;C1705970;C1881674
1678,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
1678,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
1678,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
1678,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
1678,smoking pack - yearsb  n ( % ),C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
1678,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
1678,smoking pack - years,C0037369;C0453996;C1277691;C1881674
1678,smoking in the past year,C0037369;C0453996;C1881674;C4086728
1678,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
1678,smoking : ex - smoker,C0037369;C0453996;C1881674
1678,smoking : current smoker,C0037369;C0453996;C1881674
1678,smoking * ( > $nmbr$ pack - years ),C0037369;C0453996;C1277691;C1881674
1678,smoking *,C0037369;C0453996;C1881674
1678,smoking ( ever ),C0037369;C0453996;C1881674
1678,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
1678,smoking ( a ),C0037369;C0453996;C1881674
1678,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
1678,smoking ( % ),C0037369;C0453996;C1881674
1678,smoking ' ! ',C0037369;C0453996;C1881674
1678,smoking  n ( % ),C0037369;C0453996;C1881674
1678,smoking  mean,C0037369;C0444504;C0453996;C1881674;C2347634;C2348143
1678,smoking  % current,C0037369;C0453996;C0521116;C1705970;C1881674
1678,smoking  %,C0037369;C0453996;C1881674
1678,smoking,C0037369;C0453996;C1881674
1678,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
1678,no smoking,C0037369;C0453996;C1881674
1678,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking — no . / total no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking  n ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking  %,C0037369;C0453996;C0521116;C1705970;C1881674
1678,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
1677,yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
1677,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
1677,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
1677,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1677,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight of < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight in kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1677,weight in kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight group  no . ( % ),C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
1677,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
1677,weight ab  %,C0005910;C0043100;C1305866;C1705104
1677,weight ^,C0005910;C0043100;C1305866;C1705104
1677,weight [ kg ],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight > $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight > $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight < $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight < $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight < $nmbr$,C0005910;C0043100;C1305866;C1705104
1677,weight - kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1677,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
1677,weight ( kg }  median ( min  max },C0005910;C0043100;C0549183;C0876920;C1305866;C1532757;C1705104;C2347635;C2348144;C2939193
1677,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight ( kg ) bmi ( kg / m $nmbr$ ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
1677,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight ( kg )  median ( m / n  max ),C0005910;C0043100;C0549183;C0876920;C1305866;C1532718;C1705104;C2347635;C2348144;C2939193
1677,weight ( kg )  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1677,weight ( kg )  mean   ±   sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight ( kg )  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight ( kg )  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight ( kg )  mean ( s . e . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
1677,weight ( kg )  mean ( s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
1677,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight $nmbr$ - $nmbr$,C0005910;C0043100;C1305866;C1705104
1677,weight $nmbr$ +,C0005910;C0043100;C1305866;C1705104
1677,weight $ $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n,C0005910;C0043100;C1305866;C1319635;C1705104
1677,weight # $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight  lbs,C0005910;C0043100;C0439219;C1305866;C1705104;C3161851
1677,weight  kg mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight  kg duration of pah  n ( % ),C0005910;C0022718;C0030123;C0043100;C0439209;C0449238;C1305866;C1705104;C2926735;C3203102;C4054209;C4284467
1677,weight  kg : mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight  kg *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight  kg ( mean ± s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
1677,weight  kg ( mean $nmbr$ sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight  kg $nmbr$,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight  kg  median ( range ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1514721;C1705104;C2347635;C2348144;C2348147;C2939193;C3542016;C4054209
1677,weight  kg  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight  kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,weight  kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1677,weight,C0005910;C0043100;C1305866;C1705104
1677,total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C0439175;C0439810;C0456081;C1305866;C1705104
1677,plasma dha  mean ( sd ) weight  %,C0005910;C0032105;C0043100;C0142831;C0444504;C1305866;C1550098;C1705104;C2347634;C2348143;C2348308;C2699239;C4521445
1677,per body weight  u / kg,C0005910;C1300561;C1305866
1677,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1677,median weight  kg ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1677,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
1677,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
1677,mean ± s . d . weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
1677,mean weight ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,mean body weight ( sd )  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
1677,mean body weight  kg ( range ),C0005910;C0022718;C0439209;C0444504;C1305866;C1514721;C2347634;C2348143;C2348147;C3542016;C4054209
1677,mean ( sd ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1677,mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0019664;C0019665;C0034510;C0042295;C0043100;C0262512;C0262926;C0439209;C0441074;C0444504;C0457987;C0475211;C0486293;C0549183;C0557651;C0577559;C0577573;C0600653;C0724655;C0750572;C0876920;C0918012;C1096155;C1305866;C1306372;C1318293;C1514721;C1552854;C1637833;C1705104;C1705255;C1706779;C1719797;C2004062;C2347634;C2347635;C2348143;C2348144;C2348147;C2603343;C2699239;C2911648;C2939193;C2986546;C3152252;C3539882;C3542016;C3853635;C4283905
1677,mean ( s . d . ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
1677,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
1677,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
1677,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
1677,bodyweight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight at randonization { ixrs ),C0005910;C1305866
1677,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1677,body weight *,C0005910;C1305866
1677,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight ( kg )  n ( % ),C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight  kg ^,C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight  kg ( sd ),C0005910;C0022718;C0439209;C1305866;C2699239;C4054209
1677,body weight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
1677,body weight  %,C0005910;C1305866
1677,body weight,C0005910;C1305866
1677,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .,C0000723;C0005910;C0008377;C0009667;C0010068;C0011847;C0011849;C0021308;C0031831;C0033095;C0035647;C0038454;C0043100;C0043210;C0168634;C0201950;C0205082;C0205164;C0242492;C0439209;C0439269;C0439475;C0439526;C0441074;C0449820;C0460139;C0475209;C0543421;C0596019;C0804815;C1305866;C1306345;C1320716;C1442488;C1532563;C1705104;C1705224;C1706378;C2700400;C3887665;C4050231;C4284008;C4318856;C4521762;C4552904;C4554100;C4554402
1677,^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .,C0005910;C0011847;C0011849;C0011900;C0020443;C0020538;C0025424;C0043100;C0201950;C0237753;C0428257;C0439269;C0439475;C0439828;C0441074;C0444686;C0449788;C0488055;C0489786;C0543421;C0577559;C0577573;C0600653;C0681906;C0871470;C0918012;C1096155;C1305866;C1306372;C1306620;C1441506;C1522133;C1532563;C1552854;C1637833;C1705104;C1963138;C2347108;C2347109;C2348272;C2700446;C2986546;C3152252;C3539882;C4283905;C4524803
1677,> $nmbr$ kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
1677,> $nmbr$ ( n  % ) weight  kg,C0005910;C0022718;C0043100;C0369718;C0439209;C0441922;C1305866;C1705104;C4054209
1677,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0015663;C0022709;C0023821;C0023824;C0041061;C0043100;C0185098;C0202042;C0205369;C0441074;C0444686;C0455280;C0475211;C0857690;C1305855;C1305866;C1441506;C1511726;C1705104;C1719797;C2911648;C2936173;C3245479;C3714741
1676,renal fmclicn : creatntoe clearance,C0232813;C0699829
1675,renal insufficiency — no . ( % ),C0035078;C1565489
1675,renal insufficiency or failure,C0035078;C1565489
1675,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
1675,renal insufficiency *,C0035078;C1565489
1675,renal insufficiency $nmbr$,C0035078;C1565489
1675,renal insufficiency,C0035078;C1565489
1675,renal failure,C0035078;C1963154
1674,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
1674,lack of efficacy with > $nmbr$ bdmard,C0235828
1674,lack of efficacy with > $nmbr$ anti - interleukin $nmbr$,C0235828
1674,lack of efficacy,C0235828
1674,lack of effectiveness,C0235828
1673,number of treated patients,C1522326;C2360800
1673,number of patients with fractures,C2360800
1673,number of patients with exacerbations in the previous $nmbr$ months  n ( % ),C2360800
1673,number of patients with events,C2360800
1673,number of patients with dose available,C2360800
1673,number of patients with available data,C2360800
1673,number of patients with,C2360800
1673,number of patients randomized,C2360800
1673,number of patients > $nmbr$ years ( % ),C0439234;C2360800
1673,number of patients ( % ) or mean 士 sd,C2360800
1673,number of patients ( % ) or mean ± sd,C2360800
1673,number of patients,C2360800
1673,number of ( % ) patients > $nmbr$ years,C0439234;C2360800
1673,number ( % ) of patients with event,C2360800
1673,number ( % ) of patients,C2360800
1672,number of hospitalizations in last year prior to baseline,C4086639
1672,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
1671,number of medications  n ( % ),C1718138
1671,number of antihypertensive medications used  n ( % ) no antihypertensive therapy,C0003364;C1718138
1671,number of antihypertensive medications at study entry,C0003364;C1718138
1671,number of antihypertensive medications  n ( % ),C0003364;C1718138
1670,numbers of events ( % ) :,C4330837
1670,number of events ( annualised rate [ % ] ),C4330837
1670,number of events  event per $nmbr$ person - years,C4330837
1670,number of events,C4330837
1669,number of treated lesions ( per patient ),C0449791;C1522326
1669,number of treated lesions,C0449791;C1522326
1669,number of lesions  n ( % ) a,C0449791
1668,number of individuals,C1549735
1667,number of visits  median,C1549755
1667,number of visits  mean ± sd,C0444504;C1549755;C2347634;C2348143;C2699239
1666,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
1666,type of event — no . ( % ),C1561488
1666,type of event :,C1561488
1666,type of event,C1561488
1665,type of treatment  n ( % ),C0455708
1665,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
1664,extent of disease — no . / total no . ( % ) § ^ |,C0449279;C4553144
1664,extent of disease  n ( % ),C0449279;C4553144
1664,extent of disease  %,C0449279;C4553144
1664,extent of disease,C0449279;C4553144
1664,angiographic extent of disease,C0002978;C0449279;C4553144
1663,sleeping problems in the past $nmbr$ weeks ( % ),C0700201;C2987125
1663,night - time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C2987125
1663,night - time awakenings in past $nmbr$ weeks ( sd ) *,C0860510;C2699239;C2987125
1662,pneumonia in past year,C0032285;C4086728
1662,over past $nmbr$ years  n ( % ),C4086728
1662,cigarette smoking in the past year,C0239059;C0700219;C4086728
1661,younger subjects ( aged < $nmbr$ years ),C0332239
1661,younger patients ( aged $nmbr$ years ),C0030705;C0332239
1660,older subjects ( aged > $nmbr$ years ',C0580836
1660,older patients ( aged > $nmbr$ years ),C0030705;C0580836
1659,age at diagnosis s $nmbr$ years,C0439234;C1828181;C3173302
1659,age at diagnosis of sle  years,C0024141;C0439234;C1828181;C3173302
1659,age at diagnosis of ln  years,C0439234;C0861352;C1428884;C1828181;C3173302;C3714709
1659,age at diagnosis < $nmbr$ years,C0439234;C1828181;C3173302
1659,age at diagnosis  y,C1828181;C3173302
1659,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
1658,peri - or postmenopausal,C0347985
1658,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
1658,peri - op statins : no ( n = $nmbr$ ),C0347985;C0360714
1658,peri - op beta - blockers : no ( n = $nmbr$ ),C0001645;C0347985
1657,beta - carotene ( n = $nmbr$  $nmbr$ ),C0053396;C0696105
1657,beta - carotene,C0053396;C0696105
1656,phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ ),C0031676;C0202177;C0441889;C1719844
1655,omega - $nmbr$ fatty acids,C0015684;C1719844
1655,omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl ),C0015684;C1719844
1655,omega - $nmbr$ fatty acid ( n = $nmbr$ ),C0015684;C1719844
1655,omega - $nmbr$ fatty acid,C0015684;C1719844
1655,omega - $nmbr$ fa ( n = $nmbr$ ),C1719844
1655,omega - $nmbr$ fa,C1719844
1655,number omega - $nmbr$ number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
1655,a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo,C0015684;C0451306;C1719844
1654,panel b,C0441833;C1706365;C1999270
1654,panel a,C0441833;C1706365;C1999270
1654,device group,C1706365
1653,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
1653,place !,C0442504;C1533810;C1704765;C1882509
1652,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
1652,non - diabetic patients,C0241863;C1829939
1652,diabetics,C0241863
1652,diabetic treatments !,C0087111;C0241863
1652,diabetic status  n ( % ),C0241863;C0449438
1652,diabetic status,C0241863;C0449438
1652,diabetic patients,C0030705;C0241863
1652,diabetic no,C0241863
1652,diabetic $nmbr$,C0241863
1652,diabetic,C0241863
1652,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
1651,diabetics • no ( n = $nmbr$  $nmbr$ ),C0241863
1651,diabetics - yes ( n = $nmbr$  $nmbr$ ),C0241863;C1549445;C1705108;C1710701
1651,diabetics - no ( n = $nmbr$  $nmbr$ ),C0241863
1651,diabetics ( n = $nmbr$ ),C0241863
1651,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
1651,diabetic ( no ),C0241863
1651,diabetic  n ( % ),C0241863
1650,atonic,C0541791
1649,estonia,C0014908
1648,piroxicam,C0031990
1647,meloxicam,C0083381
1646,ethacrynic acid,C0014963
1645,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
1645,zoledronic acid ( n = $nmbr$ ),C0257685
1645,zoledronic acid,C0257685
1644,valdecoxib,C0913246
1643,rofecoxib,C0762662
1642,celecoxib ( n = $nmbr$ ),C0538927
1642,celecoxib,C0538927
1641,etoricoxib group ( n = $nmbr$ $nmbr$ ),C0441848;C0972314
1641,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
1641,etoricoxib ( n = $nmbr$ ),C0972314
1641,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314
1641,etoricoxib ( n = $nmbr$  $nmbr$ ),C0972314
1641,etoricoxib,C0972314
1640,colonoscopy,C0009378;C1548837
1639,autonomic neuropathy,C0259749
1638,tonic – clonic,C3543842
1638,tonic,C3543842
1637,topical therapy,C0039798;C0087111;C0332237;C1363945
1637,topical prescription,C0033080;C0332237;C1521941
1637,topical non - prescription,C0033080;C0332237;C1518422;C1521941
1637,topical,C0332237
1636,nsclc,C0007131
1636,non – small - cell lung cancer,C0007131;C2984258;C3539721
1635,endothelin - receptor antagonists,C1134681;C2266875
1634,leukotriene receptor antagonists,C0595726;C2757015;C3542962
1634,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
1633,mineralcorticoid receptor antagonist,C4543207
1633,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
1632,mineralocorticoid receptor antagonists,C1373021;C1579268
1632,mineralocorticoid receptor antagonist n ( % ),C1579268
1632,mineralocorticoid receptor antagonist,C1579268
1632,aldosterone receptor antagonists,C1579268
1631,glucagon - like peptide - $nmbr$ receptor agonist,C0014361;C4543206
1631,glucagon - like peptide - $nmbr$ agonist,C0014361;C2987634
1630,rheumatoid arthritis,C0003873
1630,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
1630,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
1630,duration of rheumatoid arthritis  year,C0003873;C0439234;C0439508;C0449238;C2926735
1629,postbaseline binding antibodies,C0003241;C1145667;C1167622
1628,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
1627,vitamin k antagonists,C3653316
1626,histamine - $nmbr$ - receptor antagonist,C0019590;C4521896
1626,anti - histamines,C0019590
1625,patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C3863761
1625,dactylitis in > $nmbr$ digit,C3863761
1624,direct thrombin inhibitors,C0003440;C3541936
1624,antithrombin,C0003438;C0003440;C4521254
1623,dip joint arthritis,C0003864;C0932510;C4552845
1623,arthritis type *,C0003864;C0332307;C1547052;C4552845
1623,arthritis,C0003864;C4552845
1622,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
1622,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
1622,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
1622,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
1622,rec . ischemia leading to hosp,C0022116;C1424025;C2606415;C4321499
1622,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
1622,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
1622,rec . ischemia due to ecg changes,C0022116;C0678226;C1424025;C1623258;C2606415;C4321499
1622,rec . ischemia,C0022116;C1424025;C2606415;C4321499
1622,no ischemia ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1622,ischemia on cecg ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1622,ischemia on cecg ( % ),C0022116;C4321499
1622,ischemia driven revascularization,C0022116;C4321499
1622,ischemia - driven revascularization,C0022116;C4321499
1622,ischemia,C0022116;C4321499
1622,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
1622,global ischemia,C0022116;C0205246;C2348867;C4321499
1622,anti - ischaemia agents *,C0022116;C0040616;C4321499
1621,nyha ii  n ( % ),C1275491;C1710602;C4082587
1621,nyha ii,C1275491;C1710602;C4082587
1621,nyha,C1275491
1621,( nyha grade iii or iv ),C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4283820;C4283821;C4283822
1620,nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline,C1275491
1620,nyha functional classification — no . ( % ) i,C0205245;C0542341;C1275491;C2700217
1620,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
1619,no known frtrontxtfufoc cond aon,C0205309
1619,known tiromtcch * c ccndifeon,C0205309
1619,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
1619,known prothrombotic genotype,C0017431;C0205309
1618,non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
1618,non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
1618,non - smokers receiving lipid - lowering drugs  p blockers,C0337672;C4554605
1618,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
1617,amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1617,amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg,C1962523
1617,amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1617,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1617,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1617,amlodipine - amlodipine / valsartan,C1962523
1616,d - dimer levelsatinclusion,C0060323
1616,d - dimer ( ng / ml ),C0060323;C0439275
1615,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439775;C0441889;C0702240
1615,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1615,elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1615,cardiac biomarker elevation,C0439775;C0702240;C1271630
1614,current non - smoker,C0425311
1613,maintenance dose,C3714445
1612,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
1611,transient monocular blindness,C0149793
1610,regadenoson ( n = $nmbr$ ),C1698215
1610,regadenoson,C1698215
1609,peri - op amiodarone : no ( n = $nmbr$ ),C0002598;C0347985
1609,no amiodarone,C0002598
1609,i amiodarone,C0002598;C0021966;C0221138
1609,amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0002598
1609,amiodarone,C0002598
1608,amiodarone vs . placebo,C0002598
1608,amiodarone use at baseline yes $nmbr$  $nmbr$,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
1608,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
1608,amiodarone ote at baseline,C0002598;C0168634;C1442488
1608,amiodarone ( n = $nmbr$ ),C0002598
1608,amiodarone ( n  % ),C0002598
1608,amiodarone  n ( % ),C0002598
1607,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
1607,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
1607,education level,C0013621;C0013658
1607,education in years  mean,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143
1607,education > $nmbr$ yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
1607,education > $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1607,education > $nmbr$ y,C0013621;C0013622;C0013658;C0039401
1607,education < $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1607,education < $nmbr$ y,C0013621;C0013622;C0013658;C0039401
1607,education *,C0013621;C0013622;C0013658;C0039401
1607,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
1607,education ( % ),C0013621;C0013622;C0013658;C0039401
1607,education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
1607,education $nmbr$ - $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1607,education  y,C0013621;C0013622;C0013658;C0039401
1607,education,C0013621;C0013622;C0013658;C0039401
1607,age of completion of highest education  years ( sd ),C0013621;C0013622;C0013658;C0039401;C0205197;C1510829;C1522410;C1554962;C2699239
1607,> $nmbr$ years education,C0013621;C0013622;C0013658;C0039401;C0439234
1607,< $nmbr$ yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
1606,pravastatin vs usual care,C0085542
1606,pravastatin n = $nmbr$,C0085542
1606,pravastatin ( n = $nmbr$ >,C0085542
1606,pravastatin ( n = $nmbr$ ),C0085542
1606,pravastatin,C0085542
1606,diet plus pravastatin group ( n = $nmbr$ ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
1606,diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
1606,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1606,diet - i - pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
1606,diet + pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1606,diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1606,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1606,atorvastatin - pravastatin,C0085542;C0286651
1605,years [ range ],C0439234;C1514721;C2348147;C3542016
1605,total scores ( total score range : $nmbr$ - $nmbr$ ),C1514721;C2348147;C2964552;C3542016
1605,selena - sledai ( range u - $nmbr$ u $nmbr$ ) t,C0439148;C0451528;C1514721;C2348147;C3542016
1605,range of sbp,C0085805;C1514721;C2348147;C3542016
1605,range,C1514721;C2348147;C3542016
1605,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
1605,motor subscale ( range  $nmbr$ - $nmbr$ ),C1513492;C1514721;C1705994;C2348147;C3542016
1605,median pasi score { range ) ' i  i ',C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
1605,mean daily dose ( range ) — mg  i,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
1605,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1605,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1605,mean age  years ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
1605,mean age  y : ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1605,mean age  y ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1605,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
1605,health assessment questionnaire ( $nmbr$ - $nmbr$ range ),C0451208;C1514721;C2348147;C3542016
1605,haq di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
1605,haq - di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
1605,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
1605,age yr  range,C0001779;C0439234;C1514721;C2348147;C3542016
1605,age y  median ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1605,age range  y,C0001779;C1514721;C2348147;C3542016
1605,age range,C0001779;C1514721;C2348147;C3542016
1605,age [ years ]  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1605,age ( years )  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1605,age ( y )  mean ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1605,age  years : median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1605,age  years  mean ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
1605,adl subscale ( range  $nmbr$ - $nmbr$ ) *,C0001288;C1420005;C1514721;C2348147;C3542016
1605,( range ),C1514721;C2348147;C3542016
1605,$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
1605,$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
1604,right ventriculardysfunction atinclusion,C0205090;C0444532
1604,right,C0205090;C0444532
1604,r | r ' ' ' ( $nmbr$ % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
1604,r ight coronary,C0205090;C0684010;C2603358
1604,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
1604,r $nmbr$,C0205090;C0684010;C2603358
1604,r,C0205090;C0684010;C2603358
1604,c  right - sided vhd ( n = $nmbr$ ),C0205090;C0444532
1604,> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental,C0205090;C0451306;C0684010;C2603358
1603,bivalirudin used during pci,C0168273
1603,bivalirudin used,C0168273
1603,bivalirudin only,C0168273;C0205171;C1720467
1603,bivalirudin alone ( n = $nmbr$ ),C0168273;C0205171;C0439044;C0679994
1603,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
1603,bivalirudin ( n = $nmbr$ ),C0168273
1603,bivalirudin ( n = $nmbr$  $nmbr$ ),C0168273
1603,bivalirudin,C0168273
1602,ivabradine group ( n = $nmbr$ ),C0257190;C0441848
1602,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1602,ivabradine ( n = $nmbr$ ),C0257190
1602,ivabradine,C0257190
1601,rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0332287;C1739768
1601,rivaroxaban plus aspirin ( n = $nmbr$ ),C0004057;C0332287;C1739768
1601,rivaroxaban plus aspirin ( $nmbr$ % cl ),C0004057;C0332287;C0596019;C1739768
1601,rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0205171;C0439044;C0679994;C1739768
1601,rivaroxaban alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C1739768
1601,rivaroxaban + aspirin,C0004057;C1739768
1601,rivaroxaban ( n   = $nmbr$ ),C1739768
1601,rivaroxaban ( n = $nmbr$ ),C1739768
1601,rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
1601,low - dose rivaroxaban plus aspirin ( n = $nmbr$ ),C0332287;C1739768;C2608320
1601,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
1600,rivaroxaban plus,C1739768
1600,rivaroxaban +,C1739768
1600,rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
1600,rivaroxaban,C1739768
1599,stratum ii,C1710602;C4082587
1599,period ii,C0439531;C1710602;C1948053;C4082587
1599,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
1599,lavolta ii,C1710602;C4082587
1599,ii chiorthaiidone amiodipine,C1710602;C4082587
1599,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
1599,ii - iv,C0022326;C1710602;C4082587;C4265176
1599,ii ( n = $nmbr$ ),C1710602;C4082587
1599,ii $nmbr$ ( ii . $nmbr$ ),C1710602;C4082587
1599,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
1598,not hispanic or latino ( n — $nmbr$ ),C1518424
1598,not hispanic or latino ( n = $nmbr$ ),C1518424
1598,not hispanic or latino,C1518424
1598,not hispanic / latino ( n = $nmbr$  $nmbr$ ),C0086528;C1518424
1598,not hispanic / latino,C0086528;C1518424
1598,not hispanic,C1518424
1598,non - hispanic white,C0007457;C0043157;C0220938;C1518424
1598,non - hispanic or latino,C1518424
1598,non - hispanic and latino,C1518424
1598,non - hispanic / latino,C0086528;C1518424
1598,non - hispanic  non - latino,C0086528;C1518424
1598,non - hispanic,C1518424
1597,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1597,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1597,white hispanic - n ( % ),C1533020;C1533021
1597,white hispanic,C1533020;C1533021
1597,white  non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
1596,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
1596,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
1596,black hispanic - n ( % ),C1533017;C1533018
1596,black hispanic,C1533017;C1533018
1596,black  non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
1596,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0220938;C0439541;C1533017;C1533018;C1533020;C1533021
1595,hispanic — no . ( % ),C0086409
1595,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409
1595,hispanic or latino ethnic groupf,C0086409
1595,hispanic or latino ethnic groupb,C0086409
1595,hispanic or latino ethnic group *,C0086409
1595,hispanic or latino ethnic group !,C0086409
1595,hispanic or latino ( n — $nmbr$ ),C0086409
1595,hispanic or latino ( n = $nmbr$ ),C0086409
1595,hispanic or latino,C0086409
1595,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0086409;C1879937
1595,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C1879937
1595,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
1595,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937
1595,hispanic ethnic group  n ( % ),C0015031;C0086409;C0441848;C0680174
1595,hispanic / non - hispanic,C0086409;C1518422
1595,hispanic / latino ethnicity  n ( % ),C0015031;C0086409;C0086528;C0243103
1595,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
1595,hispanic / latino ( n = $nmbr$ ),C0086409;C0086528
1595,hispanic ( n = $nmbr$ l $nmbr$ ),C0086409
1595,hispanic ( n = $nmbr$ ),C0086409
1595,hispanic  n ( % ),C0086409
1595,ethnicitya hispanic or latino,C0086409
1595,ethnicity - - hispanic or latino,C0015031;C0086409;C0243103
1594,mixed hispanic,C0086409;C0205430;C3160715
1594,hispanic,C0086409
1594,biack hispanic,C0086409
1594,american hispanic ( n   = $nmbr$ ),C0086409;C0596070
1593,exercise category ( % ),C3669314
1592,age categories ( y )  n ( % ),C2916832
1592,age categories  n ( % ),C2916832
1592,age categories,C2916832
1591,associated with hiv infection,C0019693;C0332281
1591,associated with drug or toxin exposure,C0013227;C0332281;C1254351
1591,associated with drug / toxin,C0013221;C0332281
1591,associated with ctd,C0332281;C1335071;C1442905
1591,associated with corrected,C0205202;C0332281
1591,associated with an atrial septal defect,C0018817;C0332281
1590,rest ofworld,C0035253;C1622890
1590,rest ofthe world,C0035253;C1622890;C2700280
1590,rest of world n z $nmbr$,C0035253;C1622890;C2700280
1590,rest of world,C0035253;C1622890;C2700280
1590,rest of the world,C0035253;C1622890;C2700280
1590,rest - of - world ( n = $nmbr$ ),C0035253;C1622890;C2700280
1590,pao $nmbr$ at rest  mm hg,C0035253;C0232555;C0439475;C1423784;C1427155;C1622890;C4318615
1590,heart rate at rest — beats / min,C0018810;C0035253;C1622890
1590,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C1622890
1590,aapo $nmbr$ at rest  mm hg,C0035253;C0439475;C1622890
1589,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
1589,prostate volume ( cm $nmbr$ ),C1441416
1588,brain volume  cm ',C1113695
1588,brain volume  cm $nmbr$,C1113695
1587,voided volume  ml,C0042034;C0439526;C0449468;C1552835;C1690016;C1705102;C1705224;C2700258;C3887665
1587,t $nmbr$ lesion volume  mm ',C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
1587,t $nmbr$ lesion volume  mm $nmbr$,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
1587,normalized volume measures,C0449468;C1690016;C1705102;C1882115;C2700258
1586,the american college of rheumatology ) .,C0035452;C0557806;C0596070
1586,some college / tech,C0557806;C1826596
1586,some college,C0557806
1586,college degree or higher,C0441889;C0449286;C0542560;C0557806;C2348088
1585,olmesartan along with diuretic ( n - $nmbr$ ),C0012798;C1098320
1585,olmesartan along with ccb ( n - $nmbr$ ),C0006684;C1098320
1585,olmesartan / ccb - olmesartan / diuretic,C0006684;C1098320
1585,olmesartan ( n = $nmbr$ ),C1098320
1584,lesion length ≥ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1584,lesion length > $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1584,lesion length $ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1584,laa length,C1444754;C1706316
1583,stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive,C0007591;C0017654;C0021966;C0023806;C0221138;C0332257;C0369637;C0439445;C0441766;C0441923;C0456533;C0702093;C1424601;C1524029;C3813700
1583,gfr as assessed by mdrd,C0017654;C1424601
1583,gfr > $nmbr$,C0017654;C1424601
1583,gfr < $nmbr$,C0017654;C1424601
1583,gfr ( ml / min per $nmbr$ . $nmbr$ nr ),C0017654;C0027496;C0439445;C1424601;C3844738
1583,gfr $nmbr$ - $nmbr$,C0017654;C1424601
1583,gfr $nmbr$ $nmbr$,C0017654;C1424601
1583,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
1583,estimated gfr — no . ( % ) $nmbr$,C0017654;C0750572;C1424601
1583,estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
1583,estimated gfr at baseline  ml • min $nmbr$,C0017654;C0168634;C0439445;C0750572;C1424601;C1442488
1583,estimated gfr ^,C0017654;C0750572;C1424601
1583,estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
1583,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
1583,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
1583,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601;C2699239
1583,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr  ml / min,C0017654;C0439445;C0750572;C1424601
1583,estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *,C0017654;C0369637;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
1583,estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1583,estimated gfr,C0017654;C0750572;C1424601
1583,by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0076836;C0241863;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732
1583,by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !,C0017654;C0076836;C1199517;C1419603;C1424601;C3539732
1583,by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0241863;C0679646;C0702093;C1424601;C1524029;C3813700
1583,by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !,C0017654;C0439445;C0679646;C1424601
1582,glomerular filtration rate §,C0017654;C1561549
1582,glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma,C0017654;C0024443;C0439445;C1561549;C3887485
1582,glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1561549
1581,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
1581,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
1581,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
1581,lipid - lowerinq druq,C0023779
1580,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
1580,lipids — mg / dl,C0023779;C0439269
1580,lipid measures at baseline — mg / dl,C0023779
1580,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
1579,lipids,C0023779
1579,lipid values  mmol / l,C0023779;C0042295;C1532563
1579,lipid values,C0023779;C0042295
1579,lipid trial participantss,C0008976;C0023779
1579,lipid trial participantsk,C0008976;C0023779
1579,lipid modifiers,C0023779;C4284280
1579,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
1579,lipid concentrations,C0023779;C0086045
1579,lipid and lipoprotein values ( mg / dl ),C0023779
1579,lipid,C0023779
1579,drinking  n ( % ) lipid values  mmol / l,C0001948;C0023779;C0042295;C0684271;C1532563
1578,troponin positive ( n = $nmbr$ ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
1578,ruled out non - fatal pe with or,C1446409
1578,rf positive ( > $nmbr$ iu / ml )  n ( % ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1578,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1578,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1578,rf - positive  > $nmbr$ iu / ml  %,C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1578,rf  % positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1578,positive vs . negative,C0439178;C1446409;C1514241;C2825490;C3812269
1578,positive troponin or ck - mb,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
1578,positive troponin i or t  no . ( % ),C0077401;C0439178;C1446409;C1514241;C2825490;C3812269
1578,positive hla - b $nmbr$ status  n ( % ),C0439178;C0449438;C1426226;C1446409;C1514241;C2825490;C3812269
1578,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1578,positive for hla - b $nmbr$  n ( % ),C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
1578,positive cu index test  z n ( % ),C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
1578,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
1578,positive ctnl ( n = $nmbr$ ),C0439178;C1446409;C1514241;C2825490;C3812269
1578,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
1578,positive,C0439178;C1446409;C1514241;C2825490;C3812269
1578,low complement / anti - dsdna positive ( n = $nmbr$ ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
1578,hla ‐ b $nmbr$ positive    n   ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
1578,hla - b $nmbr$ positive at baseline  n ( % ),C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
1578,hla - b $nmbr$ positive  n ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
1578,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1578,anticyclic citrullinated peptide positive ^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
1578,anti - gad positive ( n = $nmbr$ ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1578,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
1578,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
1578,anti - ccp positive ( > $nmbr$ u / ml )  n ( % ),C0432633;C0439178;C0439340;C1446409;C1514241;C1525410;C1704514;C1880521;C2825490;C2945590;C3812269
1578,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
1578,acpa positive ( > $nmbr$ iu / ml )  n ( % ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1578,acpa positive  no . ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1578,acpa positive  n ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1578,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1578,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
1578,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
1577,basal insulin doset,C0650607
1577,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
1577,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
1577,basal insulin,C0650607
1576,insulin detemir,C0537270
1576,detemir / insulin glargine  %,C0537270;C0907402
1575,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
1575,linagliptin ( n z $nmbr$ ),C2746078
1575,linagliptin ( n = $nmbr$ ) ',C2746078
1575,linagliptin ( n = $nmbr$ ),C2746078
1575,linagliptin,C2746078
1575,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
1574,teaes in a $nmbr$ % of individuals,C0027361;C0237401
1574,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C1709707
1574,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0237401;C1709707
1574,other individual and exploratory end points,C0027361;C0237401
1574,normoglycaemic individuals  n ( % ),C0027361;C0237401;C0580545
1574,no . ( % ) of individuals *,C0027361;C0237401
1574,individuals with type $nmbr$ diabetes  n ( % ),C0027361;C0237401;C1320657
1574,individuals with prediabetes,C0027361;C0237401;C0362046
1574,individuals with pre - diabetes  n ( % ),C0027361;C0237401;C0362046
1574,individuals with normoglycaemia,C0027361;C0237401;C0580545
1574,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
1574,individual endpoints,C0027361;C0237401;C2349179
1573,class iv only,C0205171;C0441888;C1720467;C2698970
1573,class iv glomerulonephritis,C0017658;C0441888;C2698970
1573,class iv,C0441888;C2698970
1572,class ii ( b - blockers ),C0441886;C2698968
1572,class ii,C0441886;C2698968
1572,class > ii,C0441886;C2698968
1571,class i or no symptoms,C0441885;C1319793;C2698967
1571,class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967
1571,class i,C0441885;C1319793;C2698967
1570,time from ra diagnosis  years  median,C0011900;C0556970;C1704338;C1704656;C3538806;C4048756
1570,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
1570,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
1570,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
1570,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
1570,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
1570,diagnosis of hefh  n ( % ),C0011900;C1704338;C1704656
1570,diagnosis of diabetes  n ( % ),C0011847;C0011849;C0011900;C1704338;C1704656
1570,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
1570,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
1570,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
1570,diagnosed  y,C0011900
1570,af first diagnosis > $nmbr$ years  n ( % ),C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
1569,use of supplemental oxygen  n ( % ),C4067893;C4554557
1568,supplementary oxygen,C0030054
1568,supplemental oxygen,C4534306
1567,st segment elevation,C0520886
1567,st elevation,C0520886
1567,st - segment elevation mi,C0520886;C3810814
1567,st - segment elevation,C0520886
1567,st - elevation mi,C0520886;C3810814
1566,isolated upper gastrointestinal disease behavior  n ( % ),C0004927;C0205409;C0810300;C1548221;C2707008
1566,isolated pulmonary embolism,C0034065;C0205409;C1548221
1566,isolated impaired glucose tolerance — no .,C0205409;C1548221
1566,isolated igt,C0205409;C1548221
1565,no in - trial stroke n = $nmbr$  $nmbr$,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
1565,in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$,C0008976;C0150312;C0332285;C1707101
1565,in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0150312;C0332285;C1707101
1565,in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1521828;C1707101;C3541888;C4288115
1565,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
1565,in - clinic uas $nmbr$,C0002424;C0150312;C0332285;C0442592;C1707101
1564,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
1564,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
1564,presence of honeycombing  $nmbr$ n ( % ),C0150312;C0332468;C0349384;C0392148;C3854307
1564,presence of erosions  n ( % ),C0150312;C0333307;C0392148;C1959609;C3854307
1564,presence of enthesitis  n ( % ),C0150312;C0392148;C1282952;C3854307
1564,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
1564,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
1564,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
1564,presence of angioedema at baseline,C0002994;C0150312;C0392148;C3854307
1563,orthopnea  frequent / continuous,C0085619;C0332183;C0549178
1563,most frequent serious teaes,C0205393;C0205404;C0332183
1563,most frequent aesa,C0205393;C0332183
1563,frequent or continuous,C0332183
1563,frequent exacerbator,C0332183
1562,type of drug - eluting stent  n ( % ),C0038257;C0332307;C0457591;C1322815;C1547052
1562,non - drug - eluting stent,C1322815;C1518422
1562,drug eluting stent,C1322815
1562,drug - eluting stent — no . ( % ),C1322815
1562,drug - eluting stent implanted — no . ( % ),C1322815
1562,drug - eluting stent implanted ( at least one ),C1322815
1562,drug - eluting stent implanted,C1322815
1562,drug - eluting stent  n ( % ),C1322815
1562,drug - eluting stent,C1322815
1561,presentation to tertiary care hospital — %,C0337954;C0449450
1561,presentation *,C0449450
1561,dx at presentation  n ( % ),C0449450;C3538936
1561,acs presentation,C0449450;C0742343;C4318612
1560,syndesmophyte present  n ( % ),C0150312;C0221690;C0449450
1560,present smokerc,C0150312;C0449450
1560,present smoker,C0150312;C0337664;C0449450
1560,present ( £ $nmbr$ mg / dl ),C0150312;C0439269;C0449450
1560,present ( > $nmbr$ mg / dl ),C0150312;C0439269;C0449450
1560,present,C0150312;C0449450
1560,dm present,C0011816;C0150312;C0449450;C3250443
1559,week $nmbr$ czp dose combined ( n   =   $nmbr$ ),C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1559,week $nmbr$ czp dose combined,C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1559,sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
1559,rolofylline dose,C0166128;C0178602;C0869039;C1114758
1559,ptrend across doses,C0178602
1559,pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1559,patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % ),C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
1559,methotrexate dose | |  mg,C0024671;C0025677;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1559,methotrexate dose on day $nmbr$ — mg per wl < $nmbr$,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
1559,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
1559,leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
1559,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
1559,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
1559,edoxaban dose adjusted at randomisation  n ( % ) *,C0178602;C0869039;C1114758;C2975435
1559,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
1559,dose reduction at randomization — no . ( % )  i,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1559,dose reduction at randomization  %,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1559,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1559,dose reduced at randomization *,C0178602;C0869039;C1114758
1559,dose ratio at week $nmbr$ ( $nmbr$ % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
1559,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
1559,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
1559,dose adjusted,C0178602;C0869039;C1114758
1559,dose ( n ),C0178602;C0869039;C1114758
1559,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
1559,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1559,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
1559,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
1559,canakinumab dose,C0178602;C0869039;C1114758;C2718773
1559,baseline su dose > $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1559,baseline su dose < $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1559,baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
1559,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
1559,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
1559,all doses ( n = $nmbr$ ),C0178602
1559,all doses,C0178602
1559,( phase $nmbr$ dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
1558,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
1558,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
1558,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
1558,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
1558,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
1558,ldl cholesterol ^ :,C0023824;C0202117
1558,ldl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
1558,ldl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
1558,ldl cholesterol ( sd )  mg / dl,C0023824;C0202117;C0439269;C2699239
1558,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
1558,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
1558,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
1558,ldl cholesterol  mmol / l 丰,C0023824;C0202117;C1532563
1558,ldl cholesterol  mmol / l *,C0023824;C0202117;C1532563
1558,ldl cholesterol  mmol / l,C0023824;C0202117;C1532563
1558,ldl cholesterol  mg / dl,C0023824;C0202117;C0439269
1558,ldl cholesterol,C0023824;C0202117
1558,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
1558,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
1558,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
1558,ldl - cholesterol (,C0023824;C0202117
1558,ldl - cholesterol  mmol / lf,C0023824;C0202117;C0439190;C1416933;C2986618;C4554443
1558,ldl - cholesterol  mmol / l,C0023824;C0202117;C1532563
1558,ldl - cholesterol,C0023824;C0202117
1558,data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .,C0002780;C0023824;C0042295;C0168634;C0202117;C0369718;C0441922;C0871881;C1442488;C1511726;C1711260;C2348152;C3245479;C3714741
1558,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1442488
1558,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
1558,- ldl cholesterol,C0023824;C0202117
1558,$nmbr$ mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
1557,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1557,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
1557,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1557,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
1557,low - density lipoprotein cholesterol  %,C0023824
1557,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
1556,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0018623;C0018787;C0027976;C0030705;C0032042;C0032615;C0042508;C0201950;C0428772;C0439849;C0488728;C0543421;C0596019;C0596306;C0699792;C1275491;C1696465;C1704610;C1706408
1556,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0004083;C0018787;C0027976;C0201950;C0428772;C0439849;C0543421;C0596019;C0596306;C0699792
1556,total cholesterol ^,C0201950;C0543421
1556,total cholesterol *,C0201950;C0543421
1556,total cholesterol ( week $nmbr$ ),C0201950;C0332174;C0439230;C0543421
1556,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
1556,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
1556,total cholesterol ( mmo $nmbr$ / $nmbr$ ),C0201950;C0543421
1556,total cholesterol  mmol / l 本,C0201950;C0543421;C1532563
1556,total cholesterol  mmol / l ( sd ),C0201950;C0543421;C1532563;C2699239
1556,total cholesterol  mmol / l,C0201950;C0543421;C1532563
1556,total cholesterol  %,C0201950;C0543421
1556,total cholesterol,C0201950;C0543421
1556,tertile of total cholesterol at baseline  mean ( sd )  mmol / l,C0201950;C0543421
1556,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1555,eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0003591;C0003594;C0008377;C0023821;C0023824;C0024671;C0026410;C0031529;C0033684;C0039225;C0041004;C0201950;C0439267;C0439269;C0543421;C0577559;C0577573;C0600653;C0674390;C0918012;C1096155;C1142985;C1306372;C1532737;C1538326;C1552854;C1637833;C1705223;C1960952;C2346927;C2986546;C3152252;C3539882;C3541325;C3891451;C4054077;C4283905;C4319774;C4321396;C4521761
1555,apolipoprotein,C0003591
1555,* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0003591;C0008377;C0009247;C0023189;C0023821;C0023822;C0036919;C0039411;C0040642;C0041004;C0041405;C0041698;C0062152;C0065055;C0074554;C0178587;C0178602;C0201950;C0337445;C0369773;C0439175;C0439751;C0439810;C0444504;C0444667;C0543421;C0549183;C0599755;C0729627;C0876920;C1142985;C1518422;C1708438;C1709595;C1710181;C1824670;C2347634;C2347635;C2348143;C2348144;C2349200;C2603361;C2939193;C3272447;C3715113;C4522122;C4522255
1554,use of ace inhibitors / arbs  n ( % ),C0003015;C1524063;C3888198
1554,use of ace inhibitor  arb  or both — no . ( % ),C0003015;C1524063;C3888198;C4541021
1554,no ace inhibitor / arb,C0003015;C3888198;C4541021
1554,neither ace inhibitor nor arb,C0003015;C4541021
1554,both ace inhibitor and arb,C0003015;C4541021
1554,ace inhibitors or arbs,C0003015
1554,ace inhibitors or arb,C0003015
1554,ace inhibitors or angiotensin receptor blockers,C0003015
1554,ace inhibitors or angiotensin ii blockers,C0003015
1554,ace inhibitors or angiotensin ii,C0003015
1554,ace inhibitors or angiotensin - receptor blockers ^,C0003015
1554,ace inhibitors or angiotensin - receptor blockers,C0003015
1554,ace inhibitors and arb,C0003015
1554,ace inhibitors / sartans,C0003015;C1563745
1554,ace inhibitors / arbs  n ( % ),C0003015;C3888198
1554,ace inhibitors / arbs,C0003015;C3888198
1554,ace inhibitors / arb,C0003015
1554,ace inhibitors,C0003015
1554,ace inhibitor — no . ( % ),C0003015;C4541021
1554,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
1554,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
1554,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
1554,ace inhibitor or arb use,C0003015;C4541021
1554,ace inhibitor or arb at last follow - up,C0003015;C4541021
1554,ace inhibitor or arb at enrollment,C0003015;C4541021
1554,ace inhibitor or arb,C0003015;C4541021
1554,ace inhibitor or angiotensin receptor blocker,C0003015;C4541021
1554,ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021
1554,ace inhibitor or angiotensin ii receptor,C0003015;C4541021
1554,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C4541021
1554,ace inhibitor monotherapy,C0003015;C4541021
1554,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
1554,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
1554,ace inhibitor and / or arb,C0003015;C4541021
1554,ace inhibitor / arb  %,C0003015;C3888198;C4541021
1554,ace inhibitor / arb,C0003015;C3888198;C4541021
1554,ace inhibitor  n ( % ),C0003015;C4541021
1554,ace inhibitor  arb  or both,C0003015;C3888198;C4541021
1554,ace inhibitor  %,C0003015;C4541021
1554,ace inhibitor,C0003015;C4541021
1554,ace - inhibitors / arbs  n ( % ),C0003015;C3888198
1554,ace - inhibitors  n ( % ),C0003015
1554,ace - inhibitors,C0003015
1554,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
1554,ace - inhibitor or arb ( % ),C0003015;C4541021
1553,dipeptidyl peptidase - $nmbr$ inhibitor,C0003015;C2757044;C3536837
1553,dipeptidyl peptidase $nmbr$ inhibitors,C0003015
1553,dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
1553,angiotensin - converting enzyme inhibitors ^,C0003015;C2757044
1553,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
1553,angiotensin - converting enzyme inhibitors,C0003015;C2757044
1553,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C2757044;C3536837;C4541021
1553,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
1553,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
1553,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
1553,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
1553,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C2757044;C3536837;C4541021
1553,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
1553,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0006684;C0014122;C0022067;C0025424;C0042295;C0428257;C0439385;C0439453;C0444504;C0597357;C1319894;C1881173;C2347108;C2347109;C2347634;C2348143;C2348272;C2757044;C3536837;C3536851;C3888198;C4521885;C4541021;C4554371
1552,meglitinides ( glinides ),C0065880;C1579432;C3537178
1552,meglitinide,C0065880
1551,nateglinide n / n,C0903898
1551,nateglinide and repaglinide,C0903898
1551,nateglinide ( n = $nmbr$ ),C0903898
1550,biguanides ¶,C0005382;C0360396;C3540012
1550,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
1550,biguanides,C0005382;C0360396;C3540012
1550,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
1550,biguanide,C0005382;C3537187;C4317165
1549,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
1549,ideglira - ideg - lira,C1555441;C4308663
1549,ideglira - ideg,C4308663
1549,ideglira,C4308663
1548,triglycerides — mmol / liter,C0041004;C0439190;C0475211
1548,triglycerides — mmol / l,C0041004;C1532563
1548,triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
1548,triglycerides > $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
1548,triglycerides < $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
1548,triglycerides ( mmol / l ) :,C0041004;C1532563
1548,triglycerides ( mmol / l ),C0041004;C1532563
1548,triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
1548,triglycerides  mmol / lf,C0041004;C0439190;C1416933;C2986618;C4554443
1548,triglycerides  mmol / l ®,C0041004;C1532563
1548,triglycerides  mmol / l §,C0041004;C1532563
1548,triglycerides  mmol / l,C0041004;C1532563
1548,triglycerides  mg / l,C0041004;C0439268
1548,triglycerides  * mmol / l,C0041004;C1532563
1548,triglyceride ( mmol / l ) t,C0041004;C1532563
1548,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
1548,triglyceride ( mmol / l ),C0041004;C1532563
1548,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
1548,triglyceride  mmol / l,C0041004;C1532563
1547,triglycerides — mg / dl | |,C0041004;C0439269
1547,triglycerides — mg / dl ^,C0041004;C0439269
1547,triglycerides — mg / dl,C0041004;C0439269
1547,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1547,triglycerides mean,C0041004;C0444504;C2347634;C2348143
1547,triglycerides > $nmbr$ mg / dl,C0041004;C0439269
1547,triglycerides - mg / dl * *,C0041004;C0439269
1547,triglycerides * *,C0041004
1547,triglycerides * ( mg / dl ),C0041004;C0439269
1547,triglycerides *,C0041004
1547,triglycerides ( sd )  mg / dl,C0041004;C0439269;C2699239
1547,triglycerides ( mg / dl ) * *,C0041004;C0439269
1547,triglycerides ( mg / dl ),C0041004;C0439269
1547,triglycerides  mg / dl ^,C0041004;C0439269
1547,triglycerides  mg / dl,C0041004;C0439269
1547,triglycerides,C0041004
1547,triglyceride a,C0041004
1547,triglyceride ( mg / dl ) $nmbr$,C0041004;C0439269
1547,triglyceride ( mg / dl ),C0041004;C0439269
1547,triglyceride,C0041004
1547,- triglycerides,C0041004
1547,$nmbr$ . $nmbr$ mg / dl triglycerides ^,C0041004;C0439269
1546,triglycerides level  mg / dl,C0428475;C0439269
1546,triglyceride level,C0428475
1545,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
1545,budesonide - formoterol ( n = $nmbr$ ),C1276807
1545,budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807;C1319635
1545,budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C0439267;C1276807
1545,budesonide - budesonide / formoterol,C1276807
1544,budesonide — no . ( % ),C0054201
1544,budesonide ( n = $nmbr$ ),C0054201
1544,budesonide $nmbr$ ^ g ( n = $nmbr$ ),C0054201;C0439267
1544,budesonide  n ( % ),C0054201
1544,budesonide,C0054201
1543,absolute ( l ),C0205344
1543,absolute  litres,C0205344;C0475211
1542,absolute risk reductions,C3179139
1542,absolute risk reduction ( $nmbr$ % cl ) *,C0596019;C3179139
1541,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
1541,absolute risk difference ( $nmbr$ % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
1541,absolute difference estimate vs placebo ( $nmbr$ % ci ),C0750572;C1549031
1541,absolute change,C1549031
1540,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
1540,albiglutide ( n = $nmbr$ ),C2607479
1539,two lesions,C0205448;C0221198
1539,treated lesions ‡,C0221198;C1522326
1539,stents per lesion  n,C0038257;C0221198;C1546698
1539,stented lesions,C0038257;C0221198
1539,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1539,no . of treated lesions,C0221198;C1522326
1539,mean total stent length per lesion  mm ( sd ) ‡,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
1539,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
1539,mean stent diameter per lesion  mm ( sd ) †,C0038257;C0221198;C0552409;C1546698;C2699239;C4330985;C4554674
1539,lesions treated per patient,C0221198
1539,lesions b $nmbr$ / c,C0221198;C1546698
1539,lesions,C0221198
1539,lesion ( s ),C0221198;C1546698
1539,intervention in complex lesions,C0221198;C1292781
1539,age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
1539,age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
1539,age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
1539,age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
1539,age / gd lesion,C0001779;C0221198;C1546698
1538,pregnancy,C0032961
1537,legend,C2729544
1536,probenecid,C0033209
1535,poland,C0032356
1534,open — no . ( % ),C0175566
1534,open triple ( n = $nmbr$ ),C0175566
1534,open,C0175566
1533,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1533,histor y of congestive heart failure — no . ( % ),C0018802
1533,congestive heart failure at randomisation,C0018802;C0034656
1533,congestive heart failure ( definite ),C0018802
1533,congestive heart failure ( chf ) ( in past $nmbr$ weeks ),C0018802;C2987125
1533,congestive heart failure ( < $nmbr$ wk ),C0018802;C0332174;C0439230
1533,congestive heart failure  n ( % ),C0018802
1533,chronic heart failure,C0018802;C0264716
1532,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
1532,prior congestive heart failure,C0018802;C0332152;C2826257
1532,prior chf  %,C0018802;C0332152;C2826257
1532,prior chf,C0018802;C0332152;C2826257
1532,congestive heart failure †,C0018802
1532,congestive heart failure — %,C0018802
1532,congestive heart failure §,C0018802
1532,congestive heart failure,C0018802
1532,chf,C0018802
1531,chf score ( u ),C0018802;C0439148;C0449820;C4050231
1531,chf ( % ),C0018802
1530,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
1530,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
1530,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
1530,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
1530,prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
1530,prior heart failure  n / n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
1530,prior heart failure  n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
1530,prior heart failure  %,C0018801;C0018802;C0332152;C2826257;C4554158
1530,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
1530,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
1530,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
1530,participants without heart failure,C0018801;C0018802;C0679646;C4554158
1530,participants with heart failure,C0018801;C0018802;C0679646;C4554158
1530,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
1530,no prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
1530,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
1530,no heart failure,C0018801;C0018802;C4554158
1530,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
1530,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
1530,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
1530,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
1530,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
1530,histor y of heart failure,C0018801;C0018802;C4554158
1530,heart failure ‡,C0018801;C0018802;C4554158
1530,heart failure — no . / total no . ( % ),C0018801;C0018802;C4554158
1530,heart failure — no . ( % ),C0018801;C0018802;C4554158
1530,heart failure or lvef < $nmbr$ % associated with index acs event,C0018801;C0018802;C4554158
1530,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
1530,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
1530,heart failure at entry  no . ( % ),C0018801;C0018802;C1705654;C4554158
1530,heart failure *,C0018801;C0018802;C4554158
1530,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C4554158
1530,heart failure ( nyha ii ‐ iii )  n ( % ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
1530,heart failure ( hf )  ( % ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
1530,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
1530,heart failure $nmbr$ yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
1530,heart failure $nmbr$ month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
1530,heart failure $nmbr$ mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
1530,heart failure  no . / total no . ( % ),C0018801;C0018802;C4554158
1530,heart failure  n ( % ),C0018801;C0018802;C4554158
1530,heart failure  lvef < $nmbr$ %  or both,C0018801;C0018802;C0428772;C0488728;C4554158
1530,heart failure  hospitalized or fatal,C0018801;C0018802;C4554158
1530,heart failure,C0018801;C0018802;C4554158
1530,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
1530,congestive heart failure — no . ( % ) | |,C0018802
1530,congestive heart failure — no . ( % ) |,C0018802
1530,congestive heart failure — no . ( % ),C0018802
1530,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
1530,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
1530,cardiac failure —,C0018801;C0018802
1530,cardiac failure §,C0018801;C0018802
1530,cardiac failure *,C0018801;C0018802
1530,cardiac failure  n ( % ),C0018801;C0018802
1530,cardiac failure,C0018801;C0018802
1529,valsartan / hctz ( n = $nmbr$ ),C0020261;C0216784
1529,valsartan / hctz  n / n ( % ),C0020261;C0216784
1529,val / hctz ( n = $nmbr$ ),C0020261;C0042285;C0523975
1529,v alsartan / hctz  n ( % ),C0020261
1529,v / hctz ( n = $nmbr$ ),C0020261
1529,v / hctz,C0020261
1529,hctz * ( n = $nmbr$ ),C0020261
1529,hctz *,C0020261
1529,hctz,C0020261
1528,hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .,C0020261
1528,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C1511726;C3245479;C3714741
1527,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
1527,olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$,C0020261;C1098320
1527,hydrochlorothiazide,C0020261
1526,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1526,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
1526,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
1526,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
1526,prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1526,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1526,prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1526,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
1526,participants without hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1526,participants with hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1526,no prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1526,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1526,no prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1526,no hx of hf ( n = $nmbr$ ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1526,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
1526,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
1526,hosp . for hf,C0018488;C1313497;C1538440;C3273279
1526,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
1526,hf without known reduced ef ( n = $nmbr$ ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1526,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1526,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
1526,hf or lvef < $nmbr$ % associated with index event,C0018488;C1313497;C1538440;C3273279
1526,hf hosp .,C0018488;C1313497;C1538440;C3273279
1526,hf duration  y  n ( % ),C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1526,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1526,hf  lvd  or both,C0018488;C1313497;C1538440;C3273279
1526,hf,C0018488;C1313497;C1538440;C3273279
1526,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
1526,duration of hf  y,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1526,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
1526,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
1526,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
1526,admission for hf in previous year  n ( % ),C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
1526,admission for hf in previous year,C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
1525,non - q - wave myocardial infarction,C0542269;C3537181
1524,family history of myocardial infarction prior to age $nmbr$  %,C0455406
1523,parental history of myocardial infarction before age $nmbr$ y yes,C0030551;C1275835
1523,parental history of myocardial infarction before age $nmbr$ y,C0030551;C1275835
1523,parental history of myocardial infarction before $nmbr$ yr of age ( % ),C0030551;C1275835
1523,history of myocardial infarction ( % ),C1275835
1523,history of myocardial infarction  n ( % ),C1275835
1523,history of myocardial infarction,C1275835
1523,history myocardial infarction,C0155668;C1275835
1522,prior myocardial infarction 一 no . ( % ),C0155668
1522,prior myocardial infarction — no . { % ),C0155668
1522,prior myocardial infarction — no . / total no . ( % ),C0155668
1522,prior myocardial infarction — no . ( % ),C0155668
1522,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
1522,prior myocardial infarction ( % ),C0155668
1522,prior myocardial infarction  no . / total no . ( % ),C0155668
1522,prior myocardial infarction  n ( % ),C0155668
1522,prior myocardial infarction  %,C0155668
1522,prior myocardial infarction,C0155668
1522,> $nmbr$ prior myocardial infarction — no . ( % ),C0155668
1521,anterior myocardial infarction — no . / total no . ( % ),C0340293
1521,anterior myocardial infarction — no . ( % ),C0340293
1520,colectomy ( partial or total ),C0009274
1519,aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470
1518,history of cardiac arrhythmia,C3494593
1517,nonischemic cardiomyopathy — no . ( % ),C0878544
1517,nonischemic cardiomyopathy,C0878544
1517,combined cardiac failure  cardiomyopathy or other cardiac disorders,C0018801;C0018802;C0205195;C0878544
1517,combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % ),C0018801;C0018802;C0205195;C0878544
1517,cardiomyopathy,C0878544
1516,total mortality all,C0026565;C0026566;C0439175;C0439810
1516,total mortality,C0026565;C0026566;C0439175;C0439810
1516,shfm annual mortality,C0026565;C0026566;C0332181
1516,overall mortality,C0026565;C0026566;C0282416;C1561607
1516,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1516,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
1516,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1516,mortality outcomes,C0026565;C0026566;C1274040
1516,mortality  shock or congestive heart failure within $nmbr$ days,C0026565;C0026566;C0036974
1516,mortality,C0026565;C0026566
1516,cvd mortality,C0007222;C0026565;C0026566
1516,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
1516,all - causa mortality,C0026565;C0026566;C3903827
1515,participants n,C0679646
1515,participants  n,C0679646
1515,participants,C0679646
1515,number of participants with an event,C0237753;C0449788;C0679646
1515,number of participants,C0237753;C0449788;C0679646
1515,nondiabetic participants !,C0679646
1515,nonblack participants,C0679646
1515,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
1515,no . of participants with events ( % ),C0679646
1515,no . of participants per $nmbr$ patient - yr,C0679646
1515,no . of participants ( % ),C0679646
1515,no . of participants,C0679646
1515,no . ( % ) of participants,C0679646
1515,n participants,C0369718;C0441922;C0679646
1515,diabetic participants !,C0241863;C0679646
1515,diabetic participants,C0241863;C0679646
1515,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
1515,all participants,C0679646
1515,$nmbr$ % participants,C0679646
1514,participants taking insulin,C0679646
1514,participants randomized,C0679646
1514,participants at baseline  n,C0168634;C0679646;C1442488
1514,participants  no . ( % ),C0679646
1514,participant - reported hypertension — no . { % ),C0679646;C2698741;C4554048
1514,all participants ^ ^ ( n = $nmbr$ / $nmbr$ ),C0679646
1514,all participants * ( n = $nmbr$ / $nmbr$ ),C0679646
1514,all participants ( n = $nmbr$ ),C0679646
1514,aii participants ( n = $nmbr$ ),C0679646;C1424250;C2698414
1513,previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery,C0003483;C0205156;C1552607
1513,aortic,C0003483
1512,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
1511,acitretin,C0050559
1510,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
1510,calcification  n ( % ),C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
1509,contusion,C0009938
1508,congestion *,C0700148;C2826600
1507,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
1506,constitutional,C1511487
1505,option,C1518601;C1550456
1504,ambition,C0870128
1503,• hospitalization for unstable angina,C0002965;C0019993
1503,unstable angina requiring hospitalization,C0002965;C0019993
1503,prior hospitalizations  n ( % ),C0019993;C0332152;C2826257
1503,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
1503,no hospitalization in the past $nmbr$ months prior to baseline ( ref ),C0019993;C4331910
1503,hospitalization stratum  n ( % ),C0019993
1503,hospitalization in the past $nmbr$ months prior to baseline,C0019993;C4331910
1503,hospitalization for unstable angina,C0002965;C0019993
1503,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
1503,hospitalization for acs,C0019993;C0742343;C4318612
1503,hospitalization for / due to,C0019993
1503,hospitalization  n ( % ),C0019993
1503,hospitalisation for chf within $nmbr$ years of randomisation,C0018802;C0019993
1503,first hospitalization for chf or cv death,C0018802;C0019993;C0205435;C1279901
1502,prior hospitalization for hf  %,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1502,prior hf hospitalization ( n = $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1502,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
1502,no prior hf hospitalization ( n   = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1502,no prior hf hospitalization ( n = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1502,hospitalizations  n,C0019993
1502,hospitalizations,C0019993
1502,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
1502,hospitalization for,C0019993
1502,hospitalization,C0019993
1502,hospitalisation,C0019993
1502,hf hospitalizations  median ( iqr ),C0018488;C0019993;C0549183;C0876920;C1313497;C1538440;C2347635;C2348144;C2939193;C3273279
1502,hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279
1502,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
1502,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
1502,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
1501,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
1501,hospitalisation related to exacerbation  n ( % ),C0019993
1501,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
1500,upper abdominal pain,C0232492
1499,= cerebrospinal fluid .,C0007806;C0007807
1498,eosinoohil count,C0750480;C1705566
1498,< $nmbr$ with no historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
1498,< $nmbr$ with historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
1498,< $nmbr$ regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
1497,prior mi diagnosis :,C0332132;C3810814
1497,prior diagnosis - no . ( % ),C0332132
1497,previous diagnosis,C0332132
1497,no previous diagnosis of diabetes mellitus,C0011849;C0332132
1496,qol due to urinary symptoms,C0426359;C0518214;C0678226
1496,amputation due to diabetes — no . ( % ),C0598284;C0678226
1495,symptom onset to hospital arrival  median ( iqr )  h,C0019994;C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1555577;C1706079;C2347635;C2348144;C2939193;C4086878;C4528284
1495,symptom onset to hospital arrival  hours,C0019994;C0439227;C1510665;C1555577;C1706079;C4086878
1495,symptom onset to arrival in catheterization laboratory,C1555577;C1706079;C4086878
1495,randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079
1494,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
1493,outcomes during accord,C0680240;C1274040
1493,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0680240;C1274040
1493,outcome according to primary cancer site — no . / total no . ( % ),C0680240;C0872338;C1274040
1493,outcome according to no . of risk factors for vte,C0035648;C0680240;C1274040;C1553898
1492,chest discomfort,C0235710
1491,lipid disorder,C0154251
1490,liver disorder,C0023895
1490,hepatic disorders,C0023895
1489,neurocognitive disorders,C0029227;C4041080
1488,acute rheumatic disorders,C0001314
1487,gastrointestinal disorders,C0017178
1487,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
1486,卞 at discharge .,C0012621;C0030685;C2926602
1486,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
1486,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
1485,medications at discharge or day $nmbr$  if earlier ( % ),C0806915
1485,medications at discharge,C0806915
1485,cardiac medications at discharge  %,C0018787;C0806915;C1522601
1484,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
1484,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
1484,microvascular disease history  no . ( % ),C0443258;C0683519
1484,microvascular disease history  n ( % ),C0443258;C0683519
1484,microvascular disease history,C0443258;C0683519
1484,history of thyroid disease  n ( % ),C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
1484,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
1484,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
1484,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
1484,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
1484,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
1484,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
1484,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
1484,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
1484,history of macrovascular disease at baseline  n ( % ),C0683519;C0730226;C0850708;C0944983
1484,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
1484,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
1484,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
1484,history of fistullzing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
1484,history of fistulizing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
1484,history of fistulising disease  n [ % ],C0683519;C0730226;C0850708;C0944983
1484,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0683519;C0730226;C0850708;C0944983
1484,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
1484,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
1484,history of coronary heart disease  no . ( % ),C0018787;C0683519;C0730226;C0850708;C0944983
1484,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
1484,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
1484,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
1484,disease history,C0683519
1484,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
1483,ccv history / condition at baseline,C0168634;C0683519;C1442488
1483,ccv history / condition,C0683519
1482,levetiracetam,C0377265;C3693636
1481,infrequent exacerbator,C0521114
1480,biventricular pacemaker,C1719274
1479,implanted pacemaker,C0848753
1478,fractures,C0016658
1478,fracture,C0016658
1478,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
1478,bone fracture,C0016658
1477,fractures ( site not specified ),C0016658
1477,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
1476,prior nonvertebral fracture at age > $nmbr$ years,C0016658;C0332152;C1510829;C2826257
1476,prior nonvertebral fracture,C0016658;C0332152;C2826257
1476,nonvertebral fractures,C0016658
1476,nonvertebral fracture,C0016658
1475,atrial flutter,C0004239;C0344423;C1963068
1474,fibrillation / flutter ),C0016385;C0232197;C2242390
1474,arial flutter or fibrillation,C0016385;C2242390
1473,atrial flutter / fibrillation,C0155709
1473,atrial fibrillation / flutter  n ( % ),C0155709
1473,atrial fibrillation / flutter,C0155709
1473,atrial fibrillation / atrial flutter  %,C0155709
1472,without baseline vertebral fracture,C0080179;C0168634;C1442488
1472,with baseline vertebral fracture,C0080179;C0168634;C1442488
1472,vertebral fractures at baseline,C0080179;C0168634;C1442488
1472,vertebral fracture and / or t score s - $nmbr$ . $nmbr$,C0080179
1472,vertebral fracture and / or t score - $nmbr$ . $nmbr$,C0080179
1472,vertebral fracture,C0080179
1472,spinal fractures,C0080179;C0518450
1472,clinical vertebral fractures,C0080179;C0205210
1472,baseline vertebral fracture,C0080179;C0168634;C1442488
1471,predictive factor,C0683956
1470,heart disease risk factors,C0741920
1469,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
1469,alternative disability,C0231170;C1523987
1468,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
1468,atorvastatin factorial study,C0286651;C2826344
1467,psoriatic arthropathy,C0003872
1467,psoriatic arthritis pain ],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
1467,psoriatic arthritis  %,C0003872
1467,psoriatic arthritis,C0003872
1466,disseminated tuberculosis,C0152915
1465,ulcerative colitis,C0009324
1465,duration of ulcerative colitis,C0009324;C0449238;C2926735
1464,obstructive subscore,C0549186
1464,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
1463,unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
1463,risk group,C0242444
1462,• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke,C0011065;C0439070;C1306577;C1705160;C3538987;C4048877;C4082313;C4318503;C4552775
1462,• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days,C0011065;C0018799;C0439228;C0545743;C0581603;C1306577;C1710602;C3810814;C4082313;C4082587;C4552775
1462,• death from cv causes  major coronary event  or nonfatal stroke,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
1462,• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke,C0011065;C1306577;C4082313;C4552775
1462,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
1462,sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline,C0011065;C0022661;C0035078;C0443318;C0678226;C1306577;C2316810;C4082313;C4552775
1462,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
1462,noncardiac death,C0011065;C1306577;C4082313;C4552775
1462,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
1462,no . of deaths,C0011065;C1306577
1462,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
1462,macce ( death  mi  stroke ),C0011065;C0038454;C1306577;C3810814;C4082313;C4552775;C4554100
1462,hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci ),C0011065;C0027051;C1306577;C2985465;C4082313;C4552775
1462,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
1462,deaths  n ( % ),C0011065;C1306577
1462,deaths,C0011065;C1306577
1462,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
1462,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
1462,death or mi at $nmbr$ days,C0011065;C1306577;C4082313;C4552775
1462,death or ich,C0011065;C1306577;C4082313;C4552775
1462,death or disabling stroke,C0011065;C1306577;C4082313;C4552775
1462,death or absolute fvc decrease > $nmbr$ %,C0011065;C1306577;C4082313;C4552775
1462,death or $nmbr$ mwd decrease > $nmbr$ m,C0011065;C1306577;C4082313;C4552775
1462,death from,C0011065;C1306577;C4082313;C4552775
1462,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1462,death due to renal failure or sustained esrd,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1462,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
1462,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
1462,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
1462,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
1462,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
1462,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death *,C0011065;C1306577;C4082313;C4552775
1462,death ( all cause ),C0011065;C1306577;C4082313;C4552775
1462,death ( all - cause ),C0011065;C1306577;C4082313;C4552775
1462,death  with pe not,C0011065;C0070939;C1306577;C1880476;C4082313;C4284304;C4552775
1462,death  q wave mi or ischemia - driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775
1462,death  n ( % ),C0011065;C1306577;C4082313;C4552775
1462,death  mi  idr  st or gusto severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death  mi  idr  st  or gusto moderate / severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death  mi  idr  st  or gusto mod / sev bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death  mi  idr  st  or any timi bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1462,death  mi  idr  or st,C0011065;C1306577;C3810814;C4082313;C4552775
1462,death,C0011065;C1306577;C4082313;C4552775
1462,dead ( n = $nmbr$ ),C0011065
1462,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia,C0007226;C0011065;C0022116;C0027051;C0428953;C0439234;C0439508;C1306577;C1511726;C1720943;C2926063;C3245479;C3538987;C3714741;C3810814;C3887460;C4048877;C4082313;C4318503;C4321499;C4552775;C4552959
1462,cv death or ml,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death or hf hospitalization n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death or hf hosp .,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1462,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1462,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1462,cv death  non - fatal mi or non - fatal stroke,C0011065;C1302234;C1306577;C1518422;C1705232;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death  ml or ischemic stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1462,cv death  ml  or stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1462,cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure,C0002965;C0011065;C0019993;C0439526;C0581603;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1462,cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua,C0011065;C0018488;C0018787;C0041580;C0042014;C0056331;C0378365;C0439526;C0948008;C1306577;C1313497;C1538440;C1705224;C3273279;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1462,cv death  ml  ischemic stroke,C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1462,cv death  mi  stroke  recurrent ischemia,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death  mi  stroke  or urgent coronary revascularization,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1462,cv death  mi  stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1462,cv death  mi  or stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death  mi  or ischemic stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua,C0011065;C0018488;C0019993;C0041580;C0042014;C0376297;C0581603;C0877341;C0948008;C1306577;C1313497;C1538440;C3273279;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death  mi  ischemic stroke,C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1462,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1462,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
1462,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
1462,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death or hospitalized hf,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
1462,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
1462,cardiovascular death  nonfatal myocardial infarction  nonfatal stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
1462,cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
1462,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
1462,any death,C0011065;C1306577;C4082313;C4552775
1462,all death,C0011065;C1306577;C4082313;C4552775
1462,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1462,* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”,C0008902;C0011065;C0015127;C0205199;C0205435;C0243132;C0439234;C0566415;C0679646;C1279901;C1299582;C1306577;C1524003;C1547335;C1554210;C2698741;C2745955;C4048706;C4082313;C4321405;C4552775;C4554048
1462,$nmbr$ days composite of death / new mi / urgent revascularization and definite st,C0011065;C0205199;C0439609;C0581603;C1306577;C1547335;C3272275;C3810814;C4082313;C4552775;C4689466
1461,years since diagnosis of type $nmbr$ diabetes  n ( % ),C0439234
1461,interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % ),C0439234;C1272706;C1552654;C1552713
1461,$nmbr$ - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
1460,persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
1460,no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1460,new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1460,improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
1460,dabigatran $nmbr$ mg $nmbr$ mg % per yr,C0439234;C1319635;C2348066
1459,years with gouty arthritis,C0003868;C0439234
1459,years with gout  mean ± sd,C0018099;C0439234;C0444504;C2347634;C2348143;C2699239
1459,years with gout,C0018099;C0439234
1459,years since menopause,C0439234
1459,mean years since menopause,C0439234;C0444504;C2347634;C2348143
1459,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1459,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
1459,> $nmbr$ yr since menopause,C0439234
1459,< $nmbr$ yr since menopause,C0439234
1458,≤ $nmbr$   year,C0439234;C0439508
1458,year - $nmbr$,C0439234;C0439508
1458,year $nmbr$,C0439234;C0439508
1458,year  n ( % ),C0439234;C0439508
1458,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
1458,severe episodes in previous year — no . / patient,C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
1458,recurrent infections ( > $nmbr$ per year ),C0239998;C0439234;C0439508
1458,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
1458,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
1458,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
1458,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1458,mean ( se ) $nmbr$ - year rates per $nmbr$ population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
1458,mean $nmbr$ - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
1458,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
1458,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1458,hospitalization in previous year with management of heart failure,C0019993;C0205156;C0439234;C0439508;C1552607
1458,hospitalization for hf previous year  ( % ),C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
1458,framingham $nmbr$ - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
1458,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1458,exacerbations in previous year requiring hospitalization and / or ed visit  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1458,exacerbations in previous year requiring hospitalization  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1458,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1458,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
1458,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1458,difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
1458,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
1458,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
1458,copd exacerbation history in the previous year  n ( % ),C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
1458,> year $nmbr$,C0439234;C0439508
1458,> = medan ( $nmbr$ year - old ),C0439234;C0439508;C0580836
1458,> $nmbr$   years,C0439234
1458,> $nmbr$ yr  n ( % ),C0439234
1458,> $nmbr$ years  n ( % ),C0439234
1458,> $nmbr$ year,C0439234;C0439508
1458,< median ( $nmbr$ year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
1458,< = $nmbr$ year  n ( % ),C0439234;C0439508
1458,< $nmbr$ years  n ( % ),C0439234
1458,< $nmbr$ year,C0439234;C0439508
1458,% / yr,C0439234
1458,% / year,C0439234;C0439508
1458,$nmbr$ years or older,C0439234
1458,$nmbr$ years or more,C0439234
1458,$nmbr$ years  n ( % ),C0439234
1458,$nmbr$ year or more,C0439234;C0439508
1458,$nmbr$ - yr %,C0439234
1458,$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$,C0439234;C0439508;C1282512
1458,$nmbr$ - year risk of chd  % #,C0439234;C0439508;C1282512
1458,$nmbr$ - year risk for chd,C0439234;C0439508;C1282512
1458,$nmbr$ - year predicted risk ( % ) of,C0439234;C0439508
1458,$nmbr$ - year mortality,C0026565;C0026566;C0439234;C0439508
1458,$nmbr$ - year km %,C0439234;C0439508;C3887676
1458,$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
1458,$nmbr$ - year framingham chd risk  %,C0439234;C0439508;C1282512;C3166866
1458,$nmbr$ - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
1458,$nmbr$ $nmbr$ years  n ( % ),C0439234
1458,# $nmbr$ year,C0439234;C0439508
1457,赛 $nmbr$ years,C0439234
1457,〉 $nmbr$ years,C0439234
1457,■ $nmbr$ years,C0439234
1457,≥ $nmbr$ years,C0439234
1457,≥ $nmbr$ to < $nmbr$ years,C0439234
1457,≥ $nmbr$ . $nmbr$ years,C0439234
1457,≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years,C0439234
1457,≤ $nmbr$ years,C0439234
1457,» $nmbr$ yr,C0439234
1457,» $nmbr$ years,C0439234
1457,£ $nmbr$ yr,C0439234
1457,£ $nmbr$ years,C0439234
1457,£ $nmbr$ to < $nmbr$ years,C0439234
1457,years ),C0439234
1457,years,C0439234
1457,x $nmbr$ years,C0439234
1457,women > $nmbr$ years,C0043210;C0439234
1457,women < $nmbr$ years,C0043210;C0439234
1457,ss years,C0439234;C2699257;C3891295;C4551874
1457,s $nmbr$ years,C0439234;C0565930;C2603362
1457,older than $nmbr$ years,C0439234;C0580836
1457,formal education  years,C0439234;C0681344
1457,at $nmbr$ years,C0439234
1457,a $nmbr$ years,C0439234
1457,> l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1457,> = $nmbr$ years and < $nmbr$ years,C0439234
1457,> = $nmbr$ years,C0439234
1457,> $nmbr$ yr,C0439234
1457,> $nmbr$ years to < $nmbr$ years,C0439234
1457,> $nmbr$ years old,C0439234
1457,> $nmbr$ years n z $nmbr$,C0439234
1457,> $nmbr$ years bmi,C0439234;C0578022
1457,> $nmbr$ years ( % ),C0439234
1457,> $nmbr$ years,C0439234
1457,> $nmbr$ to < $nmbr$ years,C0439234
1457,> $nmbr$ to $nmbr$   years,C0439234
1457,> $nmbr$ to $nmbr$ years,C0439234
1457,> $nmbr$ - < $nmbr$ years,C0439234
1457,> $nmbr$ - $nmbr$ years,C0439234
1457,< l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1457,< $nmbr$ yr,C0439234
1457,< $nmbr$ years n z $nmbr$,C0439234
1457,< $nmbr$ years ( % ),C0439234
1457,< $nmbr$ years,C0439234
1457,< $nmbr$ . $nmbr$ years,C0439234
1457,( years ),C0439234
1457,$nmbr$ — < $nmbr$ years,C0439234
1457,$nmbr$ — $nmbr$ years,C0439234
1457,$nmbr$ yr,C0439234
1457,$nmbr$ years,C0439234
1457,$nmbr$ to < $nmbr$ years,C0439234
1457,$nmbr$ to $nmbr$ years,C0439234
1457,$nmbr$ e $nmbr$ years,C0439234
1457,$nmbr$ - < $nmbr$ years,C0439234
1457,$nmbr$ - $nmbr$ years,C0439234
1457,$ $nmbr$ years,C0439234
1456,baseline to year $nmbr$,C0168634;C0439234;C0439508;C1442488
1456,> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ ),C0439234
1456,> $nmbr$ years simva ( „ = $nmbr$ },C0439234
1456,> $nmbr$ years simva ( n = $nmbr$ ),C0439234
1456,> $nmbr$ years or < $nmbr$ crcl  n ( % ),C0439234
1456,> $nmbr$ years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
1456,> $nmbr$ years eze / simva ( „ = $nmbr$ },C0439234
1456,> $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1456,> $nmbr$ years baseline ldl - c,C0168634;C0439234;C1442488
1456,> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0439234
1456,< $nmbr$ years simva ( n = $nmbr$ },C0439234
1456,< $nmbr$ years simva ( n = $nmbr$ ),C0439234
1456,< $nmbr$ years eze / simva ( n = $nmbr$ },C0439234
1456,< $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1455,years ( sd ),C0439234;C2699239
1455,s $nmbr$ years ( n = $nmbr$ ),C0439234;C2986823
1455,age at menopause ( yr ),C0439234;C1625754;C1629609
1455,> = $nmbr$ yr,C0439234
1455,> = $nmbr$ years ( n = $nmbr$ ),C0439234
1455,> $nmbr$ yr ( n = $nmbr$ ),C0439234
1455,> $nmbr$ years simva,C0439234
1455,> $nmbr$ years ( n = $nmbr$ ),C0439234
1455,> $nmbr$ to < $nmbr$ yr,C0439234
1455,> $nmbr$ - $nmbr$ yr,C0439234
1455,< = $nmbr$ yr,C0439234
1455,< $nmbr$ yr ( n = $nmbr$ ),C0439234
1455,< $nmbr$ years simva,C0439234
1455,< $nmbr$ years eze / simva,C0439234
1455,< $nmbr$ years ( n = $nmbr$ ),C0439234
1455,$nmbr$ years ( n = $nmbr$ ),C0439234
1455,$nmbr$ to < $nmbr$ yr,C0439234
1455,$nmbr$ to $nmbr$ yr,C0439234
1455,$nmbr$ mo to $nmbr$ yr,C0026544;C0332177;C0439234
1455,$nmbr$ - $nmbr$ yr,C0439234
1455,$ $nmbr$ years ( n = $nmbr$ ),C0439234
1454,pbo / simva - $nmbr$ yr km rale ( % ),C0031962;C0034642;C0439234;C3887676
1454,eze / simva - $nmbr$ yr km rale ( % ),C0034642;C0439234;C3887676
1454,ed > $nmbr$ yr  no . ( % ),C0439234;C3538926
1454,> $nmbr$ yr — no . { % ),C0439234
1454,> $nmbr$ yr — no . ( % ),C0439234
1454,> $nmbr$ yr — %,C0439234
1454,> $nmbr$ yr from the united states,C0041703;C0439234
1454,> $nmbr$ yr ( % ),C0439234
1454,< $nmbr$ yr — no . { % ),C0439234
1454,< $nmbr$ yr — no . ( % ),C0439234
1454,$nmbr$ yr km % ( n ),C0439234;C3887676
1454,$nmbr$ to < $nmbr$ yr — no . { % ),C0439234
1454,$nmbr$ to < $nmbr$ yr — no . ( % ),C0439234
1454,$nmbr$ = $nmbr$ yr — no . ( % ),C0439234
1454,$nmbr$ - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
1454,$nmbr$ - $nmbr$ yr — no . ( % ),C0439234
1454,$nmbr$ - $nmbr$ yr ( % ),C0439234
1453,teaes  cases per $nmbr$ - patient years ( ci ),C0008107;C0030705;C0439234;C0868928;C1533148;C3259781
1453,rates per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1453,rate per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1453,rate per $nmbr$ - patient - years ( control vs alirocumab ) i,C0030705;C0439234;C0871208;C1521828
1453,rate per $nmbr$ - patient - years ( control vs alirocumab ) *,C0030705;C0439234;C0871208;C1521828
1453,rate / $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1453,patients per $nmbr$ patient - years,C0030705;C0439234
1453,patient - years ) hr ( unadjusted ),C0030705;C0439234
1453,event rates per $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
1453,evenls per $nmbr$  $nmbr$ palienl - years,C0439234
1453,ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
1452,placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
1452,person - years,C0027361;C0439234;C2347489
1452,no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years ),C0027361;C0439234;C1320716;C2347489
1452,no . / $nmbr$ person - yr,C0027361;C0439234;C2347489
1452,incidence  $nmbr$ person - year,C0021149;C0027361;C0220856;C0439234;C0439508;C2347489
1452,cardiovascular mortality ( per $nmbr$ person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
1452,aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0004057;C0027361;C0439234;C0441848;C2347489
1452,all - cause mortality ( per $nmbr$ person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
1451,years since symptom onset,C0439234
1451,years since pd diagnosis  mean ± sd,C0439234
1451,years since pah diagnosis,C0439234
1451,years since myocardial infarction,C0439234
1451,years since mi ( median,C0439234
1451,years since last gout flare,C0439234
1451,years since diagnosis  mean,C0439234
1451,years since diagnosis,C0439234
1451,years modified hoehn and yahr stage  n ( % ),C0439234
1451,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
1451,type $nmbr$ diabetes duration  years,C0439234;C0449238;C1320657;C2926735
1451,type $nmbr$ diabetes duration  mean ( sd )  years,C0439234;C0444504;C0449238;C1320657;C2347634;C2348143;C2699239;C2926735
1451,t $nmbr$ dm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
1451,t $nmbr$ d duration  years,C0439234;C0449238;C2603360;C2926735
1451,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
1451,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
1451,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1451,median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1451,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1451,mean ( sd ) [ range ] duration of epilepsy  years,C0014544;C0439234;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
1451,known duration of type $nmbr$ diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
1451,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
1451,ed duration > $nmbr$ yr  n ( % ),C0439234;C0449238;C2926735;C3538926
1451,duration — yr,C0439234;C0449238;C2926735
1451,duration ofdiabetes — yr,C0439234;C0449238;C2926735
1451,duration of type $nmbr$ diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
1451,duration of type $nmbr$ diabetes mellitus  years,C0439234;C0449238;C1320657;C2926735
1451,duration of type $nmbr$ diabetes ( years ),C0439234;C0449238;C1320657;C2926735
1451,duration of type $nmbr$ diabetes  years,C0439234;C0449238;C1320657;C2926735
1451,duration of t $nmbr$ dm > $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration of t $nmbr$ dm < $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration of t $nmbr$ dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration of t $nmbr$ dm  years,C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration of t $nmbr$ d ( years ),C0439234;C0449238;C2926735
1451,duration of epilepsy  years,C0014544;C0439234;C0449238;C2926735
1451,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
1451,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
1451,duration > $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1451,duration > $nmbr$ to < $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1451,duration < $nmbr$ year  n ( % ),C0439234;C0439508;C0449238;C2926735
1451,dm duration  years,C0011816;C0439234;C0449238;C2926735;C3250443
1451,> $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1451,> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1451,> $nmbr$ to < = $nmbr$ years  n ( % ),C0439234
1451,$nmbr$ moto < $nmbr$ yr  n ( % ),C0439234
1450,very good or excellent,C3641222
1449,$nmbr$ hr after glucose challenge,C3840385
1448,left anterior descending  n ( % ),C0205386;C0441998;C1547177
1448,left anterior descending,C0205386;C0441998;C1547177
1448,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
1448,descent,C0205386;C0680043
1447,venous insufficiency,C0042485
1446,acute respiratory insufficiency,C0865850
1445,sufficient,C0205410
1444,j $nmbr$ coefficient,C1707429
1444,coefficient,C1707429
1443,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
1443,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
1443,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
1443,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
1443,screening prebronchodilator fev $nmbr$  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
1443,screening hba $nmbr$ c ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
1443,screening fev $nmbr$   % predicted,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1443,screening bmi ( kg / m $nmbr$ ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
1443,screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,screening absolute reversibility fev $nmbr$  ml,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,screening ( visit $nmbr$ ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
1443,screening % reversibility fev $nmbr$,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1443,screening  mean ( sd ) morning pef  mean,C0030771;C0220908;C0220909;C0332170;C0444504;C1518922;C1542834;C1698960;C1710031;C1710032;C1710477;C2347634;C2348143;C2348164;C2699239
1443,screening  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
1443,predose fev ^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
1443,pre - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
1443,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
1443,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1443,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
1443,post - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
1443,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
1443,post - bronchodilator fev $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
1443,oad at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
1443,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
1443,lama use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1443,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1443,laba use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1443,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1443,insulin glargine dose at screening visit  iu,C0049272;C0178602;C0220908;C0220909;C0366513;C0439453;C0545082;C0694756;C0869039;C0907402;C1114758;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
1443,fev $nmbr$   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
1443,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1443,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1443,> $nmbr$ per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
1443,> $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
1442,caffeine users  n ( % ),C3532939
1442,caffeine user  n ( % ),C3532939
1442,caffeine user,C3532939
1441,caffeine consumption *,C0948365
1441,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
1440,dose of aspirin,C4696290
1440,aspirin dose at randomization,C0034656;C4696290
1440,aspirin dose  mg / d,C0439422;C4696290
1440,aspirin dose,C4696290
1440,aspirin at any dose,C4696290
1439,worsened,C1457868;C4084902
1439,significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
1439,significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
1439,significant worsening in kccq clinical,C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
1439,no worsening in pga  %,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
1438,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
1438,us site of enrollment,C1516879;C1696073;C2945843;C3888021
1438,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
1438,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
1438,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
1438,statin at enrollment,C0360714;C1516879;C1696073;C3888021
1438,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
1438,reason for enrollment in active a,C0392360;C1516879;C1696073;C3888021
1438,primary enrollment diagnoses  n ( % ),C0332137;C0801658;C1516879;C1696073;C3888021
1438,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
1438,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
1438,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
1438,medications at enrollment  n ( % ) :,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
1438,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
1438,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
1438,loop at enrollment,C0445022;C1516879;C1696073;C3888021
1438,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
1438,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
1438,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
1438,arb at enrollment,C1516879;C1696073;C3888021;C3888198
1438,age at enrolment  years,C1510829;C1516879;C1696073;C3888021
1438,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
1437,p  net difference,C0369773;C1456447;C1705241;C1705242;C2603361;C3853572;C3887809;C3890893
1437,net ep $nmbr$,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
1437,net clinical benefit : on - treatment vte or major bleeding,C0039798;C0087111;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4684590
1437,net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding,C0011065;C0038454;C1306577;C1456447;C3538987;C3810814;C3853572;C3887809;C3890893;C4048877;C4082313;C4318503;C4552775;C4554100;C4684590
1437,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
1437,net adverse clinical events at day $nmbr$,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
1436,without dyspnoea,C0013404;C1963100
1436,with dyspnoea,C0013404;C1963100
1436,no dyspnoea ( n = $nmbr$ ),C0013404;C1963100
1436,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
1436,mmrc dyspnea scale  n ( % ),C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
1436,dyspnoea ( n = $nmbr$ ),C0013404;C1963100
1436,dyspnea t,C0013404;C1963100
1436,dyspnea,C0013404;C1963100
1436,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
1436,cdr - sob,C0013404;C4521843
1436,borg dyspnea score who functional class  n ( % ),C0013404;C0449820;C1963100;C4050231
1435,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
1435,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
1435,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
1435,trough fev $nmbr$   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
1435,trough fev  response ( l ) i,C0021966;C0221138;C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
1435,stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,sri response  %,C0871261;C1420401;C1704632;C1706817;C2911692
1435,previous loss of response to infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
1435,previous loss of response to and intolerance of infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
1435,peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
1435,patients with weekly iss mid response  n ( % ) v,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
1435,patients with previous loss of response to infliximab,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
1435,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
1435,patient ' s global assessment of response to therapy score,C0871261;C1704632;C1706817;C2911692;C4054229
1435,pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$,C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
1435,pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$,C0025677;C0168634;C0871261;C1417487;C1442488;C1704632;C1706817;C2911692;C4528685
1435,pasi $nmbr$ response },C0871261;C1704632;C1706817;C2911692;C4528685
1435,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
1435,mean eq - $nmbr$ d response ( $nmbr$ % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
1435,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
1435,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
1435,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
1435,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
1435,inadequate response or intolerance to > $nmbr$ anti - tnfdrug,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
1435,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1435,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
1435,bronchodilator response  ml,C0006280;C0439526;C0871261;C1704632;C1705224;C1706817;C2911692;C3887665
1435,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
1435,acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$,C0025677;C0168634;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C2911692
1435,acr response  % acr $nmbr$,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
1435,acr response  %,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
1435,acr $nmbr$ response at week $nmbr$  n ( % ),C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
1435,acr $nmbr$ response  n / n ( % ),C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
1435,acr $nmbr$ response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
1434,nx *,C0445085
1433,npi - $nmbr$ score *,C1412208;C1549728;C3539727
1433,npi,C1412208;C1549728;C3539727
1432,ni,C0028075;C2348274;C3869926;C3869927
1432,> $nmbr$ ml / niin / l $nmbr$ ni -,C0028075;C1635169;C2348274;C3869926;C3869927
1432,< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -,C0028075;C0439445;C2348274;C3869926;C3869927
1431,≥ $nmbr$ a ( n = $nmbr$ ),C0369718;C0441922
1431,without ( n = $nmbr$ $nmbr$ ),C0369718;C0441922
1431,with ( n = $nmbr$ ),C0369718;C0441922
1431,us n = $nmbr$,C0369718;C0441922
1431,us ( n = $nmbr$ ),C0369718;C0441922
1431,other { n = $nmbr$ ),C0369718;C0441922
1431,other n ( % ),C0369718;C0441922
1431,other * ( n = $nmbr$ ),C0369718;C0441922
1431,other ( n — $nmbr$ ),C0369718;C0441922
1431,other ( n   = $nmbr$ ),C0369718;C0441922
1431,other ( n = $nmbr$ ),C0369718;C0441922
1431,other ( n = $nmbr$  $nmbr$ ],C0369718;C0441922
1431,other ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1431,other ( n  % ),C0369718;C0441922
1431,other  n ( % ),C0369718;C0441922
1431,none ( n = $nmbr$ ),C0369718;C0441922
1431,no ( n = $nmbr$ ),C0369718;C0441922
1431,no ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1431,neither n = $nmbr$  $nmbr$,C0369718;C0441922
1431,n_,C0369718;C0441922
1431,n t % ),C0369718;C0441922
1431,n observed,C0369718;C0441922
1431,n o,C0369718;C0441922
1431,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
1431,n analysed,C0369718;C0441922
1431,n = $nmbr$ t,C0369718;C0441922
1431,n = $nmbr$ lesions,C0369718;C0441922
1431,n = $nmbr$,C0369718;C0441922
1431,n =,C0369718;C0441922
1431,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
1431,n / pyr,C0369718;C0441922
1431,n / n   ( % ),C0369718;C0441922
1431,n / n ( % / yr ),C0369718;C0439234;C0441922
1431,n / n ( % ),C0369718;C0441922
1431,n / n $nmbr$ / $nmbr$,C0369718;C0441922
1431,n / n,C0369718;C0441922
1431,n .,C0369718;C0441922
1431,n - $nmbr$ pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
1431,n - $nmbr$ pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
1431,n - $nmbr$ pufa,C0032615;C0369718;C0441922
1431,n - $nmbr$ fatty acit,C0369718;C0441922
1431,n - $nmbr$ fatty acids slope lsm ± se ( mm / year ),C0015684;C0369718;C0441922
1431,n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
1431,n - $nmbr$ fatty acids ( n = $nmbr$ ),C0015684;C0369718;C0441922
1431,n - $nmbr$ fatty acids,C0015684;C0369718;C0441922
1431,n - $nmbr$ - pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
1431,n + v ( n = $nmbr$ ),C0369718;C0441922
1431,n *,C0369718;C0441922
1431,n ( stented lesions ),C0369718;C0441922
1431,n ( lesions ),C0369718;C0441922
1431,n ( iqr ),C0369718;C0441922
1431,n ( % of patients ),C0030705;C0369718;C0441922
1431,n ( % ) unless otherwise specified,C0369718;C0441922
1431,n ( % ) responders,C0369718;C0441922
1431,n ( % ) liraglutide $nmbr$ placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
1431,n ( % ),C0369718;C0441922
1431,n %,C0369718;C0441922
1431,n $nmbr$ yrs,C0369718;C0441922
1431,n $nmbr$ / n $nmbr$,C0369718;C0441922
1431,n $nmbr$,C0369718;C0441922
1431,n,C0369718;C0441922
1431,all n = $nmbr$ $nmbr$,C0369718;C0441922
1431,all n = $nmbr$  $nmbr$,C0369718;C0441922
1431,all n = $nmbr$,C0369718;C0441922
1431,all ( n = $nmbr$ f ),C0016327;C0369718;C0441922
1431,all ( n = $nmbr$ * ),C0369718;C0441922
1431,all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0369718;C0441922
1431,all ( n = $nmbr$ ),C0369718;C0441922
1431,all ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1431,a $nmbr$ n = $nmbr$,C0369718;C0441922
1431,a $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ . $nmbr$  n ( % ),C0369718;C0441922
1431,> $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ ( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
1431,> $nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
1431,> $nmbr$ %  n ( % ),C0369718;C0441922
1431,> $nmbr$  n ( % ) gender  n ( % ),C0079399;C0369718;C0441922;C1522384
1431,> $nmbr$  n ( % ),C0369718;C0441922
1431,< $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1431,< $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
1431,< $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
1431,< $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,< $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
1431,< $nmbr$ %  n ( % ),C0369718;C0441922
1431,< $nmbr$  n ( % ),C0369718;C0441922
1431,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
1431,( n = l $nmbr$ ),C0369718;C0441922
1431,( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
1431,( n = $nmbr$ ) ( n = $nmbr$ ),C0369718;C0441922
1431,( n = $nmbr$ )  ' ( n = $nmbr$ ),C0369718;C0441922
1431,( n = $nmbr$ ),C0369718;C0441922
1431,( n = $nmbr$,C0369718;C0441922
1431,( n $nmbr$ $nmbr$ ),C0369718;C0441922
1431,$nmbr$ to < $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
1431,$nmbr$ to < $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,$nmbr$ n qi,C0369718;C0376586;C0441922
1431,$nmbr$ n / n,C0369718;C0441922
1431,$nmbr$ - $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1431,$nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,$nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
1431,$nmbr$ ( n $nmbr$ $nmbr$ ),C0369718;C0441922
1431,$nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
1431,$ $nmbr$ to  $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,$ $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
1431,$ $nmbr$ %  n ( % ),C0369718;C0441922
1430,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
1430,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
1430,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
1430,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
1430,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
1430,nyha functional class $nmbr$,C0205245;C0542341;C1882083;C2700217
1430,nyha functional class  n ( % ),C0205245;C0542341;C1882083;C2700217
1430,nyha functional class,C0205245;C0542341;C1882083;C2700217
1430,functional outcome ( mrs $nmbr$ - $nmbr$ ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
1430,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
1430,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
1430,acr functional class  n ( % ),C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
1429,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
1429,physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale ),C0031843;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1522492;C1705273;C1806781;C2350002;C2964478;C4049916;C4255237
1429,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
1429,lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients ),C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1429,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1429,function subscale,C0031843;C0542341;C0700205;C1705273
1429,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
1429,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
1429,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
1428,sample sizea,C0370003;C2347026
1428,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
1428,abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .,C0000723;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0439828;C0731033;C0871472;C1256463;C1280412;C1510411;C1527178;C1704614;C1705938;C1707455;C1708728;C1739039;C1881413;C2347026;C2986759;C2986775;C3811844;C3812682;C4318736
1427,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
1427,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C0039593;C0392366;C1709380
1426,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
1426,serum creatinine concentration and randomization to losartan,C0010294;C0086045;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
1426,patients with baseline crp concentration £ $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1426,patients with baseline crp concentration < $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1426,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
1426,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
1426,ldl - c concentration,C0086045;C1446561;C3827302
1426,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
1426,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
1426,geometric c $nmbr$ concentration  mg / dl,C0086045;C0439269;C0449829;C1446561;C3827302
1426,crp concentration > $nmbr$ mg / l  n ( % ) \,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
1426,crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
1426,blood leucocyte concentration ( $nmbr$ cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
1426,blood eosinophil concentration  $nmbr$ cells per l,C0014467;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
1425,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
1425,lipid ‐ lowering therapies  n ( % ),C0585943
1425,lipid lowering therapy,C0585943
1425,lipid - lowering therapy — no . ( % ),C0585943
1425,lipid - lowering therapy - no . ( % ),C0585943
1425,lipid - lowering therapy,C0585943
1425,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
1425,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
1425,background lipid - lowering therapy,C0585943;C1706907
1424,without lipid - lowering agents,C0086440
1424,with lipid - lowering agents,C0086440
1424,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
1424,other lipid lowering drugs,C0086440
1424,lipid lowering drugs,C0086440
1424,lipid lowering agents,C0086440
1424,lipid lowering agent n ( % ),C0086440
1424,lipid - lowering drugs  n ( % ),C0086440
1424,lipid - lowering drugs,C0086440
1424,lipid - lowering drug * *,C0086440
1424,lipid - lowering drug,C0086440
1424,lipid - lowering agents ( % ),C0086440
1424,lipid - lowering agents,C0086440
1424,lipid - lowering agent §,C0086440
1424,lipid - lowering agent,C0086440
1424,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
1424,any lipid - lowering agent,C0086440
1423,tnf antagonist - failure population ( n - $nmbr$ ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
1423,tnf - naivea,C1448177
1423,tnf - naive patientsa,C1448177
1423,tnf - failurea,C1448177
1423,tnf - failure patientsa,C0231174;C0680095;C1448177
1423,prior anti - tnf treatment,C1448177;C1514463
1423,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
1422,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
1422,anti - tnf,C1448177
1421,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
1421,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
1421,rank based on treatment   =   placebo,C0667477;C0699794
1421,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
1421,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
1421,log - rank,C0667477;C0699794;C1708728;C2986775
1421,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
1421,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
1420,urinary protein - to - creatinine ratio | |,C1096054
1419,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
1419,urinary albumimcreatinine ratio,C1273442
1418,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
1418,urine albumin / creatinine ratio  mg / mmol,C0455271;C0567349;C1318330;C2348885
1418,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
1418,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
1418,urine albumin - to - creatinine ratio,C0455271;C1318330
1418,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
1418,urinary albumin : creatinine ratio ^,C0455271;C1318330
1418,urinary albumin : creatinine ratio *,C0455271;C1318330
1418,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
1418,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1418,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
1418,urinary albumin - to - creatinine ratio §,C0455271;C1318330
1418,urinary albumin - to - creatinine ratio ^,C0455271;C1318330
1417,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
1417,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
1417,albumin creatinine ratio,C0486293;C1318293
1417,albumin / creatinine ratio  n ( % ),C0486293;C1318293
1417,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
1417,albumin - to - creatinine ratio ' i  /,C0021966;C0221138;C0486293;C1318293
1417,albumin - to - creatinine ratio,C0486293;C1318293
1416,c - reactive proteinc,C0205332
1415,high - sensitivityc - reactive protein  mg / l,C0033684;C0205250;C0205332;C0439268;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1415,batellna c - reective protein,C0033684
1414,pulse — beats / min,C0232117;C0391850;C1947910
1414,pulse rate ( bpm ),C0232117
1414,pulse in beats / minute  mean ( sd ),C0232117;C0391850;C0439385;C0444504;C1947910;C2347634;C2348143;C2699239
1414,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910
1414,pulse  beats / min,C0232117;C0391850;C1947910
1413,luts = lower urinary tract symptoms  is =,C0574785
1413,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
1412,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
1412,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
1412,pah - ssc,C0030123;C3203102;C3897657;C4284467
1412,pah - sle,C0024141;C0030123;C3203102;C4284467
1412,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
1412,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
1412,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
1412,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
1411,no atopy ( n = $nmbr$ ),C0392707;C3539705
1411,atopy by phadiatop test  n ( % ),C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
1411,atopy ( specific ige ) c  n ( % ),C0205369;C0392707;C1552740;C3539705
1411,atopy ( n = $nmbr$  $nmbr$ ),C0392707;C3539705
1411,atopic ( based on phadiatop test ),C0392707
1411,atopic,C0392707
1410,apolipoprotein b ^,C0003593
1410,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
1410,apolipoprotein b,C0003593
1410,apob : apoal,C0003593;C3252643
1410,apob : apoa $nmbr$,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
1410,apob $nmbr$,C0003593;C3252643
1410,apob,C0003593;C3252643
1410,apo b *,C0003593;C3252643
1410,apo b,C0003593;C3252643
1410,apo - b,C0003593;C3252643
1409,sita / pio $nmbr$ / $nmbr$,C0030800;C2347712
1409,sita $nmbr$ + pio $nmbr$,C0030800;C2347712
1409,pio $nmbr$,C0030800;C2347712
1408,direction of hr,C0449738
1407,section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
1407,section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
1407,section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
1406,risk reduction ( $nmbr$ % cl ),C0596019;C1137094
1406,risk reduction  %,C1137094
1406,% risk reduction ( $nmbr$ % cl ),C0596019;C1137094
1405,erosion score ( $nmbr$ – $nmbr$ scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
1405,erosion score ( $nmbr$ - $nmbr$ ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
1405,erosion,C0333307;C1880549;C1959609;C3887524
1405,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
1405,> $nmbr$ erosion  n ( % ),C0333307;C1880549;C1959609;C3887524
1404,lv ejection fraction > $nmbr$ % and < $nmbr$ %,C0023128;C0489482;C0731033;C1881413;C2700378
1404,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
1404,lv ejection fraction  mean ( sd ) [ range ]  %,C0023128;C0444504;C0489482;C0731033;C1514721;C1881413;C2347634;C2348143;C2348147;C2699239;C2700378;C3542016
1404,lv ejection fraction  % ( n = $nmbr$ ),C0023128;C0489482;C0731033;C1881413;C2700378
1404,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
1404,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
1404,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
1404,ejection fraction category,C0489482;C0683312;C2700378;C3889287
1404,ejection fraction based on local reading,C0489482;C2700378
1404,ejection fraction : < $nmbr$ % ( n = $nmbr$ ),C0489482;C2700378
1404,ejection fraction *,C0489482;C2700378
1404,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
1404,ejection fraction ( % ),C0489482;C2700378
1404,ejection fraction  percent ( sd ),C0439165;C0489482;C2699239;C2700378
1404,ejection fraction  mean ( sd )  %,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
1404,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
1404,ejection fraction  %,C0489482;C2700378
1404,ejection fraction,C0489482;C2700378
1403,resection performed — no . { % ),C0015252;C0728940
1403,resection performed  %,C0015252;C0728940
1402,spironolactone ( n = $nmbr$ ),C0037982
1402,spironolactone  n ( % ),C0037982
1402,spironolactone,C0037982
1402,outcomes by treatment ( spironolactone vs placebo ),C0037982;C0085415
1402,mra ( spironolactone or eplerenone ),C0037982;C0243032;C1609165;C3891069
1401,sustained decrease of > $nmbr$ % in egfr ®,C0392756;C0443318;C0547047
1401,relative decrease > $nmbr$ %,C0080103;C0205345;C0392756;C0547047;C1547039
1401,reduced ef,C0392756
1401,primary outcome : $nmbr$ % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
1401,patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +,C0005910;C0006041;C0030705;C0392756;C0547047;C2986891
1401,absolute fvc decrease > $nmbr$ %,C0205344;C0392756;C0547047;C3714541
1401,absolute decrease > $nmbr$ %,C0205344;C0392756;C0547047
1401,a decrease of > $nmbr$ points in the cdai score,C0392756;C0547047;C2924612
1401,% with haq - di decrease > $nmbr$ . $nmbr$,C0392756;C0547047;C3826998;C4321476
1401,$nmbr$ % decrease in womac pain score,C0392756;C0547047;C0582148
1400,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
1400,rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl ),C0301630;C0392756;C0596019;C1293152;C4551656;C4554402
1400,reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %,C0019016;C0301630;C0392756;C1293152;C1825777;C3538758;C4551656
1400,reduction in odds %,C0301630;C0392756;C1293152;C4551656
1400,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
1400,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
1400,dose reduction  n ( % ),C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1400,composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes,C0205199;C0301630;C0392756;C1293152;C1547335;C4551656
1400,body weight reduction > $nmbr$ %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
1400,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1400,% reduction,C0301630;C0392756;C1293152;C4551656
1400,$nmbr$ ‐ point reduction in selena – sledai score  %,C0301630;C0392756;C0451528;C1293152;C1552961;C2347617;C3714763;C4551656
1399,serum values ^,C0042295;C0229671;C1546774;C1550100
1399,serum values,C0042295;C0229671;C1546774;C1550100
1399,serum urea nitrogen  mg / dl,C0028158;C0229671;C0439269;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
1399,serum trap - $nmbr$ b ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
1399,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
1399,serum p $nmbr$ np ( ^ g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
1399,serum n - propeptide of type $nmbr$ collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
1399,serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
1399,serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
1399,serum gastrint  pg / ml,C0229671;C0439297;C1546774;C1550100
1399,serum fg  mg / dl,C0016703;C0229671;C0439214;C0439269;C1546774;C1550100;C1638318;C2348814;C3642216
1399,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
1399,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
1399,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
1399,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
1399,serum $nmbr$ - hydroxyvitamin d  ng / ml,C0020337;C0229671;C0439275;C1546774;C1550100
1399,serum,C0229671;C1546774;C1550100
1399,patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % ),C0030705;C0220853;C0229671;C1546774;C1550100
1398,enoxaparin only,C0205171;C0206460;C1720467
1398,enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0206460
1398,enoxaparin / vka,C0206460
1398,enoxaparin ( n = $nmbr$ ),C0206460
1398,enoxaparin ( n = $nmbr$  $nmbr$ ),C0206460
1398,enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
1398,enoxaparin,C0206460
1397,enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0014025
1397,enalapril dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C3250443
1397,enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C1120110;C3250443
1397,enalapril + aliskiren ( n = $nmbr$ ),C0014025;C1120110
1397,enalapril ( n = $nmbr$ ),C0014025
1397,enalapril,C0014025
1396,not - japan n = $nmbr$  $nmbr$,C0022341;C1518422
1396,not - japan,C0022341;C1518422
1396,japan n = $nmbr$,C0022341
1396,japan and south korea,C0022341
1396,japan,C0022341
1396,calima japan ( n = $nmbr$ ),C0022341
1395,apolipoprotein a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508
1395,apolipoprotein a,C0003592;C0523508
1395,apoa - $nmbr$  g / l,C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
1395,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
1395,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
1395,apo a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
1395,apo a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
1394,apolipoprotein a - i *,C0085201;C1677784
1394,apolipoprotein a - i,C0085201;C1677784
1394,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
1394,apoa - i,C0085201;C1677784
1394,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
1394,apo a - i  mg / dl,C0085201;C0439269;C1677784
1394,apo a - i,C0085201;C1677784
1393,apixaban vs . placebo,C1831808
1393,apixaban dose ( or matching placebo ),C0178602;C0869039;C1114758;C1831808
1393,apixaban ( n = $nmbr$ ),C1831808
1393,apixaban  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1393,apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1393,apixaban,C1831808
1392,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
1392,paroxysmal af,C0235480
1392,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
1392,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
1391,paroxysmal ( n  % ),C0205311
1391,paroxysmal !,C0205311
1391,paroxysmal  n ( % ),C0205311
1391,paroxysmal,C0205311
1391,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
1390,rsg $nmbr$ mg / day,C0439422
1390,rasagiline  $nmbr$ mg / day,C0439422;C0525678
1390,no . of $nmbr$ - mg acetaminophen tablets / day,C0439422;C1243102
1390,mg / day,C0439422
1390,liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C1456408
1390,itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ ),C0165330;C0439422
1390,ics  mg / day,C0439422;C0815320;C4551720
1390,i - $nmbr$ mg / d ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
1390,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
1390,> $nmbr$ mg / day,C0439422
1390,> $nmbr$ mg / d peq,C0439422
1390,> $nmbr$ . $nmbr$ mg / day  %,C0439422
1390,< $nmbr$ mg / day,C0439422
1390,< $nmbr$ mg / d peq,C0439422
1390,$nmbr$ mg / day,C0439422
1390,$nmbr$ mg / d ( n = $nmbr$ ),C0439422
1389,$nmbr$ mg / day early - start - delayed start,C0439422
1389,$nmbr$ mg / day early - start - delayed - start,C0439422
1389,$nmbr$ mg / day early - start,C0439422
1389,$nmbr$ mg / day delayed - start,C0439422
1389,$nmbr$ mg / day - placebo,C0032042;C0439422;C1696465;C1706408
1388,≥ $nmbr$ ae,C3887670
1388,laboratory ae  n ( % },C0022877;C3244292;C3887670;C4283904
1388,due to ae,C3887670
1388,because of ae,C3887670
1388,any serious ae  n ( % ),C0205404;C3887670
1388,any ae leading to discontinuation  n ( % ),C3887670
1388,any ae  n ( % ) ‡,C3887670
1388,any ae,C3887670
1387,ae / e ' ratio ( per $nmbr$ unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
1387,ae / a ratio ( per $nmbr$ . $nmbr$ unit ),C3887670
1386,ease - $nmbr$,C1331418
1385,azl - ma,C0024443;C3887485
1384,ascot - lla,C0718674
1383,facit - f score,C0449820;C3272505;C4050231
1383,facit - f,C3272505
1382,ttf - fv,C1332112;C1705840;C4087167
1381,> $nmbr$ ft,C1881534;C3890579
1381,< $nmbr$ ft,C1881534;C3890579
1381,$nmbr$ - $nmbr$ ft,C1881534;C3890579
1380,mean score on haq - di §,C3533236;C3826998;C4321476
1380,health assessment questionnaire - disability index,C4321476
1380,haq di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
1380,haq di,C3826998;C4321476
1380,haq - di scoreff,C3826998;C4321476
1380,haq - di scored,C3826998;C4321476
1380,haq - di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
1380,haq - di score,C0449820;C3826998;C4050231;C4321476
1380,haq - di mcide,C3826998;C4321476
1380,haq - di improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3826998;C4321476
1380,haq - di improvement > $nmbr$ . $nmbr$,C2986411;C3826998;C4321476
1380,haq - di * *,C3826998;C4321476
1380,haq - di *,C3826998;C4321476
1380,haq - di ( $nmbr$ - $nmbr$ ),C3826998;C4321476
1380,haq - di  number ( % ),C0237753;C0449788;C3826998;C4321476
1380,haq - di,C3826998;C4321476
1380,( haq - di  $nmbr$ - $nmbr$ ),C3826998;C4321476
1379,mean hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
1379,hemoglobin a    ( % ),C0019016
1379,hba „ ( % ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
1379,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c   at randomization,C0019016;C0034656;C1825777;C3538758
1379,hba $nmbr$ c   ( % ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
1379,hba $nmbr$ c strata,C0019016;C1825777;C3538758
1379,hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
1379,hba $nmbr$ c distribution at baseline  n ( % ),C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
1379,hba $nmbr$ c distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
1379,hba $nmbr$ c distribution,C0019016;C0520511;C1704711;C1825777;C3538758
1379,hba $nmbr$ c category  n ( % ),C0019016;C0683312;C1825777;C3538758;C3889287
1379,hba $nmbr$ c category,C0019016;C0683312;C1825777;C3538758;C3889287
1379,hba $nmbr$ c categories  n ( % ),C0019016;C0683312;C1825777;C3538758
1379,hba $nmbr$ c at week $nmbr$,C0019016;C0332174;C0439230;C1825777;C3538758
1379,hba $nmbr$ c at $nmbr$ weeks *,C0019016;C0439230;C1825777;C3538758
1379,hba $nmbr$ c \n,C0019016;C1825777;C3538758
1379,hba $nmbr$ c > = $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c > $nmbr$ · $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c > $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
1379,hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c > $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c < $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
1379,hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c < $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c ( sd )  %,C0019016;C1825777;C2699239;C3538758
1379,hba $nmbr$ c ( n ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % ),C0019016;C0030705;C1825777;C3538758
1379,hba $nmbr$ c ( % ) all countries,C0019016;C0454664;C1825777;C3538758
1379,hba $nmbr$ c ( % ) *,C0019016;C1825777;C3538758
1379,hba $nmbr$ c ( % ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
1379,hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
1379,hba $nmbr$ c $nmbr$ - < = $nmbr$ %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c  n,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  mmol / mold,C0019016;C0369241;C0439190;C1825777;C3538758
1379,hba $nmbr$ c  median ( sd )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2699239;C2939193;C3538758
1379,hba $nmbr$ c  mean = sd  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1379,hba $nmbr$ c  mean ( sd )  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1379,hba $nmbr$ c  > $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  < $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  ( % ),C0019016;C1825777;C3538758
1379,hba $nmbr$ c  % §,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  % d,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  % *,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  % ( sd ),C0019016;C1825777;C2699239;C3538758
1379,hba $nmbr$ c  %  n ( % ) b,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  %,C0019016;C1825777;C3538758
1379,hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
1379,hba $nmbr$ c,C0019016;C1825777;C3538758
1379,hba  c ( % ),C0019016;C1825777;C3538758
1379,hba  % $nmbr$ c,C0019016;C1825777;C3538758
1379,hba   ( % ),C0019016;C1825777;C3538758
1379,glycaemic control ( hba $nmbr$ c )  n ( % ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
1379,any hba $nmbr$ c,C0019016;C1825777;C3538758
1379,$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
1379,$nmbr$ % < hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
1378,no . in the $nmbr$ mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
1378,fall in last $nmbr$ mo,C0026544;C0085639;C0238715;C0332177;C4553726
1378,duration of macular edema  mo,C0024440;C0026544;C0271051;C0332177;C0449238;C2926735
1378,duration of disease — mo,C0026544;C0332177;C0872146
1378,at least $nmbr$ / mo,C0026544;C0332177
1378,antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177
1378,> $nmbr$ mo,C0026544;C0332177
1378,< $nmbr$ mo  n ( % ),C0026544;C0332177
1378,< $nmbr$ mo,C0026544;C0332177
1378,$nmbr$ to < $nmbr$ mo,C0026544;C0332177
1378,$nmbr$ mo - $nmbr$ y,C0026544;C0332177
1378,$nmbr$ mo,C0026544;C0332177
1378,$nmbr$ - < $nmbr$ mo  n ( % ),C0026544;C0332177
1378,$nmbr$ - $nmbr$ mo,C0026544;C0332177
1377,smoking ( during the previous month ),C0332177;C0439231;C2114448
1377,serum ua < $nmbr$ mg / dl by month $nmbr$,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
1377,monthly,C0332177
1377,fpg month $nmbr$ ( mg / dl ),C0332177;C0439231;C0439269
1377,$nmbr$ week to $nmbr$ month,C0332174;C0332177;C0439230;C0439231
1377,$nmbr$ - $nmbr$ / month,C0332177;C0439231
1376,nilvadipine,C0132512
1375,sulfasalazine,C0036078
1374,hydralazine,C0020223
1373,not hispanie / latino,C0086528;C1518422
1373,latino,C0086528
1373,hispanie / latino,C0086528
1373,hispanic / latino,C0086409;C0086528
1372,haplotype,C0018591
1371,radiate,C0332301
1370,pramlintide,C0537551
1369,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
1369,fatal or nonlatal stroke,C1302234;C1705232
1369,fatal or nonlatal myocardial inlarctlon,C1302234;C1705232
1369,fatal or nonfatal stroke,C1302234;C1705232
1369,fatal or nonfatal myocardial infarction,C1302234;C1705232
1369,fatal or non - fatal stroke,C1302234;C1705232
1369,fatal or non - fatal myocardial infarction,C1302234;C1705232
1369,fatal chd and nonfatal mia,C0280604;C1302234;C1705232;C3542407
1369,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
1369,fatal bleeding,C0019080;C1302234;C1705232
1369,fatal bleed,C0019080;C1302234;C1705232
1369,fatal and nonfatal stroke,C1302234;C1705232
1369,fatal and nonfatal ml,C1302234;C1705232
1369,fatal aes,C1302234;C1412268;C1705232;C2699274
1369,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
1369,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
1369,fatal / nonfatal mi ( excluding silent mi ),C1302234;C1705232;C3810814
1369,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
1369,fatal & nonfatal ccvd,C1302234;C1705232
1369,fatal,C1302234;C1705232
1369,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
1368,af pattern,C0344434;C0449774;C4049859
1368,af or atrial flutter 卞,C0344434;C4049859
1368,af or atrial flutter !,C0344434;C4049859
1368,af duration  n ( % ),C0344434;C0449238;C2926735;C4049859
1368,af alone,C0344434;C4049859
1368,af,C0344434;C4049859
1367,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation ( n = $nmbr$ $nmbr$ ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation  no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
1367,symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % ),C0004238;C0344434;C0683368;C1457887;C1963067
1367,symptoms of atrial fibrillation in the $nmbr$ months before randomiza -,C0004238;C0344434;C0683368;C1457887;C1963067
1367,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
1367,no atrial fibrillation,C0004238;C0344434;C1963067
1367,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0205435;C0332189;C0344434;C1279901;C1963067
1367,ecg atrial fibrillation  n ( % ),C0004238;C0344434;C1623258;C1963067
1367,duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
1367,duration of last qualifying episode of atrial fibrillation > $nmbr$ days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
1367,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
1367,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation type  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1367,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
1367,atrial fibrillation or flutter — no . ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation or flutter ( ecg ) §,C0004238;C0344434;C1963067
1367,atrial fibrillation or flutter,C0004238;C0344434;C1963067
1367,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
1367,atrial fibrillation alone ),C0004238;C0344434;C1963067
1367,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation !,C0004238;C0344434;C1963067
1367,atrial fibrillation    n   ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
1367,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
1367,atrial fibrillation  %,C0004238;C0344434;C1963067
1367,atrial fibrillation,C0004238;C0344434;C1963067
1367,> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0004238;C0332189;C0344434;C1963067
1366,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
1366,higher dose edoxaban regimen,C0205250;C2348331;C2975435
1366,higher - dose edoxaban vs warfarin,C0444956;C2975435
1366,higher - dose edoxaban ( n = $nmbr$ )  n ( % / y ),C0444956;C2975435
1366,high - dose edoxaban vs warfarin,C0444956;C2975435
1366,high - dose edoxaban ( n = $nmbr$ ),C0444956;C2975435
1366,high - dose edoxaban,C0444956;C2975435
1366,edoxaban lower dose vs warfarin,C2975435
1366,edoxaban higher dose vs warfarin,C0444956;C2975435
1365,ld edoxaban vs warfarin,C0694649;C2975435
1365,hd edoxaban vs warfarin,C2975435
1365,edoxaban warfarin,C0043031;C2975435
1365,edoxaban vs . warfarin,C2975435
1365,edoxaban n = $nmbr$ n / n ( % ),C2975435
1365,edoxaban n = $nmbr$,C2975435
1365,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
1365,edoxaban ( n = $nmbr$ ),C2975435
1365,edoxaban,C2975435
1364,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
1364,standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0439475;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
1364,patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478
1364,patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
1364,patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0030705;C0037623;C0439475;C1415692;C1708288;C4318478
1364,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
1364,on bp medication  n ( % ),C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
1364,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
1364,key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac,C0015663;C0017725;C0037623;C1415692;C1708288;C2983605;C4318478
1364,intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0162425;C0439475;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
1364,bp variable  mm hg,C0037623;C0439475;C0439828;C1415692;C1708288;C4318478;C4553760
1364,bp in pre - treated patients,C0037623;C1415692;C1708288;C4318478
1364,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
1364,bp goal at week $nmbr$,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
1364,bp goal  no . ( % ),C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
1364,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
1364,bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478
1364,bp < $nmbr$ / $nmbr$  n ( % ),C0037623;C1415692;C1708288;C4318478
1364,bp - lowering treatments  n ( % ),C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
1364,bp - lowering treatment ( n = $nmbr$ ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
1363,prior pacemaker  n ( % ),C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
1363,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
1363,pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703
1363,pacemaker  n ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
1363,pacemaker  ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
1363,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
1363,cardiac pacemaker — no . ( % ),C0030163;C0037189
1362,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
1362,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
1362,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
1362,parameter  n ( % ),C0549193;C1704769;C2350001
1362,parameter  % ( $nmbr$ % ci ),C0008107;C0549193;C1704769;C2350001;C3259781
1362,parameter,C0549193;C1704769;C2350001
1362,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
1362,$nmbr$ parameter,C0549193;C1704769;C2350001
1361,octi & mate $nmbr$,C0682323;C1260875
1361,mate !,C0682323;C1260875
1361,mate,C0682323;C1260875
1361,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
1361,companion : $nmbr$ - $nmbr$ hours,C0031268;C0335343;C0439227;C0682323
1360,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
1360,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
1360,ratio of women to men — %,C0043210;C0456603;C1547037
1360,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1360,ratio of urinary albumin ( mg ) to creatinine ( g ),C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1360,ratio of ldl to hdl cholesterol,C0456603;C1547037
1360,ratio of ldl to hdl,C0456603;C1547037
1360,ratio of hrs ( $nmbr$ % cl )  p for sex interaction,C0456603;C0596019;C1547037;C1568891
1360,ratio of hrs ( $nmbr$ % ci )  p for sex interaction,C0008107;C0456603;C1547037;C1568891;C3259781
1360,ratio of fev $nmbr$ to fvc ( % ),C0456603;C1547037;C3714541
1360,ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
1360,ratio,C0456603;C1547037
1360,rate ratio { $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
1360,rate ratio vs placebo ( $nmbr$ % ci ),C0456603;C0871208;C1521828;C1547037
1360,rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl ),C0456603;C0871208;C1521828;C1547037;C2981360
1360,rate ratio ( $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
1360,rate ratio ( $nmbr$ % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
1360,rate ratio,C0456603;C0871208;C1521828;C1547037
1360,post - bronchodilator ratio of fev $nmbr$ to fvc — %,C0456603;C1547037;C2599594;C3714541
1360,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
1360,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
1360,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
1360,hzard ratio,C0456603;C1547037
1360,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
1360,fev $nmbr$ : fvc ratio,C0456603;C1547037;C3714541
1360,fev $nmbr$ / fvc ratio *,C0456603;C1547037;C3714541
1360,fev $nmbr$ / fvc ratio  % ( sd ),C0456603;C1547037;C2699239;C3714541
1360,fev $nmbr$ / fvc ratio  %,C0456603;C1547037;C3714541
1360,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
1360,e / a ratio,C0456603;C1547037
1360,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
1360,cardiothoracic ratio > $nmbr$ . $nmbr$,C0456603;C1547037;C4055270
1360,cardiothoracic ratio,C0456603;C1547037;C4055270
1360,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
1360,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1360,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1360,apob : apoa - $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1360,apob : apoa $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1360,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1359,subcutaneous unfractionated heparin,C0353681
1358,subcutaneous injections,C0021499
1357,subcutaneous ( n = $nmbr$ ),C0443315
1356,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
1356,intravenous heparin,C0354566
1355,statin intolerance $nmbr$  n ( % ),C0231199;C0360714;C1744706;C2355652
1355,previous intolerance of infliximab  n ( % ) *,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1355,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1355,intolerance ®,C0231199;C1744706;C2355652
1355,intolerance ',C0231199;C1744706;C2355652
1355,intolerance,C0231199;C1744706;C2355652
1354,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
1354,in ambulance,C0002422;C3846685
1354,ambulance ( % ),C0002422;C3846685
1354,ambulance  n ( % ),C0002422;C3846685
1354,ambulance,C0002422;C3846685
1353,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C3273373;C3665488
1353,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C2344255;C4050145
1353,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C2344255;C4050145
1353,insulin glargine   ±   oad,C0907402
1353,insulin glargine vs standard care least - squares mean ( $nmbr$ % cl ),C0907402
1353,insulin glargine n ( x ),C0907402
1353,insulin glargine n ( % ) / $nmbr$ py,C0030428;C0907402;C3538810
1353,insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ ),C0004446;C0293359;C0907402
1353,insulin glargine ( n = $nmbr$ ll ),C0907402
1353,insulin glargine ( n = $nmbr$ ),C0907402
1352,number insulin glargine,C0237753;C0449788;C0907402
1352,insulin glargine,C0907402
1352,iglar ( insulin glargine l $nmbr$ u ),C0439148;C0907402
1352,glargine n ( n / loopy ),C0907402
1352,glargine $nmbr$,C0907402
1352,glargine,C0907402
1351,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
1351,prior lipid - modifying therapy,C0023779;C0392747;C1514463
1351,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
1351,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
1350,volume change  mm ^,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952;C4330985;C4554674
1350,third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205437;C0392747;C0439612;C0439631;C0443172;C1705241;C3639721;C4319952
1350,tadalafil $nmbr$ mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
1350,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
1350,subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0168634;C0392747;C0443172;C1442488;C1705241;C2986480;C4319952
1350,st change > $nmbr$ mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
1350,sf ‐ $nmbr$ pcs  ls mean change ± se,C0023668;C0036919;C0037712;C0392747;C0443172;C0444504;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
1350,sf - $nmbr$ pcs  ls mean change from baseline   ±   se,C0023668;C0036919;C0037712;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
1350,sf - $nmbr$ bodily pain  mean change from baselinee,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
1350,sf - $nmbr$ bodily pain  mean change from baselineb,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
1350,secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
1350,second primary ( estimated change in total updrs score from baseline to wk $nmbr$ ),C0205225;C0205436;C0392747;C0439175;C0439612;C0439631;C0439810;C0443172;C0457385;C0565930;C0750572;C1561503;C1705190;C1705241;C3639721;C4319952
1350,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
1350,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
1350,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
1350,patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
1350,patients with change from baseline in psa - modified total shs score # $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
1350,pain vas  mean change from baselined,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,pain vas  mean change from baselinea,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,nominal change,C0392747;C0443172;C1705241;C4319952
1350,no change,C0392747;C0443172;C1705241;C4319952
1350,median change in atheroma volume  %,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
1350,mean percentage change from baseline to final visit,C0168634;C0392747;C0439165;C0443172;C0444504;C1442488;C1549488;C1561533;C1705241;C2347634;C2348143;C4319952
1350,mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0439175;C0439810;C0443172;C0444504;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
1350,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,mean change in sbp from baseline  mmhg  mean ( sd ),C0085805;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,mean change in radiographic end points shs  mean ± sd,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C2699239;C4319952
1350,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
1350,mean change in fev $nmbr$,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
1350,mean change in dbp from baseline  mg / dl  mean ( sd ),C0392747;C0443172;C0444504;C0536221;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952
1350,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
1350,mean change from baseline in the number of,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change from baseline in acq overall score ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change from baseline bp at week $nmbr$,C0168634;C0392747;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change from baseline  % ‐ points,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change from baseline  %,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,mean change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,mean change  % ( se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
1350,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,ls mean change from baseline ( se )  %,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls mean change from baseline $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls mean change from baseline  ml ( se ) a,C0023668;C0036919;C0168634;C0392747;C0439526;C0443172;C0444504;C1442488;C1705224;C1705241;C2347634;C2348143;C3887665;C4319952
1350,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
1350,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,ls - mean change from baseline ( $nmbr$ % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
1350,hscrp  exp ls mean change ± se ‡,C0023668;C0036919;C0392747;C0443172;C0444504;C1417055;C1705241;C2347634;C2348143;C4319952
1350,hba $nmbr$ c ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
1350,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
1350,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
1350,first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205435;C0392747;C0439612;C0439631;C0443172;C1279901;C1705241;C3639721;C4319952
1350,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
1350,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0242485;C0392747;C0443172;C0729333;C1705241;C4319952
1350,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
1350,das $nmbr$ - crp  ls mean change from baseline ( se ) §,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
1350,das $nmbr$ - crp  ls mean change from baseline ( se ) ¥,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
1350,changes in shs,C0392747;C0443172
1350,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C1705241;C4319952
1350,change to   week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1350,change to week $nmbr$ * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1350,change to week $nmbr$ *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1350,change to week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1350,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
1350,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
1350,change in sesbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,change in sedbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,change in sbp ( $nmbr$ months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
1350,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
1350,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
1350,change in psa ‐ modified shs  baseline to week $nmbr$ ‡,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
1350,change in psa ‐ modified shs  baseline to week $nmbr$,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
1350,change in pav  mean ( $nmbr$ % cl )  %,C0058890;C0392747;C0443172;C0444504;C0596019;C1705241;C2347634;C2348143;C4319952
1350,change in nt - probnp at $nmbr$ months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
1350,change in nt - probnp at $nmbr$,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
1350,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
1350,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
1350,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
1350,change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl ),C0392747;C0443172;C1705241;C4319952
1350,change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % ),C0019016;C0392747;C0443172;C1705241;C1825777;C3538758;C4319952
1350,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
1350,change in fpg $nmbr$ to month $nmbr$ ( mg / dl ),C0392747;C0443172;C1705241;C4319952
1350,change in fev $nmbr$ at week $nmbr$,C0392747;C0443172;C1705241;C3714541;C4319952
1350,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0392747;C0443172;C1705241;C4319952
1350,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
1350,change in das $nmbr$ > $nmbr$ . $nmbr$,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
1350,change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
1350,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
1350,change from,C0392747;C0443172;C1705241;C4319952
1350,change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1350,change $nmbr$,C0392747;C0443172;C1705241;C4319952
1350,change,C0392747;C0443172;C1705241;C4319952
1350,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
1350,before a change to the enrollment form was implemented in august $nmbr$ . bnp,C0348078;C0376315;C0392747;C0443172;C1516879;C1522492;C1696073;C1705241;C3888021;C4255237;C4319952
1350,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
1350,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
1350,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
1350,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
1350,basdai  mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
1350,basdai  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
1350,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
1350,asqol  ls mean change ± se,C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,asqol  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ],C0008107;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
1350,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1350,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
1350,( mean change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
1350,( mean % change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
1350,% change median baseline crp > $nmbr$ mg / l,C0392747;C0443172;C1705241;C4319952
1350,% change from baseline  mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1350,% change ( median  q $nmbr$  q $nmbr$ ),C0392747;C0443172;C1705241;C4319952
1350,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
1350,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
1350,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1350,% change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C1705241;C3259781;C4319952
1350,% change,C0392747;C0443172;C1705241;C4319952
1350,$nmbr$ year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1349,total psa ‐ modified shs,C0392747;C2986589;C3889737
1349,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
1349,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
1349,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
1349,modified has - bled score  mean ± sd,C0392747;C3889737
1349,modified has - bled > $nmbr$,C0392747;C3889737
1349,modified has - bled < $nmbr$,C0392747;C3889737
1349,modified has - bled $ $nmbr$,C0392747;C3889737
1349,modified has - bled,C0392747;C3889737
1349,modified hachinski ischemia scale  mean ( sd ) c,C0022116;C0175659;C0349674;C0392747;C0444504;C1947916;C2347634;C2348143;C2699239;C3889737;C4321499
1349,modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C0392747;C3541413;C3889737
1348,prior cardiovascular disease,C0007222;C0332152;C2826257
1348,no cardiovascular disorder $nmbr$ ',C0007222
1348,no cardiovascular disease ( n = $nmbr$ ),C0007222
1348,medical history of cv disease or heart failure  n ( % ),C0007222;C0262926
1348,cardiovascular disorder  n ( % ),C0007222
1348,cardiovascular disorder,C0007222
1348,cardiovascular disease n ( % ),C0007222
1348,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1348,cardiovascular disease history  n ( % ) *,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1348,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1348,cardiovascular disease *,C0007222
1348,cardiovascular disease ( n = $nmbr$ ),C0007222
1348,cardiovascular disease,C0007222
1348,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1348,any cardiovascular disease,C0007222
1347,current cvd / diabetes  n ( % ),C0007222;C0011847;C0011849;C0521116;C1705970
1347,$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ ),C0007222
1347,$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ ),C0007222
1346,cvd without ml ^ troke,C0007222;C0439526;C1705224;C3887665
1346,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
1346,cvd without miatroke,C0007222
1345,no cvd,C0007222
1345,cvd,C0007222
1345,combined cvd,C0007222;C0205195
1345,combined $nmbr$ - year cvd,C0007222;C0205195;C0439234;C0439508
1345,chronic cvd,C0007222;C0205191
1344,cvd subjects,C0007222
1344,cvd or mi,C0007222
1344,cvd deaths,C0007222;C0011065;C1306577
1344,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
1344,cvd  ckd,C0007222;C1561643
1343,cvd without mi or stroke ( n = $nmbr$ ),C0007222;C3810814
1343,cvd / stroke / see,C0007222;C0038454;C4554100
1343,cvd / mi / stroke / urgent vascular hospitalization,C0007222;C3810814
1343,cvd / mi / stroke / urgent coronary revascularization,C0007222;C3810814
1343,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
1343,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
1343,cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina,C0007222;C0038454;C3810814;C4554100
1343,cvd  mi  stroke  or recurrent ischemia - urgent revascularization,C0007222;C0038454;C3810814;C4554100
1343,cvd  mi  or stroke,C0007222;C3810814
1343,cv disease,C0007222
1342,atenolol use at $nmbr$ month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
1342,atenolol strategy ( n = $nmbr$ ),C0004147;C0679199
1342,atenolol strategy ( n = $nmbr$  $nmbr$ ),C0004147;C0679199
1342,atenolol strategy,C0004147;C0679199
1342,atenolol n = $nmbr$ no . ( % ),C0004147
1342,atenolol n = $nmbr$,C0004147
1342,atenolol - losartan,C0004147;C0126174
1342,atenolol *,C0004147
1342,atenolol ( « = $nmbr$ $nmbr$ ),C0004147
1342,atenolol ( no . = $nmbr$ ),C0004147
1342,atenolol ( n = $nmbr$ ),C0004147
1342,atenolol ( n = $nmbr$  $nmbr$ ),C0004147
1342,atenolol,C0004147
1341,femoral neckc,C0015811
1341,femoral access — no . / total no . ( % ),C0015811
1341,femoral access,C0015811;C0444454;C1554204
1341,femoral,C0015811
1340,serum ldl cholesterol,C0428474
1339,non ‐ hdl cholesterol,C0729627;C1535899
1339,non - hdl cholesterol j,C0729627;C1535899
1339,non - hdl cholesterol ( week $nmbr$ ),C0332174;C0439230;C0729627;C1535899
1339,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
1339,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
1339,non - hdl cholesterol,C0729627;C1535899
1339,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
1338,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
1338,placebo ‐ controlled period,C0439531;C1706408;C1948053
1337,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
1337,test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
1337,ppg post - meal test  mmol / l,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C1532563;C3831328;C4318744
1337,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
1337,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
1337,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
1337,laboratory tests,C0022885
1337,laboratory testing,C0022885
1337,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
1337,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
1336,without beta blocker,C0001645
1336,with beta blocker,C0001645
1336,use of beta - blockers,C0001645;C1524063
1336,use of beta - blocker,C0001645;C1524063
1336,no beta - blocker,C0001645
1336,beta - blockers ( all )  n ( % ),C0001645
1336,beta - blocker — no . / total no . ( % ),C0001645
1336,beta - blocker ( except sotalol ),C0001645;C0037707
1336,beta - adrenergic blocker,C0001645;C2757061;C3536830
1335,no betablocker use,C0001645;C0042153;C0457083;C1947944
1335,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
1335,betablocker use,C0001645;C0042153;C0457083;C1947944
1335,betablocker,C0001645
1335,beta blockers,C0001645
1335,beta blocker users,C0001645;C1706077
1335,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
1335,beta blocker use,C0001645;C0042153;C0457083;C1947944
1335,beta blocker  n ( % ),C0001645
1335,beta blocker  %,C0001645
1335,beta blocker,C0001645
1335,beta - blockers  n ( % ),C0001645
1335,beta - blockers  ( % ),C0001645
1335,beta - blockers,C0001645
1335,beta - blocker — no . ( % ),C0001645
1335,beta - blocker use,C0001645;C0042153;C0457083;C1947944
1335,beta - blocker n ( % ),C0001645
1335,beta - blocker !,C0001645
1335,beta - blocker  %,C0001645
1335,beta - blocker,C0001645
1334,alpha blockers,C0001641
1334,alpha - blockers,C0001641
1334,alpha - blocker / other vasodilator,C0001641
1334,alpha - blocker,C0001641
1334,alpha $nmbr$ blockers,C0001641
1333,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
1333,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
1333,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1333,oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
1333,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
1333,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
1333,lower tertile : b $nmbr$ . $nmbr$,C0441994;C1548802;C2003888
1333,lower,C0441994;C1548802;C2003888
1333,lipid lowering,C0023779;C0441994;C2003888
1333,lipid - lowering medications ^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
1333,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
1333,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1333,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1333,lipid - lowering,C0023779;C0441994;C2003888
1333,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
1333,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
1333,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
1333,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
1333,concomitant oral glucose - lowering agents  zz ( % ),C0017725;C0441994;C0442027;C2003888;C2347310;C2347852;C4521986
1333,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
1333,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
1333,> $nmbr$ glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
1332,inspiratory capacity ( l ),C0021610;C0802663
1331,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
1331,respiratory rate  breaths / min,C0231832;C0439386;C0489258
1330,upper respiratory tract inflammation,C0877266
1329,upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ ),C0041912
1329,upper respiratory tract infection,C0041912
1328,laboratory examination,C0260877
1327,laboratory measurements,C0681902
1326,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
1326,laboratory variables,C0022877;C0439828;C3244292;C4283904
1326,laboratory values,C0022877;C0042295;C3244292;C4283904
1326,laboratory measures,C0022877;C3244292;C4283904
1326,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
1326,laboratory determinations,C0022877;C0680730;C3244292;C4283904
1326,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
1325,nitrates ( oral or topical ),C0028125;C0699857;C3848573
1325,nitrates ( % ),C0028125;C0699857;C3848573
1325,nitrates  n ( % ),C0028125;C0699857;C3848573
1325,nitrates  ( % ),C0028125;C0699857;C3848573
1325,nitrates,C0028125;C0699857;C3848573
1325,nitrate — no . ( % ),C0028125;C0699857;C3848573
1325,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
1325,nitrate ( oral or topical ),C0028125;C0699857;C3848573
1325,nitrate ( oral or intravenous ),C0028125;C0699857;C3848573
1325,nitrate,C0028125;C0699857;C3848573
1324,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
1324,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1547111;C3714652;C4321495
1324,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1324,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1324,rheumatoid factor or acpa positive  or both,C0035448;C0201660
1324,rheumatoid factor and acpa positive,C0035448;C0201660
1324,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
1324,rheumatoid factor !,C0035448;C0201660
1324,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
1324,rf positive and acpa negative  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1324,rf positive  no . ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1324,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
1324,rf or acpa positive,C0035448;C0201660;C0748398;C1547111
1324,rf negative and acpa positive  n ( % ),C0035448;C0201660;C0205160;C0748398;C1513916;C1547111;C2825415;C2825491;C3853545
1324,rf and acpa positive  n ( % ),C0035448;C0201660;C0748398;C1547111
1324,rf and acpa negative $nmbr$,C0035448;C0201660;C0748398;C1547111
1324,rf and acpa negative  n ( % ),C0035448;C0201660;C0748398;C1547111
1324,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
1324,% rf +,C0035448;C0201660;C0748398;C1547111
1323,randomised patients with basdai assessment at baseline and week $nmbr$  n,C0679830;C1998004
1323,patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C0679830
1323,patient assessment of disease activity  mm,C0679830;C1292728;C4330985;C4554674
1323,patient assessment of arthritis pain  mm,C0679830;C4317006;C4330985;C4554674
1323,patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas ),C0042815;C0679830
1322,patient global assessment of disease,C0012634;C4054229
1322,patient ' s global assessment of disease,C0012634;C4054229
1322,patient ' s global assessment of,C4054229
1322,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
1322,patient ' s global assessment !,C4054229
1322,patient ' s global assessment,C4054229
1321,percent change from baseline to week $nmbr$ in auc ( mean  sem ),C3272907
1321,percent change from baseline at week $nmbr$,C3272907
1320,action tested is between the continuous variable and treatment .,C0441472;C3266814
1319,patient ' s preference not to take vka  only reason * *,C0376409
1319,patient ' s preference not to take vka  only reason,C0376409
1319,patient ' s preference not to take,C0376409
1318,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0073633;C1280500;C1518681;C2348382
1318,effect of covariates on slopes,C1280500;C1518681;C2348382
1318,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
1317,treatment effect ( hr ),C1518681
1317,genotype - specific treatment effect hazard ratio ( $nmbr$ % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
1316,use of antiplatelet agents — no . / total no . ( % ),C0085826;C1524063
1316,use of antiplatelet agents ^,C0085826;C1524063
1316,use of antiplatelet agents  n ( % ),C0085826;C1524063
1316,other antiplatelet agents  n ( % ),C0085826
1316,other antiplatelet agents,C0085826
1316,other antiplatelet agent 一 no . ( % ),C0085826
1316,antiplatelets agents,C0085826
1316,antiplatelet drugs,C0085826;C2963157
1316,antiplatelet drug,C0085826
1316,antiplatelet agents ( % ),C0085826
1316,antiplatelet agents,C0085826
1316,antiplatelet agent or anticoagulant,C0085826
1316,antiplatelet agent n ( % ),C0085826
1316,antiplatelet agent,C0085826
1315,creatinine clearance category [ ml / min ],C0439445;C0683312;C0812399;C3889287
1315,creatinine clearance category  ml / min  no . ( % ) b,C0439445;C0683312;C0812399;C3889287
1315,creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$,C0373595;C0439445;C0683312;C3889287
1315,creatine clearance category,C0373595;C0683312;C3889287
1315,creatine clearance  ml / min,C0373595;C0439445
1314,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
1314,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
1314,creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f,C0151280
1313,renal function : creatinine clearance,C0232804;C0812399
1313,creatinine clearance ， : : $nmbr$ ml / min  %,C0439445;C0812399
1313,creatinine clearance — no . ( % ),C0812399
1313,creatinine clearance — ml / min,C0439445;C0812399
1313,creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % ),C0439445;C0812399
1313,creatinine clearance < $nmbr$ ml / min ( % ),C0439445;C0812399
1313,creatinine clearance < $nmbr$ ml / min  no . / total ( % ),C0439445;C0812399
1313,creatinine clearance < $nmbr$ ml / min,C0439445;C0812399
1313,creatinine clearance ( ml / min )  mean ± sd,C0439445;C0444504;C0812399;C2347634;C2348143;C2699239
1313,creatinine clearance ( ml / min ),C0439445;C0812399
1313,creatinine clearance  no . ( % ),C0812399
1313,creatinine clearance  n ( % ),C0812399
1313,creatinine clearance  ml / min - $nmbr$ *,C0439445;C0812399
1313,creatinine clearance  ml / min,C0439445;C0812399
1313,creatinine clearance  an   ( % ),C0812399
1313,creatinine clearance,C0812399
1313,baseline creatinine clearance,C0168634;C0812399;C1442488
1312,receiving concomitant nsaids and / or cox - $nmbr$ inhibitors,C1514756
1312,receiving concomitant corticosteroids,C1514756
1312,receiving antihypertensive treatment -,C1514756
1312,receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd ),C1514756
1312,receiving antihypertensive,C1514756
1312,received drug - eluting stent,C1322815;C1514756
1312,received antihypertensive within last $nmbr$ days  n ( % ),C0003364;C0439228;C1514756
1312,received an oral aha within $nmbr$ weeks prior to screening,C1514756
1312,received > $nmbr$ prior anti - tnf therapies  n,C0279936;C0332152;C0432633;C1514756;C2826257
1312,received $nmbr$ prior anti - tnf therapy  n,C0279936;C0332152;C0432633;C1514756;C2826257
1311,types of fibrinolytic agent,C0016018;C0332307
1311,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
1311,thrombolytic agents,C0016018
1311,fibrinolytic agents before or after entry,C0016018
1311,fibrinolytic agent — no . ( % ) : t,C0016018
1311,fibrinolytic agent given,C0016018
1311,fibrinolytic agent before randomisation,C0016018;C0034656
1310,time in therapeutic range before inclusion,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
1310,time in therapeutic range  median ( iqr )  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
1310,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
1310,median time in therapeutic range for warfarin recipients  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
1310,in therapeutic range for warfarin subjects,C0043031;C0460097
1310,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C1547707;C1554109;C2946261;C3541383;C3810851
1309,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western,C0205120;C0449820;C0489786;C1552595;C1705493;C4050369
1309,height — cm,C0489786
1309,height ( cm ),C0489786
1309,height '  cm,C0489786
1309,height  inches,C0439204;C0489786
1309,height  cm *,C0489786
1309,height  cm,C0489786
1308,peripheral artery disease 一 no . ( % ),C1704436;C4025272
1308,peripheral artery disease — no . ( % ),C1704436;C4025272
1308,peripheral artery disease details,C1704436;C4025272
1308,peripheral artery disease - -,C1704436;C4025272
1308,peripheral artery disease *,C1704436;C4025272
1308,peripheral artery disease,C1704436;C4025272
1308,peripheral arterial stenosis,C4025272
1308,peripheral - artery stenosis,C4025272
1308,peripheral - artery disease — no . ( % ),C1704436;C4025272
1308,peripheral - artery disease ( % ),C1704436;C4025272
1308,peripheral - artery disease,C1704436;C4025272
1308,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
1307,peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0205390;C1300072;C1306673;C1306889
1307,peripheral artery occlusive disease,C1306889
1306,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
1306,peripheral artery diseasef,C0489868
1306,peripheral artery diseaseb,C0489868
1306,peripheral artery,C0489868
1305,pvalue for heterogeneity,C0019409;C0242960
1305,pfor heterogeneity,C0019409;C0242960;C1151635
1305,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0242960;C0289313;C1709380
1305,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0019409;C0242960;C0289313;C1709380
1305,p value for heterogeneity,C0019409;C0242960;C1709380
1305,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
1305,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
1305,heterogeneity or trend p value,C0019409;C0242960
1305,heterogeneity or trend p vaiue,C0019409;C0242960
1305,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
1305,* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .,C0019409;C0242960;C0369773;C1518681;C2603361
1304,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
1304,hypoglycemic agent,C0020616
1304,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
1304,hypoglycaemic agents,C0020616
1304,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
1304,antihyperglycemic,C0020616
1303,other hypoglycemic agent  n ( % ),C0020616
1303,other antihyperglycemic agents  not listed,C0020616
1303,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
1302,id genotype,C0009450;C0017431;C0600091;C1441613
1302,genotype,C0017431
1301,genotyping,C1285573
1301,by genotyping,C1285573
1300,feet,C0016504;C0347981
1300,beyond popliteal pedal,C0016504;C0442037;C0687080
1299,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1299,pe with / without dvt,C0070939;C1880476;C4284304
1299,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
1299,pe associated with dvt at diagnosis,C0070939;C1880476;C4284304
1299,pe and dvt,C0070939;C1880476;C4284304
1299,pe ( with or without dvt ),C0070939;C1880476;C4284304
1299,pe,C0070939;C1880476;C4284304
1299,neither pe nor dvt,C0070939;C1880476;C4284304
1298,stroke of undetermined cause,C0015127;C0038454;C1524003
1298,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
1298,pah origin / cause,C0015127;C1418251;C1524003
1298,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1298,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1298,other determined etiology,C0015127;C0521095;C1314792;C1524003
1298,other cause  n ( % ),C0015127;C1524003
1298,other cause,C0015127;C1524003
1298,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
1298,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
1298,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
1298,ischemic etiology  %,C0015127;C0475224;C1314792;C1524003
1298,ischemic etiology,C0015127;C0475224;C1314792;C1524003
1298,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
1298,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
1298,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
1298,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
1298,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
1298,etiology ( % ),C0015127;C1314792;C1524003
1298,etiology    n   ( % ),C0015127;C1314792;C1524003
1298,etiology  n ( % ),C0015127;C1314792;C1524003
1298,etiology,C0015127;C1314792;C1524003
1298,ed etiology  no . ( % ),C0015127;C1314792;C1524003;C3538926
1298,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
1298,any cause,C0015127;C1524003
1298,all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortality or hf hospitalization ^,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
1298,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortality ( n = $nmbr$ ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1298,all - cause mortalitv,C0015127;C1524003
1298,all - cause hospitalization,C0015127;C0019993;C1524003
1298,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1298,all - cause death / stroke / see,C0011065;C0015127;C0038454;C1306577;C1524003;C4082313;C4552775;C4554100
1298,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1298,all - cause,C0015127;C1524003
1298,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1298,aetiology,C0015127;C1314792;C1524003
1298,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
1297,patients with diabetic nephropathy,C0011881;C0030705;C1442864
1297,diabetic kidney disease,C0011881
1296,type ii diabetes,C0011860
1296,diabetes type ii  n ( % ),C0011860
1295,prediabetes — no . ( % ) $nmbr$,C0362046
1295,prediabetes  n ( % ),C0362046
1295,prediabetes  %,C0362046
1295,pre – diabetes mellitus  n = $nmbr$,C0362046
1295,pre – diabetes mellitus,C0362046
1295,ifg / prediabetes ^,C0362046;C1334085;C1708411
1294,type $nmbr$ diabetes 一 no . ( % ),C1320657
1294,type $nmbr$ diabetes — no . { % ) §,C1320657
1294,type $nmbr$ diabetes — no . ( % ) §,C1320657
1294,type $nmbr$ diabetes — no . ( % ),C1320657
1294,type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1320657
1294,type $nmbr$ diabetes mellitusa,C1320657
1294,type $nmbr$ diabetes mellitus ’,C1320657
1294,type $nmbr$ diabetes mellitus ' $nmbr$ ',C1320657
1294,type $nmbr$ diabetes mellitus  n ( % ),C1320657
1294,type $nmbr$ diabetes mellitus,C1320657
1294,type $nmbr$ diabetes meiiitus,C1320657
1294,type $nmbr$ diabetes . n ( % ),C1320657
1294,type $nmbr$ diabetes *,C1320657
1294,type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
1294,type $nmbr$ diabetes  no . ( % ),C1320657
1294,type $nmbr$ diabetes  n ( % ) d,C1320657
1294,type $nmbr$ diabetes  n ( % ),C1320657
1294,type $nmbr$ diabetes,C1320657
1294,no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
1294,duration of type $nmbr$ diabetes categories  n ( % ),C1320657;C1547660
1294,diabetes mellitus ( type $nmbr$ or $nmbr$ ),C1320657
1294,diabetes mellitus ( type $nmbr$ )  n ( % ),C1320657
1293,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
1293,diet group ( n = $nmbr$ ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
1293,diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949
1293,diet alone,C0012155;C0012159;C1519433;C2983588;C3668949
1293,diet ( n 二 $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1293,diet ( n = $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1293,diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1293,diet,C0012155;C0012159;C1519433;C2983588;C3668949
1292,duration of diabetes — yr ^,C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
1292,duration of diabetes mellitus,C0011849;C0449238;C2926735
1292,duration of diabetes in years  median ( iqr ),C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes > $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes < $nmbr$ yrs,C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes < $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
1292,duration of diabetes  yrs,C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes  years  median ( iqr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1292,duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C2926735
1292,duration of diabetes  y,C0011847;C0011849;C0449238;C2926735
1292,duration of diabetes  median ( iqr ),C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1292,duration of diabetes,C0011847;C0011849;C0449238;C2926735
1292,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
1292,diabetes mellitus — no . / total no . ( % ),C0011849
1292,diabetes mellitus duration ( sd )  y,C0011849;C0449238;C2699239;C2926735
1292,diabetes mellitus duration  y ( sd ),C0011849;C0449238;C2699239;C2926735
1292,diabetes mellitus duration  y,C0011849;C0449238;C2926735
1292,diabetes mellitus  no . / total no . ( % ),C0011849
1292,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
1292,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
1292,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
1292,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
1292,diabetes duration ( known )  % of patients,C0011847;C0011849;C0449238;C2926735
1292,diabetes duration  years ^,C0011847;C0011849;C0439234;C0449238;C2926735
1292,diabetes duration  years,C0011847;C0011849;C0439234;C0449238;C2926735
1292,diabetes duration  ycars “,C0011847;C0011849;C0449238;C2926735
1292,diabetes duration  y,C0011847;C0011849;C0449238;C2926735
1292,diabetes duration  n ( % ),C0011847;C0011849;C0449238;C2926735
1292,diabetes duration,C0011847;C0011849;C0449238;C2926735
1291,diabetes mellitus 一 no . ( % ),C0011849
1291,diabetes mellitus — no . ( % ),C0011849
1291,diabetes mellitus yes ( n  % ) hypertension,C0011849;C0020538;C1549445;C1705108;C1710701;C1963138
1291,diabetes mellitus n = $nmbr$  $nmbr$,C0011849
1291,diabetes mellitus [ n ( % ) ],C0011849
1291,diabetes mellitus :,C0011849
1291,diabetes mellitus ( % ),C0011849
1291,diabetes mellitus !,C0011849
1291,diabetes mellitus  § n ( % ),C0011849
1291,diabetes mellitus  no . ( % ),C0011849
1291,diabetes mellitus  n = $nmbr$,C0011849
1291,diabetes mellitus  n / n ( % ),C0011849
1291,diabetes mellitus  n ( % ) yes,C0011849;C1549445;C1705108;C1710701
1291,diabetes mellitus  n ( % ),C0011849
1291,diabetes mellitus  ( % ),C0011849
1291,diabetes mellitus  %,C0011849
1290,without diabetes,C0011847;C0011849
1290,with diabetes,C0011847;C0011849
1290,undiagnosed diabetes mellitus  n = $nmbr$,C0011849;C1408353
1290,undiagnosed diabetes mellitus,C0011849;C1408353
1290,undiagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C1408353
1290,short ( < $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
1290,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
1290,people without diabetes n = $nmbr$,C0011847;C0011849;C0027361
1290,people with diabetes n = $nmbr$,C0011847;C0011849;C0027361
1290,other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ ),C0011847;C0011849;C1704675
1290,non - diabetes,C0011847;C0011849;C1518422
1290,no diabetes mellitus,C0011849
1290,no diabetes ( p = . o $nmbr$ ),C0011847;C0011849
1290,no diabetes ( p = . $nmbr$ ),C0011847;C0011849
1290,no diabetes ( n = $nmbr$  $nmbr$ ),C0011847;C0011849
1290,no diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
1290,no diabetes,C0011847;C0011849
1290,new diabetes — no . ( % ),C0011847;C0011849;C0205314
1290,new diabetes,C0011847;C0011849;C0205314
1290,new - onset diabetes §,C0011847;C0011849;C0746890
1290,new - onset diabetes,C0011847;C0011849;C0746890
1290,n o diabetes,C0011847;C0011849;C0369718;C0441922
1290,long ( i $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
1290,long ( > $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
1290,individuals without diabetes  n = $nmbr$  $nmbr$,C0011847;C0011849;C0027361;C0237401
1290,individuals with diabetes  n = $nmbr$,C0011847;C0011849;C0027361;C0237401
1290,hx of diabetes  n ( % ),C0011847;C0011849;C0262926;C3814444
1290,high risk of diabetes,C0011847;C0011849;C0332167
1290,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
1290,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
1290,diagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C0011900
1290,diabetes — no . ( % ),C0011847;C0011849
1290,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
1290,diabetes | |,C0011847;C0011849
1290,diabetes t,C0011847;C0011849
1290,diabetes present $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849;C0150312;C0449450
1290,diabetes n ( % ),C0011847;C0011849
1290,diabetes mellitust,C0011847;C0011849
1290,diabetes mellitus,C0011849
1290,diabetes melitus,C0011847;C0011849
1290,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
1290,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
1290,diabetes classificationa,C0011847;C0011849
1290,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
1290,diabetes and untreated hypertension,C0011847;C0011849
1290,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849
1290,diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849
1290,diabetes ^,C0011847;C0011849
1290,diabetes *,C0011847;C0011849
1290,diabetes ( p = . oo $nmbr$ ),C0011847;C0011849
1290,diabetes ( p = . o $nmbr$ ),C0011847;C0011849
1290,diabetes ( p = . $nmbr$ ),C0011847;C0011849
1290,diabetes ( n [ % ] ) *,C0011847;C0011849
1290,diabetes ( n = $nmbr$ ),C0011847;C0011849
1290,diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
1290,diabetes ( % ),C0011847;C0011849
1290,diabetes $nmbr$ ( % ),C0011847;C0011849
1290,diabetes $nmbr$,C0011847;C0011849
1290,diabetes  no . ( % ) c,C0011847;C0011849
1290,diabetes  no . ( % ),C0011847;C0011849
1290,diabetes  n ( % ),C0011847;C0011849
1290,diabetes  * n ( % ),C0011847;C0011849
1290,diabetes  %,C0011847;C0011849
1290,diabetes,C0011847;C0011849
1290,all without diabetes ( n = $nmbr$ ),C0011847;C0011849
1290,all with diabetes ( n = $nmbr$ ),C0011847;C0011849
1289,extensive disease other,C0849867
1288,severe disease,C1836348
1288,$nmbr$ ( severe disease ),C1836348
1287,valvular disease ( % ),C3258293
1287,valvular disease  mitral,C3258293
1287,valvular disease,C3258293
1286,patients with cardiac disorders  n ( % ) §,C0012634;C0018799;C0030705;C0741926
1286,patients with cardiac disorders  n ( % ) c,C0012634;C0018799;C0030705;C0741926
1286,no cardiac disease,C0018799
1286,no apparent heart disease,C0018799;C0750489
1286,isehemie heart disease,C0018799
1286,cardiac disorders ( soc ),C0018799
1286,cardiac disorder  n ( % ) §,C0018799
1286,cardiac disorder,C0018799
1286,cardiac disease,C0018799
1285,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
1285,unacceptable adverse events,C0877248;C1705413;C1883420
1285,gall bladder adverse event ( n = $nmbr$ ),C0016976;C0877248
1285,any early adverse event,C0877248;C1279919
1285,any adverse event leading to study drug discontinuation  n ( % ),C0877248
1285,any adverse event ( ae ),C0877248;C3887670
1285,adverse events leading to premature treatment discontinuation,C0877248;C1705413
1285,adverse events ( any grade ),C0877248;C1705413
1285,adverse event,C0877248
1284,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
1284,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
1284,evidence or thombus  n ( % ),C3887511
1284,clinically evident vascular disease,C0042373;C3887511
1283,tenecteplase and pci ( n = $nmbr$ ),C0872913
1283,tenecteplase,C0872913
1282,diabetes status  no . ( % ),C1317301
1282,diabetes status  n ( % ),C1317301
1282,diabetes status,C1317301
1282,diabetes mellitus status,C1317301
1281,major diabetic eye disease  n ( % ),C0205082;C0205164;C0342245;C4318856;C4521762
1281,diabetic eye disease,C0342245
1280,diabetes therapy at baseline ( alone or in combination ),C0168634;C1442488;C3274787;C3539002
1280,diabetes therapy  n ( % ),C3274787;C3539002
1280,diabetes therapy,C3274787;C3539002
1279,catheter site — femoral,C0449652
1279,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
1278,catheterization performed for qualifying event,C0007430
1278,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
1278,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
1277,multivessel ( two vessel  three vessel  or left main ),C0205449;C4012475;C4037954
1276,three or more lesions,C0205449
1276,three or more drugs,C0205449
1276,three or more agents,C0205449
1276,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
1275,observation,C0302523;C0700325;C1964257;C3889687
1274,observed case,C0868928;C1441672;C1706255;C1706256
1274,observed,C1441672
1273,absent ( < $nmbr$ mg / dl ),C0332197;C0439269;C4285062
1273,absent,C0332197;C4285062
1273,absence,C0332197;C1689985
1272,fixed triple ( n = $nmbr$ ),C0205174;C0443218;C2827483;C3714578
1272,adhere,C3714578
1271,generalized,C0205246
1271,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
1271,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
1271,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
1271,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
1271,general,C0205246;C3812897;C3891294;C4521767
1270,bacterial pneumonia,C0004626
1269,previous pneumonia,C0032285;C0205156;C1552607
1269,pneumonia,C0032285
1268,neutropenia,C0023530;C0027947;C0853697
1268,leukopenia,C0023530;C0750394
1267,indomethacin,C0021246
1266,romania,C0035826
1265,coumadin,C0699129
1264,with tiotropium,C0213771
1264,tiotropium + placebo ( n [ $nmbr$ ),C0032042;C0213771;C1696465;C1706408
1264,tiotropium + placeb ( n [ $nmbr$ ),C0213771
1264,placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0032042;C0213771;C1518422;C1696465;C1706408
1264,non - tiotropium,C0213771;C1518422
1264,laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0332287;C0815320;C1696465;C1706408;C4551720
1264,laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C1696465;C1706408
1264,ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
1264,formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0060657;C0213771;C1518422
1264,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ ),C0213771;C1518422
1264,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$,C0213771;C1518422
1264,( tiotropium n = $nmbr$  placebo n =,C0032042;C0213771;C1696465;C1706408
1264,( tiotropium n = $nmbr$  placebo n,C0032042;C0213771;C1696465;C1706408
1263,tiotropium vs . salmeterol,C0213771
1263,tiotropium group ( n = $nmbr$ ),C0213771;C0441848
1263,tiotropium ( nz $nmbr$ ),C0027978;C0213771
1263,tiotropium ( n z $nmbr$ ),C0213771
1263,tiotropium ( n = $nmbr$ ),C0213771
1263,tiotropium $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1263,tiotropium $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1263,tiotropium $nmbr$ meg ( n = $nmbr$ ),C0024489;C0025175;C0072225;C0213771
1263,tiotropium $nmbr$ m g,C0213771;C0456715
1263,tiotropium $nmbr$ . $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
1263,tiotropium $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1263,tiotropium,C0213771
1262,no alcohol consumption  on average,C0001948;C1510992;C2825518
1262,alcohol use ( % ),C0001948
1262,alcohol use ( %  > $nmbr$ / day ),C0001948;C0332173;C0439228;C0439505
1262,alcohol use  n ( % ),C0001948
1262,alcohol intake never / rarely,C0001948;C0522498;C2003901
1262,alcohol intake ( a ),C0001948
1262,alcohol intake ( + ) ( % ),C0001948
1262,alcohol consumption at baseline,C0001948;C0168634;C1442488
1262,alcohol consumption > once weekly,C0001948
1262,alcohol consumption *,C0001948
1262,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
1262,alcohol consumption ( % ),C0001948
1262,alcohol consumption !,C0001948
1262,alcohol consumption  no . ( % ),C0001948
1262,alcohol consumption  n ( % ),C0001948
1262,alcohol consumption,C0001948
1261,regular alcohol consumption per week  no . ( % ),C0001948;C0205272;C0332174;C0439230
1261,drinking  n ( % ),C0001948;C0684271
1261,drinking,C0001948;C0684271
1261,alcohol use ( > $nmbr$ drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
1261,alcohol use  drinks / wk *,C0001948
1261,alcohol use  drinks / wk,C0001948
1261,alcohol use,C0001948
1261,alcohol intake  drinks / week,C0001948
1261,alcohol intake,C0001948
1260,hps,C0242994
1259,hub,C0063034;C1414372;C1708389
1258,ho,C0019905;C1832110;C3889614
1257,hc,C0020268;C0262499;C1413512
1256,white  n ( % ) medical history  n ( % ),C0007457;C0043157;C0220938;C0262926;C1704706
1256,other medical history — no . / total no . ( % ),C0262926;C1704706
1256,other medical history — no . ( % ),C0262926;C1704706
1256,other medical history  no . ( % ),C0262926;C1704706
1256,medical history — no . / total no . ( % ),C0262926;C1704706
1256,medical history — no . ( % ),C0262926;C1704706
1256,medical history — %,C0262926;C1704706
1256,medical history of diabetic retinopathy §,C0011884;C0262926
1256,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
1256,medical history and risk factors — no . ( % ),C0262926;C1704706
1256,medical history and risk factors ( % ),C0262926;C1704706
1256,medical history and risk factors  no . / total ( % ) *,C0262926;C1704706
1256,medical history and risk factors,C0262926;C1704706
1256,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
1256,medical history . no . ( % ),C0262926;C1704706
1256,medical history ( % ),C0262926;C1704706
1256,medical history    n   ( % ),C0262926;C1704706
1256,medical history  no . ( % ),C0262926;C1704706
1256,medical history  n ( % ),C0262926;C1704706
1256,medical history,C0262926;C1704706
1255,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0003209;C0003211;C0010055;C0012000;C0019664;C0019665;C0042295;C0085805;C0262512;C0262926;C0536221;C0577559;C0577573;C0600653;C0745413;C0871470;C0918012;C1096155;C1306372;C1552854;C1637833;C1705255;C2004062;C2986546;C3152252;C3539882;C3813197;C4281799;C4283905
1255,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,type $nmbr$ diabetes history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
1255,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
1255,seizure history  n ( % ),C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
1255,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
1255,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
1255,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
1255,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
1255,prior cv history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
1255,presenting history or diagnosis — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0449450;C1705255;C2004062
1255,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
1255,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
1255,parental history of ml before age $nmbr$ y yes,C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
1255,parental history of mi before age $nmbr$ y,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
1255,oad history  years,C0019664;C0019665;C0262512;C0262926;C0439234;C1705255;C2004062
1255,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1255,no history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
1255,no history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1255,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
1255,no history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
1255,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
1255,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C0011847;C0011849;C0015385;C0019664;C0019665;C0034510;C0065374;C0079399;C0085096;C0184661;C0262512;C0262926;C0280604;C0369773;C0581603;C1522384;C1704436;C1704675;C1705255;C1706779;C1709380;C2004062;C2603361;C2700391;C3274430;C3539779;C3542407;C3853635
1255,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
1255,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history ot chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
1255,history ol mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
1255,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
1255,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
1255,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
1255,history of upper gl events ( perforations  ulcers  bleeding )  n ( % ),C0018229;C0019664;C0019665;C0041582;C0262512;C0262926;C0441471;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
1255,history of upper gi events ( perforations  ulcers and bleeding ) n ( % ),C0019664;C0019665;C0041582;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
1255,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
1255,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
1255,history of tia or stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
1255,history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
1255,history of tia  n ( % ),C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
1255,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
1255,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke or transient ischemic attack,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke or tia — no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke or tia - n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke or tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke at baseline,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke / see / tia  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke / see / tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke $nmbr$,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
1255,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
1255,history of second prior mi  n ( % ),C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
1255,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
1255,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
1255,history of pci  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
1255,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
1255,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
1255,history of oxygen use - yes  n ( % ),C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
1255,history of or current cardiac disorders  %,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1255,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1255,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
1255,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
1255,history of more than $nmbr$ prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
1255,history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi or stroke  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi or stroke  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of lvh on electrocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
1255,history of lvh on echocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
1255,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
1255,history of htn  %,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
1255,history of high cholesterol ( a ) $nmbr$,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
1255,history of hf or lvef b $nmbr$ % with index event  no . ( % ),C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1255,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1255,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
1255,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
1255,history of elms  n ( % ),C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
1255,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
1255,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1255,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes { p = $nmbr$ * $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
1255,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
1255,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of cvd  n ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
1255,history of coronary revascularization  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
1255,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
1255,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
1255,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1255,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of chf  nyha class ii or iii — no . ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C1882085;C2004062
1255,history of chf  n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of chd at baseline §,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of chd at baseline d  g,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of chd at baseline  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
1255,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
1255,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
1255,history of cabg  n ( % ),C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history of bowel resections  n ( % ),C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
1255,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
1255,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
1255,history of atrial arrhythmia  n ( % ),C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
1255,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1255,history of amputation  no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1255,history of amputation  n ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1255,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
1255,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
1255,history of > $nmbr$ previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
1255,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
1255,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
1255,history coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
1255,history  pack - years,C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
1255,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
1255,fracture history ( predefined )  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,fracture history  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,ed history  n ( % yes ),C0019664;C0019665;C0262512;C0262926;C1549445;C1705108;C1705255;C1710701;C2004062;C3538926
1255,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
1255,cv disease history  no . ( % ) §,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
1255,current smokers  n ( % ) medicai history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3173209;C3241966
1255,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
1255,copd exacerbation history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
1255,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
1255,clinical history  no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
1255,clinical history  n ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
1255,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,chd history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1255,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
1255,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
1255,cad history and risk factors  n ( % ),C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
1255,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
1255,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1255,any cv history / risk factors  n ( % ),C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
1255,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
1255,* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .,C0008107;C0009667;C0019664;C0019665;C0205210;C0205447;C0262512;C0262926;C0332849;C0428475;C0439165;C0439190;C0439241;C0441889;C0475211;C0549183;C0567349;C0876920;C1137094;C1522609;C1705255;C2004062;C2347285;C2347635;C2348144;C2348885;C2939193;C3259781
1255,$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0001792;C0005847;C0008377;C0008976;C0010054;C0010055;C0012171;C0016327;C0018787;C0019664;C0019665;C0022671;C0023759;C0023779;C0023981;C0024027;C0035647;C0036453;C0038454;C0038952;C0039711;C0039798;C0074554;C0085542;C0085565;C0086153;C0087111;C0150158;C0184661;C0199176;C0204932;C0205082;C0205164;C0206579;C0220921;C0231220;C0239110;C0240951;C0242994;C0262512;C0262926;C0277793;C0280604;C0282416;C0420180;C0439394;C0439673;C0441471;C0441994;C0444504;C0446516;C0475224;C0489835;C0557651;C0565930;C0589120;C0591720;C0679698;C0680782;C0687676;C0745413;C0886296;C0948008;C1232424;C1260596;C1261512;C1273869;C1304680;C1522326;C1522577;C1522601;C1533734;C1545588;C1558950;C1561607;C1704685;C1704687;C1705169;C1705255;C1705493;C1706420;C1706495;C1736144;C1801960;C1947933;C1999167;C1999230;C2003888;C2004062;C2004580;C2347090;C2347634;C2348143;C2603343;C2603362;C2700409;C2930619;C2937358;C3274571;C3275277;C3469826;C3538994;C3541433;C3541888;C3542407;C3642216;C3642217;C3665546;C3669039;C3715044;C3810814;C3887704;C3898312;C4050014;C4084853;C4318856;C4521762;C4552904;C4553014;C4553528;C4554100
1254,sample size ( n ),C0242618
1254,sample size  n,C0242618
1254,sample size,C0242618
1253,effect size ^,C0814843
1253,effect size !,C0814843
1252,pharmaco - invasive n = $nmbr$,C0205281;C1334278
1252,pharmaco - invasive ( n = $nmbr$ ),C0205281;C1334278
1252,invasive,C0205281;C1334278
1252,early invasive *,C0205281;C1279919;C1334278
1252,early invasive $nmbr$,C0205281;C1279919;C1334278
1251,increase creatinine  > $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
1251,increase creatinine  < $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
1251,estimated creatinine clearancet,C0010294;C0750572;C1561535
1251,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
1251,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
1251,creatinine ≥ $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C1561535
1251,creatinine — mg / dl,C0010294;C0439269;C1561535
1251,creatinine ratio $nmbr$ - $nmbr$,C0010294;C0456603;C1547037;C1561535
1251,creatinine ratio,C0010294;C0456603;C1547037;C1561535
1251,creatinine clearanceb  ml / min,C0010294;C0439445;C1561535
1251,creatinine ciearance,C0010294;C1561535
1251,creatinine > $nmbr$ x baseline,C0010294;C0168634;C1442488;C1561535
1251,creatinine > $nmbr$ . $nmbr$ x baseline and above uln,C0010294;C0168634;C1442488;C1561535
1251,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
1251,creatinine ( p  mol / l ),C0010294;C0347982;C1561535
1251,creatinine ( mg / dl ),C0010294;C0439269;C1561535
1251,creatinine  pmol / l,C0010294;C0439284;C1561535
1251,creatinine  mmol 八,C0010294;C0439190;C1561535
1251,creatinine  mg / dl_,C0010294;C0439269;C1561535
1251,creatinine  mg / dl  mean,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143
1251,creatinine  mg / dl,C0010294;C0439269;C1561535
1251,creatinine,C0010294;C1561535
1250,visits $nmbr$ e $nmbr$,C0545082;C1512346;C2826704
1250,visit $nmbr$ sbp  mm hg,C0085805;C0439475;C0545082;C1512346;C2826704
1250,visit $nmbr$ ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
1250,visit $nmbr$ dbp  mm hg,C0439475;C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
1250,visit $nmbr$ blood pressures :,C0545082;C1272641;C1512346;C2826704
1250,visit,C0545082;C1512346;C2826704
1250,sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
1250,no . with visit,C0545082;C1512346;C2826704
1250,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
1250,ed visit related to exacerbation  n ( % ),C0545082;C1512346;C2826704;C3538926
1250,ed severity  visit $nmbr$ * *,C0439793;C0522510;C0545082;C1512346;C2826704;C3538926
1250,ed duration  visit $nmbr$ * *,C0449238;C0545082;C1512346;C2826704;C2926735;C3538926
1250,dbp at visit $nmbr$,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
1249,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
1249,time to randomization from symptom onset,C0034656;C0040223;C3541383
1249,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
1249,time to randomization,C0034656;C0040223;C3541383
1249,time to randomisation from symptom onset ( h ),C0034656;C0040223;C3541383
1249,time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C0439227;C1704675;C3541383
1249,time to first cv hospitalization or death from any cause,C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
1249,time to angiography — hr,C0002978;C0040223;C3541383
1249,time since start of fit  years ( meanisd ),C0040223;C3541383
1249,time since start of fit  mean ( sd )  y,C0040223;C3541383
1249,time since start insulin ( years ),C0040223;C3541383
1249,time since rheumatoid arthritis diagnosis  years,C0040223;C3541383
1249,time since randomization,C0040223;C3541383
1249,time since qualifying event,C0040223;C3541383
1249,time since psoriasis diagnosis  years $nmbr$,C0040223;C3541383
1249,time since psa onset  mean years ( sd ),C0040223;C3541383
1249,time since psa diagnosis ( years )  mean ( sd ),C0040223;C3541383
1249,time since prior alendronate use  n ( % ),C0040223;C3541383
1249,time since primary diagnosis,C0040223;C3541383
1249,time since pd diagnosis  mean ± sd,C0040223;C3541383
1249,time since pah diagnosisc ( years ),C0040223;C3541383
1249,time since onset ( h ),C0040223;C3541383
1249,time since most recent myocardial,C0040223;C3541383
1249,time since ipf diagnosisa  mean years ( sd ),C0040223;C3541383
1249,time since first psoriasis diagnosis ( y )  mean ( sd ),C0040223;C3541383
1249,time since first luts ( years ),C0040223;C3541383
1249,time since first copd diagnosis ( years ),C0040223;C3541383
1249,time since first af diagnosis  yrs,C0040223;C3541383
1249,time since epilepsy diagnosis ( years ),C0040223;C3541383
1249,time since end of fit  mean ( sd )  y,C0040223;C3541383
1249,time since diagnosis — mo,C0040223;C3541383
1249,time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
1249,time since diagnosis of type $nmbr$ diabetes - no . ( % ),C0040223;C3541383
1249,time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
1249,time since diagnosis of t $nmbr$ dm  y  n ( % ),C0040223;C3541383
1249,time since diagnosis of t $nmbr$ dm,C0040223;C3541383
1249,time since diagnosis of sle  years,C0040223;C3541383
1249,time since diagnosis of psa ( years )  mean ( sd ),C0040223;C3541383
1249,time since diagnosis of pah — yrf,C0040223;C3541383
1249,time since diagnosis of pah years #,C0040223;C3541383
1249,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
1249,time since diagnosis of ln  years,C0040223;C3541383
1249,time since diagnosis of heart failure,C0040223;C3541383
1249,time since diagnosis of diabetesa  n ( % ),C0040223;C3541383
1249,time since diagnosis of diabetes — no . ( % ),C0040223;C3541383
1249,time since diagnosis of diabetes ( years ) ( median  iqr ),C0040223;C3541383
1249,time since diagnosis of diabetes  n ( % ),C0040223;C3541383
1249,time since diagnosis of diabetes  mean ( sd ),C0040223;C3541383
1249,time since diagnosis of diabetes,C0040223;C3541383
1249,time since diagnosis of copd  years,C0040223;C3541383
1249,time since diagnosis of ciu / csuf ( y ),C0040223;C3541383
1249,time since diagnosis of ciu / csu ( years ) $nmbr$,C0040223;C3541383
1249,time since diagnosis  years,C0040223;C3541383
1249,time since copd diagnosis ( yrs ),C0040223;C3541383
1249,time since cessation of full - dose warfarin therapy,C0040223;C3541383
1249,time since cabg,C0040223;C3541383
1249,time since bph diagnosis ( years ),C0040223;C3541383
1249,time since asthma diagnosis years,C0040223;C3541383
1249,time since asthma diagnosis [ years ]  median ( range ),C0040223;C3541383
1249,time since asthma diagnosis ( years ),C0040223;C3541383
1249,time since asthma,C0040223;C3541383
1249,time since as diagnosis ( years )  mean   ±   sd,C0040223;C3541383
1249,time since as diagnosis ( years )  mean ( sd ),C0040223;C3541383
1249,time since as diagnosis  mean ( sd ) years,C0040223;C3541383
1249,time sample drawn ( h ),C0040223;C3541383
1249,time of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C1704675;C3541383
1249,time of randomization,C0034656;C0040223;C3541383
1249,time in trial,C0040223;C3541383
1249,time from randomization to pci — hr,C0034656;C0040223;C3541383
1249,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C3541383
1249,time from randomization to pci ( non - st - elevation mi )  h,C0034656;C0040223;C3541383
1249,time from randomization to coronary angiography — hr,C0034656;C0040223;C3541383
1249,time from randomization to cabg — hr,C0034656;C0040223;C3541383
1249,time from randomisation to $nmbr$ st balloon inflation ( h ),C0034656;C0040223;C3541383
1249,time from qualifying mi  yrs,C0040223;C1514624;C3541383;C3810814
1249,time from qualifying mi  %,C0040223;C1514624;C3541383;C3810814
1249,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
1249,time from psoriatic arthritis diagnosis [ a ]  years,C0003872;C0011900;C0040223;C1704338;C1704656;C3541383
1249,time from presentation to randomization — hr,C0040223;C0449450;C3541383
1249,time from parkinson ’ s disease diagnosis in months  mean ( sd ),C0011900;C0030567;C0040223;C1704338;C1704656;C3541383
1249,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
1249,time from longest event to randomisation,C0040223;C0441471;C1522425;C3541383;C4019010
1249,time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ ),C0040223;C0694649;C3541383
1249,time from index acs event to randomisation ( days ),C0040223;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
1249,time from hospitalization to randomization — hr,C0019993;C0040223;C3541383
1249,time from event to randomization — days,C0040223;C0441471;C3541383;C4019010
1249,time from acute coronary syndrome to randomization ( days ),C0040223;C0948089;C3541383
1249,time from acs to randomization ( median  iqr ),C0040223;C0742343;C3541383;C4318612
1249,time from acs to randomization,C0040223;C0742343;C3541383;C4318612
1249,time between index acs and randomization — days,C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1249,time between index acs and randomization ( days ),C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1249,time ( sec ) *,C0040223;C0565930;C3541383
1249,on oac at time of randomisation  n ( % ),C0034656;C0040223;C3541383
1249,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1249,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1249,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1249,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1249,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0040223;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
1249,mean time since diagnosis ( years ),C0040223;C0444504;C2347634;C2348143;C3541383
1249,mean time since diagnosis  y,C0040223;C0444504;C2347634;C2348143;C3541383
1249,mean time since asthma,C0040223;C0444504;C2347634;C2348143;C3541383
1249,mean time since as diagnosis  years  mean ± sd,C0040223;C0444504;C2347634;C2348143;C3541383
1249,at any time,C0040223;C3541383
1249,$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .,C0040223;C0041536;C1079230;C3541383
1248,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
1248,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
1248,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
1248,higher risk ( n = $nmbr$ ),C0332167;C3272283;C4050568;C4319571
1248,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
1248,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
1248,high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571
1248,high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571
1248,high risk *  %,C0332167;C3272283;C4050568;C4319571
1248,high risk ( ri ≥ $nmbr$ ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
1248,high risk ( n $nmbr$ $nmbr$ ),C0332167;C3272283;C4050568;C4319571
1248,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
1248,high risk ( > $nmbr$ ),C0332167;C3272283;C4050568;C4319571
1248,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
1248,high risk ( $nmbr$ - $nmbr$ ),C0332167;C3272283;C4050568;C4319571
1248,high risk,C0332167;C3272283;C4050568;C4319571
1248,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
1248,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
1248,high cardiovascular risk  n ( % ) ^,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
1248,high - risk cvd  n ( % ),C0007222;C0332167;C3272283;C4050568;C4319571
1248,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
1248,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
1248,high - risk,C0332167;C3272283;C4050568;C4319571
1248,high ( > $nmbr$ risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
1248,> $nmbr$ ( high risk ),C0332167;C3272283;C4050568;C4319571
1247,scores for global and pain assessments §,C0205246;C0449820;C2348867
1246,— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
1246,— $nmbr$ . $nmbr$ < fn t - score,C0449820;C1570610;C4050231
1246,womac stiffness score,C0427008;C0449820;C4050231
1246,womac score,C0449820;C4050231
1246,ukpds $nmbr$ - year risk score > $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1246,ukpds $nmbr$ - year risk score < $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1246,tlmi risk score,C0035647;C0449820;C4050231;C4552904
1246,timi risk score — no . / total no . ( % ) f,C0035647;C0449820;C4050231;C4552904
1246,timi risk score — no . / total no . ( % ) : c,C0035647;C0449820;C4050231;C4552904
1246,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
1246,timi risk score — %,C0035647;C0449820;C4050231;C4552904
1246,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
1246,timi risk score > $nmbr$  n ( % ),C0035647;C0449820;C4050231;C4552904
1246,timi risk score > $nmbr$  %,C0035647;C0449820;C4050231;C4552904
1246,timi risk score *,C0035647;C0449820;C4050231;C4552904
1246,timi risk score ( interaction : p = $nmbr$ . $nmbr$ ),C0035647;C0449820;C1704675;C4050231;C4552904
1246,timi risk score $nmbr$ - $nmbr$,C0035647;C0449820;C4050231;C4552904
1246,timi risk score !,C0035647;C0449820;C4050231;C4552904
1246,timi risk score  n / n ( % ),C0035647;C0449820;C4050231;C4552904
1246,timi risk score  %,C0035647;C0449820;C4050231;C4552904
1246,timi risk score,C0035647;C0449820;C4050231;C4552904
1246,tim $nmbr$ nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
1246,stroke risk score,C0449820;C1277291;C4050231
1246,shs ( $nmbr$ - $nmbr$  per $nmbr$ score ),C0449820;C4050231
1246,sf - $nmbr$ score,C0037712;C0449820;C4050231
1246,sf - $nmbr$ ( health transition score ),C0037712;C0376627;C0449820;C4050231
1246,score 一 no . ( % ),C0449820;C4050231
1246,score on the minnesota living with heart failure scaled,C0026183;C0449820;C0595998;C4050231;C4520849;C4551704
1246,score of > $nmbr$ . $nmbr$ — %,C0449820;C4050231
1246,score of $ $nmbr$  no . ( % ),C0449820;C4050231
1246,score of # $nmbr$  no . ( % ),C0449820;C4050231
1246,score > $nmbr$ . $nmbr$,C0449820;C4050231
1246,score > $nmbr$ %  % of patients,C0030705;C0449820;C4050231
1246,score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or,C0449820;C4050231
1246,score $nmbr$ . $nmbr$,C0449820;C4050231
1246,score $nmbr$ - $nmbr$,C0449820;C4050231
1246,score  no . ( % ),C0449820;C4050231
1246,score  %,C0449820;C4050231
1246,score,C0449820;C4050231
1246,rope score * *,C0449820;C1563164;C4050231
1246,rope score,C0449820;C1563164;C4050231
1246,rentrop score,C0449820;C4050231
1246,patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
1246,pasi score > $nmbr$ *,C0449820;C4050231;C4528685
1246,pasi score ( $nmbr$ - $nmbr$ ) d,C0449820;C4050231;C4528685
1246,pasi score ( $nmbr$ - $nmbr$ ),C0449820;C4050231;C4528685
1246,pasi score $nmbr$,C0449820;C4050231;C4528685
1246,pasi score ! * *,C0449820;C4050231;C4528685
1246,pasi score  $nmbr$ - $nmbr$ *,C0449820;C4050231;C4528685
1246,pasi score,C0449820;C4050231;C4528685
1246,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
1246,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
1246,modified rankin score,C0392747;C0449820;C3889737;C4050231
1246,mhis score,C0449820;C4050231
1246,mayo score ( $nmbr$ - $nmbr$ ),C0449820;C0454788;C1077578;C4050231
1246,ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
1246,jsn score ( $nmbr$ - $nmbr$ ),C0449820;C4050231
1246,jsn score,C0449820;C4050231
1246,joint space narrowing score  mean ( sd ),C0444504;C0449820;C1859695;C2347634;C2348143;C2699239;C4050231
1246,joint space narrowing score,C0449820;C1859695;C4050231
1246,iga mod $nmbr$ score  n ( % ),C0011860;C0449820;C2825347;C4050231
1246,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
1246,hit - $nmbr$ score,C0272285;C0332159;C0449820;C1708373;C4050231
1246,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
1246,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
1246,framingham risk score  arbitrary units,C0035647;C0439183;C0449820;C3166866;C4050231;C4552904
1246,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
1246,fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
1246,fn t - score < = - $nmbr$ . $nmbr$ ( % ),C0449820;C1570610;C4050231
1246,flex fn f - score < - $nmbr$ . $nmbr$,C0016327;C0449820;C1570610;C4050231
1246,femoral neck t - score,C0015815;C0449820;C4050231
1246,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
1246,femoral neck bmd t - score,C0015815;C0449820;C4050231
1246,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
1246,crusade score,C0449820;C4050231
1246,crusade bleeding score,C0019080;C0449820;C4050231
1246,crohn ' s disease activity index score ],C0449820;C0451071;C4050231
1246,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
1246,charlson comobility score  n ( % ),C0449820;C4050231
1246,cha $nmbr$ s $nmbr$ score,C0449820;C1420648;C4050231
1246,cha $nmbr$ ds $nmbr$ vasc score ( % ),C0449820;C1420648;C3714751;C4050231
1246,cha $nmbr$ ds $nmbr$ vasc score,C0449820;C1420648;C3714751;C4050231
1246,cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
1246,cha $nmbr$ ds $nmbr$ - vasc score    n   ( % ),C0449820;C1420648;C3714751;C4050231
1246,cha $nmbr$ ds $nmbr$ - vasc score,C0449820;C1420648;C3714751;C4050231
1246,cadillac score,C0449820;C4050231
1246,baseline dyspnea index score,C0449820;C1511069;C4050231
1246,accp score,C0449820;C4050231
1246,- $nmbr$ < flex fn f - score,C0016327;C0449820;C1570610;C4050231
1246,- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
1246,- $nmbr$ . $nmbr$ < ls t - score,C0023668;C0449820;C4050231
1246,- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$,C0016327;C0449820;C1570610;C4050231
1246,% improvement in enthesitis score at week $nmbr$  n,C0449820;C1282952;C2986411;C4050231
1246,% improvement in dactylitis score at week $nmbr$  n,C0239161;C0449820;C2986411;C4050231
1246,$nmbr$ ms score †,C0449820;C2349943;C3539704;C3713294;C4050231
1245,patent foramen ovale,C0016522;C0344724
1244,bare metal,C0025552
1244,bare - metal,C0025552
1243,rarely,C0522498
1242,rarely / never,C4035880
1241,married,C0024841;C0555047
1240,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
1240,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
1239,labd alone,C0396059
1238,late load,C0205087
1237,lateral,C0205093
1236,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
1235,ale < $nmbr$,C0678386;C2632076
1235,ale,C0678386;C2632076
1234,large / very large,C0442824;C0549177;C2984081
1233,large mi,C0549177;C3810814
1233,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
1232,atypical absence,C0595948
1231,arterial access site,C3272298
1231,arterial access,C0003842;C0221464;C0444454;C1554204
1230,australia and new zealand,C0004340
1230,australia / nz,C0004340;C0027978
1230,australia,C0004340
1229,africa or near east,C0001737
1229,africa *,C0001737
1229,africa ! near east,C0001737;C1707877
1229,africa  asia  or the middle east,C0001737;C0003980
1229,africa,C0001737
1228,paracetamol,C0000970
1228,acetaminophen,C0000970;C2917659
1227,paclitaxel - eluting,C0144576
1227,paclitaxel,C0144576
1226,cataract removal,C0007389
1225,cataract,C0086543;C4555209
1224,african descent,C0027567
1224,african,C0027567
1223,vessels with stenosis > $nmbr$ %,C0679403
1223,non - stenotic vessels  n ( % ),C0679403;C1518422
1223,> $nmbr$ vessels with > $nmbr$ % stenosis,C0679403
1222,polyvascular disease * status,C3176928
1222,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
1222,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
1222,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
1221,killip class — no . / total no . ( % ) i,C1881332
1221,killip class — no . ( % ) i,C1881332
1221,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
1221,killip class > $nmbr$  no . ( % ),C1881332
1221,killip class ( interaction : p = $nmbr$ . $nmbr$ ),C1704675;C1881332
1221,killip class  n ( % ) i,C1881332
1221,killip class  n ( % ),C1881332
1220,killip class *,C1881332
1220,killip class $nmbr$ / $nmbr$,C1881332
1220,killip class $nmbr$,C1881332
1220,killip class,C1881332
1220,baseline killip class,C0168634;C1442488;C1881332
1220,< $nmbr$ baseline killip class,C0168634;C1442488;C1881332
1219,ethnic origin white,C0007457;C0015031;C0043157;C0220938
1219,ethnic origin *,C0015031
1219,ethnic origin  n ( % ),C0015031
1219,ethnic origin,C0015031
1219,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
1219,ethnic group — no . ( % ) ',C0015031;C1879937
1219,ethnic group ( % ),C0015031;C1879937
1219,ethnic group,C0015031;C1879937
1219,ethnic background,C0015031
1218,othery ethnicity  n ( % ) *,C0015031;C0243103
1218,othery ethnicity  n ( % ),C0015031;C0243103
1218,hispanic ethnicity  n ( % ),C0015031;C0086409;C0243103
1218,hispanic ethnicity,C0015031;C0086409;C0243103
1218,ethnicity t,C0015031;C0243103
1218,ethnicity - no . ( % ),C0015031;C0243103
1218,ethnicity ( % ),C0015031;C0243103
1218,ethnicity $nmbr$ ',C0015031;C0243103
1218,ethnicity  not hispanic / latino    n   ( % ),C0015031;C0243103
1218,ethnicity  no . ( % ),C0015031;C0243103
1218,ethnicity  n ( % ) b,C0015031;C0243103
1218,ethnicity  n ( % ) :,C0015031;C0243103
1218,ethnicity  n ( % ) *,C0015031;C0243103
1218,ethnicity  n ( % ),C0015031;C0243103
1218,ethnicity  location,C0015031;C0243103;C0450429;C1515974;C4284930;C4284931
1218,ethnicity  hispanic / latino  n ( % ),C0015031;C0086409;C0086528;C0243103
1218,ethnicity  %,C0015031;C0243103
1218,ethnicity,C0015031;C0243103
1217,without p blockers,C0369773;C2603361
1217,with p blockers,C0369773;C2603361
1217,p   vs . placebo,C0369773;C2603361
1217,p vs placebo,C0369773;C2603361
1217,p valuey,C0369773;C2603361
1217,p valuer,C0369773;C0401806;C2603361
1217,p valuej ',C0369773;C2603361
1217,p valued,C0369773;C2603361
1217,p valuec,C0369773;C2603361
1217,p valueb,C0369773;C2603361
1217,p valuea,C0369773;C2603361
1217,p vaiue ( interaction ),C0369773;C1704675;C2603361
1217,p vaiue,C0369773;C2603361
1217,p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
1217,p interaction women vs men,C0043210;C0369773;C1704675;C2603361
1217,p interaction,C0369773;C1704675;C2603361
1217,p inter,C0369773;C2603361
1217,p int . f,C0016327;C0369773;C2603361;C3272375
1217,p inleraclion,C0369773;C2603361
1217,p for interaction *,C0369773;C1704675;C2603361
1217,p for interaction,C0369773;C1704675;C2603361
1217,p for inter - act,C0369773;C2603361
1217,p for i,C0021966;C0221138;C0369773;C2603361
1217,p blockersubgroup,C0369773;C2603361
1217,p blockers ( % ),C0369773;C2603361
1217,p blockers,C0369773;C2603361
1217,p blocker *,C0369773;C2603361
1217,p blocker,C0369773;C2603361
1217,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
1217,p [ int ],C0369773;C2603361;C3272375
1217,p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1959644;C2603343;C2603361
1217,p : interaction,C0369773;C1704675;C2603361
1217,p / interaction,C0369773;C1704675;C2603361
1217,p . o ),C0369773;C2603361
1217,p . interaction,C0369773;C1704675;C2603361
1217,p - valuec,C0369773;C2603361
1217,p - valueb,C0369773;C2603361
1217,p - valuea,C0369773;C2603361
1217,p - val . ( $nmbr$ ),C0042285;C0369773;C0523975;C2603361
1217,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
1217,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
1217,p - interaction,C0369773;C1704675;C2603361
1217,p - interactio n,C0369773;C2603361
1217,p - inter,C0369773;C2603361
1217,p - inte faction,C0369773;C2603361
1217,p - int .,C0369773;C2603361;C3272375
1217,p - int,C0369773;C2603361;C3272375
1217,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
1217,p - for interaetion,C0369773;C2603361
1217,p - blockers ( % ),C0369773;C2603361
1217,p - blockers  n ( % ),C0369773;C2603361
1217,p - blockers,C0369773;C2603361
1217,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
1217,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
1217,p - blocker intake at randomisation ( n = $nmbr$ o ),C0034656;C0369773;C1512806;C2603361
1217,p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
1217,p - blocker ( % ),C0369773;C2603361
1217,p - blocker,C0369773;C2603361
1217,p +,C0369773;C2603361
1217,p *,C0369773;C2603361
1217,p ) atients with > $nmbr$ exacerbations resulting in emergency department visit,C0369773;C2603361;C4086268
1217,p ( women vs men ),C0043210;C0369773;C2603361
1217,p ( losartan versus placebo ),C0126174;C0369773;C2603361
1217,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
1217,p ( inter ),C0369773;C2603361
1217,p $nmbr$ z $nmbr$ ( n = $nmbr$ ),C0369773;C2603361
1217,p $nmbr$ y $nmbr$ inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
1217,p $nmbr$ y $nmbr$ inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
1217,p $nmbr$ y $nmbr$ antagonists,C0243076;C0369773;C2603361
1217,p $nmbr$ y $nmbr$ antagonist,C0231491;C0369773;C2603361
1217,p $nmbr$ vs usual care,C0369773;C2603361
1217,p $nmbr$ vs placebo,C0369773;C2603361
1217,p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361
1217,p $nmbr$ interaction women vs men,C0043210;C0369773;C1704675;C2603361
1217,p $nmbr$ interaction,C0369773;C1704675;C2603361
1217,p  regional difference *,C0369773;C0682132;C2603361
1217,p  regional difference,C0369773;C0682132;C2603361
1217,p  interaction !,C0369773;C1704675;C2603361
1217,p  all vs all,C0369773;C2603361
1217,p,C0369773;C2603361
1217,no p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
1216,medical historv,C0199168;C0205476
1216,medical characteristics,C0199168;C0205476;C1521970
1216,medical and lifestyle history,C0199168;C0205476
1216,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C1279901
1216,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
1216,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
1215,american ‐ indian / alaska native,C0002460
1215,american indian or native alaskan,C0002460
1215,american indian or alaskan native,C0002460
1215,american indian or alaskan,C0002460
1215,american indian or alaska native  :,C0002460
1215,american indian or alaska native,C0002460
1215,american indian or alaska,C0002460
1215,american indian or,C0002460
1215,american indian / native alaskan,C0002460;C0682125
1215,american indian / alaskan native  n ( % ),C0002460;C0238611;C0302891;C0886378;C1524069
1215,american indian / alaskan native,C0002460;C0238611
1215,american indian / alaska native,C0002460
1215,american indian /,C0002460
1215,american indian  alaskan native  or aboriginal canadian,C0002460;C0238611
1215,american indian,C0002460
1214,surgical technique,C0683469
1213,clinical dementia rating score,C4304227
1212,clinical endpoint,C2347784
1211,sustained mucosal healingc n / n ( % ),C0026724;C0443318
1211,sustained mucosal healingc,C0026724;C0443318
1211,mucosal healingf,C0026724
1211,mucosal healingc n / n ( % ),C0026724
1210,prior clinical fracture ( since age $nmbr$ ),C0016658;C0205210;C0332152;C2826257
1210,history of clinical fracture ( > $nmbr$ years old ),C0205210;C0439234;C1272071
1210,history of clinical fracture ( > $nmbr$ years ),C0205210;C0439234;C1272071
1210,clinical fracture,C0016658;C0205210
1210,c clinical fractures ( fas ),C0016658;C0205210
1209,clinical indication at the index procedure  n ( % ),C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
1209,clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated,C0205210
1209,clinical and patient - reported characteristics at baseline and randomization,C0205210
1209,clinical and laboratory measurements,C0205210
1208,no clinical or lesion rfs for st,C0205210
1208,durable clinical responseg,C0205210
1208,durable clinical remissionh,C0205210
1208,clinical responsed,C0205210
1208,clinical remissione,C0205210
1208,clinical outcome,C0205210;C1274040
1208,clinical or lesion rf for st,C0205210
1208,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
1208,clinical details,C0205210;C1522508
1208,clinical ae  n ( % },C0205210;C3887670
1208,clinical,C0205210
1208,any clinical or lesion rf for st,C0205210
1208,any clinical ae,C0205210;C3887670
1207,dilatative  n ( % ),C0002940;C0012359;C0700124;C1322279
1207,dilatative,C0002940;C0012359;C0700124;C1322279
1206,rivastigmine ( n = $nmbr$ ),C0649350
1206,rivastigmine,C0649350
1205,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
1205,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
1205,distal,C0205108;C4522154
1204,digitalis  n ( % ),C0012252;C0304520
1204,digitalis,C0012252;C0304520
1203,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
1202,thiazides,C0541746
1202,thiazide users,C0541746;C1706077
1202,thiazide,C0541746
1201,oxidative stress,C0242606
1200,medication effects,C1319171
1199,medication adherence,C2364172
1198,use oforal glucose - lowering agent — no . ( % ),C0042153;C0457083;C1947944
1198,use ( % ),C0042153;C0457083;C1947944
1198,use,C0042153;C0457083;C1947944
1198,systemic glucocorticoid use at randomization  n ( % ),C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
1198,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
1198,sulfasalazine use at randomization    n   ( % ),C0034656;C0036078;C0042153;C0457083;C1947944
1198,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
1198,sirolimus - eluting stent use  n ( % ),C0038257;C0042153;C0072980;C0457083;C1947944
1198,saba use in past $nmbr$ days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
1198,saba use  occasions / weekt,C0042153;C0457083;C1947944
1198,rotablator use  n ( % ),C0042153;C0457083;C1260867;C1947944
1198,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
1198,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
1198,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
1198,paclitaxel - eluting stent use  n ( % ),C0038257;C0042153;C0144576;C0457083;C1947944
1198,other llt use,C0042153;C0457083;C1947944;C2347090
1198,oam use [ n ( % ) ],C0042153;C0457083;C1947944
1198,oad use  n ( % ),C0042153;C0457083;C1947944
1198,no use,C0042153;C0457083;C1947944
1198,no metformin use,C0025598;C0042153;C0457083;C1947944
1198,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
1198,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
1198,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
1198,multivitamin use,C0042153;C0301532;C0457083;C1947944
1198,mtx use at randomization  n ( % ),C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
1198,methotrexate use at randomization    n   ( % ),C0025677;C0034656;C0042153;C0457083;C1947944
1198,metformin use,C0025598;C0042153;C0457083;C1947944
1198,mesalamine use  n ( % ) a,C0042153;C0127615;C0457083;C1947944
1198,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
1198,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
1198,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
1198,low - dose aspirin use . strata *  n ( % ),C0042153;C0457083;C1947944;C2608320
1198,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
1198,lama use  n ( % ),C0042153;C0457083;C0999593;C1416775;C1947944
1198,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
1198,laba use  % patients,C0030705;C0042153;C0457083;C1947944
1198,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1198,hrt use,C0042153;C0282402;C0457083;C1947944
1198,cox - $nmbr$ selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
1198,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
1198,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
1198,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
1198,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
1198,concomitant antibiotic use  n [ % ],C0003232;C0042153;C0457083;C0521115;C1947944
1198,cholinesterase inhibitor use at baseline  no . ( % ),C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
1198,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
1198,cgm use,C0042153;C0457083;C1947944
1198,care use,C0042153;C0457083;C1947933;C1947944
1198,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
1198,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
1198,background laba use - yes  n ( % ),C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
1198,background laba use,C0042153;C0457083;C1706907;C1947944
1198,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
1198,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
1198,any use,C0042153;C0457083;C1947944
1198,antithrombotic use before enrollment  no . ( % ),C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
1198,antithrombotic use,C0042153;C0457083;C1947944
1198,antiplatelet use,C0042153;C0457083;C1947944
1198,anorexigen use,C0042153;C0457083;C1947944
1198,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
1197,ukraine,C0041580
1197,ua ( n = $nmbr$ ),C0041580;C0042014
1197,ua,C0041580;C0042014
1196,reported in ecrf,C0684224;C0700287;C4319718;C4551412
1196,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
1195,self - reported disease severity  $nmbr$ - $nmbr$ scale *,C0175659;C0349674;C0521117;C0681906;C1947916;C2700446
1195,self - reported descent  n ( % ),C0681906;C2700446
1194,respiratory - related ^,C0439849;C0445223;C0521346;C1546767
1194,related to study druga,C0439849;C0445223
1194,diabetes - related medication use    n   ( % ),C0011847;C0011849;C0240320;C0439849;C0445223
1193,dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0766326
1193,dronedarone ( n = $nmbr$ ),C0766326
1193,dronedarone,C0766326
1192,extracranial carotid stenosis  n ( % ),C0007282;C0580586
1192,carotid stenosis,C0007282
1192,carotid artery stenosis  n ( % ),C0007282
1191,aortic stenosis  n ( % ),C0003507
1191,aortic stenosis,C0003507
1190,degree of stenosis  % of diameter,C1301886;C4034225
1190,$nmbr$ degree of ica stenosis 丰,C0201519;C4034225
1189,current cigarette smoking  no . ( % ),C0239059;C0521116;C0700219;C1705970
1189,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
1189,cigarette smoking  n ( % ),C0239059;C0700219
1189,cigarette smoking,C0239059;C0700219
1189,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
1189,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
1188,use of compression stockings  no . ( % ),C0038348;C1524063
1188,compression stockings,C0038348
1187,primary trial end point,C0008976;C2986535
1187,primary renal endpoint or death,C0022646;C2986535
1187,primary renal endpoint,C0022646;C2986535
1187,primary endpoint ’,C2986535
1187,primary endpoint ^,C2986535
1187,primary endpoint :,C2986535
1187,primary endpoint $nmbr$,C2986535
1187,primary endpoint,C2986535
1187,primary end point |,C2986535
1187,primary end point *,C2986535
1187,primary end point,C2986535
1187,primary end - point,C2986535
1187,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
1186,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
1186,nace ( primary endpoint ),C2986535
1186,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
1185,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1185,primary endpoint at $nmbr$ months,C0439231;C2986535
1185,primary endpoint at $nmbr$ days,C0439228;C2986535
1185,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1185,primary end point  no . of events / total no . ( % ),C2986535
1184,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0030705;C1709707
1184,proportions  n ( % ),C1709707
1184,proportion taking pulmonary medications ( % ) b,C1709707
1184,proportion of responders n / n ( % ),C1709707
1184,proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % ),C0030705;C1709707
1184,proportion of patients who achieved acr $nmbr$ n / n ( % ),C0030705;C1709707
1184,proportion of patients in corticosteroid - free clinical remission at week $nmbr$,C0030705;C1709707
1184,proportion of days without heartburn at week $nmbr$  percentage,C0439228;C1709707
1184,proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x,C0002994;C0332296;C0439228;C1709707;C1880497;C1996904
1184,proportion,C1709707
1184,fvc ( l ) proportion taking pulmonary medications ( % ) b,C1709707;C3714541
1184,blood eosinophil proportion ( % ),C0014467;C1709707
1183,non - early crohn ' s disease,C0010346;C1279919;C1518422
1183,median crohn ' s disease duration  y ( range ),C0010346;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
1183,history of crohn ' s disease surgery  n ( % ),C0010346;C0455610
1183,early crohn ' s disease *,C0010346;C1279919
1183,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
1183,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
1183,crohn ’ s disease related surgery,C0010346
1183,crohn ' s disease duration,C0010346;C0449238;C2926735
1183,crohn ' s disease - related medication at baseline  n ( % ),C0010346
1183,crohn ' s disease,C0010346
1182,current drinker,C0556297
1182,alcohol users  n ( % ),C0556297
1182,alcohol consumption ( % ) < $nmbr$ drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
1182,alcohol > $nmbr$ drinks per week,C0332174;C0439230;C0556297
1182,alcohol  % with > $nmbr$ drink / d,C0001948;C0556297
1181,regions  n ( % ),C0017446;C0205147
1181,region 一 no . ( % ),C0017446;C0205147
1181,region — no . { % ),C0017446;C0205147
1181,region — no . ( % ),C0017446;C0205147
1181,region united states,C0017446;C0041703;C0205147
1181,region ofthe world,C0017446;C0205147;C2700280
1181,region ofenrollment — %,C0017446;C0205147
1181,region of world — no . ( % ),C0017446;C0205147;C2700280
1181,region of the world,C0017446;C0205147;C2700280
1181,region of residence ( p = $nmbr$ $nmbr$ ),C0017446;C0205147;C0237096
1181,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
1181,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
1181,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
1181,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
1181,region north america,C0017446;C0028405;C0205147
1181,region n ( % ),C0017446;C0205147
1181,region latin american,C0017446;C0205147
1181,region :,C0017446;C0205147
1181,region - north america,C0017446;C0028405;C0205147
1181,region - no . ( % ),C0017446;C0205147
1181,region - n ( % ),C0017446;C0205147
1181,region *,C0017446;C0205147
1181,region ( us ),C0017446;C0205147
1181,region ( pooled ),C0017446;C0205147
1181,region ( % ),C0017446;C0205147
1181,region    n   ( % ),C0017446;C0205147
1181,region  north america,C0017446;C0028405;C0205147
1181,region  no . / total ( % ),C0017446;C0205147
1181,region  no . ( % ) c,C0017446;C0205147
1181,region  no . ( % ),C0017446;C0205147
1181,region  n ( % ) a,C0017446;C0205147
1181,region  n ( % ),C0017446;C0205147
1181,region  latin america,C0017446;C0023122;C0205147
1181,region  europe,C0015176;C0017446;C0205147
1181,region  %,C0017446;C0205147
1181,region,C0017446;C0205147
1181,other ® region — no . ( % ),C0017446;C0205147
1181,grouped region,C0017446;C0205147;C0439745;C4319846
1181,geographical region,C0017446
1181,geographic site  %,C0017446
1181,geographic region ^,C0017446
1181,geographic region ?,C0017446
1181,geographic region - north america,C0017446;C0028405
1181,geographic region  %,C0017446
1181,geographic region,C0017446
1181,geographic location,C0017446
1181,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
1181,enrollment by region  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
1181,age years geographic region,C0017446;C1510829
1180,geographical region ( % ),C0017446
1180,geographical region  n ( % ),C0017446
1180,geographic region — number ( % ),C0017446;C0237753;C0449788
1180,geographic region — no . ( % ),C0017446
1180,geographic region - other,C0017446
1180,geographic region - europe,C0015176;C0017446
1180,geographic region  n ( % ),C0017446
1180,* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers,C0004340;C0015176;C0017446;C0205147;C0237753;C0449788;C1511726;C3245479;C3714741
1179,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
1179,venous,C0042449;C0348013
1179,vein bypass stented,C0042449;C0741847
1179,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
1179,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
1178,denosumab ( n = $nmbr$ ) n ( % ),C1690432
1178,denosumab ( n = $nmbr$ ),C1690432
1178,denosumab,C1690432
1177,prior tnf inhibitor exposure  no . ( % ),C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
1177,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
1177,prior immunosuppressive exposure  n ( % ),C0021081;C0274281;C0332152;C0332157;C2826257
1177,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
1177,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
1177,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
1177,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
1177,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
1177,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
1177,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
1177,exposure,C0274281;C0332157
1177,exposed ( n = $nmbr$ ),C0332157
1177,exposed,C0332157
1176,us resident,C1320928;C1549439;C2347958;C3835651
1175,gastroduodenum,C0391900
1175,gastroduodenal,C0450199
1174,carotid imt,C0334121;C0741968;C1704614;C4318736
1174,carotid,C0741968
1173,gastroenteritis,C0017160
1172,vasoprotectives,C0304533
1171,progestins,C0033306
1170,argentina,C0003761;C1504311
1169,no nadroparin ( n = $nmbr$ ),C0206232
1169,nadroparin vs control,C0206232
1169,nadroparin ( n = $nmbr$ ),C0206232
1169,nadroparin,C0206232
1168,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
1168,dihydropyridine ccbs,C0006684;C0012315;C0220821
1168,dihydropyridine,C0012315;C0220821
1167,thienopyridine use,C0042153;C0457083;C1120149;C1947944
1167,thienopyridine type,C0332307;C1120149;C1547052
1167,thienopyridine n = $nmbr$,C1120149
1167,thienopyridine at baseline,C0168634;C1120149;C1442488
1167,thienopyridine alone,C1120149
1167,thienopyridine ( n = $nmbr$ ),C1120149
1167,thienopyridine,C1120149
1167,planned thienopyridine at enrollment,C1120149;C1709561
1167,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
1167,no thienopyridine,C1120149
1167,- thienopyridine,C1120149
1167,+ thienopyridine,C1120149
1166,thiazolidinediones *,C1257987;C3541957
1166,thiazolidinediones,C1257987;C3541957
1166,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
1166,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
1166,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
1166,thiazolidinedione no,C0289779;C1257987;C3537039
1166,thiazolidinedione based,C0289779;C1257987;C3537039
1166,thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039
1166,thiazolidinedione,C0289779;C1257987;C3537039
1166,any thiazolidinedione,C0289779;C1257987;C3537039
1165,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
1165,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
1165,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
1165,drug discontinuation not due to death,C0013227;C0457454;C1254351;C1444662;C4552847
1165,discontinued,C1444662
1165,discontinuation of lama prior to baseline  n ( % ),C0457454;C0999593;C1416775;C1444662;C4552847
1165,discontinuation of ics / laba prior to baseline  n ( % ),C0457454;C0815320;C1444662;C4551720;C4552847
1164,discontinuations teaes,C0457454
1164,discontinuations due to ae,C0457454;C0678226;C3887670
1164,discontinuations,C0457454
1163,iv inotropic drug,C1971835
1162,inotropic agent,C0304509
1161,tiotropium + olodaterol $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1161,tiotropium + olodaterol $nmbr$ / $nmbr$,C4032878
1161,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
1160,prehospital ticagrelor ( n = $nmbr$ ),C1999375
1160,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
1160,pre - hospital ticagrelor ( n = $nmbr$ ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
1160,in hospital ticagrelor,C0019994;C1510665;C1999375
1160,in - hospital ticagrelor ( n = $nmbr$ ),C0019994;C1510665;C1999375
1159,ticagrelor pre ‐ hosp ( n = $nmbr$ ),C0332152;C0740175;C1999375;C2257086;C3669034
1159,ticagrelor in ‐ hosp ( n = $nmbr$ ),C1999375
1158,intertrochanteric,C0745355
1157,trochanter,C0162370
1156,intracranial hemorrhage †,C0151699;C4554169
1156,intracranial hemorrhage  n ( % ),C0151699;C4554169
1156,intracranial hemorrhage,C0151699;C4554169
1156,intracranial bleeding,C0151699
1156,intracranial bleed,C0151699
1155,prebronchodilator fevj ( % predicted ),C2599602
1155,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
1155,prebronchodilator fevi ( % predicted ),C0849974;C1561566;C2599602;C4528367
1155,prebronchodilator fev $nmbr$ / fvc,C2599602;C3714541
1155,prebronchodilator fev $nmbr$ ( l ) t,C2599602;C3714541
1155,prebronchodilator fev $nmbr$ ( l ),C2599602;C3714541
1155,prebronchodilator fev $nmbr$ ( % predicted normal ) t,C2599602;C3714541
1155,prebronchodilator fev $nmbr$ ( %,C2599602;C3714541
1155,prebronchodilator fev $nmbr$  l,C2599602;C3714541
1155,prebronchodilator fev $nmbr$,C2599602;C3714541
1155,prebronchodilator,C2599602
1155,pre - bronchodilator fvc ’ % pred,C2599602;C3714541
1155,pre - bronchodilator fvc ( l ),C2599602;C3714541
1155,pre - bronchodilator fevr l,C1708033;C2599602
1155,pre - bronchodilator fevr % pred,C1708033;C2599602
1155,pre - bronchodilator fevj,C2599602
1155,pre - bronchodilator fevi change,C0849974;C1561566;C2599602;C4528367
1155,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
1155,pre - bronchodilator fev ^ ( l ),C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$ / fvc ratio *,C0456603;C1547037;C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$ / fvc ( % ),C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$ ( l ),C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$ ( % predicted normal ),C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$  l *,C2599602;C3714541
1155,pre - bronchodilator fev $nmbr$,C2599602;C3714541
1155,pre - bronchodilator fev  ( l ),C2599602;C3714541
1155,pre - bronchodilator,C2599602
1155,a prebronchodilator fevl ( % predicted ),C2599602
1154,postbronchodilator fevj ( % predicted ),C2599594
1154,postbronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
1154,postbronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
1154,postbronchodilator fev $nmbr$  l,C2599594;C3714541
1154,postbronchodilator fev $nmbr$  % predicted,C2599594;C3714541
1154,postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C2599594
1154,postbronchodilator,C2599594
1154,post - bronchodilator percent of predicted fev $nmbr$  % ( sd ),C1882327;C2599594;C2699239;C3714541
1154,post - bronchodilator fvc ( l ) a,C2599594;C3714541
1154,post - bronchodilator fevx ( l ),C2599594
1154,post - bronchodilator fev i reversibility  % b,C0021966;C0221138;C0449261;C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ — liters,C0475211;C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ reversibility  % a,C0449261;C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ml,C0439526;C1705224;C2599594;C3714541;C3887665
1154,post - bronchodilator fev $nmbr$ / fvc ( % ) a,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ( l ) a,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ( l ) *,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ( l ),C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ( % predicted normal ) a,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ ( % predicted * ),C2599594;C3714541
1154,post - bronchodilator fev $nmbr$ % predictedb,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$  l *,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$  l,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$  % predicted of normal value,C2599594;C3714541
1154,post - bronchodilator fev $nmbr$  % predicted,C2599594;C3714541
1154,post - bronchodilator fev  reversibility,C0449261;C2599594;C3714541
1154,post - bronchodilator fev  / fvc,C2599594;C3714541
1154,post - bronchodilator fev  ( l ),C2599594;C3714541
1154,post - bronchodilator fev  % predicted,C2599594;C3714541
1154,post - bronchodilator fev   % predicted,C2599594;C3714541
1154,post - bronchodilator,C2599594
1154,b postbronchodilator fevl ( % predicted ),C2599594
1153,non - extensive,C0205231;C1518422
1153,no extensive colitis  n,C0009319;C0205231;C1963084
1153,extensive colitisy,C0205231
1153,extensive colitis or pancolitis,C0009319;C0205231;C1963084
1153,extensive colitis  n,C0009319;C0205231;C1963084
1153,extensive colitis,C0009319;C0205231;C1963084
1153,extensive / pancolitis,C0205231;C0868908
1153,extensive  n ( % ),C0205231
1153,extensive,C0205231
1152,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
1152,troponin negative ( n = $nmbr$ ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
1152,negative ctnl ( n = $nmbr$  $nmbr$ ),C0205160;C1513916;C2825415;C2825491;C3853545
1152,negative ( < $nmbr$ . $nmbr$ )  n ( % ),C0205160;C1513916;C2825415;C2825491;C3853545
1152,negative,C0205160;C1513916;C2825415;C2825491;C3853545
1152,anti - gad negative ( n = $nmbr$ ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
1152,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
1151,stent thrombosis or mi,C3897493
1151,stent thrombosis - related mi,C3897493
1151,stent thrombosis *,C3897493
1151,stent thrombosis,C3897493
1151,non stent thrombosis - related mi,C1518422;C3897493
1151,definite stent thrombosis,C0439544;C1704787;C3897493
1151,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
1151,any risk factor for stent thrombosis,C0035648;C3897493
1151,acute stent thrombosis ( definite or probable ),C0205178;C3897493
1151,acute stent thrombosis,C0205178;C3897493
1150,increased waist circumference,C0205217;C0442805;C0455829
1150,increased risk for thrombotic cardiovascular event ^  n ( % ),C0087086;C0205217;C0442805;C1273410
1150,augment copd,C0205217
1149,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
1148,new vertebral fracture at $nmbr$ months,C0080179;C0205314;C0439231
1148,new or worsening vertebral fracture at $nmbr$ months,C0205314
1148,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
1147,no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314
1147,no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314;C0333307;C1959609
1147,no new a or and no more than $nmbr$ new bilag b domain score  %,C0205314
1146,new use of gpa,C0205314;C1524063;C3495801;C4553145
1146,new or worsentna neohrodathv,C0205314
1146,new or worsenina neohrodathv,C0205314
1146,new or suspected thrombus,C0205314
1145,patients with eot data  n,C2707520
1145,* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .,C1880022;C2707520
1144,daytime nasal symptoms score change from baseline  mean ± se,C0231918;C0332169
1144,baseline daytime nasal symptoms score  mean ± sd,C0168634;C0231918;C0332169;C1442488
1143,took prior antihyperglycemic agent ( any ),C1515187
1143,taking statins  n ( % ) a,C0360714;C1515187
1143,taking calcium supplements at baseline  n ( % ),C0006675;C0006726;C1515187;C2936886;C3540037;C3714611
1143,taking antihypertensive treatment at,C1515187
1143,taking antihypertensive medication at baseline  no . ( % ) e,C1515187
1142,anti - ccp antibody positive  n ( % ),C0432633;C0741132;C1525410;C1704514
1142,anti - ccp antibody positive,C0741132;C4318437
1142,anti - ccp antibody - positive  n ( % ),C0432633;C0741132;C1525410;C1704514
1142,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
1142,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
1141,positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff,C0003241;C0035448;C0201660;C0439178;C0439596;C0741132;C1320283;C1446409;C1511572;C1514241;C2825490;C3812269;C4505301
1141,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
1140,patients with remission,C1277626
1139,patients ' characteristics,C0815172
1139,patient characteristics at randomization,C0034656;C0815172
1139,patient characteristics,C0815172
1138,patients with specific disease characteristics  n ( % ),C0030705;C0205369;C0599878;C1552740
1138,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
1138,patients with specific disease characteris -,C0205369;C0683521;C1552740
1137,potassium - sparing diuretic,C0304490;C3536751
1136,potential predictor,C2698872;C3245505
1136,potential injection site reactions,C0151735;C3245505
1135,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
1134,intention to treat,C0162425;C1283828
1134,intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828
1134,intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828
1134,intention - to - treat,C0162425;C1283828
1134,intent to use gp iib / iiia,C0162425;C1283828;C1550453
1134,intent to use glycoprotein iib / iiia inhibitor,C0162425;C1283828;C1550453
1134,intent to use dti,C0162425;C1283828;C1550453
1134,intent to use direct thrombin,C0162425;C1283828;C1550453
1134,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
1134,intent of conservative strategy  %,C0162425;C0679199;C1283828;C1550453
1134,intent - to - treatb,C0162425;C1283828;C1550453
1133,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .,C0001288;C0030567;C0034394;C0165921;C0353697;C0681889;C1423759;C1521736;C3273355;C3639721;C4553228;C4553229
1133,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
1133,entacapone,C0165921
1132,electrophysiological study — no . ( % ) weight — ibj,C0850293
1131,pathological q waves,C0429090
1131,pathologic q waves — no . ( % ),C0429090
1131,pathologic q waves  n ( % ),C0429090
1130,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
1130,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
1130,hemoglobin ( g r $nmbr$ ),C0205090;C0684010;C1319312;C2603358
1130,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
1130,hemoglobin ( g $nmbr$ ! ),C1319312
1130,hemoglobin  g / dlf,C1319312
1130,hemoglobin  g / dl,C0019046;C0439267;C1319312;C3642216
1130,hemoglobin  g $nmbr$ $nmbr$,C1319312
1130,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
1129,hemoglobin level  %,C0019029;C1314664
1129,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
1128,hemoglobin a ^ c  %,C0019020;C3889898
1128,hemoglobin a $nmbr$ c ( % ),C0019020;C3889898
1128,hemoglobin a $nmbr$ c  %,C0019020;C3889898
1128,hemoglobin a $nmbr$ c,C0019020;C3889898
1128,hemoglobin - a $nmbr$ c ( % ) ' • ■ * *,C0019020;C3889898
1127,troponin or ckmb value,C0041199
1127,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
1127,troponin ( - ),C0041199
1127,troponin ( + ),C0041199
1127,troponin $nmbr$ at baseline *,C0041199;C0168634;C1442488
1127,troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
1127,troponin,C0041199
1126,troponin t ( pg / ml ),C0077404;C0439297;C1420827
1126,troponin t,C0077404;C1420827
1126,elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
1125,rolofylline rx,C0166128;C1425688;C1521941;C2709207
1125,rolofylline n,C0166128
1125,rolofylline ( n = $nmbr$ ),C0166128
1125,rolofylline ( n = $nmbr$  $nmbr$ ),C0166128
1125,rolofylline $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
1125,rolofylline,C0166128
1124,theophyllines,C0039771
1124,theophylline compound,C0039771;C0205198;C1706082
1123,walking,C0080331;C4283795;C4321241;C4321242
1122,coping,C0009967
1121,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
1120,hong kong,C0019907;C2987742
1119,no smo king,C1311076;C1364142;C1423784
1118,exenatide ± oad,C0167117
1118,exenatide no . of events / total no . ( % ),C0167117
1118,exenatide n = $nmbr$,C0167117
1118,exenatide lar,C0167117
1118,exenatide er,C0167117;C3810541;C3811131
1118,exenatide,C0167117
1117,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
1117,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
1117,no antidiabetic drug,C0935929
1117,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
1117,antidiabetic medications,C0935929
1117,antidiabetic medication | |,C0935929
1117,antidiabetic medication,C0935929
1117,antidiabetic drug,C0935929
1117,antidiabetic agents,C0935929
1117,antidiabetic agent,C0935929
1117,antidiabetic,C0935929
1117,> $nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
1117,$nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
1116,estimated response rate and odds ratio,C0237629;C0750572
1116,estimated proportions ( % ) and odds ratios,C0750572;C1709707
1116,estimated means and treatment differences ( % ),C0750572;C1704970
1116,estimated means and difference,C0750572;C1704970
1116,estimated glomerular filtration,C0232809;C0750572
1116,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
1116,estimated creatinine clearance — ml / min  i,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
1116,estimated creatinine clearance < $nmbr$ rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
1116,estimated creatinine clearance < $nmbr$ ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
1116,estimated creatinine clearance < $nmbr$ ml / min *,C0439445;C0750572;C0812399
1116,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
1116,estimated creatinine clearance  !,C0750572;C0812399
1116,estimated * creatinine clearance < $nmbr$ mlvmin  %,C0750572;C0812399
1115,rate estimate ( $nmbr$ % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
1115,estimate ( $nmbr$ % cl ),C0596019;C0750572
1115,estimate ( $nmbr$ % ci ),C0008107;C0750572;C3259781
1114,investigator - reported hypoglycaemia *,C0035173
1114,investigator - reported hypoglycaemia,C0035173
1114,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
1114,investigator - determined myocardial infarction,C0035173
1114,investigator - defined drug - related aes,C0035173
1113,stent placement,C0522776
1113,stent implanted — no . ( % ),C0522776
1113,stent implanted,C0522776
1112,stratified by,C0205363
1112,stratified analyses,C0002778;C0205363;C0936012;C1524024
1111,vitamins,C0042890;C3540032;C3714649
1111,other plain vitamin preparations,C0042890
1110,vitamin e,C0042874;C3714803
1110,i vitamin e ( n = $nmbr$ ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
1110,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
1110,$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ ),C0042874;C3714803
1110,$nmbr$ vitamin e,C0042874;C3714803
1109,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
1109,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
1109,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
1109,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
1109,$nmbr$ ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
1108,vitamin c,C0003968;C2349136;C3714687;C4522080
1107,vitality,C0424589
1106,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
1106,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
1106,hospitalized !,C0701159
1106,hospitalized,C0701159
1105,urinary tract infection,C0042029;C0262655;C4554638
1104,utis,C0042029
1104,uti,C0042029;C0077906;C1412376
1103,dual ii,C0205173;C1554184;C1710602;C4082587
1103,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
1103,dual antiplatelet,C0205173;C1554184
1102,metastatic,C0036525;C1522484;C4085632
1101,epistaxis,C0014591;C4554627
1100,stating,C1301808;C1442792;C3148680
1100,state,C1301808;C1442792;C3148680
1099,statistic * *,C2348149;C2828391
1099,sample statistics,C2348149
1098,full po pulatio n,C0443225;C0946289
1098,duration of full - dose warfarin therapy before enrollment ( mo ),C0366686;C0443225;C0444917
1097,received $nmbr$ prior biologic therapy  n,C0278947;C1514756
1097,received $nmbr$ prior biologic therapies  n,C0278947;C1514756
1097,prior biologic therapy ( including anti - tnfs ),C0278947
1096,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
1096,lipid trial participants #,C0023779;C1997894;C2242969
1096,lipid trial participants  no . ( % ),C0023779;C1997894;C2242969
1096,lipid trial participants,C0023779;C1997894;C2242969
1096,lioid trial participants,C1997894;C2242969
1095,boost intensify premix i ( global patient population ),C1511253;C1874596
1095,boost intensify all ( pan - asian patient population ),C1511253;C1874596
1094,aliskiren / valsartan ( n = $nmbr$ ),C2733073
1093,sacubitril / valsartan ( n = $nmbr$ ),C4033631
1093,sacubitril / valsartan,C4033631
1092,methotrexate treatment !,C0746573
1091,active treatment,C1704532
1090,on - treatment,C4684449
1089,time to treatment  h,C0033727;C0369286;C0441932;C0564385;C3494202;C4528284
1089,time to treatment,C3494202
1088,conventional treatment ( n = $nmbr$ ),C2945704
1088,conventional treatment,C2945704
1087,teaes ( > $nmbr$ % in any treatment group ) *,C0374505
1087,teaes ( > $nmbr$ % in any treatment group ),C0374505
1087,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
1086,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
1086,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
1086,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
1086,serum creatinine — mg / dl,C0201976;C0439269;C0600061
1086,serum creatinine level,C0600061
1086,serum creatinine > $nmbr$ pmol / l . n ( % ) |,C0201976;C0439284;C0600061
1086,serum creatinine > $nmbr$ mmol / l  n ( % ),C0201976;C0600061;C1532563
1086,serum creatinine > $nmbr$ / xmol / l  n ( % ) | |,C0201976;C0600061
1086,serum creatinine . mg / dl,C0201976;C0439269;C0600061
1086,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
1086,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
1086,serum creatinine ( gmol / ),C0201976;C0600061
1086,serum creatinine  弘 mol 儿 | |,C0027960;C0201976;C0324740;C0439189;C0600061;C1456781;C1824986;C3665593
1086,serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl,C0201976;C0439269;C0600061
1086,serum creatinine  μ mol / l,C0201976;C0347982;C0600061
1086,serum creatinine  umol / lf,C0201976;C0439194;C0600061;C1416933;C2986618;C4554443
1086,serum creatinine  mg / dlb,C0024671;C0026410;C0201976;C0439269;C0600061;C0752347;C1960952;C2346927;C3890365;C4321396;C4521761
1086,serum creatinine  mg / dl,C0201976;C0439269;C0600061
1086,serum creatinine  limo $nmbr$ $nmbr$,C0201976;C0600061
1086,serum creatinine  gmol / l |,C0201976;C0600061
1086,serum creatinine  ^ mol / l,C0201976;C0347982;C0600061
1086,serum creatinine  / xmol / l | |,C0201976;C0600061
1086,serum creatinine,C0201976;C0600061
1086,preoperative serum creatinine > $nmbr$ pmol / l,C0201976;C0439284;C0445204;C0600061
1086,increase in serum creatinine,C0201976;C0442805;C0600061
1086,first serum creatinine,C0201976;C0205435;C0600061;C1279901
1086,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
1086,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0168634;C0201976;C0205173;C0600061;C1442488;C1705764
1086,composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes,C0022658;C0201976;C0205088;C0205173;C0205199;C0600061;C1547335;C1705764
1086,composite endpoint of doubling of serum creatinine  esrd,C0022661;C0035078;C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2316810;C2349179;C2826544
1086,changes in serum creatinine  pmol / l,C0201976;C0392747;C0439284;C0443172;C0600061
1086,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
1085,lowzmedium intensity,C0522510
1085,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
1085,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
1085,baseline luts severity  n ( % ) :,C0168634;C0439793;C0522510;C0574785;C1442488
1085,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
1085,baseline heart failure severity amongthose with priorheartfailure  %,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
1085,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
1084,with ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
1084,no - ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
1084,intensive therapy ( n = $nmbr$ ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
1084,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
1084,intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453
1084,intensity $nmbr$,C0522510
1084,intense,C0522510
1083,severity ofhypertension [ n ( % ) ] b,C0439793;C0522510
1083,severity of hypertensionb,C0439793;C0522510
1083,severity of heartburnb,C0439793;C0522510
1083,severity of copda  combined assessment of copd  n ( % ),C0439793;C0522510
1083,severity of copd — no . ( % ) f,C0024117;C0439793;C0522510;C1412502;C3714496
1083,severity of copd *  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
1083,severity of copd  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
1083,severity of copd  combined assessment  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
1083,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
1083,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
1083,severity n ( % ),C0439793;C0522510
1083,severity,C0439793;C0522510
1083,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
1083,nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ],C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
1083,luts severity,C0439793;C0522510;C0574785
1083,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
1083,ed severity * *  n ( % ) :,C0439793;C0522510;C3538926
1083,ed severity  no . ( % ) a,C0439793;C0522510;C3538926
1083,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
1083,any severity,C0439793;C0522510
1082,charm,C0849759
1081,chlor,C0308648
1080,chl,C0019829
1079,ct ratio > $nmbr$ . $nmbr$,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
1079,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
1079,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
1079,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
1079,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
1079,ct,C0007673;C3540513;C3813556;C3888140
1078,no cs and is,C0010182;C0271160;C3540510;C4085345
1078,no cs and imm,C0010182;C0271160;C3540510;C4085345
1078,neither cs nor imm,C0010182;C0271160;C3540510;C4085345
1078,glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
1078,glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
1078,cs use : no,C0010182;C0271160;C3540510;C4085345
1078,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
1078,cs and is,C0010182;C0271160;C3540510;C4085345
1078,cs and imm,C0010182;C0271160;C3540510;C4085345
1078,cs and im,C0010182;C0271160;C3540510;C4085345
1078,cs,C0010182;C0271160;C3540510;C4085345
1077,concurrent prednisolone,C0032950;C0205420
1077,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
1077,concurrent medication,C0013227;C0205420;C3244316;C4284232
1077,concurrent illness,C0205420;C0221423
1076,concomitant therapy  no . ( % ),C1707479
1076,concomitant therapy  n [ % ],C1707479
1076,concomitant therapy,C1707479
1076,concomitant therapies n ( % ),C1707479
1076,concomitant therapies at hospital discharge,C0586003;C1707479
1075,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
1075,concomitant cardiovascular therapy ( taken > $nmbr$ days ),C0007226;C0521115;C0587038;C1707479;C3887460
1075,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
1075,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
1075,cardiovascular therapies — no . { % ),C0587038
1074,dihydropyridine calcium - channel blocker,C2945601
1073,calcium channel,C0006685
1073,calcium - channel inhibitor,C0006685;C1999216
1073,calcium - channel blockersubgroup,C0006685
1073,calcium - channel blockerf,C0006685
1072,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
1072,combined fatal / nonfatal outcomes,C0205195;C0206277
1072,combined estimated gfr and albuminuria status,C0205195
1072,combined efficacy and safety endpoint,C0205195;C1280519;C1707887
1071,golimumab combined ( n = $nmbr$ ),C0205195;C2353893
1071,combined n = $nmbr$,C0205195
1071,combined golimumab groups,C0205195;C2353893
1071,combined end poir,C0205195;C0444930;C2746065
1071,combined end points,C0205195;C2349179
1071,combined end point,C0205195;C2349179;C2826544
1071,combined chd,C0205195;C0280604;C3542407
1071,combined ( n = $nmbr$ ),C0205195
1071,combined,C0205195
1070,other combination,C0205195;C1947911;C3811910
1070,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
1070,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
1070,combination - facilitated pci ( n = $nmbr$ ),C0205195;C1947911;C3811910
1070,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
1070,combination ( n = $nmbr$ ),C0205195;C1947911;C3811910
1070,combination,C0205195;C1947911;C3811910
1069,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
1069,chest x - ray,C0039985
1068,community hospital ( % ),C0020003
1068,community hospital  n ( % ),C0020003
1068,community hospital,C0020003
1067,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
1067,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
1067,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
1067,c peptide  nmol / l * ',C0006558;C0439282
1067,c - peptide,C0006558
1067,$nmbr$ - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
1066,calcium level,C0201925;C0428302
1065,doubling of creatinine level,C0205173;C0428279;C1705764
1065,creatinine level,C0428279
1064,scale — cognitive portion  ldl — low -,C0175659;C0349674;C0449719;C1516691;C1947916
1064,cognitive,C1516691
1063,cbz - naive,C0006949
1063,cbz - exposed,C0006949
1063,carbamazepine,C0006949;C0006950;C0682993
1062,comorbidity  no . ( % ),C0009488
1062,comorbidities other than diabetes,C0009488;C0011847;C0011849
1062,comorbidities and concomitant medications,C0009488
1062,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
1062,comorbidities ( % ),C0009488
1062,comorbidities  no . ( % ),C0009488
1062,comorbidities  n ( % ) a,C0009488
1062,comorbidities  %,C0009488
1062,comorbidities,C0009488
1062,comorbid illnesses,C0009488;C0221423
1062,comorbid diseasesa diabetesb,C0009488
1062,comorbid conditionsb,C0009488
1062,co - morbidities  n ( % ),C0009488
1062,co - morbidities  a n ( % ),C0009488
1062,co - morbidities,C0009488
1061,other - candesartan,C0717550
1061,candesartan group ( n = $nmbr$ ),C0441848;C0717550
1061,candesartan $nmbr$ / $nmbr$,C0717550
1061,candesartan,C0717550
1060,canada or united states,C0006823
1060,canada,C0006823
1059,mexico  central / south america,C0007674;C0025885;C0037713;C0205099;C1710133;C1879652
1059,central or south america,C0205099;C1879652
1059,central and south america and mexico,C0205099;C1879652
1059,central and south america,C0205099;C1879652
1059,central and eastern europe,C0205099;C1879652
1059,central / south america and mexico,C0007674;C0037713;C0205099;C1710133;C1879652
1059,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
1059,central / south,C0205099;C1710133;C1879652
1059,central / eastern europe and russia hr ( $nmbr$ % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
1059,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
1059,central / eastern,C0205099;C1707877;C1879652
1058,centre,C0205099;C3810851
1058,center location,C0205099
1058,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
1058,center,C0205099;C3810851
1057,cyp $nmbr$ a $nmbr$ inhibitors,C0243077;C1418793;C2634343
1057,cyp $nmbr$ a $nmbr$,C1418793;C2634343
1056,canvas - r,C0205090;C0684010;C2603358;C3281223
1056,canvas,C3281223
1055,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
1055,comparison : cat . $nmbr$ vs . cat . $nmbr$,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
1055,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1055,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
1055,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
1055,cat > = $nmbr$ ( n = $nmbr$  $nmbr$ ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1055,cat > = $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1055,cat > $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1055,cat < $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1055,cat . $nmbr$ n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
1054,postmenopausal  current hormone therapy use,C0019932;C0042153;C0232970;C0279025;C0457083;C0521116;C1705970;C1947944;C2827774;C4521914
1054,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
1054,currently smokes,C0521116
1054,currently smoker,C0337664;C0521116
1054,currently,C0521116
1054,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
1054,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
1054,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
1054,current prescribed medications,C0521116;C1705970;C3166216;C3202967
1054,current other ( predefined ) medical conditions,C0521116;C1705970
1054,current or prior smoking  %,C0521116;C1705970
1054,current or previous atrial fibrillation,C0521116;C1705970
1054,current or former smoker,C0521116;C1705970
1054,current nonsmokers,C0337672;C0521116;C1705970;C4554605
1054,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
1054,current n z $nmbr$,C0521116;C1705970
1054,current lra use,C0521116;C1705970
1054,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
1054,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
1054,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
1054,current enthesitis  n ( % ) ’,C0521116;C1282952;C1705970
1054,current dactylitis  n,C0239161;C0521116;C1705970
1054,current cigarette use  n ( % ),C0521116;C0694535;C1705970
1054,current cigarette use,C0521116;C0694535;C1705970
1054,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
1054,current bone disease,C0005940;C0521116;C1705970
1054,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
1054,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0521116;C1705970
1054,current alcohol use  n ( % ),C0001948;C0521116;C1705970
1054,current alcohol drinking  n ( % ),C0001948;C0521116;C0556297;C1705970
1054,current alcohol  n ( % ),C0001962;C0001975;C0521116;C1705970
1054,current / past,C0521116;C1444637;C1705970;C4284302
1054,current ( n   = $nmbr$  $nmbr$ ),C0521116;C1705970
1054,current ( % ),C0521116;C1705970
1054,current ( $nmbr$ + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
1054,current (  $nmbr$ cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
1054,current  n ( % ),C0521116;C1705970
1054,current,C0521116;C1705970
1053,types of antihypertensive medications at last visit   §,C0003364;C0332307
1053,types of antihypertensive medications at $nmbr$ year   †,C0003364;C0332307
1053,type of tnf failure  n ( % ) b,C0231174;C0332307;C0680095;C1547052;C3887647
1053,type of tnf antagonist failure  n ( “ / o ) ”,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
1053,type of tnf antagonist failure  n ( % ) ' ’,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
1053,type of stent at index procedure,C0038257;C0332307;C1547052
1053,type of mi ( % ),C0332307;C1547052;C3810814
1053,type of mi,C0332307;C1547052;C3810814
1053,type of hospital care,C0259945;C0332307;C1547052
1053,type of des at index procedure,C0011702;C0332307;C1547052;C4551552
1053,type of des,C0011702;C0332307;C1547052;C4551552
1053,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052
1053,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052
1053,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
1053,type of antihypertensive medication use among patients using antihypertensive medications  n ( % ),C0003364;C0332307;C1524063;C1547052
1053,type of af  n ( % ),C0332307;C0344434;C1547052;C4049859
1053,type of af,C0332307;C0344434;C1547052;C4049859
1053,type ic,C0020750;C0332307;C1547052;C4554818
1053,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
1053,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
1053,type / no . of valves repaired / replaced mitral,C0332307;C1547052
1053,type $nmbr$  n ( % ),C0332307;C1547052
1053,type,C0332307;C1547052
1053,stent type implanted,C0038257;C0332307;C1547052
1053,stent type,C0038257;C0332307;C1547052
1053,qualifying mi type,C0332307;C1514624;C1547052;C3810814
1053,phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
1053,endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
1053,des type,C0011702;C0332307;C1547052;C4551552
1053,barc types $nmbr$  $nmbr$  or $nmbr$,C0332307
1053,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
1053,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
1053,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
1053,af type,C0332307;C0344434;C1547052;C4049859
1053,> $nmbr$ type,C0332307;C1547052
1053,> $nmbr$ des type,C0011702;C0332307;C1547052;C4551552
1052,type of vessel involved,C1282017
1051,triple - vessel disease  n ( % ),C0856738
1050,two - vessel disease,C0581375
1050,three - vessel disease,C3272265
1050,one - vessel disease,C3275121
1049,large vessel atherosclerosis,C0003850;C0004153;C0225990
1049,large vessel,C0225990
1048,small vessel,C0225988
1047,stented vessels,C0183521
1047,stented vessel,C0183521
1046,target vessel diameter,C0449618;C1301886
1046,target vessel,C0449618
1046,number of target vessels,C0237753;C0449618;C0449788
1046,no . of target vessels,C0449618
1045,valvular heart disease — no . ( % ),C0018824;C1963123
1045,valvular heart disease  n ( % ),C0018824;C1963123
1045,valvular heart disease,C0018824;C1963123
1045,cardiac valvular disease,C0018824
1044,structural heart disease — no . ( % ) f,C1290384
1044,structural heart disease §,C1290384
1044,structural heart disease,C1290384
1043,pulmonary vascular resistance  dyne • s • cm $nmbr$,C0308914;C0456261;C0488644;C0600130
1042,jugular venous distention > $nmbr$ cm,C0425687
1042,jugular venous distension  n ( % ),C0425687
1041,vessel disease,C0042373
1041,vascular disease,C0042373
1041,previous vascular disease,C0042373;C0205156;C1552607
1041,other vascular disease — no . ( % ),C0042373
1041,other vascular disease ( cvd or pad )  %,C0007222;C0042373
1041,other vascular disease,C0042373
1041,number of vessels disease,C0042373;C0237753;C0449788
1041,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
1041,any vascular disease,C0042373
1040,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
1040,responder analyses ( achieving alc < $nmbr$ . $nmbr$ % ),C0002778;C0936012;C1524024
1040,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
1040,prespecified analysis,C0002778;C0936012;C1524024
1040,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
1040,pooled analysis of sustain $nmbr$ — $nmbr$ trials,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
1040,patients ( full analysis sety )  n,C0002778;C0030705;C0443225;C0936012;C1524024
1040,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
1040,integrated analysis set ( n = $nmbr$ ),C0002778;C0936012;C1158478;C1524024;C1705422
1040,included in analysis,C0002778;C0332257;C0936012;C1524024
1040,full analysis set  n,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
1040,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
1040,final analysis ( all patients ),C0002778;C0205088;C0936012;C1524024;C1546485;C3853528
1040,crude analysis  n ( % ),C0002778;C0936012;C1524024
1040,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0936012;C1524024
1040,analysis,C0002778;C0936012;C1524024
1040,$nmbr$ days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
1039,prior pci or cabg surgery,C0332152;C2826257;C4049621
1039,prior pci or cabg,C0332152;C2826257;C4049621
1039,prior pci  %,C0332152;C2826257;C4049621
1039,prior pci,C0332152;C2826257;C4049621
1039,prerandomization pci,C4049621
1039,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
1039,no prior pci,C0332152;C2826257;C4049621
1039,no pci,C4049621
1039,after pci,C4049621
1038,secondary pci,C0027627;C0175668;C0205436;C4049621
1038,received pci,C1514756;C4049621
1038,before pci,C4049621
1037,treated with pci — no . / total no . ( % ),C0332293;C4049621
1037,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
1037,pci — no . { % ),C4049621
1037,pci — no . ( % ),C4049621
1037,pci alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C4049621
1037,no pci or cabg — no . ( % ),C4049621
1037,multivessel pci,C4049621
1037,facilitated pci ( n = $nmbr$ ),C4049621
1037,$nmbr$ vessel pci,C0005847;C4049621
1036,reteplase / abciximab - facilitated pci ( n = $nmbr$ ),C0256103;C0288672;C4049621
1036,ret / abx - facil . pci,C0389252;C4049621
1036,combo - facilitated pci,C4049621
1036,abx - facil . pci,C4049621
1036,abciximab - facilitated pci ( n = $nmbr$ ),C0288672;C4049621
1036,abciximab - facilitated pci,C0288672;C4049621
1035,pci orcabg,C4049621
1035,pci duration,C0449238;C2926735;C4049621
1035,pci delay due to low risk,C4049621
1035,pci > $nmbr$ month ago,C0332177;C0439231;C4049621
1035,pci :,C4049621
1035,pci ( % ),C4049621
1035,pci  n ( % ),C4049621
1035,pci,C4049621
1034,pci postindex event,C0441471;C4019010;C4049621
1034,pci or cabg surgery for index event,C4049621
1034,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
1034,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
1033,tertile $nmbr$ index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
1033,pci performed,C4049621
1033,index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
1032,bb after randomisation,C0004739;C0034656;C0332297
1032,bb,C0004739;C0332297
1032,- < — ■ bb — - ►,C0004739;C0332297
1031,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
1031,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
1031,bl h / y : unilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
1031,bl h / y : bilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
1031,bl bml > $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
1031,bl bml > $nmbr$ ke / m ^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
1031,bl bml < $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
1031,bl bmioo kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
1031,bl bm $nmbr$ < $nmbr$ kg / m ^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
1031,bl,C0005918;C0006413;C1552663;C2827109
1031,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
1030,obese ( bmi £ $nmbr$ ),C0028754;C0578022
1030,bmi category ( kg / m $nmbr$ ),C0578022;C0683312;C1532718;C3889287
1030,bmi category ( % ),C0578022;C0683312;C3889287
1030,bmi category  no . ( % ),C0578022;C0683312;C3889287
1030,bmi categories  n ( % ),C0578022;C0683312
1030,bmi a $nmbr$,C0578022
1030,bmi ^,C0578022
1030,bmi > = $nmbr$,C0578022
1030,bmi > $nmbr$ obese,C0578022
1030,bmi > $nmbr$ ( % ),C0578022
1030,bmi > $nmbr$  n ( % ),C0578022
1030,bmi > $nmbr$,C0578022
1030,bmi < = $nmbr$,C0578022
1030,bmi < $nmbr$,C0578022
1030,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
1030,bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0578022
1030,bmi $nmbr$,C0578022
1030,bmi  no . ( % ),C0578022
1030,bmi  n ( % ),C0578022
1030,bmi,C0578022
1030,$nmbr$ < bmi < $nmbr$,C0578022
1029,mean bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1029,bmi   kg · m − $nmbr$,C0578022;C1532718
1029,bmi o $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
1029,bmi kg · m − $nmbr$,C0578022;C1532718
1029,bmi kg - m - $nmbr$,C0578022;C1532718
1029,bmi [ kg / m $nmbr$ ],C0578022;C1532718
1029,bmi > = $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi > $nmbr$ — no . { % ) $,C0578022
1029,bmi > $nmbr$ — no . ( % ) f,C0578022
1029,bmi > $nmbr$ kg / m $nmbr$ *,C0578022;C1532718
1029,bmi > $nmbr$ kg / m $nmbr$ ( % ),C0578022;C1532718
1029,bmi > $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
1029,bmi > $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi < $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi - kg / m $nmbr$,C0578022;C1532718
1029,bmi ( sd )  kg / m $nmbr$,C0578022;C1532718;C2699239
1029,bmi ( kg = m $nmbr$ ),C0578022;C1532718
1029,bmi ( kg / m ’ ),C0578022;C1532718
1029,bmi ( kg / m ^ ),C0578022;C1532718
1029,bmi ( kg / m ),C0578022;C1532718
1029,bmi ( kg / m $nmbr$ ) a,C0578022;C1532718
1029,bmi ( kg / m $nmbr$ ) < $nmbr$,C0578022;C1532718
1029,bmi ( kg / m $nmbr$ ) *,C0578022;C1532718
1029,bmi ( kg / m $nmbr$ ) ( sd ),C0578022;C1532718;C2699239
1029,bmi ( kg / m $nmbr$ ),C0578022;C1532718
1029,bmi ( kg / ( m ) $nmbr$ ),C0578022;C1532718
1029,bmi ( . kg / m - ) *,C0578022;C1532718
1029,bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,C0578022
1029,bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$,C0578022
1029,bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$,C0578022
1029,bmi # kg - m “ $nmbr$,C0578022;C1532718
1029,bmi  x $nmbr$ kg / m $nmbr$,C0578022;C1532718
1029,bmi  mean ± sd kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1029,bmi  mean ± sd  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1029,bmi  mean  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
1029,bmi  kg per m $nmbr$,C0578022;C1532718
1029,bmi  kg / m ’,C0578022;C1532718
1029,bmi  kg / m ^ *,C0578022;C1532718
1029,bmi  kg / m ^,C0578022;C1532718
1029,bmi  kg / m $nmbr$ uac  no . ( % ),C0578022;C1532718
1029,bmi  kg / m $nmbr$ ( sd ),C0578022;C1532718;C2699239
1029,bmi  kg / m $nmbr$  n ( % ),C0578022;C1532718
1029,bmi  kg / m $nmbr$  n,C0578022;C1532718
1029,bmi  kg / m $nmbr$  mean,C0444504;C0578022;C1532718;C2347634;C2348143
1029,bmi  kg / m $nmbr$,C0578022;C1532718
1029,$nmbr$ bmi  kg / m,C0578022;C1532718
1028,plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005893;C0006448;C0006539;C0008377;C0017887;C0019664;C0019665;C0020538;C0022709;C0030125;C0041004;C0042295;C0181074;C0205120;C0205210;C0262512;C0262926;C0332288;C0332835;C0439190;C0489786;C0578022;C0885378;C1305855;C1452534;C1552595;C1705255;C1820373;C1879745;C1883728;C1961139;C1963138;C2004062;C2828386;C2936173;C3854028;C4321248;C4522126
1028,median body mass index  kg / m $nmbr$ ( range ),C0005893;C0549183;C0578022;C0876920;C1305855;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
1028,median body mass index  kg / m $nmbr$ ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1028,mean body - mass index  kg / m $nmbr$   ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1028,mean body - mass index  kg / m $nmbr$ ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1028,bodymass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1028,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
1028,body mass index mean kg / m $nmbr$ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1028,body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
1028,body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
1028,body mass index category  no . ( % ) l,C0005893;C0578022;C0683312;C1305855;C3889287
1028,body mass index ^,C0005893;C0578022;C1305855
1028,body mass index > $nmbr$ — no . ( % ) f,C0005893;C0578022;C1305855
1028,body mass index > $nmbr$ t,C0005893;C0578022;C1305855
1028,body mass index > $nmbr$ kg / m $nmbr$ *,C0005893;C0578022;C1305855;C1532718
1028,body mass index > $nmbr$ kg / m $nmbr$  n ( % ),C0005893;C0578022;C1305855;C1532718
1028,body mass index > $nmbr$ kg / m  n ( % ),C0005893;C0578022;C1305855;C1532718
1028,body mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
1028,body mass index < $nmbr$ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body mass index :,C0005893;C0578022;C1305855
1028,body mass index - kg / m $nmbr$ t,C0005893;C0578022;C1305855;C1532718
1028,body mass index +,C0005893;C0578022;C1305855
1028,body mass index *,C0005893;C0578022;C1305855
1028,body mass index ( range ) ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
1028,body mass index ( mg / m $nmbr$ ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
1028,body mass index ( kgm _ $nmbr$ ),C0005893;C0578022;C1305855
1028,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
1028,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
1028,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m ^ ) ^,C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m ^ ),C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m $nmbr$ ) ∗,C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m $nmbr$ ) * ',C0005893;C0578022;C1305855;C1532718
1028,body mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1028,body mass index ( bmi )  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
1028,body mass index $nmbr$,C0005893;C0578022;C1305855
1028,body mass index  mean kg / m ^ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1028,body mass index  kg / m ’,C0005893;C0578022;C1305855;C1532718
1028,body mass index  kg / m ^ ^,C0005893;C0578022;C1305855;C1532718
1028,body mass index  kg / m ^ ( meanisd ),C0005893;C0578022;C1305855;C1532718
1028,body mass index  kg / m ^,C0005893;C0578022;C1305855;C1532718
1028,body mass index  kg / m $nmbr$   ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
1028,body mass index  kg / m $nmbr$ ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
1028,body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1028,body mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body mass index  * kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body mass index  %,C0005893;C0578022;C1305855
1028,body mass index,C0005893;C0578022;C1305855
1028,body - mass index ”,C0005893;C0578022;C1305855
1028,body - mass index — no . ( % ) : i :,C0005893;C0578022;C1305855
1028,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
1028,body - mass index §,C0005893;C0578022;C1305855
1028,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
1028,body - mass index ^ :,C0005893;C0578022;C1305855
1028,body - mass index ^,C0005893;C0578022;C1305855
1028,body - mass index \ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body - mass index > $nmbr$ kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
1028,body - mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
1028,body - mass index > $nmbr$,C0005893;C0578022;C1305855
1028,body - mass index : ! :,C0005893;C0578022;C1305855
1028,body - mass index - kg / m $nmbr$  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
1028,body - mass index - ! ',C0005893;C0578022;C1305855
1028,body - mass index *,C0005893;C0578022;C1305855
1028,body - mass index ) -,C0005893;C0578022;C1305855
1028,body - mass index ) ',C0005893;C0578022;C1305855
1028,body - mass index ),C0005893;C0578022;C1305855
1028,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
1028,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
1028,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m   $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m $nmbr$ ) t,C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m $nmbr$ ) *,C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
1028,body - mass index ( kg / cm $nmbr$ ),C0005893;C0578022;C1305855;C4054689
1028,body - mass index $,C0005893;C0578022;C1305855
1028,body - mass index  kq / nrn,C0005893;C0578022;C1305855;C1425210
1028,body - mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
1028,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
1028,body - mass index  !,C0005893;C0578022;C1305855
1028,body - mass index,C0005893;C0578022;C1305855
1028,* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .,C0001779;C0002871;C0004083;C0005893;C0005910;C0009253;C0010055;C0018787;C0025266;C0027976;C0030705;C0032042;C0034510;C0036864;C0040223;C0040363;C0041260;C0042295;C0043100;C0079399;C0086715;C0184661;C0205088;C0205447;C0332288;C0332307;C0332490;C0376558;C0439175;C0439209;C0439810;C0439849;C0441074;C0441833;C0441889;C0441994;C0445022;C0449820;C0475211;C0522523;C0578022;C0596306;C0596672;C0687744;C0699792;C0804628;C0886296;C1000483;C1144709;C1257890;C1273869;C1275491;C1281911;C1292769;C1305855;C1305866;C1314687;C1317554;C1444637;C1452534;C1519504;C1522384;C1547052;C1548802;C1696465;C1705104;C1705314;C1705315;C1705428;C1705429;C1706408;C1706779;C1719797;C1882084;C1883351;C2003888;C2709270;C2825907;C2911648;C3537020;C3541383;C3827682;C3853635;C4284014;C4284038;C4284302;C4554633
1027,patients with evaluable endoscopy,C0014245;C2986511
1027,endoscopy subscore  n ( % ),C0014245
1027,endoscopy subscore,C0014245
1027,endoscopic disease severity,C0014245;C0442418;C0521117
1026,prior use of osteoporosis medications  n ( % ),C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
1026,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
1026,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
1026,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
1026,osteoporosis,C0029456;C4554622
1025,pulsed blood pressure,C0232108
1024,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
1024,baseline systolic blood pressure,C4274438
1023,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0023779;C0168634;C0597357;C1442488
1023,receptor blockers  n ( % ),C0597357
1023,receptor blockers,C0597357
1023,receptor blocker,C0597357
1022,obesity t,C0028754;C1963185
1022,obesity *,C0028754;C1963185
1022,obesity ( % ) §,C0028754;C1963185
1022,obesity  % *,C0028754;C1963185
1022,obesity,C0028754;C1963185
1022,obese,C0028754
1022,> $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
1022,$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
1021,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
1021,model $nmbr$ §,C3161035;C3274659;C3714583;C3853906
1021,model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
1021,model $nmbr$ +,C3161035;C3274659;C3714583;C3853906
1021,model $nmbr$,C3161035;C3274659;C3714583;C3853906
1021,model  n,C3161035;C3274659;C3714583;C3853906
1021,crude model hr ( $nmbr$ % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
1021,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
1020,daily bowel movements,C0011135;C0332173
1020,bowel function,C0011135
1019,c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
1019,c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
1019,c $nmbr$ e $nmbr$ fab bolus,C1186706;C1511237;C1705509;C3812160
1019,bolus of heparin given,C0019134;C0770546;C1186706;C1511237;C1705509;C3812160
1019,bolus and infusion,C1186706;C1511237;C1705509;C3812160
1019,bolus and corrections,C1186706;C1511237;C1705509;C3812160
1019,bolus alone,C1186706;C1511237;C1705509;C3812160
1019,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
1019,bolus,C1186706;C1511237;C1705509;C3812160
1019,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
1018,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
1017,albumin measurements ^ ^,C0201838
1016,glycemic indexes,C1136206
1015,glycemic status f,C0016327;C1320980
1015,glycemic status,C1320980
1014,dm - ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
1014,dm + ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
1014,aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C1120110;C3250443
1014,aliskiren ( n = $nmbr$ ),C1120110
1014,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
1014,aliskiren,C1120110
1013,sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ],C0037712;C1880389;C1883221;C3541951
1013,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
1013,iief - ef domain score  visit $nmbr$ y,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
1013,iief - ef domain score  visit $nmbr$ * *,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
1013,ibdq domain scores  mean [ sd ],C1880389;C1883221;C3541951
1013,ef domain,C1880389;C1883221;C3541951
1012,syndrome  n ( % ),C0039082
1012,specific syndromes,C0039082;C0205369;C1552740;C1558916
1012,nonmetabolic syndrome ( n = $nmbr$ ),C0039082
1012,cardiometabolic syndrome  ^ n ( % ),C0039082
1011,stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
1011,statin during admission,C0184666;C0360714;C0809949
1011,risk level at admission,C0184666;C0809949;C2923839
1011,potassium at admission  mmol / l - $nmbr$,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C1532563;C3714637
1011,p blocker before admission,C0184666;C0369773;C0809949;C2603361
1011,no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
1011,no statin during admission,C0184666;C0360714;C0809949
1011,medical therapy before admission,C0184666;C0418981;C0809949
1011,before admission )  %,C0184666;C0809949
1011,aspirin before admission,C0004057;C0184666;C0809949
1011,admission k  mmol / l,C0184666;C0597277;C0809949;C1532563;C1708601
1011,admission grace score,C0184666;C0809949
1011,admission crcl,C0184666;C0809949;C1846718
1011,$nmbr$ blocker before admission,C0184666;C0809949
1010,steroid - sparing remission *,C0038317;C0544452;C0687702
1010,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
1010,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
1010,remission  n ( % ),C0544452;C0687702
1010,remission,C0544452;C0687702
1010,das $nmbr$ - esr remission  %,C0051767;C0057671;C0544452;C0687702;C3811131
1010,das $nmbr$ - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
1010,das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %,C0051767;C0057671;C0444504;C0544452;C0687702;C2347634;C2348143;C2699239;C3811131
1010,asdas inactive disease  %,C0544452
1009,ifx + aza ( n = $nmbr$ ),C0004482;C0020823
1009,azathioprine monotherapy,C0004482
1009,azathioprine ( n = $nmbr$ ),C0004482
1009,azathioprine,C0004482
1009,aza ( n = $nmbr$ ),C0004482
1008,ipah / hpah,C0152171;C0340543;C0637939;C1150929
1008,ipah  hpah  hiv  drug or toxin induced,C0013227;C0019682;C0019699;C0152171;C0340543;C0637939;C1150929;C1254351
1007,time from onset of pain to randomization — hr,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1007,pain  mm,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
1007,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1006,year from randomization,C0034656;C0439234;C0439508
1006,vka at randomization,C0034656
1006,treatmentofpulmonary embolismpriorto randomization,C0034656
1006,to randomization,C0034656
1006,thienopyridine at randomization,C0034656;C1120149
1006,renal function at randomization,C0034656;C0232804
1006,randomization,C0034656
1006,randomisation,C0034656
1006,other llt at randomization,C0034656;C2347090
1006,no vka at randomization,C0034656
1006,nihss at randomization  $nmbr$ - $nmbr$,C0034656;C1697238
1006,nihss at randomization,C0034656;C1697238
1006,medications at timing of randomization  n ( % ),C0034656;C2359859
1006,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981
1006,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
1006,length of stay ( randomization to discharge  h ),C0023303;C0034656
1006,labs at randomization,C0034656;C0587081
1006,killip class iv at randomization,C0034656;C2697847
1006,index stroke > $nmbr$ days before randomization — no . ( % ),C0034656;C0439228;C0456712
1006,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
1006,heparin at randomization,C0019134;C0034656;C0770546
1006,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
1006,edoxaban at randomization  n ( % ),C0034656;C2975435
1006,diabetes at randomization,C0011847;C0011849;C0034656
1006,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
1006,creatinine clearance at randomization,C0034656;C0812399
1006,coronary revascularization $nmbr$ days after randomization,C0034656;C0439228;C0877341
1006,at randomization,C0034656
1006,asastoppedat randomization  n,C0034656
1006,antiplatelet at randomization,C0034656
1006,antihypertensive randomization  no . ( % ) a,C0003364;C0034656
1006,age at randomization ( years ),C0034656;C1510829
1006,age at randomization,C0001779;C0034656
1006,age at randomisation,C0001779;C0034656
1006,age at lipid randomization ( y ),C0001779;C0034656;C0065033
1005,randomization to end of study,C0034656
1005,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
1005,randomization to angiography,C0002978;C0034656
1005,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
1005,randomization - to - angiography,C0002978;C0034656
1005,randomisation scheme,C0034656;C1519193
1004,randomized treatments  n ( % ),C0034656;C0087111;C3815594
1004,randomized treatment  % ( n ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
1004,randomized to receiveaspirin,C0034656;C3815594
1004,randomized to receive vitamin e,C0034656;C3815594
1004,randomized to receive beta carotene,C0034656;C3815594
1004,randomized to receive aspirin yes,C0034656;C3815594
1004,randomized to canakinumab $nmbr$ mg,C0034656;C3815594
1004,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
1004,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
1004,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
1004,randomized < $nmbr$ hr after presentation — %,C0034656;C0449450;C3815594
1004,randomized  double - blind reversal phase ( baseline = week $nmbr$ ),C0034656;C3815594
1004,randomized,C0034656;C3815594
1004,randomization to,C0034656
1004,randomization stratum,C0034656
1004,randomization groups $nmbr$ and $nmbr$,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1004,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1004,randomization - to -,C0034656
1004,randomization ),C0034656
1004,randomization  n ( % ),C0034656
1004,no . randomized,C0034656;C3815594
1004,all randomized women,C0034656;C0043210;C3815594
1003,glycaemic control group,C0005802;C0009932
1003,events / control group,C0009932;C0441471;C3541888
1003,control group,C0009932
1002,diet controlled or no,C0743195
1002,diet - controlled ( % ),C0743195
1001,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
1001,mental component,C0229992;C0449432;C1705248
1001,mental,C0229992
1000,other countries,C0454664
1000,country : argentina ( n = $nmbr$ ),C0003761;C0454664;C1504311;C1511538
1000,country  n ( % ),C0454664;C1511538
1000,country,C0454664;C1511538
1000,all countries,C0454664
999,acuity minor,C0750509
999,acuity major or,C0750509
999,acuity major,C0750509
999,acuity - defined bleeding,C0750509
999,acuity - bleeding major / minor,C0750509
998,acute reaction,C0205178;C0443286
998,acute and delayed reaction,C0205178
998,acute ( < $nmbr$ hr ),C0205178
997,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
997,not anterior,C0205094;C1518422
997,non - anterior,C0205094;C1518422
997,anterior { % ),C0205094
997,anterior or non - anterior ml,C0205094
997,anterior circulation,C0005775;C0205094;C1516559
997,anterior ( n  % ),C0205094
997,anterior,C0205094
996,standard control ( n = $nmbr$ ) no . of patients ( percent ),C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
996,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
996,rhythm - control group ( n = $nmbr$ ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
996,intensive control ( n = $nmbr$ ) no . of patients ( percent ),C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
996,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
996,good control ( < $nmbr$ ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,fair control ( $nmbr$ - $nmbr$ . $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
996,controls ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control of sitting bp at week $nmbr$,C0037623;C0243148;C0277814;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
996,control n = $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control group ( n = $nmbr$ ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
996,control baseline ( n - $nmbr$ ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
996,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control ( nz $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control ( n z $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control ( n - $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,control $nmbr$ months ( n - $nmbr$ ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
996,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
996,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
996,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
996,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
996,( % ) control ( $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
996,% asthma control days {  #,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
995,controlled : acq - $nmbr$ < $nmbr$ . $nmbr$,C2587213;C2911690;C2919686
995,controlled $nmbr$ — no . ( % ),C2587213;C2911690
995,controlled,C2587213;C2911690
994,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
994,lo ( lo - lo ),C0206579;C1232424
994,$nmbr$ . $nmbr$ ( lo . i ),C0021966;C0206579;C0221138;C1232424
994,$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ ),C0206579;C1232424
993,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
993,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
993,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
993,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
993,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
993,$nmbr$ to < $nmbr$ cells,C0007584;C0007634
992,white blood cell count  cellsx $nmbr$,C0023508;C0427512
992,white - cell count — x $nmbr$ _ $nmbr$ / liter,C0023508;C0427512;C0475211
992,blood leukocyte count ( $nmbr$ cells per l ),C0023508;C0023516;C0347983;C0427512
991,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
991,> $nmbr$ cells / ul,C0439378
991,< $nmbr$ cells / ul $nmbr$ $nmbr$,C0439378
990,$nmbr$ hr prandial glucose ' * ’,C0017725;C1998602;C4553624
989,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
989,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
989,no . of background glucose - lowering therapies  no . ( % ),C0017725;C0087111;C0441994;C1706907;C2003888
989,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
989,glucose - lowering therapy  n ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
989,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
989,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
989,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
989,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
989,glucose  non - fasting or random ( nmol / l ),C0017725
989,blood glucose - lowering treatments  n ( % ),C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
989,blood glucose - lowering drugs  excluding insulin  n ( % ),C0005802;C0013227;C0017725;C0018938;C0441994;C2003888;C3687832
988,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
988,implantable cardioverter - defibrillator,C0162589;C2825184
987,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
987,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
986,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
986,mean fecal calprotectin level  mg / g stool ( sd ),C0015733;C0183622;C0441889;C0444504;C0456079;C0950624;C1300563;C1335798;C1366582;C1547707;C2347634;C2348143;C2699239;C2946261
986,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
985,total cholesterol - to - hdl cholesterol ratio,C0428619
984,serum cholesterol ( mg / l ) *,C0439268;C0587184
984,serum cholesterol  mg / dld,C0024671;C0026410;C0439269;C0587184;C1414063;C1960952;C2346927;C2826331;C4321396;C4521761
984,serum cholesterol  mg / dl,C0439269;C0587184
983,lathosterol ( jimol / l ),C0064673
983,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
982,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
981,terol  hdl - c  high - density lipoprotein cholesterol,C0023822
981,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
981,high density lipoprotein cholesterol  mg / dl ^,C0023822;C0439269
981,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
981,high - density lipoprotein cholesterol metabolic syndrome  patients were to,C0023822;C0030705;C0524620
981,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
981,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
981,high - density lipoprotein cholesterol  mg / dl,C0023822;C0439269
981,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
980,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
980,hdl cholesterol §,C0023822;C0392885
980,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
980,hdl cholesterol ^ :,C0023822;C0392885
980,hdl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
980,hdl cholesterol < $nmbr$ mg / dl *,C0023822;C0392885;C0439269
980,hdl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
980,hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women ),C0023822;C0025266;C0392885
980,hdl cholesterol *,C0023822;C0392885
980,hdl cholesterol ( sd )  mg / dl,C0023822;C0392885;C0439269;C2699239
980,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
980,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
980,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
980,hdl cholesterol  mmol / 冲,C0023822;C0392885;C0439190
980,hdl cholesterol  mmol / l *,C0023822;C0392885;C1532563
980,hdl cholesterol  mmol / l,C0023822;C0392885;C1532563
980,hdl cholesterol  mg / dl,C0023822;C0392885;C0439269
980,hdl cholesterol  ( mmol / l ),C0023822;C0392885;C1532563
980,hdl cholesterol,C0023822;C0392885
980,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
980,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
980,hdl - cholesterol  mmol / le,C0023190;C0023822;C0392885;C0439090;C0439190;C1423767;C2697858
980,hdl - cholesterol  mmol / l,C0023822;C0392885;C1532563
980,hdl - cholesterol,C0023822;C0392885
980,- hdl cholesterol,C0023822;C0392885
979,median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl,C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
979,lp ( a ) §,C0065058;C1439335;C4553379
979,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
979,lp ( a ) ( week $nmbr$ ),C0065058;C0332174;C0439230;C1439335;C4553379
979,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
979,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
979,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
979,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
979,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0020538;C0065058;C0125953;C0521116;C0578022;C1096202;C1439335;C1705970;C1963138
979,baseline lp ( a )  mg / dl,C0065058;C0168634;C0439269;C1439335;C1442488;C4553379
978,temporal data and management strategy,C0442043;C1511726;C2362314;C3245479;C3714741
978,pci data,C1511726;C3245479;C3714741;C4049621
978,no ef data | |,C1511726;C3245479;C3714741
978,fpg data ',C1511726;C3245479;C3714741
978,data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C0023820;C0031831;C0062152;C0073187;C0178587;C0205251;C0332173;C0337445;C0428883;C0439475;C0549183;C0804815;C0876920;C1305849;C1511726;C1550472;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741;C3890211;C4048187;C4321351;C4484261;C4522223
978,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status,C0205250;C0449820;C1511726;C3245479;C3714741
978,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
978,data missing,C1511726;C3245479;C3714741
978,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1518422;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
978,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
978,data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .,C0009235;C0010055;C0021966;C0022718;C0023190;C0023821;C0023823;C0035487;C0047420;C0162577;C0189695;C0221138;C0439090;C0439209;C0522520;C0522523;C0545743;C0549183;C0597153;C0700307;C0876920;C1305855;C1423767;C1444656;C1511726;C1514721;C1522231;C1548817;C1655741;C1826843;C2347635;C2348144;C2348147;C2697858;C2936173;C2939193;C3245479;C3542016;C3714741;C4054209
978,data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .,C0023820;C0023821;C0030705;C0042295;C0205120;C0489786;C1305855;C1511726;C1516606;C1552595;C3245479;C3714741
978,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C1511726;C3245479;C3714741
978,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation,C0439453;C0439836;C1511726;C1719797;C2911648;C3245479;C3714741
978,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C0007226;C0007447;C0010055;C0018787;C0022709;C0027051;C0037455;C0184661;C0238884;C0439453;C0439836;C0565930;C0886296;C1273869;C1511726;C1516705;C1719797;C2603362;C2911648;C3245479;C3714741;C3887460;C4049621
978,data  ' ' n,C1511726;C3245479;C3714741
978,available data,C0470187;C1511726;C3245479;C3714741
978,at c data,C1511726;C3245479;C3714741
978,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$,C0000723;C0021308;C0022709;C0035647;C0205369;C0439526;C0439836;C1511726;C1514721;C1705224;C1719797;C2348147;C2911648;C3245479;C3542016;C3714741;C3887665;C4552904
978,* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0009247;C0012634;C0018787;C0074554;C0280604;C0369773;C0439751;C0444504;C0444667;C0599755;C1142985;C1511726;C1710181;C2347634;C2348143;C2603361;C3245479;C3542407;C3714741
978,* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .,C1511726;C3245479;C3714741
978,* data are expressed as median ± sd  except,C1511726;C3245479;C3714741
978,* data are expr,C1511726;C3245479;C3714741
977,valve replacement / repair with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
977,valve repair / replacement with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
977,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
977,surgical repair of vsd or pda > $nmbr$ - year duration,C0018818;C0374711
976,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0168634;C0449381;C1442488;C4281788
976,haemodynamics and lv function,C0019010;C4281788
975,who / idf impaired fasting glucose,C1272092
975,impaired fasting glucose §,C1272092
975,impaired fasting glucose ( > $nmbr$ mg / dl ) ( % ),C0439269;C1272092
975,impaired fasting glucose,C1272092
975,ada impaired fasting glucose,C1060325;C1272092;C3811629
974,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
974,impaired glucose tolerance or impaired fasting glucose,C0271650
974,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0271650
973,percent impairment while working due to asthma,C0221099;C0439165;C0684336
973,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
973,mild impairment ( £ $nmbr$ to,C0221099;C0684336;C2945599
973,mild impairment ( $nmbr$ to < $nmbr$ ),C0221099;C0684336;C2945599
973,mild impairment ( $nmbr$ to $nmbr$ ml / min ),C0221099;C0439445;C0684336;C2945599
973,mild impairment  < $nmbr$ to < $nmbr$,C0221099;C0684336;C2945599
973,mild impairment,C0221099;C0684336;C2945599
972,impaired fasting glucosex,C0221099
972,impaired fasting glucose level ( n = $nmbr$ ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
972,impaired fasting giucose levei ( n = $nmbr$ ),C0221099
971,clinical disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869583;C4050231
971,clinical disease activity index,C3869583
970,simplified disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869582;C4050231
970,simplified disease activity index score,C0449820;C3869582;C4050231
970,simplified disease activity index,C3869582
969,high disease activity : > $nmbr$ . $nmbr$  n ( % ),C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
969,disease activity ],C1292728
969,disease activity ( n ( % ) ),C1292728
969,disease activity,C1292728
968,disease stage,C0699749
967,decreased appetite,C0232462
966,disease severity,C0521117
966,copd disease severity,C0024117;C0521117;C1412502;C3714496
965,polyarticular arthritis  no rheumatoid nodules,C0162323
964,prior antiinflammatory / antirheumatic products  n ( % ),C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
964,anti - inflammatory drugs,C0003209
963,cardiac catheterization,C0018795
963,cardiac catheterisation or pci for index event,C0018795
962,cardiac rhythm disorders,C0264886
962,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
962,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
961,prior cardiac resynchronization therapy  n ( % ),C0332152;C1167956;C2826257
961,cardiac resynchronization therapy n ( % ),C1167956
961,cardiac resynchronization therapy,C1167956
960,prior urate lowering therapies  n ( % ),C0441994;C0729829;C0935936;C1514463;C2003888
960,prior treatment — no . ( % ),C1514463
960,prior treatment — %,C1514463
960,prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
960,prior treatment,C1514463
960,prior tnfi treatment,C1514463
960,prior therapy  %,C1514463
960,prior lev treatment    n   ( % ),C0023556;C1514463
960,prior lev treatment,C0023556;C1514463
960,prior ed therapy,C1514463;C3538926
959,conversion to sinus rhythm in < $nmbr$ days,C1321500
958,sinus rhythm at baseline,C0168634;C0232201;C1442488
958,sinus rhythm,C0232201
957,prior arrhythmias  n ( % ),C0003811;C0332152;C2826257
957,cardiac arrhythmia  n ( % ),C0003811;C0264886;C1560249
957,cardiac arrhythmia,C0003811;C0264886;C1560249
957,arrhythmias,C0003811
957,arrhythmia !,C0003811
957,arrhythmia,C0003811
956,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
956,the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .,C0205225;C0439612;C0439631;C0871424;C1079230;C1547647
956,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
956,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
956,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
956,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
956,primary pcit,C0205225;C0439612;C0439631
956,primary pci no .,C0205225;C0439612;C0439631;C4049621
956,primary pci n = $nmbr$,C0205225;C0439612;C0439631;C4049621
956,primary pci ( n = $nmbr$ ),C0205225;C0439612;C0439631;C4049621
956,primary pci,C0205225;C0439612;C0439631;C4049621
956,primary outcomes,C0205225;C0439612;C0439631;C1274040
956,primary outcome plus revascularization or nonfatal hf,C0205225;C0332287;C0439612;C0439631;C0581603;C1274040
956,primary outcome ( $nmbr$ - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
956,primary outcome ! ( n = $nmbr$ ),C0205225;C0439612;C0439631;C1274040
956,primary outcome !,C0205225;C0439612;C0439631;C1274040
956,primary outcome,C0205225;C0439612;C0439631;C1274040
956,primary nonresponse,C0205225;C0439612;C0439631
956,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
956,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
956,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
956,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
956,primary composite ^,C0205199;C0205225;C0439612;C0439631;C1547335
956,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
956,primary angioplasty ( n = $nmbr$ ),C0162577;C0205225;C0439612;C0439631;C1548817
956,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .,C0007787;C0011849;C0205225;C0439612;C0439631;C1272706;C1552654;C1552713
956,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
956,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
956,primary *,C0205225;C0439612;C0439631
956,primary,C0205225;C0439612;C0439631
956,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
956,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
956,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
956,fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % ),C0016017;C0205225;C0439612;C0439631;C1305868;C4049621
956,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
956,accord primary  n ( % ),C0205225;C0439612;C0439631;C0680240
956,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
955,• any stroke,C0038454;C4554100
955,time from qualifying stroke to randomization,C0038454;C0040223;C1514624;C3541383;C4554100
955,time from onset of qualifying stroke to randomization,C0038454;C0449244;C1514624;C4554100
955,stroke — no . / total no . ( % ),C0038454;C4554100
955,stroke — no . ( % ),C0038454;C4554100
955,stroke thought due to atherothrombotic disease,C0038454;C4554100
955,stroke subtype  n ( % ),C0038454;C0449560;C4554100
955,stroke subtype,C0038454;C0449560;C4554100
955,stroke ortiab,C0038454;C4554100
955,stroke ortia,C0038454;C4554100
955,stroke or transient ischemic attack,C0038454;C4554100
955,stroke or tia — no . ( % ),C0038454;C4554100
955,stroke or tia,C0038454;C4554100
955,stroke or systemic embolism,C0038454;C4554100
955,stroke or systemic,C0038454;C4554100
955,stroke or see,C0038454;C4554100
955,stroke or se ( s / se ),C0038454;C4554100
955,stroke or pvd  ( % ),C0038454;C4554100
955,stroke or cerebrovascular disease,C0038454;C4554100
955,stroke or,C0038454;C4554100
955,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
955,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
955,stroke non - fatal,C0038454;C4554100
955,stroke n = $nmbr$,C0038454;C4554100
955,stroke n ( % ),C0038454;C4554100
955,stroke deaths,C0011065;C0038454;C1306577;C4554100
955,stroke at entry ( vs transient ischemic attack ),C0038454;C1705654;C4554100
955,stroke at entry,C0038454;C1705654;C4554100
955,stroke any,C0038454;C4554100
955,stroke and tia  n ( % ),C0038454;C4554100
955,stroke / transient ischemic attack,C0038454;C4554100
955,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
955,stroke / see,C0038454;C4554100
955,stroke / se,C0036919;C0038454;C4554100
955,stroke / non -,C0038454;C4554100
955,stroke / m $nmbr$,C0038454;C0369637;C0441923;C4554100
955,stroke / embolism,C0013922;C0038454;C1704212;C4554100
955,stroke ( vs tia ),C0038454;C4554100
955,stroke ( fatal / nonfatal ),C0038454;C4554100
955,stroke  total,C0038454;C4554100
955,stroke  see  or death,C0038454;C4554100
955,stroke  see  or cv death,C0038454;C4554100
955,stroke  n ( % ),C0038454;C4554100
955,stroke  fatal and nonfatal,C0038454;C4554100
955,stroke,C0038454;C4554100
955,sensorimotor stroke,C0038454;C4554100
955,qualifying stroke,C0038454;C1514624;C4554100
955,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
955,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
955,prior stroke,C0038454;C0332152;C2826257;C4554100
955,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
955,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
955,nonfatal stroke ®,C0038454;C4554100
955,nonfatal stroke ( n = $nmbr$ ),C0038454;C4554100
955,nonfatal stroke,C0038454;C4554100
955,nondisabling  nonfatal stroke,C0038454;C4554100
955,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
955,no stroke n = $nmbr$ $nmbr$,C0038454;C4554100
955,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
955,no stroke ( n = $nmbr$ ),C0038454;C4554100
955,no prior stroke,C0038454;C0332152;C2826257;C4554100
955,no . of strokes / no . of patients in category ( and % ),C0038454
955,no . of strokes ( % ),C0038454
955,new stroke *,C0038454;C0205314;C4554100
955,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
955,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
955,hemispheric stroke n = $nmbr$,C0038454;C0205139;C4554100
955,fatal stroke,C0038454;C1302234;C1705232;C4554100
955,fatal / nonfatal stroke  n ( % ),C0038454;C1302234;C1705232;C4554100
955,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
955,disabling stroke,C0038454;C4554100
955,atherothrombotic stroke  n ( % ),C0038454;C4554100
955,any stroke ( n = $nmbr$ ),C0038454;C4554100
955,any stroke,C0038454;C4554100
955,all stroke,C0038454;C4554100
955,a stroke,C0038454;C4554100
954,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
954,cerebrovascular accident,C0038454
953,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
953,recent cardiovascular eventf,C0007226;C0332185;C3887460
953,primary cardiovascular endpoint,C0007226;C2986535;C3887460
953,previous history of cardiovascular events,C0007226;C2004062;C3887460
953,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
953,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
953,exploratory cardiovascular and death outcomes,C0007226;C3887460
953,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
953,cardiovascular status,C0007226;C0449438;C3887460
953,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3887460
953,cardiovascular mortality  mi  or revascularization,C0007226;C0026565;C0026566;C3810814;C3887460
953,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
953,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
953,cardiovascular hospitalization,C0007226;C0019993;C3887460
953,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
953,cardiovascular death ( n = $nmbr$ ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
953,cardiovascular death  mi  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
953,cardiovascular and respiratory,C0007226;C3887460
953,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C3887460
953,cardiovascular,C0007226;C3887460
953,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
953,any cardiovascular diseased,C0007226;C3887460
953,all cardiovascular,C0007226;C3887460
952,other cardiovascular risk factors,C0850624
952,nonglycemic cardiovascular risk factors,C0850624
952,cardiovascular risk factors — no . { % ),C0850624
952,cardiovascular risk factors — no . / total no . ( % ),C0850624
952,cardiovascular risk factors and medical history,C0850624
952,cardiovascular risk factors and history — no . ( % ),C0850624
952,cardiovascular risk factors and history ( % ),C0850624
952,cardiovascular risk factors and history,C0850624
952,cardiovascular risk factors alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C0850624
952,cardiovascular risk factors  no . ( % ),C0850624
952,cardiovascular risk factors  n ( % ),C0850624
952,cardiovascular risk factors,C0850624
952,cardiovascular risk factor — no . { % ),C0850624
952,at least two cardiovascular risk factors,C0205448;C0850624
951,patients with microvascular complications  n ( % ),C0009566;C0030705;C0443258;C1171258
951,microvascular outcome,C0443258;C1274040
951,microvascular eye diseased,C0015392;C0443258;C0700042
951,microvascular complicationsb,C0443258
951,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
950,prior cardiovascular history,C0332152;C1880008;C2826257
950,past cardiovascular history  no . ( % ),C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
950,cardiovascular history 一 no . ( % ),C1880008
950,cardiovascular history — no . / total no . ( % ),C1880008
950,cardiovascular history — no . ( % ),C1880008
950,cardiovascular history,C1880008
949,endovascular — no . ( % ),C0524425
949,endovascular,C0524425
948,without cerebrovascular disease,C0007820
948,with cerebrovascular disease,C0007820
948,prior cerebrovascular disease,C0007820;C0332152;C2826257
948,only cerebrovascular disease,C0007820;C0205171;C1720467
948,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
948,cerebrovascular disorders  n ( % ),C0007820
948,cerebrovascular disease n ( % ),C0007820
948,cerebrovascular disease  n ( % ),C0007820
948,cerebrovascular disease  %,C0007820
948,cerebrovascular disease,C0007820
948,cerebral vascular disease,C0007820
947,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
947,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
947,cerebrovascular or peripheral arterial disease    n   ( % ),C1880018
947,cerebrovascular or peripheral arterial disease  n ( % ),C1880018
947,cerebrovascular or peripheral arterial disease,C1880018
947,cerebrovascular,C1880018
946,cardiovascu lar subg roup,C0276828;C1419115;C3814448
945,previous cardiovascular events,C0205156;C1320716;C1552607
945,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
945,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
945,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
945,cardiovascular events,C1320716
944,cardiovascular medications  %,C0007220
944,cardiovascular medications,C0007220
944,cardiovascular medication usage,C0007220;C0457083
944,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
944,baseline cardiovascular medications  n ( % ),C0007220;C0168634;C1442488
944,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
944,baseline cardiovascular medication,C0007220;C0168634;C1442488
943,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0814908;C1522609;C3887950
942,value for nteraction,C1522609
942,value *,C1522609
942,value,C1522609
942,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
942,d - value,C1522609
942,baseline value,C0168634;C1442488;C1522609
942,/ ’ - value $nmbr$ ’,C1522609
942,/ ’ - value,C1522609
941,ta ( n = $nmbr$ ),C0039297;C1506978;C1705538;C3272501;C4553364
941,ta,C0039297;C1506978;C1705538;C3272501;C4553364
940,ga / a,C0016993
940,ga,C0016993
940,a / ga,C0016993
939,with baseline crp level of > $nmbr$ mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
939,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
939,week $nmbr$ - baseline,C0168634;C0332174;C0439230;C1442488
939,use at baseline  n,C0042153;C0168634;C0457083;C1442488;C1947944
939,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
939,triglycerides at baseline,C0041004;C0168634;C1442488
939,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
939,treated at baseline,C0168634;C1442488;C1522326
939,supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0019016;C0039224;C0168634;C0392747;C0443172;C0456603;C0730345;C1442488;C1547037;C1705241;C1706074;C1825777;C3538758;C4319952
939,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
939,subpopulation analyses according to baseline hba $nmbr$ c,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
939,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
939,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
939,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
939,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
939,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
939,smokers ( at baseline ),C0168634;C0337664;C1442488
939,smoker at baseline,C0168634;C0337664;C1442488
939,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
939,sbp at baseline,C0085805;C0168634;C1442488
939,sbp  baseline,C0085805;C0168634;C1442488
939,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
939,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
939,ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml,C0168634;C0456603;C1442488;C1547037
939,ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll,C0168634;C0456603;C1442488;C1547037
939,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
939,pt baseline ( week $nmbr$ ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
939,pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
939,post - bronchodilator fev $nmbr$  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594;C3714541
939,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
939,parameters at baseline,C0168634;C0449381;C1442488
939,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
939,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
939,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
939,open - label phase ( baseline = week $nmbr$ ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
939,one at baseline,C0168634;C0205447;C1442488
939,on steroid at baseline,C0038317;C0168634;C1442488
939,on statins at baseline,C0168634;C0360714;C1442488
939,on aspirin at baseline,C0004057;C0168634;C1442488
939,on antihypertensive medication at baseline  n ( % ) ‡,C0003364;C0168634;C1442488
939,ocs at baseline,C0168634;C1442488
939,nvf at flex baseline - $nmbr$ < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
939,normonatremic ( > $nmbr$ meq / l ) at baseline,C0168634;C0439375;C1442488
939,normoalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
939,none at baseline,C0168634;C1442488
939,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
939,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
939,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
939,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
939,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
939,no chd at baseline,C0168634;C0280604;C1442488;C3542407
939,no aspirin at baseline,C0004057;C0168634;C1442488
939,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
939,nihss at baseline,C0168634;C1442488;C1697238
939,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
939,mtx at baseline  n ( % ),C0025677;C0168634;C1417487;C1442488
939,mtx at baseline,C0025677;C0168634;C1417487;C1442488
939,mtss at baseline observed case,C0168634;C1442488
939,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
939,mmrc at baseline,C0168634;C1442488;C3826977
939,microalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C0730345;C1442488
939,memantine use at baseline  no . ( % ),C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
939,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
939,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
939,medication use at baseline  n ( % ),C0168634;C0240320;C1442488
939,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
939,macroalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
939,low ( < $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
939,low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
939,ldl - c at baseline :,C0168634;C1442488
939,killip at baseline,C0168634;C1442488
939,intensified baseline ( n - $nmbr$ ),C0168634;C1442488
939,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
939,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
939,improvement from baseline ≥   $nmbr$,C0168634;C1442488;C2986411
939,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
939,hyponatremic ( < $nmbr$ meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
939,hypertension severity at baseline  n ( % ),C0168634;C1442488;C4013784
939,hscrp at baseline,C0168634;C1442488
939,high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
939,high ( > $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
939,hdl - c at baseline .,C0168634;C1442488;C3715113
939,hba $nmbr$ c   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
939,hba $nmbr$ c at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
939,hba $nmbr$ c at baseline  %,C0019016;C0168634;C1442488;C1825777;C3538758
939,hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
939,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0017480;C0168634;C0301630;C0392747;C0392756;C0443172;C0456603;C0679646;C1273442;C1293152;C1442103;C1442488;C1522544;C1547037;C1547049;C1704695;C1705241;C1705242;C1707455;C2698741;C2986759;C3854019;C4551656;C4554048
939,for baseline hemoglobin < $nmbr$ g $nmbr$ ',C0168634;C1319312;C1442488
939,for baseline hemoglobin $nmbr$ g $nmbr$ ’,C0168634;C1319312;C1442488
939,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
939,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
939,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
939,flex baseline bmd  g / cm ^ ( meanisd ),C0168634;C0439267;C1442488
939,fev $nmbr$   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
939,fev $nmbr$ at baseline,C0168634;C1442488;C3714541
939,fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
939,fev  at baseline,C0168634;C1442488;C3714541
939,fbg baseline,C0168634;C1442488
939,elevated baseline crp,C0168634;C0742906;C1442488
939,dlqi improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3899393
939,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
939,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
939,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
939,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
939,db baseline ( week $nmbr$ ),C0168634;C0332174;C0439230;C1418892;C1442488
939,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
939,csdmard use at baseline ^,C0042153;C0168634;C0457083;C1442488;C1947944
939,crcl at baseline < $nmbr$ ml / min,C0168634;C0439445;C1442488;C1846718
939,crcl at baseline  ml / min,C0168634;C0439445;C1442488;C1846718
939,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
939,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
939,corticosteroid use at baseline,C0168634;C0239126;C1442488
939,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
939,concentrations at baseline,C0086045;C0168634;C1442488
939,comparison with baseline,C0168634;C1442488;C1707455
939,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
939,coiticosieroids at baseline,C0168634;C1442488
939,ckd at baseline,C0168634;C1442488;C1561643
939,chd at baseline,C0168634;C0280604;C1442488;C3542407
939,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .,C0168634;C0392747;C0443172;C1442488
939,changes at baseline,C0168634;C0392747;C0443172;C1442488
939,change from baseline to week $nmbr$ in weekly size of largest hive score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to week $nmbr$ in weekly no . of hives score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to week $nmbr$ in weekly iss,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to week $nmbr$ in uas $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to week $nmbr$ in dlqi scorez,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to final apbm,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to eos  uu / ml,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline to eos  mg / dl,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline stage $nmbr$ ckd,C0168634;C0597205;C0679846;C1442488;C1561643
939,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in rescue medication use ( puffs per day ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in pre - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in post - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in mean $nmbr$ - h sbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in mean $nmbr$ - h dbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in hba $nmbr$ c ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in fevj ( mb ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in das $nmbr$ - esr  mean $nmbr$ sd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in acq - $nmbr$ score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in acq - $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in % predicted fev $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline at week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline  mmhg,C0168634;C0392747;C0439475;C0443172;C1442488;C1705241;C4319952
939,change from baseline  mg / dl  mean ( sd ),C0168634;C0392747;C0439269;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952
939,change from baseline  median ( iqr ),C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
939,change from baseline  adjusted mean ( $nmbr$ % ci )  %,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline  adjusted mean ( $nmbr$ % ci ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,body mass index ( kg / m $nmbr$ ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
939,bmi at baseline ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
939,biomarkers at baseline,C0005516;C0168634;C1442488
939,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
939,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
939,baseline £ std  mm,C0168634;C1442488;C4330985;C4554674
939,baseline who functional class,C0168634;C1442488
939,baseline who function class,C0168634;C1442488
939,baseline vfx,C0168634;C1442488
939,baseline variable,C0168634;C0439828;C1442488;C4553760
939,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
939,baseline use of adm  n ( % ),C0168634;C0215825;C1442488;C1524063;C4521767
939,baseline uric acid,C0041980;C0168634;C1442488
939,baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
939,baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ ),C0168634;C0567349;C1442488;C2348885
939,baseline uas $nmbr$,C0168634;C1442488
939,baseline uacr > $nmbr$ mg / g,C0168634;C1300563;C1442488
939,baseline uacr < $nmbr$ mg / g,C0168634;C1300563;C1442488
939,baseline trl - c by quintiles,C0168634;C1442488;C1508496
939,baseline triglycerides in $nmbr$ classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
939,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
939,baseline triglycerides > $nmbr$ mg / dl and,C0041004;C0168634;C0439269;C1442488
939,baseline triglycerides < $nmbr$ mg / dl,C0041004;C0168634;C0439269;C1442488
939,baseline triglycerides,C0041004;C0168634;C1442488
939,baseline trig > $nmbr$ millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
939,baseline treatments  n ( % ) a,C0087111;C0168634;C1442488
939,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
939,baseline tophusa,C0168634;C1442488
939,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
939,baseline tg > $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
939,baseline tg < $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
939,baseline tg,C0168634;C0337445;C1442488
939,baseline tc  mg / dl,C0039411;C0040642;C0041405;C0041698;C0168634;C0439269;C1442488;C1824670;C3272447;C4522122
939,baseline tbp,C0168634;C1442488
939,baseline tava,C0168634;C1442488
939,baseline t - score at femoral neck  n ( % ),C0015815;C0168634;C0449820;C1442488;C4050231
939,baseline ste in worst lead  mm,C0023175;C0168634;C0181586;C1420459;C1442488;C1442948;C1522166;C1522538;C2348269;C3275067;C3811127;C4330985;C4554674
939,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
939,baseline smoking status,C0168634;C1442488;C1519386
939,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
939,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
939,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
939,baseline shs ( $nmbr$ - $nmbr$ ),C0168634;C1442488
939,baseline sgrq total score,C0168634;C1442488;C2964552
939,baseline sgrq score,C0168634;C1442488
939,baseline serum mg > = $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
939,baseline serum mg < $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
939,baseline serum k +  meq / l,C0168634;C0302353;C0439375;C1442488
939,baseline serum calcium level  n ( % ),C0036785;C0168634;C0728876;C1442488
939,baseline scales  median ( range ),C0168634;C1442488
939,baseline sbp { p = o - $nmbr$ ),C0085805;C0168634;C1442488
939,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
939,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
939,baseline sbp,C0085805;C0168634;C1442488
939,baseline rst - segment elevation  mm,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488;C4330985;C4554674
939,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
939,baseline risk factors,C0035648;C0168634;C1442488;C1553898
939,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
939,baseline ptga,C0168634;C1442488
939,baseline pssi score  mean ( sd ),C0168634;C1442488
939,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C1442488
939,baseline prediabetes,C0168634;C0362046;C1442488
939,baseline ppasi score  mean ( sd ),C0168634;C1442488
939,baseline post - bronchodilator fev $nmbr$   ( sd )  ml,C0168634;C0439526;C1442488;C1705224;C2599594;C2699239;C3714541;C3887665
939,baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use,C0168634;C1442488
939,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use,C0168634;C1442488
939,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium,C0168634;C1442488
939,baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use,C0168634;C1442488
939,baseline post - bronchodilator % predicted fev  < $nmbr$ %,C0168634;C1442488
939,baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
939,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
939,baseline pcsi < $nmbr$ a,C0168634;C1442488
939,baseline pava,C0135567;C0168634;C1442488
939,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
939,baseline ocs use : yes,C0168634;C1442488
939,baseline numberf of adm classes  n ( % ),C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
939,baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
939,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
939,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
939,baseline nihss score  median ( range ),C0168634;C1442488;C1697238
939,baseline nihss,C0168634;C1442488;C1697238
939,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
939,baseline nbp,C0168634;C1442488
939,baseline mssbp / msdbp  mm hg,C0168634;C0439475;C1442488
939,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
939,baseline microalbumin : < $nmbr$,C0168634;C0201838;C1442488;C2362049
939,baseline metformin,C0025598;C0168634;C1442488
939,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
939,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
939,baseline medical therapy  n ( % ),C0168634;C0418981;C1442488
939,baseline medical therapy,C0168634;C0418981;C1442488
939,baseline measurements,C0168634;C0242485;C1442488
939,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
939,baseline lvef  %,C0168634;C0428772;C0488728;C1442488
939,baseline lvef,C0168634;C0428772;C0488728;C1442488
939,baseline los angeles grade of eo  n ( % ),C0024015;C0168634;C1442488
939,baseline lipids  mg / dl,C0023779;C0168634;C0439269;C1442488
939,baseline lipids,C0023779;C0168634;C1442488
939,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
939,baseline lipid parameters  mg / dl  mmol / l or g / l,C0023779;C0168634;C0439269;C0449381;C1442488;C1532563
939,baseline lipid and lipoprotein values,C0023779;C0168634;C1442488
939,baseline lipid and apolipoprotein levels,C0023779;C0168634;C1442488
939,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
939,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
939,baseline ldl ‐ c  mg / dl,C0168634;C0439269;C1442488
939,baseline ldl - c strata  n ( ° / o ),C0168634;C1442488
939,baseline ldl - c > $nmbr$ mg / dl,C0168634;C0439269;C1442488
939,baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
939,baseline ldl - c :,C0168634;C1442488
939,baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
939,baseline ldl - c  mg / dl,C0168634;C0439269;C1442488
939,baseline ldl - c,C0168634;C1442488
939,baseline insulin dose ( u = kg ) [ lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
939,baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
939,baseline if have $nmbr$ yr follow - up *,C0168634;C1442488
939,baseline ics use : yes,C0168634;C0815320;C1442488;C4551720
939,baseline ics use : no,C0168634;C0815320;C1442488;C4551720
939,baseline ics use  n ( % ),C0168634;C0815320;C1442488;C4551720
939,baseline ics dose  n ( % ),C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
939,baseline ics,C0168634;C0815320;C1442488;C4551720
939,baseline ibdq total score  mean,C0168634;C0444504;C1442488;C2347634;C2348143;C2964552
939,baseline hstni,C0168634;C1442488
939,baseline hs - crp tertiles ( mg / i ],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
939,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
939,baseline height ( cm ),C0168634;C0489786;C1442488
939,baseline heart rate,C0018810;C0168634;C1442488
939,baseline hdl ‐ c  mg / dl,C0168634;C0439269;C1442488;C3715113
939,baseline hdl - c  mg / dl,C0168634;C0439269;C1442488;C3715113
939,baseline hdl - c,C0168634;C1442488;C3715113
939,baseline hbalc ’,C0168634;C1442488
939,baseline hbalc ^,C0168634;C1442488
939,baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ),C0168634;C1442488;C3829066
939,baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
939,baseline hbalc > $nmbr$ % to < $nmbr$ %,C0168634;C1442488
939,baseline hbalc > $nmbr$ %,C0168634;C1442488
939,baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
939,baseline hbalc < $nmbr$ %,C0168634;C1442488
939,baseline hbalc,C0168634;C1442488
939,baseline hba ^ c,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
939,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
939,baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
939,baseline hba $nmbr$ c concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
939,baseline hba $nmbr$ c ^,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
939,baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
939,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c  %,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hba $nmbr$ c,C0019016;C0168634;C1442488;C1825777;C3538758
939,baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$,C0062408;C0168634;C0439267;C1442488
939,baseline hb $nmbr$ g i $nmbr$ n = $nmbr$,C0062408;C0086706;C0168634;C1442488
939,baseline glycated,C0168634;C1442488
939,baseline fvc  l,C0168634;C1442488;C3714541
939,baseline fpg  mg / dl,C0168634;C0439269;C1442488
939,baseline fpg,C0168634;C1442488
939,baseline fev $nmbr$ % predicted,C0168634;C1442488;C3714541
939,baseline fev $nmbr$ #,C0168634;C1442488;C3714541
939,baseline fev $nmbr$  l *,C0168634;C1442488;C3714541
939,baseline fev $nmbr$,C0168634;C1442488;C3714541
939,baseline fev  ( l ),C0168634;C1442488;C3714541
939,baseline fecal caicrctectin,C0015733;C0168634;C1442488
939,baseline fc - ldl - c,C0168634;C1442488;C2983605
939,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
939,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
939,baseline estimated gfr,C0168634;C1442488
939,baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C1442488
939,baseline ecro < $nmbr$ mumin,C0168634;C1442488
939,baseline ecrcl k $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
939,baseline ecrcl $nmbr$ $nmbr$ ml / min,C0168634;C0439445;C1442488
939,baseline ecrcl,C0168634;C1442488
939,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
939,baseline dipeptidyl peptidase $nmbr$,C0022709;C0168634;C1442488
939,baseline diabetes mellitus therapy  n ( % ),C0168634;C0948092;C1442488
939,baseline diabetes,C0011847;C0011849;C0168634;C1442488
939,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
939,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
939,baseline dad ( n   = $nmbr$ + $nmbr$ ),C0168634;C1442488;C3641946
939,baseline cv treatment  n ( % ) y,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
939,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
939,baseline crp levels ≥ $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
939,baseline crp levels < $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
939,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
939,baseline crp < $nmbr$ mg / l,C0168634;C0439268;C1442488;C3890735;C4048285
939,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
939,baseline crp,C0168634;C1442488;C3890735;C4048285
939,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
939,baseline crcl  ml / min,C0168634;C0439445;C1442488;C1846718
939,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
939,baseline characteristic,C0168634;C1442488
939,baseline chads $nmbr$ a  c,C0007928;C0168634;C1413373;C1442488
939,baseline cdr - sb ( n   = $nmbr$ + $nmbr$ ),C0038111;C0168634;C1442488;C3811240;C4521843
939,baseline cdai score  mean ( sd ),C0168634;C0683448;C1413248;C1442488;C3273706
939,baseline cdai score  mean ( s . d . ),C0168634;C0683448;C1413248;C1442488;C3273706
939,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
939,baseline cardiovascular disease,C0007222;C0168634;C1442488
939,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
939,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
939,baseline bp  mean ( sd ) *,C0168634;C0488053;C1442488;C2699239
939,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
939,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
939,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi > $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi < $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi ( kg / m ^ ),C0168634;C0578022;C1442488;C1532718
939,baseline bmi ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
939,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
939,baseline bmi,C0168634;C0578022;C1442488
939,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
939,baseline basfi,C0168634;C1442488
939,baseline basdai,C0168634;C1442488;C1998004
939,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
939,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
939,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
939,baseline antihyperglycemic medications  n ( % ),C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
939,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
939,baseline anti - hyperglycemic medications  n ( % ),C0013227;C0168634;C0432633;C0802604;C1442488;C2598133;C4284232
939,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
939,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
939,baseline alc < $nmbr$ . $nmbr$ %,C0168634;C1424945;C1442488;C3811058
939,baseline albuminuria,C0001925;C0168634;C1442488
939,baseline albumin : < $nmbr$,C0001924;C0168634;C1442488
939,baseline age,C0001779;C0168634;C1442488
939,baseline adas - cog $nmbr$,C0168634;C1442488;C3539026
939,baseline a $nmbr$ c ( % ) [ lsm ( se ) ],C0036919;C0168634;C1442488
939,baseline a $nmbr$ c ( % ),C0168634;C1442488
939,baseline ^ ste  mm,C0168634;C1420459;C1442488;C3811127;C4330985;C4554674
939,baseline / concomitant therapies,C0168634;C1442488;C1707479
939,baseline - adjusted hr,C0168634;C1442488
939,baseline - - mdrd,C0168634;C1442488;C3839656
939,baseline ( sd ),C0168634;C1442488;C2699239
939,baseline ( n ),C0168634;C1442488
939,baseline ( mmol / l ),C0168634;C1442488;C1532563
939,baseline % predicted fev $nmbr$,C0168634;C1442488
939,baseline % bsa involvement,C0168634;C1314939;C1442488
939,baseline $nmbr$ - mlnute walk distance :,C0168634;C0429886;C1442488
939,baseline $nmbr$ - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
939,baseline $nmbr$ - hour mean sbp  mm hg,C0085805;C0168634;C0439227;C0439475;C0444504;C0564385;C1442488;C2347634;C2348143
939,baseline  no . ( % ),C0168634;C1442488
939,baseline  mm hg,C0168634;C0439475;C1442488
939,baseline  mg / dl ( mmol / l ),C0168634;C0439269;C1442488;C1532563
939,baseline  % ( n ),C0168634;C1442488
939,baseline,C0168634;C1442488
939,b - blockers at baseline,C0168634;C1442488
939,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
939,atrial fibrillation on baseline ecg  n ( % ),C0168634;C0344434;C1442488
939,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
939,at baseline — no . ( % ),C0168634;C1442488
939,at baseline,C0168634;C1442488
939,asthma control test score at baseline,C0168634;C1442488;C2733224
939,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
939,aspirin dose at baseline  mg,C0004057;C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4086581;C4321396;C4521761;C4696290
939,aspirin at baseline,C0004057;C0168634;C1442488
939,asa use at baseline  n ( % ),C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
939,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
939,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
939,alc < $nmbr$ . $nmbr$ % at baseline  n ( % ),C0168634;C1424945;C1442488;C3811058
939,albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
939,age at baseline years,C0168634;C1442488;C1510829
939,age at baseline in years  mean ( sd ),C0001779;C0168634;C1442488
939,age at baseline ( years ),C0168634;C1442488;C1510829
939,af on baseline ecg  n ( % ),C0168634;C0344434;C1442488;C1623258;C4049859
939,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488
939,adjusted for all baseline variables $nmbr$,C0168634;C0439828;C0456081;C1442488
939,adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up,C0168634;C0439828;C0456081;C1442488;C1704675
939,a from baseline,C0168634;C1442488
939,a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %,C0168634;C1442488
939,a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %,C0168634;C1442488
939,> $nmbr$ mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
939,> $nmbr$ med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
939,> $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
939,< $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
939,( baseline ),C0168634;C1442488
939,% predicted ” fev  at baseline  % *,C0168634;C0681842;C1442488;C1882327;C3714541
939,% change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
939,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
939,$nmbr$ med at baseline,C0168634;C1442488;C4321267
938,two or more at baseline,C0205448
938,two or more antihypertensive medications,C0205448
938,two of the above,C0205448
938,ast > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
938,alt > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
938,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0010287;C0013175;C0026845;C0035173;C0205448;C0332281;C0439849;C0445223;C0521095;C0683368;C0805162;C1266129;C1415181;C1457887;C1516048;C1519815;C1704788;C3539106;C3891303;C4083049;C4553172
937,two or more,C0205448
937,two arm,C0205448;C0446516;C3715044;C4553528
936,symptom bother,C1457887;C3854129
936,symptom - free days in the past $nmbr$ weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
936,placebo ( symptom days a week ),C0032042;C0439228;C1457887;C1696465;C1706408;C3854129
936,number of symptom days per week,C0237753;C0439228;C0449788;C1457887;C3854129
936,hf symptom worsened,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
936,hf symptom unchanged,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
936,budesonide { symptom days a week ),C0054201;C0439228;C1457887;C3854129
936,budesonide ( symptom days a week ),C0054201;C0439228;C1457887;C3854129
936,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
936,> lto £ $nmbr$ symptom days per week,C0677547;C1457887;C3854129
936,> $nmbr$ symptom days per week,C0677547;C1457887;C3854129
936,$nmbr$ to $nmbr$ symptom days per week,C0677547;C1457887;C3854129
935,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
935,time from symptoms to randomization  h,C0040223;C0683368;C1457887;C3541383
935,time from symptoms onset to $nmbr$ st balloon inflation ( h ),C0449244;C0683368;C1457887
935,time from symptom onset to start of fibrinolytic therapy — hr,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
935,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
935,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
935,time from symptom onset to balloon inflation,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
934,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
934,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
934,who fc ii symptoms at baseline $nmbr$,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
934,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
934,systemic symptoms,C0205373;C0683368;C1457887
934,symptoms and feelings,C0683368;C1457887
934,symptoms,C0683368;C1457887
934,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
934,no symptoms,C0683368;C1457887
934,hf symptoms and signs,C0018488;C0683368;C1313497;C1457887;C1538440;C3273279
934,group d ( high risk  more symptoms )  n ( % ),C0332167;C0441848;C0683368;C1457887;C3272283;C4050568;C4319571
934,group b ( low risk  more symptoms )  n ( % ),C0441848;C0683368;C1457887;C3272281;C3538919
934,daytime symptoms more than twice per week,C0332169;C0683368;C1457887;C1720725;C1948050
934,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
934,asthma symptoms in the past $nmbr$ weeks,C0004096;C0683368;C1457887;C2984299;C2987125
934,$nmbr$ = no symptoms,C0683368;C1457887
934,$nmbr$ = minor symptoms  no limitations,C0026193;C0205165;C0683368;C1457887
933,pancreatic cancer,C0235974;C0346647;C2984259
932,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
932,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
931,pacific islander,C0242191
931,other pacific islander,C0242191
930,charlson comorbidity index  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4546361
930,charlson comorbidity index,C4546361
929,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0037455;C0175659;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460
929,ccs class §,C1879987
928,cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901
928,cardiogenic shock,C0036980
927,carotid artery — no . ( % ),C0007272;C0162859
927,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
927,carotid artery diseaset,C0007272;C0162859
926,cardiac death,C0376297
925,cardiac rhythm,C0232187
924,cardiac therapy §,C3654025
924,cardiac therapy  n ( % ) d,C3654025
924,cardiac therapy,C3654025
923,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
923,other cardiac surgery  n ( % ),C0018821;C0524727
923,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
922,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
922,chronic bronchitis ( n = $nmbr$ ),C0008677
922,chronic bronchitis ( itt ) ( n = $nmbr$ ),C0008677
922,chronic bronchitis ( % ),C0008677
922,chronic bronchitis !,C0008677
922,chronic bronchitis,C0008677
921,with higher classes indicating greater limitations on physical activity owing to,C0205250;C0456387;C1518526;C1705943;C4019422
921,renal biopsy class,C0194073;C0456387;C1518526;C1705943
921,non - hdl - c in $nmbr$ classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
921,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
921,modified acc / aha lesion class b $nmbr$ or cj,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
921,modified acc / aha lesion class b $nmbr$ / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
921,modified acc - aha lesion class b $nmbr$ or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
921,kilip class,C0456387;C1518526;C1705943
921,egfr in $nmbr$ classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
921,class ll - iv,C0456387;C1518526;C1705943
921,class l / ll heart failure,C0456387;C1518526;C1705943
921,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
921,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
921,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
921,class > $nmbr$,C0456387;C1518526;C1705943
921,class $nmbr$ or no symptoms,C0456387;C1518526;C1705943
921,class $nmbr$ antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
921,class $nmbr$,C0456387;C1518526;C1705943
921,calculated ldl - c in $nmbr$ classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
921,baseline trl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
921,baseline lp ( a ) in $nmbr$ classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
921,baseline hdl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
921,baseline hba $nmbr$ c in $nmbr$ classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
921,baseline albumin / creatinine ratio in $nmbr$ classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
921,age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
921,acc / aha lesion class b $nmbr$ or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
920,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205191;C0679831
920,chronic cox $nmbr$ inhibitors,C0085387;C0205191
920,chronic bronchitist,C0205191
919,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
919,coronary angiography — no . ( % ),C0085532;C1548829
919,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
919,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
919,coronary angiography and intervention,C0085532;C1548829
919,coronary angiography,C0085532;C1548829
918,rosuvastatin + fenofibric acid,C0060179;C0965129
918,rosuvastain + fenofibric acid   n   =   $nmbr$,C0060179
918,rosuvastain + fenofibric acid $nmbr$ = $nmbr$,C0060179
918,fenofibric acid   n   =   $nmbr$,C0060179
918,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
918,fenofibric acid - $nmbr$ - low - dose statin,C0060179;C0360714;C0445550;C1708745
918,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
918,fenofibric acid $nmbr$ = $nmbr$,C0060179
918,fenofibric acid,C0060179
918,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
918,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179
917,undetermined etiology  n ( % ),C0478157
917,undetermined etiology,C0478157
916,metformin • pioglitazone,C1635037
916,metformin ? pioglitazone,C1635037
915,antidepressant,C0003289
914,linear regression,C0023733;C2346679
913,inversion,C0021943;C0021945;C1705687;C2349984
912,undetermined  other  or cardioembolism,C0205258;C3536725;C4082977
912,undetermined,C0205258;C3536725;C4082977
912,indeterminate or unknown,C0205258
912,indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ ),C0205258;C1513839
912,indeterminate ! !,C0205258
911,health practices,C0018684
910,health habits,C0679786
909,hiatus hernia,C3489393
909,esophageal hiatal hernia *,C3489393
908,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
908,bph - related health status,C0005001;C1704272
908,benign prostatic hyperplasia,C1704272
907,idiopathic / familial,C0015576;C0241888;C0332240
907,idiopathic,C0332240
907,cryptogenic,C0332240
906,other supraventricular tachycardia,C0039240;C1963244;C3815188
905,lelt ventricular hypertrophy *,C0340279
904,left ventricular ejection,C2733342
904,left ventricular dysfunction,C0242698
903,ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446
902,supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833
901,ventricular tachyarrhythmias,C3827656
900,demographic data,C4684639
899,variable demographic characteristics,C0439828;C0683970;C4553760
899,demographic features,C0683970
899,demographic feature,C0683970
899,demographic characteristics,C0683970
898,= sia,C1225105;C1551538
897,ebria,C1917247
896,india,C0021201;C2700456
895,pyrexia,C0015967
894,dyspepsia,C0013395;C4552968
893,paresthesia,C0030554;C4553220
892,east asia,C0015631
891,aphasia,C0003537
890,austria,C0004348
889,australasia,C0282279;C1257882
888,myalgia,C0231528;C4552646
887,malaysia,C0024552
886,antimalarial,C0003374;C3536844;C4552582
885,arthralgia,C0003862;C4551938
884,ai $nmbr$,C0003504;C4551710
883,trait,C0599883
882,gait,C0016928
881,hiv,C0019682;C0019699
880,fh ii,C1854107
879,$nmbr$ nil,C0442734
878,$nmbr$ ix,C0015491
877,oil,C0028908;C0032085;C1517288;C3541397
877,- oil,C0028908;C0032085;C1517288;C3541397
876,sotalol,C0037707
875,cilostazol,C0055729
874,salbutamol  %,C0001927
874,albuterol use,C0001927;C0042153;C0457083;C1947944
873,hrqol,C4279947;C4300252
873,health - related quality of life,C4279947
872,algorithm $nmbr$,C0002045;C1553907
871,allopurinol $nmbr$ mg ( n = $nmbr$ ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
871,allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
871,allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
871,allopurinol,C0002144
870,alcohol abuse,C0085762;C4050601
869,alcohol usef  n ( % ),C0001962;C0001975
869,alcohol useb,C0001962;C0001975
869,alcohol drinker  n ( % ),C0001962;C0001975;C0556338
869,alcohol drinker,C0001962;C0001975;C0556338
869,alcohol ^,C0001962;C0001975
869,alcohol > $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
869,alcohol < = $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
869,alcohol,C0001962;C0001975
868,no history of hypertension ( n = $nmbr$ ),C0455527
868,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
868,history of systemic hypertension,C0205373;C0455527
868,history of hypertension — no . ( % ),C0455527
868,history of hypertension for $nmbr$ mo or more,C0455527
868,history of hypertension ^  %,C0455527
868,history of hypertension . no . ( % ),C0455527
868,history of hypertension - n ( % ),C0455527
868,history of hypertension *,C0455527
868,history of hypertension ( n = $nmbr$ ),C0455527
868,history of hypertension ( a ) c,C0455527
868,history of hypertension ( % ),C0455527
868,history of hypertension  no . ( % ),C0455527
868,history of hypertension  n ( % ),C0455527
868,history of hypertension,C0455527
868,history of diagnosed hypertension prior to randomization  n ( % ),C0011900;C0455527
868,history of diagnosed hypertension n ( % ),C0011900;C0455527
868,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
867,helicobacter pylori infection ( + ) ( n ),C0850666
867,h . pylori infection,C0850666
866,no methotrexate  hydroxychloroquine  or sulfasalazine treatment,C0020336;C0025677
866,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
866,hydroxychloroquine,C0020336
865,history of a transient ischaemic attack,C0455536
864,history of hyperlipidemia ( % ),C4695788
863,history of hypercholesterolemia  n ( % ),C1533076
863,history of hypercholesterolemia,C1533076
862,history of falls in year before randomization,C1561668;C2919132
862,history of falls,C1561668;C2919132
861,history of peripheral vascular disease,C1881056
860,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
860,history of cardiovascular disease — no . { % ),C0455539
860,history of cardiovascular disease — no . ( % ) ^ |,C0455539
860,history of cardiovascular disease — no . ( % ),C0455539
860,history of cardiovascular disease,C0455539
859,history of cerebrovascular disease — no . { % ),C0585890
859,history of cerebrovascular disease,C0585890
858,history of alcohol use,C0551571;C0552479
857,history of pvd  no . ( % ),C4534349
857,history of pvd  n ( % ),C4534349
857,history of pvd,C4534349
856,no history of migraine,C0455512
855,no history of cancer,C0455471
855,history of cancer,C0455471
854,no history of heart failure at baseline,C0455531
854,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
854,history of heart failure — no . { % ),C0455531
854,history of heart failure — no . ( % ),C0455531
854,history of heart failure at baseline,C0455531
854,history of heart failure  no . ( % ),C0455531
854,history of heart failure  n ( % ),C0455531
854,history of heart failure,C0455531
854,history of congestive heart failure,C0455531;C0742742
854,any history of congestive heart failure,C0455531;C0742742
853,rhabdomyolysis or myopathy,C0035410;C4552660
853,rhabdomyolysis ( n = $nmbr$ ),C0035410;C4552660
853,rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln,C0026848;C0035410;C4552660
853,rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0026848;C0035410;C4552660
853,rhabdomyolysis,C0035410;C4552660
852,no htn,C0020538
852,htn hx,C0020538;C0262926;C3814444
852,htn,C0020538
851,resistant htn n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
851,resistant htn : spiro n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
851,resistant htn : placebo n = $nmbr$,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
851,no resistant htn n = $nmbr$  $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
850,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
850,treated hypertension :,C0020538;C1522326;C1963138
850,treated for hypertension  %,C0020538;C1522326;C1963138
850,systemic hypertension,C0020538
850,systemic arterial hypertension  n ( % ),C0020538
850,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
850,prior hypertension,C0020538;C0332152;C1963138;C2826257
850,previous hypertension,C0020538;C0205156;C1552607;C1963138
850,no hypertension ( n = $nmbr$ ),C0020538;C1963138
850,no hypertension,C0020538;C1963138
850,isoiated systoiic hypertension *,C0020538;C1963138
850,hypertension 本,C0020538;C1963138
850,hypertension 一 no . ( % ),C0020538;C1963138
850,hypertension — no . / total no . ( % ),C0020538;C1963138
850,hypertension — no . ( % ) |,C0020538;C1963138
850,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
850,hypertension — no . ( % ),C0020538;C1963138
850,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
850,hypertension §,C0020538;C1963138
850,hypertension severity,C0020538;C0439793;C0522510;C1963138
850,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
850,hypertension requiring medical treatment,C0020538;C1963138
850,hypertension n ( % ),C0020538;C1963138
850,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
850,hypertension and left ventricular hypertrophy,C0020538;C1963138
850,hypertension absent,C0020538;C1963138
850,hypertension ^,C0020538;C1963138
850,hypertension : no ( n = $nmbr$ ),C0020538;C1963138
850,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
850,hypertension *,C0020538;C1963138
850,hypertension ( n 二 $nmbr$ ),C0020538;C1963138
850,hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication ),C0020538;C0037623;C0439475;C1415692;C1708288;C1963138;C4318478
850,hypertension ( > $nmbr$ / $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
850,hypertension ( % ) : t,C0020538;C1963138
850,hypertension ( % ),C0020538;C1963138
850,hypertension $nmbr$ ( % ),C0020538;C1963138
850,hypertension !,C0020538;C1963138
850,hypertension    n   ( % ),C0020538;C1963138
850,hypertension  treated,C0020538;C1963138
850,hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % ),C0020538;C1963138
850,hypertension  n / n ( % ),C0020538;C1963138
850,hypertension  n ( % ) yes,C0020538;C1549445;C1705108;C1710701;C1963138
850,hypertension  n ( % ),C0020538;C1963138
850,hypertension  * n ( % ),C0020538;C1963138
850,hypertension  ( % ),C0020538;C1963138
850,hypertension  %,C0020538;C1963138
850,hypertension,C0020538;C1963138
850,hyper - tension,C0020538;C1963138
850,high blood pressure,C0020538;C2926615
850,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
850,elevated blood pressure,C0020538;C0497247
850,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
850,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
850,duration of hypertension  y,C0020538;C0449238;C1963138;C2926735
850,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
850,arterial hypertension — no . ( % ),C0020538
850,arterial hypertension *,C0020538
850,arterial hypertension  no . ( % ),C0020538
850,arterial hypertension  n ( % ),C0020538
850,arterial hypertension,C0020538
850,> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :,C0020538;C1532718;C1963138
849,age of onset < $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
849,age of onset $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
849,age of onset,C0206132;C3175530
849,age of asthma onset  years,C0004096;C0206132;C0439234;C2984299;C3175530
849,age at onset  y,C0206132;C3870509
849,age at disease onset  years *,C0012634;C0206132;C0439234;C3870509
849,age at disease onset  n ( % ) *,C0012634;C0206132;C3870509
848,onset of chest pain,C0024902;C0206132;C0332162
848,onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
847,stage $nmbr$ b : > = $nmbr$ and < $nmbr$,C0441781
847,stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441781;C0441923
847,stage $nmbr$ b,C0441781
846,safety variable,C0036043;C0439828;C1705187;C4553760
846,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
846,safety population,C0032659;C0036043;C1257890;C1705187
846,safety    n   ( % ) b,C0036043;C1705187
846,safety  %,C0036043;C1705187
845,participation in phase a,C0205390;C0679823;C1710475
845,double - dummy phase * *,C0205390;C1710475;C4684647
844,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
844,stage iv,C0205390;C1300072;C1306673
844,stage > $nmbr$ chronic kidney disease ( % ),C0205390;C1300072;C1306673
844,stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ ),C0205390;C1300072;C1306673
844,stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ ),C0205390;C1300072;C1306673
844,stage $nmbr$ a ckd cohort ( secondary analysis ),C0205390;C1300072;C1306673
844,stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users ),C0205390;C1300072;C1306673
844,stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
844,stage $nmbr$ a : > = $nmbr$ and < $nmbr$,C0205390;C1300072;C1306673
844,stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
844,stage $nmbr$ a,C0205390;C1300072;C1306673
844,stage $nmbr$ : > = $nmbr$,C0205390;C1300072;C1306673
844,stage $nmbr$ : < $nmbr$,C0205390;C1300072;C1306673
844,stage $nmbr$ ( four - variable modification of diet in kidney disease ),C0205390;C1300072;C1306673
844,stage $nmbr$ ( cockcroft - gault ),C0205390;C1300072;C1306673
844,stage $nmbr$,C0205390;C1300072;C1306673
844,hoehn and yahr stage ( range  $nmbr$ - $nmbr$ ),C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
844,hoehn and yahr stage ( baseline )  mean ( sd ),C0168634;C0205390;C0444504;C1300072;C1306673;C1442488;C2347634;C2348143;C2699239
844,hoehn and yahr stage,C0205390;C1300072;C1306673
844,hoehn & yahr stage ( “ on ” )  n ( % ),C0205390;C1300072;C1306673
844,hoehn & yahr stage ( “ off ” )  n ( % ),C0205390;C1300072;C1306673
844,hoehn & yahr stage,C0205390;C1300072;C1306673
843,age subgroups,C0001779;C1079230
843,age subgroup  y,C0001779;C1079230;C1515021
843,- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C0001779;C1079230;C4684719
843,( b ) age subgroups,C0001779;C1304659
842,age when diabetes first diagnosed — yr,C0001779
842,age when diabetes first diagnosed ( years )  mean ( sd ),C0001779
842,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
841,aged ≥ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
841,aged a $nmbr$ years,C0001779;C0001792;C1999167
841,aged ^ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
841,aged < $nmbr$ years,C0001779;C0001792;C0439234;C1999167
841,aged $nmbr$ y or older  n ( % ),C0001779;C0001792;C1999167
841,age ≥ $nmbr$ yearsa,C0001779
841,age — y  meantsd,C0001779
841,age   ≥ $nmbr$   y  n ( % ),C0001779
841,age ± sd ( yrs ),C0001779;C2699239
841,age £ $nmbr$,C0001779
841,age s $nmbr$,C0001779
841,age groups  n ( % ),C0001779;C0441848
841,age group ( y ),C0001779;C0441858
841,age group  n ( % ),C0001779;C0441848
841,age a $nmbr$,C0001779
841,age ^ $nmbr$,C0001779
841,age [ year ]  mean ± sda,C0001779;C0276477;C0439234;C0439508;C0444504;C1428349;C1553165;C2347634;C2348143
841,age > = $nmbr$,C0001779
841,age > : $nmbr$,C0001779
841,age > $nmbr$ vears n = $nmbr$,C0001779
841,age > $nmbr$,C0001779
841,age >,C0001779
841,age < $nmbr$ y,C0001779
841,age < $nmbr$ vears n = $nmbr$,C0001779
841,age < $nmbr$,C0001779
841,age :,C0001779
841,age . y,C0001779
841,age *,C0001779
841,age ( yrs ) < $nmbr$,C0001779
841,age ( yrs ) $nmbr$ - $nmbr$,C0001779
841,age ( yrs )  mean *,C0001779;C0444504;C2347634;C2348143
841,age ( yr )  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
841,age ( y ) [ mean - sd ],C0001779;C0444504;C2347634;C2348143;C2699239
841,age ( y )  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
841,age ( sd )  y,C0001779;C2699239
841,age & $nmbr$,C0001779
841,age $nmbr$ y,C0001779
841,age $nmbr$ - $nmbr$,C0001779
841,age $nmbr$ + y,C0001779
841,age $nmbr$ +,C0001779
841,age $nmbr$ $nmbr$ y,C0001779
841,age $nmbr$,C0001779
841,age  yt,C0001779;C1412122
841,age  yrs ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
841,age  yrs  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
841,age  yr  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
841,age  yf $nmbr$ - $nmbr$,C0001779
841,age  ya,C0001779
841,age  y < $nmbr$,C0001779
841,age  y . o .,C0001779
841,age  y ( sd ),C0001779;C2699239
841,age  y ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
841,age  y,C0001779
841,age  x,C0001779
841,age  n ( % ),C0001779
841,age  mean yr,C0001779;C0439234;C0444504;C2347634;C2348143
841,age  mean,C0001779;C0444504;C2347634;C2348143
841,age,C0001779
840,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
840,age\\yr,C0001779;C0439234
840,age — yrf,C0001779
840,age — yr race — no . ( % ) f,C0001779;C0439234
840,age — yr,C0001779;C0439234
840,age — y £,C0001779
840,age yrs,C0001779
840,age s * $nmbr$ yr,C0001779;C0439234
840,age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers,C0001779
840,age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers,C0001779
840,age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes,C0001779
840,age b $nmbr$ y ( n = $nmbr$ ),C0001779
840,age ^ $nmbr$ yrs  n ( % ),C0001779
840,age > = $nmbr$ yrs,C0001779
840,age > $nmbr$ yrs *,C0001779
840,age > $nmbr$ yrs  n ( % ),C0001779
840,age > $nmbr$ yrs  %,C0001779
840,age > $nmbr$ yrs,C0001779
840,age > $nmbr$ yr 十,C0001779;C0439234
840,age > $nmbr$ yr — no . ( % ),C0001779;C0439234
840,age > $nmbr$ yr and st - segment changes,C0001779;C0439234
840,age > $nmbr$ yr and elevated biomarkers,C0001779;C0439234
840,age > $nmbr$ yr ( % ),C0001779;C0439234
840,age > $nmbr$ yr  no . ( % ),C0001779;C0439234
840,age > $nmbr$ yr,C0001779;C0439234
840,age > $nmbr$ y * *,C0001779
840,age > $nmbr$ y *,C0001779
840,age > $nmbr$ y ( n = $nmbr$ ),C0001779
840,age > $nmbr$ y ( % ),C0001779
840,age > $nmbr$ y  n / n ( % ),C0001779
840,age > $nmbr$ y  n ( % ),C0001779
840,age > $nmbr$ y  %,C0001779
840,age > $nmbr$ y,C0001779
840,age > $nmbr$  y,C0001779
840,age > $nmbr$  %,C0001779
840,age < $nmbr$ yrs,C0001779
840,age < $nmbr$ yr or > $nmbr$ yr,C0001779;C0439234
840,age < $nmbr$ yr,C0001779;C0439234
840,age < $nmbr$ y ( n = $nmbr$ ),C0001779
840,age . . . . . . . . y ( n = $nmbr$ ),C0001779
840,age ( yrs ),C0001779
840,age ( yr ) *,C0001779;C0439234
840,age ( yr )  mean ( sd ) bmd t - score  mean ( sd ),C0001779;C0439234;C2699239;C3533236
840,age ( yr ),C0001779;C0439234
840,age ( yij,C0001779
840,age ( year ),C0001779;C0439234;C0439508
840,age ( y ) ∗,C0001779
840,age ( y ),C0001779
840,age ( p = o - $nmbr$ ),C0001779
840,age ' ^ $nmbr$ yrs,C0001779
840,age ' $nmbr$ y ( n $nmbr$ ),C0001779
840,age $nmbr$ - $nmbr$ y ( n = $nmbr$ ),C0001779
840,age $nmbr$ + yrs,C0001779
840,age $nmbr$ * $nmbr$ yr,C0001779;C0439234
840,age $ $nmbr$ yrs,C0001779
840,age # $nmbr$ yrs,C0001779
840,age  yrs *,C0001779
840,age  yrs,C0001779
840,age  yr  n ( % ),C0001779;C0439234
840,age  yr,C0001779;C0439234
840,age  year,C0001779;C0439234;C0439508
840,> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
840,< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
839,old stroke *,C1536121
838,aldosterone use,C0002006;C0042153;C0457083;C1947944
838,aldosterone blockers,C0002006
838,aldosterone blocker  %,C0002006
838,aldosterone blocker,C0002006
837,dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0754659
837,dutasteride ( n = $nmbr$ ),C0754659
837,dutasteride,C0754659
837,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
836,ras - aldosterone inhibitor ^,C0002006;C0002007;C0034678;C0525678;C1514727
836,aldosterone inhibitor,C0002007
836,aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004
836,aldosterone antagonists,C0002007;C2757004
836,aldosterone antagonist,C0002007;C2757004;C3536833
835,salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .,C0086706;C0939232
835,salmeterol - fluticasone group ( n = $nmbr$ ),C0441848;C0939232
835,fluticasone - salmeterol ( n = $nmbr$ ),C0939232
835,fluticasone - fluticasone / salmeterol,C0939232
834,cluster seizures,C0036572;C1555715;C1704332
834,cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
834,cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
834,cluster $nmbr$ : diuretic ( n = $nmbr$ ),C1555715;C1704332
833,steroid use at baseline,C0168634;C0281991;C1442488
833,steroid use  %,C0281991
833,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
832,western europe plus other,C0043129
832,western europe hr ( $nmbr$ % cl ),C0043129;C0596019
832,western europe and other,C0043129
832,western europe and lebanon,C0043129
832,western europe and israel,C0043129
832,western europe and australia,C0043129
832,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
832,western europe / australia,C0004340;C0015176;C0043128;C0043129
832,western europe ( n   = $nmbr$  $nmbr$ ),C0043129
832,western europe ( n = $nmbr$ ),C0043129
832,western europe ( including south africa ),C0043129
832,western europe ( % ),C0043129
832,western europe  israel  australia  or south africa,C0004340;C0015176;C0022271;C0043128;C0043129
832,western europe,C0043129
831,estrogens,C0014939;C3537250;C3541386;C3714615
830,no estrogen,C0014939;C2936882;C4542544
830,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
830,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
830,estrogen ( ' % ? ),C0014939;C2936882;C4542544
830,estrogen,C0014939;C2936882;C4542544
829,strategy,C0679199
829,planned treatment strategy,C0599880;C0679199
829,early invasive strategy ( n = $nmbr$  $nmbr$ ),C0205281;C0679199;C1279919;C1334278
829,conservative strategy ( n = $nmbr$  $nmbr$ ),C0679199
828,central europe,C0682369
827,eastern and central europe,C1707877
827,east europe,C0015176;C1707877
826,southern europe,C0037724
825,eastern european,C0239309
824,eastern europe and africa,C0015177
824,eastern europe ( n   = $nmbr$  $nmbr$ ),C0015177
824,eastern europe ( n = $nmbr$ ),C0015177
824,eastern europe ( % ),C0015177
824,eastern europe  africa,C0001737;C0001741;C0015176;C0015177
824,eastern europe,C0015177
823,western friroce,C1705493
823,western eu  australia  new zealand,C0015179;C0027978;C0043128;C0324547;C1705493;C3665627;C4289954
823,western,C1705493
822,repaired s - p shunts,C0205340
822,repaired chd,C0205340;C0280604;C3542407
821,pre - specified trial endpoints,C2826245
821,pre - specified hr ( $nmbr$ % cl ),C2826245
820,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
820,prevalent vertebral fracture  n ( % ),C0033105;C0080179;C0220900
820,prevalent vertebral fracture,C0033105;C0080179;C0220900
820,prevalent cvd,C0007222;C0033105;C0220900
820,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
819,vte / vte - related deathsb  n / n ( % ),C0439849;C0445223;C0630906
819,vte / vte - related deathsa  n / n ( % ),C0439849;C0445223;C0630906
819,any vte or vte - related death — no . ( % ),C0630906
819,any vte - related death,C0425043;C0630906
818,unprovoked vte n ( % ),C0630906
818,previous vte — no . ( % ),C0205156;C0630906;C1552607
818,previous vte n ( % ),C0205156;C0630906;C1552607
818,previous vte  n ( % ),C0205156;C0630906;C1552607
818,previous vte,C0205156;C0630906;C1552607
817,sri ‐ $nmbr$ response rate  %,C0237629;C1420401
816,preferred term  %,C1709637;C2347664
815,fevi reversibility — %,C3830088
814,reversibility to salbutamol  %,C1271924
813,reversible to bronchodilator  b %,C0006280;C0205343
813,reversible to albuterolc  d  n ( % ),C0205343
813,reversible ( % ),C0205343
813,reversible,C0205343
813,non - reversible ( % ),C0205343;C1518422
812,preamendment,C1548596
811,before amendment ( % ),C0680532;C2346732
811,before amendment,C0680532;C2346732
811,after amendment ( % ),C0680532;C2346732
811,after amendment,C0680532;C2346732
810,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
810,treatment arm,C1522541
810,by treatment arm,C1522541
809,preoperative heart rate ( beats per minute ),C0018810;C0445204
809,heart rates ( beats / minutes ),C0018810
809,heart rate 一 beats / min,C0018810
809,heart rate — bpm,C0018810
809,heart rate — beats / min,C0018810
809,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
809,heart rate at baseline  bpm,C0018810;C0168634;C1442488
809,heart rate > $nmbr$ bpm,C0018810
809,heart rate < $nmbr$ bpm,C0018810
809,heart rate ( sd )  bpm,C0018810;C2699239
809,heart rate ( sd ),C0018810;C2699239
809,heart rate ( min − $nmbr$ ),C0018810;C0702093;C1524029;C3813700
809,heart rate ( bpm ) *,C0018810
809,heart rate ( bpm ),C0018810
809,heart rate ( beats per minute ),C0018810
809,heart rate ( beats per min ),C0018810
809,heart rate ( beats / min ),C0018810
809,heart rate  bpm,C0018810
809,heart rate  beats per minute,C0018810
809,heart rate  beats per min,C0018810
809,heart rate  beats / min,C0018810
809,heart rate  / min,C0018810;C0702093;C1524029;C3813700
809,heart rate,C0018810
809,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
809,baseline heart rate ( beats / min ),C0018810;C0168634;C1442488
809,$nmbr$ - lead ecg heart rate  beats / min,C0018810;C0179504
808,heart rate ( bpm $nmbr$ ) *  * *,C0018810
808,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
808,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
808,heart rate  beats / min  mean ± sd,C0018810
808,heart rate  b . p . m . mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
807,saba reversibility,C0449261
807,reversibility ’ ' %,C0449261
807,reversibility — %,C0449261
807,reversibility to,C0449261
807,reversibility stratum *,C0449261
807,reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
807,reversibility of fev $nmbr$ ( % ),C0449261;C3714541
807,reversibility > $nmbr$ % ( n = $nmbr$ ),C0449261
807,reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
807,reversibility < $nmbr$ % ( n = $nmbr$ ),C0449261
807,reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
807,reversibility : > $nmbr$ - < $nmbr$ %,C0449261
807,reversibility : > $nmbr$ %,C0449261
807,reversibility : < $nmbr$ %,C0449261
807,reversibility *,C0449261
807,reversibility ( % ) t,C0449261
807,reversibility ( % ),C0449261
807,reversibility %,C0449261
807,reversibility  %,C0449261
807,reversibility,C0449261
807,fev $nmbr$ reversibility  % b,C0449261;C3714541
807,fev $nmbr$ reversibility  % *,C0449261;C3714541
807,fev $nmbr$ % reversibility ( sd ),C0449261;C2699239;C3714541
807,fev $nmbr$ % reversibility,C0449261;C3714541
807,bronchial reversibility %,C0205039;C0449261;C1442216
807,albuterol reversibility  %,C0001927;C0449261
807,airway reversibility  mean  %,C0178987;C0444504;C0449261;C0458827;C2347634;C2348143
807,airway reversibility  %,C0178987;C0449261;C0458827
807,airflow reversibility — no . ( % ) |,C0231999;C0449261
807,absolute reversibility in fev $nmbr$  ml *,C0205344;C0439526;C0449261;C1705224;C3714541;C3887665
807,% reversibility in fev ^ at,C0449261;C3714541
807,% reversibility,C0449261
807,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
806,reversibility [ % ]  median ( range ),C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
806,reversibility ( % predicted fev $nmbr$ ) *,C0449261
806,reversibility ( % )  median ( range ) c,C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
805,weekly iss {,C0332174;C1740819;C1845118
805,weekly iss $nmbr$,C0332174;C1740819;C1845118
805,weekly,C0332174
805,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
804,network,C0150775;C1513822;C1705739;C1882071
803,enox,C3147679
802,belgium,C0004950
801,jejunum,C0022378
800,eu,C0015179;C3665627
800,eastern eu,C0015179;C1707877;C3665627
799,region  europe union,C0015179;C0017446;C0205147
799,european union,C0015179
798,hla - b $nmbr$,C0019737;C0550853;C1415561
797,hl 土 $nmbr$ . $nmbr$,C1453952;C4085347
796,yes  no,C1512698
796,( yes / no ),C1512698
795,p . b “ int,C1539794;C3272375
795,p . b * int,C1539794;C3272375
795,int . p *,C3272375
794,xho  p = o - $nmbr$,C4050013
793,tp vs no tp,C0036183;C3541334
792,cox bsl onlyc,C1549954;C1565830
792,cox bsl + yr $nmbr$ hbd,C0439234;C1549954;C1565830
791,p value for dm vs . no dm,C4086240
790,cha $nmbr$ ds $nmbr$ - vasc > $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc < $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc # $nmbr$,C1420648;C3714751
790,cha $nmbr$ ds $nmbr$ - vasc,C1420648;C3714751
790,baseline cha $nmbr$ ds $nmbr$ - vascb  c,C0168634;C1420648;C1442488;C3714751
789,a $nmbr$ s - hydroxy -,C0700307
788,qids - sr $nmbr$,C4331197
787,adcs - adl score *,C0449820;C3641947;C4050231
787,adcs - adl,C3641947
786,mtss cfb,C0009002;C1824728
785,tass ’,C0559483
784,class iii,C0441887;C2698969
783,das $nmbr$ score,C0051767;C0057671
783,das $nmbr$ - hscrp,C0051767;C0057671
783,das $nmbr$ - esr lda,C0051767;C0057671;C3811131;C4553195
783,das $nmbr$ - esr,C0051767;C0057671;C3811131
783,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t,C0051767;C0057671;C3811131
783,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *,C0051767;C0057671;C3811131
783,das $nmbr$ - $nmbr$ ( esr ) $nmbr$,C0051767;C0057671;C3811131
783,das $nmbr$ - $nmbr$ ( esr ),C0051767;C0057671;C3811131
783,das $nmbr$ ( esr ),C0051767;C0057671;C3811131
783,das $nmbr$,C0051767;C0057671
782,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
782,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
782,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
782,updrs  part iii ( motor ),C0439070;C0449719;C1513492;C1705160;C1705994;C1709471;C3639721
782,nyha iii or iv § ( n = $nmbr$ $nmbr$ ),C0439070;C1275491;C1705160
782,nyha iii or iv,C0439070;C1275491;C1705160
782,nyha iii  n ( % ),C0439070;C1275491;C1705160
782,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
782,ncep atp - iii metabolic syndrome features  n ( % ),C0439070;C0524620;C1705160;C2744579;C4552600
782,iii or iv,C0439070;C1705160
782,iii and iv ejection fraction,C0439070;C1705160
782,iii and iv,C0439070;C1705160
782,iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted,C0439070;C1705160;C3714541
782,iii / iv,C0022326;C0439070;C1705160;C4265176
782,iii - iv,C0022326;C0439070;C1705160;C4265176
782,iii ( n z $nmbr$ ),C0439070;C1705160
782,iii ( $nmbr$ ),C0439070;C1705160
782,iii & iv,C0022326;C0439070;C1705160;C4265176
782,iii,C0439070;C1705160
782,ii / iii,C0439070;C1705160;C1710602;C4082587
782,ii - iii,C0439070;C1705160;C1710602;C4082587
782,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
782,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
782,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
782,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
782,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
781,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
781,no gi bleed,C1708130;C3539617;C4050121
781,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
781,gi bleed,C1708130;C3539617;C4050121
781,$nmbr$ - gi,C1708130;C3539617;C4050121
780,six - minute walk distance  m,C0012751;C0369637;C0441923;C3900196
780,moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
780,min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923;C0702093;C1524029;C3813700
780,mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
780,mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
780,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
780,mab,C0003250;C0369637
780,m being,C0369637;C0441923
780,m,C0369637;C0441923
780,k - m % n,C0369637;C0441923;C0597277;C1708601
780,k - m %,C0369637;C0441923;C0597277;C1708601
780,hr ( b . p . m . ),C0369637;C0441923
780,gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1424601
780,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area,C0017446;C0017654;C0205146;C0369637;C0439445;C0441923;C0489451;C0750572;C1424601
780,cardiac index  l • mn ' • m $nmbr$,C0026327;C0026405;C0369637;C0428776;C0441923;C4285072
780,baseline pfd  m,C0016065;C0168634;C0369637;C0441923;C1442488;C1839454;C2827389;C3889643
780,baseline mwd  m,C0168634;C0369637;C0441923;C1442488
780,baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
780,baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
780,baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
780,baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
780,baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
780,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
780,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
780,baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
780,baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
780,baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
780,baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
780,azl - m / cld ( n = $nmbr$ ),C0369637;C0441923
780,azl - m + hctz ( n = $nmbr$ ),C0020261;C0369637;C0441923
780,azl - m + cldb,C0369637;C0441923
780,azl - m $nmbr$ mg + cld $nmbr$ mg,C0369637;C0441923;C1319635
780,azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ ),C0369637;C0441923;C2827881
780,azl - m,C0369637;C0441923
780,> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
780,> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923
780,> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
780,> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
780,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
780,< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
780,$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1705224;C3887665
780,$nmbr$ to < $nmbr$ m um in,C0369637;C0441923
780,$nmbr$ mwt ( m ),C0369637;C0441923
780,$nmbr$ mwd decrease > $nmbr$ m,C0369637;C0392756;C0441923;C0547047
780,$nmbr$ mwd  m,C0369637;C0441923
780,$nmbr$ mw distance  m,C0012751;C0024548;C0026385;C0369637;C0441923;C0556966
780,$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
780,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
780,$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
779,ipah / fpah / drug and toxin,C0013227;C0152171;C1254351;C1419079
779,epilepsy drug,C0013227;C0014544;C1254351
779,due to drug - relateda ae,C0013227;C1254351;C3887670
779,drug ‐ relateda,C0013227;C1254351
779,drug naive,C0013227;C1254351
779,drug eluting,C0013227;C1254351
779,drug and insulint,C0013227;C1254351
779,drug - relateda,C0013227;C1254351
779,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
779,drug - related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
779,drug - related teaes,C0013227;C0439849;C0445223;C1254351
779,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
779,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
779,drug - eluting,C0013227;C1254351
779,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
779,any drug - related ae  n ( % ),C0013227;C0439849;C0445223;C1254351;C3887670
779,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
779,> $nmbr$ drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
779,> $nmbr$ drug - related,C0013227;C0439849;C0445223;C1254351
778,other drugs — no . ( % ),C0013227;C3687832
778,other drugs,C0013227;C3687832
778,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
778,no . of drugs,C0013227;C3687832
778,lowering drugs,C0013227;C0441994;C2003888;C3687832
778,immunomodulatory drugs,C0013227;C3687832
778,glycemic drugs,C0005802;C0013227;C3687832
778,drugs used in diabetes  n ( % ),C0013227;C3687832
778,drugs used in diabetes,C0013227;C3687832
778,drugs and toxins,C0013227;C3687832
778,concomitant drugs  %,C0013227;C0521115;C3687832
778,concomitant drugs,C0013227;C0521115;C3687832
778,annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^,C0013227;C3687832
777,use of medications for pah — no . ( % ),C0013227;C0802604;C1524063;C2598133;C4284232
777,use of medication from randomization through $nmbr$ hr — no . / total no . ( % ),C0013227;C1524063;C3244316;C4284232
777,use of medication for pah,C0013227;C1524063;C3244316;C4284232
777,use of medication at baseline — no . ( % ),C0013227;C1524063;C3244316;C4284232
777,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
777,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
777,systemic sle medications  n ( % ),C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
777,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
777,study medication  pre - dose,C0013227;C0557651;C2603343;C3244316;C4284232
777,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
777,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
777,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
777,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
777,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
777,periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *,C0013227;C0024671;C0026410;C0070166;C0439269;C0802604;C1960952;C2346927;C2598133;C4284232;C4321396;C4521761
777,periprocedural medications  n ( % ),C0013227;C0802604;C2598133;C4284232
777,periprocedural medications,C0013227;C0802604;C2598133;C4284232
777,other medications,C0013227;C0802604;C2598133;C4284232
777,other medication usage,C0013227;C0457083;C3244316;C4284232
777,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,no . of previous ciu / csu medications  mean ( median ),C0013227;C0205156;C0444504;C0549183;C0578870;C0802604;C0876920;C1552607;C2347634;C2347635;C2348143;C2348144;C2598133;C2939193;C4284232
777,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
777,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
777,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
777,medications through day $nmbr$,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
777,medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232
777,medications on admission  %,C0013227;C0802604;C2598133;C4284232
777,medications in use at baseline — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
777,medications in use at baseline — no . ( % ),C0013227;C0802604;C2598133;C4284232
777,medications in use at baseline  n ( % ),C0013227;C0802604;C2598133;C4284232
777,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0802604;C1510665;C2598133;C4284232
777,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0802604;C2598133;C4284232
777,medications during hospitalization or at discharge,C0013227;C0019993;C0802604;C2598133;C4284232
777,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
777,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
777,medications at baselinet,C0013227;C0802604;C2598133;C4284232
777,medications at baseline  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
777,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
777,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
777,medications *,C0013227;C0802604;C2598133;C4284232
777,medications ( % ),C0013227;C0802604;C2598133;C4284232
777,medications  no . ( % ),C0013227;C0802604;C2598133;C4284232
777,medications  n ( % of patients ),C0013227;C0030705;C0802604;C2598133;C4284232
777,medications  n ( % ),C0013227;C0802604;C2598133;C4284232
777,medications  n,C0013227;C0802604;C2598133;C4284232
777,medications,C0013227;C0802604;C2598133;C4284232
777,medication — no . ( % ),C0013227;C3244316;C4284232
777,medication within $nmbr$ days before enrolment,C0013227;C0439228;C3244316;C4284232
777,medication useb,C0013227;C3244316;C4284232
777,medication use — no . { % ),C0013227;C3244316;C4284232
777,medication use — no . ( % ) ^ |,C0013227;C3244316;C4284232
777,medication use — no . ( % ),C0013227;C3244316;C4284232
777,medication use  no . / total no . ( % ),C0013227;C3244316;C4284232
777,medication taken alone or in combination,C0013227;C3244316;C4284232
777,medication prior to admission  ( % ),C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
777,medication in use at the baseline,C0013227;C3244316;C4284232
777,medication continued into double - blind treatment period,C0013227;C3244316;C4284232
777,medication at randomization  n ( % ),C0013227;C0034656;C3244316;C4284232
777,medication at randomization  %,C0013227;C0034656;C3244316;C4284232
777,medication at randomization,C0013227;C0034656;C3244316;C4284232
777,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
777,medication $nmbr$ ( $nmbr$ . $nmbr$ ),C0013227;C3244316;C4284232
777,medication  n ( % ),C0013227;C3244316;C4284232
777,medication,C0013227;C3244316;C4284232
777,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
777,lipid medication  n ( % ),C0013227;C0023779;C3244316;C4284232
777,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
777,dm medication  n ( % ) c,C0011816;C0013227;C3244316;C3250443;C4284232
777,discharge medication  n ( % ),C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
777,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
777,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
777,creatinine $nmbr$ . $nmbr$ mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
777,concomitant pd medications at baseline  n ( % ) c  d,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
777,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications in > $nmbr$ % of subjects  no . ( % ),C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
777,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
777,concomitant medications ( yes )  n ( % },C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
777,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications  no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications  n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications  * n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications  %,C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
777,concomitant medication — no . { % ) | ace inhibitor,C0013227;C0521115;C3244316;C4284232
777,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
777,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
777,concomitant medication ( > $nmbr$ % ),C0013227;C0521115;C3244316;C4284232
777,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
777,concomitant medication  no . ( % ),C0013227;C0521115;C3244316;C4284232
777,concomitant medication  n [ % ],C0013227;C0521115;C3244316;C4284232
777,concomitant medication  n ( % ) d,C0013227;C0521115;C3244316;C4284232
777,concomitant medication  n ( % ),C0013227;C0521115;C3244316;C4284232
777,concomitant medication,C0013227;C0521115;C3244316;C4284232
777,concomitant asthma medications  n ( % ),C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
777,cardiac medications during indexhospitalization and / or discharge,C0013227;C0018787;C0802604;C1522601;C2598133;C4284232
777,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
777,cardiac medications during index hospitalization  %,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
777,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
777,cardiac medications during index hospital stay and / or discharge,C0013227;C0428776;C0802604;C2598133;C3489408;C4284232
777,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
777,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
777,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
777,baseline medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
777,baseline cv medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
777,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
777,any medication,C0013227;C3244316;C4284232
777,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
777,antithrombotic medications  n ( % ),C0013227;C0802604;C2598133;C4284232
777,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
777,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
777,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
777,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
777,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
777,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
777,> $nmbr$ concomitant medication,C0013227;C0521115;C3244316;C4284232
776,rest pain,C0234253
775,bodily pain,C3890602
774,uncertain,C0087130;C4085655
773,shoulder pain,C0037011
772,neoplasia  n ( % ),C0027651;C1882062
772,neoplasia,C0027651;C1882062
772,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
771,western european includinq australia  israel  and south africa,C0004340;C0022271;C0043128;C0239307;C0239312;C1535514
771,non - european trial,C0008976;C0239307;C1518422;C1535514
771,non - european,C0239307;C1518422;C1535514
771,european trial,C0008976;C0239307;C1535514
771,european subcategories,C0239307;C1515010;C1535514
771,european or arab,C0239307;C1535514
771,european,C0239307;C1535514
770,severity of copda  airflow limitation  n ( % ),C0231999;C0439793;C0443288;C0449295;C0522510
770,severity of copd  airflow limitation  n ( % ),C0024117;C0231999;C0439793;C0443288;C0449295;C0522510;C1412502;C3714496
770,severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
770,severity of airflow limitation ( gold $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
770,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
770,restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852
770,$nmbr$ = some restrictions  no help needed,C0443288
769,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
769,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
769,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1552654;C1552713;C4086878
769,interval from randomization to angiography,C0034656;C1272706;C1552654;C1552713
769,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
769,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
769,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
769,interval between clinical evaluation and initiation of treatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
768,centrilobular emphysema,C0221227
767,regional anaesthesia,C0002911
767,general anaesthesia,C0002915;C2930406
766,centrally acting sympathomimetics,C3653511
765,central america and south america,C0007674
764,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
764,neuraxial alonee,C3714787
764,central nervous system,C3540014;C3714787
763,other anti - platelet agents,C0005821;C0040616
762,nonaspirin antiplatelet agent,C0085826;C0722138
762,nonaspirin antiplatelet,C0722138
761,requiring assistance,C0018896;C1269765
761,$nmbr$ = help needed  still independent,C1269765;C1552861
760,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
760,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
760,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0542331;C1299392;C1442858
760,pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
760,pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
760,large shunt,C0232180;C0542331;C0549177;C1442858
760,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
760,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
760,assoc  with corrected congenital shunts,C0009678;C0205202;C0232180;C0542331;C1442858;C1744681
759,normal renal function,C0232805
758,erectile dysfunction,C0242350;C1961100
757,severe dysfunction,C3274777
756,cognitive functioning,C0392334;C0392335
755,social functioning,C0037395
755,social function,C0037395
754,physical functioning,C0516981;C4049916
754,physical function,C0516981;C4049916
754,assessment of physical function ( $nmbr$ - $nmbr$  haq - di ),C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C3826998;C4049916;C4321476
753,serious decline in kidney function *,C0205404;C0232804
753,serious decline in kidney function $nmbr$,C0205404;C0232804
753,renal function subgroups,C0232804;C1079230
753,renal function : ! : n ( % ),C0232804
753,renal function *,C0232804
753,renal function ( ml / min ),C0232804;C0439445
753,renal function  severe,C0232804
753,renal function  moderate,C0232804
753,renal function  bn ( % ),C0005005;C0034700;C0232804;C1706574;C4551963
753,renal function,C0232804
753,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0868945
752,black / african american *,C0085756
752,black / african american,C0085756
752,black / african - american ( $nmbr$ . $nmbr$ % ),C0085756
752,black / af rican american,C0085756;C0344434;C4049859
752,african - american / african heritage ( n = $nmbr$ ),C0085756;C2986513
751,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
751,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
751,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
751,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
751,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
751,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
751,non - black  us,C0005680;C0027567;C0085756;C0439541;C1518422
751,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
751,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
751,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
751,black or african heritage,C0005680;C0027567;C0085756;C0439541
751,black or african american,C0005680;C0027567;C0085756;C0439541
751,black or african america,C0005680;C0027567;C0085756;C0439541
751,black or african - american,C0005680;C0027567;C0085756;C0439541
751,black / african - american,C0085756
751,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541
751,african americans,C0085756
751,african american n = $nmbr$,C0085756
751,african american / black,C0005680;C0027567;C0085756;C0439541
751,african american  n ( % ),C0085756
751,african american,C0085756
751,african america,C0085756
751,african - latin american,C0085756
751,african - american,C0085756
751,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541
751,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
751,$nmbr$ fe black *,C0005680;C0027567;C0085756;C0439541;C3848561
750,non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
750,non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
750,non - black race ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
750,non - black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541;C1518422
750,non - black  worldwide,C0005680;C0027567;C0085756;C0439541;C1518422
750,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541
750,black race — no . / total no . ( % ) f,C0005680;C0027567;C0085756;C0439541
750,black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680
750,black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -,C0005680
750,black race ( n = $nmbr$ vs $nmbr$ ),C0005680
750,black race  n ( % ),C0005680
750,black race,C0005680
750,black or asian,C0005680;C0027567;C0085756;C0439541
750,black or african,C0005680;C0027567;C0085756;C0439541
750,black and other,C0005680;C0027567;C0085756;C0439541
750,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
750,black /,C0005680;C0027567;C0085756;C0439541
750,black *,C0005680;C0027567;C0085756;C0439541
750,black ( n — $nmbr$ ),C0005680;C0027567;C0085756;C0439541
750,black ( n   = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
750,black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
750,black  worldwide,C0005680;C0027567;C0085756;C0439541
750,black  us,C0005680;C0027567;C0085756;C0439541
750,black  no . ( % ),C0005680;C0027567;C0085756;C0439541
750,black  n ( % ),C0005680;C0027567;C0085756;C0439541
750,black,C0005680;C0027567;C0085756;C0439541
749,pasi ^ i,C0021966;C0221138;C4528685
749,pasi < $nmbr$ *,C4528685
749,pasi *,C4528685
749,pasi $nmbr$ a,C4528685
749,pasi $nmbr$  no . / total no . ( % ) $nmbr$,C4528685
749,pasi $nmbr$,C4528685
749,pasi # $nmbr$ at week $nmbr$,C0332174;C0439230;C4528685
749,pasi,C4528685
748,past smoker,C0337664;C1444637;C4284302
748,past or nonsmoker ( n = $nmbr$ ),C1444637;C4284302
748,past or nonsmoker,C1444637;C4284302
748,past or never,C1444637;C4284302
748,past or current angina pectoris,C1444637;C4284302
748,past or current,C1444637;C4284302
748,past,C1444637;C4284302
748,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
748,current / past smoker,C1444637;C3173209;C3241966;C4284302
747,ptca or pci,C2936173
747,ptca only,C0205171;C1720467;C2936173
747,ptca < $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
747,ptca / cabg,C0010055;C2936173
747,ptca,C2936173
747,prior ptca or pci,C0332152;C2826257;C2936173
747,prior ptca or cabg,C0332152;C2826257;C2936173
747,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
747,percutaneous transluminal coronary angioplasty,C2936173
747,both ptca and cabg,C2936173
746,perindopril - indapamide,C1273169
745,pctindopnl - indapamide ( n = $nmbr$ ),C0021186
744,tpm - naive,C0076829
744,tpm - exposed,C0076829
744,topiramate,C0076829
743,proximal to the splenic flexure,C0205107;C0227387;C4489236
743,proximal gl tract  n ( % ),C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
743,proximal gi tract,C0017189;C0205107;C4489236
743,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
743,proximal - mainleft,C0205107;C4489236
743,proximal,C0205107;C4489236
742,lower - limb angioplasty or bypass surgery,C0745788
741,coronary angioplasty or stenting,C0002997;C0190211
741,balloon angioplasty — no . ( % ),C0002996;C0002997
741,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
741,balloon angioplasty,C0002996;C0002997
740,pulmonary disease — no . ( % ),C0024115
740,pulmonary disease,C0024115
739,pulmonary embolism only,C0034065;C0205171;C1720467
739,pulmonary embolism,C0034065
738,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
738,st ‐ str ≥ $nmbr$ % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
738,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
738,post svc,C0231957;C0687676;C1704687;C3469826
738,post - salbutamol fev $nmbr$ / fvcb  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
738,post - salbutamol fev $nmbr$ ( l ) b  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
738,post - cabg,C0010055;C0687676;C1704687;C3469826
738,post - albuterol % predicted fev $nmbr$ mean ( sd ) e,C0001927;C0687676;C1704687;C3469826
738,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
737,lone atrial fibrillation — no . ( % ) §,C0340489
736,coronary risk factors — no . ( % ),C2024776
735,glatiramer acetate  no . ( % ),C0289884
734,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
733,abdominal aortic — no . ( % ),C0003484
732,dopamine agonist use  no . ( % ),C0178601;C3536925
731,fluindione  no . ( % ),C0117899
730,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
729,adults ( aged   ≥ $nmbr$ y )  no . ( % ),C0001675
729,adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % ),C0205653
728,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
728,elevated crp ( > ulnt )  n ( % ),C0742906
728,elevated crp  n ( % ),C0742906
727,simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /,C0033228;C0074554;C0332287;C1319635
727,fenofibrate ( n = $nmbr$ ),C0033228
726,fluticasone furoate and vilanterol ( n = $nmbr$ ),C1948374
726,fluticasone furoate  n = $nmbr$,C1948374
725,no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c,C0068000;C1948062
724,notatincreased fall risk ( n - $nmbr$  $nmbr$ ),C1268740
724,at increased fall risk ( n - $nmbr$ ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
723,riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ ),C0683610;C4553947
722,normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
722,low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
721,prevention )  n ( % ) patients on llt ( other than statin )  n ( % ),C0030705;C0199176;C1706420;C2347090;C2700409
721,gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$,C0199176;C1706420;C2700409
720,leeds enthesitis index ^ score > $nmbr$ — no . { % ),C0451148
720,leeds enthesitis index  mean ( sd ) ’ ’ * ’,C0444504;C0451148;C2347634;C2348143;C2699239
719,left ventricular systolic dysfunction  n ( % ),C1277187;C1963159;C4553199
718,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C1556315
718,right ventricular dysfunction  n / n ( % ) j,C0242707;C1556315
717,negative for helicobacter pylori — no . / total no . ( % ),C4688581
717,helicobacter pylori - negative  n ( % ),C4688581
716,method of identification ofstenosis ( % ),C1301921
715,current medication — no . ( % ),C0746467
715,current medication  n ( % ),C0746467
714,geographical location  n ( % ),C4545686
713,lacunar infarction  n ( % ),C0333559
712,injection - site reaction  n ( % ),C0151735;C4551923
711,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
711,maintenance use — no . ( % ),C0024501
711,maintenance ocs use  n ( % ),C0024501
710,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
709,draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177
708,abdominal or perianal fistula at baseline  n ( % ),C0000726
707,chronic sinusitis + nasal polypsd  n ( % ),C0028429;C0149516;C4520890
706,involved intestinal area  n ( % ),C0021853;C1879646
705,bone erosion ( judged by physician )  n ( % ),C0587240
704,residual perfusion defect > $nmbr$ % on lung scan  no . ( % ),C1457869;C1518040;C1609982
703,[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ ),C0043476
702,irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,C4082285
701,- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r,C0722969
700,vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
700,vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
700,vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
700,vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
700,vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
700,umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ ),C0205999
700,umec / vi $nmbr$ . $nmbr$ / $nmbr$,C0205999
700,hazard ratio  umec / vi vs . tio ( $nmbr$ % ci ),C0205999;C2985465
700,$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %,C0205999
700,$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %,C0205999
699,apo a - l ( g / l ),C0628062
698,tnf - r $nmbr$ a ( ng / ml ),C1363984;C1706001
697,tg  mmol / l [ mg / dl ],C0337445;C3642216;C3898312
697,tg  mmol / l ( mg / dl ) [ median ],C0337445;C0549183;C0876920;C2347635;C2348144;C2939193;C3642216;C3898312
697,tc  mmol / l ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3642216;C3898312;C4522122
697,ldl - c  mmol / l ( mg / dl ),C3642216;C3898312
697,hdl - c  mmol / l ( mg / dl ),C3642216;C3715113;C3898312
697,fpg  mmol / l ( mg / dl ),C3642216;C3898312
696,eos serum k +  meq / l,C0302353;C0439375;C1623465;C1861303
696,elevated bun ( > $nmbr$ . $nmbr$ meq / l ),C0151539;C0439375
696,baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
696,baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
696,baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
695,acarbose 一 no . ( % ),C0050393
694,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
693,pace  no . ( $nmbr$ ),C0287990;C1552930;C4048252
692,< $nmbr$ vr — no . ( % ),C3476815
692,$nmbr$ - $nmbr$ vr — no . ( % ),C3476815
691,age group — no . ( % ),C0027362;C2348001
691,age group ( ≥ $nmbr$ years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
691,age group ( ≥ $nmbr$ ) — no . ( % ),C0027362;C2348001
691,age group  no . ( % )  y,C0027362;C2348001
691,age group  no . ( % ),C0027362;C2348001
691,age cohort  no . ( % ),C2348001
690,hscrp > $nmbr$ . $nmbr$ mga .,C0065879
690,hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ ),C0065879
690,$nmbr$ / $nmbr$ mga ( n = $nmbr$ ),C0065879
689,nfs > $nmbr$ . $nmbr$ ( high ),C1555018
689,nfs < - $nmbr$ . $nmbr$ ( low ),C1555018
689,low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
689,high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
688,bilateral disease ( % ) ' j ' ' j ',C1511113
687,vascular disease indicator no ( n = $nmbr$ ),C0021212;C0042373;C1235732;C1522602
687,ischemic heart disease indicator no ( n = $nmbr$ l ),C0010054;C0021212;C0151744;C1235732;C1522602
686,patient ' s history of :,C0679831;C1369882
686,medical history  n ( % of patients ),C0679831;C1369882;C1609576
685,umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
685,tio $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
685,sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$,C0021027;C0305052;C0360506;C4521536
685,qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
685,olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
685,olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
685,ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
685,ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0205999;C0305052;C0360506;C4554348
685,ff $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506;C4554348
684,proteinuria ( > $nmbr$ g / $nmbr$ h )  %,C0033687;C0560020;C1962972;C4554346
684,proteinuria $nmbr$ ( g / day ),C0033687;C0439417;C1962972;C4554346
684,protein in urine    ≥ $nmbr$ +,C0033687
683,greater than or equal to $nmbr$ mm hg,C0439093
683,greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439093
683,greater than or equal to $nmbr$ %,C0439093
682,total group ( n = $nmbr$ ),C0439175;C0439810;C0441848
682,rate - control group ( n = $nmbr$ ),C0441848;C0489879
682,no epa group n = $nmbr$,C0441848
682,no - diuretics group ( n = $nmbr$ ),C0012798;C0441848
682,nc group ( n = $nmbr$ ),C0027964;C0028407;C0067895;C0265987;C0441848
682,group c ( n = $nmbr$ ),C0441848
682,group b ( n = $nmbr$ ),C0441848
682,group a ( n = $nmbr$ ),C0441848
682,fatty acid group ( n = $nmbr$ ),C0015684;C0441848
682,epa group n = $nmbr$,C0441848
682,diuretics group ( n = $nmbr$ ),C0012798;C0441848
682,device group ( n = $nmbr$ ),C0025080;C0441848;C0699733
682,colesevelam hydrochloride group ( n = $nmbr$ ),C0441848;C0541154
682,c group ( n = $nmbr$ ),C0441848
682,benazepril - hydrochlorothiazide group ( n = $nmbr$ ),C0441848;C0717481
682,benazepril - amlodipine group ( n = $nmbr$ ),C0051696;C0053091;C0441848
682,aspirin group ( n = $nmbr$ ),C0004057;C0441848
682,antiplatelet - only group ( n = $nmbr$ ),C0205171;C0441848;C1720467
682,antiplatelet - onl group ( n = $nmbr$ ),C0441848
681,risedronate n / n ( % ),C0246719
681,risedronate ( n   =   $nmbr$ ),C0246719
681,risedronate ( n = $nmbr$ ),C0246719
680,nintedanib ( n   =   $nmbr$ ),C2930789
680,nintedanib ( n = $nmbr$ ),C2930789
679,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
679,dha ( n = $nmbr$ ),C0142831;C2348308
678,drinker ( % ) a,C0556338
678,drinker ( % ),C0556338
678,drinker ( $nmbr$ to $nmbr$ drinks / week ),C0332174;C0439230;C0452428;C0556338
678,drinker ( $nmbr$ - $nmbr$ drinks / week ),C0556338
678,drinker  n ( % ),C0556338
677,s wave in v $nmbr$ ( mm ),C0456681;C4301968
676,s $nmbr$ gallop  n ( % ),C2986823
676,s $nmbr$ ( n = $nmbr$ ),C2986823
676,$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ ),C2986823
675,sr ii b $nmbr$ - cjl $nmbr$,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
675,rerapamil - sr strategy ( n = $nmbr$ ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
674,psoriasis body surface area > $nmbr$ %,C0005902;C0033860
674,affected body - surface area > $nmbr$ % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
673,pre - bronchodilator fevi / fvc  %,C0802741;C2599602;C3815113
673,fevi / fvc ( % ),C0802741;C3815113
672,angioedema present  n ( % ) {,C0002994;C0150312;C0449450
672,angioedema present  n ( % ) $nmbr$,C0002994;C0150312;C0449450
672,angioedema ( adjudicated )  n ( % ),C0002994
671,nutraceuticals  n ( % ),C1518478
671,any llt other than nutraceuticals  n ( % ),C1518478;C2347090
670,ca - channel blockers  n ( % ),C0870261;C3887642
669,tachyarrhythmias  n ( % ),C0080203
668,scalp psoriasis  n ( % ),C0406326
668,facial psoriasis  n ( % ),C1276112
667,type b $nmbr$ / c lesions  n ( % ),C4264484
666,> $nmbr$ y pathogenesis  n ( % ),C0543483;C0699748
665,injectable anti ‐ hyperglycaemic  n ( % ),C0432633;C1272883
665,anti ‐ tnf ‐ na ï ve    n   ( % ),C0042469;C0432633;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
665,anti ‐ hyperglycaemic agent  n ( % ),C0432633;C1321567
665,anti - tnf - naive  n ( % ),C0432633;C1448177
664,dose adjustment n ( % ),C2826232
663,nos $nmbr$ glu $nmbr$ asp g . t  n ( % ),C0125690;C0326287;C0439267;C1518425
663,nos $nmbr$ $nmbr$ c . t  n ( % ),C0326287;C1518425
663,nos $nmbr$ $nmbr$ a . g  n ( % ),C0326287;C1518425
662,digital clubbing  n ( % ),C0009080;C0149651
661,laba plus ics  n ( % ),C0332287;C0815320;C4551720
661,icsa plus laba  n ( % ),C0332287
660,smoking habit  n ( % ),C4505437
659,paternal history  n ( % ),C0424909
659,maternal history  n ( % ),C0559473
658,prior analgesic products  n ( % ),C0002771;C0332152;C2826257
658,analgesic medication  n ( % ),C0002771
657,low - trauma fracture since age $nmbr$  n ( % ),C0521170
656,bowel stricturing  ' n ( % ),C0267465
655,freedom from gtc seizures  n ( % ),C1299590
654,pr / virgin islands  n ( % ),C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
653,prothrombin mutation ( % ),C1610621
652,respiratory medication taken at baseline  n ( % ),C0418986
652,respiratory medication ( % ),C0418986
652,( b ) concomitant respiratory medications [ n ( % ) ],C0418986;C0521115
651,distal anastomosis ( % ),C0448964
650,fistula at baseline  n ( % ),C0016169;C0168634;C1442488
650,fistula  ' n ( % ),C0016169
649,chronic cardiovascular disease  no . ( % ),C1290380
648,mitral valve disease ( n = $nmbr$ $nmbr$ ),C0026265;C4553832
648,aortic valve disease ( n = $nmbr$ $nmbr$ ),C1260873;C4553103
647,pm  n ( % ),C0030266;C4049155
647,lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients ),C0030266;C0523452;C2611142;C4049155
646,avm ( n = $nmbr$ ),C0003857;C0279476
646,avm % △ ( se ),C0003857;C0036919;C0279476
645,jvp $ $nmbr$ cm h $nmbr$ o,C0455483
645,jvd $ $nmbr$ cm h $nmbr$ o  %,C0425687;C0455483
644,$nmbr$ % c . i .,C1547546
643,ama 士 s . e .,C0002461;C0279755;C2825862
643,am △ 士 s . e .,C3813124;C3890196;C4520798
642,tah ( n = $nmbr$ ),C0404079
642,dmab ( n = $nmbr$ ),C0012411
641,ivc ( n = $nmbr$ ),C4085887
641,igm ( n = $nmbr$ ),C1706005
641,igl ( n = $nmbr$ ),C0021037;C0314619;C2247518
641,ifx ( n = $nmbr$ ),C0020823
640,alive ( n = $nmbr$ ),C2584946;C4551704
639,peace ( n = $nmbr$ ),C0680443
638,sal ( n   = $nmbr$  $nmbr$ ),C0036140;C0037494;C0206136
638,sal ( n = $nmbr$ ),C0036140;C0037494;C0206136
637,sun - $nmbr$ ( $nmbr$ ),C0038817;C0376223
636,li $nmbr$ ( $nmbr$ . $nmbr$ ),C0023617;C3495095
635,ibs ( $nmbr$ . $nmbr$ ),C0022104;C0432306
634,no mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
634,mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
633,ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
633,ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
632,t ( n = $nmbr$  $nmbr$ ),C2986835
631,europa ( n = $nmbr$ l $nmbr$ ),C0242751
630,phi ( n = $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
630,phi ( n - $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
630,pgi - s  n ( % ) y :,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
629,wc ( cm ),C0013123;C2825512
628,exact ( b ),C2828393;C4050514
627,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
627,imt ( $nmbr$ ),C0334121;C1704614;C4318736
626,bl alc < $nmbr$ . $nmbr$ %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
626,alc at weeko ( % ),C1424945;C3811058
626,alc at week $nmbr$ ( % ),C0332174;C0439230;C1424945;C3811058
626,alc > = $nmbr$ . $nmbr$ %,C1424945;C3811058
626,alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,C1424945;C3811058
626,alc < $nmbr$ . $nmbr$ %,C1424945;C3811058
626,alc ( % ),C1424945;C3811058
625,normal weight ( bmi < $nmbr$ ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
625,normal ( bmi < $nmbr$ ),C4229017
624,ib ( $nmbr$ . $nmbr$ ),C2744579;C3890035;C4283819
624,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
623,platelet  $nmbr$ / l,C0456525
622,plaque ( n  % ),C0011389;C0241148;C0332461;C0333463;C4316797
621,plaque score ( $nmbr$ - $nmbr$ ),C0429153
620,lce  n = $nmbr$,C1423759;C3273355
619,vilanterol  n = $nmbr$,C2935023
618,range iga modified $nmbr$ score  n ( % ),C1514721;C2348147;C2825347;C3542016
618,iga $nmbr$ / $nmbr$,C2825347
617,racec  n ( % ),C4287599
616,fraction ( % ),C1264633;C1554103
615,strain ( % ),C0080194;C0456178;C1518614;C2987481
614,attack ( % ),C0277793;C1261512;C1304680
613,atv n ( % ),C0210243;C0674679;C1145759;C1334862
612,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
611,elms  n ( % ),C0330531;C2980688
611,el  n ( % ),C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
610,kl $nmbr$ ( % ),C1366480;C1416656;C1704887
609,aicd  ( % ),C0972395;C2611803;C3537205;C3546309
608,origin [ n ( % ) ],C0079946;C0439659;C1550512
607,hla - b $nmbr$  n ( % ) ⁎ ⁎,C1426226
606,cgi - s  n ( % ) z :,C4526016
605,infected  n ( % ) a,C0439663
604,necrosis  n ( % ) a,C0027540;C1334928
603,clean  n ( % ) a,C1947930
602,alprostadil n / n %,C0002335
602,alprostadil n / n,C0002335
602,alprostadil ( n = $nmbr$ ),C0002335
601,aggressive ( n = $nmbr$ ),C0001807;C0580822
601,aggressive ( $nmbr$ ),C0001807;C0580822
600,vasp pri - defined hpr ( % patients ),C0034044;C0255567;C1421428;C1826843;C3539761;C3539762
599,low risk ( ri = $nmbr$ - $nmbr$ ),C0035487;C1826843;C3272281;C3538919
599,( ri = $nmbr$ ),C0035487;C1826843
598,ixekizumab every $nmbr$ weeks ( n = $nmbr$ ),C3489764
597,certolizumab pegol ( n = $nmbr$ ),C1872109
597,certolizumab group ( n = $nmbr$ ),C0441848;C1872109
596,post - fibrinolysis angioplasty ( n = $nmbr$ ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
596,fibrinolysis ( n = $nmbr$ ),C0016017;C1305868
595,levosimendan ( n   = $nmbr$ ),C0246904
594,nebivolol ( n = $nmbr$ ),C0068475
593,oxypurinol ( n = $nmbr$ ),C0030086
592,blisibimod ( n = $nmbr$ ),C3713826
591,roflumilast ( n = $nmbr$  $nmbr$ ),C0965618
590,montelukast ( n = $nmbr$ ),C0298130
589,inconsistent fao ( n [ $nmbr$ ),C0016457;C0442809
588,colesevelam ( n = $nmbr$ ),C0541155
587,cholecystectomy ( n = $nmbr$ ),C0008320
586,normotensive ( n = $nmbr$ ),C2712122
585,no colchicine ( n = $nmbr$ ),C0009262
585,colchicine ( n = $nmbr$ ),C0009262
584,readmission ( n = $nmbr$ ),C1548168;C4489276
584,no readmission ( n = $nmbr$ ),C1548168;C4489276
583,bempedoic acid ( n = $nmbr$ ),C3659310
582,semuloparin ( n = $nmbr$ ),C2700104
581,dalteparin ( n = $nmbr$ ),C0206461
580,solifenacin ( n = $nmbr$ ),C1099677
580,sildenafil ( n = $nmbr$ ),C0529793
579,mar ( itt ) ( n = $nmbr$ ),C3829202;C4255469
578,r $nmbr$ + ezio ( n = $nmbr$ ),C0687673
578,r $nmbr$ ( n = $nmbr$ ),C0687673
577,£ $nmbr$ yo ( n = $nmbr$ ),C1413296
577,< $nmbr$ yo ( n = $nmbr$ ),C1413296
576,$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ ),C1881833
575,umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ ),C0439211;C3463985
575,tio i $nmbr$ mcg ( n = $nmbr$ ),C0021966;C0221138;C0439211;C3463985
574,metoprolol group ( n = $nmbr$ ),C0025859;C0441848
574,metoprolol ( n = $nmbr$ $nmbr$ ),C0025859
573,monitoring group ( n = $nmbr$ ),C0150369;C0441848;C1283169
573,monitoring ( n = $nmbr$ ),C0150369;C1283169
572,> $nmbr$ days to $nmbr$ year ( n = $nmbr$ ),C0556972
571,non - carrier ( n = $nmbr$ ),C2986416
570,entocort ec ( n = $nmbr$ ),C1170256
569,tirofiban ( n = $nmbr$ ),C0247025
569,heparin ± tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
569,heparin plus tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0332287;C0770546
569,heparin + tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
568,$nmbr$ early intervention ( n = $nmbr$ ),C0242687;C1964029
567,eplerenone ( n   = $nmbr$ ),C0961485
566,canrenone ( n z $nmbr$ ),C0006882
565,teriparatide n / n ( % ),C0070093
565,teriparatide ( n   =   $nmbr$ ),C0070093
564,ularitide n / n ( % ),C0077910
564,ularitide ( n = $nmbr$ ),C0077910
563,hypertrophy per ecg ( n = $nmbr$ $nmbr$ ),C0020564;C1623258
563,hypertrophy  n ( % ),C0020564
562,unbound pcsk $nmbr$ ( nmol / l ),C0439282
562,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
562,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
562,testosterone ( nmol / l ),C0039601;C0439282
562,hscrp ( nmol / l ),C0439282
562,cholesterol ( nmol / l ),C0008377;C0439282
561,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
561,$nmbr$ - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
560,phosphorus  mmol $nmbr$ $nmbr$,C0031705;C0080014;C0439190;C3714498
559,glycemic variability  mmol / lc,C0005802;C0439190;C2827666
559,fpg ( mmol / $nmbr$ ),C0439190
559,fpg  mmol / lt,C0023376;C0230426;C0439190;C3887647;C4521399
558,homa - ir ( mu / l ^ mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
558,homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b,C0022065;C0022071;C0439190;C0439342;C0444504;C1448132;C2347634;C2348143;C2699239
558,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
558,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
558,> $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
558,> $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
558,< $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
558,< $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
558,( mu / l $ mmol / l ) b,C0439190;C0439342
557,troponin i ( pg / ml ),C0077401;C0439297
557,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
557,n - terminal pro - brain natriuretic peptide  pg / ml,C0439297;C3272900
557,endothelin $nmbr$ ( pg / ml ),C0079284;C0439297
557,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
557,avp pg / ml,C0439297;C1098706;C1568204;C1708407
557,> $nmbr$ ng / l,C0439297
556,kim $nmbr$ ( pg / ml ),C0439297
556,interleukin - $nmbr$ ( ng / l ),C0021764;C0439297;C1527200
556,interleukin $nmbr$ ( pg / ml ),C0021764;C0439297;C1527200
556,il - $nmbr$ range  ng / l,C0020898;C0021764;C0022271;C0439297;C1514721;C2348147;C3542016
556,il - $nmbr$ ( pg / ml ),C0020898;C0021764;C0022271;C0439297
556,il - $nmbr$  ng / l,C0020898;C0021764;C0022271;C0439297
556,> ulnand < $nmbr$ ng / l,C0439297
555,tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$,C0439297
555,tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$,C0439297
555,nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0439297;C1095989;C1317554;C1417808;C2825907;C2982014;C4284038
555,np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
555,np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
555,normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205307;C0231683;C0439166;C0439297;C1095989;C1417808;C2347086;C2982014;C4553972
555,elevated bnp ( $nmbr$ pg / ml )  %,C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
555,elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
555,bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp > $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp > $nmbr$ pg / ml  n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
555,bnp < $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
555,> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
555,> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
555,> = $nmbr$ ng / l ( n = $nmbr$ ),C0439297
555,> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
555,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
555,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ),C0439297
555,$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
555,$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
554,serum total ige  iu / ml,C0439458;C1441420
554,anti - dsdna ( > $nmbr$ iu / ml )  %,C0439458;C0741099
553,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
553,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
553,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
553,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
553,fasting serum glucose  mg / dl,C0015663;C0202041;C0439269;C3534430
553,fasting serum glucose  median ( sd )  mg / dl,C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3534430
553,fasting serum glucose  mean ( sd ) mg / dl,C0015663;C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
552,feno  $nmbr$ mg dn = $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
552,feno  $nmbr$ dn = $nmbr$ ),C1333964;C1707618
552,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) ',C1319635;C1333964;C1707618
552,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ),C1319635;C1333964;C1707618
551,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
551,plasma lipoproteins  mmol / l,C0023820;C0032105;C1532563;C1550098;C4521445
551,plasma creatine  mg / dl,C0010286;C0032105;C0439269;C1550098;C4521445
550,neutrophils  $nmbr$ / nl,C0027778;C0027950;C0560008;C3892223
550,monocytes  $nmbr$ / nl,C0026473;C0027778;C0560008;C3892223
550,leukocytes  $nmbr$ / nl,C0023516;C0027778;C0560008;C3892223
549,lansoprazole ( n = $nmbr$ ),C0050940
549,lansoprazole $nmbr$ mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
548,三 $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
548,≥ $nmbr$ to < $nmbr$ %,C0040363;C0041260;C1883351
548,study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental,C0031809;C0037712;C0040363;C0041260;C0205485;C0229992;C0348078;C0376315;C0449432;C0557651;C1282927;C1509143;C1522492;C1551338;C1705248;C1806781;C1883351;C2350002;C2603343;C3481509;C4255237;C4554251
548,naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes,C0040363;C0041260;C0199168;C0205476;C1274040;C1883351
548,> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
548,> $nmbr$ to s $nmbr$ yrs,C0040363;C0041260;C1883351
548,> $nmbr$ to < $nmbr$ uln,C0040363;C0041260;C1519815;C1883351
548,> $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
548,> $nmbr$ to $nmbr$,C0040363;C0041260;C1883351
548,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
548,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
548,> $nmbr$ % to < $nmbr$ %,C0040363;C0041260;C1883351
548,$nmbr$ to less than $nmbr$,C0040363;C0041260;C1883351
548,$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ ),C0040363;C0041260;C1883351
548,$nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
548,$nmbr$ to < $nmbr$ ( % ),C0040363;C0041260;C1883351
548,$nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
548,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % ),C0040363;C0041260;C1883351
548,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
548,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
548,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
548,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
548,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
548,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
547,non ‐ haemorrhagic stroke — no . ( % ),C0333275;C1518422
547,hemorrhagic,C0333275
547,haemorrhagic,C0333275
546,• hemorrhagic stroke,C0553692
546,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
546,hemorrhagic stroke ( n = $nmbr$ ),C0553692
546,hemorrhagic stroke,C0553692
546,haemorrhagic stroke — no . ( % ),C0553692
546,haemorrhagic stroke,C0553692
545,hematocrit  %,C0018935;C0518014
544,hematologic,C0018943;C0205488
544,haematological,C0018943;C0200627
543,fragile,C0302113
543,e major non - vertebral fragility fractures ( fas ),C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
543,d non - vertebral fragility fractures ( fas ),C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
542,verapamil ( n  % ),C0042523
542,use of verapamil or quinidine,C0042523;C1524063
541,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
541,characteristics no . of participants,C1521970
541,characteristics *,C1521970
541,characteristics,C1521970
541,characteristic_name,C0027365;C1521970;C1547383;C4522128
541,characteristic †,C1521970
541,characteristic at baseline,C0168634;C1442488;C1521970
541,characteristic and treatment,C1521970
541,characteristic age — yr,C0001779;C0439234;C1521970
541,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
541,characteristic age,C0001779;C1521970
541,characteristic ^,C1521970
541,characteristic / outcome,C1274040;C1521970
541,characteristic *,C1521970
541,characteristic ( a ),C1521970
541,characteristic,C1521970
540,infarct characteristics,C0021308;C1521970
540,glycemic characteristics,C0005802;C1521970
540,ed characteristics,C1521970;C3538926
540,e ( characteristic n,C1521970
540,characteristic  no . ( % ),C1521970
540,arthritis characteristics,C0003864;C1521970;C4552845
540,anthropometric characteristics,C0003188;C1521970
540,angiographic characteristics  no . ( % ),C0002978;C1521970
539,number ( s ) of features present,C0237753;C0449788;C1521970;C1706388;C2346469;C2348519
539,feature,C1521970;C1706388;C2346469;C2348519
539,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
538,metastatic disease,C0027627;C2939419;C2939420
537,secondary p,C0027627;C0175668;C0205436
537,secondary outcomes,C0027627;C0175668;C0205436;C1274040
537,secondary outcome,C0027627;C0175668;C0205436;C1274040
537,secondary nonresponse,C0027627;C0175668;C0205436
537,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
537,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
537,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
537,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
537,secondary end points $nmbr$,C0027627;C0175668;C0205436;C2349179
537,secondary end points,C0027627;C0175668;C0205436;C2349179
537,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
537,secondary *,C0027627;C0175668;C0205436
537,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
537,secondary # $nmbr$,C0027627;C0175668;C0205436
537,key secondary end points,C0027627;C0175668;C0205436;C2349179
536,recent use of allopurinol ( within $nmbr$ days of,C0002144;C0332185;C1524063
536,recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % ),C0013778;C0332185;C0439228
536,recent cardioversion ( within $nmbr$ days before randomization ) —,C0013778;C0332185;C0439228
536,recent,C0332185
535,oral contraceptives,C0009905
535,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151
534,relative risk ( $nmbr$ % confidence interval ),C0009667;C0242492
534,$nmbr$ % confidence interval,C0009667
533,elective surgery,C0206058
533,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
532,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
532,select lipids and lipoproteins,C1707391
531,percentages,C0439165;C1549488;C1561533
531,percentage with disease duration < $nmbr$ years,C0439165;C0439234;C0872146;C1549488;C1561533
531,percentage points,C0439165;C1549488;C1561533
531,percentage of p,C0439165;C1549488;C1561533
531,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
531,percentage of females,C0086287;C0439165;C1549488;C1561533
531,percentage of days without heartburn,C0439165;C0439228;C1549488;C1561533
531,percentage of bsa involved,C0439165;C1549488;C1561533
531,percentage,C0439165;C1549488;C1561533
531,mean percentage of nights without heartburn,C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
531,between - treatment comparison of percentage change from baseline in total hip bmd,C0439165;C1299575;C1549488;C1561533;C1707455
530,percentage of time in therapeutic inr range  mean ( sd ),C0040223;C0439165;C1549488;C1561533;C3541383
530,percent work time missed due to asthma,C0040223;C0043227;C0439165;C3541383
530,percent overall work impairment due to asthma,C0439165
530,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C3541383
529,pci indication,C0392360;C3146298;C4049621
529,indication for stent,C0038257;C0392360;C3146298
529,indication for pci,C0392360;C3146298;C4049621
529,indication,C0392360;C3146298
528,intermittent claudication,C0021775
528,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
528,claudication ( fontaine class > $nmbr$ ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
528,claudication,C0021775;C0311395;C1456822
527,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
527,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
527,inclusion criteria — no . ( % ),C1512693
527,inclusion criteria,C1512693
527,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C1512693;C3251812
526,included in this study ( n = $nmbr$ ),C0332257;C0557651;C2603343
526,( including hypertension ),C0332257
525,symptomatic localization - related,C0231220;C0475264;C1744691
525,infarct localization  n ( % ),C0021308;C0475264;C1744691
525,infarct localization,C0021308;C0475264;C1744691
525,infarct localisation,C0021308;C0475264;C1744691
525,disease localization ' ’  n ( % ),C0012634;C0475264;C1744691
525,disease localization  n ( % ),C0012634;C0475264;C1744691
525,cryptogenic localization - related,C0332240;C0475264;C1744691
524,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
524,bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
524,bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
524,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
524,bifurcation  n ( % ),C0184906;C3146289
524,bifurcation,C0184906;C3146289
523,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
523,qualifying myocardial infarction,C1514624
523,qualifying mi < $nmbr$ yrs prior,C1514624;C3810814
523,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
523,qualifying mi $ $nmbr$ yrs prior,C1514624;C3810814
522,qualifying high - risk features — %,C1514624
522,qualifying hba $nmbr$ c ( % ),C0019016;C1514624;C1825777;C3538758
521,qualifying symptomatic event  n ( % ) a,C1514624
521,qualifying peripheral arterial disease,C1514624
521,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
521,qualifying events,C0441471;C1514624;C3541888
521,qualifying event — no . ( % ),C0441471;C1514624;C4019010
521,qualifying event,C0441471;C1514624;C4019010
521,qualifying cv event  n ( % ),C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
521,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
521,pciperformed for qualifying event,C0441471;C1514624;C4019010
521,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
521,at qualifying event,C0441471;C1514624;C4019010
521,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C4019010
521,anatomic extent of qualifying event  n ( % . ) x,C0220784;C0439792;C0441471;C1514624;C4019010
520,patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C1512346;C3810541;C3811131;C4086268
520,patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030673;C4086268
519,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C4086268
519,exacerbations requiring hospitalisation ( past year ) ( % ),C4086268
519,exacerbations in previous $nmbr$ mo ( n )  mean ( sd ),C0026544;C0205156;C0332177;C0444504;C1552607;C2347634;C2348143;C2699239;C4086268
519,exacerbations in past $nmbr$ mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
519,exacerbation within previous $nmbr$ mo  no . ( % ),C0026544;C0205156;C0332177;C1552607;C4086268
519,exacerbation within $nmbr$ mo  %,C0026544;C0332177;C4086268
519,exacerbation historyh  n ( % ),C4086268
518,patients with > $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268
518,patients with > $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268
518,patients with > $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268
518,patients with > $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268
518,no . of exacerbations in past year,C4086268
518,exacerbations in the year before study,C0439234;C0439508;C4086268
518,exacerbations in the prev . year : $nmbr$,C0439234;C0439508;C1552852;C4086268
518,exacerbations in the past $nmbr$ months n,C4086268;C4331910
518,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
518,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
518,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
517,s $nmbr$ exacerbations,C0565930;C2603362;C4086268
517,hospitalized for an exacerbation,C0701159;C4086268
517,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
517,exacerbations,C4086268
517,> $nmbr$ exacerbations,C4086268
517,$nmbr$ exacerbations,C4086268
517,$nmbr$ exacerbation,C4086268
517,$ $nmbr$ exacerbations,C4086268
516,use of cgm interaction test p - value ^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
516,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
516,pvaluefor interaction $nmbr$ - $nmbr$,C1704675
516,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C1704675;C1709380
516,p value for interaction by region,C1704675;C1709380
516,p value for interaction - dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
516,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
516,p value for interaction ( age continuous ),C0001779;C1704675;C1709380
516,p value for interaction  dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
516,p - value for interaction *,C1704675;C1709380
516,p - value for interaction $nmbr$ :,C1704675;C1709380
516,p - value for interaction $nmbr$ . $nmbr$,C1704675;C1709380
516,interaction p value 中,C1704675;C1709380
516,interaction p value ∗,C1704675;C1709380
516,interaction p value §,C1704675;C1709380
516,interaction p value *,C1704675;C1709380
516,interaction p value $nmbr$ . $nmbr$,C1704675;C1709380
516,interaction p value !,C1704675;C1709380
516,interaction p value,C1704675;C1709380
516,interaction p vaiue,C1704675
516,interaction p - valuef,C1704675
516,interaction p - value *,C1704675;C1709380
516,interaction p - value $nmbr$,C1704675;C1709380
516,interaction p - value,C1704675;C1709380
516,interaction p - vaiue,C1704675
516,interaction j $nmbr$ - valuet,C1704675
516,interaction : treatment by psoriasis p valueb,C1704675;C3258078
516,interaction : treatment by psoriasis p value $nmbr$,C1704675;C1709380;C3258078
516,age - interaction,C0001779;C1704675
516,/ ’ interaction,C1704675
515,p interaction = $nmbr$ . $nmbr$,C0369773;C1704675;C2603361
515,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
515,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
515,interaction p = $nmbr$ . $nmbr$,C1704675
514,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
514,rvalue for interaction,C1704675
514,pfor interaction,C1151635;C1704675
514,lue for interaction,C1704675
514,interaction pf,C1704675;C3815179
514,interaction p,C1704675
514,interaction - p,C1704675
514,interaction $nmbr$,C1704675
514,interaction,C1704675
514,albuminuria_p_interaction,C0001925;C1704675
514,( $nmbr$ % cl ) interaction,C0596019;C1704675
513,influenza,C0021400;C0021403
512,insufficient,C0205412;C0231180;C0439856
512,inadequate,C0205412;C0439856
511,ment,C0084844;C1538994
510,nnt,C1417750
509,selena - sledai total score,C0451528;C2964552
509,selena - sledai > $nmbr$  %,C0451528
508,irregular or ulcerated ica plaquef,C0205271
508,irregular or ulcerated ica p ) laque : [ :,C0205271
507,locally advanced,C1517927
506,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
506,sexually active $nmbr$ ( % ),C0241028
506,sexually active,C0241028
505,delayed reaction,C0205421;C0443286;C1545665;C3272602
505,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
505,delayed - start group ( n = $nmbr$ ),C0205421;C0439659;C0441848;C1545665;C3272602
505,delayed - eptifibatide group ( n = $nmbr$ ),C0205421;C0253563;C0441848;C1545665;C3272602
505,delayed,C0205421;C1545665;C3272602
504,use of antihypertensive drugs,C0003364;C1524063
504,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
504,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
504,patients on antihypertensive medications  n ( % ) | |,C0003364;C0030705
504,other blood pressure - lowering drugs,C0003364
504,other blood - pressure drug,C0003364
504,other antihypertensive medications,C0003364
504,other antihypertensive drug,C0003364
504,one antihypertensive medication,C0003364;C0205447
504,no antihypertensive medication,C0003364
504,any blood - pressure - lowering drug 一 no . ( % ),C0003364
504,any antihypertensive drug,C0003364
504,antihypertensives  n ( % ),C0003364
504,antihypertensive treatments,C0003364;C0087111
504,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
504,antihypertensive medication or,C0003364
504,antihypertensive medication ),C0003364
504,antihypertensive medication $nmbr$ ',C0003364
504,antihypertensive medication,C0003364
504,antihypertensive agents ( n per patient ),C0003364;C0030705
504,antihypertensive agents  n ( % ),C0003364
504,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
504,> $nmbr$ antihypertensive medications,C0003364
504,> $nmbr$ antihypertensive medication  no . ( % ),C0003364
504,$nmbr$ antihypertensive medication,C0003364
503,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
503,other antihypertensive agents,C0003364
503,other antihypertensive,C0003364
503,other anti - hypertensives,C0003364
503,other anti - hypertensive,C0003364
503,any antihypertensive agent,C0003364
503,any anti - hypertensive agent,C0003364
503,antihypertensives ' *,C0003364
503,antihypertensives,C0003364
503,antihypertensive use,C0003364;C0042153;C0457083;C1947944
503,antihypertensive medication use  n ( % ),C0003364;C0042153;C0457083;C1947944
503,antihypertensive medication  open - label  no . ( % ),C0003364
503,antihypertensive drugs,C0003364
503,antihypertensive drug  %,C0003364
503,antihypertensive agents *,C0003364
503,antihypertensive agents,C0003364
503,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
503,antihypertensive,C0003364
503,anti - hypertensives,C0003364
503,anti - hypertensive,C0003364
502,untreated at baseline,C0168634;C0332155;C1442488
502,untreated,C0332155
501,new zealand,C0027978;C0324547
501,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
500,transaminases increased,C0002594;C0919834
499,osteoprotegerin decreased,C0538161;C1308614;C1336645
498,pancreas,C0030274
497,ggt increased,C1415053
496,q wave,C0429089;C1305738
496,non - q wave,C0429089;C1305738;C1518422
496,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
495,stable angina — no . ( % ),C0340288
495,stable angina ( n = $nmbr$  $nmbr$ ),C0340288
495,stable angina ( n - $nmbr$  $nmbr$ ),C0340288
495,stable angina  n ( % ),C0340288
495,stable angina,C0340288
495,histor y of stable angina,C0340288
495,chronic stable angina,C0340288
494,sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg,C0443318;C2732140
494,sustain $nmbr$ : semaglutide vs . placebo,C0443318;C2732140
494,sustain $nmbr$ : semaglutide vs . iglar,C0443318;C2732140
494,sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg,C0443318;C2732140
494,sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo,C0443318;C2732140
494,sustain $nmbr$,C0443318;C2732140
494,sustain,C0443318;C2732140
493,• unstable angina,C0002965
493,unstable angina — no . ( % ),C0002965
493,unstable angina §,C0002965
493,unstable angina age,C0001779;C0002965
493,unstable angina > $nmbr$ mo ago,C0002965;C0026544;C0332177
493,unstable angina *,C0002965
493,unstable angina ( n = $nmbr$  $nmbr$ ),C0002965
493,unstable angina  n ( % ),C0002965
493,unstable angina,C0002965
493,rest angina past $nmbr$ h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
493,rest angina but not past $nmbr$ h,C0002965;C0152172
493,rest angina,C0002965;C0152172
493,no rest angina,C0002965;C0152172
493,histor y of unstable angina,C0002965
493,* * * unstable angina,C0002965
492,worsening angina,C0002965
492,due worsening angina,C0002965;C0678226;C3146286
491,tnf antagonist - naive ®,C0231491;C1448177
491,tnf antagonist - naive subgroup ( n - $nmbr$ ),C0231491;C1079230;C1448177;C1515021
491,tnf antagonist - naive ' ’,C0231491;C1448177
491,tnf antagonist - exposed,C0231491;C1448177
491,tnf antagonist,C0231491;C1448177
491,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
491,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
491,prior tnf antagonist  n [ % ] ‘ *,C0231491;C0332152;C1448177;C2826257
491,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
491,antagonist,C0231491
490,ras antagonist  %,C0034678;C0231491;C0525678
490,miami k antagonist received,C0231491;C0597277;C1551421;C1708601
490,adp antagonist,C0231491;C0523452
489,vitamin k antagonist naive,C1096489;C2267235
489,vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ ),C1096489;C2267235
489,vitamin k antagonist experienced  n ( % ),C1096489;C2267235
489,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
489,vitamin k antagonist,C1096489;C2267235
489,previous use of vitamin k antagonist for > $nmbr$ days — no . ( % ),C0205156;C1096489;C1524063;C1552607;C2267235
489,long - term vitamin k antagonist,C0443252;C1096489;C2267235
488,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
488,heparins and fondaparinux,C0019134
488,heparin only,C0019134;C0205171;C0770546;C1720467
488,heparin dose regimen,C0019134;C0770546;C2348331
488,heparin  ‘ ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546
488,heparin  fondaparinux or brvalirudin use between - oex event,C0019134;C0770546;C1098510
488,heparin,C0019134;C0770546
488,additional heparin,C0019134;C0770546;C1524062
487,unfractionated heparin — no . ( % ),C0019134;C2825026
487,unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % ),C0019134;C2825026
487,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0019134;C2825026
487,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
487,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
487,unfractionated heparin ( n = $nmbr$ ),C0019134;C2825026
487,unfractionated heparin ( n = $nmbr$  $nmbr$ ),C0019134;C2825026
487,unfractionated heparin,C0019134;C2825026
487,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C2825026
487,both unfractionated heparin and low - molecular - weight heparin,C0019134;C2825026
486,favors dabigatran,C0309049;C2348066
486,factors dabigatran,C1521761;C2348066;C2827422
485,dabigatran ( n = $nmbr$ ),C2348066
485,dabigatran $nmbr$   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066
485,dabigatran $nmbr$ vs . warfarin p ( inter ),C2348066
485,dabigatran $nmbr$ mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
485,dabigatran $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran  $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran  $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,dabigatran,C2348066
485,$nmbr$ mg dabigatran ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
485,$nmbr$ mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
484,brazil,C0006137
483,brachial,C0445456
482,basal only,C0205112;C0205171;C1720467
482,basal,C0205112
481,rash,C0015230
480,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
479,cyclosporine ( n = $nmbr$ ),C0010592;C0010594
479,cyclosporin,C0010592;C0010594
478,ticlopidine ( n = $nmbr$ ),C0040207
478,ticlopidine,C0040207
477,diclofenac group ( n = $nmbr$ $nmbr$ ),C0012091;C0441848
477,diclofenac ( n = $nmbr$ ),C0012091
477,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091
477,diclofenac ( n = $nmbr$  $nmbr$ ),C0012091
477,diclofenac,C0012091
476,microalbuminuria — no . / total no . ( % ),C0730345
476,microalbuminuria — no . ( % ),C0730345
476,microalbuminuria or proteinuria,C0730345
476,microalbuminuria or macroalbuminuria §,C0730345
476,microalbuminuria or macroalbuminuria,C0730345
476,microalbuminuria ( uacr $nmbr$ – $nmbr$ ),C0730345
476,microalbuminuria  n ( % ),C0730345
476,microalbuminuria  mg / g cr,C0201975;C0730345;C1300563;C3539604;C3711669;C4084730;C4553336;C4553337
476,microalbuminuria,C0730345
476,high microalbuminuria to macroalbuminuria ( n = $nmbr$ ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
475,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
475,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
475,micro - or macroalbuminuria  no . ( % ),C0085672;C1553035;C3811161;C4049106
475,micro - or macroalbuminuria  n ( % ) §,C0085672;C1553035;C3811161;C4049106
475,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
475,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0085672;C1553035;C1561643;C2984010;C3811161;C4049106
475,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
474,latin america or south africa,C0023122
474,latin america hr ( $nmbr$ % cl ),C0023122;C0596019
474,latin america ( n = $nmbr$ ),C0023122
474,latin america,C0023122
473,latin american subgroup,C1079230;C1515021;C1553378
473,latin american,C1553378
472,native american or alaskan native,C0282204;C1515945
472,native american or alaska native,C0282204;C1515945
472,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
472,native american,C0282204;C1515945
471,inhaled anticholinergic §,C0004048;C0242896;C3537004
471,anticholinergics,C0242896;C3537307;C3540711
471,anticholinergic use  n ( % ),C0042153;C0242896;C0457083;C1947944;C3537004
471,anticholinergic drug,C0242896
471,anticholinergic,C0242896;C3537004
471,anti - cholinergics ( short - acting ) a,C0242896
471,anti - cholinergics ( long - acting ),C0242896
470,criterion reached first  n ( % ),C0243161
470,criteria for subcortical vad ( by mri )  %,C0077973;C0243161;C0815275
470,by who / simon broome criteria,C0243161;C0443058
469,entry criteria ( % ),C0243161;C1705654
469,entry criteria,C0243161;C1705654
469,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
469,criterion,C0243161
469,clinical criteria $nmbr$,C0205210;C0243161
468,acute infection without septic shock,C0036983;C0275518
467,measured at home with automated device,C0444706;C3541902
467,measured at clinic visit with usual device,C0008952;C0444706;C3541902
467,measured at clinic visit with automated device §,C0008952;C0444706;C3541902
466,less than high school,C0439092;C0599395;C0683862;C0870649
466,education  high school or higher,C0683862
465,no antianginal drug,C0013227;C1254351;C1874267;C3537168
465,new anti - anginal therapy,C1874267;C3242274;C3537168
465,intensification of antianginal therapy,C1511484;C1874267;C3537168
465,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
465,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C1874267;C3537168
465,$nmbr$ antianginal drugs,C0013227;C1874267;C3537168;C3687832
465,$nmbr$ antianginal drug,C0013227;C1254351;C1874267;C3537168
464,use of antiarrhythmic agent,C0003195;C0301380;C1524063
464,other antiarrhythmics ^,C0003195
464,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
464,antiarrhythmics,C0003195
464,antiarrhythmic drugs    n   ( % ),C0003195
464,antiarrhythmic drug,C0003195;C0301380
464,antiarrhythmic agent,C0003195;C0301380
464,antiarrhythmic,C0003195;C3537142
464,anti arrhythmic,C0003195;C3537142
463,physician ' s judgment that vka inappropriate ],C0022423;C0031831;C0804815
463,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815
463,physician ' s judgment that vka,C0022423;C0031831;C0804815
463,physician ' s ga  $nmbr$ - $nmbr$ mmvas,C0016993;C0031831;C0804815
463,physician,C0031831;C0804815
462,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1709908
462,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1511726;C1709908;C3245479;C3714741
461,puerto rican,C0034043
460,puerperium,C0034042;C0086839;C1879329
459,upper limb fracture,C0178316
458,upper limbs,C1140618
458,upper limb fractures,C1140618
458,upper limb,C1140618
457,inferior mi *  %,C0340305;C3542426
456,anterior mi,C3536746
455,inferior or posterior,C0542339;C0678975
455,inferior / posterior,C0205095;C0542339;C0678975
455,inferior ( n  % ),C0542339;C0678975
455,inferior ( % ),C0542339;C0678975
455,inferior,C0542339;C0678975
454,hyperkalemia * ’,C0020461;C4552983
454,hyperkalemia ( > $nmbr$ . $nmbr$ meq / l ),C0020461;C0439375;C4552983
454,hyperkalemia  n ( % ),C0020461;C4552983
454,hyperkalaemia ( investigator reported ),C0020461;C0035173;C4552983
454,hyperkalaemia,C0020461;C4552983
453,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C4555212
453,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
453,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
453,hyperlipidemia §,C0020473;C0428465;C4555212
453,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
453,hyperlipidemia | |,C0020473;C0428465;C4555212
453,hyperlipidemia ^,C0020473;C0428465;C4555212
453,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
453,hyperlipidemia ( % ),C0020473;C0428465;C4555212
453,hyperlipidemia  n / n ( % ),C0020473;C0428465;C4555212
453,hyperlipidemia  n ( % ),C0020473;C0428465;C4555212
453,hyperlipidemia  %,C0020473;C0428465;C4555212
453,hyperlipidemia,C0020473;C0428465;C4555212
453,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
453,hyperlipidaemia  n ( % ) yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
453,hyperlipidaemia,C0020473;C0428465;C4555212
452,interquartile range — yr,C0439234;C1711350
452,interquartile range — ml / min,C0439445;C1711350
452,interquartile range height — cm,C0489786;C1711350
452,interquartile range,C1711350
452,* interquartile range,C1711350
452,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
451,interruption ( n = $nmbr$ ),C0332453;C1512900
451,interruption,C0332453;C1512900
450,interim analysis ( all patients ),C4684691
450,interim analysis,C4684691
449,intermediate risk ( ri = $nmbr$ ),C0035487;C1826843;C3640764
449,intermediate risk,C3640764
448,intermediate - acting,C0205103;C1550465;C2827755;C3889971
448,intermediate ( $nmbr$ - $nmbr$ ),C0205103;C1550465;C2827755;C3889971
448,intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205103;C1550465;C2827755;C3889971
448,intermediate ( $nmbr$ )  %,C0205103;C1550465;C2827755;C3889971
448,intermediate,C0205103;C1550465;C2827755;C3889971
448,inter p - value,C0205103;C1548610
448,inter . p - value,C0205103;C1548610
448,inter .,C0205103;C1548610
447,unfractionated only,C0205171;C1720467
447,ufh only,C0205171;C1720467
447,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
447,st - depression only,C0205171;C0520887;C1720467
447,past only,C0205171;C1444637;C1720467;C4284302
447,oad only,C0205171;C1720467
447,lieum only  n ( % ),C0205171;C1720467
447,legs only,C0205171;C1140621;C1720467
447,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
447,laba ( only monotherapy ),C0205171;C1720467
447,jbs - $nmbr$ secondary prevention only $nmbr$,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
447,jbs - $nmbr$ primary prevention only $nmbr$,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
447,image only,C0205171;C1704254;C1704922;C1720467;C3542466
447,ileum only  n ( % ),C0020885;C0205171;C1720467
447,handihaler only  n,C0205171;C1720467
447,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
447,diskus only  n,C0205171;C1553480;C1720467
447,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
447,class v only,C0205171;C0457166;C1720467;C1880098
447,antimalarials only,C0003374;C0205171;C1720467
447,( women only ),C0043210;C0205171;C1720467
447,$nmbr$ ( only $nmbr$ distal ),C0205108;C0205171;C1720467;C4522154
446,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
446,heparin alone ( n = $nmbr$ ),C0019134;C0205171;C0439044;C0679994;C0770546
446,fluticasone alone ( n = $nmbr$ ),C0082607;C0205171;C0439044;C0679994
446,basal alone,C0205112;C0205171;C0439044;C0679994
446,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
446,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
446,aspirin alone ( n = $nmbr$ ),C0004057;C0205171;C0439044;C0679994
446,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
446,alone,C0205171;C0439044;C0679994
445,single vessel disease,C0037179;C0042373;C0087136;C0205171
445,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
445,single - vessel disease,C0037179;C0042373;C0087136;C0205171
445,single,C0037179;C0087136;C0205171
444,nc,C0027964;C0028407;C0067895;C0265987
444,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0023823;C0027964;C0028407;C0038257;C0067895;C0265987;C0717550;C1518422;C1739039;C2757044;C3811844;C3812682;C4551552
443,tjc ( / $nmbr$ joints ),C0022417;C0392905
443,tjc ( $nmbr$ joints ),C0022417;C0392905
443,sjc ( / $nmbr$ joints ),C0022417;C0392905
443,sjc ( $nmbr$ joints ),C0022417;C0392905
443,primary study joint  n ( % ),C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
443,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
442,heparin plus gpi ( n = $nmbr$  $nmbr$ ),C0019134;C0332287;C0770546;C1415351
442,heparin plus a gpi ( n = $nmbr$ ),C0019134;C0770546;C1415351
442,gpi used during pci,C1415351
441,electrocardiographic findings — no . ( % ),C0438154
441,electrocardiographic findings at randomization,C0034656;C0438154
441,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
441,ecg findings,C0438154
440,ugt induction status : per aeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
440,ugt induction status : as randomizeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
440,octave induction $nmbr$ and $nmbr$,C0205263;C0857127
440,octave induction $nmbr$,C0205263;C0857127
440,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
440,inducing,C0205263
440,baseline of induction )  n ( % ),C0168634;C0205263;C0857127;C1442488
440,baseline of induction,C0168634;C0205263;C0857127;C1442488
439,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178
439,dyspnea  frequent / continuous,C0013404;C0332183;C0549178;C1963100
439,dyspnea  % ( frequent / continuous ),C0013404;C0332183;C0549178;C1963100
439,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
439,$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
438,continuous,C0549178
438,continued use of gpa,C0549178;C1524063;C3495801;C4553145
438,continued treatment study,C0549178;C3161471
438,continued thienopyridine n = $nmbr$ subjects,C0549178;C1120149
438,continued thienopyridine n ( % ),C0549178;C1120149
438,continued thienopyridine ( n = $nmbr$ ),C0549178;C1120149
438,continued thienopyridine ( n $nmbr$ $nmbr$ ),C0549178;C1120149
438,continued thienopyridine %,C0549178;C1120149
438,continue thienopyridine n = $nmbr$,C0549178
437,clinical presentation of vte at initial diagnosis — no . ( % ),C0630906;C2708283
437,clinical presentation,C2708283
436,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
436,medically important infectionsa,C3898777;C4084912
435,previous hospitalization for heart failure,C0205156;C1552607;C3898876
435,hospitalization for heart failure within previous $nmbr$ mo — no . ( % ),C3898876
435,hospitalization for heart failure within $nmbr$ mo,C3898876
435,hospitalization for heart failure or cv death,C3898876
435,hospitalization for heart failure or cv,C3898876
435,hospitalization for heart failure n ( % ),C3898876
435,hospitalization for heart failure,C3898876
435,hospitalisation for heart failure,C3898876
435,heart failure hospitalizations,C3898876
435,heart failure hospitalisation or cv death,C3898876
434,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
434,no . of infusions,C0574032
434,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
434,infusion administered — no . / total no . ( % ),C0574032;C1827465
434,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
434,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
433,no hemoconcentration hemoconcentration,C0549409;C0854379
432,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
432,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
431,posterior circulation,C0005775;C0205095;C1516559
430,no regular consumption,C0009830;C0205272;C1947907
429,new - onset atrial fibrillation,C0741281
428,diagnostic catheterization,C0596429
427,thrombus aspiration done per lesion †,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
427,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
427,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
426,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
426,anti - thrombotics,C0087086
425,one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$,C0205447
425,one or more medications,C0205447
425,one or more exacerbations,C0205447
425,one or more copd exacerbations ( n / n [ % ] ),C0205447
425,one or more blood pressure medications  n ( % ),C0205447
425,one of the above,C0205447
425,one - third radius,C0034627;C0205437;C0205447;C1306504
425,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
425,at least one drug - eluting stent,C0205447;C1322815
424,one tnfi and,C0205447
424,one tnfi *,C0205447
424,one lesion,C0205447;C0221198;C1546698
423,tnfi - na ï ve  n ( % ),C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
423,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
423,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
423,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
423,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
423,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
423,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
423,n / a,C1272460
423,n . a .,C1272460
423,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
423,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C1272460;C1546968;C1879645;C3259781;C4049872;C4552882
423,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
422,a / v ( n = $nmbr$ ) v ( n = $nmbr$ ),C0560268;C1272460;C3887614
422,a / v ( n = $nmbr$ ),C1272460
422,a $nmbr$ c [ n ( % ) ],C1272460
422,a $nmbr$ + e $nmbr$ ( n = $nmbr$ ),C1272460
421,recent treatment ( < $nmbr$ months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
421,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
421,mycophenolate mofetil,C0209368
421,mmf ( n = $nmbr$ ),C0083765;C0209368;C3848524
421,inadequate response ( > $nmbr$ months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
420,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
420,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
420,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
420,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
420,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
420,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
420,managed medically — no . / total no . ( % ),C1273870
420,acs management  no . ( % ),C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
419,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
419,nstemi ( n = $nmbr$  $nmbr$ ),C3537184;C4255010
419,nstemi ( % ),C3537184;C4255010
419,nstemi,C3537184;C4255010
419,nste - mi,C3537184;C4255010
419,non - stemi,C3537184
419,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
418,any recurrent stroke,C2242682
418,all recurrent strokes,C1836785
417,in - stent restenosis of des,C0011702;C3272317;C4551552
417,in - stent restenosis,C3272317
416,past treatment for paod,C2945691
415,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
415,prestudy treatment status,C0749659
414,standard treatment ( n - $nmbr$ ),C4684780
413,planned treatment duration  n ( % ),C4528394
412,bare metal stent  n ( % ),C2825200
412,bare metal stent,C2825200
412,bare - metal stent — no . ( % ),C2825200
412,bare - metal stent,C2825200
412,all bare metal stents,C2825200
411,male patients *,C0150904
411,male patients  n ( % ),C0150904
410,female patients ^,C0150905
410,female patients  n ( % ),C0150905
409,very elderly patients ( n - $nmbr$ ),C0442824;C0870602;C2984081
409,elderly patients ( n — $nmbr$ ),C0870602
408,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
408,gamma glutamyltransferase  u / l,C0017040;C0439339
408,elevated creatine kinase mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
408,elevated creatine kinase - mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
407,mean score,C3533236
407,mean mmse score,C0451306;C3533236
407,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
407,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
406,mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C3533236
406,mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C1880389;C1883221;C3533236;C3541951;C3641331
405,mean systolic blood pressure ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
405,mean systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
405,mean diastolic blood pressure ( sd )  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
405,mean diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
405,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
405,mean blood pressure  mm hg,C0428886;C0439475;C0488053
405,mean arterial pressure  last,C0428886
405,mean arterial pressure  baseline,C0168634;C0428886;C1442488
405,mean ( s . d . ) systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
405,mean ( s . d . ) diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
404,number stent > $nmbr$,C0038257;C0237753;C0449788
404,number ste  t > $nmbr$,C0237753;C0449788;C1420459;C3811127
404,number resulting in hospital admission,C0237753;C0449788
404,number resulting in emergency department visit,C0237753;C0449788
404,number resulting in ed visit,C0237753;C0449788
404,number randomized,C0237753;C0449788
404,number of “ off ” periods,C0237753;C0449788
404,number of stents implanted,C0038257;C0237753;C0449788
404,number of stents ( per patient ),C0038257;C0237753;C0449788
404,number of stents,C0038257;C0237753;C0449788
404,number of stent = l or $nmbr$ or $nmbr$,C0038257;C0237753;C0449788
404,number of stent = $nmbr$,C0038257;C0237753;C0449788
404,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
404,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
404,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
404,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
404,number of previous anti - tnf treatments for psa  n ( % ),C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
404,number of people ( n ),C0027361;C0237753;C0449788
404,number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C4086268
404,number of exacerbations in the last $nmbr$ months  mean ± sd,C0237753;C0449788;C4086268
404,number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C4086268
404,number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C4086268
404,number of exacerbations in previous year  mean ( sd ),C0237753;C0449788;C4086268
404,number of exacerbations in previous $nmbr$   months,C0237753;C0449788;C4086268
404,number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C4086268
404,number of exacerbations in last $nmbr$ months,C0237753;C0449788;C4086268
404,number of exacerbations $nmbr$ months before randomisation,C0237753;C0439231;C0449788;C4086268
404,number of exacerbations,C0237753;C0449788;C4086268
404,number of exacerbation in the previous $nmbr$ months  n ( % ),C0237753;C0449788;C4086268
404,number of er visits in last year prior to baseline,C0237753;C0449788;C3810541;C3811131
404,number of e,C0237753;C0449788
404,number of copd exacerbations within $nmbr$ months  mean ( sd ),C0237753;C0449788;C0740304
404,number of copd exacerbations in the previous year    n   ( % ),C0237753;C0449788;C0740304
404,number of copd exacerbations in the previous year  n ( % ),C0237753;C0449788;C0740304
404,number of concomitant csdmards  n ( % ),C0237753;C0449788;C0521115
404,number of concomitant aedsc,C0237753;C0449788;C0521115
404,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
404,number of co - aeds  n ( % ),C0180309;C0237753;C0449788;C3245499
404,number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0237881;C0349790;C0449788;C0750502;C1546944
404,number of antihypertensive agent reported,C0003364;C0237753;C0449788
404,number of antidiabetes drugs at screening  n ( % ),C0013227;C0237753;C0449788;C3687832
404,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
404,number of ( % ) females,C0086287;C0237753;C0449788
404,number and % of participants with events  and incidence rate per $nmbr$ person - year,C0237753;C0449788
404,number ( % ) reporting migraine on $nmbr$ - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
404,number ( % ),C0237753;C0449788
404,number,C0237753;C0449788
404,non - epa number of <,C0237753;C0449788;C1518422
404,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
404,mean number of exacerbations in previous y ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
404,mean number of exacerbations in previous $nmbr$ months ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
404,mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
404,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
404,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
404,event number,C0237753;C0441471;C0449788;C4019010
404,> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,> q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,> median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,> median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,> median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,> $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
404,< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,< q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
404,< median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,< median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,< median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
404,< $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
403,rales  n ( % ),C0034642;C0240859
403,rales  ( % ),C0034642;C0240859
403,rales,C0034642;C0240859
403,pulmonary rales  n ( % ),C0034642
403,pulmonary rales,C0034642
402,radial access — no . / total no . ( % ),C0442038;C0920847
402,radial access,C0442038;C0444454;C0920847;C1554204
402,radial,C0442038;C0920847
401,shock risk indext,C0035647;C0036974;C4552904
401,risk stratum,C0035647;C4552904
401,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
401,risk category ( points ),C0035647;C0683312;C3889287;C4552904
401,risk categories,C0035647;C0683312;C4552904
401,risk at,C0035647;C4552904
401,risk *,C0035647;C4552904
401,risk,C0035647;C4552904
401,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
401,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
401,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
401,cardiovascular risk  n ( % ),C0007226;C0035647;C3887460;C4552904
401,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
401,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
401,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
401,$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ ),C0035647;C3538987;C4048877;C4318503;C4552904
401,$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ ),C0035647;C4552904
400,prior surgery for cd  n [ % ],C0007928;C0034283;C0455610;C4552032
400,prior surgery for cd  n ( % ),C0007928;C0034283;C0455610;C4552032
400,prior surgery : no,C0455610
400,prior oabg surgery,C0455610
400,prior cabg surgery,C0010055;C0455610
400,history of cabg surgery  n ( % ),C0010055;C0455610
400,history of cabg surgery,C0010055;C0455610
399,prasugrel or ticagrelor,C1620287
399,prasugrel,C1620287
398,timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci,C0005847;C0441800;C0919553;C3244287;C3272266;C3810814
398,timi flow grade $nmbr$ of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
398,rankin grade,C0441800;C0919553;C3244287
398,nerd grade,C0441800;C0919553;C3244287
398,mmrc grade  n ( % ),C0441800;C0919553;C3244287;C3826977
398,mmrc grade,C0441800;C0919553;C3244287;C3826977
398,mean mmrc grade  units ( sd ),C0439148;C0441800;C0444504;C0919553;C1519795;C2347634;C2348143;C2699239;C3244287;C3826977;C3853603
398,initial timi flow grade $nmbr$,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
398,grade > $nmbr$,C0441800;C0919553;C3244287
398,grade $nmbr$ ( severe copd )  n ( % ),C0441800;C0919553;C3244287
398,grade $nmbr$ ( moderate copd )  n ( % ),C0441800;C0919553;C3244287
398,grade $nmbr$,C0441800;C0919553;C3244287
398,gold grade $nmbr$,C0018026;C0441800;C0919553;C1304897;C3244287
398,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
398,final timi flow grade < $nmbr$,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
398,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
398,dyspnea – mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
397,right coronary,C0225808
396,right coronary artery  n ( % ),C1261316
396,right coronary artery,C1261316
395,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
395,acute coronary syndrome $nmbr$,C0948089
395,acute coronary syndrome,C0948089
394,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
394,current cigarette smoker  n ( % ),C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
394,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
394,current cigarette  n ( % ),C0521116;C0677453;C1704760;C1705970;C3890423
394,cigarette users,C0677453;C1704760;C1706077;C3890423
393,cigarette smoker *,C0337667
393,cigarette smoker  no . ( % ),C0337667
393,cigarette smoker,C0337667
392,smoking consumption pack - years,C0425291;C1277691
392,number of pack years,C0237753;C0449788;C1277691
392,number of pack - years,C0237753;C0449788;C1277691
392,nicotine pack - years,C0028040;C1277691
392,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
391,smoking history ( pack - years ) ∗,C1277691;C1519384
391,smoking history ( pack - years ),C1277691;C1519384
391,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
391,smoking history  pack - years,C1277691;C1519384
391,pack years,C1277691
391,pack - years smoked,C1277691
391,pack - years ( iqr ),C1277691
390,overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
390,non - us ( n = $nmbr$ ),C1518422
390,non - epa ( n = $nmbr$ ),C1518422
390,non - cana ( n = $nmbr$ ),C1418845;C1518422
389,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
389,not hospitalized for heart failure in the year prior to study enrollment,C1518422
388,not treated,C1518422
388,not tested,C1518422
388,not reported,C1518422
388,not provided,C1518422
388,not perfused,C1518422
388,not on an aha,C0050451;C0772110;C1518422
388,not localized,C1518422
388,not collected ^,C1518422
388,no . of non - tnfi,C1518422
388,all non - mn,C0026327;C0026405;C1518422;C4285072
387,not reported in ecrf,C1518422
387,not reported / unknown,C1518422
387,not present at screening  but within previous year,C1518422
387,non - statin ( n = $nmbr$ ),C0360714;C1518422
387,non - st — elevation mi,C0520886;C1518422;C3810814
387,non - st - segment elevation mi,C0520886;C1518422;C3810814
387,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
387,non - st - segment elevation,C0520886;C1518422
387,non - st - elevation mi,C0520886;C1518422;C3810814
387,non - lad,C1518422
387,non - ischemic,C0475224;C1518422
387,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
387,non - ischaemic ( n = $nmbr$ o $nmbr$ ),C0475224;C1518422
387,non - ischaemic ( n = $nmbr$ ),C0475224;C1518422
387,non - ischaemic,C0475224;C1518422
387,non - inhaled steroid use  n ( % ),C0586793;C1518422
387,non - hispanicwhite,C1518422
387,non - hishnic,C1518422
387,non - hdl - c / hdl - c,C1518422;C3715113
387,non - hdl - c *,C1518422;C3715113
387,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
387,non - hdl - c  mmol / l,C1518422;C1532563;C3715113
387,non - hdl - c,C1518422;C3715113
387,non - hdl,C1518422;C3715113
387,non - east asianf,C1518422;C1707877
387,non - east asian §,C0078988;C1518422;C1707877
386,not receiving,C1518422
386,not estimable,C1518422
386,non - us,C1518422
386,non - u . s .,C1518422
386,non - trial p blocker,C0008976;C1518422
386,non - trial antiplatelet,C0008976;C1518422
386,non - rollover,C0517067;C0543436;C1518422
386,non - rheumatic valvular heart disease,C0264757;C1518422
386,non - metsyn,C1518422
386,non - mets,C0812270;C1518422;C1705694;C2939420
386,non - ics +,C0815320;C1518422;C4551720
386,non - hdlc,C1518422;C1704429
386,non - dm,C0011816;C1518422;C3250443
386,non - diabetics ( n = $nmbr$ ),C0241863;C1518422
386,non - diabetics,C0241863;C1518422
386,non - diabetic ( n = $nmbr$ ),C0241863;C1518422
386,non - diabetic,C0241863;C1518422
386,non - cortical,C0001613;C0007776;C0022655;C1518422
386,non - c,C1518422
386,non - / ex - tobacco user,C1518422;C3853727
385,women taking estrogen,C0043210
385,women ethnic origin,C0015031;C0043210
385,women ( n = $nmbr$ vs $nmbr$ ),C0043210
385,women ( n = $nmbr$ ) events,C0043210;C0441471;C3541888
385,women ( n = $nmbr$ )  n / n ( % ),C0043210
385,women ( n = $nmbr$ ),C0043210
385,women,C0043210
385,woman,C0043210;C4281745
384,£ $nmbr$ ( men ) / £ $nmbr$ ( women ),C0025266;C0043210
384,women — no . ( % ),C0043210
384,women t,C0043210
384,women men,C0025266;C0043210
384,women / men [ % ],C0025266;C0043210
384,women / men  %,C0025266;C0043210
384,women - no . ( % ),C0043210
384,women ( n ( % ) ),C0043210
384,women ( % ),C0043210
384,women  no . ( % ),C0043210
384,women  n ( % ) *,C0043210
384,women  n ( % ),C0043210
384,women  > $nmbr$ cm,C0043210
384,women  < $nmbr$ cm,C0043210
384,women  %,C0043210
384,no . women,C0043210
384,men : women ( % ),C0025266;C0043210
384,men / women,C0025266;C0043210
384,hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women ),C0019046;C0025266;C0043210
384,hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
384,gmi ( women ),C0043210
384,all women,C0043210
384,< $nmbr$ ( men ) / < $nmbr$ ( women ),C0025266;C0043210
384,( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
384,$nmbr$ - $nmbr$ ( women ),C0043210
383,middle third,C0442050
382,migraine without aura,C0338480
382,migraine with aura,C0154723
381,spirometry,C0037981
381,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
381,baseline spirometry,C0037981;C0168634;C1442488
380,triglycerides $nmbr$ st third,C0036056;C0041004;C0205437;C3272372
380,triglycerides $nmbr$ nd third,C0041004;C0205437
380,triglycerides $nmbr$  d third,C0041004;C0205437
380,third yeart,C0205437
380,slowest third,C0205437;C0439834
380,omega - $nmbr$ fa intake $nmbr$ st third,C0036056;C0205437;C1512806;C1719844;C3272372
380,omega - $nmbr$ fa intake $nmbr$ nd third,C0205437;C1512806;C1719844
380,omega - $nmbr$ fa intake $nmbr$  d third,C0205437;C1512806;C1719844
379,within $nmbr$ h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
379,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
379,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
379,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
379,procedure * *,C0184661;C2700391;C3274430;C3539779
379,procedure,C0184661;C2700391;C3274430;C3539779
379,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
379,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
379,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
379,interventional or surgical procedures,C0184661;C3274035
379,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
379,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
379,baseline procedure  n ( % ),C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
378,with dm ( n proactive intervention ( n = $nmbr$ a ),C0011816;C0184661;C0886296;C1273869;C3250443
378,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
378,proactive intervention ( n = $nmbr$ a ),C0184661;C0886296;C1273869
378,prior coronary intervention or coronary artery bypass grafting,C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
378,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
378,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
378,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
378,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
378,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
378,intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869
378,intervention .,C0184661;C0886296;C1273869
378,intervention ( n = $nmbr$ ),C0184661;C0886296;C1273869
378,intervention,C0184661;C0886296;C1273869
378,experimental intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869;C1517586
378,coronary intervention,C0018787;C0184661;C0886296;C1273869
377,provoked,C1444748
376,improved,C0184511;C0332272;C1561611;C4084203
375,pfor trend,C1151635;C1521798;C4554533
375,pfor,C1151635
374,pnd,C1417807;C1956415;C4552608
374,paroxysmal nocturnal dyspnea,C1956415
373,esrd or death,C0022661;C0035078;C2316810
373,esrd or $nmbr$ % dedine in gfr,C0022661;C0035078;C2316810
373,esrd or $nmbr$ % decline in gfr,C0022661;C0035078;C2316810
373,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
373,esrd *,C0022661;C0035078;C2316810
373,esrd ',C0022661;C0035078;C2316810
373,esrd,C0022661;C0035078;C2316810
373,end - stage renal disease,C0022661;C2316810
372,esr ( mm / h ),C0456680;C3811131
372,esr,C3811131
371,europe n z $nmbr$,C0015176
371,europe ii,C0015176;C1710602;C4082587
371,europe i,C0015176;C0021966;C0221138
371,europe and russia,C0015176
371,europe and canada,C0015176
371,europe and australia,C0015176
371,europe / lsrael,C0015176
371,europe ( zone $nmbr$ ),C0015176;C1710706
371,europe ( plus south africa ),C0015176;C0037712;C0332287
371,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
371,europe ( including south africa ),C0015176
371,europe ( eu ),C0015176;C0015179;C3665627
371,europe $nmbr$ ¶,C0015176
371,europe $nmbr$ +,C0015176
371,europe $nmbr$ ( n = $nmbr$ ),C0015176
371,europe $nmbr$ ( n = $nmbr$  $nmbr$ ),C0015176
371,europe $nmbr$,C0015176
370,west europe,C0015176;C1705493
370,w europe,C0015176
370,w est europe,C0015176;C3811127;C3890902
370,w . europe,C0015176
370,non europe,C0015176;C1518422
370,europe,C0015176
370,e europe,C0015176
370,e . europe,C0015176
369,mildly impaired,C0750532;C2945599
369,mild teaes,C2945599
369,mild or moderate copd,C2945599
369,mild ed,C2945599;C3538926
369,mild ( n = $nmbr$ ),C2945599
369,mild ( n $nmbr$ = $nmbr$ ) $nmbr$,C2945599
369,mild ( ipss < $nmbr$ ),C1019118;C1998280;C2827405;C2945599;C3811063
369,mild ( iief - ef $nmbr$ - $nmbr$ ),C2945599;C3641331
369,mild ( gold $nmbr$ ),C0018026;C1304897;C2945599
369,mild ( > $nmbr$ to < $nmbr$ ),C2945599
369,mild ( < $nmbr$ ),C2945599
369,mild ( $nmbr$ - $nmbr$ ),C2945599
369,mild,C2945599
369,< mild,C2945599
369,$nmbr$ - $nmbr$ ( mild ),C2945599
368,mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] ),C2945599
368,mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0392756;C0439526;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
367,ind / gly n = $nmbr$,C0017890;C0523677;C4049864
367,ind / gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
367,ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$,C0017890;C0523677;C2827928;C4049864
367,ind / gly,C0017890;C0523677;C4049864
367,ind + gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
367,gly,C0017890;C0523677
367,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
367,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
366,inguinal hernia repair,C0021446
365,insulin - dependent diabetes mellitus,C0011854
365,insulin - dependent diabetes,C0011854
364,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
364,insulin aspart,C0123677;C1708521
363,insulin treatment  n ( % ),C0745343
363,insulin treatment,C0745343
362,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
362,insulin dose ( u ),C0366513;C0439148
362,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
362,insulin dose  u,C0366513;C0439148
361,insulin use at baseline,C0168634;C0240016;C1442488
361,insulin use    n   ( % ),C0240016
361,insulin use,C0240016
360,insulins and analogs,C0021641;C3537244;C4049919
360,insulins,C0021641;C3537244;C4049919
359,insulin sensitivity — % §,C0920563;C4049919
359,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
358,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
358,immunosuppressive agents only,C0021081;C0205171;C1720467
358,immunosuppressants onlyff,C0021081
358,immunosuppressants only,C0021081;C0205171;C1720467
358,immunosuppressants and antimalarials only,C0021081
358,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
358,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
357,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
357,immunosuppressive use  n ( % ),C0021081;C0042153;C0457083;C1947944
357,immunosuppressants,C0021081
357,immunosuppressant use  %,C0021081;C0042153;C0457083;C1947944
357,immunosuppressant ^ ^,C0021081
357,immunosuppressant ^,C0021081
357,immunosuppressant ( with or without corticosteroid ),C0021081
357,any immunosuppressive agent,C0021081
356,mild to moderate renal impairment *,C1299392;C1565489
356,mild to moderate,C1299392
356,mild / moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
356,mild - to - moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
356,mild - < moderate,C1299392
355,withdrew consent,C2349954
355,withdrawals  n / n ( % ),C1710677;C2349954;C2825032;C3812880;C4049634
354,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
354,amlodipine vs chlorthalidone overweight,C0051696
354,amlodipine vs chlorthalidone obese,C0051696
354,amlodipine vs chlorthalidone normal,C0051696
354,amlodipine and valsartan,C0051696
354,amlodipine / vaisartan ( n = $nmbr$ ),C0051696
354,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
354,amlodipine / lisinopril $nmbr$,C0051696;C0065374
353,amlodipine ( n = $nmbr$ ),C0051696
353,amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
353,amlodipine $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
353,amlodipine,C0051696
353,! amlodipine,C0051696
352,self - rated health status,C0018759;C0036588;C0871208;C1551994
351,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
351,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
351,rosuvastatin n ( rate ) $nmbr$,C0871208;C0965129;C1521828
351,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
351,rosuvastatin  n ( rate ),C0871208;C0965129;C1521828
351,rates,C0871208;C1521828
351,rate ‡,C0871208;C1521828
351,rate †,C0871208;C1521828
351,rate of sares,C0871208;C1521828
351,rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
351,rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
351,rate in all participants  % / y,C0679646;C0871208;C1521828
351,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
351,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
351,rate / $nmbr$ pyo,C0033809;C0871208;C1521828
351,rate * ( n ),C0871208;C1521828
351,rate *,C0871208;C1521828
351,rate  % / y,C0871208;C1521828
351,rate,C0871208;C1521828
351,proportion of > = $nmbr$ % responder rates,C0871208;C1521828;C1709707
351,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
351,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
351,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
351,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
351,km rates { % ) e / s,C0871208;C1521828;C3887676
351,km rate ( % ),C0871208;C1521828;C3887676
351,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
351,kaplan - meier rates  % i i,C0021966;C0221138;C0871208;C1521828
351,kaplan - meier rates  %,C0871208;C1521828
351,k ( rate ),C0597277;C0871208;C1521828;C1708601
351,health - care use rate ( peryear ),C0814514;C0871208;C1521828
351,filtration rate $nmbr$ - $nmbr$,C0016107;C0871208;C1521828
351,crude rate,C0871208;C1521828
351,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
351,> $nmbr$ % responder rate  n ( % ),C0871208;C1521828
351,$nmbr$ yr . km rate,C0439234;C0871208;C1521828;C3887676
351,$nmbr$ - yr rate / $nmbr$ participants,C0439234;C0679646;C0871208;C1521828
351,$nmbr$ - y rate per $nmbr$ persons ( se )  n,C0027361;C0036919;C0871208;C1521828
351,$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci ),C0008107;C0871208;C1521828;C3259781
351,$nmbr$ - wk kaplan - meier rate  %,C0332174;C0439230;C0871208;C1521828
350,pedal edema  slight / moderate / marked,C0205081;C0522501;C0574002;C1706089;C1881878;C2937276;C2945599;C4049705;C4049706;C4050469;C4085643;C4321335
350,patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
350,no . of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderately impaired,C0205081;C1881878;C4085643;C4321491
350,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate severe ( n = $nmbr$ ) ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate risk ( > $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
350,moderate risk ( $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
350,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
350,moderate renal impairment  n ( % ) *,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe renal disease  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe renal disease  b   n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate impairment ( $nmbr$ to < $nmbr$ ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate impairment ( $nmbr$ to $nmbr$ ml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate impairment  < $nmbr$ to < $nmbr$,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % ),C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
350,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate copdb [ n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
350,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate chronic kidney disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate / severe reduction in egfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate / severe exacerbations  patient subgroups  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate / severe exacerbation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate / low,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate - to -,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate - < severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( s $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( n $nmbr$ = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
350,moderate ( iief - ef $nmbr$ - $nmbr$ ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
350,moderate ( gold $nmbr$ ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( > $nmbr$ to < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( > $nmbr$ and < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( > $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ < ipss < $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ - $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ % < fev  < $nmbr$ % predicted ),C0205081;C1881878;C3714541;C4049705;C4049706;C4085643;C4321335
350,moderate ( $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate  n ( % ) a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate  gold $nmbr$,C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
350,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,> $nmbr$ - $nmbr$ ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
350,> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,$nmbr$ - $nmbr$ ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
350,$nmbr$ ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
349,severely impaired,C0205082
349,severe to end - stage impairment ( $nmbr$ ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
349,severe teaes,C0205082;C4050465;C4050466
349,severe renal impairment,C0205082;C1565489;C4050465;C4050466
349,severe or worse airflow limitation,C0205082;C4050465;C4050466
349,severe or very severe smoking status,C0205082;C4050465;C4050466
349,severe or very severe copd,C0205082;C4050465;C4050466
349,severe or very severe,C0205082;C4050465;C4050466
349,severe or moderate,C0205082;C4050465;C4050466
349,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
349,severe n z $nmbr$,C0205082;C4050465;C4050466
349,severe impairment ( egfr < $nmbr$ ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
349,severe impairment ( < $nmbr$ ),C0205082;C0221099;C0684336;C4050465;C4050466
349,severe hyperkalemiac,C0205082;C4050465;C4050466
349,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
349,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
349,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
349,severe exacerbations,C0205082;C4050465;C4050466;C4086268
349,severe ed,C0205082;C3538926;C4050465;C4050466
349,severe copdc [ n z $nmbr$ ],C0205082;C4050465;C4050466
349,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
349,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
349,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
349,severe / lite threatening,C0205082;C4050465;C4050466
349,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
349,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
349,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
349,severe ( n $nmbr$ = $nmbr$ ),C0205082;C4050465;C4050466
349,severe ( itt ) ( n = $nmbr$ ),C0205082;C4050465;C4050466
349,severe ( ipss > $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
349,severe ( iief - ef < $nmbr$ ),C0205082;C3641331;C4050465;C4050466
349,severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205082;C3641331;C4050465;C4050466
349,severe ( gold $nmbr$ ),C0018026;C0205082;C1304897;C4050465;C4050466
349,severe ( fev  < $nmbr$ % predicted ),C0205082;C3714541;C4050465;C4050466
349,severe ( > $nmbr$ ),C0205082;C4050465;C4050466
349,severe  n ( % ) b,C0205082;C4050465;C4050466
349,severe  gold $nmbr$,C0018026;C0205082;C1304897;C4050465;C4050466
349,severe,C0205082;C4050465;C4050466
349,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
349,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
349,more severe ^,C0205082;C0205172;C4050465;C4050466
349,more severe,C0205082;C0205172;C4050465;C4050466
349,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
349,less severe $nmbr$,C0205082;C0439092;C0547044;C4050465;C4050466
349,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
349,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
349,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
349,at least $nmbr$ severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
349,$nmbr$ - $nmbr$ ( severe ),C0205082;C4050465;C4050466
348,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
348,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
348,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
348,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
348,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
348,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
348,major or clinically relevant non - major bleeding,C0205082;C0205164;C4318856;C4521762
348,major or clinically relevant non - major bleed,C0205082;C0205164;C4318856;C4521762
348,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
348,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
348,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
348,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
348,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
348,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
348,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
348,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
348,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
348,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
348,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
348,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
348,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
348,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
348,major bleeding $nmbr$ to $nmbr$,C0019080;C0205082;C0205164;C4318856;C4521762
348,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
348,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
348,major and crnm bleeds,C0205082;C0205164;C4318856;C4521762
348,major amputationsb,C0205082;C0205164;C4318856;C4521762
348,major amputations at week $nmbr$,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
348,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
348,major / crnm bleed,C0205082;C0205164;C4318856;C4521762
348,major,C0205082;C0205164;C4318856;C4521762
348,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
348,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
348,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
348,history of major microvascular disease  n ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
348,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
348,history of major macrovascular disease  n ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
348,history of major cardiovascular disease  n ( % ),C0205082;C0205164;C0455539;C4318856;C4521762
348,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
348,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
348,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
348,combined major macrovascular events  neohrodathv . and all - cause mortalitv ■,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
348,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
348,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
348,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
348,> $nmbr$ % stenosis of major artery  n ( % ),C0038449;C0205082;C0205164;C4318856;C4521762
348,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
347,left atrial dimension  cm,C0018792;C0439534;C2950135
346,left anterior descending coronary artery,C0226032
346,left anterior descending artery  n ( % ),C0226032
346,left anterior descending artery,C0226032
346,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
345,life - threatening bleeding  disabling stroke  and death,C0019080;C0038454;C1546953;C2826244;C3537125;C4554100
345,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
345,life - threatening,C1546953;C2826244;C3537125
344,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
344,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
344,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
343,complete ulcer healing at week $nmbr$,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
343,complete healinga,C0205197;C0725685;C3853530;C4283785
343,complete clinical response at week $nmbr$,C0205197;C3853530;C4283785
342,type of insulin,C0457592
342,type of basal insulin  n ( % ),C0205112;C0332307;C0457592;C0650607;C1547052
342,insulin type  n ( % ),C0457592
341,non - enzyme inducing,C0014442;C1518422;C4521602
341,enzyme inducing,C0014442;C4521602
340,juvenile myoclonic epilepsy,C0270853
339,functional assessment of chronic illness,C0008679;C0278372
338,no . fingernails,C0222001
337,( incl . uncertain ),C0268281;C1418854
336,type of intervention,C3274412
335,social interaction,C0037420
334,time intervals  h,C0033727;C0369286;C0441932;C0564385;C0872291;C4528284
334,time intervals,C0872291
333,t wave inversion,C0520888
333,t - wave inversion only,C0205171;C0520888;C1720467
333,t - wave inversion,C0520888
333,symmetric t wave inversions,C0332516;C0520888;C2699744
333,symmetric t - wave inversions,C0332516;C0520888;C2699744
332,referent,C1706462
332,reference,C1514811;C1706462
332,no ( reference ),C1514811;C1706462
332,< $nmbr$ mg dl ( reference ),C0439269;C1514811;C1706462
332,$nmbr$ . $nmbr$ ( referent ),C1706462
332,$nmbr$ . $nmbr$ ( reference ),C1514811;C1706462
331,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
331,definite,C0439544;C1704787
331,$nmbr$ days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
330,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
330,proportion of predicted normal fev $nmbr$ value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
330,percentage of predicted pre - bronchodilator fev ^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
330,percent of predicted value before bronchodilation ^,C1882327
330,fevj % predicted !  t,C0681842;C1882327
330,fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C3714541
330,fev $nmbr$   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
330,fev $nmbr$ ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
330,> $nmbr$ % predicted to < $nmbr$ % predicted,C0681842;C1882327
330,> $nmbr$ % predicted arr ( n = $nmbr$ ),C0681842;C1882327;C2170357;C4084934
330,> $nmbr$ % predicted,C0681842;C1882327
330,< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),C0681842;C1882327;C2170357;C4084934
330,< $nmbr$ % predicted,C0681842;C1882327
330,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
330,% predicted prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541
330,% predicted pre - bronchodilator fev $nmbr$  % *,C0681842;C1882327;C2599602;C3714541
330,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
330,% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l,C0681842;C1882327
330,% predicted post - bronchodilator fev  ( sd ) ml,C0681842;C1882327
330,% predicted,C0681842;C1882327
330,% of predicted normal value *,C0086715;C0681842;C1882327
330,% of predicted,C0681842;C1882327
329,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
329,stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0441781;C1739039;C3811844;C3812682
329,severe impairment ( egfr < $nmbr$ ml / min / m ^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
329,severe impairment ( egfr < $nmbr$ )  n ( % ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
329,renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,renal function ( egfr ) according to mdrd  n ( % ),C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
329,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % ),C0232804;C0369637;C0439445;C0441923;C0680240;C1739039;C3811844;C3812682;C3839656
329,prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g ),C0022658;C0033105;C0220900;C0439445;C1739039;C3811844;C3812682
329,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C1739039;C3811844;C3812682
329,moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
329,moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
329,moderate impairment ( egfr $nmbr$ - $nmbr$ ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
329,mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
329,mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
329,mild impairment ( egfr $nmbr$ - $nmbr$ ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
329,mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
329,mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
329,mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
329,fgf - $nmbr$ low / egfr > $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
329,fgf - $nmbr$ low / egfr < $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
329,fgf - $nmbr$ high / egfr > $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
329,fgf - $nmbr$ high / egfr < $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
329,established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease,C0022658;C0205156;C0369637;C0439445;C0441923;C0443211;C1272684;C1300563;C1552607;C1739039;C3811844;C3812682
329,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
329,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr using cg / mdrd formulae  % of patients,C1739039;C3811844;C3812682
329,egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
329,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
329,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
329,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
329,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
329,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
329,egfr at baseline  $nmbr$ ml / min ( % ) b,C0168634;C0439445;C1442488;C1739039;C3811844;C3812682
329,egfr and albuminuria,C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
329,egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr > $nmbr$  n ( % ),C1739039;C3811844;C3812682
329,egfr > $nmbr$,C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
329,egfr < $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
329,egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
329,egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$  n ( % ),C1739039;C3811844;C3812682
329,egfr < $nmbr$  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr < $nmbr$,C1739039;C3811844;C3812682
329,egfr -,C1739039;C3811844;C3812682
329,egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0441923;C1739039;C3811844;C3812682
329,egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
329,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr ( ml / min / $nmbr$ - $nmbr$ mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
329,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
329,egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
329,egfr ( mdrd )  n ( % ),C1739039;C3811844;C3812682;C3839656
329,egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0162734;C0369637;C0439445;C0441923;C1561643;C1739039;C3811844;C3812682;C4281721
329,egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0071744;C0162734;C0369637;C0439445;C0441923;C1413772;C1561643;C1739039;C3811844;C3812682;C4281721
329,egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
329,egfr $nmbr$ to < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
329,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
329,egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
329,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr $nmbr$ - $nmbr$,C1739039;C3811844;C3812682
329,egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ ),C0205307;C0231683;C0439166;C0439445;C1739039;C2347086;C3811844;C3812682;C4553972
329,egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$,C0026327;C0026405;C0369637;C0439526;C0441923;C1705224;C1739039;C3811844;C3812682;C3887665;C4285072
329,egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439232;C0439526;C0441923;C0700321;C0702093;C1282918;C1705224;C1739039;C2347166;C3811844;C3812682;C3887665
329,egfr  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr  ml / min / bsa,C0439445;C1739039;C3811844;C3812682
329,egfr  ml / min ( mdrd ),C0439445;C1739039;C3811844;C3812682;C3839656
329,egfr  ml / min,C0439445;C1739039;C3811844;C3812682
329,egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1300574;C1532718;C1705224;C1739039;C3811844;C3812682;C3887665
329,egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
329,egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
329,egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
329,egfr,C1739039;C3811844;C3812682
329,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .,C0005823;C1739039;C3811844;C3812682
329,baseline egfr ≥ $nmbr$ to < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
329,baseline egfr < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
329,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
328,estimated glomerular filtration rate — no . ( % ),C3811844
328,estimated glomerular filtration rate §,C3811844
328,estimated glomerular filtration rate | |,C3811844
328,estimated glomerular filtration rate ^,C3811844
328,estimated glomerular filtration rate < $nmbr$,C3811844
328,estimated glomerular filtration rate - no . ( % ) : :,C3811844
328,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
328,estimated glomerular filtration rate  n ( % ),C3811844
328,estimated glomerular filtration rate,C3811844
327,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
327,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
327,serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C0302353;C0543465;C1532563
327,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
327,serum potassium  meq / l,C0302353;C0439375;C0543465
327,serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0302353;C0543465;C1532563
327,serum biochemistry potassium  mmol / l,C0005477;C0302353;C0543465;C1532563
327,hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
326,serum albumin concentration  g / l,C0001924;C0036773;C0086045;C0229671;C0439294;C0456615;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
326,serum albumin - adjusted calcium ( mg / dl ),C0036773;C0728877
326,serum albumin  g / l,C0036773;C0439294;C0456615;C0728877
326,serum albumin  g / dl,C0036773;C0439267;C0728877
326,serum albumin  g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
325,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
325,serum uric acid  n,C0455272;C0700634
325,serum uric acid  mg / dl,C0439269;C0455272;C0700634
325,serum urate ( mg / dl )  n ( % ),C0439269;C0455272
325,serum urate ( mg / dl ),C0439269;C0455272
325,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
324,serum sodium — mmol / liter,C0439190;C0475211;C0523891
324,serum sodium — meq / liter,C0439152;C0475211;C0523891
324,serum sodium . meq / l,C0439375;C0523891
324,serum sodium  meq / l,C0439375;C0523891
323,upadacitinib $nmbr$ mg ( n = l $nmbr$ ),C0439268
323,hscrp range  mg / l,C0439268;C1514721;C2348147;C3542016
323,hscrp > $nmbr$ mg / l,C0439268
323,hscrp  mg / l,C0439268
323,elevated hscrp > $nmbr$ mg / l  n ( % ),C0205250;C0439268;C3163633
323,cld $nmbr$ mg ( n = l $nmbr$ ),C0439268
323,canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
323,canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
323,> $nmbr$ mg / l ( n = $nmbr$ ),C0439268
323,< $nmbr$ mg / l ( n = $nmbr$ ),C0439268
323,$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ ),C0439268
322,≤ $nmbr$ mg / l,C0439268
322,hscrp > $nmbr$ to < $nmbr$ mg / l,C0439268
322,hscrp > $nmbr$ . $nmbr$ mg / l,C0439268
322,hscrp < $nmbr$ . $nmbr$ mg / l,C0439268
322,hscrp ( mg / l ) c,C0439268
322,hscrp ( mg / l ),C0439268
322,hs - crp mg / l,C0439268;C3890735;C4048285
322,hs - crp j $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
322,hs - crp _ = $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
322,hs - crp > $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
322,hs - crp < $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
322,hs - crp ( mg / l ),C0439268;C3890735;C4048285
322,hs - crp  mg / l,C0439268;C3890735;C4048285
322,crp — mg / l,C0439268;C3890735;C4048285
322,crp < $nmbr$ mg / l  n,C0439268;C3890735;C4048285
322,crp ( mg / l ) : < $nmbr$,C0439268;C3890735;C4048285
322,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
322,crp ( mg / l )  n,C0439268;C3890735;C4048285
322,crp ( mg / l ),C0439268;C3890735;C4048285
322,crp $ $nmbr$ mg / l  n,C0439268;C3890735;C4048285
322,crp  mg / l *,C0439268;C3890735;C4048285
322,crp  mg / l,C0439268;C3890735;C4048285
322,about $nmbr$ mg / l or more,C0439268
322,about $nmbr$ mg / l,C0439268
322,> $nmbr$ mg / l,C0439268
322,> $nmbr$ . $nmbr$ mg / l,C0439268
322,< $nmbr$ mg / l,C0439268
322,< $nmbr$ . $nmbr$ mg / l,C0439268
322,( ≥ $nmbr$ mg / l ),C0439268
322,( < $nmbr$ mg / l ),C0439268
322,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l,C0439268
321,uae ( p  g / min ),C0560021;C1519789
320,uacr  pg / mg,C1627892
320,( pg / mg ),C1627892
319,≤ $nmbr$ u / kg / day,C1532634
319,> $nmbr$ u / kg / day,C1532634
318,≥ $nmbr$ ng / ml,C0439275
318,wap $nmbr$ c ( ng / ml ),C0439275
318,vegfr ( ng / ml ),C0439275;C1568520
318,troy ( ng / ml ),C0439275;C1420811;C1883402
318,tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$,C0439275
318,t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C2603360
318,syndecan - $nmbr$ ( ng / ml ),C0075691;C0439275;C1419891
318,sdc ( ng / ml ),C0439275;C1419891;C3273112
318,sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C1419891;C3273112
318,sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml,C0439275;C1419891;C3273112
318,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
318,ptx $nmbr$ ( ng / ml ),C0030899;C0439275
318,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
318,psa level  ng / ml,C0439275;C4086720
318,procalcitonin ( ng / ml ),C0072027;C0439275
318,proadm ( ng / ml ),C0439275
318,pigr ( ng / ml ),C0439275;C1418569
318,pentraxin - $nmbr$ ( ng / ml ),C0439275
318,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
318,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
318,ntpro - cnp ( ng / ml ),C0439275;C3889729
318,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
318,neuropilin ( ng / ml ),C0287275;C0439275
318,mpo ( ng / ml ),C0439275
318,mmp - $nmbr$ ( ng / ml ) *,C0439275;C0623362;C0919336
318,mmp - $nmbr$ ( ng / ml ),C0439275;C0623362;C0919336
318,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
318,ltbr ( ng / ml ),C0439275;C1416931
318,gdf - $nmbr$ ( ng / ml ),C0439275;C1418244
318,galectin - $nmbr$ ( ng / ml ),C0439275;C0607430
318,esam ( ng / ml ),C0439275;C1424976
318,ctn - l  ng / ml,C0439275;C0917591
318,ctn - i  ng / ml,C0021966;C0221138;C0439275;C0917591
318,crp ( ng / ml ),C0439275;C3890735;C4048285
318,ck - mb  ng / ml,C0010290;C0439275
318,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
318,> $nmbr$ . $nmbr$ ng / ml,C0439275
318,< $nmbr$ ng / ml,C0439275
318,< $nmbr$ . $nmbr$ ng / ml,C0439275
317,nt probnp > $nmbr$ ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
317,> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
317,< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
316,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
316,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
316,uacr   ≥ $nmbr$   mg / mmol ∗,C0567349;C2348885
316,uacr   < $nmbr$   mg / mmol ∗,C0567349;C2348885
316,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
316,s $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
316,s $nmbr$ . $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
316,mg / mmol,C0567349;C2348885
316,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
316,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
316,> $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
316,< $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
316,. $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
316,$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
316,$nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
316,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
315,triglyceride ( mm,C0041004;C4330985;C4554674
315,subcortical wml load diameter  mm  mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
315,subcortical wml load diameter  mm   mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
315,stent diameter < $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
315,stent diameter $ $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
315,sokolow - lyon voltage  mm,C0598352;C4330985;C4554674
315,sokolow - lyon ( mm ) *,C4330985;C4554674
315,sokolow - lyon  mm,C4330985;C4554674
315,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
315,ptgada ( mm ),C4330985;C4554674
315,platelets xlooo / mm ^,C0005821;C0443116;C1963076;C4330985;C4554674
315,platelet count  x $nmbr$ mm $nmbr$,C0032181;C1287267;C4330985;C4554674
315,physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
315,physician global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
315,phgada ( mm ),C4330985;C4554674
315,patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm ),C0042815;C4054229;C4330985;C4554674
315,patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
315,patient global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
315,patient ' s ga  $nmbr$ - $nmbr$ mm vas,C0016993;C0030705;C0042815;C3536884;C3827561;C4330985;C4554674
315,pain vas  $nmbr$ - $nmbr$ mm,C0042815;C4330985;C4554674
315,pain ( $nmbr$ mm vas ),C0042815;C4330985;C4554674
315,pain ( $nmbr$ - $nmbr$ mm vas ),C0042815;C4330985;C4554674
315,pain  $nmbr$ - $nmbr$ mm vas,C0042815;C4330985;C4554674
315,mssbp  mm hga,C4330985;C4554674
315,msdbp  mm hga,C4330985;C4554674
315,lvdd ( mm ),C4330985;C4554674
315,long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
315,fibrous  mm ’,C0016059;C0439709;C4330985;C4554674
315,fibrofatty  mm ^,C4330985;C4554674
315,esr — mm / hr,C3811131;C4330985;C4554674
315,esr ( mm / hour ) git config - - global user . name  your name,C0205246;C0439227;C0564385;C1418224;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4554674
315,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
315,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
315,esr  mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
315,esr  $nmbr$ - $nmbr$ mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
315,blood pressure  mean ( sd )  mm hgt,C0428886;C2699239;C4330985;C4554674
315,> $nmbr$ to < $nmbr$ cells / mm ’,C0007584;C0007634;C4330985;C4554674
315,> $nmbr$ to < $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
315,> $nmbr$ mm ( n = $nmbr$ ),C4330985;C4554674
315,> $nmbr$ mm,C4330985;C4554674
315,> $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
315,> $nmbr$ . $nmbr$ mm,C4330985;C4554674
315,< = $nmbr$ . $nmbr$ mm,C4330985;C4554674
315,< $nmbr$ mm,C4330985;C4554674
315,< $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
315,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
315,$nmbr$ - $nmbr$ mm,C4330985;C4554674
315,$nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
314,sbp ≥ $nmbr$ mmhg,C0085805;C0439475
314,sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg,C0085805;C0439475
314,sbp > $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
314,sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg,C0085805;C0439475
314,sbp > $nmbr$ mmhg,C0085805;C0439475
314,sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
314,sbp > $nmbr$ mm hg,C0085805;C0439475
314,sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
314,sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg,C0085805;C0439475
314,sbp < $nmbr$ mmhg,C0085805;C0439475
314,sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
314,sbp < $nmbr$ mm hg,C0085805;C0439475
314,sbp ( mmhg ) < $nmbr$,C0085805;C0439475
314,sbp ( mmhg ) *,C0085805;C0439475
314,sbp ( mmhg ),C0085805;C0439475
314,sbp ( mm hg ),C0085805;C0439475
314,sbp  mmhg,C0085805;C0439475
314,sbp  mm   hg,C0085805;C0439475
314,sbp  mm   hg,C0085805;C0439475
314,sbp  mm hg,C0085805;C0439475
314,s $nmbr$ mmhg,C0439475;C0565930;C2603362
314,mssbp ( mm hg ),C0439475
314,mssbp  mm hg,C0439475
314,msdbp ( mm hg ),C0439475
314,msdbp  mm hg,C0439475
314,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
314,apasp ( per mmhg ),C0439475
314,> = $nmbr$ mmhg,C0439475
314,> $nmbr$ mmhg,C0439475
314,> $nmbr$ mm hg — no . ( % ),C0439475
314,< $nmbr$ mmhg,C0439475
314,< $nmbr$ mm hg — no . ( % ),C0439475
314,< $nmbr$ mm hg heart rate,C0018810;C0439475
314,< $nmbr$ / < $nmbr$ mm hg,C0439475
314,< $nmbr$ / $nmbr$ mm hg +,C0439475
314,< $nmbr$ / $nmbr$ mm hg,C0439475
314,$nmbr$ to < $nmbr$ mm hg — no . { % ),C0439475
314,$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
314,$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
313,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
313,mssbp > $nmbr$ mmhg,C0439475
313,mssbp < $nmbr$ mmhg,C0439475
313,dbp ≥ $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
313,dbp mm hg,C0439475;C0536221;C3813197;C4281799
313,dbp < $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
313,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
313,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
313,dbp  mmhg,C0439475;C0536221;C3813197;C4281799
313,dbp  mm   hg ( sd ),C0439475;C0536221;C2699239;C3813197;C4281799
313,dbp  mm   hg,C0439475;C0536221;C3813197;C4281799
313,dbp  mm hg,C0439475;C0536221;C3813197;C4281799
313,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
312,sl $nmbr$ mm hg,C0439475
312,mm hg,C0439475
312,iop  mm hg,C0439475;C0578862
312,change in bp  mm hg,C0439475;C1268766
312,^ $nmbr$ mm hg,C0439475
312,> = $nmbr$ - < $nmbr$ mmhg,C0439475
312,> $nmbr$ to < $nmbr$ mm hg,C0439475
312,> $nmbr$ mm hg,C0439475
312,> $nmbr$ / > $nmbr$ mm hg,C0439475
312,> $nmbr$ . $nmbr$ mm hg,C0439475
312,> $nmbr$ - < $nmbr$ mmhg,C0439475
312,< $nmbr$ mm hg,C0439475
312,< $nmbr$ . $nmbr$ mm hg,C0439475
312,$nmbr$ to < $nmbr$ mmhg,C0439475
312,$nmbr$ to < $nmbr$ mm hg,C0439475
312,$nmbr$ to $nmbr$ mm hg,C0439475
312,$nmbr$ o - i $nmbr$ mm hg,C0021966;C0221138;C0439475;C0483204
312,$nmbr$ mmhg,C0439475
312,$nmbr$ mm hg,C0439475
312,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg,C0439475
312,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg,C0439475
312,$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg,C0439475
311,systolic pressure — mm hg,C0439475;C0871470
311,systolic pressure  mm hg,C0439475;C0871470
311,systolic blood pressurea  mm hg,C0005767;C0005768;C0039155;C0229664;C0439475
311,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
311,sitting blood pressure — mmhg,C0439475;C0580946
311,mean pulmonary artery pressure  mm hg,C0439475;C3854605
311,diastolic pressure  mm hg,C0428883;C0439475
311,diastolic blood pressurea  mmhg,C0005767;C0005768;C0012000;C0229664;C0439475
311,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
311,at home systolic pressure > $nmbr$ mm hg,C0439475;C0871470;C4534363
311,at home systolic pressure < $nmbr$ mm hg,C0439475;C0871470;C4534363
311,at home diastolic pressure > $nmbr$ mm hg,C0428883;C0439475;C4534363
311,at home diastolic pressure < $nmbr$ mm hg,C0428883;C0439475;C4534363
311,at clinic systolic pressure > $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
311,at clinic systolic pressure < $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
311,at clinic diastolic pressure > $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
311,at clinic diastolic pressure < $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
310,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
310,within $nmbr$ h after,C0033727;C0369286;C0441932;C0564385;C4528284
310,within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
310,use of h $nmbr$ bloekers  n ( % ),C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
310,urgency episodes / $nmbr$ h,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
310,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
310,nocturia episodes / $nmbr$ h,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
310,micturitions / $nmbr$ h,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
310,mean $nmbr$ - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
310,mean $nmbr$ - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
310,interval from clopidogrel loading  h,C0033727;C0070166;C0369286;C0441932;C0564385;C1272706;C1552654;C1552713;C1708715;C4528284
310,incontinence episodes / $nmbr$ h,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
310,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
310,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
310,h $nmbr$ receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
310,h $nmbr$ - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
310,h,C0033727;C0369286;C0441932;C0564385;C4528284
310,first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
310,duration of symptoms  h,C0033727;C0369286;C0436359;C0441932;C0564385;C4528284
310,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .,C0018802;C0033727;C0034787;C0038894;C0038895;C0042153;C0369286;C0439228;C0441932;C0457083;C0543467;C0564385;C1274039;C1511726;C1622222;C1947944;C3245479;C3714741;C3888198;C4528284
310,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C0019588;C0030705;C0033727;C0062408;C0237753;C0369286;C0441932;C0449788;C0564385;C0871420;C1711350;C1739039;C2699239;C3538987;C3666909;C3811844;C3812682;C3887460;C4048877;C4318503;C4528284
310,baseline $nmbr$ - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
310,b + h ( n = $nmbr$ ),C0033727;C0369286;C0441932;C0564385;C4528284
310,after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
310,> = $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
310,> $nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
310,> $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
310,> $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
310,< $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
310,< $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
310,$nmbr$ — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
310,$nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
310,$nmbr$ - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
310,$nmbr$ - $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
309,om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ ),C0023465;C0023467;C0028971;C1319635;C1705272
309,olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0020261;C0386393;C1319635
309,feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ ),C1319635
308,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
308,$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg,C1319635;C4044947
307,vas ( $nmbr$ - $nmbr$ ),C0042815;C3536884;C3827561
307,ptga ( $nmbr$ - $nmbr$ cm vas ),C0042815;C3536884;C3827561
307,physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4050369
307,physician ' s assessment of disease activity ( vas )  mm,C0031831;C0042815;C0456681;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
307,patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4054228
307,( $nmbr$ - $nmbr$ - cm vas ),C0042815;C3536884;C3827561
306,psa pain ( vas ),C0042815;C3810537;C3813209
306,pain ( vas ),C0042815
305,ups score  mean ( sd ),C0334463;C3542434
304,dpi ( other than diskus )  n,C1553480
303,hope patients with coronary - artery disease ( n = $nmbr$ ),C0010054;C0010068;C0030705;C0392347;C1956346
303,hope ( n = $nmbr$ ),C0392347
302,quintile ( n ),C1508496
302,quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ ),C1508496
302,quintile  range  mg / dl,C0439269;C1508496;C1514721;C2348147;C3542016
301,door - to - balloon time — hr,C4296144
300,^ $nmbr$ - cell function — % §,C0007613
299,gaviscon da ( n = $nmbr$ ),C0011318;C0061146;C3668815
299,> $nmbr$ da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
298,watchman ( n = $nmbr$ ),C0335390
298,device = watchman filter,C0180860;C0335390
297,$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t,C0718146
296,e $nmbr$ / s $nmbr$ vs s $nmbr$,C3846405
296,e $nmbr$ / s $nmbr$ vs e $nmbr$,C3846405
296,e $nmbr$ / s $nmbr$ ( n = $nmbr$ ),C3846405
295,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
295,ae ' ( per cm / s ),C0439392;C3887670
294,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
294,igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
294,igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0439340
294,igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
293,( $nmbr$ % ell ' ll  * non - hdl - c,C1427925;C3273466
293,( $nmbr$ % ell ' ll,C1427925;C3273466
292,ssomgdayp . eq .,C0205163;C0439185
292,eq - $nmbr$ dprofile - mobility  n ( % ),C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
292,eq - $nmbr$ d mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
292,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf,C0205163;C0439185
292,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc,C0205163;C0439185
292,eq - $nmbr$ d ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
292,< $nmbr$ mgday p . eq .,C0205163;C0439185
291,coronary heart disease risk equivalents  n ( % ) c,C0439185;C1277690;C4049980
291,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
290,qrs width  ms,C0487742;C2349943;C3539704;C3713294
290,qrs duration > $nmbr$ ms  n ( % ),C0429025;C0488377;C2349943;C3539704;C3713294
290,qrs duration  ms,C0429025;C0488377;C2349943;C3539704;C3713294
290,qrs > $nmbr$ ms *,C2349943;C3539704;C3713294
290,qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients,C2349943;C3539704;C3713294
290,qrs > $nmbr$ ms  % ( n ),C2349943;C3539704;C3713294
290,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C1514463;C2349943;C3539704;C3713294
290,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
290,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
290,ms < $nmbr$  n [ % ],C2349943;C3539704;C3713294
290,ms $nmbr$ - $nmbr$  n [ % ],C2349943;C3539704;C3713294
290,corneii product  mm - ms,C1514468;C1704444;C2349943;C3539704;C3713294;C4330985;C4554674
289,scr  gmol / l,C1539487;C4050416
288,$nmbr$ - h ppg ( mmol / l ) *,C1418888;C2827804
288,$nmbr$ - h ppg ( mmol / l ),C1418888;C2827804
288,$nmbr$ - h pmg ( mmol / l ),C2827804
288,$nmbr$ - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
287,fpi  m - u / ml ( pmol / l ),C0369637;C0439192;C0439284;C0439340;C0441923;C0456616;C1880521;C2945590
287,fpi  gu / ml ( pmol / l ),C0120446;C0439192;C0439284;C0439526;C1635169;C1705224;C3887515;C3887665
287,estradiol ( pmol / l ),C0014912;C0439284
287,estradiol ( e $nmbr$ ) ( pmol / l ),C0014912;C0439284
287,$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284;C0694666;C4553350
287,$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284
286,total cholesterol > $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
286,total cholesterol > $nmbr$ ' $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
286,total cholesterol < $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
286,total cholesterol < $nmbr$ $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
286,total cholesterol  mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
286,ldl cholesterol  mmol / lt,C0023376;C0023824;C0202117;C0230426;C0439190;C3887647;C4521399
286,hdl cholesterol  mmol / lt,C0023376;C0023822;C0230426;C0392885;C0439190;C3887647;C4521399
286,$nmbr$ . $nmbr$ ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
285,£ $nmbr$ . $nmbr$ mmol / l,C1532563
285,serum phosphate  mmol / l,C0036820;C1532563
285,ppg  mmol / l,C1418888;C1532563
285,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
285,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
285,mmol / l [ n ],C1532563
285,mmol / l ),C1532563
285,mmol / l,C1532563
285,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
285,ldl - c   *   ( mmol / l ),C1532563
285,ldl - c < $nmbr$ . $nmbr$ mmol / l,C1532563
285,ldl - c * ( mmol / l ),C1532563
285,ldl - c ( mmol / l ),C1532563
285,ldl - c  mmol / l,C1532563
285,ldl ( mmol / l ),C1532563
285,k ( mmol / l ),C0597277;C1532563;C1708601
285,k  mmol / l,C0597277;C1532563;C1708601
285,hdl - c ( mmol / l ),C1532563;C3715113
285,hdl - c  mmol / l,C1532563;C3715113
285,hdl ( mmol / l ),C1532563;C3715113
285,free fatty acids ( mmol / l ),C0015688;C1532563
285,fpg ( mmol / l ),C1532563
285,fpg  mmol / l,C1532563
285,fpg  ( mmol / l ),C1532563
285,ffa ( mmol / l ),C0015688;C1532563
285,fbg ( mmol / l ),C1532563
285,fbg  mmol / l,C1532563
285,bun  mmol / l,C1532563
285,[ $nmbr$ . $nmbr$ mmol / l ] ),C1532563
285,> $nmbr$ mmol / l,C1532563
285,> $nmbr$ . $nmbr$ mmol / l,C1532563
285,> $nmbr$ - $nmbr$ mmol / l,C1532563
285,> $nmbr$ + $nmbr$ mmol / l,C1532563
285,> $nmbr$ ' $nmbr$ mmol / l,C1532563
285,< $nmbr$ mmol / l,C1532563
285,< $nmbr$ . $nmbr$ mmol / l,C1532563
285,< $nmbr$ - $nmbr$ mmol / l,C1532563
285,( mmol / l ],C1532563
285,( mmol / l ),C1532563
285,( < $nmbr$ . $nmbr$ mmol / l ),C1532563
285,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l,C1532563
285,$nmbr$ - hour ppg  mmol / l,C0439227;C0564385;C1418888;C1532563
285,$nmbr$ - $nmbr$ mmol / l,C1532563
284,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
284,serum calcium  mmol / l,C0036785;C0728876;C1532563
284,ldl - c  mmol / l ( sd ),C1532563;C2699239
284,glucose  mmol / l,C0017725;C1532563
284,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
284,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
284,elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0553704;C1532563
284,> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C1532563
283,≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
283,≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol ),C3829066
283,≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
283,mmol / mol,C3829066
283,mean hba $nmbr$ c  mmol / mol †,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
283,hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$,C0332174;C0439230;C3829066
283,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
283,hbalc < $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
283,hbalc ( mmol / mol ),C3829066
283,hbalc  mmol / mol,C3829066
283,hbaj ( - ( %  mmol / mol ),C3829066
283,hba ] c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ ca  % ( mmol / mol ),C0019016;C1825777;C3538758;C3829066;C3887642
283,hba $nmbr$ c   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c ( sd )  mmol / mol,C0019016;C1825777;C2699239;C3538758;C3829066
283,hba $nmbr$ c ( mmol / mol [ se ] ),C0019016;C0036919;C1825777;C3538758;C3829066
283,hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c  mmol / mole,C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c  mmol / mol ( mean ),C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
283,hba $nmbr$ c  mmol / mol,C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c  ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
283,hba $nmbr$ c  % [ mmol / mol ],C0019016;C1825777;C3538758;C3829066
283,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
283,alc ( mmol / mol ),C1424945;C3811058;C3829066
283,a $nmbr$ c ( mmol / mol ),C3829066
283,a $nmbr$ c  % ( mmol / mol ),C3829066
283,>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
283,> = $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
283,> $nmbr$ % ( > $nmbr$ mmol / mol ),C3829066
283,< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
283,< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
283,< $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
283,< $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
283,% hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
282,> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol ),C3829066
282,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
282,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
282,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
281,mean ( s . d . ) hbalc  mmol / mol,C0444504;C2347634;C2348143;C3829066
281,ls mean ( $nmbr$ % ci )  mmol / mol,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781;C3829066
281,hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % ),C3829066
281,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
281,hba $nmbr$ c  mean ( sd )  % [ mmol / mol ],C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
281,baseline mean ( sd )  % [ mmol / mol ],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
280,≥ $nmbr$ ml / min,C0439445
280,• ? sd ml / min,C0439445;C2699239
280,£ $nmbr$ ml / min,C0439445
280,s $nmbr$ ml / min,C0439445;C0565930;C2603362
280,ecrcl < $nmbr$ ml / min,C0439445
280,ecrcl  ml / min,C0439445
280,creat clearance > $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
280,creat clearance < $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
280,crcl > $nmbr$ ml / min,C0439445;C1846718
280,crcl > $nmbr$ - < $nmbr$ ml / min,C0439445;C1846718
280,crcl < $nmbr$ ml / min,C0439445;C1846718
280,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
280,crcl ( ml / min ),C0439445;C1846718
280,crcl  ml / min,C0439445;C1846718
280,^ $nmbr$ ml / min,C0439445
280,> $nmbr$ to < $nmbr$ ml / min,C0439445
280,> $nmbr$ ml min ) $nmbr$,C0439445
280,> $nmbr$ ml / min,C0439445
280,< = $nmbr$ ml / min,C0439445
280,< $nmbr$ ml / min — %,C0439445
280,< $nmbr$ ml / min,C0439445
280,$nmbr$ – ≤ $nmbr$ ml / min,C0439445
280,$nmbr$ – < $nmbr$ ml / min,C0439445
280,$nmbr$ to < $nmbr$ ml / min,C0439445
280,$nmbr$ ml / min,C0439445
280,$nmbr$ - < $nmbr$ ml / min,C0439445
280,$nmbr$ - $nmbr$ ml min ) $nmbr$,C0439445
280,$nmbr$ - $nmbr$ ml min  $nmbr$,C0439445
280,$nmbr$ - $nmbr$ ml / min,C0439445
280,$nmbr$ - $nmbr$ ( < $nmbr$ ml / min ),C0439445
280,$nmbr$ ( $nmbr$ to < $nmbr$ ml / min ),C0439445
280,$nmbr$ ( $ $nmbr$ ml / min ),C0439445
279,stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
279,stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
279,stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
279,chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
278,〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
278,≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
278,rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C0871208;C1521828
278,mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C2945599
278,mean — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
278,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
278,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
278,mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439092;C0439445;C0441923
278,gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
278,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
278,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §,C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
278,estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
278,estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C3811844;C3839656
278,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
278,estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
278,estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
278,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143;C2699239;C3811844
278,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
278,egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$,C0369637;C0439445;C0441923
278,egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % ),C0369637;C0439445;C0441923
278,egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa,C0369637;C0439445;C0441923
278,egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$,C0369637;C0439445;C0441923
278,egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr — ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
278,egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
278,egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
278,egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ - $nmbr$ m ^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ - $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min per $nmbr$ + $nmbr$ m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
278,egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
278,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd ),C0369637;C0439445;C0441923;C1739039;C2699239;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682;C3839656
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
278,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923
278,ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
278,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0040363;C0041260;C0369637;C0439445;C0441923;C1739039;C1883351;C3811844;C3812682
278,> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
278,> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
278,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,> $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445
278,> $nmbr$ ml / min ( n = $nmbr$ ),C0439445
278,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
278,< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
278,< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % ),C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,< $nmbr$ ml / min ( n = $nmbr$ ),C0439445
278,. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923
278,( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
278,( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
278,(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
278,$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0483204
278,$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
278,$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
278,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$,C0439445
278,$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
278,$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ ),C0439445
278,$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
277,ors ( $nmbr$ % cis ) :,C0069590;C1963718
276,$nmbr$ tq - fi ' i,C0021966;C0221138;C3555502;C4050619
276,$nmbr$ . $nmbr$ ( fi . $nmbr$ ),C4050619
275,l . l ± $nmbr$ . $nmbr$,C3539687
275,l ( < l ),C3539687
275,< $nmbr$ . $nmbr$ l - g / l,C0439267;C3539687
275,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l ),C3539687
275,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ ),C3539687
275,$nmbr$ l ( l $nmbr$ ),C3539687
275,$nmbr$ . l ( $nmbr$ l . $nmbr$ ),C3539687
275,$nmbr$ . l ( $nmbr$ . l ),C3539687
275,$nmbr$ . $nmbr$ ± l . l,C3539687
275,$nmbr$ . $nmbr$ ( $nmbr$ l . l ),C3539687
275,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l ),C3539687
274,> l : $nmbr$ hrs : min ( n = $nmbr$ ),C0439393;C1568891
274,> = $nmbr$ l_ / min,C0439393
274,> = $nmbr$ l / min,C0439393
274,< $nmbr$ l / min,C0439393
273,s / se  mb or death,C0024853;C0036919;C0565930;C2603362
273,$nmbr$ mq / kq *,C0024853
272,ssed as ls means,C0023668;C1704970
272,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
272,ls / ul $nmbr$ $nmbr$,C0023668;C1300557
271,less than $nmbr$ y ears,C0013443;C0439092;C0521421
271,< $nmbr$ y ears,C0013443;C0521421
270,≥ $nmbr$ kg / m $nmbr$,C1532718
270,≥ $nmbr$  kg / m $nmbr$,C1532718
270,£ $nmbr$ kg / m $nmbr$,C1532718
270,s $nmbr$ kg / m ^,C0565930;C1532718;C2603362
270,s $nmbr$ kg / m $nmbr$,C0565930;C1532718;C2603362
270,kg / m $nmbr$ ),C1532718
270,kg / m $nmbr$,C1532718
270,bmp kg - m “ $nmbr$,C0053932;C0279266;C1532718;C4281808
270,bm $nmbr$ ( kg / m $nmbr$ ),C0006416;C1532718
270,a $nmbr$ kg / m $nmbr$,C1532718
270,[ kg / m ^ ],C1532718
270,> = $nmbr$ kg / m $nmbr$,C1532718
270,> $nmbr$ kg / m ’,C1532718
270,> $nmbr$ kg / m ^,C1532718
270,> $nmbr$ kg / m $nmbr$,C1532718
270,> $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
270,> $nmbr$ - s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
270,> $nmbr$ - ^ $nmbr$ kg / m ’,C1532718
270,> $nmbr$ - < s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
270,< $nmbr$ kg / m ^,C1532718
270,< $nmbr$ kg / m $nmbr$,C1532718
270,< $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
270,< $nmbr$  kg / m $nmbr$,C1532718
270,$nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ kg / m ’,C1532718
270,$nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ - < $nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ - $nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
270,$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
269,bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ ),C0032659;C0578022;C1257890;C1532718
269,bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi ( kg / m $nmbr$ ) cardiovascular history,C0578022;C1532718;C1880008
269,bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
269,bmi  kg / m $nmbr$ cholesterol  mg / dl,C0008377;C0439269;C0578022;C1532718
269,> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
269,> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
269,> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
269,< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
269,< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
268,overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ ),C0497406;C1532718
268,obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ ),C0006416;C0028754;C1532718;C1963185
268,obesity ( body mass index > $nmbr$ kg / m $nmbr$ ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
268,obesity ( bmi £ $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718;C1963185
268,obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %,C0028754;C0578022;C1532718;C1963185
268,obese ( bmi > $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718
268,obese ( > $nmbr$ kg / m ^ $nmbr$ ),C0028754;C1532718
268,obese ( > $nmbr$ kg / m $nmbr$ ) b,C0028754;C1532718
268,obese ( > $nmbr$ kg / m $nmbr$ ),C0028754;C1532718
268,lean ( < $nmbr$ kg / m $nmbr$ ),C1532718
268,> $nmbr$ kg / m ^ ( obesity ),C0028754;C1532718;C1963185
268,> $nmbr$ kg / m $nmbr$ smokers,C0337664;C1532718
268,$nmbr$ kg / m $nmbr$ or more,C1532718
267,( fxs ),C0016667
266,$nmbr$ ( mono ),C1551432;C1551969
265,$nmbr$ % ( ito $nmbr$ ),C0022283
265,$nmbr$ % ( - ito $nmbr$ ),C0022283
264,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
264,m / f,C1306057
264,gender ( m / f )  ( % ),C0079399;C1306057;C1522384
263,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
262,spondylitis with peripheral arthritis,C0038012;C0238694
262,asymmetric peripheral arthritis,C0238694;C0332514
261,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0175673
260,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
260,glycoprotein llb / llla inhibitors,C0017968;C0243077
260,glycoprotein llb / llia inhibitor,C0017968;C1999216
260,glycoprotein llb / illa inhibitor,C0017968;C1999216
260,glycoprotein ilb / iiia inhibitor before pci ],C0017968;C1999216;C4049621;C4697913
260,glycoprotein iib / iiiareceptorinhibitor,C0017968
259,monoamine oxidase b inhibitors,C2917290;C3653412
258,α - glucosidase inhibitor,C1512211
258,a - glucosidase inhibitors ' $nmbr$,C1512211
258,a - glucosidase inhibitors,C1512211
258,a - glucosidase inhibitor,C1512211
257,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
256,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
255,renin inhibitors,C2917241;C3653375
255,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
254,sglt - $nmbr$ inhibitors ^,C3665045
253,p - gp inhibitor,C3898062
252,factor xa inhibitor,C2825027;C4553708
251,converting enzyme inhibitor,C0014432;C0919438;C4521603
251,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
250,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
250,gpiib - iiia inhibitors,C0016011;C0243077
250,gp iib / iiia inhibitors,C0016011;C0243077
250,gp iib / iiia inhibitor used,C0016011;C1999216
250,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
250,glycoprotein iib / iiia inhibitort,C0016011
250,glycoprotein iib / iiia inhibitors,C0016011;C0243077
250,glycoprotein iib / iiia inhibitor,C0016011;C1999216
250,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0016011;C0168273;C0243077
250,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
249,tnf inhibitors,C0243077;C1448177
249,raas inhibitors,C0243077
249,non - tnf inhibitors,C0243077;C1448177;C1518422
249,no ilb / iiia inhibitors,C0243077;C4697913
249,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
249,inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^,C0243077
249,ilb / iiia inhibitors,C0243077;C4697913
249,gp llb / llla inhibitors,C0243077;C1705010;C3811116
248,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
247,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
247,raas inhibitor,C1999216
247,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
247,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
247,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
247,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
246,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
246,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
246,p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
246,other sglt - $nmbr$ inhibitor,C1999216
245,tnf inhibitor,C1448177;C1999216
245,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
245,inhibitor,C1999216
244,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
244,renin inhibitor,C1960108;C3537174;C4521920
243,previous pde $nmbr$ inhibitors,C0031638;C0205156;C1552607
243,pde $nmbr$ inhibitors,C0031638
243,pde $nmbr$ inhibitor monotherapy,C0031638
242,platelet aggregation inhibitors excluding heparin,C0032177
242,platelet aggregation inhibitors  n ( % ),C0032177
241,smoking classification  n ( % ),C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
241,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
241,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
241,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
241,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
241,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
241,classification of epilepsy type  n ( % ),C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
241,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
240,study protocol,C1507394;C2348563;C2599718
240,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
240,coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high,C0007226;C0442711;C1277690;C1507394;C1522729;C1698058;C2348563;C2599718;C3715209;C3887460;C4282383
240,atv $nmbr$ mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
240,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
239,time of symptom onset to randomization ( hrs ),C1320528
239,time of symptom onset to balloon inflation ( hrs ),C1320528
239,time from symptom onset of ra  years  median,C0439234;C1320528;C3538806;C4048756
239,time from onset of symptoms to start of fibrinolytic therapy — hr,C1320528
239,time from onset of symptoms to randomization — days,C1320528
239,time from onset of symptoms to presentation — hr,C1320528
238,time from sx onset to baseline ecg  min,C0449244;C1519428;C3539997;C3815196
238,time from onset to randomization  h  mean ± sd,C0449244
238,time from onset to medication  h  mean ± sd,C0449244
237,time since last dose of,C0946444
237,time from last dose of p $nmbr$ y $nmbr$ inhibitor  days,C0439228;C0946444;C1999216
236,mostly satisfied,C0205393;C0750554
236,mostly dissatisfied,C0205393;C0750554
236,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
236,most frequent infections,C0205393;C0239998
235,time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ ),C0019994;C0040223;C1510665;C1959907;C3541383
235,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1959907;C3541383
235,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
235,pci - hospital,C0019994;C1510665;C4049621
235,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
235,in - hospital,C0019994;C1510665
235,hospital factor # $nmbr$,C0019994;C1510665;C1521761;C2827422
235,duration from hospital admission to pci  h ( median  iqr ),C0019994;C0449238;C1510665;C1959907;C2926735
234,russia and georgia,C0035970
234,russia / ukraine / belarus,C0006539;C0035970;C0041580
234,russia / georgia ( n = $nmbr$ ),C0017452;C0017454;C0035970
234,russia / georgia,C0017452;C0017454;C0035970
233,russia,C0035970
233,rs - totala,C0035970;C3714753;C3813325
233,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
233,rs - breathlessnessb,C0035970;C3714753;C3813325
233,rs $nmbr$ ( cc ) & rs $nmbr$,C0008318;C0035970;C3538933;C3714753;C3813325
233,rs $nmbr$ ( ac ) & rs $nmbr$,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
233,rs $nmbr$ ( aa ) & rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
233,rs $nmbr$ & rs $nmbr$,C0035970;C3714753;C3813325
233,rs $nmbr$,C0035970;C3714753;C3813325
233,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
232,usa and canada,C0041703
232,usa / canada,C0006823;C0041703
232,usa ( n = $nmbr$ ),C0041703
232,usa ( n = $nmbr$  $nmbr$ ),C0041703
232,usa,C0041703
232,united states or canada,C0041703
232,united states and canada,C0041703
232,united states ( n   = $nmbr$  $nmbr$ ),C0041703
232,united states  canada,C0006823;C0041703
232,united states,C0041703
232,u . s . sites,C0041703;C0205145
232,u . s . site,C0041703;C0205145;C1515974;C2825164
232,non usa,C0041703;C1518422
232,non - united states,C0041703;C1518422
231,group b,C4522078
231,gold group b,C0018026;C1304897;C4522078
230,group a,C0441835;C4522145
230,gold group a,C0018026;C0441835;C1304897;C4522145
229,group c,C0441837
229,gold group c,C0018026;C0441837;C1304897
228,group d,C0441838
228,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
228,gold group d,C0018026;C0441838;C1304897
227,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
227,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
227,age groups,C0027362
227,age group 一 ％,C0027362;C2348001
227,age group $nmbr$,C0027362;C2348001
227,age group,C0027362;C2348001
226,hemoglobin ale *,C0019046;C0678386;C2632076
226,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
226,hemoglobin  mg / dl,C0019046;C0439269
226,hemoglobin  g / l,C0019046;C0439267;C0439294;C0456615;C0635222
226,hemoglobin,C0019046
226,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
226,haemoglobin ( mg / dl ),C0019046;C0439269
226,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
226,haemoglobin  mg / dl,C0019046;C0439269
226,glyeated haemoglobin,C0019046
226,for combined hemoglobin groups,C0019046;C0205195
225,hemoglobin aj ^ ( % ),C0004486;C0019046;C0230613
225,baseline hemoglobin aj ^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
224,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
224,previous warfarin use  no . ( % ),C0043031;C0205156;C1552607
224,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
224,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
224,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
224,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C1552607
224,previous use of systemic steroids  n ( % ),C0205156;C0205373;C0281991;C1552607
224,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607
224,previous use of nonbiologic systemic therapy  n ( % ),C0205156;C1515119;C1524063;C1552607
224,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1524063;C1552607
224,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
224,previous use of biologic systemic therapy  n ( % ),C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
224,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
224,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
224,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
224,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
224,previous treatment with a laba and / or lama  n ( % ) c,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
224,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
224,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
224,previous tnf antagonist exposure  n ( % ),C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
224,previous tnf - antagonist use  n ( % ),C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
224,previous tia or stroke,C0007787;C0205156;C0917805;C1054154;C1552607
224,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
224,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
224,previous therapies  n ( % ),C0087111;C0205156;C1552607
224,previous systemic treatment  n ( % ),C0205156;C0678812;C1552607
224,previous stroke 一 no . ( % ),C0205156;C1552607
224,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0205156;C1552607
224,previous stroke — no . ( % ),C0205156;C1552607
224,previous stroke yes ( n  % ) previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C3841753;C4552959
224,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
224,previous stroke ortia $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
224,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
224,previous stroke or transient ischemic attack — no . / total,C0038454;C0205156;C1552607;C4554100
224,previous stroke or transient ischemic attack  no . / total no . ( % ),C0038454;C0205156;C1552607;C4554100
224,previous stroke or tl a $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
224,previous stroke or tl a,C0038454;C0205156;C1552607;C4554100
224,previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
224,previous stroke or tia ( % ),C0038454;C0205156;C1552607;C4554100
224,previous stroke or tia  n ( % ),C0038454;C0205156;C1552607;C4554100
224,previous stroke or tia,C0038454;C0205156;C1552607;C4554100
224,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
224,previous stroke *,C0038454;C0205156;C1552607;C4554100
224,previous stroke  n ( % ),C0038454;C0205156;C1552607;C4554100
224,previous stroke,C0038454;C0205156;C1552607;C4554100
224,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
224,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
224,previous segments resection ( s ) *,C0205156;C1552607;C2987624
224,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
224,previous revascularization,C0205156;C0581603;C1552607
224,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
224,previous renal disease  n ( % ),C0022658;C0205156;C1552607
224,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1552607
224,previous ptca,C0205156;C1552607;C2936173
224,previous percutaneous coronary intervention  %,C0205156;C1532338;C1552607
224,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
224,previous pde $nmbr$ - i therapy  no . ( % ),C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
224,previous pci or cabg,C0205156;C1552607;C4049621
224,previous pci / cabg  n ( % ),C0010055;C0205156;C1552607;C4049621
224,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
224,previous pci  n ( % ),C0205156;C1552607;C4049621
224,previous pci,C0205156;C1552607;C4049621
224,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
224,previous oral antidiabetic medication use  n ( % ),C0205156;C0935929;C1527415;C1552607
224,previous or current use of im or cs : no,C0205156;C1552607
224,previous or current use of im and cs : no,C0205156;C1552607
224,previous or current im use : no,C0205156;C1552607
224,previous or current cs use : no,C0205156;C1552607
224,previous oad ( % ),C0205156;C1552607
224,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
224,previous myocardiaunfarction,C0205156;C1552607
224,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,previous myocardial infarction  no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,previous myocardial infarction  n ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
224,previous mi — no . ( % ),C0205156;C1552607;C3810814
224,previous mi and t $nmbr$ dm,C0205156;C1552607;C3810814
224,previous mi ( % ),C0205156;C1552607;C3810814
224,previous mi  n ( % ),C0205156;C1552607;C3810814
224,previous mi  %,C0205156;C1552607;C3810814
224,previous mi,C0205156;C1552607;C3810814
224,previous metformin use  %,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
224,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
224,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
224,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
224,previous labd alone,C0205156;C0396059;C1552607
224,previous ischemic stroke ortia,C0205156;C0948008;C1552607
224,previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
224,previous ischemic stroke  n ( % ),C0205156;C0948008;C1552607
224,previous infliximab therapy — no . of patients ( % ) * *,C0205156;C1552607;C4076075
224,previous infliximab therapy | |,C0205156;C1552607;C4076075
224,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
224,previous infarction,C0021308;C0205156;C1552607
224,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
224,previous ics alone,C0205156;C0815320;C1552607;C4551720
224,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
224,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
224,previous htn  n ( % ),C0020538;C0205156;C1552607
224,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
224,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
224,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
224,previous exposure to systemic psoriasis therapyb ( yes )  n ( % ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
224,previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
224,previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
224,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0597277;C1552607;C1708601;C2825076;C3714656
224,previous events  no . ( % ),C0205156;C0441471;C1552607;C3541888
224,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
224,previous dmards use  n ( % ),C0205156;C0242708;C1552607
224,previous dmards  mean ± sd,C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
224,previous dm  n ( % ),C0011816;C0205156;C1552607;C3250443
224,previous dm,C0011816;C0205156;C1552607;C3250443
224,previous disease — no . ( % ) f,C0012634;C0205156;C1552607
224,previous disease and drug use,C0012634;C0205156;C1552607
224,previous disease :,C0012634;C0205156;C1552607
224,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
224,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
224,previous diabetes mellitus,C0011849;C0205156;C1552607
224,previous diabetes,C0011847;C0011849;C0205156;C1552607
224,previous cvd ^,C0007222;C0205156;C1552607
224,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
224,previous coronary revascularization,C0205156;C0877341;C1552607
224,previous coronary revascularisation,C0205156;C0877341;C1552607
224,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
224,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
224,previous congestive heart failure,C0018802;C0205156;C1552607
224,previous clinical stroke or transient ischemic attack ( % ),C0038454;C0205156;C0205210;C1552607;C4554100
224,previous clinical stroke or tia,C0038454;C0205156;C0205210;C1552607;C4554100
224,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
224,previous chf — no . ( % ),C0018802;C0205156;C1552607
224,previous chf  n ( % ),C0018802;C0205156;C1552607
224,previous chf,C0018802;C0205156;C1552607
224,previous cardiovascular disease !,C0007222;C0205156;C1552607
224,previous cancerc,C0205156;C1552607
224,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
224,previous cancer  n ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
224,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
224,previous cad  n ( % ),C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
224,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
224,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
224,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
224,previous cabg  n ( % ),C0010055;C0205156;C1552607
224,previous cabg,C0010055;C0205156;C1552607
224,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
224,previous bdmard received,C0205156;C1552607
224,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
224,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
224,previous antiparkinson medication  no . ( % ),C0003405;C0205156;C1552607
224,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
224,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
224,previous anti - tnf therapy  n [ % ],C0205156;C0279936;C0432633;C1552607
224,previous angioplasty  n ( % ),C0162577;C0205156;C1548817;C1552607
224,previous angina pectoris,C0002962;C0205156;C1552607
224,previous angina  n ( % ),C0002962;C0205156;C1552607
224,previous analgesic products n ( % ),C0002771;C0205156;C1552607
224,previous ami  n ( % ),C0205156;C1552607;C4319936
224,previous ami,C0205156;C1552607;C4319936
224,previous af,C0205156;C0344434;C1552607;C4049859
224,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0205156;C0413234;C0666743;C1552607
224,previous a - blocker use,C0205156;C1552607
224,previous a - blocker,C0205156;C1552607
224,previous $nmbr$ ari use,C0205156;C1412533;C1552607;C4521376
224,previous $nmbr$ - ari use ( % ),C0205156;C1412533;C1552607;C4521376
224,previous,C0205156;C1552607
224,poor  tried previous glucocorticoid / non - laba,C0017710;C0032854;C0205156;C0542537;C1518422;C1552607;C2700379
224,poor  tried previous glucocorticoid + laba,C0017710;C0032854;C0205156;C0542537;C1552607;C2700379
224,phototherapy previous systemic treatment  n ( % ),C0031765;C0205156;C0678812;C1552607
224,participated in a previous febuxostat studyb  n ( % ),C0205156;C0249529;C1552607
224,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
224,no previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
224,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
224,no previous myocardial infarction $nmbr$ / $nmbr$,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
224,no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
224,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
224,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
224,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
224,no . of previous csdmards  n ( % ),C0205156;C1552607
224,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
224,good  tried previous glucocorticoid + laba,C0017710;C0205156;C0205170;C1552607
224,good  tried previous glucocorticoid,C0017710;C0205156;C0205170;C1552607
224,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
224,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
224,cardioversion in previous $nmbr$ wk,C0013778;C0205156;C0332174;C0439230;C1552607
224,> $nmbr$ previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
224,> $nmbr$ in previous,C0205156;C1552607
224,: mi  previous pci and chronic obstructive pulmonary disease .,C0205156;C1552607;C3810814;C4049621
223,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
223,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
223,former or never diabetes,C0205156;C0750523
223,former or never,C0205156;C0750523
223,former or current smokers ( % ),C0205156;C0750523
223,former n z $nmbr$,C0205156;C0750523
223,former / current smoker ( n = $nmbr$ $nmbr$ ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
223,former / current smoker  n ( % ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
223,former ( n   = $nmbr$  $nmbr$ ),C0205156;C0750523
223,former  n ( % ),C0205156;C0750523
223,former,C0205156;C0750523
222,women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0043210;C0439269;C1532563
222,uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
222,uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
222,uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
222,uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0015895;C0041980;C0439269
222,uric acid ( mg / dl ),C0041980;C0439269
222,mg / dl fpg ( mmol / l ),C0439269;C1532563
222,men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0025266;C0439269;C1532563
222,ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
222,hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563;C3715113
222,fpg  mg / dl ( mmol / l ),C0439269;C1532563
222,change  mg / dl ( mmol / l ),C0392747;C0439269;C0443172;C1532563;C1705241;C4319952
222,> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +,C0439269;C1532563
222,< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
222,( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] ),C0439269;C1532563
222,$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b,C0036056;C0439269;C1532563;C3272372
222,$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d,C0439190;C0439269;C0567349;C0694666;C2348885;C3642216;C4553350
222,$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c,C0439269
221,total cholesterol — mg / dl,C0201950;C0439269;C0543421
221,total cholesterol > $nmbr$ mg / dl,C0201950;C0439269;C0543421
221,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
221,total cholesterol ( sd )  mg / dl,C0201950;C0439269;C0543421;C2699239
221,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
221,total cholesterol $nmbr$ > $nmbr$ mg / dl,C0201950;C0439269;C0543421
221,total cholesterol $nmbr$ < $nmbr$ mg / dl,C0201950;C0439269;C0543421
221,total cholesterol  mg / dl ^,C0201950;C0439269;C0543421
221,total cholesterol  mg / dl  ^,C0201950;C0439269;C0543421
221,total cholesterol  mg / dl,C0201950;C0439269;C0543421
221,toial cholcsierol ( mg / dl ),C0439269
221,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
221,lipid levels — mg / dl,C0428460;C0439269
221,cholesterol  mg / dl total,C0201950;C0439269;C0543421
220,tg > $nmbr$ mg / dl  n ( ° / o ),C0337445;C0439269
220,tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ ),C0337445;C0439269;C3715113
220,tg ( mg / dl ),C0337445;C0439269
220,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
220,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
220,non - hdl - c  mg / dl,C0439269;C1518422;C3715113
220,non - hdl ( mg / dl ) < $nmbr$,C0439269;C1518422;C3715113
220,ldl - c > $nmbr$ mg / dl,C0439269
220,ldl - c < $nmbr$ mg / dl  no . ( % ),C0439269
220,ldl - c < $nmbr$ mg / dl,C0439269
220,ldl - c ( mg / dl ) < $nmbr$,C0439269
220,ldl - c ( mg / dl ) * *,C0439269
220,ldl - c ( mg / dl ),C0439269
220,ldl - c $nmbr$ - $nmbr$ mg / dl,C0439269
220,ldl - c  mg / dl *,C0439269
220,ldl - c  mg / dl,C0439269
220,hdl < $nmbr$ mg / dl,C0439269;C3715113
220,hdl - c < $nmbr$ mg / dl_,C0439269;C3715113
220,hdl - c < $nmbr$ mg / dl . n ( % ),C0439269;C3715113
220,hdl - c < $nmbr$ mg / dl  no . ( % ),C0439269;C3715113
220,hdl - c < $nmbr$ mg / dl,C0439269;C3715113
220,hdl - c ( mg / dl ) *,C0439269;C3715113
220,hdl - c ( mg / dl ),C0439269;C3715113
220,hdl - c  mg / dl,C0439269;C3715113
220,hdl - c  $nmbr$ mg / dl  n ( % ),C0439269;C3715113
220,hdl ( mg / dl ),C0439269;C3715113
220,hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl,C0019016;C0037623;C0439269;C0439475;C1415692;C1708288;C1825777;C3538758;C4318478
220,fsg ( mg / dl ),C0439269
220,fpg ( mg / dl ) x,C0439269
220,fpg ( mg / dl ),C0439269
220,fpg  ( mg / dl ),C0439269
220,fbg ( mg / dl ),C0439269
220,< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl,C0439269;C0439475
219,total cholesterol level  mg / dl,C0439269;C0878805;C1445957
219,tgs ( mg / dl ),C0439269;C1156212;C1537574
219,h dl cholesterol < $nmbr$ mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
219,fasting glucose level  mg / dl,C0202045;C0439269
219,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
219,cholesterol — mg / dl,C0008377;C0439269
219,cholesterol ( mg / dl ),C0008377;C0439269
219,cholesterol  mg / dl,C0008377;C0439269
219,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
219,blood urea nitrogen  mg / dl,C0005845;C0439269;C0600137
219,baseline fasting tgs  mg / dl,C0015663;C0168634;C0439269;C1156212;C1442488;C1537574
218,plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
218,plasma cholesterol — mg / dl,C0439269;C0858034
218,glucose — mg / dl,C0017725;C0439269
218,glucose ( mg / dl ),C0017725;C0439269
218,glucose  mg / dl  mean,C0017725;C0439269;C0444504;C2347634;C2348143
217,> $nmbr$ mg / dl simva ( „ = $nmbr$ ),C0439269
217,> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ],C0439269
217,> $nmbr$ mg / dl simva,C0439269
217,> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ ),C0439269
217,> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ },C0439269
217,> $nmbr$ mg / dl eze / simva,C0439269
217,> $nmbr$ mg / dl chd status,C0280604;C0439269;C0449438;C3542407
217,< $nmbr$ mg / dl simva ( n = $nmbr$ ],C0439269
217,< $nmbr$ mg / dl simva ( n = $nmbr$ ),C0439269
217,< $nmbr$ mg / dl simva,C0439269
217,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ },C0439269
217,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ ),C0439269
217,< $nmbr$ mg / dl eze / simva,C0439269
216,≥ $nmbr$ to < $nmbr$ mg / dl,C0439269
216,hscrp  mg / dl,C0439269
216,crp > $nmbr$ mg / $nmbr$  n [ % ],C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
216,crp > $nmbr$ . $nmbr$ mg / dl  n ( % ),C0439269;C3890735;C4048285
216,crp ( mg / dl ) < $nmbr$ . $nmbr$,C0439269;C3890735;C4048285
216,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
216,crp ( mg / dl ),C0439269;C3890735;C4048285
216,crp  mg / dl,C0439269;C3890735;C4048285
216,creatinine  mg / dl ( sd ),C0010294;C0439269;C1561535;C2699239
216,> $nmbr$ to < $nmbr$ mg dl,C0439269
216,> $nmbr$ to < $nmbr$ mg / dl,C0439269
216,> $nmbr$ & < $nmbr$ mg / dl,C0439269
216,> $nmbr$  < $nmbr$ mg / dl,C0439269
216,( sd )  mg / dl,C0439269;C2699239
216,( mg / dl ± sd ),C0439269;C2699239
216,$nmbr$ to < $nmbr$ mg / dl,C0439269
215,≥ $nmbr$ mg / dl,C0439269
215,£ $nmbr$ mg / dl,C0439269
215,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
215,ppg  mg / dl,C0439269;C1418888
215,mg / dl,C0439269
215,metsyn with ldl > $nmbr$ . $nmbr$ mg / dl,C0439269
215,lpa  mg / dl,C0439269;C1096202;C1439335;C3539666;C4049711;C4553379
215,glycemia  mg / dl,C0005802;C0439269
215,fpg  mg / dl,C0439269
215,fc - ldl - c  mg / dl,C0439269;C2983605
215,fbs > = $nmbr$ mg / dl,C0439269;C3812213
215,fbs < $nmbr$ mg / dl,C0439269;C3812213
215,bun ( mg / dl ),C0439269
215,bun  mg / dl,C0439269
215,apolipoprotein b ( mg / dl ),C0003593;C0439269
215,apolipoprotein b $nmbr$  mg / dl,C0003593;C0439269
215,apolipoprotein b  mg / dl,C0003593;C0439269
215,apolipoprotein a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508
215,apob ( mg / dl ),C0003593;C0439269;C3252643
215,apob  mg / dl,C0003593;C0439269;C3252643
215,apoal ( mg / dl ) *,C0439269
215,apoal  mg / dl,C0439269
215,apoa $nmbr$  mg / dl,C0003592;C0439269;C0523508;C4553344;C4553379
215,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
215,apo b ( mg / dl ),C0003593;C0439269;C3252643
215,apo b  mg / dl,C0003593;C0439269;C3252643
215,albumin ( mg / dl ),C0001924;C0439269
215,> = $nmbr$ mg / dl,C0439269
215,> $nmbr$ mg dl,C0439269
215,> $nmbr$ mg / dl — %,C0439269
215,> $nmbr$ mg / dl,C0439269
215,> $nmbr$ . $nmbr$ mg / dl,C0439269
215,< $nmbr$ mg / dl *,C0439269
215,< $nmbr$ mg / dl,C0439269
215,< $nmbr$ . $nmbr$ mg / dl,C0439269
215,( mg / dl ),C0439269
215,$nmbr$ mg / dl,C0439269
215,$nmbr$ - $nmbr$ mg / dl *,C0439269
215,$nmbr$ - $nmbr$ mg / dl,C0439269
215,$nmbr$ $nmbr$ mg / dl,C0439269
214,week $nmbr$ — mg / liter ^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,week $nmbr$ — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,vonoprazan $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
214,vildagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
214,viidagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
214,vi $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
214,uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
214,upa $nmbr$ mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
214,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
214,toricoxib $nmbr$ mg n = $nmbr$ ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib $nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib $nmbr$ mg bid [ n = $nmbr$ |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib $nmbr$ mg bid ( n   = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
214,tofacitinib  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
214,tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
214,tiotropium / olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
214,tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
214,tiotropium + olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
214,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
214,tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
214,tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
214,tiotropium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
214,tiotropium $nmbr$ mg ( n = $nmbr$,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
214,ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
214,ticagrelor $nmbr$ mg no diabetes n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
214,ticagrelor $nmbr$ mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
214,ticagrelor $nmbr$ mg diabetes n = $nmbr$,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
214,ticagrelor $nmbr$ mg $nmbr$ yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
214,ticagrelor $nmbr$ mg $nmbr$ year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
214,ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
214,ticagrelor  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
214,tcz - sc $nmbr$ mg every other week ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1960952;C2346927;C4321396;C4521761
214,tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
214,tadalafil $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
214,tadalafil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
214,tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
214,tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
214,t $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
214,sotagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
214,sita $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
214,simvastatin $nmbr$ mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
214,silodosin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
214,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
214,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
214,serum triglycerides  mg / dle,C0024138;C0024671;C0026410;C0439269;C0542495;C1960952;C2346927;C3542918;C4321396;C4521761
214,semaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
214,secukinumab intravenous $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,secukinumab $nmbr$   mg no load ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,secukinumab $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,secukinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,secukinumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
214,sc belimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
214,saxa $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,saxa $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,sal $nmbr$ mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
214,rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
214,rosuva $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
214,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
214,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
214,r $nmbr$ mg + fa ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
214,r $nmbr$ mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
214,r $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
214,r $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
214,r $nmbr$ mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
214,pravastatin $nmbr$ mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
214,placebofigolimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,placebo → golimumab $nmbr$ mg / $nmbr$ mga  b,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
214,placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
214,pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
214,pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
214,p - value d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
214,omalizumab $nmbr$ mg ( n [ $nmbr$ ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
214,olodaterol $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
214,olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
214,no . of $nmbr$ - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
214,middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
214,mepolizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
214,mepolizumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
214,mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
214,male acr definition  ^ . g / mg,C0024671;C0026410;C0086582;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
214,lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
214,lovastatin $nmbr$ mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,llraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,liraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
214,liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
214,iv - $nmbr$ mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
214,indacaterol $nmbr$ mg [ n z $nmbr$ ],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
214,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
214,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
214,i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
214,i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
214,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
214,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
214,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
214,hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl ),C0024671;C0026410;C0439269;C0596019;C1960952;C2346927;C2348066;C2985465;C4321396;C4521761
214,golimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
214,golimumab $nmbr$ mg ( n = $nmbr$ ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
214,golimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
214,golimumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
214,glycopyrronium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
214,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
214,gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
214,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
214,fp $nmbr$ mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
214,fluvastatin $nmbr$ mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
214,feno $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,female acr definition  ^ g / mg,C0024671;C0026410;C0043210;C0086287;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
214,febuxostat $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
214,febuxostat $nmbr$ mg daily n = $nmbr$ n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
214,febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
214,febuxostat $nmbr$ mg daily n = $nmbr$,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
214,febuxostat $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
214,famotidine $nmbr$ mg ( n = $nmbr$ ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,fa $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ ),C0013014;C0024671;C0026410;C0031831;C0439269;C1707664;C1960952;C2346927;C2348314;C3540849;C4321396;C4521761
214,eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
214,eze $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
214,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etoricoxib $nmbr$ mg  n = $nmbr$  n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
214,etn $nmbr$ mg + mtx n = $nmbr$,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
214,esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
214,ertuglrflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,ertugliflozin $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg vs placebo / glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg vs placebo / giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
214,ertuglifldzin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,erlugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,empagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
214,empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
214,empaglifiozin $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,eduglinozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,dupiiumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
214,dulaglutide $nmbr$ . $nmbr$ mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
214,dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
214,dulaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
214,dose equivalent  mg ( sd ) ),C0024671;C0026410;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C2699239;C4321396;C4521761
214,dose  mg,C0024671;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,diclofenac $nmbr$ mg  n = $nmbr$  n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ ),C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
214,dapagliflozin $nmbr$ mg group ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
214,dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
214,dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
214,dapagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
214,daily dose > $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
214,daily dose $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
214,daily dose $nmbr$ - $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
214,dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
214,dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
214,dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
214,dabigatran  $nmbr$ mg  vs . warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
214,czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg ( n $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg  % ( n / n ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,czp $nmbr$ mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
214,crp — mg / liter ^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
214,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
214,cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,carisbamate $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
214,carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
214,canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2974540;C4321396;C4521761
214,cana $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
214,cana $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
214,cana $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
214,cana $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
214,cana $nmbr$ mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
214,budesonide mmx $nmbr$ mg  ( n = $nmbr$ ),C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
214,benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
214,belimumab $nmbr$ mg sc ( n $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
214,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
214,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
214,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
214,baseline aspirin dose < $nmbr$ mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
214,baricitinib $nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,baricitinib $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,baricitinib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,baricitinib $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,baricitinib  $nmbr$ mg daily ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
214,b . benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
214,azl - m $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
214,atv $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
214,atv $nmbr$ mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
214,atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ ),C0008107;C0023668;C0024671;C0026410;C0286651;C0439269;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
214,atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
214,ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,ato $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,aspirin $nmbr$ mg ( n = $nmbr$ ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,asa > $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
214,asa < $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
214,aplxaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
214,apixaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
214,apixaban  $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
214,apixaban  $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
214,amlodipine / wlsartan i $nmbr$ / $nmbr$ mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
214,amlodipine / valsartan $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
214,aml / val $nmbr$ / $nmbr$ mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
214,aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761;C4554402
214,ami $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
214,ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
214,alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
214,alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
214,alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
214,> $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,> $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,> $nmbr$ . $nmbr$ mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,> $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,< $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,< $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,< $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
214,* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023822;C0023824;C0024671;C0025266;C0026410;C0168634;C0202117;C0337445;C0368910;C0392885;C0439269;C1142985;C1305855;C1442160;C1442488;C1552663;C1960952;C2346927;C2360800;C2827109;C3642216;C3715113;C4321396;C4521761
214,* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .,C0010054;C0010068;C0012634;C0018787;C0024671;C0026410;C0027361;C0237753;C0333482;C0360714;C0439269;C0449788;C0948008;C1956346;C1960952;C2346927;C4081854;C4321396;C4521761
214,$nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
214,$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg ew n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg eow n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg / kgf ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg / $nmbr$ mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
214,$nmbr$ mg / $nmbr$ mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
214,$nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
213,bpearson ' s chi ‐ square test .,C0008041
212,rankin scale ≥ $nmbr$,C0451405
211,karnofsky score 竺 $nmbr$,C0206065
211,karnofsky score < $nmbr$,C0206065
210,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
210,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
210,abaloparatide - sc  n ( % ),C0282380;C4042342
209,apoe e $nmbr$ carriers  no . ( % ),C0003595;C0007294;C0523511;C1412481
209,ala carriers,C0007294;C0523459;C3888236
208,carrier ( n = $nmbr$ ),C0007294;C0560175;C1325398;C1706209;C3273162
208,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
208,apoe   ε $nmbr$ carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
207,ada $nmbr$ / $nmbr$ n [ $nmbr$,C1060325;C3811629
207,ada $nmbr$ / $nmbr$ ( n [ $nmbr$ ),C1060325;C3811629
207,ada  yes,C1060325;C1549445;C1705108;C1710701;C3811629
207,ada  no,C1060325;C3811629
206,adas — cog score,C0449820;C3539026;C4050231
206,adas - cog score *,C0449820;C3539026;C4050231
206,adas - cog,C3539026
205,advanced  n ( % ),C0205179
205,advanced,C0205179
204,peri - op ace - inhibitors / arbs : no ( n = $nmbr$ ),C0003015;C0347985;C3888198
204,arbs or ace inhibitors,C3888198
204,arb or ace inhibitor  n ( % ),C3888198
204,arb or ace inhibitor,C3888198
204,arb monotherapy,C3888198
204,arb - arb / ccb,C0006684;C3888198
204,arb + ccb ( n = $nmbr$ ),C0006684;C3888198
204,arb ( n  % ),C3888198
204,arb  n ( % ),C3888198
204,acei / arb therapy  n ( % ),C0039798;C0087111;C1363945;C3888198
204,acei / arb and bb after randomisation,C3888198
204,ace inhibitor / arb therapy,C1444755;C3888198
203,without acei / arb,C3888198
203,with acei / arb,C3888198
203,previously on acei + arb,C3888198
203,baseiine acei / arb,C3888198
203,arbs,C3888198
203,arb / ace,C1452534;C3888198;C4284014
203,arb  %,C3888198
203,arb,C3888198
203,aceis / arbs,C3888198
203,acei / arb,C3888198
203,ace / arb users,C1452534;C1706077;C3888198;C4284014
203,ace / arb use,C1452534;C3888198;C4284014
203,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
203,ace / arb,C1452534;C3888198;C4284014
202,stent plus abciximab,C0038257;C0288672;C0332287
202,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
202,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
202,abciximab vs . primary,C0288672
202,abciximab no . / total ( % ),C0288672
202,abciximab ( n = $nmbr$ ),C0288672
202,abciximab,C0288672
202,$nmbr$ abciximab ( n = $nmbr$ ),C0288672
201,baseline abi  affected limb,C0168634;C1328319;C1442488;C3888326
201,ankle / brachial index,C1328319;C3888326
201,ankle - brachial index £ $nmbr$ . $nmbr$,C1328319;C3888326
201,ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % ),C1328319;C3888326
201,ankle - brachial index < $nmbr$ . $nmbr$,C1328319;C3888326
201,abi > $nmbr$ . $nmbr$,C1328319;C3888326
201,abi < $nmbr$ . $nmbr$,C1328319;C3888326
201,abi # $nmbr$ . $nmbr$,C1328319;C3888326
201,abi,C1328319;C3888326
200,± standard deviation . triglyceride,C0041004;C0871420
200,sd = standard deviation  bmi = body mass index  ed = erectile,C0871420;C1305855;C2699239;C3538926
200,rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
199,western europe  australia  new zealand  middle east,C0026068;C0043129;C4289954
199,western europe  australia  new zealand  middle eai,C0043129;C0444598;C0549183;C1552826;C4289954
199,western europe  australia  new zealand  and middle east,C0043129;C4289954
199,western europe  australia  new zealand,C0043129;C4289954
199,the netherlands  australia  new zealand  and south africa,C0027778;C4289954
199,australia / new zealand,C4289954
199,asia / australia / new zealand,C0003980;C4289954
198,history of osteoporotic fracture  n ( % ) a,C4075937
197,history of asthma - related intubation — no . ( % ),C0455544
196,history of microalbuminuria — no . ( % ),C3532606
195,history of atrial fibrillation or flutter treatment at randomisation,C0729790
195,history of atrial fibrillation or flutter,C0729790
195,history of atrial fibrillation or fl utter,C0729790
195,history of atrial fibrillation and / or flutter,C0729790
195,history of atrial fibrillation / flutter  ( % ),C0016385;C0232197;C0729790;C1998417;C2242390
195,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
195,history of atrial fibrillation  type 一 no . ( % ),C0332307;C0729790;C1547052
195,history of atrial fibrillation  n ( % ),C0729790
195,history of atrial fibrillation,C0729790
194,history of percutaneous coronary intervention,C1320647;C4554713
193,history of gestational diabetes mellitus — no . ( % of women ),C2183115
192,history of diabetes mellitus ( n = $nmbr$ ),C0455488
192,history of diabetes mellitus  no . ( % ),C0455488
192,history of diabetes mellitus  n ( % ),C0455488
192,history of diabetes mellitus,C0455488
191,history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %,C0205267;C2315493
191,history of claudication,C2315493
190,hazard ratio for event ( $nmbr$ % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
190,hazard ratio [ $nmbr$ % ci ],C0008107;C2985465;C3259781
190,hazard ratio * ( and $nmbr$ % ci ),C2985465
190,hazard ratio * ( $nmbr$ % ci ),C0008107;C2985465;C3259781
190,hazard ratio ( $nmbr$ % confidence interval ) *,C0009667;C2985465
190,hazard ratio ( $nmbr$ % confidence interval ),C0009667;C2985465
190,hazard ratio ( $nmbr$ % ci ) vs . placebo,C0008107;C2985465;C3259781
190,hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes,C0008107;C1320657;C2985465;C3259781
190,hazard ratio ( $nmbr$ % ci ) - j -,C0008107;C2985465;C3259781
190,hazard ratio ( $nmbr$ % ci ) *,C0008107;C2985465;C3259781
190,hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis,C0008107;C2985465;C3259781
190,hazard ratio ( $nmbr$ % ci ),C0008107;C2985465;C3259781
190,hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
190,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
189,unadjusted hazard ratio ( $nmbr$ % cl ),C0596019;C1439367;C2985465
189,unadjusted hazard ratio ( $nmbr$ % ci ),C0008107;C1439367;C2985465;C3259781
189,adjusted hazard ratio *,C0456081;C2985465
189,adjusted hazard ratio ( $nmbr$ % cl ) *,C0456081;C0596019;C2985465
189,adiusted hazard ratio *,C2985465
188,hazard ratio with low ( $nmbr$ % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
188,hazard ratio with high ( $nmbr$ % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
188,hazard ratio with,C2985465
188,hazard ratio vs . placebo,C2985465
188,hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value,C2985465
188,hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value,C2985465
188,hazard ratio and $nmbr$ % confidence interval,C2985465
188,hazard ratio [ $nmbr$ % cl ],C0596019;C2985465
188,hazard ratio ( $nmbr$ % confi dence interval ),C1272706;C1552654;C1552713;C2985465
188,hazard ratio ( $nmbr$ % cl ],C0596019;C2985465
188,hazard ratio ( $nmbr$ % cl ) *,C0596019;C2985465
188,hazard ratio ( $nmbr$ % cl ),C0596019;C2985465
188,hazard ratio ( $nmbr$ % c,C2985465
188,hazard ratio $nmbr$ ),C2985465
188,hazard ratio $nmbr$,C2985465
188,hazard ratio,C2985465
187,risk factors — no . ( % ),C0035648;C1553898
187,risk factors specified as inclusion criteria — no . ( % ) f,C0035648;C1553898
187,risk factors only,C0035648;C0205171;C1553898;C1720467
187,risk factors for stroke  no . ( % ),C0035648;C1553898
187,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
187,risk factors for recurrent vte — no . ( % ) f,C0035648;C0630906;C1455761;C1553898;C2945760
187,risk factors and medical history,C0035648;C1553898
187,risk factors and immobility level  n ( % ),C0035648;C1553898
187,risk factors and diabetes status ( % ),C0035648;C1553898
187,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
187,risk factors ( % ),C0035648;C1553898
187,risk factors  no . ( % ),C0035648;C1553898
187,risk factors  %,C0035648;C1553898
187,risk factors,C0035648;C1553898
187,risk factor ( predefined ) for falling at screening  n ( % ),C0035648
187,risk factor,C0035648
187,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
187,qualifying risk factor — no . ( % ),C0035648;C1514624
187,qualifying risk factor  n ( % ),C0035648;C1514624
187,qualifying risk factor,C0035648;C1514624
187,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
187,other risk factors,C0035648;C1553898
187,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
187,non - transient risk factors for recurrent vte  n ( % ),C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
187,no . of risk factors for venous thromboembolism  no . ( % ),C0035648;C1553898
187,no . of risk factors ( % ) | |,C0035648;C1553898
187,multiple risk factors,C0035648;C0439064;C1553898
187,multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %,C0035648;C0280604;C0439064;C1553898;C3542407
187,diagnoses / risk factors  n ( % ],C0011900;C0035648;C1553898
187,diagnoses / risk factors  n ( % ),C0011900;C0035648;C1553898
187,cvd risk factors ( age > $nmbr$ ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
187,cvd risk factors ( age > $nmbr$ ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
187,cv risk factors and history,C0035648;C1553898;C3538987;C4048877;C4318503
187,chd risk factors #,C0035648;C0280604;C1553898;C3542407
187,chads $nmbr$ risk factors  n ( % ),C0007928;C0035648;C1413373;C1553898
187,> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
187,> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
187,> $nmbr$ chd risk factors,C0035648;C0280604;C1553898;C3542407
186,score on asthma control questionnaire * *,C4706265
185,health assessment questionnaire score,C2960025
184,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
184,score on st . george ' s respiratory questionnaire ^ ^,C3472502
183,table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0168634;C0370003;C0947343;C1315074;C1442488;C1706074;C2347026;C4684572
183,table $nmbr$ . selected baseline characteristics of the study patients . *,C0039224;C1706074
183,table $nmbr$ . characteristics of the patients at baseline . *,C0039224;C0815172;C1706074
183,table $nmbr$ . characteristics of patients treated with losartan and atenolol *,C0039224;C0815172;C1706074
182,alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0001899;C0057041;C1415274;C3887708
182,alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708
182,alanine aminotransferase  u / l,C0001899;C0057041;C0439339;C1415274;C3887708
181,aspartate aminotransferase increased,C0004002
181,aspartate aminotransferase  u / l,C0004002;C0439339
180,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C1532338;C2826257
180,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
180,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
180,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
180,percutaneous coronary revascularization,C1532338
180,percutaneous coronary intervention §,C1532338
180,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338
180,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C1532338
180,percutaneous coronary intervention n ( % ),C1532338
180,percutaneous coronary intervention done *,C1532338
180,percutaneous coronary intervention  n ( % ),C1532338
180,percutaneous coronary intervention,C1532338
180,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
180,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0181074;C0332835;C0917805;C1054154;C1532338;C1961139
179,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
179,toast classification of qualifying stroke  no . ( % ),C1514624;C1710306;C4521230
179,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
179,toast classification,C1710306;C4521230
178,angina class iii or iv — no . ( % ),C0264677
178,angina class iii or iv prior myocardial infarction,C0264677
178,angina class iii or iv prior,C0264677
177,radiographic progression based on change from baseline > sdc,C0242656;C0444708;C0449258
177,progression of albuminuria,C0001925;C0242656;C0449258
177,first disease - progression outcome to occur §,C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1947900;C3542417;C4552808
177,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
177,albuminuria progression,C0001925;C0242656;C0449258
177,% patients with no progression,C0030705;C0242656;C0449258
176,transfusions,C0005841;C0199960;C1879316
176,transfusion ≥ $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C0439148;C1519795;C1879316;C3853603
176,transfusion,C0005841;C0199960;C1879316
176,blood transfusion,C0005841;C0281867
176,any blood transfusion,C0005841;C0281867
176,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
175,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
175,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
175,qualifying type of atherosclerosis  n ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
175,qualifying atherosclerosis,C0003850;C0004153;C1514624
175,large - artery atherosclerosis,C0003850;C0004153;C0226003
175,atherosclerosis ^  n ( % ),C0003850;C0004153
175,atherosclerosis,C0003850;C0004153
175,arteriosclerosis,C0003850
174,blood glucose,C0005802
174,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
173,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
173,blood - glucose control,C3267174
172,fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0428568;C0439269;C1261430;C1532563
172,fasting blood glucose > $nmbr$ mg / dl,C0428568;C0439269;C1261430
172,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
172,fasting blood glucose,C0428568;C1261430
171,red blood cell counting  $nmbr$ / l,C0005767;C0005768;C0022827;C0229664;C0332575;C0750480;C1260956;C1705566;C4049926
171,blood bilirubin increased,C0005437;C0005767;C0005768;C0229664
171,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
171,any blood,C0005767;C0005768;C0229664
170,total population n,C3258257
170,total population ( n = $nmbr$ ),C3258257
170,total population,C3258257
170,total ho population ( n = $nmbr$ ),C0019905;C1832110;C3258257;C3889614
170,total carmelina population,C3258257
169,total study population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
169,total study population ( n = $nmbr$  $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
169,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
169,total study itt population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
169,study population,C2348561
168,vasodilator,C0042402;C3537240
168,other vasodilators §,C0042402
168,other vasodilator,C0042402;C3537240
168,iv vasodilator,C0022326;C0042402;C3537240;C4265176
168,both iv vasodilator and inotrope,C0022326;C0042402;C3537240;C4265176
167,with prior mi / stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C3810814;C4554100
167,prior years taking warfarin,C0332152;C0439234;C2826257
167,prior vka use for > $nmbr$ d  %,C0042153;C0332152;C0457083;C1947944;C2826257
167,prior use of systemic,C0205373;C0332152;C1524063;C2826257
167,prior use of synthetic dmards  n ( % ),C0242708;C0332152;C1524063;C1883254;C2826257
167,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
167,prior use of conventional dmards only ( biologic - nai ' ve )  n ( % ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
167,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
167,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
167,prior use of $ $nmbr$ systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
167,prior tnfi  n ( % ),C0332152;C2826257
167,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
167,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
167,prior tnf antagonist failure  n [ % ],C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
167,prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
167,prior thienopyridine ( - ),C0332152;C1120149;C2826257
167,prior thienopyridine ( + ),C0332152;C1120149;C2826257
167,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
167,prior stroke — no . ( % ),C0332152;C2826257
167,prior stroke or tza,C0038454;C0332152;C2826257;C4554100
167,prior stroke or tia  %,C0038454;C0332152;C2826257;C4554100
167,prior stroke or tia,C0038454;C0332152;C2826257;C4554100
167,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
167,prior stroke / mi  n ( % ),C0038454;C0332152;C2826257;C3810814;C4554100
167,prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
167,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
167,prior statin use ( n = $nmbr$ ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
167,prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
167,prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
167,prior revascularization ( % ),C0332152;C0581603;C2826257
167,prior revascularization,C0332152;C0581603;C2826257
167,prior peripheralarterialdisease,C0332152;C2826257
167,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
167,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
167,prior or new diabetes,C0332152;C2826257
167,prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
167,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
167,prior om,C0028971;C0332152;C1705272;C2826257
167,prior oad :,C0332152;C2826257
167,prior oac,C0332152;C2826257
167,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
167,prior nsaid  n ( % ) a,C0003211;C0332152;C2826257;C3536840
167,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
167,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
167,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
167,prior migraine *,C0149931;C0332152;C2826257
167,prior migraine,C0149931;C0332152;C2826257
167,prior mi within $nmbr$ y  no . ( % ),C0332152;C2826257;C3810814
167,prior mi n = $nmbr$,C0332152;C2826257;C3810814
167,prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
167,prior mi ( n - $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
167,prior mi  n / n ( % ),C0332152;C2826257;C3810814
167,prior mi  %,C0332152;C2826257;C3810814
167,prior mi,C0332152;C2826257;C3810814
167,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
167,prior lev use,C0023556;C0332152;C2826257
167,prior lev,C0023556;C0332152;C2826257
167,prior known stenosis > $nmbr$ %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
167,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
167,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
167,prior immunosuppressant failurec,C0021081;C0332152;C2826257
167,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
167,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
167,prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
167,prior gestational diabetes,C0085207;C0332152;C2826257
167,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
167,prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
167,prior dm,C0011816;C0332152;C2826257;C3250443
167,prior diabetes,C0011847;C0011849;C0332152;C2826257
167,prior cvd,C0007222;C0332152;C2826257
167,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
167,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
167,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
167,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
167,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
167,prior conventional synthetic dmards  n ( % ),C0242708;C0332152;C0439858;C1883254;C2826257
167,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
167,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
167,prior cardiovascular event  ',C0332152;C1320716;C2826257
167,prior cardiovascular event,C0332152;C1320716;C2826257
167,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
167,prior cabg  %,C0010055;C0332152;C2826257
167,prior cabg,C0010055;C0332152;C2826257
167,prior brachytherapy,C0006098;C0332152;C2826257
167,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
167,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
167,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
167,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
167,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
167,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
167,prior anti - tnf therapy,C0281481;C0332152;C2826257
167,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
167,prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0002978;C0332152;C2826257
167,prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °,C0002978;C0332152;C2826257
167,prior af ablation  n ( % ),C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
167,prior aeds  ≥ $nmbr$  n ( % ),C0180309;C0332152;C2826257
167,prior admb,C0332152;C2826257
167,prior acbi or arb use,C0332152;C2826257
167,prior a - blocker use,C0332152;C2826257
167,prior,C0332152;C2826257
167,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
167,number of prior aeds    n   ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
167,number of prior aeds  n ( % ) b,C0180309;C0237753;C0332152;C0449788;C2826257
167,number of prior aeds  n ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
167,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
167,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
167,no prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
167,no prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
167,no prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
167,no prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
167,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
167,no prior mi n = $nmbr$,C0332152;C2826257;C3810814
167,no prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
167,no prior mi,C0332152;C2826257;C3810814
167,no prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
167,no prior dm,C0011816;C0332152;C2826257;C3250443
167,no prior cvd,C0007222;C0332152;C2826257
167,no prior cabg,C0010055;C0332152;C2826257
167,no prior admc,C0332152;C2826257
167,no . of prior tnfi,C0332152;C2826257
167,no . of prior bdmards,C0332152;C2826257
167,no . of prior aedsd,C0332152;C2826257
167,no . of prior aeds  n ( % ) $nmbr$ - $nmbr$,C0180309;C0332152;C2826257
167,no . of prior aeds  n ( % ),C0180309;C0332152;C2826257
167,no . of prior aeds  c n ( % ),C0180309;C0332152;C2826257
167,duration of prior statin therapy ^,C0332152;C0360714;C0444917;C2826257
167,dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
167,dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
167,$nmbr$ prior tnf antagonist failures  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
167,$nmbr$ prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
167,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
167,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
167,# of prior bdmards,C0332152;C2826257
166,st ‐ str ≥ $nmbr$ % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
166,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
166,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
166,pre fev $nmbr$,C0332152;C0740175;C2257086;C3669034;C3714541
166,pre - treatedforhypertension [ n ( % ) ],C0332152;C0740175;C2257086;C3669034
166,pre - mixed insulin,C0205430;C0332152;C0740175;C2257086;C3160715;C3669034
166,fev $nmbr$ reversibilityz ( pre / post salbutamol )  %,C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
166,fev $nmbr$ reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
166,fev $nmbr$ reversibility  pre - / post - albuterol  %,C0001927;C0332152;C0449261;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
166,fev $nmbr$ ( pre - albuterol )  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
166,fev $nmbr$  pre - albuterol  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
166,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
165,leading to study withdrawal,C0332152;C1522538
165,leading to study drug discontinuation,C0332152;C1522538
165,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
165,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
164,yes vs . no,C1549445;C1705108;C1710701
164,yes *,C1549445;C1705108;C1710701
164,yes ( stopped for trial ),C1549445;C1705108;C1710701
164,yes ( n = $nmbr$ ),C1549445;C1705108;C1710701
164,yes ( n  % ),C1549445;C1705108;C1710701
164,yes ( any ),C1549445;C1705108;C1710701
164,yes ( % ),C1549445;C1705108;C1710701
164,yes ',C1549445;C1705108;C1710701
164,yes  z $nmbr$ cm,C1549445;C1705108;C1710701
164,yes  yes,C1549445;C1705108;C1710701
164,yes  unknown,C1549445;C1705108;C1710701
164,yes  r $nmbr$ y,C1549445;C1705108;C1710701
164,yes  proliferative,C1549445;C1705108;C1710701
164,yes  o $nmbr$ cm,C1549445;C1705108;C1710701
164,yes  non - proliferative,C1549445;C1705108;C1710701
164,yes  non - insulin - treated,C1549445;C1705108;C1710701
164,yes  n ( % ),C1549445;C1705108;C1710701
164,yes  insulin - treated,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
164,yes  $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
164,yes,C1549445;C1705108;C1710701
164,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
164,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
164,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
164,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
164,partner  n ( % yes ),C0682323;C1549445;C1705108;C1710701;C3887537
164,no  yes,C1549445;C1705108;C1710701
164,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
164,naive : yes,C1549445;C1705108;C1710701
164,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
164,etn  yes,C0014758;C0717758;C1549445;C1705108;C1710701
164,diabetic yes,C0241863;C1549445;C1705108;C1710701
164,diabetesh yes,C1549445;C1705108;C1710701
164,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
164,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
164,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
164,[ no / yes ] ( % ),C1549445;C1705108;C1710701
163,steroids § §,C0038317
163,steroids ( other ),C0038317
163,steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
163,steroids ( inhaled ) a,C0038317
163,steroids  n ( % ),C0038317
163,steroid - free cr - $nmbr$,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
163,no steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
162,other steroids,C0038317
162,baseline steroids,C0038317;C0168634;C1442488
161,sensitive responders ( n = $nmbr$ ),C0020517;C0332324;C1522640
161,sensitive responder ( n = $nmbr$ ),C0020517;C0332324;C1522640
161,sensitive,C0020517;C0332324;C1522640
161,hypersensitivity  n ( % ),C0020517;C0520946
161,allergic disease by historyb  n ( % ),C0020517;C0851444
160,traditional nsaid use,C0003211;C3536840;C3897349
160,traditional nsaid,C0003211;C0443324;C1548559;C3536840
160,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0032790;C3536840
160,postoperative nsaid or glucocorticoid use,C0003211;C0032790;C3536840
160,other nsaids,C0003211
160,nsaid   at   least   once,C0003211;C3536840
160,nsaid use — no . / total no . ( % ),C0003211;C3536840
160,nsaid,C0003211;C3536840
160,non - steroidal anti - inflammatory drugs,C0003211
160,never nsaid,C0003211;C2003901;C3536840
160,cox - $nmbr$ selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
160,cox - $nmbr$ selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
160,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
159,high density lipoprotein ( mg / dl ),C0023821;C0439269
159,high - density lipoprotein ],C0023821
159,high - density lipoprotein  mg / dl,C0023821;C0439269
159,high - density lipoprotein,C0023821
158,low - density lipoprotein choles -,C0023823
158,low - density lipoprotein ^,C0023823
158,low - density lipoprotein  mg / dl,C0023823;C0439269
158,low - density lipoprotein,C0023823
157,highly sensitive responders ( n = $nmbr$ ),C0439822
157,highly sensitive responder ( n = $nmbr$ ),C0439822
157,highly sensitive,C0439822
156,no high - intensity statin,C0360714;C4081854
156,high ‐ intensity statins ‡,C0360714;C4081854
156,high intensity,C4081854
156,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
156,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
156,high - intensity statin *,C0360714;C4081854
156,high - intensity statin,C0360714;C4081854
155,hypotension  n ( % ),C0020649;C3163620
155,hypotension,C0020649;C3163620
154,hypertensive  n ( % ),C0857121
154,hypertensive,C0857121
153,antihypertensive therapy — no . ( % ),C0585941
153,antihypertensive therapy  n ( % ),C0585941
153,antihypertensive therapy,C0585941
153,anti - hypertensive therapy - no . ( % ),C0585941
153,anti - hypertensive therapy,C0585941
152,uc disease durslion,C0012634
152,priorvascular disease  %,C0012634
152,polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
152,polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
152,polyvascular disease * and type $nmbr$ diabetes status,C0012634
152,polyvascular disease * ( n = $nmbr$ ),C0012634
152,polyvascular disease ( n = $nmbr$ ),C0012634
152,no polyvascular disease * ( n = $nmbr$ $nmbr$ ),C0012634
152,no polyvascular disease ( n = $nmbr$ $nmbr$ ),C0012634
152,no multivessel disease,C0012634
152,multivessel disease,C0012634
152,microvascular disease *,C0012634;C0443258
152,microvascular disease  n ( % ),C0012634;C0443258
152,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
152,macrovascular disease  n ( % ),C0012634
152,established maerovaseular disease and albuminuria,C0012634;C0443211;C1272684
152,established disease,C0012634;C0443211;C1272684
152,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
152,cerebrovascuiar disease,C0012634
151,site of disease — no . ( % ),C0012634;C2945843
151,multivessel disease 一 no . ( % ),C0012634
151,multivessel disease — no . ( % ),C0012634
151,multivessel disease  no . ( % ),C0012634
151,multivessel disease  n ( % ),C0012634
151,left main disease  n ( % ),C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
151,disorders ( soc ),C0012634
151,disease and quality - of - life scores  mean ( sd ),C0012634
151,disease and quality - of - life scores,C0012634
151,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
150,underlying disease,C0012634;C4067746
150,peripherai arteriai disease,C0012634
150,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
150,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
150,coronarv arterv disease,C0012634
149,disease site — no . of patients ( % ) |,C0012634;C0205145;C1515974;C2825164
149,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
149,disease site  n [ % ],C0012634;C0205145;C1515974;C2825164
149,disease hare . no . ( % ) i,C0012634
149,disease extent  n ( % ),C0012634;C0439792
148,priorbone disease,C0012634
148,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0332152;C0392747;C2826257;C3687832
148,prior disease,C0012634;C0332152;C2826257
148,disease,C0012634
148,any disease,C0012634
147,prespecified medical conditions  n ( % ) f,C0012634;C0016327;C0199168;C0205476;C0348080;C1705253;C3864998
147,presenting condition  n ( % ),C0012634;C0348080;C0449450;C1705253;C3864998
147,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
147,history of other medical conditions  n ( % ),C0012634;C0262926;C0348080;C1705253;C3864998
147,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
147,condition $nmbr$ ( $nmbr$ . $nmbr$ ),C0012634;C0348080;C1705253;C3864998
147,any condition,C0012634;C0348080;C1705253;C3864998
147,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .,C0012634;C0014442;C0018801;C0344434;C0348080;C0387288;C1705253;C3864998;C4049859;C4521602
146,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
145,chronic inflammatory disease,C1290886
144,inflammatory disease,C1290884
143,inflammatory bowel disease,C0021390
143,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
142,type of reflux disease,C0232483;C0457464;C1882919;C4317146
141,gastrooesophageal reflux disease,C0017168;C4553201
141,gastroesophageal reflux disease,C0017168;C4553201
140,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
140,family history of coronary artery disease,C2317524
139,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
139,family history of coronary disease,C0018787;C0850707
138,chronic kidney diseased,C2364010
137,chronic pulmonary disease,C0746102
136,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
136,carotid artery disease,C0007273
135,congenital heart disease,C0152021
134,rheumatic heart disease,C0035439
133,connective tissue disease,C0009782
133,connective - tissue disease,C0009782
133,associated with connective tissue disease,C0009782;C0332281
133,assoc  with connective tissue disease,C0009782
132,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
132,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
132,components,C0449432
132,component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called,C0205250;C0449432;C0449820;C1705248;C4551823
131,treatment throughout study,C1521826;C3161471
131,study treatment — no . / total no . ( % ),C1521826
131,previous treatment in the healing study  n ( % ),C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
130,study treatment,C1521826
130,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
129,use of anti - hypertensive agents  n ( % ) *,C0432633;C0450442;C0857121;C1254351;C1521826;C1524063
129,two agents,C0205448;C0450442;C1254351;C1521826
129,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
129,p - blocking agents  selective,C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C2603361
129,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
129,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
129,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
129,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
129,oral agent and / or insulin therapy,C0442027;C0450442;C1254351;C1521826;C4521986
129,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
129,no . of agents,C0450442;C1254351;C1521826
129,conventional agents *,C0439858;C0450442;C1254351;C1521826
129,anyantianginal agent,C0450442;C1254351;C1521826
129,any bp - lowering agents ^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
129,antialdosterone agents,C0450442;C1254351;C1521826
129,anti ‐ platelet agents  n ( % ),C0005821;C0432633;C0450442;C1254351;C1521826
129,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
129,> $nmbr$ oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
128,modmy al randcnxzaton,C0202311
127,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
127,total cataract,C3665439
126,clinically relevant non,C1518422;C2347946
126,any relevant infarct,C0021308;C2347946
125,oral medications,C0304289
125,oral anti - dm drug status  no . ( % ),C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
125,concomitant oral anti - dm drugs  no . ( % ) a,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
124,oral anticoagulants,C0354604
124,oral anticoagulant — no . / total no . ( % ),C0354604
124,oral anticoagulant n ( % ),C0354604
124,oral anticoagulant drugs  n ( % ),C0354604
124,oral anticoagulant drugs,C0354604
124,oral anticoagulant agent,C0354604
124,oral anticoagulant  n ( % ),C0354604
124,oral anticoagulant,C0354604
123,concomitant anticoagulant  antithrombotic or nsaid  n ( % ),C0003280;C0521115;C0848112;C3536711
123,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
123,anticoagulant group ( n = $nmbr$ ),C0003280;C0441848;C0848112;C3536711
123,anti - coagulants - no . ( % ),C0848112
123,anti - coagulants,C0848112
122,periprocedural anticoagulant,C0003280;C0848112;C3536711
122,other anticoagulant,C0003280;C0848112;C3536711
122,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
122,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
122,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
122,any anticoagulant,C0003280;C0848112;C3536711
122,anticoagulants,C0003280
122,anticoagulant,C0003280;C0848112;C3536711
121,organic,C0747055
120,orthopaedic,C0029355
119,postprandial indices,C0376674;C4033634
119,fasting indices,C0015663;C4033634
118,somnolence,C0013144;C2830004;C4553740
117,psycholeptics,C3653516
116,psychogenic,C0458006
115,pro / pro homozygotes,C0019904;C1120626
114,progression to diabetes,C1735364
113,proctosigmoiditis,C0033252
112,hormones,C0019932
112,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
111,primary composite endpoint ‡,C0205199;C1547335;C2986535
111,primary composite end point ‡,C0205199;C1547335;C2986535
111,primary composite end point,C0205199;C1547335;C2986535
111,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
111,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
111,composite ocular end point ^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
111,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
111,composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp,C0037623;C0205199;C1415692;C1547335;C1708288;C2349179;C2826544;C4318478
111,composite endpoint,C0205199;C1547335;C2349179;C2826544
111,composite,C0205199;C1547335
111,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
111,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
110,use $nmbr$ - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
110,no use of $nmbr$ - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
110,$nmbr$ - asa compounds  n ( % ),C0004057;C0205198;C1706082;C3853627
110,$nmbr$ - aminosalicylic compounds — no . ( % ),C0205198;C1706082
109,cabg — no . { % ),C0010055
109,cabg — no . ( % ),C0010055
109,cabg or valve,C0010055
109,cabg or ptca / pci,C0010055
109,cabg or ptca ( % ),C0010055
109,cabg or pci,C0010055
109,cabg or angioplasty,C0010055
109,cabg only,C0010055;C0205171;C1720467
109,cabg > $nmbr$ month ago,C0010055;C0332177;C0439231
109,cabg ( % ),C0010055
109,cabg  n ( % ),C0010055
108,timi non - cabg major,C0010055;C1518422
108,safety : non - cabg - related bleeding,C0010055;C0036043;C1518422;C1705187
108,non - cabg related bleeding at $nmbr$ h,C0010055;C1518422
108,non - cabg or combined,C0010055;C1518422
107,hx cabg,C0010055;C0262926;C3814444
107,cabg :,C0010055
107,cabg,C0010055
106,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
106,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
106,prior aortocoronary bypass surgery,C0010055;C0455610
106,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
106,multivessel coronary - artery bypass grafting,C0010055
106,coronary bypass surgery,C0010055
106,coronary bypass  n ( % ),C0010055
106,coronary artery bypass surgery,C0010055
106,coronary artery bypass grafting n ( % ),C0010055
106,coronary artery bypass grafting,C0010055
106,coronary artery bypass graft — no . ( % ),C0010055;C1260596
106,coronary artery bypass graft  n ( % ),C0010055;C1260596
106,coronary artery bypass graft,C0010055;C1260596
106,coronary artery bypass,C0010055
106,coronary - artery bypass grafting §,C0010055
106,coronary - artery bypass grafting,C0010055
105,cabg surgery by no . of vessels $nmbr$,C0010055;C0042381;C3714645
105,cabg performed during index hospitalization,C0010055
104,other oral hypoglycemic drug ( s ),C0359086
104,oral hypoglycemics,C0359086
104,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
104,oral hypoglycemic drug,C0359086
104,oral hypoglycemic agentsj,C0359086
104,oral hypoglycemic agents,C0359086
104,oral hypoglycemic agent,C0359086
104,oral hypoglycemic,C0359086
104,oral hypoglycaemics only,C0205171;C0359086;C1720467
104,oral antihyperglycaemic  n ( % ),C0359086
104,any oral hypoglycemic drug 一 no . ( % ),C0359086
104,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .,C0000723;C0003211;C0010055;C0033572;C0038952;C0042295;C0043210;C0205163;C0205166;C0205171;C0220921;C0237753;C0332490;C0359086;C0439165;C0444099;C0449788;C0600061;C0678226;C0679138;C0679199;C0679831;C1123023;C1305855;C1532338;C1549488;C1561533;C1706317;C1720467;C3146286;C4520765
103,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
103,neither ace - i nor arb use,C0021966;C0221138;C1452534;C4284014
103,ace ‐ i or arb,C0021966;C0221138;C1452534;C4284014
103,ace or arb,C1452534;C4284014
103,ace - lorarb,C1452534;C4284014
103,ace - l / arbs,C1452534;C3888198;C4284014
103,ace - i or arb use at baseline,C0021966;C0221138;C1452534;C4284014
103,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
103,ace - i or arb  % ( n ),C0021966;C0221138;C1452534;C4284014
103,ace - i or arb,C0021966;C0221138;C1452534;C4284014
103,ace - i or angiotensin receptor blocker,C0021966;C0221138;C1452534;C4284014
103,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
103,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
103,ace - i ( n  % ),C0021966;C0221138;C1452534;C4284014
103,ace,C1452534;C4284014
102,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
102,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
102,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
102,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
102,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
102,cancer — no . ( % ),C0006826;C0998265;C1306459
102,cancer §,C0006826;C0998265;C1306459
102,cancer n ( % ),C0006826;C0998265;C1306459
102,cancer * *,C0006826;C0998265;C1306459
102,cancer *,C0006826;C0998265;C1306459
102,cancer ( n = $nmbr$ ),C0006826;C0998265;C1306459
102,cancer  fatal and nonfatal,C0006826;C0998265;C1306459
102,cancer,C0006826;C0998265;C1306459
102,all cancer,C0006826;C0998265;C1306459
102,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
102,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
101,ccbs  ( % ),C0006684
101,ccb,C0006684
101,caleium ehannel bloekers ( ccb ),C0006684
101,calcium channel blockers  n ( % ),C0006684;C2757014
101,calcium channel blockers,C0006684;C2757014
101,calcium channel blocker ( % ),C0006684;C3536851;C4521885
101,calcium channel blocker,C0006684;C3536851;C4521885
101,calcium channel antagonists  n ( % ),C0006684;C2757014
101,calcium - channel blockers ( % ),C0006684;C2757014
101,calcium - channel blockers,C0006684;C2757014
101,calcium - channel blocker *,C0006684;C3536851;C4521885
101,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
101,calcium - channel blocker,C0006684;C3536851;C4521885
101,calcium - channel antagonists,C0006684;C2757014
101,baseiine ccb,C0006684
101,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
100,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
100,non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199;C1518422
100,calcium antagonists  n ( % ),C0006684
100,calcium antagonists,C0006684
100,calcium antagonist — no . ( % ),C0006684
100,calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199
100,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
100,calcium antagonist,C0006684
99,shared epitope  a % positive,C0003316;C0237876;C1522138
98,fatty acid composition,C0015684;C0486616;C1555710
97,normal cognitive,C2712133
96,impaired cognitive,C0338656
95,parameter statistics,C0681933
94,subgroup statistics,C0038215;C0600673;C1079230;C1515021
94,statistics,C0038215;C0600673
93,lesion characteristics,C1286326
92,subject characteristics,C0681884;C1519021;C1706465
92,study eye characteristics,C0015392;C0700042;C1568011
91,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
91,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
91,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
91,sgrq total score  units,C0439148;C1519795;C2964552;C3853603
91,or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
91,mtss units,C0439148;C1519795;C3853603
91,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
91,c $nmbr$ - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
91,% anti - ccp + ( > $nmbr$ units ),C0439148;C1519795;C3853603;C4318437
90,ended > $nmbr$ days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
90,end of trial,C0008976;C0444930;C2746065
90,dual iv - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
90,dual ii - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
90,dual i extension - end of trial hba $nmbr$ c,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
89,trial $nmbr$,C0008976
89,trial,C0008976
89,cure trial,C0008976;C1880198
89,completed trial,C0008976;C0205197;C3854010
89,combined trials,C0008976;C0205195
89,all trials,C0008976
88,trial completers,C0008976
88,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
87,tx $nmbr$,C0041403
87,tx,C0041403
87,triglycerides tx difference vs pbo  ls mean % change from baseline ( se ),C0041004;C0041403;C1705241;C1705242
87,low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023824;C0041403;C1705241;C1705242
87,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
87,insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0021641;C0041403;C1533581;C1579433;C1705241;C1705242;C3714501
87,homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters,C0041403;C1705241;C1705242
87,homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0022065;C0022071;C0041403;C1448132;C1705241;C1705242
87,homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
87,high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023822;C0041403;C1705241;C1705242
87,hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
87,hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0019016;C0041403;C1705241;C1705242;C1825777;C3538758
87,fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
87,c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0006558;C0041403;C1705241;C1705242
87,apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0041403;C1705241;C1705242
86,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
86,chlorthalidone vs lisinopril,C0008294
86,chlorthalidone vs doxazosin,C0008294
86,chlorthalidone vs amlodipine,C0008294
86,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
86,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
86,chlorthalidone ( n = $nmbr$ ),C0008294
86,chlorthalidone $nmbr$,C0008294
86,chlorthalidone,C0008294
86,amlodipione - chlorthalidone,C0008294
86,amlodipine / chlorthalidone,C0008294;C0051696
86,$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
86,$nmbr$ chlorthalidone ( n = $nmbr$ ),C0008294
86,$nmbr$ chlorthalidone,C0008294
86,$nmbr$ amlodipine - chlorthalidone,C0008294;C0051696
85,colon or rectum,C0009368;C3888384
85,colon only  n ( % ),C0009368;C0205171;C1720467;C3888384
85,colon only  ' n ( % ),C0009368;C0205171;C1720467;C3888384
85,colon only,C0009368;C0205171;C1720467;C3888384
85,colon,C0009368;C3888384
85,all of the colon,C0009368;C3888384
84,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
83,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
83,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
82,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
81,rotigotine n = $nmbr$,C1700683;C4318637
81,rotigotine ( n = $nmbr$ ),C1700683;C4318637
80,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
80,pioglitazone only,C0071097;C0205171;C1720467
80,pioglitazone group ( n = $nmbr$ ),C0071097;C0441848
80,pioglitazone ( n = $nmbr$ ),C0071097
80,pioglitazone ( n = $nmbr$  $nmbr$ ),C0071097
80,pioglitazone,C0071097
79,rosiglitazone versus metformin,C0289313
79,rosiglitazone versus glyburide,C0289313
79,rosiglitazone ( n = $nmbr$ ),C0289313
79,rosiglitazone $nmbr$ mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
79,rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
79,rosiglitazone,C0289313
78,arthritis mutilans,C0702102
77,zotarolimus - eluting,C1700035
77,zotarolimus,C1700035
76,sirolimus eluting stent,C0038257;C0072980
76,sirolimus - eluting,C0072980
76,sirolimus,C0072980
75,cross - clamp,C0175721;C1883710;C2828360;C3810601
74,cromoglicate,C0010347
73,first co - primary,C0205435;C1279901;C3245499
73,colombia,C3245499
72,diastolic bp ( mmhg ) *,C0428883;C0439475
72,diastolic bp ( mmhg ),C0428883;C0439475
72,diastolic bp ( mm hg ),C0428883;C0439475
72,diastolic bp  mmhg ( sd ),C0428883;C0439475;C2699239
72,diastolic bp  mmhg,C0428883;C0439475
72,diastolic bp  mm hg,C0428883;C0439475
72,diastolic bp,C0428883
72,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
72,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
72,diastolic blood pressure > $nmbr$ mm hg,C0428883;C0439475;C1305849
72,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
72,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
72,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
72,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
72,diastolic blood pressure  mmhg,C0428883;C0439475;C1305849
72,diastolic blood pressure  mm   hg,C0428883;C0439475;C1305849
72,diastolic blood pressure  mm hq,C0428883;C1305849;C4330985;C4554674
72,diastolic blood pressure  mm hg ^,C0428883;C0439475;C1305849
72,diastolic blood pressure  mm hg ( sd ),C0428883;C0439475;C1305849;C2699239
72,diastolic blood pressure  mm hg,C0428883;C0439475;C1305849
72,diastolic blood pressure  and lp ( a ),C0428883;C1305849
72,diastolic blood pressure  ( mm hg ),C0428883;C0439475;C1305849
72,diastolic blood pressure,C0428883;C1305849
72,< $nmbr$ . $nmbr$ mm hg diastolic blood pressure,C0428883;C0439475;C1305849
71,diastolic — mm hg,C0012000;C0439475
71,diastolic fmmhff ' ),C0012000
71,diastolic ( mmhg ),C0012000;C0439475
71,diastolic ( mm hg ),C0012000;C0439475
71,diastolic  treated at baseline,C0012000
71,diastolic  total,C0012000;C0439175;C0439810
71,diastolic,C0012000
70,systolic — mm hg,C0039155;C0439475
70,systolic ( mmhg ),C0039155;C0439475
70,systolic ( mm hg ),C0039155;C0439475
70,systolic  treated at baseline,C0039155
70,systolic  total,C0039155;C0439175;C0439810
70,systolic,C0039155
70,peak systolic pressure gradient,C0039155;C4687747
70,mean systolic pressure gradient,C0039155;C4687744
70,left ventricular systolic or diastolic dysfunction,C0039155;C0225897
69,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
69,loading dose of clopidogrel or ticlopidine,C0070166;C3714444
69,intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
69,clopidogrel n / n { % ),C0070166
69,clopidogrel n / n ( % ),C0070166
69,clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
69,clopidogrel ( n = $nmbr$ ),C0070166
69,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166
69,clopidogrel ( n = $nmbr$  $nmbr$ ),C0070166
69,clopidogrel  $nmbr$ mg loading doset,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C4321396;C4521761
69,clopidogrel  $nmbr$ mg loading dose !,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
69,clopidogrel  $nmbr$ mg *,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C4321396;C4521761
69,clopidogrel  $nmbr$ - mg loading dose,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
69,$nmbr$ mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
68,clopidogrel or ticlopidine,C0070166
68,clopidogrel no . of patients % ),C0070166
68,clopidogrel given before procedure,C0070166
68,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
68,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
68,clopidogrel / total no . of patients % %,C0070166;C0439175;C0439810
68,clopidogrel / ticlopidine,C0040207;C0070166
68,clopidogrel %,C0070166
68,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166
68,clopidogrel  %,C0070166
68,clopidogrel,C0070166
67,clopidogrel plus aspirin ( n = $nmbr$ ),C0004057;C0070166;C0332287
67,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
67,clopidogrel plus aspirin,C0004057;C0070166;C0332287
67,clopidogrel + aspirin ( n = $nmbr$ ),C0004057;C0070166
67,clopidogrel ( n = $nmbr$ ) n / n ( % ),C0070166
67,aspirin plus clopidogrel ( n = $nmbr$ ),C0004057;C0070166;C0332287
67,aspirin i clopidogrel ( n = $nmbr$  $nmbr$ ),C0004057;C0021966;C0070166;C0221138
67,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0070166
67,aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0070166
67,aspirin $nmbr$ clopidogrel,C0004057;C0070166
66,no digoxin scd  no . ( % / y ),C0012265
66,no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % ),C0012265
66,digoxin scd  no . ( % / y ),C0012265
66,digoxin or digitalis preparations,C0012265
66,digoxin or digitalis preparation,C0012265
66,digoxin or digitalis glycoside,C0012265
66,digoxin n = $nmbr$ ( $nmbr$ % ),C0012265
66,digoxin n ( % ),C0012265
66,digoxin / digitalis glycoside,C0012253;C0012265
66,digoxin  n ( % ),C0012265
66,digoxin  ( % ),C0012265
66,digoxin  % ( n ),C0012265
66,digoxin  %,C0012265
66,digoxin,C0012265
65,local eosinophil count,C0200638;C0205276;C0750879
65,eosinophil count,C0200638;C0750879
65,central eosinophil count,C0200638;C0205099;C0750879;C1879652
65,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
65,blood eosinophil count cells / mm $nmbr$ no .,C0005773;C0200638;C0750879;C4330985;C4554674
65,blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0229664;C0439231;C0750480;C0750879;C1705566;C4330985;C4554674
65,blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
64,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
64,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
64,blood eosinophil count ( $nmbr$ cells per l ),C0200638
63,eosinophils £ $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils $nmbr$ % ( n - $nmbr$ ),C0014467;C0200638
63,eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
63,eosinophils,C0014467;C0200638
63,eosinophil low,C0014467
63,eosinophil high,C0014467
63,blood eosinophils count,C0014467
63,blood eosinophils  mean ( range )  cells / mlb,C0005773;C0007584;C0007634;C0014467;C0200638;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
63,blood eosinophils  mean ( range )  cells / ml,C0014467;C0444504;C1514721;C2347634;C2348143;C2348147;C2699156;C3542016
63,blood eosinophils  cells / ml,C0014467;C2699156
63,blood eosinophil count  geometric mean ( sd loge scale ) cells / ll,C0014467
63,blood eosinophil,C0014467
62,lisinopril vs amlodipineb,C0065374
62,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
62,lisinopril ( n = $nmbr$ ),C0065374
62,lisinopril,C0065374
62,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
62,ii lisinopril,C0065374;C1710602;C4082587
62,i lisinopril ( n = $nmbr$ ),C0021966;C0065374;C0221138
62,$nmbr$ lisinopril,C0065374
61,lisinopril vs chlorthalidone overweight,C0065374
61,lisinopril vs chlorthalidone obese,C0065374
61,lisinopril vs chlorthalidone normal,C0065374
61,lisinopril vs chlorthalidone,C0065374
61,lisinopril / chlorthalidone,C0008294;C0065374
61,lisinopril - chlorthalidone,C0008294;C0065374
61,ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
61,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
61,$nmbr$ lisinopril - chlorthalidone,C0008294;C0065374
60,type of end point,C0332307;C1547052;C2349179;C2826544
60,other prespecified end points,C2349179
60,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
60,endpoints,C2349179
60,endpoint week $nmbr$,C0332174;C0439230;C2349179;C2826544
60,endpoint rate,C0871208;C1521828;C2349179;C2826544
60,endpoint / baselinec,C2349179;C2826544
60,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
60,endpoint *,C2349179;C2826544
60,endpoint,C2349179;C2826544
60,end points,C2349179
60,end point,C2349179;C2826544
60,end - point ( sd ),C2349179;C2699239;C2826544
60,coronary endpoint,C0018787;C2349179;C2826544
60,coronary end point,C0018787;C2349179;C2826544
60,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
59,primary end points,C0205225;C0439612;C0439631;C2349179
59,other end points,C2349179
59,additional endpoints,C1524062;C2349179
58,tender and swollen joints — mean no . : :,C0234234
58,tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .,C0234234
58,tender,C0234234
58,number of tender joints ( $nmbr$ assessed ),C0234234;C0449813
58,number of tender joints ( $nmbr$ - $nmbr$ ),C0234234;C0449813
57,weight at baseline,C1303013
57,baseline body weight quartile,C1303013;C2828255
56,placebo - famotidine $nmbr$ - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
56,placebo - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
56,famotidine $nmbr$ - famotidine $nmbr$,C0015620
55,ex - drinker,C0337679
54,non - / ex - drinker,C0457801
54,former / non - drinker,C0205156;C0457801;C0750523
53,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
53,lower - target group ( n = $nmbr$ ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
53,higher - target group ( n = $nmbr$ ),C0205250;C0441848;C1521840;C2986546
53,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
53,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
53,( % of target ) ∗,C1521840;C2986546
52,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
52,suit index  nmol / mmol,C0600653;C0918012;C1532564;C1533073;C1552854;C1637833;C2986546
52,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
52,revascularization during index hospitalization  %,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
52,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
52,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
52,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
52,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
52,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
52,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
52,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
52,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
52,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
52,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
52,no revascularization for index acs event  no . ( % ),C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
52,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
52,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
52,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
52,mass index,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
52,lv mass index ( mg / m $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
52,lv mass index ( g / m $nmbr$ - $nmbr$ ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
52,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
52,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
52,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
52,insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
52,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
52,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
52,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
52,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
52,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
52,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
52,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event not confirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
52,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event  n / n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event  n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
52,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
52,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
52,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
52,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
52,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
52,extent of index pe ' ( n  % of pe patients ),C0030705;C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
52,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,extent of index dvt ' ( n  % of dvt patients ' ),C0030705;C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
52,eq $nmbr$ da health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
52,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
52,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
52,cu index test  n ( % ) $nmbr$,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
52,cornell index  pv,C0030840;C0032463;C0600653;C0918012;C1552854;C1637833;C2986546
52,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
52,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
52,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
52,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
52,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
52,body weight index ( kg / m $nmbr$ ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
52,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
52,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
52,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
51,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
51,angiotensin receptor blockers,C0521942;C0815017
51,angiotensin ii receptor blockers,C0521942;C2757003
51,angiotensin ii receptor blocker,C0521942;C3536793
50,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
50,angiotensin receptor blocker and / or ace,C0034787;C1622222
50,angiotensin receptor blocker,C0034787;C1622222
50,angiotensin receptor,C0034787;C1622222
50,angiotensin - receptor blocker,C0034787;C1622222
50,angiotensin - receptor,C0034787;C1622222
49,angiotensin receptive blocker,C0003018;C0544683;C4521302
49,angiotensin ll - receptor blocker,C0003018;C4521302
49,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302
49,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
49,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
49,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
49,angiotensin -,C0003018;C4521302
48,incidence rate per $nmbr$ person years,C0027361;C0439234;C1708485;C2347489
48,incidence rate per $nmbr$ person - years,C0027361;C0439234;C1708485;C2347489
48,incidence rate of cv events  n ( % ),C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
48,incidence rate no . ( / $nmbr$ person - years ),C1708485
48,incidence rate *,C1708485
48,incidence rate ( per $nmbr$ person - yr ),C0027361;C0439234;C1708485;C2347489
48,incidence rate ( n ) a,C1708485
48,incidence rate ( n ),C1708485
48,incidence rate,C1708485
48,incidence [ n / n ( rate per $nmbr$ person - years ) ],C0027361;C0439234;C1708485;C2347489
48,$nmbr$ - y incidence rate ( se ) per $nmbr$ participants,C0036919;C0679646;C1708485
47,no incident dm or change in fg > $nmbr$,C0011816;C1551358;C3250443
47,incident or worsening nephropathy,C1551358
47,incident dm or change in,C0011816;C1551358;C3250443
46,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
46,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
46,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
46,air + ig ( n = $nmbr$ ),C0001861;C0021027;C0305052;C0360506;C3536832
46,air ( n = $nmbr$ ),C0001861;C3536832
45,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
45,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
45,allergic rhinitis,C1334103;C2607914;C4552864
44,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
44,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
44,modified rankin scale — no . ( % ) |,C2984908;C3854213
44,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
44,modified rankin scale at screening  $nmbr$ - $nmbr$,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
43,enrolled into osler,C4684790
43,enrolled in the americas,C0002454;C0596070;C4684790
43,enrolled in russia or georgia,C0035970;C4684790
43,enrolled from re - cover study — no . ( % ),C4684790
43,enrolled from re - cover ii study — no . ( % ),C4684790
42,no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C1960636
42,no dysglycaemia or mets,C1960636
42,dysglycemic categories  n ( % ),C0683312;C1960636
42,dysglycaemia or mets,C1960636
41,initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l ),C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0589507;C1059964;C1158830;C1704686;C4551529
40,tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$,C0439278;C1540071
39,insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro,C0293359
39,all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
38,antibodies to infliximab  n ( % ) * *,C3533054
37,antidiabetes drug usage [ % ( n ) ],C0242510
36,beta - blockers through hospital discharge or day $nmbr$ — %,C0001645;C0586003
36,ace inhibitors through hospital discharge or day $nmbr$ — %,C0003015;C0586003
35,elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl,C0020649;C0231220;C0439269;C0700225;C3163620
35,elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ ),C0439269;C0700225
35,elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl,C0439269;C0700225
35,elevated creatinine ( > $nmbr$ pmol / l ),C0151578;C0439284;C0700225
34,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
34,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
34,erythrocyte sedimentation rate  mm / hour,C0439227;C0564385;C1176468;C1619634;C4330985;C4554674
33,mild dysfunction or normal,C3274775
33,mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274775
32,study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ ),C0013175;C0237400;C0439228;C1708715
32,actual or estimated weight  kg,C0237400
32,actual ( l ),C0237400
31,ecg abnormality at entry,C0522055;C1705654
31,any electrocardiographic abnormality — no . ( % ),C0522055
30,on drug treatment ( % ),C0150270;C3469597
30,days of study - drug administration ( % ) * * $nmbr$ day,C0150270;C2826182;C3469597
29,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
29,treatment with antiplatelet drugs,C3469597
28,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
28,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
28,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
28,mri substudy ( n = $nmbr$ ),C0024485;C1824234;C3890166
27,dexlansoprazole mr ( n = $nmbr$ ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
27,dexlansoprazole mr $nmbr$ mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
27,dexlansoprazole mr $nmbr$ mg  n = $nmbr$,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
27,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
26,t - score at femoral neck,C0015815;C3854607
26,mean femoral neck t score,C0015815;C3533236
26,femoral neck bmd ( g / cm $nmbr$ ),C0015815;C0439267
26,femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0015815;C0439267;C2699239
26,femoral neck,C0015815
25,tanezumab ( all doses combined ) + nsaida,C2346819
25,tanezumab ( all doses combined ),C2346819
25,tanezumab $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
25,tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
25,tanezumab $nmbr$ . $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
25,tanezumab $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
24,cyclo,C1172566
23,acm,C0001143;C1549040
22,acid,C0001128;C0202406
22,acd,C4554601
21,lcl,C3658298
20,focal,C0205234
19,locf ),C2825507
19,$nmbr$ locf ),C2825507
18,ocn,C1412791;C2347392
17,concern,C2699424
16,with placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
16,with placebo,C0032042;C1696465;C1706408
16,vorapaxar placebo $nmbr$ - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
16,vorapaxar placebo $nmbr$ - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
16,vorapaxar placebo $nmbr$ - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
16,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
16,statin + placebo ( n = $nmbr$ ),C0032042;C0360714;C1696465;C1706408
16,rerandomization to placebo ( n = $nmbr$ ) f,C0016327;C0032042;C1696465;C1706408
16,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
16,placebo §,C0032042;C1696465;C1706408
16,placebo |,C0032042;C1696465;C1706408
16,placebo to ustekinumab $nmbr$ mgt,C0032042;C1608841;C1696465;C1706408
16,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
16,placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
16,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
16,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
16,placebo plus statin ( n = $nmbr$ ),C0032042;C0332287;C0360714;C1696465;C1706408
16,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
16,placebo patients with events / total,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo no diabetes n = $nmbr$,C0032042;C1696465;C1706408
16,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
16,placebo no . of events / no .,C0032042;C1696465;C1706408
16,placebo no . / total no .,C0032042;C1696465;C1706408
16,placebo no . / total ( % ),C0032042;C1696465;C1706408
16,placebo no . ( $nmbr$ - y km % ),C0032042;C1696465;C1706408
16,placebo n [ $nmbr$,C0032042;C1696465;C1706408
16,placebo n = $nmbr$ subjects,C0032042;C1696465;C1706408
16,placebo n = $nmbr$ n ( % ),C0032042;C1696465;C1706408
16,placebo n = $nmbr$,C0032042;C1696465;C1706408
16,placebo n / n ( % ),C0032042;C1696465;C1706408
16,placebo n / n,C0032042;C1696465;C1706408
16,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
16,placebo n ( rate ) $nmbr$,C0032042;C0871208;C1521828;C1696465;C1706408
16,placebo n ( % ),C0032042;C1696465;C1706408
16,placebo n,C0032042;C1696465;C1706408
16,placebo mortality rate  events per $nmbr$ person - y,C0026565;C0027361;C0032042;C0205848;C0441471;C1696465;C1706408;C2347489;C3541888
16,placebo monthly ( n = $nmbr$ ),C0032042;C0332177;C1696465;C1706408
16,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
16,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
16,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
16,placebo km %,C0032042;C1696465;C1706408;C3887676
16,placebo group ( n = $nmbr$ ) ’ j ',C0032042;C0441844;C1696465;C1706408
16,placebo group ( n = $nmbr$ ) f,C0016327;C0032042;C0441848;C1696465;C1706408
16,placebo group ( n = $nmbr$ ),C0032042;C0441848;C1696465;C1706408
16,placebo every $nmbr$ weeks ( n = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo estimated mean,C0032042;C1696465;C1706408
16,placebo dr = $nmbr$ ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
16,placebo dn = $nmbr$ ),C0032042;C1333964;C1696465;C1706408;C1707618
16,placebo diabetes n = $nmbr$,C0011847;C0011849;C0032042;C1696465;C1706408
16,placebo croup  n / n ( % ),C0010380;C0032042;C1696465;C1706408
16,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
16,placebo analysed ( % ),C0032042;C1696465;C1706408
16,placebo allocation,C0032042;C1696465;C1706408;C1706778
16,placebo [ n z $nmbr$ ],C0032042;C1696465;C1706408
16,placebo [ n = $nmbr$ |,C0032042;C1696465;C1706408
16,placebo [ n = $nmbr$ ],C0032042;C1696465;C1706408
16,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
16,placebo / simva,C0032042;C1696465;C1706408
16,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
16,placebo /,C0032042;C1696465;C1706408
16,placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
16,placebo - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
16,placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$,C0032042;C0033228;C1532737;C1696465;C1706408
16,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
16,placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg,C0032042;C1319635;C1696465;C1706408;C1871983
16,placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] ),C0032042;C1696465;C1706408
16,placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$,C0032042;C1619966;C1696465;C1706408
16,placebo + statin ( n = $nmbr$  $nmbr$ ),C0032042;C0360714;C1696465;C1706408
16,placebo + statin,C0032042;C0360714;C1696465;C1706408
16,placebo + pioglitazone ( n = $nmbr$ ),C0032042;C0071097;C1696465;C1706408
16,placebo + mtx ( n = $nmbr$ ),C0025677;C0032042;C1417487;C1696465;C1706408
16,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
16,placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ ),C0004446;C0032042;C0907402;C1696465;C1706408
16,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
16,placebo ( » = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( « = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( w = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n — $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n   =   $nmbr$ ) b,C0032042;C1696465;C1706408
16,placebo ( n   =   $nmbr$ ) a,C0032042;C1696465;C1706408
16,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n   =   $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n   = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n   = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n z $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n [ $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = l $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ o ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ l ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ i $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ * ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ) †,C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ) n ( % ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ) i -,C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ) ',C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ )  n ( % ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n = $nmbr$,C0032042;C1696465;C1706408
16,placebo ( n : $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n - $nmbr$ . $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n - $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( n $nmbr$ $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( lsm ),C0032042;C1696465;C1706408
16,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
16,placebo ( % ),C0032042;C1696465;C1706408
16,placebo ( $nmbr$ = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo ( $nmbr$  $nmbr$ . $nmbr$ % ),C0032042;C1696465;C1706408
16,placebo %,C0032042;C1696465;C1706408
16,placebo $nmbr$ yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
16,placebo $nmbr$ year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
16,placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
16,placebo $nmbr$ / $nmbr$,C0032042;C1696465;C1706408
16,placebo $nmbr$ . $nmbr$ pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
16,placebo $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
16,placebo $nmbr$  $nmbr$,C0032042;C1696465;C1706408
16,placebo $nmbr$,C0032042;C1696465;C1706408
16,placebo  n   =   $nmbr$,C0032042;C1696465;C1706408
16,placebo  n = l $nmbr$,C0032042;C1696465;C1706408
16,placebo  n = i $nmbr$,C0032042;C1696465;C1706408
16,placebo  n = $nmbr$,C0032042;C1696465;C1706408
16,placebo  n / n ( % ),C0032042;C1696465;C1706408
16,placebo  n *,C0032042;C1696465;C1706408
16,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
16,placebo  n ( % ),C0032042;C1696465;C1706408
16,placebo  n,C0032042;C1696465;C1706408
16,placebo  events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
16,placebo  ( n = $nmbr$ ),C0032042;C1696465;C1706408
16,placebo  % > ( n / n ),C0032042;C1696465;C1706408
16,placebo  % ( n / n ),C0032042;C1696465;C1706408
16,placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ ),C0032042;C0439526;C1696465;C1705224;C1706408;C3887665
16,placebo,C0032042;C1696465;C1706408
16,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
16,n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
16,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
16,losartan plus placebo ( n = $nmbr$ ),C0032042;C0126174;C0332287;C1696465;C1706408
16,i placebo ( n = $nmbr$ ),C0021966;C0032042;C0221138;C1696465;C1706408
16,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
16,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3259781;C3538758;C3829066;C4319952;C4553351
16,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
16,hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1532563;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
16,feno placebo ( lsm ),C0032042;C1696465;C1706408
16,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
16,duration from clopidogrel / placebo to pci  min ( median  iqr ),C0032042;C0070166;C0449238;C1696465;C1706408;C2926735
16,dapagliflozin placebo no . of events / no . of patients,C0032042;C1696465;C1706408;C2353951
16,copd - placebo ( n = $nmbr$ ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
16,copd - placebo ( $nmbr$ pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
16,comparison with placebo,C0032042;C1696465;C1706408;C1707455
16,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
16,canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
16,baseline to eom placebo ( n = $nmbr$ ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
16,aspirin plus placebo ( n = $nmbr$ ),C0004057;C0032042;C0332287;C1696465;C1706408
16,any placebo,C0032042;C1696465;C1706408
16,> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
16,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0524620;C1142985;C1696465;C1706408
16,= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
16,< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
16,- $nmbr$ placebo,C0032042;C1696465;C1706408
16,$nmbr$ placebo n = $nmbr$,C0032042;C1696465;C1706408
16,$nmbr$ placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
16,$nmbr$ placebo,C0032042;C1696465;C1706408
15,impacts,C1825598;C4049986
14,empa,C2699863
13,mras,C1335594;C1367476
12,mca,C0149566
11,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
11,demography,C0011298
11,demographics and clinical characteristics,C0011298;C1704791
11,demographics age ( years ),C0011298;C1510829;C1704791
11,demographics age  years  mean ( sd ),C0011298;C0444504;C1510829;C1704791;C2347634;C2348143;C2699239
11,demographics,C0011298;C1704791
11,demographic and medical variables,C0011298
11,demographic and clinical characteristics,C0011298
11,demographic and clinical,C0011298
11,demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0011298
11,demographic,C0011298
11,baseline demographics,C0011298;C0168634;C1442488;C1704791
11,( a ) demographics,C0011298;C1704791
10,demographic variable,C0011298;C0439828;C4553760
10,demographic factors,C0011292;C0011298
10,demographic characteristic,C0011298;C1521970
9,muscle twitching,C0015644;C0231530
8,muscle spasms,C0037763
7,musculoskeletal stiffness,C0427008;C0497254;C2707260
7,musculoskeletal,C0497254;C2707260
6,febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$,C0249529;C3886073
6,febuxostat - febuxostat / lesinurad $nmbr$,C0249529;C3886073
6,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
5,febuxostat $nmbr$ mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
5,febuxostat,C0249529
4,with rehospitalization  urgent coronary revascularization,C0439609;C0877341;C3272275
4,urgent coronary revascularization,C0439609;C0877341;C3272275
4,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
4,prior coronary revascularization ( pci or cabg ),C0332152;C0877341;C2826257;C4049621
4,prior coronary revascularization  no . ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization  n / n ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization,C0332152;C0877341;C2826257
4,coronary revascularization procedure,C0877341
4,coronary revascularization,C0877341
4,coronary revascularisation §,C0877341
4,coronary revascularisation,C0877341
4,any coronary revascularization,C0877341
3,• urgent coronaiy revascularization > $nmbr$ days,C0439228;C0439609;C0581603;C3272275
3,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
3,urgent revascularizati on,C0439609;C3272275
3,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
3,$nmbr$ days urgent revascularization,C0439228;C0439609;C0581603;C3272275
2,with revascularisation,C0581603
2,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
2,target - vessel revascularization,C0449618;C0581603
2,revascularization in $nmbr$ days,C0439228;C0581603
2,revascularization,C0581603
2,revascularisation but no antiplatelets  lipid - lowering agents  or p blockers,C0581603
2,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
2,revascularisation  n ( % ),C0581603
2,peripheral revascularization ( n = $nmbr$ ),C0205100;C0581603
2,peripheral revascularization,C0205100;C0581603
2,peripheral revascularisation,C0205100;C0581603
2,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
2,pci revascularization,C0581603;C4049621
2,no revascularisation,C0581603
2,no peripheral revascularization ( n = $nmbr$  $nmbr$ ),C0205100;C0581603
2,carotid revascularization,C0581603;C0741968
2,arterial revascularization,C0003842;C0221464;C0581603
2,any revascularization,C0581603
2,any peripheral revascularization,C0205100;C0581603
1,之 $nmbr$,
1,≥ $nmbr$ yearsa,
1,≥ $nmbr$ teae,
1,≥ $nmbr$ bpm ( n = $nmbr$ ),
1,≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
1,≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %,
1,≥ $nmbr$ %,
1,≥ $nmbr$,
1,≤ $nmbr$ . $nmbr$ %,
1,≤ $nmbr$ %,
1,≤ $nmbr$,
1,• j . the body - mass index is the weight in kilograms divided by the square of the,
1,“ off ”,
1,— no . ( % ),
1,β ‐ blocker,
1,β blockers,
1,β blocker,
1,β - blockers,
1,β - blocker,
1,» $nmbr$ y,
1,« = $nmbr$,
1,« $nmbr$ - $nmbr$,
1,£ $nmbr$ . $nmbr$ yrs,
1,£ $nmbr$ . $nmbr$ % * *,
1,£ $nmbr$ %,
1,£ $nmbr$,
1,| interactior $nmbr$ p,
1,| ? > - blocker ( n  % ),
1,| ? ) - blocker  %,
1,zt = $nmbr$,
1,zotarolimust,
1,z\tonastaiin,
1,yearl,
1,yaa,
1,y $nmbr$,
1,xanthinesg,
1,x ? = l - $nmbr$  p = $nmbr$ - $nmbr$,
1,x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$,
1,x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
1,x / n *,
1,x / n,
1,x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$,
1,x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
1,x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$,
1,x $nmbr$  n ( % ),
1,wssng,
1,woscops,
1,womens,
1,without revascularsation,
1,without antiplatelets,
1,without an sfua,
1,with antiplatelets,
1,with an sfua,
1,whiteb,
1,while ethnic origin,
1,while,
1,wegu,
1,wafarin,
1,w hite,
1,w,
1,vs . warfarin,
1,vs . placebo,
1,vora,
1,vldm n = $nmbr$,
1,vka naxve,
1,vka naive  n ( % ),
1,vka naive,
1,vka experienced,
1,vka ( n   = $nmbr$ ),
1,vka  only reason,
1,vka,
1,vhd,
1,versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg,
1,versus tiotropium $nmbr$ . $nmbr$ pg,
1,versus olodaterol $nmbr$ pg,
1,veflonzumao,
1,vdz n = \ $nmbr$,
1,vdz n = $nmbr$,
1,vdz / vdz [ n = $nmbr$ ],
1,vdhmtss,
1,vadas score *,
1,v ( n = $nmbr$ ),
1,v $nmbr$ ( n = $nmbr$,
1,ustekinu,
1,usteki,
1,useofmedical therapyathospitaldischarge,
1,us w = $nmbr$,
1,us,
1,urti,
1,ure,
1,upcr  n ( % ),
1,unstableangina,
1,unprovoked,
1,univariable or ( $nmbr$ % ci )  p value *,
1,univariable,
1,uniti - $nmbr$ and uniti - $nmbr$ im - uniti,
1,uniti - $nmbr$,
1,unfractionated,
1,undeterminedc,
1,undergoing major vascular surgery,
1,uncover - $nmbr$,
1,uncodable,
1,uncerlain,
1,umied,
1,ulpasi $nmbr$,
1,uistekinumab,
1,ufh,
1,ucr,
1,ucl,
1,uc [ gemini $nmbr$ ] ‘,
1,uc ( n   =   $nmbr$ ),
1,uc,
1,uas $nmbr$ {,
1,uas $nmbr$,
1,uacr not available,
1,uacr ( mgg - $nmbr$ ),
1,uacr  n ( % ) †,
1,uacr,
1,uac =,
1,tzd,
1,tvr,
1,transradial,
1,transfemoral,
1,tpasi $nmbr$,
1,toward,
1,totai mortaiity,
1,tolal choleslerol,
1,tnt and ideal ( pooled ),
1,tngtycerides a median,
1,tngtycerides < median,
1,tngtycendes a median,
1,tnglycendes < median,
1,tnfi naive,
1,tnfi exposed,
1,tnfi and other bdmardst  n ( % ),
1,tnfi - naive,
1,tnfi - exposed †,
1,tnfi ( no other bdmard taken ) t  n ( % ),
1,tjc  $nmbr$ - $nmbr$,
1,tjc,
1,tiotropiumc,
1,tion — no . ( % ),
1,tio ( n $nmbr$ $nmbr$ ),
1,tio,
1,timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h,
1,timi ≥ $nmbr$ and spoke,
1,timi ≥ $nmbr$,
1,timi score,
1,timi risk scoret,
1,timi minor,
1,timi major or minor bleeding,
1,timi major or,
1,timi major,
1,timi clinically significant,
1,timi - defined bleeding,
1,timi - bleeding major / minor,
1,ticlopidin,
1,thromboaspiration — no . ( % ),
1,thromboaspiration,
1,thiazolidinedionesc,
1,thiazolidinedioneb,
1,texcaps,
1,tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
1,tertile $nmbr$ ( n = $nmbr$ ),
1,tertile $nmbr$,
1,terlile $nmbr$,
1,teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % ),
1,teaes leading to discontinuation of study drug,
1,teaes,
1,tbp,
1,tamong those enrolling via bnp stratum . the study - qualifying bnp or,
1,symptomaticb,
1,sulfonylureasb,
1,sulfonylureaa,
1,subtrochanteric,
1,subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -,
1,subgroupt,
1,sua < $nmbr$ . $nmbr$,
1,strokezsee,
1,stratum *,
1,stratum  n ( % ),
1,stratum,
1,still taking alendronate at study entry  n ( % ),
1,std n ( n / loopy ),
1,statisticd,
1,statini,
1,stalin,
1,sso - $nmbr$,
1,ssi - $nmbr$,
1,spoke,
1,spirono ( n = $nmbr$ ),
1,spiralcomputedtomographyangiography,
1,spga > $nmbr$,
1,sonti amenca,
1,some walking,
1,some,
1,soe or sue,
1,socalone ( n = $nmbr$ ),
1,soc,
1,smokingb,
1,smmse < $nmbr$,
1,smmse,
1,smi :,
1,sk . $nmbr$,
1,sjc  $nmbr$ - $nmbr$,
1,sjc,
1,sita $nmbr$,
1,sirius,
1,since onset,
1,since diagnosis,
1,simva n = $nmbr$ n ( % ),
1,simva ( „ = $nmbr$ },
1,simva ( n = $nmbr$ ),
1,simva ( % ),
1,simva,
1,sgrq scores  mean ( sd ),
1,sgrq responder ( % ),
1,severitya,
1,sesbp,
1,sedbp,
1,scd ( % ),
1,saxagiiptin,
1,saxa + met n = $nmbr$,
1,saxa + dapa + met n = $nmbr$,
1,samac,
1,sack,
1,sabae,
1,sabaa,
1,saba §,
1,saba ( inhaled )  c   n ( % ),
1,saba,
1,saaca,
1,rvw,
1,rvfac ( % ),
1,rvalue,
1,rrr,
1,rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
1,rr *,
1,rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ },
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$,
1,rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’,
1,rr,
1,rosigiitazone ± oad,
1,revive ii,
1,revive i,
1,resllzumab,
1,reqion,
1,remodeling,
1,reinfarction,
1,regiont,
1,redon,
1,recervng,
1,recervini },
1,rca  n ( % ),
1,rca,
1,ratet n ( % ),
1,ratet,
1,rarertd antocagibtcn before andorrtzafon,
1,ranozaline,
1,ranotazine vs . placebo km failure rate,
1,randomly assigned to diuretic,
1,randomly assigned to calcium channel blocker,
1,randomly assigned to ace,
1,randomize,
1,randomised to canakinumab $nmbr$ mg,
1,raee,
1,racey  z,
1,racea,
1,qveral,
1,quicki,
1,qtc > $nmbr$ n = $nmbr$,
1,qtc < $nmbr$ n = $nmbr$,
1,qmi,
1,q ( q $nmbr$ \,
1,q $nmbr$ w ( n = $nmbr$ ),
1,q $nmbr$ w ( n $nmbr$ $nmbr$ ),
1,q $nmbr$ - q $nmbr$,
1,q $nmbr$ ( n   = $nmbr$ ),
1,pvaluefor any mi versus no mi,
1,pvalue ∗,
1,pvalue,
1,ptga ⁎ ⁎ ⁎,
1,ptga  $nmbr$ - $nmbr$,
1,psychoactivesd,
1,psaqol,
1,prosthetic,
1,prosper,
1,priorother ( predefined ) medical conditions,
1,priorother ( not predefined ) medical conditions,
1,priorheartfailure  %,
1,previously taken tnfi  %,
1,previously taken methotrexate  %,
1,previously taken dmards other than methotrexate  %,
1,previously taken any other dmards  n ( % ),
1,previously failed anti - tnf treatment  no . ( % ),
1,previously,
1,prediabeticb,
1,prediabetese,
1,ppci in - $nmbr$,
1,ppci ( n = $nmbr$ ),
1,ppci,
1,postamendment,
1,poslmenopausal  no ht,
1,pollent s $nmbr$,
1,pollent < $nmbr$,
1,poci ( n = $nmbr$ ),
1,poci,
1,poba  n ( % ),
1,pnorpci,
1,pnorcabg,
1,plaeebo,
1,placeboa,
1,pinteraction = $nmbr$ . $nmbr$,
1,pinteraction,
1,piacebo ( n = $nmbr$ ) no . of participants with events ( % ),
1,piacebo,
1,phakic,
1,persisent,
1,pdq - $nmbr$,
1,pasia,
1,paod,
1,pacific,
1,overally,
1,overallb,
1,overaii ( n = $nmbr$ ),
1,overaii,
1,otherz,
1,otherx,
1,othert,
1,othersc,
1,otherj ^ :,
1,otherf,
1,otherd,
1,otherc,
1,otherb,
1,othera,
1,other †,
1,other — no . ( % ),
1,other vasculars,
1,other uc - related gi surgical procedure,
1,other teaes,
1,other or missing data,
1,other bdmards ( no tnfi taken ) t  n ( % ),
1,other bdmard §,
1,other antiplatelet,
1,other ^,
1,other : :,
1,other * ’,
1,other *,
1,other ',
1,other $nmbr$,
1,other !,
1,other  no . ( % ),
1,other,
1,oretal,
1,oralb,
1,or_value,
1,or 、 ( $nmbr$ % ci ),
1,or ulcerations  ® n ( % ),
1,or taking antihypertensive medication,
1,or severe,
1,or raloxifene,
1,or primary outcome,
1,or placebo treatment,
1,or no microalbuminuria or macroalbuminuria,
1,or morbidity and mortality,
1,or esrd,
1,or death,
1,or [ $nmbr$ % cl ],
1,or [ $nmbr$ % ci ],
1,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$,
1,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,
1,or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$,
1,or ( unadjusted ),
1,or ( itt ) ( n = $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),
1,or ( $nmbr$ % cl ),
1,or ( $nmbr$ % ci ) a,
1,or ( $nmbr$ % ci ),
1,or $nmbr$ _value,
1,or $nmbr$ % ci,
1,or $nmbr$,
1,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ ),
1,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
1,or,
1,op  vfx,
1,op  no vfx,
1,onsetofaf  no . ( % ),
1,on or after e ^ andomization,
1,on omt ( n = $nmbr$ ),
1,on omt,
1,on $nmbr$,
1,olaemia  n ( % ),
1,ol / l ),
1,off omt ( n = $nmbr$ ),
1,off omt,
1,octi,
1,octave sustain,
1,ocs use,
1,ocs reduced / stopped,
1,ocs maintained / increased,
1,ocs  n ( % ),
1,ocs,
1,obesityj,
1,oascvd,
1,oam,
1,oads  n ( % ),
1,oad,
1,oac experienced  bn   ( % ),
1,nyhaiiioriv,
1,nyhaii,
1,numbera,
1,numab,
1,ntbnp ( n = $nmbr$ ),
1,nsteacs,
1,nothfref,
1,northamerica,
1,normoalbuminuria — no . / total no . ( % ),
1,normoalbuminuria — no . ( % ),
1,normoalbuminuria §,
1,normoalbuminuria or microalbuminuria,
1,normoalbuminuria  no . ( % ),
1,normoalbuminuria,
1,normalfunction or mild impairment,
1,normai fasting giucose levei ( n = $nmbr$ ),
1,noppi,
1,nonwhite race — no . ( % ) ejection fraction,
1,nonwhite,
1,nonvertebral,
1,nonuser,
1,nonreversible,
1,nonischemic,
1,noninducing,
1,nonfatal,
1,noneh,
1,none 一 no . ( % ),
1,none or seldom,
1,none or diet,
1,none ( cdmard - naive or past use at baseline ),
1,none,
1,nondiabetic,
1,nondiabetes,
1,noncaucasian,
1,noncardiovascular,
1,nonblack race — no . ( % ) f,
1,nonblack race — no . ( % ) - j -,
1,nonblack ( n = $nmbr$ ),
1,nonblack,
1,nonanterior,
1,nominal p vs placebo,
1,noliecervrig,
1,noirecerving,
1,no vhd,
1,no ststm,
1,no or unknown,
1,no op  vfx,
1,no op  no vfx,
1,no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years,
1,no ocs,
1,no oam,
1,no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),
1,no laba  no ics  n ( % ),
1,no ipst ( n = $nmbr$  $nmbr$ ),
1,no ipst,
1,no immomtedion,
1,no ?,
1,no . of tnfi among non - tnfi naive,
1,no . of panents . total no . $nmbr$ % ),
1,no . of,
1,no . needed to treat ( $nmbr$ % cl ) *,
1,no . evenls,
1,no . a,
1,no . *,
1,no . ( % ) *,
1,no . ( % ) ',
1,no . ( % ) $nmbr$ ( $nmbr$ ),
1,no . ( % ),
1,no .,
1,no *,
1,no ( % ),
1,no ( $nmbr$ . $nmbr$ ),
1,no $nmbr$  $nmbr$,
1,no  no,
1,no,
1,nkf stage,
1,nitratesf,
1,niacini,
1,nerd,
1,neohrodathv . and all - cause mortalitv,
1,neither uh or lmw heparin,
1,neither,
1,nd not due to swelling or ich,
1,nd,
1,nct $nmbr$,
1,nbp,
1,napsit,
1,napsi score ( $nmbr$ - $nmbr$ ) of target fingernail,
1,naive : no,
1,naive ( no treatment for current flare ),
1,naive ( n = $nmbr$ ),
1,naive,
1,myopathyt,
1,myoclonic,
1,multivariable or ( $nmbr$ % ci )  p value *,
1,multivariable,
1,mucocutaneous,
1,mtss at,
1,mtss ( $nmbr$ - $nmbr$ ),
1,mtss,
1,mssbp / msdbp,
1,mssbp,
1,msfc timed $nmbr$ - foot walk test .,
1,msfc timed $nmbr$ - foot walk test  median seconds,
1,msdbp,
1,monteiukast vs placebo,
1,monteiukast ( n = $nmbr$ ),
1,monteiukast,
1,monotherapy $nmbr$,
1,monotherapy,
1,moderatez,
1,moderatey,
1,moderatex,
1,mnapsi,
1,mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ],
1,mhi,
1,mfns ( n = $nmbr$ ),
1,metsyn,
1,metrex modified intention - to - treat population with an eosinophilic phenotypey,
1,metforminmonotherapy,
1,merformin,
1,mepo ( n = $nmbr$ ),
1,mensa,
1,mellitus,
1,mcs score ( $nmbr$ – $nmbr$ scale ),
1,mcs score,
1,mbesc  n / n ( % ),
1,mbesb  n / n ( % ),
1,mbes / crbesc,
1,mbes / crbesb  n / n ( % ),
1,mafcaiancy at randorrtzaton,
1,maf,
1,macroalbuminuriaf,
1,macroalbuminuria — no . / total no . ( % ),
1,macroalbuminuria — no . ( % ) drug therapy — no . ( % ),
1,macroalbuminuria ( uacr > $nmbr$ ),
1,macroalbuminuria  n ( % ),
1,macroalbuminuria,
1,macce ( % ),
1,macce,
1,lvmi ( $nmbr$,
1,lunchb,
1,lntensityd,
1,llpasi $nmbr$,
1,lleocolon,
1,ll ( $nmbr$ ),
1,ll $nmbr$ ( $nmbr$ ),
1,ll  n ( % ),
1,lixi,
1,lithe,
1,lisrs,
1,lgm ( n = $nmbr$ ),
1,leader,
1,ldu - c,
1,ldl cholesterolt,
1,ldl choleslerol,
1,ldl cholesicrol ( minol / l ),
1,ldl - csmedian,
1,ldl - c ( measured ) *,
1,ldl - c ( measured )  mean ( sd ),
1,ldl - c ( calculated ) *,
1,ldl - c ( calculated )  mg / dl  mean ( sd ),
1,ldl - c ( calculated )  mean ( sd ),
1,ldl - c,
1,ldl *,
1,ldl $nmbr$ - c,
1,ldl  - c,
1,ldl,
1,ldi - b > $nmbr$ ( n = $nmbr$ ),
1,ldi $nmbr$,
1,lcz $nmbr$ ( n = $nmbr$ ),
1,lcz $nmbr$,
1,lc  n = $nmbr$,
1,lb,
1,lavolta $nmbr$,
1,latin and north america,
1,latin ameriea,
1,latin,
1,lamad,
1,lad,
1,labaa,
1,laba or lamab n = $nmbr$,
1,laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl ),
1,laba or lama ’,
1,laba or lama,
1,laba alone,
1,laba - inhaled glucocorticoid use at screening,
1,laba ( inhaled )  d   n ( % ),
1,laba ',
1,laba  no ics  n ( % ),
1,laba  n ( % ),
1,laba,
1,laaca,
1,laa,
1,killip ciass,
1,kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % ),
1,jvp > $nmbr$ cm,
1,jvp ( 〉 $nmbr$ cm ),
1,jvp  ( % ),
1,j $nmbr$ - blocker  % ( n ),
1,j $nmbr$ - blocker,
1,ization — no . ( % ),
1,ixeq $nmbr$ w  n = $nmbr$,
1,itt,
1,itherchdt,
1,ith vs . without ),
1,it $nmbr$ . $nmbr$,
1,islander,
1,ish,
1,is only,
1,is domain luts severity ( % ),
1,irofiban,
1,iqr,
1,ipst ( n = $nmbr$ ),
1,ipst,
1,iorii ( n z $nmbr$ ),
1,interact !,
1,intensified ( n 二 $nmbr$ ),
1,insulina  n ( % ),
1,insulina,
1,insuiin giargine ± oad,
1,inhixanab $nmbr$ mgikg versus piacom,
1,inhaledb,
1,indzgly,
1,incidencea,
1,in thirds,
1,in,
1,immobazaton,
1,im use : no,
1,im or cs use : no,
1,im on ] y,
1,im and cs use : no,
1,im - uniti,
1,ileocolonic ( both ileum and colon ),
1,ileocolon,
1,ijb ^,
1,iiiv,
1,ii or iii,
1,ii = $nmbr$,
1,ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$,
1,ii ( $nmbr$ ),
1,ii $nmbr$ ± $nmbr$,
1,ii,
1,igt or ifg,
1,igm,
1,iglarlixi ( n   =   $nmbr$ ),
1,iglarlixi,
1,iglar ( n   =   $nmbr$ ),
1,iglar,
1,igelow ( n = $nmbr$  $nmbr$ ),
1,idr,
1,idiopathica,
1,idegasp – biasp $nmbr$,
1,idegasp bid,
1,ideg,
1,icsusers atbaseline  n ( % ),
1,icsf,
1,icsa,
1,ibdq score |,
1,hypoglycemiat,
1,hypoglycaemiad  %,
1,hypertensiont,
1,hyperlipidmemia,
1,hyperlension,
1,hyperkalemiab,
1,hypercholesterolemiat,
1,hydochlorothiazide ( n = $nmbr$ ),
1,hvpertension,
1,hvpercholesterolemia,
1,hvookalemia,
1,hscrp §,
1,hscrp,
1,hr ‡,
1,hr vs placebo ( $nmbr$ % ci ),
1,hr vs control ( $nmbr$ % cl ) *,
1,hr vs . warfarin ( $nmbr$ % ci ),
1,hr is < $nmbr$ if pravastatin is better than diet alone,
1,hr and $nmbr$ % ci *,
1,hr * or rr † ( $nmbr$ % ci ),
1,hr * or rr †,
1,hr ( enl vs lcz ) ( $nmbr$ % cl ),
1,hr ( bpm ),
1,hr ( adjusteda ),
1,hr ( $nmbr$ s % a ),
1,hr ( $nmbr$ % c ! ),
1,hr $nmbr$ and $nmbr$ % cl,
1,hr $nmbr$ . $nmbr$,
1,hr  bpm,
1,hr,
1,hosji fcrhypoglycemia,
1,hordic,
1,homa - p,
1,homa - b,
1,homa,
1,highjj,
1,hhf ( n = $nmbr$ ),
1,hfref ( n = $nmbr$ ),
1,hfref,
1,hfpef ( ef n $nmbr$ )  ( % ),
1,hdm n = $nmbr$,
1,hdlcholesterol,
1,hd ( n = $nmbr$ ),
1,hcru ( a ),
1,hbau  %,
1,hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),
1,hbalc > = $nmbr$ % ( n - $nmbr$ ),
1,hbalc > $nmbr$ %,
1,hbalc < medan,
1,hbalc < $nmbr$ %,
1,hbalc ( % ),
1,hbalc  %,
1,hbalc,
1,hbaie ( % ),
1,hbaie  %,
1,hbaic — %,
1,hbaic ( % ),
1,hbai,
1,has - bledo,
1,has - bled score ’,
1,has - bled score > $nmbr$,
1,has - bled score,
1,has - bled > $nmbr$,
1,has - bled $nmbr$ - $nmbr$,
1,handihaler and diskus  n,
1,hale,
1,gusto severe or,
1,gusto severe,
1,gusto moderate or severe bleeding,
1,gusto moderate or severe,
1,gusto moderate / severe bleeding,
1,gusto moderate / severe bleed,
1,gusto moderate / severe,
1,gusto moderate,
1,gusto - defined bleeding,
1,gusto - bleeding severe / moderate,
1,granulating  n ( % ) a,
1,golden - $nmbr$ and - $nmbr$,
1,golden - $nmbr$,
1,glulisine monotherapy,
1,glulisine + oad,
1,glacial $nmbr$,
1,giimepiride ± oad,
1,giargine,
1,getgoal - s,
1,gertder,
1,gentype,
1,gendar,
1,fpg,
1,fpci vs . ppci in women,
1,fpci vs . ppci in men,
1,fibrofatty,
1,fibrinolysist,
1,fibrate or other lipid - lowering agent,
1,fibrate,
1,fh $nmbr$,
1,fenofibric,
1,feno + eze,
1,feno,
1,femoralneck t - scorebybaselinevfxstatus,
1,femalesex,
1,femaleb,
1,femaie,
1,fas,
1,eze / simva ( „ = $nmbr$ },
1,eze / simva ( n = $nmbr$ ),
1,eze / simva,
1,eze,
1,extenswe,
1,evomab + soc,
1,evomab ( n = $nmbr$ ),
1,evomab,
1,ever smoked ( current / former ),
1,ever been on a vka,
1,ever,
1,ethnieity,
1,erd *  n ( % ),
1,epa ( n = $nmbr$ ),
1,epa,
1,enrope + sonth afriea,
1,endpointc,
1,enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ ),
1,enact - $nmbr$ trial,
1,empagllflozln,
1,empagllflozin,
1,ef b $nmbr$ %,
1,ef > $nmbr$ % n = $nmbr$,
1,ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % ),
1,ef > $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1,ef > $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef > $nmbr$ %,
1,ef < $nmbr$ % n = $nmbr$,
1,ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % ),
1,ef < $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1,ef < $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef < $nmbr$ %,
1,ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % ),
1,ef $nmbr$ - $nmbr$ %,
1,ef  %,
1,educ ssy,
1,educ > $nmbr$ y,
1,educ $nmbr$ - $nmbr$ y,
1,edo,
1,e / e ' ( septal ),
1,e $nmbr$ + a $nmbr$ -,
1,e $nmbr$ + a $nmbr$,
1,e $nmbr$ ( n = $nmbr$ ),
1,e,
1,dyslipidaemiat,
1,dyslipidaemiaj,
1,dosing,
1,diureties,
1,diureticff,
1,diurciic,
1,discontinu - ation,
1,disabling or fatal stroke,
1,disabling or fatal,
1,differencevs . pbof,
1,diff_measure,
1,did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ ),
1,did not enrol into osler,
1,diabeticb,
1,diabetesz,
1,diabetesf,
1,diabetese,
1,diabetesc,
1,denotes angiotensin - converting enzyme .,
1,deathsb,
1,dcct a $nmbr$ c,
1,dapagliflozint,
1,dapaglifloz . in  n,
1,dapaglifloiin  n *,
1,dapa + met n = $nmbr$,
1,dabetes,
1,currentd,
1,csii,
1,cse ] +,
1,crude,
1,crt - p + d  n ( % ),
1,crt - p,
1,crt - d,
1,crt,
1,crpnonr ?,
1,crj,
1,crci > $nmbr$ - < $nmbr$,
1,crci > $nmbr$,
1,covariates,
1,covariate,
1,corticosteroidsa,
1,controlld,
1,continuation ( n = $nmbr$ ),
1,continuation,
1,conservative,
1,conieosieroids and / or $nmbr$ - mp,
1,comorbidites  n ( % ),
1,combo vs . primary,
1,combinationf,
1,coexisting conditions — no . ( % ),
1,cm,
1,clopiodogrel,
1,clonic,
1,ckdc  n ( % ),
1,cigarettesmoking  %,
1,ciass ll - iv,
1,chda,
1,charlson,
1,characteristicsa,
1,characteristica,
1,chajdsrvasc $nmbr$ - $nmbr$,
1,chajdsj - vasc > $nmbr$,
1,chajdsj - vasc $nmbr$ - $nmbr$,
1,chajdsa - vasc $nmbr$ - $nmbr$,
1,chadsj > $nmbr$,
1,chadsj < $nmbr$,
1,chadsa < $nmbr$,
1,cerebral,
1,cdmard,
1,ccq score § §,
1,cclear < $nmbr$,
1,cclear $nmbr$ - $nmbr$,
1,cclear $nmbr$ +,
1,causaslan,
1,caucasiana ( % ),
1,catscorecategory  n ( % ),
1,cardiovasculardeath,
1,cardiovascuiar mortaiity,
1,cardioembolism,
1,cardioembolic,
1,cancert,
1,canagiiflozin,
1,cabgorptca,
1,c,
1,bsa involved  % $nmbr$,
1,bsa affected  mean ± sd  %,
1,bsa affected  %,
1,bsa > $nmbr$ %  n ( % ) t,
1,bsa ( % ),
1,bsa  % *,
1,breakfastb,
1,brandomization was stratified by diabetic status .,
1,both ( % ),
1,both,
1,bms,
1,bmit,
1,bmij,
1,bmia,
1,blockers,
1,blocker,
1,blaic > $nmbr$ . $nmbr$ %,
1,blaic < $nmbr$ . $nmbr$ %,
1,blaek / afriean - ameriean,
1,blaek,
1,biolimus a $nmbr$ - eluting stent ¶,
1,bilag a  b or c domain score  n ( % ),
1,bid,
1,biasp $nmbr$ bid,
1,biasp $nmbr$,
1,biack non - hispanic,
1,biack,
1,bi ( $nmbr$ . $nmbr$ ),
1,bempedoic,
1,bdmard - naive,
1,basfi *,
1,baselinec,
1,baselineb,
1,baseiine diuretic,
1,barc $nmbr$ - $nmbr$,
1,b pooled new and worsened vertebral fractures ( mfas ),
1,b includes both ex - smokers and nonsmokers .,
1,b - blockers  n ( % ),
1,b - blockers,
1,b - blocker,
1,b + a ( n = $nmbr$ ),
1,b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .,
1,b  vhd ( n = $nmbr$ ),
1,b,
1,austrafca and new zealand,
1,attain,
1,atorvastatinb,
1,atenoioi ( n = $nmbr$ ),
1,at or above the median,
1,at or above median,
1,at least $nmbr$ flare,
1,at,
1,asui score  mean ( sd ),
1,asui score  mean,
1,associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % ),
1,aslan,
1,as,
1,arvfac ( per $nmbr$ % ),
1,arteriai access,
1,aqe ^ $nmbr$,
1,aqe < $nmbr$,
1,aqc < $nmbr$,
1,apolipoproiein b ( mij / $nmbr$ ),
1,apolipoproiein a $nmbr$ ( tng / $nmbr$ ),
1,apobe,
1,apoal,
1,apo bt,
1,any timi bleeding,
1,any teaes,
1,any teae,
1,any other llts ( other than statin ),
1,any other lipid ‐ lowering therapy  n ( % ),
1,any other antihyperglycaemic drugs,
1,any bleeding,
1,any ( including corticosteroid ),
1,any,
1,antithrombotic and anticoagulant medications,
1,antithrombotic,
1,antiplateletsa,
1,antiplatelets or anticoagulants,
1,antiplatelets  any,
1,antiplatelets,
1,antiplatelet — no . / total no . ( % ),
1,antiplatelet — no . ( % ),
1,antiplatelet or anticoagulant therapy,
1,antiplatelet or anticoagulant,
1,antiplatelet or anti - inflammatory drugs,
1,antiplatelet,
1,antihyperglycemictherapies  %,
1,anti - p $nmbr$,
1,annt or bnnh ( $nmbr$ % ci ),
1,aniagonisi,
1,anesthesiad  n ( % ),
1,and vfx status,
1,and physical examination,
1,and microalbuminuria or macroalbuminuria,
1,and infusion,
1,and either an ace inhibitor or angiotension receptor blocker,
1,and / or discharge,
1,and / or aza at baseline,
1,amputationsa,
1,ampd $nmbr$,
1,am_delta,
1,am_ % delta,
1,am pef ( sd )  l / min,
1,alvef ( per $nmbr$ % ),
1,allopurinolt,
1,allogliptin,
1,all teaes *,
1,all teaes,
1,all subjects - n,
1,all subjects,
1,all strokes *,
1,all strokes  n ( % ),
1,all strokes,
1,all rosuva,
1,all responders  ( n = $nmbr$ ),
1,all randomly assigned,
1,all randomized all - cause mortality or hospitalization for worsening hf ^,
1,all randomized all - cause mortality,
1,all randomized,
1,all patientsb,
1,all participantst ( n = $nmbr$ / $nmbr$ ),
1,all participantsa,
1,all other,
1,all noncompleters,
1,all itt sutajects,
1,all grafts,
1,all diabetesd,
1,all completers ( n $nmbr$ $nmbr$ ),
1,all completers,
1,all bleeding,
1,all bleed,
1,all,
1,ali,
1,alathosterol ( % ),
1,aiorvasiaiin,
1,aiirocumab ( n = $nmbr$ ),
1,aiirocumab,
1,aget  y,
1,ageadj,
1,agea,
1,afcaps /,
1,adverse eventy,
1,adjustedaor,
1,adjustedahr,
1,acholesterol ( % ),
1,acenocoumaroi,
1,aceis  n ( % ),
1,aceis,
1,acei vs . non - acei,
1,acei use,
1,acei or arb pre - randomisation,
1,acei or arb post - randomisation,
1,acei or arb,
1,acei and / or arb,
1,acei  n ( % ),
1,acei,
1,acecoumarol  no . ( % ),
1,absolutedifferenceestimate vs placebo ( $nmbr$ % ci ),
1,aab $nmbr$ ( % ),
1,a vs . c,
1,a from baselineb,
1,a excludes two randomized patients with unknown diabetes status at baseline .,
1,a a ( $nmbr$ ( % ),
1,a / c,
1,a . beuralizuinab $nmbr$ ing q $nmbr$ w,
1,a - blockers,
1,a - blocker,
1,a ) those receiving no inhaled pre - treatment maintenance medication,
1,a $nmbr$ vs placebo,
1,a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %,
1,a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,
1,a $nmbr$ c > $nmbr$ . $nmbr$ %,
1,a $nmbr$ c < $nmbr$ . $nmbr$ %,
1,a $nmbr$ c ( % ),
1,a $nmbr$ c  %,
1,a $nmbr$ c,
1,a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$,
1,a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),
1,a $nmbr$,
1,a  no vhd ( n = $nmbr$ $nmbr$ ),
1,a,
1,^ - blockers,
1,^ - blocker,
1,^ $nmbr$ y  n ( % ),
1,^ $nmbr$ - $nmbr$,
1,^ $nmbr$,
1,\ $nmbr$ %,
1,\ $nmbr$,
1,[ } ifrerence vs . placebo  % ( $nmbr$ % cl ),
1,> lto < $nmbr$ ( n = $nmbr$ ),
1,> is years,
1,> ii,
1,> = $nmbr$ yea ' s,
1,> = $nmbr$ y,
1,> = $nmbr$ mmhq,
1,> = $nmbr$ . $nmbr$,
1,> = $nmbr$ * ( % ),
1,> = $nmbr$ ( % ),
1,> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol ),
1,> = $nmbr$,
1,> - $nmbr$ cm,
1,> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$,
1,> - $nmbr$ . $nmbr$ - vfx,
1,> - $nmbr$ . $nmbr$ + vfx,
1,> - $nmbr$ . $nmbr$,
1,> $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ — no . { % ),
1,> $nmbr$ yrs,
1,> $nmbr$ yearstos is years,
1,> $nmbr$ y . n ( % ),
1,> $nmbr$ y ( n = $nmbr$ ),
1,> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,> $nmbr$ y  no . ( % ),
1,> $nmbr$ y  n ( % ),
1,> $nmbr$ y,
1,> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ or incident vitrectomy or photocoagulation,
1,> $nmbr$ oads,
1,> $nmbr$ nd and < $nmbr$ rd quartile,
1,> $nmbr$ mon ( n = $nmbr$ ),
1,> $nmbr$ mlymin,
1,> $nmbr$ microg / l,
1,> $nmbr$ lb,
1,> $nmbr$ ky / nr,
1,> $nmbr$ hr,
1,> $nmbr$ enroll,
1,> $nmbr$ cm,
1,> $nmbr$ but < $nmbr$ mg / dl,
1,> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ ),
1,> $nmbr$ bpm ( n = $nmbr$ ),
1,> $nmbr$ beats / min,
1,> $nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1,> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$,
1,> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ and < $nmbr$ years,
1,> $nmbr$ and < $nmbr$ mg / dl,
1,> $nmbr$ and < $nmbr$ %,
1,> $nmbr$ and < $nmbr$,
1,> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ ),
1,> $nmbr$ < $nmbr$,
1,> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$ yrs,
1,> $nmbr$ . $nmbr$ bpm,
1,> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$ ( % ),
1,> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
1,> $nmbr$ . $nmbr$ %,
1,> $nmbr$ . $nmbr$,
1,> $nmbr$ - < $nmbr$,
1,> $nmbr$ - $nmbr$ cm,
1,> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
1,> $nmbr$ - $nmbr$ - $nmbr$,
1,> $nmbr$ - $nmbr$,
1,> $nmbr$ ( % ),
1,> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),
1,> $nmbr$ % and < $nmbr$ %,
1,> $nmbr$ % $nmbr$,
1,> $nmbr$ %,
1,> $nmbr$ $nmbr$,
1,> $nmbr$  no . ( % ),
1,> $nmbr$  < = $nmbr$,
1,> $nmbr$  < $nmbr$,
1,> $nmbr$,
1,= $nmbr$ ’ ),
1,= $nmbr$,
1,< = $nmbr$ . $nmbr$ %,
1,< = $nmbr$ %,
1,< = $nmbr$,
1,< - $nmbr$ . $nmbr$ cm,
1,< - $nmbr$ . $nmbr$ - vfx,
1,< - $nmbr$ . $nmbr$ + vfx,
1,< - $nmbr$ . $nmbr$,
1,< $nmbr$ — no . { % ),
1,< $nmbr$ — no . ( % ),
1,< $nmbr$ » < $nmbr$ y,
1,< $nmbr$ { % ),
1,< $nmbr$ yrs,
1,< $nmbr$ yea ' s,
1,< $nmbr$ y ( n = $nmbr$ ),
1,< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,< $nmbr$ y  n ( % ),
1,< $nmbr$ y,
1,< $nmbr$ xuln,
1,< $nmbr$ nwrrtn,
1,< $nmbr$ no . ( % ),
1,< $nmbr$ mon ( n = $nmbr$ ),
1,< $nmbr$ mlymin,
1,< $nmbr$ mlmin ) $nmbr$,
1,< $nmbr$ microg / l,
1,< $nmbr$ lb,
1,< $nmbr$ ky / nr,
1,< $nmbr$ hr,
1,< $nmbr$ enroll,
1,< $nmbr$ cm,
1,< $nmbr$ bpm ( n = $nmbr$ ),
1,< $nmbr$ beats / min,
1,< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ ),
1,< $nmbr$ . $nmbr$ yrs,
1,< $nmbr$ . $nmbr$ bpm,
1,< $nmbr$ . $nmbr$ ( % ),
1,< $nmbr$ . $nmbr$ %,
1,< $nmbr$ . $nmbr$,
1,< $nmbr$ - $nmbr$,
1,< $nmbr$ ( % ),
1,< $nmbr$ %,
1,< $nmbr$,
1,/ j - valuc ! l,
1,/ $nmbr$ - blockers,
1,/ $nmbr$ - blocker,
1,. $nmbr$,
1,- ° - $nmbr$  wom -,
1,- bi -,
1,- $nmbr$ . $nmbr$ ± lno ^,
1,- $nmbr$ . $nmbr$ to - $nmbr$ cm,
1,- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll,
1,- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ ),
1,* $nmbr$ to < $nmbr$ y,
1,( sem ),
1,( ofl ),
1,( iqr ),
1,( e - blocker,
1,( cm ),
1,( a blocker,
1,( : > blockers,
1,( % ) ( $nmbr$ . $nmbr$ ),
1,( % ) ( $nmbr$ - $nmbr$ ),
1,( % ) $nmbr$ - $nmbr$,
1,( $nmbr$ blocker,
1,( $nmbr$ - blockers,
1,( $nmbr$ - blocker,
1,% phg,
1,% fhg,
1,% $nmbr$ - $nmbr$,
1,%,
1,$nmbr$ — em,
1,$nmbr$ — < $nmbr$,
1,$nmbr$ — $nmbr$ nlmw,
1,$nmbr$ ± ll,
1,$nmbr$ §,
1,$nmbr$ yrs or more,
1,$nmbr$ yrs l,
1,$nmbr$ yrs,
1,$nmbr$ y,
1,$nmbr$ tol ( n = $nmbr$ ),
1,$nmbr$ to < $nmbr$ — no . { % ),
1,$nmbr$ to < $nmbr$ mumin,
1,$nmbr$ to < $nmbr$ hr,
1,$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,$nmbr$ to $nmbr$ y  n ( % ),
1,$nmbr$ tcz,
1,$nmbr$ rrmnl ),
1,$nmbr$ q $nmbr$ w ( n = $nmbr$ ),
1,$nmbr$ or more,
1,$nmbr$ or greater,
1,$nmbr$ or $nmbr$ — no . / total no . ( % ),
1,$nmbr$ or $nmbr$ step,
1,$nmbr$ or $nmbr$ high cardiovascular risk categories,
1,$nmbr$ or $nmbr$ high - risk categories,
1,$nmbr$ or $nmbr$ days,
1,$nmbr$ or $nmbr$ d / wk,
1,$nmbr$ or $nmbr$ d / mo,
1,$nmbr$ or $nmbr$  no . / total no . ( % ),
1,$nmbr$ or $nmbr$  n ( % ),
1,$nmbr$ or $nmbr$,
1,$nmbr$ oam,
1,$nmbr$ oads,
1,$nmbr$ oad,
1,$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$,
1,$nmbr$ mortis,
1,$nmbr$ montlts,
1,$nmbr$ mgrdl,
1,$nmbr$ mentis,
1,$nmbr$ is ( $nmbr$ . $nmbr$ ),
1,$nmbr$ ii ( $nmbr$ . $nmbr$ ),
1,$nmbr$ e < $nmbr$ %  n ( % ),
1,$nmbr$ e < $nmbr$ %,
1,$nmbr$ e $nmbr$,
1,$nmbr$ c . t,
1,$nmbr$ blockers,
1,$nmbr$ blocker,
1,$nmbr$ b ( $nmbr$ b to > $nmbr$ a ),
1,$nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1,$nmbr$ < - $nmbr$,
1,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ / $nmbr$ ( $nmbr$ ),
1,$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ / $nmbr$,
1,$nmbr$ . $nmbr$ ± ii . $nmbr$,
1,$nmbr$ . $nmbr$ ± b . b,
1,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$,
1,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1,$nmbr$ . $nmbr$ yrs,
1,$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ per $nmbr$ pyr,
1,$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr,
1,$nmbr$ . $nmbr$ or more,
1,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ - < $nmbr$,
1,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ ( ll . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1,$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ % or more,
1,$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ % ( $nmbr$ ),
1,$nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$,
1,$nmbr$ - up and / or aza at baseline,
1,$nmbr$ - blockers,
1,$nmbr$ - blocker,
1,$nmbr$ - < $nmbr$ yrs,
1,$nmbr$ - < $nmbr$ y,
1,$nmbr$ - < $nmbr$ mvmin,
1,$nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$ - < $nmbr$ ( % ),
1,$nmbr$ - < $nmbr$ %,
1,$nmbr$ - < $nmbr$,
1,$nmbr$ - $nmbr$ — no . ( % ),
1,$nmbr$ - $nmbr$ yrs,
1,$nmbr$ - $nmbr$ y  n ( % ),
1,$nmbr$ - $nmbr$ hr,
1,$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^,
1,$nmbr$ - $nmbr$ . $nmbr$,
1,$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
1,$nmbr$ - $nmbr$  no . / totalno . ( % ),
1,$nmbr$ - $nmbr$,
1,$nmbr$ +  no . ( % ),
1,$nmbr$ +,
1,$nmbr$ ( or $nmbr$  if female only ),
1,$nmbr$ ( oo $nmbr$ - o . $nmbr$ ),
1,$nmbr$ ( > $nmbr$ % ),
1,$nmbr$ ( < $nmbr$ % ),
1,$nmbr$ ( $nmbr$ si,
1,$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e,
1,$nmbr$ ( $nmbr$ e < $nmbr$ % ),
1,$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze ),
1,$nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % ),
1,$nmbr$ ( $nmbr$ % ),
1,$nmbr$ ( $nmbr$  $nmbr$ ),
1,$nmbr$ % - $nmbr$ %,
1,$nmbr$ % ( oto $nmbr$ ),
1,$nmbr$ % $nmbr$,
1,$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ ),
1,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ $nmbr$,
1,$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$,
1,$ $nmbr$ and  $nmbr$ years,
1,$ $nmbr$ %,
1,$ $nmbr$,
